



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:

C12N 15/12, 5/10, 1/21, C07K 14/47,
16/18, C12N 1/21, C07K 14/47, 16/18,
C12Q 1/68, G01N 33/50, 33/53, 33/68,
A61K 38/17

A2

(11) International Publication Number:

WO 98/39448

(43) International Publication Date: 11 September 1998 (11.09.98)

(21) International Application Number: PCT/US98/04493

(22) International Filing Date: 6 March 1998 (06.03.98)

(30) Priority Data:

60/040,162	7 March 1997 (07.03.97)	US
60/040,333	7 March 1997 (07.03.97)	US
60/038,621	7 March 1997 (07.03.97)	US
60/040,161	7 March 1997 (07.03.97)	US
60/040,626	7 March 1997 (07.03.97)	US
60/040,334	7 March 1997 (07.03.97)	US
60/040,336	7 March 1997 (07.03.97)	US
60/040,163	7 March 1997 (07.03.97)	US
60/043,580	11 April 1997 (11.04.97)	US
60/043,568	11 April 1997 (11.04.97)	US

(Continued on the following page)

(71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hills Road, Laytonsville, MD 20882 (US). FISCHER, Carrie, L. [US/US]; 5810 Hall Street, Burke, VA 22015 (US). SOPER, Daniel, R. [US/US]; 15050 Stillfield, Place, Centerville, VA 22020 (US). CARTER, Kenneth, C. [US/US]; 11601 Brandy Hall Lane, North Potomac, MD 20878 (US). BEDNARIK, Daniel, P. [US/US]; 8822 Blue Sea Drive, Columbia, MD 21046 (US). ENDRESS, Gregory, A. [US/US]; 9729 Claggett Farm Drive, Potomac, MD 20854 (US). YU, Guo-Liang [CN/US]; 13524 Straw Bale Lane, Darnestown, MD 20878 (US). NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). FENG, Ping [CN/US]; 4 Relda Court, Gaithersburg, MD 20878 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). GREENE, John, M. [US/US]; 872 Diamond Drive, Gaithersburg, MD 20878 (US). FERRIE, Ann, M. [US/US]; 13203 L Astoria Hill Court, Germantown,

MD 20874 (US). DUAN, Roxanne [US/US]; 4541 Fairfield Drive, Bethesda, MD 20814 (US). HU, Jing-Shan [CN/US]; 1247 Lakeside Drive #3034, Sunnyvale, CA 94086 (US). FLORENCE, Kimberly, A. [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). BREWER, Laurie, A. [US/US]; 14920 Mount Nebo Road, Poolesville, MD 20837 (US). MOORE, Paul, A. [GB/US]; Apartment #104, 1908 Holly Ridge Drive, McLean, VA 22102 (US). SHI, Yanggu [CN/US]; 437 West Side Drive, Gaithersburg, MD 20878 (US). LAFLEUR, David, W. [US/US]; 1615 Q Street, N.W. #807, Washington, DC 20009 (US). LI, Yi [CN/US]; 1247 Lakeside Drive #3034, Sunnyvale, CA 94086 (US). ZENG, Zhizhen [CN/US]; 13950 Saddlevue Drive, Gaithersburg, MD 20878 (US). KYAW, Hla [BU/US]; 520 Sugarbush Circle, Frederick, MD 21703 (US).

(74) Agents: BROOKES, Anders, A. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 10850 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: 186 HUMAN SECRETED PROTEINS

(57) Abstract

The present invention relates to 186 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

60/043,314	11 april 1997 (11.04.97)	US	60/047,596	23 May 1997 (23.05.97)	US	60/056,637	22 August 1997 (22.08.97)	US
60/043,569	11 april 1997 (11.04.97)	US	60/047,612	23 May 1997 (23.05.97)	US	60/056,903	22 August 1997 (22.08.97)	US
60/043,311	11 april 1997 (11.04.97)	US	60/047,632	23 May 1997 (23.05.97)	US	60/056,888	22 August 1997 (22.08.97)	US
60/043,671	11 april 1997 (11.04.97)	US	60/047,601	23 May 1997 (23.05.97)	US	60/056,879	22 August 1997 (22.08.97)	US
60/043,674	11 april 1997 (11.04.97)	US	60/047,595	23 May 1997 (23.05.97)	US	60/056,880	22 August 1997 (22.08.97)	US
60/043,669	11 april 1997 (11.04.97)	US	60/047,599	23 May 1997 (23.05.97)	US	60/056,894	22 August 1997 (22.08.97)	US
60/043,312	11 april 1997 (11.04.97)	US	60/047,588	23 May 1997 (23.05.97)	US	60/056,911	22 August 1997 (22.08.97)	US
60/043,313	11 april 1997 (11.04.97)	US	60/047,585	23 May 1997 (23.05.97)	US	60/056,636	22 August 1997 (22.08.97)	US
60/043,672	11 april 1997 (11.04.97)	US	60/047,586	23 May 1997 (23.05.97)	US	60/056,874	22 August 1997 (22.08.97)	US
60/043,578	11 april 1997 (11.04.97)	US	60/047,590	23 May 1997 (23.05.97)	US	60/056,910	22 August 1997 (22.08.97)	US
60/043,576	11 april 1997 (11.04.97)	US	60/047,594	23 May 1997 (23.05.97)	US	60/056,864	22 August 1997 (22.08.97)	US
60/043,670	11 april 1997 (11.04.97)	US	60/047,589	23 May 1997 (23.05.97)	US	60/056,631	22 August 1997 (22.08.97)	US
60/047,600	23 May 1997 (23.05.97)	US	60/047,593	23 May 1997 (23.05.97)	US	60/056,845	22 August 1997 (22.08.97)	US
60/047,615	23 May 1997 (23.05.97)	US	60/047,614	23 May 1997 (23.05.97)	US	60/056,892	22 August 1997 (22.08.97)	US
60/047,597	23 May 1997 (23.05.97)	US	60/047,501	23 May 1997 (23.05.97)	US	60/056,632	22 August 1997 (22.08.97)	US
60/047,502	23 May 1997 (23.05.97)	US	60/048,974	06 June 1997 (06.06.97)	US	60/056,664	22 August 1997 (22.08.97)	US
60/047,633	23 May 1997 (23.05.97)	US	60/048,964	06 June 1997 (06.06.97)	US	60/056,876	22 August 1997 (22.08.97)	US
60/047,583	23 May 1997 (23.05.97)	US	60/049,610	13 June 1997 (13.06.97)	US	60/056,881	22 August 1997 (22.08.97)	US
60/047,617	23 May 1997 (23.05.97)	US	60/051,926	08 July 1997 (08.07.97)	US	60/056,909	22 August 1997 (22.08.97)	US
60/047,618	23 May 1997 (23.05.97)	US	60/052,874	16 July 1997 (16.07.97)	US	60/056,875	22 August 1997 (22.08.97)	US
60/047,503	23 May 1997 (23.05.97)	US	60/055,724	18 August 1997 (18.08.97)	US	60/056,862	22 August 1997 (22.08.97)	US
60/047,592	23 May 1997 (23.05.97)	US	60/056,886	22 August 1997 (22.08.97)	US	60/056,887	22 August 1997 (22.08.97)	US
60/047,581	23 May 1997 (23.05.97)	US	60/056,877	22 August 1997 (22.08.97)	US	60/056,908	22 August 1997 (22.08.97)	US
60/047,584	23 May 1997 (23.05.97)	US	60/056,889	22 August 1997 (22.08.97)	US	60/056,884	22 August 1997 (22.08.97)	US
60/047,500	23 May 1997 (23.05.97)	US	60/056,893	22 August 1997 (22.08.97)	US	60/057,761	05 September 1997 (05.09.97)	US
60/047,587	23 May 1997 (23.05.97)	US	60/056,630	22 August 1997 (22.08.97)	US	60/057,650	05 September 1997 (05.09.97)	US
60/047,492	23 May 1997 (23.05.97)	US	60/056,878	22 August 1997 (22.08.97)	US	60/057,669	05 September 1997 (05.09.97)	US
60/047,598	23 May 1997 (23.05.97)	US	60/056,662	22 August 1997 (22.08.97)	US	60/058,785	12 September 1997 (12.09.97)	US
60/047,613	23 May 1997 (23.05.97)	US	60/056,872	22 August 1997 (22.08.97)	US	60/061,060	02 October 1997 (02.10.97)	US
60/047,582	23 May 1997 (23.05.97)	US	60/056,882	22 August 1997 (22.08.97)	US			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

186 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and
5 their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or
10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum
15 (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or
25 secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include
30 the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using
35 secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig

analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 12301 Park Lawn Drive, Rockville,
5 Maryland 20852, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained
10 in SEQ ID NO:X, the complement thereof, or the cDNA contained within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42° C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed
15 by washing the filters in 0.1x SSC at about 65°C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages
20 of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even
25 lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include
30 Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such
35 as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a

complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

5 The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be
10 single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability
15 or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

 The polypeptide of the present invention can be composed of amino acids joined
20 to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs,
25 as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be
30 branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a
35 nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine,

formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Polynucleotides and Polypeptides of the Invention

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

This gene is expressed primarily in testes tumor and to a lesser extent in fetal brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer particularly of the testes, and defects of the central nervous system such as seizure and neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly cancer of the testes and central nervous system,

expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., testes and other reproductive tissue, brain and other tissue of the nervous system, and blood cells, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of testicular cancer and treatment of central nervous system disorders since this gene is primarily expressed in the testes tumor and developing brain.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

This gene is expressed primarily in cancer tissues, such as breast cancer and Wilm's tumor, and to a lesser extent in fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, and/or tumors, particularly, those found in the breast, and developmental abnormalities or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the glandular tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., mammary tissue, and fetal tissue and, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 314 as residues: Pro-11 to Thr-18, Leu-43 to Pro-50, Gly-64 to Leu-72, and Leu-81 to Lys-86.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of cancers and/or tumors, particularly, those found in the breast since expression is mainly in cancer/tumor tissues. May serve as therapeutic proteins for proliferation/differentiation of fetal tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

This gene is expressed primarily in CD34 depleted buffy coat and to a lesser extent in spleen, chronic lymphocytic leukemia.

- 5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: blood disorders or leukemias, diseases of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for
- 10 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
- 15 cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of blood disorders or
- 20 leukemias, diseases of the immune system since expression is in tissues related to immune function.

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

This gene is expressed primarily in CD34 depleted buffy coat.

- 25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: blood disorders or lymphocytic diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification
- 30 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual
- 35 having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of blood disorders since expression is in tissues related to immune function.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 5

This gene is expressed primarily in CD34 depleted buffy coat.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: blood or immune
10 diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and cancerous
15 and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 317 as residues:
20 Pro-13 to Lys-21.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of blood disorders since expression is in tissues related to immune function.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 6

This gene is expressed primarily in CD34 depleted buffy coat.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: blood or immune
30 diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., and blood cells, and
35 cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level

in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 318 as residues: Lys-31 to Lys-39.

5 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of blood diseases since it is expressed in tissues related to immune function.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

10 This gene is expressed primarily in CD34 depleted buffy coat and to a lesser extent in pineal gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: diseases of the immune system and brain associated diseases. Similarly, polypeptides and antibodies directed to
15 these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and pineal gland, and cancerous and wounded tissues) or
20 bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
25 corresponding to this gene are useful for treatment/diagnosis of blood disorders, immune diseases or brain associated diseases (specifically of the pineal gland) since expression is in tissues related to immune function.

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

30 The translation product of this gene shares sequence homology with an organic cation transporter which is thought to be important in organic cation uptake in the kidney and liver. (See Accession No. 2343059.) Preferred polypeptide fragments comprise the amino acid sequence ITIAIQMCLVNXELYPTFVRNXGVMVCSSLCDIGGIITP FIVFRLREVWQALPLILFAVLGLLAAGVTLLLPETKGVALPETMKDAENLGRKAKPKENTTYLK
35 VQTSEPSGT (SEQ ID NO: 615) or TMKDAENLGRKAKPKENT (SEQ ID NO: 616) as well as N-terminal and C-terminal deletions of these fragments. Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: hepatic and renal diseases where drug elimination/cation exchange (organic cation uptake) in the liver and kidney are problematic. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic or renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., kidney and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 320 as residues: Asn-64 to Asn-74, and Gln-81 to Gly-87.

The tissue distribution and homology to organic cation transporter indicate that polynucleotides and polypeptides corresponding to this gene are useful as a polyspecific transporter that is important for drug elimination in the liver (and possibly kidney) since expression is found in the liver.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

This gene is expressed primarily in eosinophil induced with IL-5 and to a lesser extent in fetal liver and spleen. This gene also maps to chromosome 15, and therefore can be used in linkage analysis as a marker for chromosome 15.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: diseases of the immune system, particularly allergies or asthma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, liver, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the

standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating/diagnosis of diseases involving eosinophil reactions since expression seems to be concentrated in eosinophils and other tissues involved in immunity such as the liver and spleen.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

This gene is expressed primarily in tissues of hematopoietic lineage and to a lesser extent in Hodgkins lymphoma. Any frame shifts in this sequence can easily be clarified using known molecular biology techniques.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, and immune deficiency or dysfunction. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., hematopoietic cells, lymphoid and reticuloendothelial tissues, and cancerous tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/ diagnosis for lymphomas or immune dysfunction or as a therapeutic protein useful in immune modulation based on expression in anergic T-cells and lymphomas.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

This gene is expressed primarily in neutrophils and to a lesser extent in activated lymphoid cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the cell type present in a biological sample and for diagnosis of diseases and conditions: inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders

of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
5 tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 323 as residues: Glu-40 to Lys-46.

The tissue distribution indicates that polynucleotides and polypeptides
10 corresponding to this gene are useful for modulation of an immune reaction or as a growth factor for the differentiation or proliferation of neutrophils for the treatment of neutropenia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 12

15 This gene is expressed primarily in brain and to a lesser extent in activated T-cells. It is likely that the open reading frame containing the predicted signal peptide continues in the 5' direction. Preferred polypeptide fragments comprise the amino acid sequence PRVRNSPEDLGLSLTGDSCKL (SEQ ID NO:617).

Therefore, polynucleotides and polypeptides of the invention are useful as
20 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: neurodegenerative disorders including ischemic shock, alzheimers and cognitive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a
25 number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and brain, and other tissue of the nervous system and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from
30 an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 324 as residues: Ser-5 to Glu-14, Ile-21 to Pro-35, Ser-65 to Asp-81, Cys-89 to Val-96, Lys-136 to Ser-145, Ile-152 to Met-169, and Arg-189 to Lys-196.

35 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnostic/treatment for cancers of the given tissue or in the treatment of neurological disorders of the CNS.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

This gene was also recently cloned by other groups, naming this calcium-activated potassium channel gene, hKCa4. (See Accession No. AF033021, see also, Accession No. 2584866.) This gene is mapped to human chromosome 19q13.2. A second signal sequence likely exists upstream from the predicted signal sequence as described in Table 1. Preferred polypeptide fragments comprise: QADDLQATVAALCVLRGGGPWAG SWLSPKTPGAMGGDLVLGLGALRRRKRL (SEQ NO: 618); or EQEKSLAGWALVLAXXGIGL MVLHAEMLWFGGCSAVNATGHLSDTLWLIPITFLTIGYGDVVPGMTWVGKIVCLCTGVMGVCC TALLVAVVARKLEFNKAEKHVHNFMMDIQYTKEMKESAAARVLQEAWMFYKHTRRKESHAAR XHQRXLLAAINAFRQVRLKHRKLREQVNSMVDISKMHMILYDLQQNLSSSHRALEKQIDTLAG KLDALTELLSTALGPRQLPEPSQQSK (SEQ ID NO: 619), as well as N-terminal and C-terminal deletions. Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in breast lymph node and T-cells, and to a lesser extent in placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: hematologic and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., lymphoid tissue, blood cells and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 325 as residues: Arg-13 to Lys-23.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment/diagnosis of hematologic and diseases involving immune modulation based on distribution in the lymph node and T-cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

This gene was recently cloned by another group, calling it PAPS synthase. (See Accession No. e1204135.) Preferred polypeptide fragments comprise the amino acid sequence YQAHHVS RNKRGQVVGTRGGFRGCTVWLTGLSGAGK (SEQ ID NO: 620).

5 Also preferred are the polynucleotide fragments encoding this polypeptide fragment.

It has been discovered that this gene is expressed primarily in benign prostate hyperplasia, Human Umbilical Vein Endothelial Cells and to a lesser extent in smooth muscle and Human endometrial stromal cells-treated with estradiol.

Therefore, polynucleotides and polypeptides of the invention are useful as
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: inflammation, ischemia, and restenosis, based on endothelial cell and smooth muscle cell expression, and prostate diseases such as benign prostate hyperplasia or prostate cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing
15 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate or vessels of the circulatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., prostate, endothelial cells, smooth muscle, and endometrium, and cancerous and wounded tissues) or bodily
20 fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 326 as residues: Arg-21 to Asp-26, Lys-35 to Lys-44,
25 Glu-49 to Asn-58.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating/diagnosing diseases or conditions where the endothelial cell lining of the veins and arteries of underlying smooth muscle are involved.

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

This gene is expressed primarily in human 6 week embryo and to a lesser extent in placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as
35 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: developmental anomalies or fetal deficiencies. Similarly, polypeptides and antibodies directed to these

polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly developmental in nature, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., embryonic tissue, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 327 as residues Lys-50 to Glu-57.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection of developmental abnormalities.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

This gene is expressed primarily in kidney and amygdala and to a lesser extent in fetal tissues. This gene is mapped to chromosome 14, and therefore is useful in linkage analysis as a marker for chromosome 14.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) present in a biological sample and for diagnosis of diseases and conditions: kidney diseases, neurological disorders and developmental abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s). For a number of disorders of the above tissues, particularly of the renal system or developing fetal tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., kidney, amygdala, and fetal tissues, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment or diagnosis of conditions affecting the brain, kidneys and fetal development.

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

This gene is expressed primarily in ovarian cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: solid tumors similar to ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., ovarian and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 329 as residues Ser-51 to Val-56.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of solid tumors of the reproductive system such as ovarian cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 18

This gene is expressed primarily in brain medulloblastoma. Preferred polypeptide fragments comprise the amino acid sequence: IRHEQHPNFSLEMHSGSSLLFLPQL ILILPVCAHLHEELNC (SEQ ID NO: 643) and SFFISEEKGHLLQAERHPWVAGALVGVSGLTLTTCSGPTEKPKATKNYFLKRLQEMHIRAN (SEQ ID NO: 644), as well as N-terminal and C-terminal deletions. Also preferred are polynucleotide fragments encoding these polypeptide fragments.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumors particularly of the CNS or Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the Central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating medulloblastoma or similar tumors.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

This gene is expressed primarily in adipocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: obesity. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the adipose tissues expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adipocytes and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating obesity by regulating the function and number of adipocytes

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

25 This gene is expressed primarily in B cell lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, of the immune system with an emphasis on B cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the tumors of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

30
35

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of B cell derived
5 tumors based on its expression in b cell lymphomas

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

This gene is expressed primarily in immune cells and to a lesser extent in fetal tissues

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: inflammatory diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell
15 type(s). For a number of disorders of the above tissues or cells, particularly of the immune expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., cells of the immune system, and fetal tissues, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an
20 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:333 as residues Asp-10 to Pro-19, Ser-74 to Tyr-79, Glu-95 to Lys-110.

The tissue distribution indicates that polynucleotides and polypeptides
25 corresponding to this gene are useful for treatment of diseases involving alterations in T cell activity.

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

It has been discovered that this gene is expressed primarily in ovarian tumor.

30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumors particularly of the ovary. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s)
35 or cell type(s). For a number of disorders of the above tissues or cells, particularly of tumors of the reproductive organs. expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., ovarian

and other reproductive tissue and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 334 as residues: Leu-22 to Gln-27.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of ovarian tumors as it has only been identified in ovarian tumors.

FEATURES OF PROTEIN ENCODED BY GENE NO: 23

It has been discovered that this gene is expressed primarily in fetal tissues and to a lesser extent in osteoclastoma cell line

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: osteoporosis or arthritis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone cells, and fetal tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of conditions of abnormal bone remodeling due to enhanced activity of osteoclasts. This may be useful as a specific marker for malignancies derived from osteoclasts or their precursors.

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

The translation product of this gene shares sequence homology with a periplasmic ribonuclease which is thought to be important in degrading extracellular polynucleotides

It has been discovered that this gene is expressed primarily in serum treated smooth muscle cells

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: vascular disease such as restenosis. Similarly, polypeptides and antibodies directed to these polypeptides are
5 useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vasculature expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., smooth muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
10 spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 336 as residues: Gln-30 to Lys-36, and Pro-41 to Arg-48.

15 The tissue distribution and homology to ribonucleases indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment of pathological conditions of smooth muscle associated with bacterial or viral infiltration

FEATURES OF PROTEIN ENCODED BY GENE NO: 25

20 This gene is expressed primarily in Early Stage Human Brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: human brain development and related diseases. Similarly, polypeptides and antibodies directed to
25 these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the human brain development and related diseases, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
30 fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to this gene indicate that polynucleotides
35 and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases affecting human brain development and related diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

It has been discovered that this gene is expressed primarily in human brain tissue.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: human brain diseases and other diseases related to brain diseases, which may be caused by brain diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in
10 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the human brain diseases, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
15 plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

 The tissue distribution and homology to the gene indicate that polynucleotides
20 and polypeptides corresponding to this gene are useful for diagnosis and treatment of human brain diseases and other diseases related.

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

It has been discovered that this gene is expressed primarily in Anergic T-cells.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: immune diseases, inflammatory diseases and diseases related to T lymph cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological
30 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune diseases, inflammatory diseases and diseases related to T lymph cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and cancerous and wounded tissues) or bodily fluids (e.g.,
35 serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to the gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for immune diseases,
5 inflammatory diseases and diseases related to T lymph cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

The translation product of this gene shares sequence homology with *Shigella flexneri* positive transcriptional regulator CriR (criR) gene which is thought to be
10 important in regulation of gene expression.

This gene is expressed primarily in human synovial sarcoma and normal human brain tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
15 biological sample and for diagnosis of diseases and conditions: human brain diseases particularly sarcomas of the synovium. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the human brain and synovium and other related human
20 brain diseases, expression of this gene at significantly higher or lower levels may be routinely detected in certain (e.g., synovial tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,
25 the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of human synovial sarcoma and other related human brain diseases.

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

This gene is expressed in bone marrow, infant brain, fetal liver and spleen, prostate and to a lesser extent in pineal gland, adipose tissue, kidney, adrenal gland, umbilical vein endothelial cells, and T cells.

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: diseases related to bone marrow or

hematoplastic tissues, prostate, kidney, adrenal gland, and cardiovascular tissue or organs. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the diseases related to

5 hematoplastic tissues, immune system, prostate, kidney, adrenal gland, and cardiovascular tissue or organs, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone marrow, hematopoietic cells, pineal gland, adipose tissue, kidney, adrenal gland, endothelial cells, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g.,

10 serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to the gene indicate that polynucleotides

15 and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases related to hematoplastic tissues, immune system, prostate, kidney, adrenal gland, and cardiovascular tissue or organs.

FEATURES OF PROTEIN ENCODED BY GENE NO: 30

20 This gene is expressed primarily in meningea and to a lesser extent in breast and adult brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: Diseases of the

25 meningea and related brain diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the meningea and related brain diseases, expression of this gene at significantly higher or lower levels may be routinely detected in certain

30 tissues and cell types (e.g., miningea, mammary tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the

35 disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the meningea and related brain diseases.

5 **FEATURES OF PROTEIN ENCODED BY GENE NO: 31**

This gene is expressed in meningea, fetal spleen, osteoblast and to a lesser extent in activated T-cells, endometrial stromal cells, fetal lung, HL-60, thymus, testis and endothelial cells.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: meningeal disease, osteoporosis, immune diseases, and hematoplastic diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for identification of the tissue(s) or cell type(s). For a number of disorders of the
15 above tissues or cells, particularly of the meningeal diseases, osteoporosis, immune diseases, and hematoplastic diseases, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, endometrium, lung, thymus, testis, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal
20 fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

 The tissue distribution and homology to gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of
25 meningeal, osteoporosis, immune diseases, hematoplastic diseases, testis diseases and lung diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

 This gene is expressed primarily in human thymus and to a much lesser extent
30 in infant brain, T-cells, smooth muscle, endothelial cells, bone marrow, human ovarian tumor and keratinocytes testes, osteoclastoma, breast, and tonsils.

 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: Diseases involving the
35 thymus, particularly thymic cancer and diseases involving T-cell maturation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a

number of disorders of the above tissues or cells, particularly of the thymus, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., thymus, brain, and other tissue of the nervous system, blood cells, bone marrow, ovaries, and testes, and other reproductive tissue, mammary
5 tissue, tonsils, melanocytes and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution and homology to gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the thymus particularly thymic cancer and diseases involving T-cell maturation.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 33**

 This gene is expressed primarily in human tonsils, and placenta, and to a lesser extent in adipocytes, melanocyte, and infant brain.

 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions: inflammatory diseases, immune diseases, and obesity. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the inflammatory diseases, immune diseases, and obesity, expression of
25 this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., tonsils, placenta, adipocytes, melanocytes, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard
30 gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

 The tissue distribution and homology to this gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases such as inflammation, immune diseases, and obesity.

35

FEATURES OF PROTEIN ENCODED BY GENE NO: 34

This gene is expressed in activated T cells, and to a lesser extent in pituitary, testis, and breast lymph node.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: diseases relating to T cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the disorders of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., pituitary, testes and other reproductive tissue, mammary tissue, and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of immune disorders.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 35

This gene is expressed primarily in infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the diseases relating to neurological disorders, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain, and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurological disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 36

This gene is expressed primarily in infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions: neurological disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in
providing immunological probes for differential identification of the tissue(s) or cell
10 type(s). For a number of disorders of the above tissues or cells, particularly of the
diseases relating to neurological disorders, expression of this gene at significantly
higher or lower levels may be routinely detected in certain tissues and cell types (e.g.,
brain and other tissue of the nervous system, and cancerous and wounded tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
15 tissue or cell sample taken from an individual having such a disorder, relative to the
standard gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of neurological
disorders.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 37

This gene is expressed primarily in human ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
25 biological sample and for diagnosis of diseases and conditions: ovarian cancer.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in
providing immunological probes for differential identification of the tissue(s) or cell
type(s). For a number of disorders of the above tissues or cells, particularly of the
ovarian disorders such as those involving germ cells, ovarian follicles, stromal cells,
30 expression of this gene at significantly higher or lower levels may be routinely detected
in certain tissues and cell types (e.g., ovary and other reproductive tissue, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or spinal fluid) or another tissue or cell sample taken from an individual having
such a disorder, relative to the standard gene expression level, i.e., the expression level
35 in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of ovarioopathy.

FEATURES OF PROTEIN ENCODED BY GENE NO: 38

This gene is expressed primarily in lymph node breast cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions: breast cancer. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in providing
immunological probes for differential identification of the tissue(s) or cell type(s). For a
10 number of disorders of the above tissues or cells, particularly of the breast cancer,
expression of this gene at significantly higher or lower levels may be routinely detected
in certain tissues and cell types (e.g., mammary tissue and lymphoid tissue, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or spinal fluid) or another tissue or cell sample taken from an individual having
15 such a disorder, relative to the standard gene expression level, i.e., the expression level
in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for used as a diagnostic marker for breast cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 39

20 This gene is expressed primarily in brain and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions: neuronal disorders such
as trauma, brain degeneration, and brain tumor. Similarly, polypeptides and antibodies
25 directed to these polypeptides are useful in providing immunological probes for
differential identification of the tissue(s) or cell type(s). For a number of disorders of
the above tissues or cells, particularly of the brain, expression of this gene at
significantly higher or lower levels may be routinely detected in certain tissues and cell
types (e.g., brain and other tissue of the nervous system, and cancerous and wounded
30 tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder, relative to
the standard gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
35 corresponding to this gene are useful for diagnosis and therapeutic treatment of
neuronal disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

5 This gene is expressed in early stage human embryo, adrenal gland tumor, and immune tissues such as fetal liver, fetal spleen, T-cell, and myeloid progenitor cell line and to a lesser extent in ovary, colon cancer, and a few other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumorigenesis including
10 adrenal gland tumor, colon cancer and various other tumors, developmental and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cancer tissues, early stage human tissues, and immune system,
15 expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, spleen, blood cells, bone marrow, ovary and other reproductive tissue, and colon, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard
20 gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and therapeutic treatment of immune and developmental disorders, and tumorigenesis.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 41

This gene is expressed primarily in fetal lung, endothelial cells, liver, thymus and a few other immune tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as
30 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: immune disorders such as immune deficiency and autoimmune diseases, pulmonary diseases, liver diseases, and tumor matasis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification
35 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal lung, liver, endothelial cells, and immune tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain

tissues and cell types (e.g., lung, endothelial cells, liver, thymus, and other tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of immune disorders and pulmonary and hepatic diseases. Its promoter may also be used for immune system and lung-specific gene therapies. The expression of this gene in endothelial cells indicates that it may also involve in angiogenesis which therefore may play role in tumor matasis.

FEATURES OF PROTEIN ENCODED BY GENE NO: 42

This gene is expressed primarily in liver, thyroid, parathyroid and to a lesser extent in fetal lung, stomach and early embryos.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: metabolic regulation, obesity, hepatic failure, hepatocellular tumors or thyroiditis and thyroid tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive/endocrine system expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, thyroid, parathyroid, lung, stomach, and embryonic tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and the extracellular locations indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of digestive/endocrine disorders, including metabolic regulation, hepatic failure, malabsorption, gastritis and neoplasms.

FEATURES OF PROTEIN ENCODED BY GENE NO: 43

This gene is expressed primarily in Schizophrenic adult brain, pituitary, front cortex, hypothalamus and to a lesser extent in retina, adipose and stomach cancer and placenta.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: schizophrenia and other neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification
10 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nerve system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., retinal tissue, adipose, stomach, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
15 cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful in treatment/detection of disorders in the nerve
20 system, including schizophrenia, neurodegeneration, and neoplasia. Additionally, a secreted protein in brain may serve as an endocrine.

FEATURES OF PROTEIN ENCODED BY GENE NO: 44

The translation product of this gene shares sequence homology with GTP
25 binding proteins which are thought to be important in signal transduction and protein transport.

This gene is expressed primarily in umbilical vein and microvascular endothelial cells, GM-CSF treated macrophage, anergic T cells, osteoblast, osteoclast, CD34+ cells and to a lesser extent in gall bladder.

30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: bone formation and growth, osteonecrosis, osteoporosis, angiogenesis and/or hematopoiesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing
35 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal and hematopoiesis systems, expression of this gene at significantly higher or lower levels

may be routinely detected in certain tissues and cell types (e.g., endothelial cells, blood cells, bone, and gall bladder, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to GTP binding proteins indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment/detection of bone formation and growth, osteonecrosis, osteoporosis, and/or hematopoiesis because its involvement in the growth signaling or angiogenesis.

FEATURES OF PROTEIN ENCODED BY GENE NO: 45

The translation product of this gene shares sequence homology with signal sequence receptor gamma subunit which is thought to be important in protein translocation on endoplasmic reticulum.

This gene is expressed primarily in adrenal gland, salivary gland, prostate, and to a lesser extent in endothelial cells and smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: protein secretion. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the secretory organs, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adrenal gland, salivary gland, prostate, endothelial cells, and smooth muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to SSR gamma subunit indicate that polynucleotides and polypeptides corresponding to this gene are useful for endocrine disorders, prostate cancer, xerostomia or sialorrhea.

35 FEATURES OF PROTEIN ENCODED BY GENE NO: 46

This gene is expressed primarily in osteoclastoma cells and to a lesser extent in melanocyte, amygdala, brain, and stomach.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: ossification, osteoporosis, fracture, osteonecrosis, osteosarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., melanocytes, amygdala, brain and other tissue of the nervous system, and stomach, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful in intervention of ossification, osteoporosis, fracture, osteonecrosis and osteosarcoma.

FEATURES OF PROTEIN ENCODED BY GENE NO: 48

The translation product of this gene shares sequence homology with proline rich proteins which is thought to be important in protein-protein interaction.

This gene is expressed primarily in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: neurological and psychological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nerve system and endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to proline-rich proteins indicate that polynucleotides and polypeptides corresponding to this gene are useful in intervention

and detection of neurological diseases, including trauma, neoplasia, degenerative or metabolic conditions in the central nerve system. Additionally, the gene product may be a secreted by the brain as an endocrine.

5 **FEATURES OF PROTEIN ENCODED BY GENE NO: 49**

The translation product of this gene shares sequence homology with the AOCB gene from *Aspergillus nidulans* which is important in asexual development.

This gene is expressed primarily in infant brain and to a lesser extent in the developing embryo, trachea tumors, B-cell lymphoma and synovial sarcoma.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: neurodegenerative diseases, leukemia and sarcoma's. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential
15 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., embryonic tissue, blood cells, trachea, and synovial tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
20 spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in infant brain and sarcoma's and homology to a gene involved in a key step of eukaryotic development (fungal spore formation) indicates
25 that the protein product of this clone could play a role in neurological diseases such as schizophrenia, particularly in infants. The existence of the gene in a B-cell lymphoma indicates the gene may be used in the treatment and detection of leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 50

30 This gene is expressed primarily in fetal lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: pulmonary disorders including lung cancer. Similarly, polypeptides and antibodies directed to these
35 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or

lower levels may be routinely detected in certain tissues and cell types (e.g., lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene only in fetal lung indicates that it plays a key role in development of the pulmonary system. This would suggest that misregulation of the expression of this protein product in the adult could lead to lymphoma or sarcoma formation, particularly in the lung. It may also be involved in predisposition to certain pulmonary defects such as pulmonary edema and embolism, bronchitis and cystic fibrosis.

FEATURES OF PROTEIN ENCODED BY GENE NO: 51

This gene is expressed primarily in hematopoietic cell types and fetal cells and to a lesser extent in all tissue types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: defects in the immune system and hematopoiesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., hematopoietic cells, and fetal tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene predominantly in hematopoietic cells and in the developing embryo indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and treatment of lymphomas and disease states affecting the immune system or hematopoiesis disorders such as leukemia, AIDS, arthritis and asthma..

FEATURES OF PROTEIN ENCODED BY GENE NO: 52

This gene is expressed primarily in prostate and to a lesser extent in fetal spleen, fetal liver, infant brain and T cell leukemias.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: prostate disorders, prostate cancer, leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, and/or prostate gland expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., thymus, spleen, liver, brain and other tissue of the nervous system, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene in prostate indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection or treatment of prostate disorders or prostate cancer. Its distribution in fetal liver and fetal spleen indicates it may play a role in the immune system and its misregulation could lead to immune disorders such as leukemia, arthritis and asthma.

FEATURES OF PROTEIN ENCODED BY GENE NO: 53

The translation product of this gene shares sequence homology with dynein.

This gene is expressed primarily in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: neuro-degenerative diseases of the brain. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly neuro-degenerative diseases expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The predominant tissue distribution in the brain and homology to dynein, a microtubule motor protein involved in the positioning of cellular organelles and molecules indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection/treatment of neurodegenerative diseases, such as Alzheimers,
5 Huntingtons, Parkinsons diseases and shizophrenia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 54

The translation product of this gene shares sequence homology with ubiquitin-conjugation protein, an enzyme which is thought to be important in the processing of
10 the Huntingtons Disease causing gene.

This gene is expressed primarily in brain and to a lesser extent in activated macrophages.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
15 biological sample and for diagnosis of diseases and conditions: neurodegenerative disease states including Huntington's disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of brain tissues. For a number of disorders of the above tissues or cells, particularly of the neurological systems expression of this gene at
20 significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level
25 in healthy tissue or bodily fluid from an individual not having the disorder.

The predominant tissue distribution of this gene in the brain and its homology to a Huntington interacting protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the regulation of the expression of the Huntington disease gene and other neurodegenerative diseases including
30 spinocerebular ataxia types I and III, dentatorubropallidoluysian and spinal bulbar muscular atrophy. In addition, the existence of elevated levels of free ubiquitin pools in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis indicates that the ubiquitin pathway of protein degradation plays a role in these disease states. Thus, considering the gene described here is homologous to a ubiquitin-conjugation
35 protein it may play a general role in neurodegenerative conditions.

FEATURES OF PROTEIN ENCODED BY GENE NO: 56

This gene is expressed primarily in T-cells (anergic T-cells, resting T-Cells, apoptotic T-cells) and lymph node (breast), as well as brain (hypothalamus, hippocampus, pituitary, infant brain, early-stage brain).

- 5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: immune (e.g. immunodeficiencies, autoimmunities, inflammation, leukemias & lymphomas) and neurological (e.g. Alzheimer's disease, dementia, schizophrenia) disorders. Similarly,
- 10 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous, hematopoietic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood
- 15 cells, lymphoid tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- 20 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful in the intervention or detection of pathologies associated with the hematopoietic and immune systems, such as anemias (leukemias). In addition, the expression in brain (including fetal) might suggest a role in developmental brain defects, neuro-degenerative diseases or behavioral abnormalities
- 25 (e.g. schizophrenia, Alzheimer's, dementia, depression, etc.).

FEATURES OF PROTEIN ENCODED BY GENE NO: 57

- This gene is expressed primarily in lung, and to a lesser extent in a variety of other hematological cell types (e.g. Raji cells, bone marrow cell line, activated
- 30 monocytes).

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: pulmonary and/or hematological disfunction. Similarly, polypeptides and antibodies directed to these
- 35 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vasculo-pulmonary and hematopoietic systems, expression of this

gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., lung and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the
5 standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful in the intervention and detection of pathologies associated with the vasculo-pulmonary system. In addition the expression of this gene
10 in a variety of leukocytic cell types and a bone marrow cell line might suggest a role in hematopoietic and immune system disorders, such as leukemias & lymphomas, inflammation, immunodeficiencies and autoimmunities.

FEATURES OF PROTEIN ENCODED BY GENE NO: 58

15 The translation product of this gene shares sequence homology with adenylate kinase isozyme 3 (gil163528 GTP:AMP phosphotransferase (EC 2.7.4.10) [Bos taurus]), which is thought to be important in catalyzing the phosphorylation of AMP to ADP in the presence of ATP or inorganic triphosphate.

This gene is expressed primarily in fetal liver, heart and placenta, and to a lesser
20 extent in many other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: hepatic, cardiovascular or reproductive disorders. Similarly, polypeptides and antibodies directed to these
25 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic, cardiovascular and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, heart, and placenta, and cancerous and wounded tissues) or
30 bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
35 corresponding to this gene are useful for the treatment and diagnosis of conditions related to hepatic function and pathogenesis, in particular, those dealing with liver development and the differentiation of hepatocyte progenitor cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 59

This gene is expressed primarily in CD34 positive cells (Cord Blood).

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions: hematopoietic
differentiation and immune disorders. Similarly, polypeptides and antibodies directed to
these polypeptides are useful in providing immunological probes for differential
10 identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of hematopoietic and immune systems, expression of this
gene at significantly higher or lower levels may be routinely detected in certain tissues
and cell types (e.g., hematopoietic cells, and blood cells, and cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
15 another tissue or cell sample taken from an individual having such a disorder, relative to
the standard gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful in the detection and treatment of conditions
associated with CD34-positive cells, and therefore as a marker for cell differentiation in
20 hematopoiesis, as well as immunological disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 60

The translation product of the predicted open reading frame of this contig has
sequence identity to the murine gene designated Insulin-Like Growth Factor-Binding
25 Protein (IGFBP)-1 as described by Lee and colleagues (Hepatology 19 (3), 656-665
(1994)).

This gene is expressed exclusively in hemangiopericytoma.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
30 biological sample and for diagnosis of hemangiopericytoma and other pericyte or
endothelial cell proliferative disorders. Similarly, polypeptides and antibodies directed
to these polypeptides are useful in providing immunological probes for differential
identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the circulatory and immune systems, expression of this
35 gene at significantly higher or lower levels may routinely be detected in certain tissues
and cell types (e.g., pericyte or endothelial cells, and liver, and cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or

another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Polynucleotides and polypeptides corresponding to this gene are useful as cell growth regulators since IGFBP-1-like molecules function as modulators of insulin-like growth factor activity. In addition, since IGFBP-1 is expressed at high levels following hepatectomy and during fetal liver development, polynucleotides of the present invention may also be used for the diagnosis of developmental disorders. Further, polypeptides of the present invention may be used therapeutically to treat developmental liver disorders as well as to regulate hepatocyte and supporting cell growth following hepatectomy or to treat liver disorders.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hemangiopericytoma and liver disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 61

This gene is expressed primarily in schizophrenic frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: nervous system and cognitive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the frontal cortex and CNS expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, treatment and diagnosis of frontal cortex, neuro-degenerative and CNS disorders

FEATURES OF PROTEIN ENCODED BY GENE NO: 62

This gene is expressed primarily in human adrenal gland tumor, and to a lesser extent in human kidney, medulla and adult pulmonary tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: metabolic, endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are
5 useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and nervous system disorders and neoplasia, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adrenal gland, kidney, brain and other tissue of the nervous system,
10 pulmonary tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, treatment and diagnosis of neurological and endocrine disorders including neoplasia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 63

20 This gene is expressed primarily in human adipocytes, and to a lesser extent in spleen, 12-week old human, and testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: immune, metabolic and
25 growth disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adipocytes,
30 spleen, and testes and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis and treatment of immune, developmental and metabolic disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 64

- One translated product of this clone is homologous to the mouse zinc finger protein PZF. (See Accession No. 453376; see also Gene 152 (2), 233-238 (1995).) Preferred polypeptide fragments correspond to the highly conserved domains shared between mouse and man. For example, preferred polypeptide fragments comprise the amino acid sequence: LQCEICGFTCRQKASLNWHMKKHDADSFYQFSCNICGKKFEKKDSVVAHKAKSH PEV (SEQ ID NO: 621); ITSTDILGTNPESLTQPSD (SEQ ID NO: 622); NSTSGECLLLEAGM SKSY (SEQ ID NO: 623); CSGTERVSLMADGKIFVSGSGSGTEGLVMNSDILGATTEVLIEDSD SAGP (SEQ ID NO: 624); IQYVRCEMEGCGTVLAHPRYLQHHIKYQHLLKKKYVCPHPSCGRLF RLQKQLLRHAKHHT (SEQ ID NO: 625); DQRDYICEYCARAFKSSHNLAVHRMIHTGEK (SEQ ID NO: 626); RSSRTSVSRHRDTENTRSSRSKTGSLQLICKSEPNTDQLDY (SEQ ID NO: 627); PFKDDPRDETYKPHLERETPKPRKSG (SEQ ID NO: 630); QYVRCEMEGCGTVLAHPRYLQ HHIKYQHLLKKKYVCPHPSCGRLFRLQKQLLRHAKHHTD (SEQ ID NO: 629); or residues 151-182 of QRDYICEYCARAFKSSHNLAVHRMIHTGEKHY (SEQ ID NO: 628). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in Rhabdomyosarcoma, melanocyte and colon cancer tissue and to a lesser extent in smooth muscle, pancreatic tumor, and apoptotic T-cells.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to,. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hemopoetic, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., striated muscle, melanocytes, colon, smooth muscle, pancreas, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis and treatment of cancer and hemopoetic disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 65

This gene is expressed primarily in human adipose and salivary gland tissue and to a lesser extent in human bone marrow and fetal kidney.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: metabolic and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic and hemopoetic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adipose, salivary gland, bone marrow, and kidney, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis of metabolic and immune disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 66

This translated product of this gene was recently identified as oxytocinase splice variant 1. (See Accession Nos. 2209276 and d1010078.) Preferred polypeptide fragments comprise the amino acid sequence: EMFDSLSTYFKGSSLLMLKTYLSEDFVQHAAVVLHLNHSYASIQSDDLWDSFNEVTNQTLDVKRMKWTWLQKGFPLVTVQKKGKELFIQQRFFLNMKPEIQPSDTRYM (SEQ ID NO: 631). Also preferred are polynucleotide fragments encoding this polypeptide fragment.

FEATURES OF PROTEIN ENCODED BY GENE NO: 67

This gene is expressed primarily in hemopoetic cells, particularly apoptotic T-cells, and to lesser extent in primary dendritic cells and adipose tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of apoptotic T-cells, primary dendritic cells, and adipose tissue present in a biological sample and for diagnosis of diseases and conditions: hemopoetic diseases including cancer and general immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly of the oral and intestinal mucosa as well as hemopoetic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., hematopoietic cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of diseases of the immune system, including cancer, hemopoetic and infectious diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 68

This gene is expressed primarily in kidney cortex and to a lesser extent in infant brain, heart, uterus, and blood.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of kidney tissue present in a biological sample and for diagnosis of diseases and conditions: soft tissue cancer, inflammation, kidney fibrosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and endocrines systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., kidney, brain, and other nervous tissue, heart, uterus, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of cancer and fibroses.

FEATURES OF PROTEIN ENCODED BY GENE NO: 69

The translation product of this gene shares strong sequence homology with vertebrate and invertebrate protein tyrosine phosphatases.

This gene is expressed primarily in endometrial tumors, melanocytes, myeloid progenitors and to a lesser extent in infant brain, adipocytes, and several hematopoietic stem cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of transformed hematopoietic and epithelial cells present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, of skin and endometrium, leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and hemopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endometrium, melanocytes, bone marrow, adipocytes, hematopoietic cells, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and sequence similarity with tyrosine phosphatases indicate that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of cancer and hematopoietic disorders.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 70

This gene is expressed primarily in osteoclastoma, breast, and infant brain and to a lesser extent in various fetal and transformed bone, ovarian, and neuronal cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: degenerative conditions of the brain and skeleton. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone, mammary tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of degenerative, neurological and skeletal disorders.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 71

This gene was originally cloned from tumor cell lines. Recently another group has also cloned this gene, calling it the human malignant melanoma metastasis-suppressor (KiSS-1) gene. (See Accession No. U43527.) Preferred polypeptide fragments comprise the amino acid sequence: LEKVASVGNSRPTGQQLLESLGLLA (SEQ ID NO: 632); VHREEASCYCQAEPSGDL (SEQ ID NO: 633); RPALRQAGGGTREPRQKRWAGL (SEQ ID NO: 634); and AVNFRPQRSQSM (SEQ ID NO: 635). Any frame shifts can easily be resolved using known molecular biology techniques.

This gene is expressed primarily in many types of carcinomas and to a lesser extent in many normal organs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer particularly melanomas, and other hyperproliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of transformed organ tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. As a tumor suppressor gene, increase amounts of the polypeptide can be used to treat patients having a particular cancer.

The tissue distribution indicates that this gene and the translated product is useful for diagnosing and study of cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 72

This gene is expressed primarily in striatum and to a lesser extent in adipocytes and hemangiopericytoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of striatal cells present in a biological sample and for diagnosis of diseases and conditions: neurological, fat and lysosomal storage

diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., striatal tissue, adipocytes, and vascular tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis, study and treatment of neurodegenerative and growth disorders.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 73**

This gene is expressed primarily in bone marrow stromal cells and to a lesser extent in smooth muscle, testes, endothelium, and brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of bone marrow present in a biological sample and for diagnosis of diseases and conditions: connective tissue and hematopoietic diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone marrow, stromal cells, smooth muscle, testes and other reproductive tissue, endothelium, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis, and treatment of connective tissue and blood diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 74

This gene is expressed primarily in brain, fetal liver and lung and to a lesser extent in retina, spinal chord, activated T-cells and endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of brain and regenerating liver present in a biological sample and for diagnosis of diseases and conditions: CNS and spinal chord injuries, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
10 particularly of the nervous and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, liver, pulmonary tissue, blood cells, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from
15 an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of hematopoietic and
20 neurological conditions.

FEATURES OF PROTEIN ENCODED BY GENE NO: 75

The translation product of this gene shares sequence homology with GTP binding proteins (intracellular).

25 This gene is expressed primarily in bone marrow, brain, and melanocytes and to a lesser extent in various endocrine and hematopoietic tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: hematopoietic and
30 nervous system conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone
35 marrow, melanocytes, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder,

relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to nucleotide binding factors indicate that polynucleotides and polypeptides corresponding to this gene are useful for study,
5 diagnosis, and treatment of brain degenerative, skin and blood diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 76

This gene is expressed primarily in activated T-cells and to a lesser extent in retina, brain, and fetal bone.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of activated T-cells and developing brain present in a biological sample and for diagnosis of diseases and conditions: immune deficiencies and skeletal and neuronal growth disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes
15 for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous, immune, and skeletomuscular sustems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, brain and other tissue of the nervous system, retinal tissue, and bone, and cancerous and wounded tissues) or
20 bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
25 corresponding to this gene are useful for diagnosis, study and treatment of cancer, urogenital, and brain degenerative diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 77

This gene is expressed primarily in fetal liver, activated monocytes, osteoblasts
30 and to a lesser extent in synovial, brain, and lymphoid tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of myeloid and lymphoid present in a biological sample and for diagnosis of diseases and conditions: inflammation, immune deficiencies, cancer. Similarly, polypeptides and antibodies directed to these
35 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and skeleton, expression of this gene at significantly

higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, blood cells, bone, synovial tissue, brain and other tissue of the nervous system, and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample
5 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis, and treatment of lymphoid
10 and mesenchymal cancers and nervous system diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 78

The translation product of this gene shares sequence homology with polymerase polypeptide precursor which is thought to be important in DNA repair and replication

15 This gene is expressed primarily in infant brain and to a lesser extent in tumors and tumor cell lines

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
20 not limited to, especially of the neural system and developing organs. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system expression of this gene at significantly higher or lower levels may be routinely detected
25 in certain (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 The tissue distribution and homology to polymerase polypeptide precursor indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancers especially of the neural system and developing organs

35 FEATURES OF PROTEIN ENCODED BY GENE NO: 79

This gene is expressed primarily in muscle and endothelial cells and to a lesser extent in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: vascular diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in
5 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain (e.g., muscle, endothelial cells, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
10 plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
15 corresponding to this gene are useful for treatment and diagnosis of disorders of the vascular and neural system including cardiovascular and endothelial.

FEATURES OF PROTEIN ENCODED BY GENE NO: 80

This gene is expressed primarily in placenta and to a lesser extent in fetal liver
20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: developmental disorders and disorder of the haemopoietic system, fetal liver and placenta. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing
25 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of developmental disorders and disorder of the haemopoietic system, fetal liver and placenta, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta and liver, and cancerous and wounded tissues) or
30 bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
35 corresponding to this gene are useful for diagnosis and treatment of developmental disorders and disorders of the haemopoietic system, fetal liver and placenta.

FEATURES OF PROTEIN ENCODED BY GENE NO: 81

This gene is expressed primarily in bone marrow, placenta and tissues and organs of the hematopoietic system.

- 5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: disorders of the bone and haemopoietic system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification
- 10 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, bone and hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone marrow, placenta, and hematopoietic cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal
- 15 fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders of the
- 20 immune, bone and hematopoietic system

FEATURES OF PROTEIN ENCODED BY GENE NO: 82

- The translation product of this gene shares sequence homology with secretory carrier membrane protein which is thought to be important in protein transport and
- 25 export. Any frame shifts in coding sequence can be easily resolved using standard molecular biology techniques. Another group recently cloned this gene, calling it SCAMP. (See Accession No. 2232243.)

This gene is expressed primarily in prostate, breast and spleen, and to a lesser extent in several other tissues and organs.

- 30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: disorders of the breast prostate and spleen. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification
- 35 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly disorders of the breast prostate and spleen, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell

types (e.g., prostate, mammary tissue, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to secretory carrier membrane protein indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders of the breast, prostate and spleen.

10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 83**

This gene is expressed primarily in developing organs and tissue like placenta and infant brain and to a lesser extent in developed organs and tissue like cerebellum and heart.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: neurological diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, heart, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of the neural system including neurological disorders and cancer.

30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 84**

The translation product of this gene shares sequence homology with ATPase 6 in *Trypanosoma brucei* which is thought to be important in metabolism.

This gene is expressed primarily in tumor and fetal tissues and to a lesser extent in melanocytes, kidney cortex, monocytes and ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions: metabolism disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., fetal tissues, melanocytes, kidney, blood cells, ovary and other tissue of the reproductive system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to ATPase indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of metabolism disorders, especially in fetal and tumor tissue growth.

FEATURES OF PROTEIN ENCODED BY GENE NO: 85

The translation product of this gene shares sequence homology with the immunoglobulin superfamily of proteins which are known to be important in immune response and immunity.

This gene is expressed primarily in stromal cells, colon cancer, lung, amygdala, melanocyte and to a lesser extent in a variety of other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: defects of stromal cell development and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the stromal cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., stromal cells, colon, lung, amygdala, and melanocytes, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to immunoglobulin indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of immune system disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 86

The translation product of this gene shares sequence homology with transcription initiation factor eIF-4 gamma which is thought to be important in gene transcription.

This gene is expressed primarily in tumor tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumorigenesis.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly in tumor tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endometrium and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to transcription initiation factor eIF-4 gamma indicate that polynucleotides and polypeptides corresponding to this gene are useful for gene regulation in tumorigenesis.

FEATURES OF PROTEIN ENCODED BY GENE NO: 87

The translation product of this gene shares sequence homology at low level in prolines with secreted basic proline-rich peptide II-2 which is thought to be important in protein structure or inhibiting hydroxyapatite formation in vitro.

This gene is expressed primarily in endometrial tumor and fetal lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: endometrial tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscular/skeletal and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endometrium, and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample

taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- 5 The tissue distribution and homology to secreted basic proline-rich peptide II-2 indicate that polynucleotides and polypeptides corresponding to this gene are useful for inhibiting hydroxyapatite formation or establishing cell/tissue structure.

FEATURES OF PROTEIN ENCODED BY GENE NO: 88

- 10 This gene is expressed primarily in: amniotic cells induced with TNF in culture; and to a lesser extent in colon tissue from a patient with Crohn's Disease; parathyroid tumor; activated T-cells; cells of the human Caco-2 cell line; adenocarcinoma; colon; corpus colosum; fetal kidney; pancreas tumor; fetal brain; early stage brain, and anergic T-cells.

- 15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system; 20 e.g., tumors, expression of this gene at significantly higher or lower levels may be routinely detected in certain (e.g., amniotic cells, colon, kidney, pancreas, parathyroid, brain and other tissue of the nervous system, blood cells, hematopoietic cells, liver, spleen, bone, testes and other reproductive tissue, brain and other tissue of the nervous system, and epithelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., 25 serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- 30 The tissue distribution indicates that the protein product of this clone is useful for modulating tumorigenesis and other immune system conditions such as disorders in immune response.

FEATURES OF PROTEIN ENCODED BY GENE NO: 89

- 35 This gene is expressed primarily in fetal liver/spleen and hematopoietic cells and to a lesser extent in brain, osteosarcoma, and testis tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions: leukemia and hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., hematopoietic cells, liver, spleen, bone, testes, and other reproductive tissue, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hematopoietic and immune disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 90

The translation product of this gene shares weak sequence homology with mouse Gcap1 protein which is developmentally regulated in brain.

This gene is expressed primarily in infant and adult brain and fetal liver/spleen and to a lesser extent in smooth muscle, T cells, and a variety of other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: neurological or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous, hematopoietic, immune, and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, blood cells, liver, spleen, and smooth muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and its homology to Gcap1 protein indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders in neuronal, hematopoietic, immune, and endocrine systems.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 91

This gene is expressed primarily in brain and hematopoietic cells and to a lesser extent in tumor tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: disorder in nervous, hematopoietic, immune systems and tumorigenesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous, hematopoietic, immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of disorders in the nervous, hematopoietic, and immune systems.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 92

The translation product of this gene shares sequence homology with neuroendocrine-specific protein A which is thought to be important in neurologic systems.

30 This gene is expressed primarily in brain tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: neural disorders and degeneration disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central or peripheral nervous systems, expression of this gene at

significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., hematopoietic cells, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having
5 such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to neuroendocrine-specific protein A indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment or diagnosis of neural disorders and degeneration disease.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 93

The translation product of this gene shares sequence homology with collagen-like protein and prolin-rich protein which are thought to be important in connective tissue function and tissue structure.

15 This gene is expressed primarily in fetal liver/spleen and brain tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: neuronal or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these
20 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, spleen, and brain and other tissue of the nervous system, and
25 cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to collagen-like protein and proline-rich
30 proteins indicate that polynucleotides and polypeptides corresponding to this gene are useful for supporting brain and hematopoietic tissue function and diagnosis and treatment of disorders in these functions.

FEATURES OF PROTEIN ENCODED BY GENE NO: 94

35 This gene is expressed primarily in embryonic tissues and tumor tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to,. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system (e.g., tumors), expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., embryonic tissue and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancer.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 95**

This gene is expressed primarily in brain tumor, placenta, and melanoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: brain tumor or melanoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain or melanocytes, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, placenta, and melanocytes, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the translation product of this gene is useful in the diagnosis and treatment of brain tumors and melanoma.

FEATURES OF PROTEIN ENCODED BY GENE NO: 96

The translation product of this gene shares sequence homology with a yeast membrane protein, SUR4, which encodes for APA1 that acts on a glucose-signaling pathway that controls the expression of several genes that are transcriptionally regulated by glucose.

This gene is expressed primarily in fetal liver, and to a lesser extent in placenta and breast tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: defects of fetal liver or defects of glucose-regulated ATPase activities in tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal immune/hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, placenta, and mammary tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to yeast SUR4 membrane protein indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of defects of fetal liver or defects of glucose-regulated ATPase activities.

FEATURES OF PROTEIN ENCODED BY GENE NO: 97

This gene is expressed primarily in fetal liver, brain, and amniotic fluid.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: defects of the fetal immune system and adult brain. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal immune system and adult brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of this clone is useful for detecting defects of the fetal immune and hematopoietic systems since fetal liver is

the predominant organ responsible for hematopoiesis in the fetus. In addition, the gene product of this gene is thought to be useful for detecting certain neurological defects of the brain.

5 **FEATURES OF PROTEIN ENCODED BY GENE NO: 98**

The translation product of this gene shares sequence homology with an yolk protein precursor, Vitellogenin which is thought to be important in binding lipids such as phosvitin.

This gene is expressed primarily in amniotic cells and fetal liver.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: defects in amniotic cells, fetal liver development and the fetal immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes
15 for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the [insert system where a related disease state is likely, e.g., immune], expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., amniotic cells, and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,
20 urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution and homology to vitellogenin indicate that the protein product of this clone is useful for treatment and diagnosis of defects in amniotic cells, fetal liver development and the fetal immune system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 99

30 This gene is expressed primarily in placenta, endometrial tumor, osteosarcoma and stromal cells.

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumor of the endometrium or bone, and osteosarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the obstetric system (e.g. placenta,

endometrium) and the bones, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, endometrium, bone, and stromal cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of tumors and abnormalities of the endometrium, and the bones because of its abundance in the aforementioned tissues..

FEATURES OF PROTEIN ENCODED BY GENE NO: 100

This gene is expressed primarily in hepatocellular tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: hepatocellular tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of hepatocellular cancer because of its abundant expression in this tissue.

FEATURES OF PROTEIN ENCODED BY GENE NO: 101

This gene is expressed primarily in Corpus Colosum, fetal lung and infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: defects of the Corpus Colosum or defects of the fetal lung. Similarly, polypeptides and antibodies directed to

these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the Corpus Colosum and brain in general, and fetal lung, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., lung, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of defects of the Corpus Colosum and brain in general, and defects of fetal lung.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 102**

This gene is expressed primarily in T cells and stromal cells, and to a lesser extent in adrenal gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: defects of T cell immunity and stromal cell development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, stromal cells, and adrenal gland, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of defects of T cell immunity and stromal cell development because of its abundant expression in these tissues.

35 **FEATURES OF PROTEIN ENCODED BY GENE NO: 103**

This gene is expressed primarily in infant brain and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: defects of the brain and nervous system. Similarly, polypeptides and antibodies directed to these polypeptides
5 are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, especially brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and placenta, cancerous and
10 wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of this clone is useful
15 for detecting defects of the brain, especially in young children.

FEATURES OF PROTEIN ENCODED BY GENE NO: 105

This gene is expressed primarily in human osteoclastoma and to a lesser extent in human pancreas tumor.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer particularly osteoclastoma and pancreatic tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing
25 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly in transformed tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone and pancreas, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
30 another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of some types of tumors, particularly pancreatic cancer and
35 osteoclastoma.

FEATURES OF PROTEIN ENCODED BY GENE NO: 106

This gene is expressed primarily in fetal liver/spleen, and to a lesser extent in activated T-Cells.

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions: immune disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in
providing immunological probes for differential identification of the tissue(s) or cell
10 type(s). For a number of disorders of the above tissues or cells, particularly of the
immune system, expression of this gene at significantly higher or lower levels may be
routinely detected in certain tissues and cell types (e.g., liver, spleen, and blood cells,
and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual
15 having such a disorder, relative to the standard gene expression level, i.e., the
expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis or treatment of immune disorders.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 107

This gene is expressed primarily in human embryo and to a lesser extent in
spleen and chronic lymphocytic leukemia.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
25 biological sample and for diagnosis of diseases and conditions: leukemia. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in providing
immunological probes for differential identification of the tissue(s) or cell type(s). For a
number of disorders of the above tissues or cells, particularly of the immune or
hemopoietic systems, expression of this gene at significantly higher or lower levels may
30 be routinely detected in certain tissues and cell types (e.g., embryonic tissue, spleen,
and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from
an individual having such a disorder, relative to the standard gene expression level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not having the
35 disorder.

The tissue distribution indicates that the protein product of this clone is useful
for the diagnosis and treatment of leukemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 108

This gene is expressed primarily in placenta, and to a lesser extent in early stage human brain and in lung.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: fetal developmental abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s)
10 or cell type(s). For a number of disorders of the above tissues or cells, particularly in fetal and amniotic tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, brain and other tissue of the nervous system, and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
15 tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of this is useful for production of growth factor(s) associated with fetal development. Preferred
20 polypeptides comprise the full-length polypeptide shown in the sequence listing, truncated however, at the amino terminus and beginning with QTIE.

FEATURES OF PROTEIN ENCODED BY GENE NO: 109

This gene is expressed primarily in fetal spleen, and to a lesser extent in B-Cell
25 lymphoma and T-Cell lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing
30 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., spleen and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal
35 fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of this clone is useful for the treatment and diagnosis of human lymphomas.

FEATURES OF PROTEIN ENCODED BY GENE NO: 110

5 The translation product of this gene shares sequence homology with sarcoma amplified sequence (SAS), a tetraspan receptor which is thought to be important in malignant fibrous histiocyoma and liposarcoma.

This gene is expressed primarily in human osteoclastoma, and to a lesser extent in pineal gland and infant brain.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: malignant fibrous histiocyoma and liposarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification
15 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone, pineal gland, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal
20 fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to sarcoma amplified sequence (SAS) indicate that the protein product of this clone is useful for treatment of, osteosarcoma,
25 malignant fibrous histiocyoma and liposarcoma and related cancers, particularly sarcomas.

FEATURES OF PROTEIN ENCODED BY GENE NO: 111

30 The translation product of this gene shares sequence homology with 6.8K proteolipid protein, mitochondrial - bovine.

This gene is expressed primarily in Wilm's tumor and to a lesser extent in cerebellum and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
35 biological sample and for diagnosis of diseases and conditions: Wilm's tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly of the immune or renal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to 6.8K proteolipid protein indicate that the protein product of this clone is useful for diagnostic and therapeutics associated with tumors, particularly Wilm's tumor disease.

FEATURES OF PROTEIN ENCODED BY GENE NO: 112

This gene is expressed primarily in embryonic tissue and to a lesser extent in osteoblasts, endothelial cells, macrophages (GM-CSF treated), and bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., embryonic tissue, bone, endothelial cells, blood cells and bone marrow, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment or diagnosis of immune disorders. Preferred polypeptides encoded by this gene comprise the following amino acid sequence: MITDVQLAIFANMLGVSLFLVVLVYHYVAVNNPKKQE (SEQ ID NO: 636).

FEATURES OF PROTEIN ENCODED BY GENE NO: 113

This gene is expressed primarily in hepatocellular tumor, and to a lesser extent in fetal liver/spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumors, particularly hepatocellular tumors. Similarly, polypeptides and antibodies directed to these

5 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,

10 urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of this clone is useful

15 for diagnosis and treatment of tumors, particularly hepatocellular tumors.

FEATURES OF PROTEIN ENCODED BY GENE NO: 114

The translation product of this gene exhibits a very high degree of sequence identity with the human Pig8 gene which is thought to be important in p53 mediated

20 apoptosis. The sequence of this gene has since been published by Polyak and colleagues (Nature 389, 300-306 (1997)). In addition, the predicted translation product of this contig exhibits very high sequence homology with a murine gene denoted as EI24 which is also thought to be important in p53 mediated apoptosis.

This gene is expressed primarily in infant brain and activated T-cells and to a

25 lesser extent in bone marrow, fetal liver, and prostate.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, and tissue damage by radiation and anti-cancer drugs. Similarly,

30 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the

35 nervous system, blood cells, bone marrow, liver, and prostate, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder,

relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to human Pig8 and murine EI24 genes indicate that polynucleotides and polypeptides corresponding to this gene are useful for preventing apoptosis in patients being treated with anti-oncogenic drugs such as etoposide, hydroperoxycyclophosphamide, and X-irradiation, since this protein product is upregulated in cells undergoing such treatment where p53 was overexpressed. It may also be useful in the treatment of hematopoietic disorders and in boosting numbers of hematopoietic stem cells by interfering with the apoptosis of progenitor cells. The mature polypeptide is predicted to comprise the following amino acid sequence:

EEMADSVKTFQLDLARGIKDSIWGICTISKLDARIQQKREEQRRRRASSVLAQRRRAQSIERKQES
 EPRIVSRIFQCCAWNGGVFWFSLLLFYRVFIPVLQSVTARIIGDPSLHGDVWSWLEFFLTISIFSA
 LWVLPFLVLSKVVNATWFQDIADLAFEVSGRKPHFPFVSVKIADMLFNLLLQALFLIQGMFVSL
 FPIHLVGQLVSLHMSLLYSLYCFEYRWFNKGIEMHQRLSNIERNWPYYFGFGLPLAFLTAMQ
 SSIISGCLFSILFPLFIISANEAKTPGKAYLFQLRLFSLVVFLSNRLFHKTVYQLQSALSSSTSAEK
 FPSPHPSAKLKATAGH (SEQ ID NO: 637). Accordingly, polypeptides comprising the foregoing amino acid sequence are provided as are polynucleotides encoded such polypeptides.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 115

This gene is expressed primarily in stromal cells and to a lesser extent in multiple sclerosis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: affecting the nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., stromal cells and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of multiple sclerosis and other autoimmune diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 116

This gene is expressed primarily in the gall bladder

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions: gall stones or infection
of the digestive system. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential identification
of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
10 particularly of the digestive system or renal system, expression of this gene at
significantly higher or lower levels may be routinely detected in certain tissues and cell
types (e.g., gall bladder and tissue of the digestive system, and cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder, relative to
15 the standard gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for possible prevention of digestive disorders
where there may be a lack of digestive enzymes produced or in the detection and
20 possible prevention of gall stones.

FEATURES OF PROTEIN ENCODED BY GENE NO: 117

The translation product of this gene shares sequence homology with dystrophin
gene which is thought to be important in building and maintenance of muscles.

25 This gene is expressed primarily in placenta and to a lesser extent in fetal brain
and fetal liver, and spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions: muscular dystrophy,
30 Duchenne and Becker's muscular dystrophies. Similarly, polypeptides and antibodies
directed to these polypeptides are useful in providing immunological probes for
differential identification of the tissue(s) or cell type(s). For a number of disorders of
the above tissues or cells, particularly of the skeletal muscle system, expression of this
gene at significantly higher or lower levels may be routinely detected in certain tissues
and cell types (e.g., placenta, brain and other tissue of the nervous system, muscle,
35 liver, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from

an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to the dystrophin gene indicate that
5 polynucleotides and polypeptides corresponding to this gene are useful for diseases related the degenerative myopathies that are characterized by the weakness and atrophy of muscles without neural degradation; such as Duchenne and Becker's muscular dystrophies.

10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 118**

This gene is expressed primarily in olfactory tissue and to a lesser extent in cartilage.

Therefore, polynucleotides and polypeptides of the invention are useful as
15 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: connective tissue diseases; chondrosarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the connective tissue, expression of this gene at significantly higher or
20 lower levels may be routinely detected in certain tissues and cell types (e.g., olfactory tissue and cartilage, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the
25 disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for tumors of connective tissues, osteoarthritis and the treatment and diagnosis of chondrosarcoma.

30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 119**

This gene is expressed primarily in Activated Neutrophils and to a lesser extent in fetal spleen, and CD34 positive cells from cord blood.

Therefore, polynucleotides and polypeptides of the invention are useful as
35 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: allergies, defects in hematopoiesis and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential

identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and hematopoiesis system the, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and spleen, and cancerous and
5 wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
10 corresponding to this gene are useful for reducing the allergic effects felt by allergy suffers by neutralizing the activity of the immune system, especially since neutrophils are abundant in persons suffering from allergies and other inflammatory conditions.

FEATURES OF PROTEIN ENCODED BY GENE NO: 120

15 The translation product of this gene shares sequence homology with poly A binding protein II which is thought to be important in RNA binding for transcription of RNA to DNA

This gene is expressed primarily in colon and to a lesser extent in brain and immune system.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: colon cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a
25 number of disorders of the above tissues or cells, particularly of the immune and digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., colon, tissue and cells of the immune system, and brain or other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal
30 fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to poly A binding protein II indicate that polynucleotides and polypeptides corresponding to this gene are useful for detection
35 and treatment of colon cancer and other disorders of the digestive system..

FEATURES OF PROTEIN ENCODED BY GENE NO: 121

The translation product of this gene shares sequence homology with thymidine diphosphoglucose 4.6 dehydrase which is thought to be important in the metabolism of sugar.

- 5 This gene is expressed primarily in fetal liver and spleen and to a lesser extent in infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: diabetes. Similarly,
10 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, spleen, and brain and other tissue of the
15 nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- 20 The tissue distribution and homology to thymidine diphosphoglucose 4.6 dehydrase indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment of persons with diabetes since it appears that this protein is needed in the metabolism of sugar in to its more basic components.

25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 122**

The translation product of this gene shares sequence homology with ceruloplasmin which is thought to be important in the metabolism and transport of iron and copper. Ceruloplasmin also contains domains with homology to clotting factors V and VIII. Defects in the circulating levels of ceruloplasmin (aceruloplasminemia) have
30 been associated with certain disease conditions such as Wilson disease, and the accompanying hepatolenticular degeneration.

This gene is expressed primarily in brain and retina and to a lesser extent in endothelial cells.

- Therefore, polynucleotides and polypeptides of the invention are useful as
35 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: diseases marked by defects in iron metabolism; aceruloplasminemia not characterized by defects in the

known ceruloplasmin gene locus; nonclassical Wilson disease; movement disorders; and tumors derived from a brain tissue origin. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, retina, and nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, retinal tissue, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to ceruloplasmin indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment of patients with aceruloplasminemia, or other defects in iron and/or copper metabolism. Mutations in this locus could also be diagnostic for patients currently experiencing or predicted to experience aceruloplasminemia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 123

This gene is expressed primarily in brain and B cell lymphoma and to a lesser extent in fetal liver and spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: B cell lymphoma; tumors and diseases of the brain and/or spleen; hematopoietic defects. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, blood cells, liver, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of disorders in neuronal,

hematopoietic, and immune systems. It could potentially be useful for neurodegenerative disorders and neuronal and/or hematopoietic cell survival or proliferation.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 124

This gene is expressed primarily in osteoclastoma, dermatofibrosarcoma, and B cell lymphoma and to a lesser extent in endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer in particular osteoclastoma, dermatofibrosarcoma, and B cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the bone, immune, and circulatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone, epidermis, blood cells, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancers and lymphoma; osteoporosis; and the control of cell proliferation and/or differentiation.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 125

This gene is expressed primarily in immune tissues and hematopoietic cells, particularly in activated T cells and neutrophils, spleen, and fetal liver, and to a lesser extent in infant adrenal gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: defects in T cell activation; hematopoietic disorders; tumors of a hematopoietic and/or adrenal gland origin. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and/or endocrine systems, expression of this gene at significantly higher

or lower levels may be routinely detected in certain tissues and cell types (e.g., cells and tissues of the immune system, hematopoietic cells, blood cells, liver, and adrenal gland, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual
5 having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune and/or hematopoietic disorders;
10 diseases related to proliferation and/or differentiation of hematopoietic cells; defects in T cell and neutrophil activation and responsiveness; and endocrine and/or metabolic disorders, particularly of early childhood.

FEATURES OF PROTEIN ENCODED BY GENE NO: 126

15 This gene is expressed primarily in placenta and endothelial cells and to a lesser extent in melanocytes and embryonic tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumors of an endothelial
20 cell origin; angiogenesis associated with tumor development and metastasis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system and developing embryo, expression of this gene at significantly higher or lower levels
25 may be routinely detected in certain tissues and cell types (e.g., placenta, endothelial cells, melanocytes, and embryonic tissues, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily
30 fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of developmental disorders; inhibition of angiogenesis; and vascular patterning.

35 FEATURES OF PROTEIN ENCODED BY GENE NO: 127

This gene is expressed primarily in endothelial cells and hematopoietic tissues, including spleen, tonsils, leukocytes, and both B- and T-cell lymphomas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumors of an endothelial cell and/or hematopoietic origin; leukemias and lymphomas. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and vascular systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endothelial cells, hematopoietic cells, spleen, tonsils, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the manipulation of angiogenesis; the differentiation and morphogenesis of endothelial cells; the proliferation and/or differentiation of hematopoietic cells; and the commitment of hematopoietic cells to distinct cell lineages.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 128

This gene is expressed primarily in kidney medulla and to a lesser extent in spleen from chronic myelogenous leukemia patients, prostate cancer, and some other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumors of a kidney origin; chronic myelogenous leukemia; prostate cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the kidney and spleen, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., kidney, spleen, and prostate, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of kidney disorders and cancer, particularly chronic myelogenous leukemia and prostate cancer. It may also be useful for the enhancement of kidney tubule regeneration in the treatment of acute renal failure.

FEATURES OF PROTEIN ENCODED BY GENE NO: 129

This gene is expressed primarily in adult and infant brain and to a lesser extent in mesenchymal or fibroblast cells, as well as tissues with a mesenchymal origin.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumors of a brain and/or mesenchymal origin; neurodegenerative disorders; cancer; fibrosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and of mesenchymal cells and tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis of tumors of a brain and/or mesenchymal origin; neurodegenerative disorders; cancer; and fibrosis, based upon the expression of this gene within those tissues. Fibrosis is considered as mesenchymal cells and fibroblasts are the primary cellular targets involved in this pathological condition.

FEATURES OF PROTEIN ENCODED BY GENE NO: 130

This gene is expressed primarily in hepatocellular cancer and to a lesser extent in fetal tissues as well as testes tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: liver cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing

immunol gical probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, fetal tissue, and testes and other

5 reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of liver cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 131

This gene is expressed only in infant early brain.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: development and diseases of the nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification
20 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
25 tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating diseases of the brain in children and in
30 treating nervous system disorders such as Alzheimer's disease, schizophrenia, dementia, depression, etc.

FEATURES OF PROTEIN ENCODED BY GENE NO: 132

This gene is expressed primarily in brain and to a lesser extent in glioblastoma.

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: Alzheimer's disease,

schizophrenia, depression, mania, and dementia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating brain disorders such as Alzheimer's disease, schizophrenia, depression, mania, and dementia.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 133**

The translation product of this gene shares sequence homology with ribitol dehydrogenase of bacteria which is thought to be important in metabolism of sugars.

This gene is expressed primarily in macrophage and to a lesser extent in T-cell lymphoma and lung.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tissue destruction in inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 The tissue distribution and homology to ribitol dehydrogenase indicate that polynucleotides and polypeptides corresponding to this gene are useful for altering macrophage metabolism in diseases such as inflammation where macrophages are causing excess tissue destruction.

FEATURES OF PROTEIN ENCODED BY GENE NO: 134

This gene is expressed primarily in pancreatic tumor and to a lesser extent in synovial sarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to,. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and connective tissue systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., pancreas, and synovial tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating and diagnosing various cancers.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 135

This gene is expressed primarily in T cell lines such as Raji and to a lesser extent in infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: immune system disorders and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating and diagnosing inflammatory diseases

such as rheumatoid arthritis, sepsis, inflammatory bowel disease, and psoriasis, as well as neutropenia.

FEATURES OF PROTEIN ENCODED BY GENE NO: 136

5 The translation product of this gene shares high sequence homology with SAR1 subfamily of GTP-binding proteins which is thought to be important in vesicular transport in mammalian cells.

 This gene is expressed primarily in serum-stimulated smooth muscle cells and to a lesser extent in a T-cell lymphoma.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: diseases affecting vesicular transport. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification
15 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and smooth muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample
20 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

 The tissue distribution and homology to GTP-binding proteins indicate that polynucleotides and polypeptides corresponding to this gene are useful for gene therapy
25 in treating the large number of diseases involved in defective vesicular transport within cells..

FEATURES OF PROTEIN ENCODED BY GENE NO: 137

 The translation product of this gene shares sequence homology with a protein
30 found in *C. elegans* cosmid F25B5.

 This gene is expressed primarily in a fetal tissues and to a lesser extent in melanocytes.

 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
35 biological sample and for diagnosis of diseases and conditions: abnormal fetal development, especially of the pulmonary system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes

for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal pulmonary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., fetal tissue, pulmonary tissue, and melanocytes, and
5 cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
10 corresponding to this gene are useful for treatment and diagnosis of diseases affecting the pulmonary system, such as emphysema.

FEATURES OF PROTEIN ENCODED BY GENE NO: 138

This gene is expressed primarily in gall bladder and to a lesser extent in smooth
15 muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: digestive system disease and gall bladder problems. Similarly, polypeptides and antibodies directed to these
20 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., gall bladder and tissue of the digestive system, and smooth muscle, and cancerous and
25 wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
30 corresponding to this gene are useful for treating diseases of the digestive system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 139

This gene is expressed primarily in placenta and to a lesser extent in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as
35 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: abnormal fetal development. Similarly, polypeptides and antibodies directed to these polypeptides are

useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of developing tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, and brain and other
5 tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating and diagnosing abnormal fetal development.

FEATURES OF PROTEIN ENCODED BY GENE NO: 140

15 This gene is expressed primarily in smooth muscle and to a lesser extent in ovary, prostate cancer, and activated monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: hypertension and
20 atherosclerosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., smooth
25 muscle, ovary and other reproductive tissue, prostate, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating diseases of the circulatory system, such as hypertension, atherosclerosis, etc.

FEATURES OF PROTEIN ENCODED BY GENE NO: 141

35 This gene is expressed primarily in fetal spleen and to a lesser extent in placenta and bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: anemia and other diseases affecting blood cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory and pulmonary systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., spleen, placenta, bone marrow, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the generation of red and white blood cells and for the diagnosis of disease of these cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 142

The predicted translation product of this contig is a human homolog of the murine tetracycline/sugar transporter molecule recently reported by Matsuo and colleagues (Biochem. Biophys. Res. Commun. 238 (1), 126-129 (1997)).

This gene is expressed primarily in synovium and to a lesser extent in endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: rheumatoid arthritis and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and lymphatic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., synovial tissue, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of inflammatory diseases, such as rheumatoid arthritis, leukemia, neutropenia, inflammatory bowel disease, psoriasis, sepsis, and the like.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 143

This gene is expressed primarily in placenta and to a lesser extent in melanocyte, fetal liver and spleen, and bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: abnormal early development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, melanocytes, liver, spleen, and bone marrow, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15
20

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of abnormal early development phenomena and diseases.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 144

This gene is expressed primarily in fetal liver and spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: anemia and neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and blood systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the

30
35

expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful in hematopoiesis and bone marrow regeneration as it is most abundant in fetal tissues responsible for the generation of hematopoietic cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 145

The translation product of this gene shares sequence homology with protein tyrosine phosphatase which is thought to be important in transducing signal to activate cells such as T cell, B cell and other cell types.

This gene is expressed primarily in T cells and tissues in early stages of development and to a lesser extent in cancers.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: immuno-related diseases and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., embryonic and fetal tissue, undifferentiated cells, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to the protein tyrosine phosphatase family indicate that polynucleotides and polypeptides corresponding to this gene are useful for modulating the immune system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 146

This gene is expressed primarily in T cell and to a lesser extent in B cell, macrophages and tumor tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: immuno-disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in

providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for regulating the immune system therefore can be used in treating diseases such as autoimmune diseases and cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 147

This gene is expressed primarily in placenta and to a lesser extent in endothelial cells, testis tumor, ovarian cancer, uterine cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, endothelial cells, testis and ovary and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 148

This sequence has significant homology to mouse torsin A. Recently, another group cloned the human Torsin A gene. (See, Accession No. 2358279; see also Nature Genet. 17, 40-48 (1997).)

This gene is expressed primarily in osteoclastoma, T-cell, and placenta and to a lesser extent in fetal lung, fetal liver, fetal brain, adult brain and tumor tissues

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: disease conditions in hematopoiesis and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoiesis system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, bone, placenta, lung, liver, and brain and other tissues of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating blood related diseases such as deficiencies in red blood cell, white blood cell, platelet and other hematopoiesis cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 149

This gene is expressed primarily in T cell, prostate and prostate cancer, endothelial cells and to a lesser extent in monocyte, dendritic cell, bone marrow, salivary gland, colon cancer, stomach cancer, pancreatic tumor, uterine cancer, fetal spleen and osteoclastoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: immuno-related diseases and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, prostate, endothelial cells, dendritic cells, bone marrow, salivary gland, colon, stomach, pancreas, uterus, spleen and bone, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 150

5 This gene was recently cloned by another group, calling it eIF3-p66. (See
Accession No. 2351378.) This gene plays a role in RNA binding and macromolecular
assembly, and therefore, any mutations in this gene would likely result in a diseased
phenotype. Preferred polypeptide fragments comprise the amino acid sequence:
MAKFMTPIQDNPSGWGPCAVPEQFRDMPYQPFSGDRLGKVADWTGATYQDKRYTNKYSS
10 QFGGGSQYAYFHEEDESFLVDTARTQKTAYQRNRMFAQRNLRRDKDRRNLQFNLQILP
KSAKQKERERIRLQKKFQKQFVVRQKWDQKSQKPRDSSVEVRSDWEVKEEMDFPQLMKMRY
LEVSEPQDIECCGALEYDYKAFDRITRSEKPLRXXKRIFHTVTTTDDPVIRKLAKTQGNVFATD
AILATLMSCTRSVYSWDIVVQVRVGSKLFFDKRDNSDFLLTVSETANEPQDEGNSFNSPRNL
AMEATYINHNFSQQCLRMGKERYNFPNPNPFVEDDMDKNEIASVAYRYRSGKLGDDIDLIVRC
15 EHDGVMTGANGEVSFINIKTLNEWDSRHCNGVDWRQKLD SQRGAVIATELKNNSYKLARWTC
CALLAGSEYLKLGYSRYHVKDSSRHVILGTQQFKPNEFASQINLSVENAWGILRCVIDICMKL
EEGKYLILKDPNKQVIRVYSLPDGTFSS (SEQ ID NO: 638), as well as N-terminal and C-
terminal deletions of this polypeptide fragment.

20 This gene is expressed primarily in T cell, bone marrow, embryo and
endothelial cells and to a lesser extent in testis tumor and endometrial tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions: immune diseases and
tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful
25 in providing immunological probes for differential identification of the tissue(s) or cell
type(s). For a number of disorders of the above tissues or cells, particularly of the
immune system and reproductive system, expression of this gene at significantly higher
or lower levels may be routinely detected in certain tissues and cell types (e.g.,
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
30 fluid or spinal fluid) or another tissue or cell sample taken from an individual having
such a disorder, relative to the standard gene expression level, i.e., the expression level
in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for immune disorders and cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 151

This gene is expressed primarily in testis and to a lesser extent in T cell, spinal cord, placenta, neutrophil and monocyte.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: male reproductive and endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive, immune and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., testis and other reproductive tissue, blood cells, tissue of the nervous system, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for regulating immune and reproductive functions.

FEATURES OF PROTEIN ENCODED BY GENE NO: 152

The translation product of this gene shares sequence homology with tyrosyl-tRNA synthetase which is thought to be important in cell growth.

This gene is expressed primarily in brain, liver, keratinocytes, tonsils, and heart.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer autoimmune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, liver, keratinocytes, tonsils, heart expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissues of the nervous system, liver, keratinocytes, tonsils and heart, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard

gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to tyrosyl-tRNA synthetase indicate that polynucleotides and polypeptides corresponding to this gene are useful for modulating cell growth.

FEATURES OF PROTEIN ENCODED BY GENE NO: 153

This gene is homologous to the *Drosophila* transcriptional regulator dre4. (See Accession No. 2511745.) Dre4 is a gene required for steroidogenesis in *Drosophila melanogaster* and encodes a developmentally expressed homologue of the yeast transcriptional regulator CDC68. Preferred polypeptide fragments comprise the amino acid sequence: KKRHTDVQFYTEVGEITTDLGKHQHMHDRDDLYAEQMEREMRHKLKTAFKN FIEKVEALTKEELEFEVPPFRDLGFNGAPYRSTCLLQPTSSALVNATEWPPFVVTLDEVELIHFXR VQFHLKNFDMVIVYKDYSSKVTMNAIPVASLDPIKEWLNCDLKYTEGVQSLNWTIMKTITVD DPEGFFEQGGWSFL (SEQ ID NO: 639), as well as N-terminal and C-terminal deletions of this fragments. Also preferred are polynucleotide fragments encoding this polypeptide fragment.

This gene is expressed primarily in fetal liver, spleen, placenta, lung, T cell, thyroid, testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: brain tumor, heart and liver diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal liver, spleen, placenta, lung, T cell, thyroid, testes expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, spleen, placenta, lung, blood cells, thyroid, and testes and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 FEATURES OF PROTEIN ENCODED BY GENE NO: 154

This gene is expressed primarily in brain and to a lesser extent in fetal heart, testis, spleen, lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: heart, liver and spleen diseases, immunological diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, fetal heart, testis, spleen, lung expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, heart, testes and other reproductive tissue, spleen, and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 155

Activation of T cells through the T cell antigen receptor (TCR) results in the rapid tyrosine phosphorylation of a number of cellular proteins, one of the earliest being a 100 kDa protein. This gene is the human equivalent of murine valosin containing protein (VCP). VCP is a member of a family of ATP binding, homo-oligomeric proteins, and the mammalian homolog of *Saccharomyces cerevisiae* cdc48p, a protein essential to the completion of mitosis in yeast. Both endogenous and expressed murine VCP are tyrosine phosphorylated in response to T cell activation. Thus we have identified a novel component of the TCR mediated tyrosine kinase activation pathway that may provide a link between TCR activation and cell cycle control.

This gene is expressed primarily in brain, liver, spleen, placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, liver, spleen, placenta expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, liver, spleen, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from

an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution and homology to VCR indicate that polynucleotides and polypeptides corresponding to this gene are useful for treating cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 156

10 The translation product of this gene shares sequence homology with rat growth response protein which is thought to be important in cell growth. A group recently cloned the human homolog of this gene, calling it insulin induced protein 1. (See Accession No. 2358269, see also, Genomics 43 (3), 278-284 (1997).) Preferred polypeptide fragments comprise the amino acid sequence: RSGLGLGITIAFLATLITQF LVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMGVPEKPHSD (SEQ ID NO: 640), as well as N-terminal and C-terminal deletions of this polypeptide fragment. Also
15 preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in brain, liver, placenta, heart, spleen, lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, liver, placenta, heart, spleen.
25 expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, liver, placenta, heart, spleen, and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the
30 standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to growth-response protein indicate that polynucleotides and polypeptides corresponding to this gene are useful for modulating cell growth.

FEATURES OF PROTEIN ENCODED BY GENE NO: 157

This gene is expressed primarily in Glioblastoma, endometrial tumor, lymphoma and pancreas tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: Glioblastoma, Endometrial tumor, lymphoma and pancreas tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endometrium, lymphoid tissue, pancreas, and tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 158

The translation product of this gene shares sequence homology with IGE receptor which is thought to be important in allergy and asthma.

This gene is expressed primarily in T cell, and fetal liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: allergy and asthma and other immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to IgE receptor indicate that polynucleotides and polypeptides corresponding to this gene are useful for allergy and asthma.

5 **FEATURES OF PROTEIN ENCODED BY GENE NO: 159**

The translation product of this gene shares sequence homology with immunoglobulin heavy chain which is thought to be important in immune response to the antigen.

10 This gene is expressed primarily in activated neutrophil and to a lesser extent in activated T cell, monocyte and heart.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: infection, inflammation and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are
15 useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and heart, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
20 fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to immunoglobulin heavy chain variable region indicate that polynucleotides and polypeptides corresponding to this gene are
25 useful for making the ligand to block specific antigen which cause certain disease.

FEATURES OF PROTEIN ENCODED BY GENE NO: 160

The translation product of this gene shares sequence homology with mouse X inactive specific transcript protein which is thought to be important in X chromosome
30 inactivation.

This gene is expressed primarily in HSA172 cell and to a lesser extent in normal ovary tissue, ovarian cancer, frontal cortex and brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
35 biological sample and for diagnosis of diseases and conditions: ovarian tumor, schizophrenia and other neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for

differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., ovary and other reproductive tissue, and brain and other
5 tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution and homology to X inactive specific transcript protein indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of reproductive system tumors and CNS tumors.

FEATURES OF PROTEIN ENCODED BY GENE NO: 161

15 This gene is expressed primarily in adipose cell and to a lesser extent in liver and prostate.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: obesity and liver
20 disorder. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the adipose cell, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adipose cells, liver, and
25 prostate, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of obesity and liver disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 162

35 The translation product of this gene shares sequence homology with yeast ubiquitin activating enzyme homolog which is thought to be important in protein posttraslation processing.

This gene is expressed primarily in stromal cell and to a lesser extent in retina, H. Atrophic Endometrium, colon carcinoma and myeloid progenitor cell.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: defects of stromal cell development, neuronal growth disorders and tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., retinal cells, endometrium, colon, and bone marrow, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to ubiquitin-activating enzyme homolog indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of some type of tumors, fucosidosis and neuronal growth disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 163

This gene is expressed primarily in primary breast cancer and hemangiopericytoma and to a lesser extent in adult brain and cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: breast cancer, leukemia and cerebellum disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., mammary tissue, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of various tumors and disease involved in neural system.

5 **FEATURES OF PROTEIN ENCODED BY GENE NO: 164**

The translation product of this gene shares sequence homology with proline rich proteins. Recently, another group has also cloned this gene, calling it CD84 leukocyte antigen, a new member of the Ig superfamily. (See Accession No. U82988, see also, Blood 90 (6), 2398-2405 (1997).)

10 This gene is expressed primarily in Weizmann olfactory tissue and osteoclastoma and to a lesser extent in anergic T-cell.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: osteoporosis and immune disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., olfactory tissue, bone, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution and homology to the Ig superfamily indicate that the protein product of this clone is useful for treatment of osteoporosis, autoimmune disease, and other immune disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 165

30 This gene is expressed primarily in atrophic endometrium and colon cancer and to a lesser extent in some fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system,

expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endometrium, colon, and fetal tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having
5 such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of tumors, specifically endometrium and colon tumors.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 166

This gene is expressed primarily in human primary breast cancer and to a lesser extent in activated monocyte. Although the predicted signal sequence is identified in Table 1, other upstream sequences are also relevant. Preferred polypeptide fragments comprise
15 the amino acid sequence: VTQPKHLSASMGGSV EIPFSFYYPWELAXXPXVRISWRRGHFHGQSFYSTRPPSIHKDYVNRLFLNWTEGQESGFLRISNLRKEDQSVYFCRVELDTRRSG (SEQ ID NO: 641), as well as N-terminal and C-terminal deletions. Also preferred are polynucleotide fragments encoding these polypeptide fragments.

Therefore, polynucleotides and polypeptides of the invention are useful as
20 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system,
25 expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., mammary tissue, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in
30 healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of breast cancer.

FEATURES OF PROTEIN ENCODED BY GENE NO: 167

35 This gene is expressed primarily in fetal tissues and to a lesser extent in adult lung. This gene has also been mapped to chromosomal location 9q34, and thus, can be used as a marker for linkage analysis for chromosome 9.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the embryo tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., fetal tissues, and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 168

The translation product of this gene shares sequence homology with Ig Heavy Chain which is thought to be important in immune response.

This gene is expressed primarily in prostate cancer tissue specifically

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: prostate cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., prostate, tissue and cells of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 169

The translation product of this gene shares sequence homology with cytosolic acyl coenzyme-A hydrolase, which is thought to be important in neuron-specific fatty acid metabolism. The gene represented by this contig has since been published by Hajra and colleagues (GenBank Accession No. U91316).

This gene is expressed primarily in human pituitary gland and to a lesser extent in colorectal cancer tissue. This gene has also been observed in the LNCAP cell line.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: hyperlipidemias of familial and/or idiopathic origins. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly blood, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., pituitary and colon, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to rat cytosolic acyl coenzyme-A hydrolase indicate that polynucleotides and polypeptides corresponding to this gene are useful for the detection or treatment of hyperlipidemia disease states by virtue of the ability of specific drugs to activate the enzyme.

FEATURES OF PROTEIN ENCODED BY GENE NO: 170

The translation product of this gene shares sequence homology with a *Caenorhabditis elegans* gene which is thought to be important in organism development.

This gene is expressed primarily in human synovial sarcoma tissue, bone marrow, and to a lesser extent in human brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, of bone, specifically synovial sarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the bone, connective tissues and possibly immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., synovial tissue, bone marrow, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another

tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution and homology to *Caenorhabditis elegans* indicate that polynucleotides and polypeptides corresponding to this gene are useful as a diagnostic and/or therapeutic modality directed at the detection and/or treatment of connective tissue sarcomas or other related bone diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 171

10 The translation product of this gene shares sequence homology with beta1-6GlcNAc transferase which is thought to be important in the transfer and metabolism of beta1-6, N-acetylglucosamine. This gene product has previously been shown to suppress melanoma lung metastasis in both syngeneic and nude mice, decreased invasiveness into the matrigel, and inhibition of cell attachment to collagen and laminin
15 without affecting cell growth.

This gene is expressed primarily in human testes and prostate tissues, and to a lesser extent in kidney, medulla, and pancreas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer particularly melanoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at
25 significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., testes and other reproductive tissue, prostate, kidney, pancreas, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard
30 gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to beta1-6GlcNAc transferase indicate that the protein product of this clone is useful for the development of diagnostic and/or therapeutic modalities directed at the detection and/or treatment of cancer, the metastasis
35 of malignant tissue or cells. Defects in this potentially secreted enzyme may play a role in metastasis.

FEATURES OF PROTEIN ENCODED BY GENE NO: 172

This gene is expressed primarily in fetal spleen and liver.

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions: immune disorders,
Wilm's tumor disease, hepatic disorders, and hematopoietic disorders. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in providing
immunological probes for differential identification of the tissue(s) or cell type(s). For a
10 number of disorders of the above tissues or cells, particularly of the hematopoiesis and
immune systems, expression of this gene at significantly higher or lower levels may be
routinely detected in certain tissues and cell types (e.g., spleen and liver, and cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or another tissue or cell sample taken from an individual having such a
15 disorder, relative to the standard gene expression level, i.e., the expression level in
healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the treatment and identification of fetal defects
along with correcting diseases that affect hematopoiesis and the immune system.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 173

The translation product of this gene shares sequence homology with ret II
oncogene which is thought to be important in Hirschsprung disease and many types of
cancers.

25 This gene is expressed in multiple tissues including the lymphatic system, brain,
and thyroid.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for identification of the tissue(s) or cell type(s) present in a biological sample
and for diagnosis of diseases and conditions: Hirschsprung disease and multiple
30 cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful
in providing immunological probes for identification of the tissue(s) or cell type(s). For
a number of disorders of the above tissues or cells, particularly of the immune and
central nervous system, expression of this gene at significantly higher or lower levels
may be routinely detected in certain tissues and cell types (e.g., lymphoid tissue,
35 thyroid, and brain and other tissue of the nervous system, and cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder, relative to

the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to ret II oncogene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of various cancers. It would also be useful for the diagnosis and treatment of Hirschsprung disease. Preferred polypeptides of the invention comprise the amino acid sequence: MEAQQVNEAESAREQLQXLHDQIAGQKASKQELETelerLKQEFHYIEDLY RTKNTLQSRIDRDEEIQKLRNQLTNKTLNSSQSELENRLHQLTETLIQKQTMLESLSSTEKNSL VFQLERLEQQMNSASGSSSNGSSINMSGIDNGEGTRLRNVPVLFNDTETNLAGMYGKVRKAAS
 10 SIDQFSIRLGIFLRRYPRIARVFVIYMALLHLWVMIVLLTYTPM HHDQPYGK (SEQ ID NO: 642).

FEATURES OF PROTEIN ENCODED BY GENE NO: 174

The translation product of this gene shares sequence homology with testis enhanced gene transcript which is thought to be important in regulation of human development.

This gene is expressed primarily in infant brain and to a lesser extent in a variety of other tissues and cell types, including the prostate, testes, monocytes, macrophages, dendritic cells, keratinocytes, and adipocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: neurological, developmental, immune and inflammation disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, prostate, testes and other reproductive tissue, blood cells, keratinocytes, and adipocytes, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to testis enhanced gene transcript indicate that the protein product of this clone is useful for diagnosis and treatment of disorders involving the developing brain and the immune system.

FEATURES OF PROTEIN ENCODED BY GENE NO: 175

This gene is expressed primarily in prostate and to a lesser extent in various other tissues, including placenta.

- 5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers, especially of the prostate. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for
- 10 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., prostate and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
- 15 sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of prostate disorders and cancer. It may also be useful for
- 20 the diagnosis and treatment of endocrine disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 176

- The translation product of this gene shares sequence homology with *Sacchomyces cerevisiae* YNT20 gene which is thought to be important in
- 25 mitochondrial function.

This gene is expressed at a particularly high level in muscle tissue.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases related to such tissues and cell types
- 30 including: muscle wasting diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neuromuscular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell
- 35 types (e.g., muscle and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to the YNT20 gene indicate that this protein is useful for treatment and detection of neuromuscular diseases caused by loss
5 of mitochondrial function. For example this gene or its protein product could be used in replacement therapy for such diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 177

This gene is expressed primarily in the brain and to a lesser extent in kidney,
10 placenta, smooth muscle, heart and lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: neuromuscular diseases, degenerative diseases of the central nervous system, and heart disease.
15 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neuromuscular system, central nervous system, and heart, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell
20 types (e.g., brain and other tissue of the nervous system, kidney, placenta, muscle, heart and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the
25 disorder.

This gene or its protein product could also be used for replacement therapy for the above mentioned diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 178

The translation product of this gene shares sequence homology with caldesmon
30 which is thought to be important in the cellular response to changes in glucose levels.

This gene is expressed primarily in multiple tissues including brain and retina.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for identification of the tissue(s) or cell type(s) present in a biological sample
35 and for diagnosis of diseases and conditions: central nervous system disorders and retinopathy. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly of the CNS disorders and retinopathy, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and retinal tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to caldesmon indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment of retinopathies.

FEATURES OF PROTEIN ENCODED BY GENE NO: 179

The translation product of this gene shares sequence homology with mouse fibrosin protein which is thought to be important in regulation of fibrinogenesis in certain chronic inflammatory diseases.

This gene is expressed primarily in amniotic cells and breast tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of breast cancer and abnormal embryo development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., amniotic cells, and mammary tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to fibrosin indicate that the protein product of this clone is useful for treatment of breast cancer. This gene or its protein product could be used in replacement therapy for breast cancer. In addition the protein product of this gene is useful in the treatment of chronic inflammatory diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 180

This gene is expressed several infant tissues including brain and liver and various adult tissues including brain, lung, liver, testes, and prostate.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, brain cancer, lung cancer, liver cancer and cancers of the reproductive system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, hepatic system, and reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, lung, liver, testes and other reproductive tissue, and prostate, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene product indicates that the protein product of this clone is involved in growth regulation and could be used as a growth factor or growth blocker in a variety of settings including treatment of cancers.

20 **FEATURES OF PROTEIN ENCODED BY GENE NO: 181**

This gene is expressed primarily in activated monocytes and to a lesser extent in melanocytes and dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of immune system diseases and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, melanocytes, and dendritic cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein product of this clone could be involved in growth regulation and could be used as a growth factor or growth blocker in a variety of settings including treatment of cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 182

This gene is expressed primarily in placenta and several tumors of various tissue origin and to a lesser extent in normal tissues including liver, lung, brain, and skin,

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of cancers of all kinds. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders
10 of the above tissues or cells, particularly of the central nervous system, respiratory system and skin, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, lung, brain and other tissues of the nervous system, and skin, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
15 cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The high expression of this gene in multiple tumors indicates that the protein product of the clone may be involved in cell growth control and therefore would be
20 useful for treatment of certain cancers. Likewise molecules developed to block the activity of the protein product of this clone could be used to block its potential role in tumor growth promotion.

FEATURES OF PROTEIN ENCODED BY GENE NO: 183

25 The translation product of this gene shares sequence homology with the mouse Ndr1 gene which is thought to be important in cancer progression.

This gene is expressed multiple cell types and tissues including brain, lung, kidney, bone marrow, liver, and spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as
30 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of all types of cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous, immune, and endocrine
35 systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, lung, kidney, bone marrow, liver and spleen, and cancerous and wounded

tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- 5 The tissue distribution and homology to Ndr1 gene, which is thought to be involved in cancer progression, indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment of certain cancers. Likewise molecules developed to block the activity of the protein product of this clone could be used to block its potential role in tumor growth promotion.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 184

This gene is expressed primarily in early stage human brain and liver and to a lesser extent in several other fetal tissues.

- 15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: brain and liver cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the
20 central nervous system and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, liver, and fetal tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder,
25 relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The expression of this gene in embryonic tissues indicates that the protein could be involved in growth regulation and could be used as a growth factor or growth blocker in a variety of settings including treatment of cancers.

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 185

This gene is expressed primarily in infant and embryonic brain.

- 35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of degenerative nervous system disorders and brain cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., embryonic tissue, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The expression of this gene in embryonic tissues indicates that the protein could be involved in growth regulation and could be used as a growth factor or growth blocker in a variety of settings including treatment of cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 186

This gene is expressed primarily in multiple tissues including placenta, fetal lung, fetal liver, and brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of all types of cancers including liver, brain and lung. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, pulmonary system, and hepatic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, lung, liver, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The expression of this gene in embryonic tissues indicates that the protein could be involved in growth regulation and could be used as a growth factor or growth blocker in a variety of settings including treatment of cancers.

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
1	HTTEZ21	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	11	582	1	582	177	313	1	18	19	22
1	HTTEZ21	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	197	1020	296	830	442	499	1	18	19	22
2	HGBBW52	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	12	465	1	465	81	314	1	30	31	128
2	HGBBW52	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	198	524	229	343	196	500	1	20	21	33
3	HCUFM41	97897 02/26/97 209043 05/15/97	ZAP Express	13	474	1	474	1	315	1	24	25	28
3	HCUFM41	97897 02/26/97 209043 05/15/97	ZAP Express	199	332	1	319	35	501	1	24	25	28

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
4	HCUFQ22	97897 02/26/97 209043 05/15/97	ZAP Express	14	314	1	298	122	122	316	1	34	35	64
5	HCUFV01	97897 02/26/97 209043 05/15/97	ZAP Express	15	613	1	613	30	30	317	1	18	19	21
6	HCUGA50	97897 02/26/97 209043 05/15/97	ZAP Express	16	356	1	356	239	239	318	1	22	23	39
7	HCUIM14	97897 02/26/97 209043 05/15/97	ZAP Express	17	414	183	414	278	278	319	1	26	27	33
8	HLDOU93	97897 02/26/97 209043 05/15/97	pCMVSPORT 3.0	18	469	1	469	77	77	320	1	44	45	88
9	HEIAX07	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	19	550	1	550	129	129	321	1	21	22	23

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
9	HEIAX07	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	200	376	9	376		1	502	1	8	9	15
10	HSAXR76	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	20	741	55	741	190	190	322	1			27
11	HNGJJ68	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	21	991	1	991	62	62	323	1	30	31	64
11	HNGJJ68	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	201	1192	253	1137		409	503	1			19
12	HCFAW04	97897 02/26/97 209043 05/15/97	pSport1	22	653	1	653	64	64	324	1	30	31	196
12	HCFAW04	97897 02/26/97 209043 05/15/97	pSport1	202	589	1	513	109	109	504	1			29

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
13	HLMV65	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	23	1486	596	1418	102	102	325	1	54	55	252
13	HLMV65	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	203	847	1	839	87	87	505	1	30	31	75
13	HLMV65	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	204	852	75	850		690	506	1			10
13	HTXEF04	209235 09/04/97	Uni-ZAP XR	205	1354	54	1354	100	100	507	1	33	34	207
14	HPMFD84	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	24	2323	1017	2059	1242	1242	326	1	21	22	68
14	HPMFD84	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	206	1378	113	1226	303	303	508	1	25	26	36
15	HE6DB26	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	25	683	1	683	304	304	327	1	30	31	84

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
15	HE6DB26	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	207	1166	281	884	567	567	509	1	18	19	19
16	HHFFL33	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	26	2036	14	1959	214	214	328	1	20	21	36
17	HODBD33	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	27	717	1	717	70	70	329	1	30	31	63
17	HODBD33	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	208	697	2	697	33	33	510	1	31	32	32
18	HMDAE90	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	28	495	1	495	39	39	330	1	24	25	35
19	HOUAW01	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	29	556	1	556	116	116	331	1	19	20	23

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
20	HBJAE44	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	30	434	1	434	78	78	332	1	35	36	40
21	HCFME41	97897 02/26/97 209043 05/15/97	pSport1	31	715	1	715	87	87	333	1	30	31	111
21	HCFME41	97897 02/26/97 209043 05/15/97	pSport1	209	932	274	932	387	387	511	1	27	28	28
22	HOGCO71	97897 02/26/97 209043 05/15/97	pCMVSPORT 2.0	32	486	1	486	137	137	334	1	21	22	106
23	HOSEX08	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	33	725	1	725	436	436	335	1	30	31	50
23	HOSEX08	97897 02/26/97 209043 05/15/97	Uni-ZAP XR	210	661	1	647	81	81	512	1	25	26	26

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
24	HSKNJ72	97897 02/26/97 209043 05/15/97	pBluescript	34	437	1	437	85	336	1	30	31	48
25	HEBEB69	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	35	943	1	943	196	337	1	30	31	41
25	HEBEB69	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	211	592	1	534	72	513	1	24	25	33
26	HE6EH18	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	36	604	1	604	375	338	1	20	21	76
26	HE6EH18	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	212	938	1	509	17	514	1	30	31	47
27	HSAUZ47	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	37	349	1	349	201	339	1	20	21	31

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
28	HSSDM73	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	38	672	1	672	22	340	1	38	39	42
29	HBMVK68	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	39	1908	135	1908	309	341	1	20	21	26
30	HMKDC66	97898 02/26/97 209044 05/15/97	pSport1	40	458	93	458	147	342	1	24	25	26
31	HMKCU94	97898 02/26/97 209044 05/15/97	pSport1	41	1153	500	1153	427	343	1	30	31	157
31	HMKCU94	97898 02/26/97 209044 05/15/97	pSport1	213	1079	502	896	739	515	1	23	24	43
32	HRDEW41	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	42	1983	1092	1983	27	344	1	11	12	520

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
32	HRDEW41	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	214	3791	2757	3357		2030	516	1			3
33	HTOJN06	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	43	1406	1	695		19	345	1	19	20	39
34	HBGDA21	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	44	1391	851	1153	74	74	346	1	30	31	234
34	HBGDA21	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	215	1334	822	1036		638	517	1	18	19	174
35	HFGAK75	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	45	1569	768	1569	14	14	347	1	19	20	169
35	HFGAK75	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	216	1511	770	1404	844	844	518	1	32	33	43

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
36	HHPBD40	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	46	1924	1	1681	62	62	348	1	19	20	43
37	HOVCL83	97898 02/26/97 209044 05/15/97	pSport1	47	475	252	396	141	141	349	1	37	38	78
38	HBCAY62	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	48	346	1	346	61	61	350	1	19	20	24
39	HBICM48	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	49	1366	882	1300	177	177	351	1	30	31	274
39	HBICM48	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	217	642	192	581		448	519	1			13
40	HLTCL35	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	50	1405	110	1404	61	61	352	1	30	31	47

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
40	HLTCL35	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	218	1241	1	1241	172	520	1	21	22	30
41	HLHCK50	97898 02/26/97 209044 05/15/97	Uni-ZAP XR	51	504	207	485	222	353	1			3
42	HRSAN45	97899 02/26/97 209045 05/15/97	ZAP Express	52	777	1	214	113	354	1	24	25	52
43	HSNBB14	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	53	602	1	419	41	355	1	59	60	132
43	HSNBB14	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	219	1080	186	686	399	521	1	26	27	47
44	HMABL38	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	54	1749	222	1749	166	356	1	30	31	204

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT ³ of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
44	HMABL38	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	220	1258	149	1190	254	522	1	18	19	26
45	HSKDK47	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	55	1896	596	1614	650	357	1	33	34	47
46	HOSFH03	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	56	1753	555	1753	414	358	1	18	19	73
46	HOSFH03	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	221	1693	554	1693	526	523	1	25	26	58
47	HOGAV75	97899 02/26/97 209045 05/15/97	pCMVSPORT 2.0	57	1220	690	1024	128	359	1	30	31	102
47	HOGAV75	97899 02/26/97 209045 05/15/97	pCMVSPORT 2.0	222	1196	712	1163	1097	524	1			19

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
48	HFCAI74	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	58	1049	362	1049	335	360	1	33	34	48
49	HAGBI17	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	59	1776	854	1737	189	361	1	30	31	179
49	HAGBI17	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	223	1791	979	1791	1164	525	1	18	19	40
50	HLFBC91	97899 02/26/97 209045 05/15/97	pBluescript SK-	60	443	1	443	164	362	1	21	22	25
51	HPRCA31	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	61	2888	1909	2888	90	363	1	30	31	224
51	HPRCA31	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	224	2517	1597	2517	1953	526	1	18	19	57

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
52	HPRCE95	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	62	1851	1568	1736	139	139	364	1	30	31	349
52	HPRCE95	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	225	2424	299	2309		530	527	1	17	18	21
53	HHTLC66	97899 02/26/97 209045 05/15/97	ZAP Express	63	3542	883	3492	964	964	365	1	25	26	467
54	HMADJ02	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	64	883	237	883	229	229	366	1	30	31	152
54	HMADJ02	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	226	1080	242	1033	436	436	528	1	24	25	39
55	HPRCU93	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	65	1541	1	1541	236	236	367	1	30	31	373

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
55	HPRCU93	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	227	1336	4	1336	946	946	529	1	25	26	128
56	HSAXS65	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	66	732	41	698	163	163	368	1	18	19	83
56	HSAXS65	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	228	2043	1133	1756	1262	1262	530	1	20	21	82
57	HKTAG35	209011 04/28/97	Uni-ZAP XR	67	629	1	629	264	264	369	1			21
57	HMEFX42	97899 02/26/97 209045 05/15/97	Lambda ZAP II	229	540	25	536	227	227	531	1			20
58	HHFHN61	97899 02/26/97 209045 05/15/97	Uni-ZAP XR	68	1751	375	1751	95	95	370	1	19	20	227
59	HCWEF90	97899 02/26/97 209045 05/15/97	ZAP Express	69	508	1	508	22	22	371	1	30	31	79

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
59	HCWFEF90	97899 02/26/97 209045 05/15/97	ZAP Express	230	448	9	448		1	532	1	22	23	75
60	HHGCM20	97899 02/26/97 209045 05/15/97	Lambda ZAP II	70	245	1	245	93	93	372	1	1	2	51
61	HFRAU10	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	71	361	1	361	1	1	373	1	30	31	61
61	HFRAU10	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	231	407	1	407	210	210	533	1	17	18	60
62	HATDT67	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	72	713	8	713	169	169	374	1	30	31	40
62	HATDT67	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	232	830	190	580	329	329	534	1	28	29	39

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
63	HOUBG93	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	73	862	1	862	67	67	375	1	30	31	44
63	HOUBG93	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	233	932	138	905	287	287	535	1			2
64	HMWEX24	97900 02/26/97 209046 05/15/97	Uni-Zap XR	74	4602	4162	4525	730	730	376	1	30	31	203
64	HMWEX24	97900 02/26/97 209046 05/15/97	Uni-Zap XR	234	2786	2406	2739	2577	2577	536	1	22	23	36
65	HSGBA84	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	75	1255	1	1195	112	112	377	1	28	29	29
66	HTOCD52	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	76	475	1	475	13	13	378	1	30	31	136

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
66	HTOCD52	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	235	458	1	458	26	26	537	1			14
67	HTGCP16	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	77	465	25	299	74	74	379	1	33	34	41
68	HKIXR69	97900 02/26/97 209046 05/15/97	pBluescript	78	1907	1627	1730	26	26	380	1	30	31	468
68	HKIXR69	97900 02/26/97 209046 05/15/97	pBluescript	236	591	1	444	251	251	538	1			18
69	HETGJ09	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	79	1168	136	1168	267	267	381	1	20	21	29
70	HOBNC61	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	80	1285	132	1285	292	292	382	1	27	28	29

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
71	HFFAH94	97900 02/26/97 209046 05/15/97	Lambda ZAP II	81	1290	768	1054	701	383	1	21	22	138
72	HBIAY5	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	82	684	1	684	119	384	1	30	31	74
73	HSQEL25	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	83	2024	1609	1953	200	385	1	30	31	521
73	HSQEL25	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	237	1286	391	959	1204	539	1	9	10	11
74	HEBEG68	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	84	931	14	537	85	386	1	25	26	137
75	HBIAB39	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	85	825	59	802	66	387	1	30	31	186

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
75	HBIAB39	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	238	734	1	734	1	540	1	37	38	108
75	HBIAB39	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	239	809	80	794	294	541	1	15	16	106
76	HTXDU73	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	86	1238	36	918	17	388	1			1
77	HOEAS24	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	87	1460	9	1458	166	389	1	53	54	299
77	HOEAS24	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	240	2201	841	2080	507	542	1	43	44	136
77	HOEAS24	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	241	1661	311	1520	390	543	1	35	36	424

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
78	HTEIY30	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	88	1395	567	1395	639	639	390	1	36	37	49
79	HSKNE46	97900 02/26/97 209046 05/15/97	pBluescript	89	1186	352	1186	540	540	391	1	49	50	61
79	HSKNE46	97900 02/26/97 209046 05/15/97	pBluescript	242	1146	329	1146	564	564	544	1	21	22	39
80	HPMFL27	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	90	1821	1203	1614	1503	1503	392	1	30	31	79
81	HMWDN32	97900 02/26/97 209046 05/15/97	Uni-Zap XR	91	862	253	862	359	359	393	1	32	33	36
82	HPRAX55	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	92	696	349	696	98	98	394	1	30	31	180

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
82	HPRAX55	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	243	1350	265	1230	348	348	545	1	32	33	58
83	HHFFW36	97900 02/26/97 209046 05/15/97	Uni-ZAP XR	93	1886	1	1759	197	197	395	1			21
84	HE2PL77	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	94	1774	742	1772	785	785	396	1	21	22	60
85	HSDFV29	209076 05/22/97	Uni-ZAP XR	95	2503	1	1648	206	206	397	1	32	33	152
85	HCQAV53	97901 02/26/97 209047 05/15/97	Lambda ZAP II	244	1529	72	911	191	191	546	1	20	21	33
86	HTPEG42	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	96	2801	418	2801	234	234	398	1	30	31	480
86	HTPEG42	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	245	1537	1	1537	125	125	547	1	21	22	367

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
87	HLHDR57	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	97	1631	916	1	1	399	1	1	2	423
88	HAUAV32	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	98	504	26	197	197	400	1	23	24	78
88	HAUAV32	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	246	506	1	499	183	548	1	32	33	77
89	HNEBI60	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	99	1416	145	456	456	401	1	18	19	74
89	HNEBI60	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	247	1348	84	1348	363	549	1	21	22	47
90	HSHCJ16	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	100	2847	1	2847	2	402	1			20

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
91	HTSEL31	97901 02/26/97 209047 05/15/97	pBluescript	101	1394	608	1346	602	602	403	1	23	24	87
92	HAUBL57	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	102	794	1	794	518	518	404	1	30	31	92
92	HAUBL57	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	248	1766	42	1766	356	356	550	1	30	31	168
92	HAUBL57	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	249	2664	47	1708		147	551	1	18	19	124
93	HODAS59	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	103	1544	898	1531	975	975	405	1			21
94	HE6CT48	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	104	871	106	871	248	248	406	1	34	35	174

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT3' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
94	HE6CT48	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	250	865	97	865	258	552	1	19	20	177
95	HMDAA61	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	105	404	1	404	16	407	1	21	22	64
95	HMDAA61	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	251	2082	852	2074	829	553	1	22	23	72
96	HAQBK61	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	106	1542	506	1542	122	408	1	51	52	280
96	HAQBK61	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	252	1482	508	1482	633	554	1	15	16	45
96	HCUHB01	209215 08/21/97	ZAP Express	253	834	1	834	82	555	1	40	41	251
97	HAQBF73	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	107	2327	1528	2327	465	409	1	30	31	284

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
97	HAQBF73	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	254	1508	885	1508		988	556	1			19
98	HAQBT94	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	108	1062	157	1062	172	172	410	1	28	29	187
99	HETHE07	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	109	2539	275	2501	903	903	411	1	30	31	237
99	HETHE07	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	255	2514	592	2431	176	176	557	1	30	31	217
99	HETHE07	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	256	2357	465	2288		1151	558	1	12	13	82
100	HLQAB52	97901 02/26/97 209047 05/15/97	Lambda ZAP II	110	1751	969	1751	4	4	412	1	46	47	192

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
100	HLQAB52	97901 02/26/97 209047 05/15/97	Lambda ZAP II	257	689	218	655	314	314	559	1	18	19	95
100	HEONN58	209119 06/12/97	pSport1	258	2377	5	2377	25	25	560	1	28	29	54
101	HCRAM28	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	111	1117	1	1117		1	413	1	19	20	21
101	HIBEK16	209627 02/12/98	Other	259	1193	69	1135	242	242	561	1	24	25	108
102	HE2BG03	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	112	1313	128	1313	271	271	414	1	30	31	51
102	HE2BG03	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	260	1262	26	1262	35	35	562	1	35	36	50
103	HEBDJ82	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	113	1654	553	1654	709	709	415	1			32

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
104	HCUBC79	97901 02/26/97 209047 05/15/97	ZAP Express	114	1171	540	1171	337	416	1	30	31	163
104	HCUBC79	97901 02/26/97 209047 05/15/97	ZAP Express	261	1179	626	1161	335	563	1	30	31	253
104	HCUBC79	97901 02/26/97 209047 05/15/97	ZAP Express	262	1162	629	1131	942	564	1			18
105	HSVAF07	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	115	842	373	800	100	417	1	65	66	174
105	HSVAF07	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	263	735	290	735		565	1			
105	HSVAF07	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	264	783	416	783		566	1	33	34	73

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
106	HT3AM65	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	116	1640	187	1470	581	581	418	1	30	31	50
106	HT3AM65	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	265	1638	301	1405	119	119	567	1	30	31	263
106	HT3AM65	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	266	1455	148	1188	438	438	568	1	24	25	70
107	HE6DK18	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	117	952	418	906	499	499	419	1	28	29	120
108	HEBEK93	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	118	1256	21	1079	301	301	420	1	30	31	159
108	HEBEK93	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	267	1086	25	1050	227	227	569	1	23	24	34

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
109	HJPCM10	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	119	1143	171	1051	175	421	1	50	51	154
109	HJPCM10	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	268	1003	21	1003	115	570	1	34	35	104
109	HJPCM10	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	269	1234	174	1015	232	571	1	27	28	132
110	HSXBL78	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	120	1782	1	1720	138	422	1	32	33	204
111	HOEAW81	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	121	610	18	609	50	423	1	30	31	67
111	HOEAW81	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	270	574	1	566	337	572	1	27	28	32

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
112	HOEAP41	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	122	526	185	375	143	143	424	1	21	22	25
113	HEAAR60	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	123	2081	1179	1976	48	48	425	1	30	31	299
113	HEAAR60	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	271	1731	889	1626	886	886	573	1	18	19	28
114	HTXGS75	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	124	1717	764	1640	76	76	426	1			13
115	HOVBA03	97902 02/26/97 209048 05/15/97	pSport1	125	804	1	804	145	145	427	1	15	16	198
115	HOVBA03	97902 02/26/97 209048 05/15/97	pSport1	272	1320	77	637	280	280	574	1	22	23	40

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
116	HGBGK76	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	126	431	1	431	73	73	428	1	38	39	47
116	HGBGK76	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	273	315	1	515	43	43	575	1	20	21	30
117	HBMUW78	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	127	3752	3465	3752	748	748	429	1	30	31	370
117	HBMUW78	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	274	2995	2738	2995	2777	2777	576	1	18	19	29
118	HASAS24	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	128	1144	669	1144	896	896	430	1			30
119	HSIDN55	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	129	1830	1234	1830	1265	1265	431	1			24

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
120	HGBGZ64	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	130	1864	1505	1741	1578	1578	432	1	37	38	53
121	H6EBJ64	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	131	2041	1	1214	46	46	433	1	35	36	176
121	H6EBJ64	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	275	1990	8	1128	71	71	577	1	16	17	92
122	HOECP43	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	132	2012	853	1986	1127	1127	434	1	22	23	77
123	H2CBV31	97902 02/26/97 209048 05/15/97	pBluescript SK-	133	1669	670	1632	962	962	435	1	25	26	32
124	HPCAD23	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	134	1565	281	1565	274	274	436	1	25	26	30

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT3' NT of Clone Seq.	5' NT of Clone Seq. Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
125	HSPAG15	97902 02/26/97 209048 05/15/97	pSport1	135	2007	1101	2007	1124	437	1	39	40	69
126	HELGH31	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	136	1291	1	1180	107	438	1			19
127	HUSHH48	97902 02/26/97 209048 05/15/97	Lambda ZAP II	137	1906	1	1906	184	439	1	30	31	43
127	HUSHH48	97902 02/26/97 209048 05/15/97	Lambda ZAP II	276	2436	572	2436	726	578	1	30	31	42
128	HL YAU95	97902 02/26/97 209048 05/15/97	pSport1	138	1935	1044	1794	1183	440	1	18	19	33
129	HHSCV65	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	139	1446	572	1347	585	441	1	25	26	53

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Start Codon	5' NT of First Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
130	HTTAD57	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	140	1109	639	1109	676	676	442	1	24	25	64
131	HEBGA37	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	141	497	9	497	95	95	443	1			34
132	HEBFU93	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	142	269	1	269	1	1	444	1	30	31	89
132	HEBFU93	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	277	782	408	781		571	579	1	31	32	70
133	HSGSC60	97902 02/26/97 209048 05/15/97	Lambda ZAP II	143	1269	55	1262	55	55	445	1	25	26	350
134	HPMGD24	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	144	1944	97	1871	306	306	446	1	16	17	49

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
135	HPTVC60	97902 02/26/97 209048 05/15/97	pBluescript	145	1021	526	1021	74	447	1	30	31	278
135	HPTVC60	97902 02/26/97 209048 05/15/97	pBluescript	278	961	524	961	545	580	1	23	24	110
136	HSKNE18	97902 02/26/97 209048 05/15/97	pBluescript	146	1285	5	1285	116	448	1	30	31	199
136	HSKNE18	97902 02/26/97 209048 05/15/97	pBluescript	279	1228	9	1228	324	581	1	26	27	30
137	HMWIF35	97902 02/26/97 209048 05/15/97	Uni-Zap XR	147	1386	169	1272	165	449	1	30	31	258
137	HMWIF35	97902 02/26/97 209048 05/15/97	Uni-Zap XR	280	1327	169	1208	160	582	1	23	24	71

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
138	HMWGI25	97902 02/26/97 209048 05/15/97	Uni-Zap XR	148	2098	721	2044	784	784	450	1	18	19	87
139	HSKGF03	97902 02/26/97 209048 05/15/97	pBluescript	149	1847	1689	1847	241	241	451	1	33	34	315
139	HSKGF03	97902 02/26/97 209048 05/15/97	pBluescript	281	799	1	799		243	583	1	12	13	47
140	HMSKE75	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	150	1569	113	1517	417	417	452	1	21	22	52
141	HCM SH30	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	151	1540	538	1540	48	48	453	1	30	31	383
141	HCM SH30	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	282	2196	270	2196	294	294	584	1	32	33	39

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
142	HTWCB92	97902 02/26/97 209048 05/15/97	pSport1	152	1719	690	1575	6	6	454	1	52	53	186
143	HBMDM46	97902 02/26/97 209048 05/15/97	pBluescript	153	863	1	863	195	195	455	1	26	27	163
143	HBMDM46	97902 02/26/97 209048 05/15/97	pBluescript	283	1185	277	1166	621	621	585	1			19
144	HFAMG13	97902 02/26/97 209048 05/15/97	Uni-ZAP XR	154	1101	1	512	40	40	456	1	21	22	46
145	HFXHL79	97903 02/26/97 209049 05/15/97	Lambda ZAP II	155	2031	669	2031	411	411	457	1	23	24	105
145	HFXHL79	97903 02/26/97 209049 05/15/97	Lambda ZAP II	284	1634	615	1485	878	878	586	1	20	21	23

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
146	HSNAK17	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	156	1981	1458 1809	1592	1592	458	1	23	24	70
146	HSNAK17	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	285	1795	1458 1749	1562	1562	587	1	33	34	69
147	HCFBC03	97903 02/26/97 209049 05/15/97	pSport1	157	915	45 912	22	22	459	1	22	23	155
147	HCFBC03	97903 02/26/97 209049 05/15/97	pSport1	286	858	46 858	224	224	588	1	30	31	77
147	HSJAP03	209139 07/03/97	Uni-ZAP XR	287	915	1 915	22	22	589	1	22	23	155
148	HSKGO26	97903 02/26/97 209049 05/15/97	pBluescript	158	2117	51 1422	32	32	460	1	23	24	332
149	HCQAV96	97903 02/26/97 209049 05/15/97	Lambda ZAP II	159	2395	1509 2382	1440	1440	461	1			5

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
150	HSHCC16	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	160	2120	1223	2108	1416	1416	462	1			14
151	HTLEF62	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	161	900	482	900	46	46	463	1	30	31	285
151	HTLEF62	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	288	1517	783	1517	1062	1062	590	1			24
152	HTLAD94	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	162	1003	1	1003	288	288	464	1	30	31	80
152	HTLAD94	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	289	3865	217	1195	281	281	591	1	16	17	38
153	HTSFQ12	97903 02/26/97 209049 05/15/97	pBluescript	163	2196	1607	2180	1611	1611	465	1	30	31	47

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
154	HE6FL83	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	164	1945	271	1840	299	299	466	1	63	64	96
154	HE6FL83	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	290	1910	279	1818	355	355	592	1	39	40	69
155	HTXFJ55	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	165	2933	489	2871	258	258	467	1	30	31	399
155	HTXFJ55	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	291	3276	486	2838		525	593	1	45	46	308
156	HJPCJ76	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	166	2243	343	2221		341	468	1			1
157	HLTED27	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	167	1816	1130	1816	284	284	469	1	31	32	273

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
157	HLTED27	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	292	1695	1098	1548	1306	1306	594	1			22
158	HMKBA64	97903 02/26/97 209049 05/15/97	pSport1	168	945	1	787	208	208	470	1	18	19	192
159	HNFIP24	97903 02/26/97 209049 05/15/97	pBluescript	169	902	46	816	19	19	471	1	26	27	234
160	HCELB21	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	170	1883	798	1869	1001	1001	472	1	45	46	105
160	HCELB21	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	293	1501	438	1501	510	510	595	1			24
161	HAWBA28	97903 02/26/97 209049 05/15/97	pBluescript SK-	171	2100	1642	2100	1722	1722	473	1	23	24	32

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
162	HSAAS44	97903 02/26/97 209049 05/15/97	pBluescript SK-	172	1930	187	1930	65	65	474	1	30	31	571
162	HSAAS44	97903 02/26/97 209049 05/15/97	pBluescript SK-	294	2683	183	2683	431	431	596	1			24
163	HAFAL73	97903 02/26/97 209049 05/15/97	pBluescript SK-	173	1509	962	1451	122	122	475	1	30	31	312
163	HAFAL73	97903 02/26/97 209049 05/15/97	pBluescript SK-	295	1454	961	1420	976	976	597	1			1
164	HSAWF26	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	174	3173	2197	2972	51	51	476	1	21	22	329
164	HSAWF26	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	296	828	52	828	305	305	598	1			8

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
165	HEAAL31	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	175	991	374	970	60	60	477	1	24	25	178
165	HEAAL31	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	297	2416	1387	2413	1473	1473	599	1	18	19	25
166	HFKFX55	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	176	1290	499	1290		688	478	1	25	26	52
167	H2LAO11	97903 02/26/97 209049 05/15/97	pBluescript SK-	177	2290	1	2290	173	173	479	1	22	23	62
168	HPFDZ95	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	178	549	1	549	11	11	480	1	21	22	27
168	HPFDZ95	97903 02/26/97 209049 05/15/97	Uni-ZAP XR	298	545	1	545	17	17	600	1	21	22	27

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
169	HP1TU11	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	179	1509	294	1352	92	92	481	1	30	31	339
169	HP1TU11	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	299	1530	385	1530	562	562	601	1	23	24	61
170	HCFAE79	97904 02/26/97 209050 05/15/97	pSport1	180	1316	985	1250	995	995	482	1	26	27	32
171	HTEDJ34	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	181	777	1	777	51	51	483	1	30	31	48
171	HTEDJ34	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	300	997	244	997	300	300	602	1	23	24	29
172	HODCW06	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	182	791	1	791	14	14	484	1	29	30	38

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
173	HFTAR26	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	183	1405	346	1405	575	575	485	1	20	21	61
174	H2MBF44	97904 02/26/97 209050 05/15/97	pBluescript SK-	184	1596	75	1596	131	131	486	1	24	25	346
174	H2MBF44	97904 02/26/97 209050 05/15/97	pBluescript SK-	301	2345	75	2345	233	233	603	1	56	57	69
175	HE8BI92	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	185	2293	355	2288	67	67	487	1	30	31	237
175	HE8BI92	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	302	2369	2	1946		60	604	1	9	10	24
176	HFTBR48	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	186	1212	462	1180	257	257	488	1	30	31	200

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
176	HFTBR48	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	303	1181	424	1149	663	663	605	1	23	24	35
177	HE9CM64	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	187	1605	770	1554	166	166	489	1	30	31	351
177	HE9CM64	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	304	1537	719	1515		787	606	1	43	44	130
178	HATAV51	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	188	1516	960	1516	8	8	490	1	30	31	265
178	HATAV51	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	305	1493	1	1261	54	54	607	1	18	19	23
179	HAQAF27	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	189	681	287	681		401	491	1			25

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
180	HCEEK08	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	190	1014	703	1014	360	360	492	1	30	31	159
180	HCEEK08	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	306	577	1	577	175	608	1				6
181	HAFUAU18	97904 02/26/97 209050 05/15/97	pBluescript SK-	191	2779	2207	2630	1153	493	1	30	31	279	
181	HAFUAU18	97904 02/26/97 209050 05/15/97	pBluescript SK-	307	2860	163	2860	21	609	1	30	31	232	
181	HAFUAU18	97904 02/26/97 209050 05/15/97	pBluescript SK-	308	876	275	876	302	610	1	32	33	34	
182	HETBY74	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	192	1923	30	1923	45	494	1	33	34	193	

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
183	HTOAF35	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	193	2346	1160	2286	178	178	495	1	30	31	205
183	HTOAF35	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	309	2025	840	2025	971	971	611	1	18	19	21
184	HCRBX32	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	194	3054	2004	3054	434	434	496	1	11	12	147
184	HCRBX32	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	310	3026	1966	3026		2131	612	1			9
185	HEBGB80	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	195	907	152	907	297	297	497	1	30	31	64
185	HEBGB80	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	311	712	67	712	107	107	613	1	18	19	29

Gene No.	cDNA Clone ID	ATCC Deposit No: Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	Predicted First AA of Secreted Portion	Last AA of ORF
186	HFAMH74	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	196	1290	84	809	225	225	498	1	30	31	94
186	HFAMH74	97904 02/26/97 209050 05/15/97	Uni-ZAP XR	312	1289	785	1289	927	927	614	1	28	29	30

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below).

It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

- 5 The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources
- 10 using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

Signal Sequences

- 15 Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1
- 20 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra.*) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

- 25 In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results
- 30 shown in Table 1.

- As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., +
- 35 or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely

uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

10 **Polynucleotide and Polypeptide Variants**

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

15 "Identity" per se has an art-recognized meaning and can be calculated using published techniques. (See, e.g.: (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, (1988); BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS, Smith, D.W., ed., Academic Press, New York, (1993); COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, (1994); SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, (1987); and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, (1991).) While there exists a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans. (Carillo, H., and Lipton, D., SIAM J Applied Math 48:1073 (1988).) Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in "Guide to Huge Computers," Martin J. Bishop, ed., Academic Press, San Diego, (1994), and Carillo, H., and Lipton, D., SIAM J Applied Math 48:1073 (1988). Methods for aligning polynucleotides or polypeptides are codified in computer programs, including the GCG program package (Devereux, J., et al., Nucleic Acids Research (1984) 12(1):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F. et al., J. Molec. Biol. 215:403 (1990), Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711 (using the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981)).)

When using any of the sequence alignment programs to determine whether a particular sequence is, for instance, 95% identical to a reference sequence, the parameters are set so that the percentage of identity is calculated over the full length of the reference polynucleotide and that gaps in identity of up to 5% of the total number of nucleotides in the reference polynucleotide are allowed.

A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990).) The term "sequence" includes nucleotide and amino acid sequences. In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB search of a DNA sequence to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, and Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, and Window Size=500 or query sequence length in nucleotide bases, whichever is shorter. Preferred parameters employed to calculate percent identity and similarity of an amino acid alignment are: Matrix=PAM 150, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty=0.05, and Window Size=500 or query sequence length in amino acid residues, whichever is shorter.

As an illustration, a polynucleotide having a nucleotide sequence of at least 95% "identity" to a sequence contained in SEQ ID NO:X or the cDNA contained in the deposited clone, means that the polynucleotide is identical to a sequence contained in SEQ ID NO:X or the cDNA except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the total length (not just within a given 100 nucleotide stretch). In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to SEQ ID NO:X or the deposited clone, up to 5% of the nucleotides in the sequence contained in SEQ ID NO:X or the cDNA can be deleted, inserted, or substituted with other nucleotides. These changes may occur anywhere throughout the polynucleotide.

Further embodiments of the present invention include polynucleotides having at least 85% identity, more preferably at least 90% identity, and most preferably at least 95%, 96%, 97%, 98% or 99% identity to a sequence contained in SEQ ID NO:X or the cDNA contained in the deposited clone. Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the polynucleotides having at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity

will encode a polypeptide identical to an amino acid sequence contained in SEQ ID NO:Y or the expressed protein produced by the deposited clone.

Similarly, by a polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference polypeptide, is intended that the amino acid sequence of the polypeptide is identical to the reference polypeptide except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the total length of the reference polypeptide. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

Further embodiments of the present invention include polypeptides having at least 80% identity, more preferably at least 85% identity, more preferably at least 90% identity, and most preferably at least 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence contained in SEQ ID NO:Y or the expressed protein produced by the deposited clone. Preferably, the above polypeptides should exhibit at least one biological activity of the protein.

In a preferred embodiment, polypeptides of the present invention include polypeptides having at least 90% similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 97%, 98%, or 99% similarity to an amino acid sequence contained in SEQ ID NO:Y or the expressed protein produced by the deposited clone.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an

organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level.

Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

5 Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988
10 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

15 Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible
20 amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

25 Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form
30 are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

35 Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make

phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

5 The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid
10 substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then
15 be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino
20 acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues
25 Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues,
30 where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino
35 acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

Polynucleotide and Polypeptide Fragments

10 In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in
15 length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

20 Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, and 701 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly
25 recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the
30 deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, and 161 to the end of the coding
35 region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about"

includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies

In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983).)

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

5 In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

10 Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if
15 it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

20 As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')₂ fragments) which are capable of specifically binding to protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these fragments are preferred,
25 as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Fusion Proteins

30 Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular
35 locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

5 Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the
10 polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

 Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of
15 immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86
20 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

 Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion
25 proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified,
30 would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol.
35 Chem. 270:9459-9471 (1995).)

 Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In

preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the claimed invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS,

293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and
5 ptc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

10 Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the
15 present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity
20 chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids,
25 tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be
30 non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most
35 proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes
5 known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention
10 can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic
15 cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can
20 be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using
25 fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to
30 mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross
35 hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage

analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the

present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

5 The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" 10 which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an 15 individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely 20 small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from 25 polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the 30 present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present 35 invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers
5 for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The
10 following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-
15 3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and
20 technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-
25 radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, 131I, 112In, 99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or
30 intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety
35 needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20

millicuries of ^{99m}Tc . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention could be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules

may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

5 A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders
10 may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

15 A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to:
20 blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.
25

Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood
30 coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.
35

A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from

inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Infectious Disease

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Haemophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria,

Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect
5 any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis,
10 Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide
15 of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide
20 of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

25 A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal
30 disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and
35 skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

Chemotaxis

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat

disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

5 A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or
10 small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural
15 receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell
20 membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

25 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations,
30 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

35 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The

antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Other Activities

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining

whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the

amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at
5 least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at
10 least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a
15 polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in
20 the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1;
25 and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining
30 whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of
35 polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an

amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5 Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in
10 said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained
15 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a
20 sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample
25 obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid
30 sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

35 Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least

90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated

polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lafmid BA	plafmid BA
pSport1	pSport1
pCMVSPORT 2.0	pCMVSPORT 2.0
pCMVSPORT 3.0	pCMVSPORT 3.0
pCR [®] 2.1	pCR [®] 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation

of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors
5 contain an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., *Focus* 15:59 (1993).) Vector lacmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue,
10 Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., *Bio/Technology* 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the
15 corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone
20 identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited
25 sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported.
30 The oligonucleotide is labeled, for instance, with ³²P- γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as
35 those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection

agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μ l of reaction mixture with 0.5 μ g of the above cDNA template. A convenient reaction mixture is 1.5-5 mM $MgCl_2$, 0.01% (w/v) gelatin, 20 μ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to

remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of

conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

10 A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product
15 into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

20 The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are
25 identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The
30 cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by
35 centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic

agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number XXXXXX.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

- 5 The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

- Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at
10 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

- 15 The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

- 20 The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction:

- Following high speed centrifugation (30,000 xg) to remove insoluble particles,
25 the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

- To clarify the refolded polypeptide solution, a previously prepared tangential
30 filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a

stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem
5 columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column
10 volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from
15 Commassie blue stained 16% SDS-PAGE gel when 5 μ g of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and
25 Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated
30 homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription,
35 translation, secretion and the like, including a signal peptide and an in-frame AUG as

required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five µg of a plasmid containing the polynucleotide is co-transfected with 1.0 µg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417 (1987). One µg of BaculoGold™ virus DNA and 5 µg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 µl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μ Ci of 35 S-methionine and 5 μ Ci 35 S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),

pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the

naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested
5 with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid
10 pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μ g of the expression plasmid pC6 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that
15 confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri
20 dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 -
25 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins.
30 These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the
35 polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having

more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in

5 Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

10 For example, if pC4 (Accession No.209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that
15 the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a
20 heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGCC
CAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCTCTTCCCCCAAAACC
25 CAAGGACACCCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGT
GGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG
GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCC
30 ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
GTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT
GACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGA
GAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGG
ACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCA
35 GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC
ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGC
GACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Production of an Antibody from a Polypeptide

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody

whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

5 It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively, secreted protein-binding fragments can be produced through the application of
10 recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art.
15 (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

20

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in
25 Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well
30 (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml
35 DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in

5 Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of

10 transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off

15 PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (see below) with 2mm glutamine and 1x penstrep.

20 (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B

25 adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

30 It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an

35 activity in a particular assay.

HGS-CHO-5 medium formulation:**Inorganic Salts**

CaCl ₂ (anhyd)	116.6 mg/L
CuSO ₄ ·5H ₂ O	0.00130
Fe(NO ₃) ₃ ·9H ₂ O	0.050
FeSO ₄ ·7H ₂ O	0.417
KCl	311.80
MgCl ₂	28.64
MgSO ₄	48.84
NaCl	6995.50
NaHCO ₃	2400.0
NaH ₂ PO ₄ ·H ₂ O	62.50
Na ₂ HPO ₄	71.02
ZnSO ₄ ·7H ₂ O	.4320

5 Lipids

Arachidonic Acid	.002 mg/L
Cholesterol	1.022
DL-alpha-Tocopherol-Acetate	.070
Linoleic Acid	0.0520
Linolenic Acid	0.010
Myristic Acid	0.010
Oleic Acid	0.010
Palmitic Acid	0.010
Palmitic Acid	0.010
Pluronic F-68	100
Stearic Acid	0.010
Tween 80	2.20

Carbon Source

D-Glucose	4551 mg/L
-----------	-----------

Amino Acids

L-Alanine	130.85 mg/ml
L-Arginine-HCL	147.50
L-Asparagine-H ₂ O	7.50
L-Aspartic Acid	6.65
L-Cystine-2HCL-H ₂ O	29.56
L-Cystine-2HCL	31.29
L-Glutamic Acid	7.35
L-Glutamine	365.0
Glycine	18.75
L-Histidine-HCL-	52.48

H ₂ O	
L-Isoleucine	106.97
L-Leucine	111.45
L-Lysine HCL	163.75
L-Methionine	32.34
L-Phenylalanine	68.48
L-Proline	40.0
L-Serine	26.25
L-Threonine	101.05
L-Tryptophan	19.22
L-Tyrosine-2Na-2H ₂ O	91.79
L-Valine	99.65

Vitamins

Biotin	0.0035 mg/L
D-Ca Pantothenate	3.24
Choline Chloride	11.78
Folic Acid	4.65
i-Inositol	15.60
Niacinamide	3.02
Pyridoxal HCL	3.00
Pyridoxine HCL	0.031
Riboflavin	0.319
Thiamine HCL	3.17
Thymidine	0.365
Vitamin B ₁₂	0.680

Other Components

HEPES Buffer	25 mM
Na Hypoxanthine	2.39 mg/L
Lipoic Acid	0.105
Sodium Putrescine-2HCL	0.081
Sodium Pyruvate	55.0
Sodium Selenite	0.0067
Ethanolamine	20uM
Ferric Citrate	0.122
Methyl-B-Cyclodextrin complexed with Linoleic Acid	41.70
Methyl-B-Cyclodextrin complexed with Oleic Acid	33.33
Methyl-B-Cyclodextrin complexed with Retinal Acetate	10

5

Adjust osmolarity to 327 mOsm

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	<u>ISRE</u> <u>Ligand</u>	<u>JAKs</u>				<u>STATS</u>	<u>GAS(elements) or</u>
		<u>tyk2</u>	<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
5	<u>IFN family</u>						
	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS
	(IRF1>Lys6>IFP)						
	IL-10	+	?	?	-	1,3	
10	<u>gp130 family</u>						
	IL-6 (Pleiotrohic)	+	+	+	?	1,3	GAS
	(IRF1>Lys6>IFP)						
	IL-11(Pleiotrohic)	?	+	?	?	1,3	
15	OnM(Pleiotrohic)	?	+	+	?	1,3	
	LIF(Pleiotrohic)	?	+	+	?	1,3	
	CNTF(Pleiotrohic)	-/+	+	+	?	1,3	
	G-CSF(Pleiotrohic)	?	+	?	?	1,3	
	IL-12(Pleiotrohic)	+	-	+	+	1,3	
20	<u>g-C family</u>						
	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP
	>>Ly6)(IgH)						
25	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
30	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS
	(IRF1>IFP>>Ly6)						
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS
35	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
	EPO	?	-	+	-	5	
40	CAS>IRF1=IFP>>Ly6)						GAS(B-
	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
45	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCG
 10 AAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATG
 20 ATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCC
 CTAATCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGC
 CCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGC
 CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTT
 TGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a

neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using
5 Sall and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

10 Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be
15 substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

20 **Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS
25 signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-
30 SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

35 Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI

+ 10% serum with 1% Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required
5 number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with supernatants
10 containing a polypeptide as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100
15 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred
20 directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in
25 an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material
30 for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells.

5 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

15 Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 uM CaCl_2 . Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

25 These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

30

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes,
5 EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or
10 differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

15 The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

20 5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)
5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the
25 EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and
30 allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done
35 every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

NF- κ B (Nuclear Factor κ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF- κ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- κ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- κ B is retained in the cytoplasm with I- κ B (Inhibitor κ B). However, upon stimulation, I- κ B is phosphorylated and degraded, causing NF- κ B to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- κ B include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF- κ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- κ B would be useful in treating diseases. For example, inhibitors of NF- κ B could be used to treat those diseases
 5 related to the acute or chronic activation of NF- κ B, such as rheumatoid arthritis.

To construct a vector containing the NF- κ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- κ B binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:
 10 5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
 TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

20 5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
 ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCCTAACTCCGCCCA
 TCCCGCCCCCTAACTCCGCCCCAGTTCCGCCCATTTCTCCGCCCCATGGCTGACT
 AATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTC
 CAGAAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:
 25 3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2- promoter plasmid (Clontech) with this NF- κ B/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not
 30 preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- κ B/SV40/SEAP cassette is removed from the above NF- κ B/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the

NF- κ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF- κ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 μ l of 2.5x dilution buffer into Optiplates containing 35 μ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 μ l Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 μ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4

15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 ul of 12 ug/ml fluo-3 is added to each well. The plate is incubated at 37°C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to $2-5 \times 10^6$ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1×10^6 cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-3. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular

signaling even which has resulted in an increase in the intracellular Ca^{++} concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

5 The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In
10 addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

 Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the
15 cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

20 Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

25 Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine
30 (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento,
35 CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are

used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

- To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium.
- 5 Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim
- 10 (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation,
- 15 the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

- Generally, the tyrosine kinase activity of a supernatant is evaluated by
- 20 determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

- 25 The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the
- 30 components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

- Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction
- 35 mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This

allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as
5 above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of
10 tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or compliment to the assay of protein tyrosine
15 kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase,
20 Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then
25 rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C
30 until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts
35 filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and
5 Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

10

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from
15 these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

20 PCR products is then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

25 PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals is identified by mutations not present in unaffected individuals.

30 Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the
35 corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera
5 (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and
10 translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

15 A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

20 For example, antibody-sandwich ELISAs are used to detect soluble polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the
25 polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide.

30 Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate.

35 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on

the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23: Formulating a Polypeptide

5 The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for
10 purposes herein is thus determined by such considerations.

 As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 $\mu\text{g/kg/day}$ to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day , and
15 most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 $\mu\text{g/kg/hour}$ to about 50 $\mu\text{g/kg/hour}$, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes
20 and the interval following treatment for responses to occur appears to vary depending on the desired effect.

 Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal
25 patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

30 The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al.,
35 Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric

acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of

about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile.

5 Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized 10 formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

15 The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the 20 present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by 25 administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

30 For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

5 For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

10

Example 26: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and
15 separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS,
20 penicillin and streptomycin, is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

25 pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified
30 using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions
35 appropriate for ligation of the two fragments. The ligation mixture is then used to

transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

5 The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

10 Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the
15 titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is being produced.

20 The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

25 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference.

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Human Genome Sciences, Inc. et al.
- (ii) TITLE OF INVENTION: 186 Human Secreted Proteins
- 10 (iii) NUMBER OF SEQUENCES: 644
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Human Genome Sciences, Inc.
- 15 (B) STREET: 9410 Key West Avenue
- (C) CITY: Rockville
- (D) STATE: Maryland
- 20 (E) COUNTRY: USA
- (F) ZIP: 20850
- 25
- (v) COMPUTER READABLE FORM:
- 30 (A) MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage
- (B) COMPUTER: HP Vectra 486/33
- (C) OPERATING SYSTEM: MSDOS version 6.2
- 35 (D) SOFTWARE: ASCII Text
- (vi) CURRENT APPLICATION DATA:
- 40 (A) APPLICATION NUMBER:
- (B) FILING DATE: March 6, 1998
- 45 (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- 50 (A) APPLICATION NUMBER:
- (B) FILING DATE:
- 55

(viii) ATTORNEY/AGENT INFORMATION:

5

(A) NAME: A. Anders Brookes, Esq.

(B) REGISTRATION NUMBER: 36,373

(C) REFERENCE/DOCKET NUMBER: PS002.PCT

10

(vi) TELECOMMUNICATION INFORMATION:

15

(A) TELEPHONE: (301) 309-8504

(B) TELEFAX: (301) 309-8439

20

(2) INFORMATION FOR SEQ ID NO: 1:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 733 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GGGATCCGGA GCCCAAATCT TCTGACAAAA CTCACACATG CCCACCGTGC CCAGCACCTG	60
AATTGAGGG TGCACCGTCA GTCTTCCTCT TCCCCCAAAC ACCCAAGGAC ACCCTCATGA	120
35 TCTCCCGGAC TCTGAGGTC ACATGCGTGG TGGTGGACGT AAGCCACGAA GACCCCTGAGG	180
TCAAGTTCAA CTGGTACGTG GACGGCGTGG AGGTGCATAA TGCCAAGACA AAGCCCGGGG	240
AGGAGCAGTA CAACAGCAG TACCGTGTGG TCAGCGTCTT CACCGTCTTG CACCAGGACT	300
40 GGCTGAATGG CAAGGAGTAC AAGTGCAAGG TCTCCAACAA AGCCCTCCCA ACCCCCATCG	360
AGAAAACCAT CTCCAAAGCC AAAGGGCAGC CCCGAGAACC ACAGGTGTAC ACCCTGCCCC	420
45 CATCCCGGGA TGAGCTGACC AAGAACCAGG TCAGCCTGAC CTGCCTGGTC AAAGGCTTCT	480
ATCCAAGCGA CATGCGCGTG GAGTGGGAGA GCAATGGGCA GCGGAGAAC AACTACAAGA	540
CCACGCCCTCC CGTGTGGAC TCCGACGGCT CCTTCTTCTT CTACAGCAAG CTCACCGTGG	600
50 ACAAGAGCAG GTGGCAGCAG GGAACGTCT TCTCATGCTC CGTGATGCAT GAGGCTCTGC	660
ACAACCACTA CACGCAGAAG AGCCTCTCCC TGTCCTCGGG TAAATGAGTG CGACGGCCCGC	720
55 GACTCTAGAG GAT	733

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Trp Ser Xaa Trp Ser
1 5

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 86 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GCGCCTCGAG ATTTCCCCGA AATCTAGATT TCCCCGAAAT GATTTCCTCG AAATGATTTC 60
CCCGAAATAT CTGCCATCTC AATTAG 86

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GCGCAAGCT TTTTGCAAAG CCTAGGC 27

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 271 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CTCGAGATTT CCCCAGAAATC TAGATTTCCT CGAAATGATT TCCCCGAAAT GATTTCCTCG 60

AAATATCTGC CATCTCAATT AGTCAGCAAC CATAGTCCCG CCCCTAACTC CGCCCATCCC 120
GCCCCCTAACT CGCCCCAGTT CGCCCCATTC TCGCCCCCAT GGCTGACTAA TTTTITTTTAT 180
5 TTATGCAGAG GCCGAGGCCG CCTCGGCTC TGAGCTATT CAGAAGTAGT GAGGAGGCTT 240
TTTGGAGGC CTAGGCTTTT GCAAAAAGCT T 271

10

(2) INFORMATION FOR SEQ ID NO: 6:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CGGCTCGAGG GATGACAGCG ATAGAACCCC GG 32

25

(2) INFORMATION FOR SEQ ID NO: 7:

30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GCGAAGCTTC GCGACTCCCC GGATCGCCT C 31

40

(2) INFORMATION FOR SEQ ID NO: 8:

45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGGGACTTTC CC 12

55

(2) INFORMATION FOR SEQ ID NO: 9:

60 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 73 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GGGGCCTCGA GGGGACTTTC CCGGGGACTT TCCGGGGACT TTCCGGGACT TTCCATCCTG 60
10 CCATCTCAAT TAG 73

15

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 256 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

25 CTCGAGGGGA CTTTCCCGGG GACTTTCCGG GGACTTTCCG GGACTTTCCA TCTGCCATCT 60
CAATTAGTCA GCAACCATAG TCCCGCCCTT AACTCCGCCC ATCCCGCCCC TAACTCCGCC 120
30 CAGTTCGGCC CATCTCCGC CCCATGGCTG ACTAATTTTT TTTATTTATG CAGAGGCCGA 180
GGCCGCTCG GCCTCTGAGC TATTCCAGAA GTAGTGAGGA GGCTTTTTTG GAGGCCTAGG 240
CTTTTGCAAA AAGCTT 256

35

(2) INFORMATION FOR SEQ ID NO: 11:

40

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 582 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GGCACGAGGT AATTCTACC AGAAATTTC AGAGCATTAT GTAGGTAGAA AAAAATGCAA 60
50 GCAAGCTGTT AAAGATCTTG GATCCCATTA TATAGTATGT ATAGCTGAAA TCTGTAATTC 120
AATCACTTTT TCCTTTTAT CCTCTAACCA AAAAATTGTT TAATTTTGCA TCCCAAATGT 180
55 TTTTAATCTT TGTATATTTT TAAAAATCC TTTTCTCCTC ATCATGCTT TTTTGTGGT 240
TGTAATAGA CTTACTTGCA CTTGAAGAT GAGTTACTCC TTGTCATCTT ACAAATATGT 300
GATATGGTAA TTTTCATAAC AGATGTCAGT TTTGAACCA GAATGGTGA TTTGTTTATA 360
60 AGAAAAAAC TGGCTTCATT TCTGTGAAAT TGCTCTTTGA AAATTTCTTT TTACACGTGT 420

AAGCCAACTG AGATACCGTG ATGGTGTGA TTCTTTCAA TGATGCTTAC CATCTATTTT 480
AGCCACTGAG CCTTTTATTA TTGTCTATT TGTAAGTTT ATTTGTCTTA ACTCATTTAA 540
TAAATATACT GTTTATCTGT TTCTGAAAAA AAAAAAAAAA AA 582

10

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 465 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

GTITGGGGGT GAGGCCGAGC TGCTGCGGGG CTTCGTGCGC GGCCAGGACA CAGCTACTCG 60
CAGGGCGGCG GCGCCTGGCT ATGATGTTCC TCACCCAGGG CCGGCCTCTG CCCTCTACTC 120
25 GTGCCAGGCC CACTTGCCAG GCAGGAGCCC TCCCCAAGCC TTCAGGGCTG CTCGGAGTCA 180
CCTGTITGAA TGGACTAAAA GGACCCCTGT GTGGGAACAG GTGCTCCCCA AACACCCCTGC 240
TGCTGGCTGC CAGGCAGGCC CTCTGGAAGG GAAGGGGCGAG GACTCATCAG GACCTCCCTG 300
30 GACCCCTGCA GGCAGGCAG CTTGGGCCCC AGCCCAAGCA TTGGCTCTG CTGCCCCCAA 360
GGGGACAGGA AGCCTCTTGG GCCTCTTCCC TTCTTGACA AGGCCCCCTG CCTTTGCCTC 420
35 ACATAAACTG TACAGTATTT TCATTAAAAG CCTCTTTCAT AAAAA 465

40

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 474 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

50 ATGCAATTC TGCTACAGC CTTCTGTTG GTGCCACTC TGGCTCTTTG TGATGTCCCC 60
ATATCCCTAG GCTTCTCCCC CTCCTAGAAG GCCTTCTTGA TAGATTAGAA AATAAGAATG 120
AGTGACATTT CCTATGTGA TATAAGAAGG AGCCACAAGA CATGTCITTTT AAATAAAAGG 180
55 ACAGTGCCA TCCTTTTAGC TGCCGAATAG AACCTTGGTC TCATCCTCCT GGAGCTAGGC 240
CTTTAAACA GCTTCTGTGT TTCTCATTTG TCTCAGTGT TTGCCAGGT TTTATCGGAA 300
60 AGATAATGTT CGTTTAAAA TATTCCTAA TGAGGCGGG CGTGGTGGCT CAGCCCTGTA 360

ACCTTAGCAM TTGGGGGCTG AGCGGGTGA TCACGAGGTC AGGAGATCGA GACCATCCTG 420
5 GSTAACATGG TGAAACCCCG TCTCTACTAA AAATACAAA AAAAAAAAAA AAAA 474

10 (2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 314 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
15 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

20 TTATGTTGGG GAGCAAGACC TGATAGCCAG CCITTACATG GGAGTATAAT TCTGTCTCTCC 60
ATCTCATAAG CCCAGTACC TGAGCCAGAA TGATTATAAC CAACCACACT GTCTCTTTAT 120
CATGGATGGC TTAGCAGTA GGTATTATTC ATCATGCCA TTGTAGCTC TACAGTGGTT 180
25 TATAGTAATT TCTCATCTTT TAAGTCTCTC CCTCAGTGCC TGTGTATATC AAATCATTG 240
CTCTCTCANG CAGTTGAGCT CTGCATCTC CCYTATGGG GAGAGCTGTG TTGGAGAGAG 300
AGAATATNAC TTCC 314
30

35 (2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 613 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
40 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

45 CTCATATGCG CGTCTGGCTA AAAGTGAACA TGCCATTGAT CAATCTGCTT TPATTATATT 60
ATGTTCTTAA TGGTGGCAAG CAAGACAAGA AGTAGAAGA AAGATGGTGT AAGCTCAAGA 120
ACCCACTAAA TCTATCCTAT GGCCTGGGTT CACCCAGCCT GCTTTGTGGA TTTTGTCTCA 180
50 CTATAACAGA GCTCCCAAGG AGACTGCAGA GTCAGCTCCC TTAAGCACTG TAACTAAAGC 240
CTAACTCTTC CGTTCCACCC AACAATGTYC CCAGCTCATC CTCTTTCCCR AAGTCCOCTT 300
TCTGCCCCAG ATGCGAATTG CATTTAACTA ATCCTCAAGT GAAATGTCCA CACAGRATTC 360
55 CATTTTAATT AGCATACCAT AGTTTGTGTG CAAATTTGCT TTCAGARGAC TCCCATTGCA 420
GCTGCTCAGA GACGCTAAGG GCAGGGCCTC TTGAWGCTTT CCCGATAGCT TTCAGCTGCA 480
60 ATAGCTCTTA GGCAGAATGC CATGAGCGTC CTGCCCAACT GTATTACTGG GGAACACCTG 540

ATTGGCTAGA AGTTGATCCT CCTGTAACCT TTCTGAGTTC TTTACATTTA CTCGTGAAAC 600
CCAAATATGC CAC 613

5

10 (2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 356 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
15 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

20 CCCCCCAT TGAACCTGG GCTGTGAAAG TTTTGCCTG TGTGGGTCGT TCTGTGTGGC 60
GCTTGGTGTG TGGRTCCTAA CTCTGTGTGC AAAGTGGCAG CAGCCAATCA TGAAGCGCCC 120
TTATTTTATAG TTGCAGATGA CCAGGTCTCC CCCCCACAGC CTCTGTCTGG TCCCTCATTG 180
25 GTGAGTGGTC TGCCCTGCCA AGGAGCCTGA TTGGTGGGAA ATGGCATCAT CTAATATGAT 240
GGGAAGGCAT TTGGTCTCTG TTATGTTTAT TACAACATCA TTGCACTCTG GGACTCCAGT 300
CCCTGAAAAC GTAATTTGTG GTGTTACCAA AGGACCACAG GGGAAAAAAA AAAAAA 356

30

35 (2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 414 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
40 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

45 GAAACTANAT CCGGGGCTT TTAACNGGTA CTTGGGAAAT AAGTATTGGG TAATCACTAA 60
GNGGACATTG ACTGCACCAA ACCAAAGCTA TAGAAAGAAA TGATTGACTT TTAAAAATAT 120
ATTACATTA ACTGTCTAG GATACTTCTC TTGAGGCTTT GGAAACTTC TTCCTTGAAA 180
50 TTGTCATATC CACTCCAGTT CTGTACCAA AGATTTTAAT CTTCAGATCG CAATTTCCTC 240
TCTCCAGAA AAAAGTACTA CAACAGGCTC AAGGGATATG CTTTGGTGGT CAAGGGATTA 300
CACTATGGTT TTCTTCTGT TCACAATGGT ATTTACAGGA GACCTTGTC TCAGAGGACG 360
55 TACTGAACAT TCATTATGAC TTTGGATTG ATCAGAGGTT TAAAAAAA AAAA 414

60

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 469 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

10 AATCACCATT GCAATACAAA TGATCTGCCT GGTGAATGYT GAGCTGTACC CCACATTTCGT 60
CAGGAACYTC GGAGTGATGG TGTGTTCTC CCTGTGTGAC ATAGGTGGGA TAATCACCCC 120
15 CTTTCATAGTC TTCAGGCTGA GGGAGGTCG GCAAGCCTTG CCCCTCATTT TGTTCGCGT 180
GTTGGGCTG CTGCGCGG GAGTGACCT ACTTCTTCCA GAGACCAAGG GGGTCGCTTT 240
20 GCCAGAGACC ATGAAGGACG CCGAGAACCT TGGGAGAAAA GCAAAGCCCA AAGAAAACAC 300
GATTACCTT AAGGTCCAAA CCTCAGAACC CTCGGGCACC TGAGAGAGAT GTTTGCGGC 360
GATGTCGTGT TGGAGGATG AAGATGGAGT TATCTCTGC AGAAATTCCT AGACGCCTTC 420
25 ACTTCTCTGT ATTCTCTCTC ATACTTGCT ACCCCCAAAT TAATATCAG 469

30 (2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 550 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

40 CCCCCCCCC CCCCACACT TTCAGGAGTC ACCCCCAGC ATTTGGGGTT GGGTTGGCCC 60
TACTCCAGCC TGGAGCTCCC TGAGGGAGCC TGCACTCCCT GCTCCCAATC CCCGCTACTG 120
45 GTGCAGGAT GCAGCCTGGA GCTGGCGTCC TTGTTCTGGG CTTGCTGCTG CCGCCACCCC 180
AGAGCCCCAG CCTGTCTGA ATTGACATCA GTGCTTCCCT GAACTGCCTC CCCCACCCCT 240
GGCATTATC CCAGAAACT TTATGTTTTC TAGAAGCTAA GCAGCTGCTG GGAATCAGGG 300
50 ACTGGTGCAG GTAGGCTGAG TGGCAGCTCA GTCTTAGAAG GTCTCTGAAG ATCTGGACTG 360
AGGACCTTGC TACTCCCCAA GCCAGAGCCC ATCAGCCAGG CCTGCTGTGA GCCACCTGCC 420
TGTGGAGTGC TGAGCTCAAC CAAAGGCTGG CAAGCTCTGG GCTCATTTA AGGGATTCTG 480
55 ATGAGCCGAT GGGCCCTGGA GGCAGCCCAT TAAAGCATCT GGCTCGTTTT TGAAGAAAAA 540
AAAAAAAAA 550

(2) INFORMATION FOR SEQ ID NO: 20:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 741 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

	TCTTGAAGAG TGTACAGTAC AGGATTATTA TAATGAAAGT TTATATCAAC AGGGTTTCGT	60
15	TGGCTCTGCA TATATTATAA GCAAAGAGA TTGGTAAAGT GCCACAGTAT TCCAGATAAC	120
	TTTTCAGTTG CGGCCTTTCT TCTCGTTCTT TAATTGAAA CCTAGATACA TGCAGTAAAA	180
20	ACTAGGAGAA TGACTTTTAC CCTTGGGGAC AGCCAAGTTT TGTGATAAAA CCTATTTCTT	240
	AGCATGCCTT CAGGAAGTTG TGCCAGACCC TAGATTGTGA AGGACCCACT GTTCTTCTGT	300
	TGTACGAGCT CCTGAACCA TTGTTACAGAG GACCAATGTC ACATCGCTTC ATGGGCATGG	360
25	NCCATGGGAG CATCTGGGTG ATATCTGTCT ACAGTATTGG CTCTTCTGGG AGGCTGATAC	420
	ACAAGGCCTC TCTTCCACAT GATCATTTGC AAACCTCCCC CAGCCCCCTAC CATCCAATGT	480
30	GGAAGGAAAA CAAGAACTGC CTGAAGAAGA GTCCAAGCTA CAGATACACA GCGTGTGCAT	540
	TGCGGCTGTC ACCTTCCTCC TOCCACTTCT GTATCCTCAG AGATGCTGGG TGGATGTTTC	600
	CTTAACCTCA GCTGACTTCC CTGTGAATGT CTAATGCTAG TTCAGGGCCT CCAGGCATTG	660
35	ATTGTGTACAG TGGTAACTCC CAATGAGGCT TCTGTTATCA TTTGGTGTGC TTTTCTGTG	720
	ATTAAAAGAA ATGATTTTCC C	741

40

(2) INFORMATION FOR SEQ ID NO: 21:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 991 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

	GGCAGGATC TCCCCTGGGG AAGTTTTTCT TTTTCAGGAG GGAGGAGGGC TTTCCAGGT	60
55	AATGTGTCTA GAGTGTGGG CAGAAAATCT GGGACCACAC CACACCAGTT CTCTCCTTAA	120
	TCCAGTCAT TTGCCTTCTA TCCCAGCTAT GTTTCAGTGT TCCTCTGGGT GTTTCAGA	180
	GCAACAAGAA ATGAATAAAT CTCTGGTGAG TTGTTATTTT GTTCTTCACT TTGTTTACA	240
60	CTGTATTTTC TGAGTTTATG GGTGTCTGTG AATTAAAAAG GAAAAGTAGA AATAAGTAAA	300

	ACTCAGGTTG AAGGAAATAT ACATAAATAA GATAAAGCTG ACCTGTAGAT ATAGCAGGTT	360
5	ATAAAGCTTA GAGTGTCTA AGTTGAGTGC AAATTTTCCT CTGATCTTTC TGATGCCGAA	420
	CAAAAAGCA GTCATGTTTG TTATGTGATT GGAATGGAAC CCGAGAAGAG AGCATGCTGT	480
	GTCTTGTTGG GACAGGAAAG CTGCGTGCA CCAAGTCTGA ACCACCACCT TCATGGTGAC	540
10	ATAGATTATG TGCTGGAACA TATTTACAC CCGCCTGGCA GTAAACACTT GTAGTGTGT	600
	GCACTGGAAA CGGTCATCTT CCGCTAAAGC ACGCGGTGTT GTGCAGCGGA AATGGTCATC	660
15	TGCTGCTAAA ACACAGCTTC CATCGTAATG TATGCTCCTT ACTCAAAGAG TGTGGTCCCA	720
	AACAGCCTTT GGGAGTCTCT CCTTGATTCA TGGATGAAAC CTGGAACATC TTGAGGACTG	780
	AGTTAACCAT AGGTCCTTAA ATAACCTCC ACACGTTTTT CTTAGTTTAT CTCTACATCC	840
20	AGGGTGTGCA GCAGCCTGTT CAAAGTCATA TTTTCIGGGA AATATTTCCTA GTGTTTATTT	900
	GCACTTTAGC CCACTCTGTG TAGCCTTATT TCTTCTAAAC TCACCATTAA TCTGAATAAT	960
25	AGTCAAATTT AGGGGGACTG TATTTGCCTT A	991
30	(2) INFORMATION FOR SEQ ID NO: 22:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 653 base pairs	
	(B) TYPE: nucleic acid	
35	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:	
40	CCACGCGTCC GGAATTCCCC TGAGGATCTT GGGCTATCTT TGACAGGGGA TTCTTGCAAG	60
	TTGATGCTTT CTACAAGTGA ATATAGTCAG TCCCCAAGA TGGAGAGCTT GAGTTCTCAC	120
	AGAATTGATG AAGATGGAGA AAACACACAG ATTGAGGATA CGGAACCCAT GTCTCCAGTT	180
45	CTCAATTCTA AATTGTGTTCC TGCTGAAAAT GATAGTATCC TGATGAATCC AGCACAGGAT	240
	GGTGAAGTAC AACTGAGTCA GAATGATGAC AAAACAAAGG GAGATGATAC AGACACCAGG	300
50	GATGACATTA GTATTTTAGC CACTGGTTGC AAGGGCAGAG AAGAAACGGT AGCAGAAGAA	360
	GTTTGTATTG ATCTCACTTG TGATTCGGGG AGTCAGGCAG TTCCGTCACC AGCTACTCGA	420
	TCTGAGGCAC TTCTAGTGT GTTAGATCAG GAGGAAGCTA TGGAAATTAA AGAACCCAT	480
55	CCAGAGGAGG GGTCTTCAGG GTCTGAGGTG GAAGAAATCC CTGAGACACC TTGTGAAAGT	540
	CAAGGAGAGG AACTCAAAGA AGAAAATATG GAGAGTGTTC CGTTGCACCT TTCTCTGACT	600
60	GAAACTCAGT CCCAAGGGTT GTGCTTCGG AGGCATCCAA AAAAAAAAAA AAA	653

(2) INFORMATION FOR SEQ ID NO: 23:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1486 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

10

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

15	GGCAGGCTGA CGACCTGCAA GCCACAGTGG CTGCCCTGTG CGTGCTGCGA GGTGGGGGAC	60
	CCTGGGCAGG AAGCTGGCTG AGCCCCAAGA CCGCGGGGC CATGGGCGGG GATCTGGTGC	120
	TTGGCCTGGG GGCTTTGAGA CGCCGAAAGC GCTTGCTGGA GCAGGAGAAG TCTCTRGCCG	180
20	GCTGGGCACT GGTGCTGGCA SGARCTGGCA TTGGACTCAT GGTGCTGCAT GCAGAGATGC	240
	TGTGGTTCCG GGGGTGCTCG GCTGTCAATG CCACTGGGCA CCTTTCAGAC ACACTTTGGC	300
	TGATCCCCAT CACATTCTTG ACCATCGGCT ATGGTGACGT GGTGCCGGGC ACCATGTGGG	360
25	GCAAGATCGT YTGCTGTGC ACTGGAGTCA TGGGTGTCTG CTGCACAGCC CTGCTGGTGG	420
	CCGTGGTGGC CCGGAAGCTG GAGTTTAACA AGGCAGAGAA GCACGTGCAC AACTTCATGA	480
30	TGGATATCCA GTATACCAAA GAGATGAAGG AGTCCGCTGC CCGAGTGCTA CAAGAAGCCT	540
	GGATGTTCTA CAAACATACT CGCAGGAAGG AGTCTCATGC TGCCCGCANG CATCAGCGCA	600
35	ANCTGCTGGC CGCCATCAAC GCGTTCGGCC AGGTGCGGCT GAAACACCGG AAGCTCCGGG	660
	AACAAGTGAA CTCCATGGTG GACATCTCCA AGATGCACAT GATCCTGTAT GACCTGCAGC	720
	AGAATCTGAG CAGCTCACAC CGGGCCCTGG AGAAACAGAT TGACACGCTG GCGGGGAAGC	780
40	TGGATGCCCT GACTGAGCTG CTTAGCACTG CCCTGGGGCC GAGGCAGCTT CCAGAACCCA	840
	GCCAGCAGTC CAAGTAGCTG GACCCACGAG GAGGAACCAG GCTACTTTCC CCAGTACTGA	900
45	GGTGGTGGAC ATCGTCTCTG CCACTCCTGA CCCAGCCCTG AACAAAGCAC CTCAAGTGCA	960
	AGGACCAAAG GGGGCCCTGG CTTGGAGTGG GTTGGCTTGC TGATGGCTGC TGGAGGGGAC	1020
	GCTGGCTAAA GTGGGKAGGC CTTGGCCAC CTGAGGCCCC AGGTGGGAAC ATGGTCACCC	1080
50	CCACTCTGCA TACCCTCATC AAAACACTC TCACTATGCT GCTATGGACG ACCTCCAGCT	1140
	CTCAGTTACA AGTGCAGGCG ACTGGAGGCA GGACTCCTGG GTCCCTGGGA AAGAGGGTAC	1200
55	TAGGGGCCCG GATCCAGGAT TCTGGGAGGC TTCAGTTACC GCTGGCCGAG CTGAAGAACT	1260
	GGGTATGAGG CTGGGGGGG GCTGGAGGTG GCGCCCCCTG GTGGGACAAC AAAGAGGACA	1320
	CCATTTTTC AGAGCTGCAG AGAGCACCTG GTGGGGAGGA AGAAGTGTA CTCACCAGCC	1380
60	TCTGCTCTTA TCTTTGTAAT AAATGTTAAA GCCAGAAAAA AATAAAAAAA AAAAAAAAAA	1440

AACTCGAGGG GGGCCCRKAC CCAATCWCCC TATAGTAKAC GTANNN

1486

5

(2) INFORMATION FOR SEQ ID NO: 24:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2323 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

CTTCGCCGTT TCTCTGCCA GGGAGGTCC CGGCTTCCCG TGGAGGCTCC GGACCAAGCC	60
CCTTCAGCTT CTCCCTCCCG ATCGATGTGC TGCCGCCGCC GCGGCCGCCG TCCCGCGTCC	120
TTCCGTCTCT GCTCCCGGA CCCGGCTCCG CGCAGCCAGC CAGCATGTGC GGGATCAAGA	180
AGCAAAAGAC GGAGAACCAG CAGAAATCCA CCAATGTAGT CTATCAGGCC CACCATGTGA	240
GCAGGAATAA GAGAGGGCAA GTGGTGGAA CAAGGGGTGG GTTCGAGGA TGTACCGTGT	300
GGCTAACAGG TCTCTCTGGT GCTGGGAAA ACAACGATAA GTTTTGCCCT GGAGGAGTAC	360
TTGTCTCCCA TGCCATCCCT GTTAATTCCT GGATGGGGAC AATGTCCGTC ATGGCCTTAA	420
CAGATCCCC CAGATGGCTT CATGGCCCC AAAGCATGGA AGGTCTGAC AGATTATTAC	480
AGGTCCCTGC AGAAGAACTA AGCCTTTGGT CCAGAGTTTC TTTCTGAAGT GCTCTTTGAT	540
TACCTTTTCT ATTTTATGA TTAGATGCTT TGTATTAAAT TGCTTCTCAA TGATGCATTT	600
TAATCTTTTA TAATGAAGTA AAAGTTGTGT CTATAATTAA AAAATATAT ATATATATAC	660
ACACACACAT ATACATACAA AGTCAAACTG AAGACCAAAT CTTAGCAGGT AAAAGCAATA	720
TTCTTATACA TTTCATAATA AAATTAGCTC TATGTATTTT CTACTGCACC TGAGCAGGCA	780
GGTCCAGAT TTCTTAAGGC TTGTTTGAC CATGTGTCTA GTTACTTGCT GAAAAGTGAA	840
TATATTTTCC AGCATGTCTT GACAACCTGT ACTCTTCCAA TGTCATTTAT CAGTTGTAAA	900
ATATATCAGA TGTGTCTCT TCTGTACAAT TGACAAAAA AAAAATTTTT TTTTCTCACT	960
CTAAAGAGG TGTGGCTCAC ATCAAGATTC TTCTGATAT TTTACCTCAT GCTGTACAAA	1020
GCCTTAATGT TGTAAATATA TCTTACGTGT TGAAGACCTG ACTGGAGAAA CAAATGTGC	1080
AATAACGTGA ATTTTATCTT AGAGATCTGT GCAGCCTATT TCTGTCACAA AAGTTATATT	1140
GTCTAATAAG AGAAGTCTTA ATGGCTCTG TGAATAATGT AACTCCAGTT ACACGGTGAC	1200
TTTTAATAGC ATACAGTGAT TTGATGAAAG GACGTCAAAC AATGTGGCGA TGTGTTGGAA	1260
AGTTATCTTT CCCGCTCTTT GCTGTGGTCA TTGTGTCTTG CAGAAAGGAT GGCCCTGATG	1320

CAGCAGCAGC GCCAGCTGTA ATAAAAAATA ATTCACTA TCAGACTAGC AAGGCACTAG 1380
 AACTGGAAAA GACCACAGAA AACAAAGAAT CCAACCCCTT CATCTTACAG GTGAACAAAC 1440
 5 TGTGATGATG CACATGTATG TGTMTTGTA GCTGTGAGCA CCGTAACAAA ATGTAAATTT 1500
 GCCATTATTA GGAAGTGCTG GTGGCAGTGA AGAAGCACCC AGGCCACTTG ACTCCCAGTC 1560
 10 TGGTGCCCTG TCTACACCAG ACAACACAGG AGCTGGGTCA GATTCCCTC AGCTGCTTAA 1620
 CAAAGTTCTT CGAACAGAAA GTGCTTACAA AGCTGCCCTC TCGGATACTG AAAGGTCGAG 1680
 TTTTCTGAAC TGCACTGATT TTATTGCAGT TGAAAAAAA AAAAGCTAT TCCAAAGATT 1740
 15 TCAAGCTGTT CTGAGACATC TTCTGATGGC TTTACTTCCT GAGAGGCAAT GTTTTACTT 1800
 TATGCATAAT TCATTGTTGC CAAGGAATAA AGTGAAGAAA CAGCACCTTT TAATATATAG 1860
 GTCTCTCTGG AAGAGACCTA AATTAGAAAG AGAAAACGTG GACAATTTTC ATATTCTCAT 1920
 20 TCTTAAAAAA CACTAATCTT AACTAACAAA AGTCTTTTG AGAATAAGTT ACACACAATG 1980
 GCCACAGCAG TTTGTCTTAA ATAGTATAGT GCCTATACTC ATGTAATCGG TTACTIONA 2040
 25 CTGCCCTTAA AAAAAAAAC CAGCATATTT ATTGAAAACA TGAGACAGGA TTATAGTGCC 2100
 TTAACCGATA TATTTTGTA CTTAAAAAT ACATTTAAAA CTGCTCTTCT GCTCTAGTAC 2160
 CATGCTTAGT GCAATGATT ATTTCTATGT ACAACTGATG CTGTCTCTTA TTTAATAAA 2220
 30 TTTATCAGAG TGAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA 2280
 AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAA 2323

35

(2) INFORMATION FOR SEQ ID NO: 25:

40

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 683 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

GGCACGAGCC TGTGTGGTCA TGTTCCTCGT GGTGCAGTAC CTGACATGAG CCAGCCACGC 60
 50 TCAGTGGCTG AACAGCATTC CCACAGCCTG CAAGTGTGTG TGTGTGTGAA AGAGAGAGGG 120
 GGGCCAGAG CCGCCTTTTG AAATGTTTGC CTGTCTGAAC TGTGAAGACA CTTGGGAGTG 180
 55 ATTGIGGCT AATTCCAAC CTGCTCTGTT TTCTGTGACA TCTTGGAGGG GAGCTAGTGC 240
 CACACCATGC GCGGTGCTTA GAAATGAAAA AGTCCCGGT CTGTCTCTCT CACTCTCGCT 300
 CTCATGGGGG AGGGAAGAA TGGCTTTGGT GGCTTTGTTT ACACAGCTGA TGGTGTCTGG 360
 60 GAAGGTGTCC ACAGTGAGCC TGTGTGAGG ACTGTCCACA CGGTTACAC TTGTACCAT 420

	GGCTGCCTTT TACGGGATGG GAGCCTTCTC CGGATCTTTT GTTCTTCTGC ACCTCTTGTA	1140
	GCTACTGCCG GTGCAAGGTT GTAGATGTTA TTCCCCAGGA GCCTGGGCTK GGGGGCTGAG	1200
5	CTGGGCTGAA TGCAAAAGCA TGCAACCAGA AGGCGGGCAA GGGGAGGAAA AGCAGGCCCTG	1260
	GCCTCATTGG TCCCTGGAG ATGTCTGTAG CAGTCAGCTC CAGCTTGGGC CTGGGGAAGC	1320
10	AGCCTGACCA AGGCGCTCAG GTGTGCCTGT TACAAGAAGA ACCTGCAGAA GGATAATTG	1380
	CACATGGAGC TGTGATAACA CTAATGTTGA TTTTTTTTTT TTTTACAAGT CATCAGRGAT	1440
	GTITGCAAAG TGAGTTTTAT TTTTGTGTA TTCTTTATC TTTACTTAA GGTGAATGTG	1500
15	TATTCTCTG GGAGGAATAG GAAGAAAACA GGAATGTTAA TAATGTCGAA CAGAAAACCT	1560
	CCTCCCTTAT TAATATATAA TCTCATGTA TTTATGCCNT AATGTAAGCT GACTTTTAAA	1620
20	AAGCTTTCTT TTGTGTCATG CCTGTGCAG GCATCTGTAT TGTACATGCA TGCCTTTCGT	1680
	CCTGTTTTCC TGTATAAAGT TAGTGAACAA AGAAATATTT TTGCCCTAGT TCATGTTGCC	1740
	AAGCAATGCA TATTTTTTAA ATTTGTCATA TATGGAAAGA GCATGTTTGT TACATGTAAA	1800
25	AGCTTTACTG ATATACAGAT AACTAATGT TTGAAGATGC TGTCTTTGC AAGGTACAG	1860
	TTTTCAAATG TTGTTACCAG TGAAACACCC TTGTGGTTTA AACTTGCTAC AATGTATTTA	1920
30	TTATTCATTT CCTCCCATGT AACTAAGAAT CATGGCTATA TTTATATCA ACGTTATATT	1980
	GAAAGTGAAG GGAAATGATT AATACAAGGT TTTGTAACAA AAAAAANAA ANNAAA	2036

35

(2) INFORMATION FOR SEQ ID NO: 27:

40

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 717 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

	GGCAAGAGAT AACATAGGCA CAATAACT GTATGTCTAC TTCTAGGATT ATAAGGAATT	60
	AACATGAGA TGACATTTCC ATTTGAGAAG AAAATAGTTG CTTTCAGTGC CTTTATTG	120
50	ATTCTGGAG AGAGCAGACT CGCACCAACA TTCAACCCCA GCGCTGATAT GACAGTAATC	180
	CTCAGAGGCA GAGCCAGCA CAAACAGCA ATGCTAGAAA GTTACAATTG GAAAGTTTCC	240
55	TGCCAGCTTC GGAATGACA CTGCAAAGCT GATGCCAGAA ACTGCCAGAG TAATCTCTCT	300
	CATTACTGCT CTACCCACCC ACTTTCAGCT CCCCAAATTA ACTAGTGCAG TTGACTAATC	360
	CTCTTACCT TTATCATTTA GGTGAGGCAT TGCACAAAA CTCTCGACTT TGCCATATAA	420
60	GGGCTGTGGT TCTCTGTGGT CCTGGATAAG AGGCATCACC ATTATCTGGA AACATGCAGT	480

AAATGCAGAT TCTTCATCTT CTCCCAGAC CTCTGAGTT AGAAATTCAC AAGTTCTCCA 540
GGTGATCTCA TACATGCTAA AGTTTGAGAA CCATTGAGTA AAGTTAATGC ATTAAGAAGA 600
GATTAGATAG GGATGGTGGC GTATCTTCTT ACAGTTTCCC TGTTAACAAG AAAGTCAGAG 660
GTCAGTTGAT CAGACATTAG ATTATTTATT GCTAAACTA AAAAAAATTA AAAAAA 717

10

(2) INFORMATION FOR SEQ ID NO: 28:

15

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 495 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

GAATTCGGCA CGAGCAGCAT CCTAATTITA GTTTGGAGAT GCATTCTAAA GGATCTTCTC 60
TATTGCTTTT TCTCCACAA TTAATCTTGA TTCTGCCTGT CTGTGCACAT TTGCATGAGG 120
AACTGAAC TGTTTTCAT AGGTAAATGA GAGACTGAGT TTTTTCATTT CTGAAGAGAA 180
AGGGCATT TG CTCTACAAG CTGAAAGGCA CCCCTGGGTG GCTGGGGCCC TCGTGGGAGT 240
TTCTGGGGGA TTGACCCCTTA CAACATGCAG TGGCCCTACA GAAAAACCTG CAACTAAAAA 300
TTATTTTTTA AAAAGGCTCC TCCAGGAAAT GCATATAAGG GCTAATCACC CAGTATTTTG 360
ARGCTTCGAA GARGTAATAR AMCCCTGGAG AGAGAAACTG AGACATGTAA GAGGGTGGGA 420
ATGACTCAGT GGTGGCACAC TATGGAGTCC TGCCCAACAG TAGCACACAT CAACCCACTA 480
CACAGAAATC CTAGG 495

40

(2) INFORMATION FOR SEQ ID NO: 29:

45

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 556 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

AGCTTAAAGT CATGATTCAT TAGGGGAATG CAAGGCAAAA CCATGATGAG AATGCCCTA 60
GACACCTCTT AGAAGAGCTG CTAGAAAGGC AGACAGCACC AAGCGCTTAA ATGAGATGGG 120
GGCACTGGTG CTTCTTCTGT GCCTACTGGT AGGGGTGCAG CAGAGTGGTT CAGTCTGGGA 180
CAGTTAGCTG GACATCAGT GGACCAACA CACGCATTTT CTGGGTACT TACCAAGGAG 240

60

5 AATAGAAAGC AGGCAGATCT TTACAGCAGC TCTTACCTGW TTGCAAAACA ATGGAAATGC 300
CCACATGTCC ACAAACAAGT KTGTGGTCTG CCTGTGCCAT GAAGCACAGT GTGGCTGAGC 360
GTCAAGAGTC CCCACACTCA AAGGAGGCAG CAGATACAGG GCTGCACACT GTGTGATTCC 420
ACACATGTGA CATTCTGGAC ACGGACATGC TGGATGGCAA AACGAGCATC GGGCTGAGAG 480
10 GACTGCTGAG AAGGGGAACG GGGCTGCTGG GATGTGGGTT GATTGTAGCA GTAGCTCATG 540
GAGATGTGAC CTCAAA 556

15

(2) INFORMATION FOR SEQ ID NO: 30:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 434 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

CTAAATGGTG ACTGTGGCTT TGTGAGACA GGCCCAAAAT GGTAGGTGTG AACACAACAT 60
GCACAGAATG AGGAGACATG CAGAGTGCTG AAATACTGTC CTGGACAGAT GTGTTACATG 120
30 ACTTCTTTT CAGCTTATTT CTGTGGCCTG CCTTTGAAGA TAGAGCTTTG TTGATATTTA 180
CATTAAACCA AATTGTATAA YATGTTCCTA TTCTGACATG TTATTTAGCA AARGAAAAAR 240
35 GAGTAATCTT ACATCAGCAT CTTTAGTGCA TGCTAAAAGA TTAAAAATGT CTTTGGGGA 300
ACATGTTTGG TATACATAAA TGTTTAGATA GAAATATTTA TAGAATNCTC TATGTGAGTA 360
TINATCTCCC TATGTATATT TATATCTAGA TGTGTCAATC TTTGTATTGA TATGAAATGC 420
40 TATGAATAGT GAGA 434

45

(2) INFORMATION FOR SEQ ID NO: 31:

50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 715 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

CCACGCGTCC GATCTCAGC CTCCGACACT ATTGCGAGCC ATACACAACC TGGTGTGAGG 60
AAACGTACTC CCAAATAAG CCAAGATGC AAAGTTTGGT TCAATGGGGG TTAGACAGCT 120
60 ATGACTATCT CCAAATGCA CTCCTGGAT TTTTCCGAG ACTTGGTGTT ATGGTTTTC 180

CTGGCCTTAT TGGACTCCTT TTGGCTAGAG GTTCAAAAAT AAAGAAGCTA GTGTATCCGC 240
CTGGTTTCAT GGGATTAGCT GOCTCCTCT ATTATCCACA ACAAGCCATC GTGTTTGCCC 300
AGGTCAGTGG GGAGAGATTA TATGACTGGG GTTTACGAGG ATATATAGTC ATAGAAGATT 360
TGTGGAAGGA GAACTTTCAA AAGCCAGGAA ATGTGAAGAA TTCACCTGGA ACTAAGTAGA 420
AAACTCCATG CTCTGCCATC TTAATCAGTT ATAGGTAAAC ATTGGAATC CATAGAATAA 480
ATCAGTATTT CTACAGAAAA ATGGCATAGA AGTCAGTATT GAATGTATTA AATTGGCTTT 540
CTTCTTCAGG AAAAAGTAGA CCAGACCTCT GTTATCTTCT GTGAAATCAT CCTACAAGCA 600
AACTAACCTG GAATCCCTTC ACCTAGAGAT AATGTACAAG CCTTAGAACT CCTCATTTCTC 660
ATGTTGCTAT TTATGTACCT AATTAAAACC CAAGTTAAAA AAAAAAAAAA AAAAA 715

20

(2) INFORMATION FOR SEQ ID NO: 32:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 486 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

GAGCCAGTGC CGGCGAAAGG GGACCTCCT CTACTTCCTG CCACAGACCC TGTCCCCACA 60
CACTTCCTGC CCCTGCTCTG CTGGGAGGCC ACTTCCTCCC CCAGTGCTGG ATTCCACCCC 120
CAGCTCACCC TCAAACATGG CCCCCTCTCT CCTCTGCTT GCCCCTCTCT GCTCCCTGGA 180
GGCTGTTCTG TCCTCCCCTC TTGAAAAGCA ATGCCAGCTT CCTGGGATCT TCTGCCAACT 240
CCAGCTACCA TGCCCTTTGC TCCTGTCAGC TCAGCTCCTC AAGGGAATTG TCTAMCCTCG 300
GTGTCTGCT TCCCTCCCTC AACCTCCTCA CCCTGCTCCA AGCTGGCATC TGCCCCCTCA 360
CTGCACAGAA CGGVTCCCCC ACCACCTGCC TTTACAGGA GGAAGCAGCA ACATGGAAGA 420
ANCGAACTAT AGGGGCTACA ANGATGCTCA GCTCTGATCC CGAAGGCAAA AAGNATCTTT 480
GGGCAC 486

50

55

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 725 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

5 GTTCTCTGG TAATAATTAG GTTATTCCCA GAAGCACAGT GTCATTCTTT AAATAAAAGC 60
 TTCTCTGTTT AAAGCTTTTC AAAGGAGCAG ACCACCTTGA AGATTCCCC TAGGGTTGAT 120
 ATGTGTCTAA TTCAATTTAT AAAAATTATT CTGTCTTCA TTTTAAAGCT TTGGCTATAT 180
 10 AGTCAGAAAT GTCCTAAATA ACAAACTATT TTGTATTTAA TTTAGGGAAG ACTAAAGGGA 240
 AGAAAAATGA AACTCAGTC TTTATGTAAG CTCCAAGGAT ATTAGGGCTT AAAGGGCTTT 300
 TCTAGTTTTA TGAGAATTG TACTACTGAT TTTTATATAT TCCTGTTTTT GATGAACAGA 360
 15 TCTCTGGGA AATTGTTGAG TTACAATGGC ATTTCACTGT GATCCCTCTC AAGCTCAGAT 420
 CAGTCTATA ACCCAATGAC AACCCTCTC TTGGTTTAC TGCTCTGTA AATGTCAGCT 480
 20 CAAGTTTCCC AGAAGTCGTG TGTTTATGAT GAGTCAGAGT GCTTTTCTC GGTGGGACAG 540
 TTGCTGGCCC TCTTAATTTT GGTGTATGTG CTCCAAGTA TCTAAACCTC CAGTCTGATC 600
 25 TGTATATGCT ATCCTAACTG TTAATTGTAT TATTGATTAT GTTGATTATC TTGCTTGAAG 660
 GTTCATACCT TTCAATTGA TAGAAATAAA GTTTTTTCT GCTTATAAAA AAAAAAAAAA 720
 AAAAA 725

30

(2) INFORMATION FOR SEQ ID NO: 34:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 437 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 40 (D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

CACACAGCAT GCTGCCCTCA GACGTGTCCA TCCTGTACCA CATGAAAACG CTGCTGCTCC 60
 45 TGCAAGATAC TGAGAGATTG AAGCATGCTC TGGAAATGTT CCCAGAACAT TGCACGATGC 120
 CTCTGCTTT TATTGGCTCT TGTGAAATC AAATTGGAAG ATCTTCAGTC CCAGCTGCAC 180
 50 CCAACGTGGA AAAGTATTC AGGTCCATCC CCAAGGAACC AACACCGATG ACATGGACTC 240
 AGGAATCTTA TAACCTACGT GGAATCTTC CATCCGTACA TTGTGTGCA CATGCCACTC 300
 ATCACCTGGC GTGCCAGAT CTOGCARGG CAACACCTG TGATAATTC AGGTGATTCT 360
 55 CTACATCTGC AGCTTGAGGT TAGCCTCATA TCACATTACA TTCTCACTAN AAACNAAAAA 420
 AAAAAAAAAA AACTCNA 437

60

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 943 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

GGCAGGAGCT GGAACAGAGA CTAAATCCCA CGAAACTGAC ATTGTTAAAC AACTAAAAAC 60
AGAAGTACTT ACCTCTTGAA GATTTAATAT ATAATGGTTG ACATGATACA TGTACATGAT 120
15 GAATGACCAG ATGCTTATGG TCTACATTTT CCTTTATCCT GTTAGTATTA CCTTCCTTAA 180
TCTTTGTTCA TTAACATGCT AATTCCTCTT CAGTGTATTAT TTTCTAGTGA CAGAATGCTA 240
20 ACATTTCTTA CACCCCTGGCA GAAGGGAGAG AAATGTGTTT TGGGGTGGGT AACTAAATTT 300
TTGAGTGAAG TATCATAAGA TGANAATGGA AANAAGGAGA CACAAANAGT TATNACAAAA 360
AAACAATGGT TTTTITAGCC ATTTGACTGG CTCITTTAAAT AGTCTACAAG ACATTCACGT 420
25 TTAACATCAC TTTTAGTGAA ATAAAATGTG CCATACTAGT ATGTGCTTCA AAAGGGCAAA 480
TGTCCTTTAG TGCCCTAAGG CTAAATTTTG GTCATTTGAC ATCAGAGATG TTGTAAGTAT 540
30 TGCACCTAAT ACGCACCTAT TTNTCAATAG TGTTATTTT TGGNTAGCAT TTTTITTACC 600
ACTATNTGTG TGATAGCTTT TTGTTCTNIN AGGTTGNAAN ATGACAGTGC TNATNTCAA 660
CAGATTACCC ATNTGCAGAA CTAAGGGAAG CNATTTATGT ATGAAAGNAA TTNTTGAATT 720
35 NGTCATTMTT AACCNVTGNA TTAAAGCTTA GACTAAATAG TAATATATNG TGGGNAGGAT 780
TTTGGTTTIG TGATATTTNT GTGNATTAAG GNATAGATGT TAACCNITAT TTTGTAGNAA 840
40 AGTGANTTGT ATGTGGTTAA TTATAAATAA AACTGGTACC AGGNAAAAAA AAAAAAAAN 900
NAAAAAAAA AAAAAAAAA AAAAAAAAA AAAAAAAAA AAA 943

45

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 604 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

GGCAGAGAA ATCTTCATGC TGTAGTCACT CCAGACCATG GAGTGGCTTT CCAGCTGAAT 60
60 GAATCCTATG TCTCGCGTGC AGGTGGTTGG TTTTCAATGT TCTTGCTAAT TTTTTTCTA 120

TTGGATCTTG GGAGTTTCTT TGTTTGCTC CTGTGTTGTC CCAGCTTTAA TAAAACCAGG 180
 CGCAAACAAA AACCATAGCA TTCTGAACAA TAGGGGGCCC ACATTGGACC CAGTATGTCA 240
 5 CTTTAATGGA CTTCAAGAAA AAATCTGAAT GGGAAAAATG AACTAGGAA TGTATACTCC 300
 ACACATTTTA TGCCATATAA TGGTGTGTTT TCCTAATTTT GTTCTTGTG GCGAAATGTG 360
 10 GCTTCAAAT TAAAATGACC TTTTCTTCTT TGAAACTTTT TGTTTTGACT TGTATAATTA 420
 AGGGTTTGGA AAGATTCATA ATTCTGAGAG AGGTTTGCAA CCAGGAGATA CAAAGAAGTC 480
 TCAGTAGTAA TCTGTTCAT GTGCTTTTAC AGCCAGCTAC ATTTAAGGAT GTATTAGTTA 540
 15 CAGAAATTAT ATGTCTGTGT ATGTGTCTCT ACTCAATAAA GTACATGCCT CCACAAAAAA 600
 AAAA 604

20

(2) INFORMATION FOR SEQ ID NO: 37:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 349 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

GTGAGTGCCC GGGAGCCCCG AGGCCCTGOC CCTAAGAAGG ATATCTYTRA CCGCTCCCTT 60
 GTCCACACCC TAACCCCCCA GCTGCTCAGG CAGTGGGCAC ATGGCAGGGG CCTCACTGGG 120
 35 GGCACATAGA GCATTTGGGG GACTGCGAGT GCTCACCTTT GACTTCCTGC AGGTGGGGG 180
 AAAACCAGAT CATGATGACC AAAGTYTACA TATTCTTGAT CTTTCATGGT CTGATCCTGC 240
 40 CCTCCCTGGG TCTCACCAGG TATATGCCAC CACYTTCTGY TCTAAATTC GAATAAGAGT 300
 CACATCAGGA GAGCACTGTC CCCAGGANAA TGCAACGGG TTGGCAGCA 349

45

(2) INFORMATION FOR SEQ ID NO: 38:

- 50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 672 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

GTAGTCGTTG CGTTGCCGG GATGGCGAAG ATCTGCCCGT TTGAAGTGT AAAACGCACC 60
 60 TCGGTACCGG TGCTTGTTGG TTTGGTGATT GTWATCGTTG CTACAGAGCT GATGGTGCCA 120

	GGAAACGGCAG CAGCGGTCAC AGGCAAGTAA ATAGTAATGC CGGAGCAAGT TTCCTCCGGC	180
	TTTATCATGT CACCCACTGT GGTATATGCG TTGTGGTCTG CCAACTTTGC CGTGAACAAT	240
5	TTCAGCAATA ATCAGATGGC GGCTGGCGCA ATATTCAAGA TAAOGCCTGG CAGTGGTGCG	300
	GCTGATGGTT CAGTGCTGC GSCACCGTTT YTGCCGTATG TTGCACACCA GGNCTTTTAA	360
10	ACAGTTTTCG SACCOCGTTT AGCGTCAAGG GTTCAATGCC GGTCCGTAGC TCGTCCTTAG	420
	GTTCACCGCG AGCATAAGCA TTAAACATCT CATCAATTG CTTCTGGCTG GCGCTATCAA	480
	TACTTTCCAG CATATGTTTA CGCTGGCGGA AACGGGTTAG CGTTTGCCCC ARCMGWTGAT	540
15	AGGCAATGGG CTTAATGAGA TAATCAAATA CACCACAAG TACGGCTTCA GACACCGTTT	600
	CCATATCGCT GGCTGCAGTG GTAAACACCA CGTCCCGGG ATAATGCGCC TGCACCAATT	660
20	CATGCAGTAA AT	672
25	(2) INFORMATION FOR SEQ ID NO: 39:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 1908 base pairs	
	(B) TYPE: nucleic acid	
30	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:	
35	AGAGTTGATA TTTTGTAGAA CAGTAATTTT ACTTTTAAGG AAATTGGCTA GCTCTTTGAC	60
	TNNAGAGCTG TAGGAAGCTC AACATTTCTT TGTAGAGAAC GTTGCTTTTT TTGGATTGTA	120
	CAGGTATAAA AACATTGCTT TTGTGAATT GTATAGGTGT AAAAAGGGAA TAACTGTATG	180
40	CAGGTTTGAA AAGGAAATGT GCTTTAGGCA TGAGTCATAA GATGCCATTG TACTGTAGG	240
	CATTTTATTT TCCTTTAGAA ATGGACATCA GCTCTTCTCT TCTGACTGGT AACACATAGC	300
45	CCCAAAGCAT GAGATTATTT TTCATTGGGT TTTTATTGTT GTTTAGTTTT GGTITGTTAC	360
	GCCAGCCCGAG TCTGTCTGCG GAACACTGAC TCTGCTCTCT AATGAGAACA AAGTTAGAAA	420
	TCTGCCGATA ACCTAAAATA ATTTAGAAAT GAATTAAAAA TGTGAAATCG GGTAAAGTG	480
50	ATGATGATAA AATAGCATGC AAGAAACAAG CTCCTTCCAT CAGACTTGGC TACTGTTTTT	540
	TTCTGGTACG ATTTGGTTTG GAAGAGCCTC TTGTTTCCTT CTCTTTGGGG TATGTCTTCG	600
55	TTTCTTAATA TGTTTGTAAC ATTATTGAGA TATAATTAC ATACCTTACA ATTCACTTAT	660
	TTTAAGGGTA CAATTTAGTG GTTTTAGTG TATTACAAA GTTGTAAC CGTGACCACA	720
	GTCAATTTTA GAACATTTTG TTACCCCAA AAGAAACCTT GTACCCTTGA GCAGTCACCT	780
60	CTCATTTTCT CCCAGTCCCC ACCCATCCC CGAGCCCKG GAACCACTAA TCTATTCTC	840

	TCTCTGTAGA TTGCTTATT CTGGTCATTT CATATAAATG GAATTCCTACA ATATTCGGTC	900
5	TTTTGGGACT GGCTTCCCAA ATATGATTTT CTATATGGAG TGAGAAAATT CTTCTCATCT	960
	TGAGAACTCT TATTGCTGTG AAAGGGAGTG GTTGGTAAAA TCAATAGATT TCAGGCAAGA	1020
	GGGCCAGATA CCTAACAGGT TTTCTCCGT GAATCTTATG CTGAGTAGTT TTTCTCATA	1080
10	ACCAAGCAIT TATGATATAT TACTACTTAT AATACTGTGG CTAGTCTCTA GAATGGATGT	1140
	TGAAATCTTT GCCTCCTCAG TCGGGAAGAG TCCTGCTAAA AATCAGGCTA AAAATCAGGC	1200
15	CAAAAATCAG GCCAAATGAC TTGGCAAATA ATTGACAAAG TGGTTTTTAC GTGTGTCTAT	1260
	CTTTGCTAGC AGCTTGTATA CCTCAGGCCA GGTGAGCTCC CCAAATTTCT TTTTTCATTT	1320
	ACTCCAGTGA GTTTCTGCTG TCTTTTCAA GATGTACCA TAGGACTTAA AGGTGATTTG	1380
20	GATGCGTTGT AACACTGCTA AATATGCTAA GTACAGAAIT TTATCTACAG TACTGTGAGA	1440
	CAGTCAATTA TTGCCTAGGG TACTTCAAAA ATATGATGTG AGCTAGTTAA GCCTTTGCTT	1500
25	GACTGATTC AGTGATATTC AGAAGTGTGT ACCAATCAAG GCTCTTTAAA ATACGGAACG	1560
	ACTCACTTAA TAACCAGGA ACCAGCCAAA TACTGTGCAG CCGCAGAATA TGCATATCAA	1620
	TGAGTTGGAG GTGATTATTC TCTGTAACTC CCTAATGATT GTTTTCTAAG CATTGTGGCT	1680
30	TCTCAGTGGC TTGACAGCAT CTTCTGGTT GTATGTGGCC TGTTTACATG ATGTATTGAA	1740
	TAATGTGTGT TGTGTGAGC ATCAATGCCT GTAACACCAA ACTAAACACG TGTTTTGGG	1800
35	ATATGTTTCC AATCTTTAAA TGACCTTGCC CTGTCCAATA AATAAATGAT TGTCTCACC	1860
	TGTTAAAAA AAAAAAATT AAAAAACTG GNGGGGGGC CCGGTACN	1908

40

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

45

- (A) LENGTH: 458 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

	CCTCAAAAAA AAAAANGAAA GGAAAGAGGT CTCTACACAA GCGCGTGATT CTTCATGGCA	60
	AGGGATAACA TCAGAAATGT TTCATTTYCK GCTATTAGTT TCCATTCCTT TCCCCATCCA	120
55	GGCATAAAGA GAAACAAAAG ACAATGATGG TATTCTCTGT GTCCCTCAGCT TTGGCACTTT	180
	TGTTGATGTT GCTAAGGAGC AGTGACCTTG CTAAAAAGAC TGAATAATCC ACCCACTGAA	240
60	TAGCTAACCT GGGGAGGAAA TGAAAATTTT CTTTGTGGAT CTCCCCAAAT CCATTGTGT	300

	CACCAGGCCC TCCAGAACC TCCTCAGTTC CTTCACAGTG CAACCCCTGTG TACTTGGCCC	360
	GCAACCCAAT AGTATTGTGC CTCACCTTCAC CTTCATGGG CAACTGCCCT CCCTTCTGGA	420
5	CATAAACCT CATATTTTAA ATNAAGTTGA AATTTGAA	458
10	(2) INFORMATION FOR SEQ ID NO: 41:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 1153 base pairs	
	(B) TYPE: nucleic acid	
15	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:	
20	GGCAGAGC CTCGACCCA GGTGGTCTGG AGCCTGCCGG GAGAGTGGTG GCATCTGAGA	60
	GGCTGGTCTG GACTGTGGT TGGGGGAGGT GGGAGCTGTT TTAACCGTGT GCCCCCTCTC	120
25	CTGTGCCGGC GTGGGCATCC CCCGGGGCAG TGGAAACCCGG GCGCTCCTCC AGCTTCCGAG	180
	TCCAGCCAGC CTGGGCGCGG GCGCGCCCC GAGACACCCG AGGAGTCCGT TCCTCCCTGG	240
	TTACGTGGAC TGTGGAGCTG GTCTCTGTG GCTCAGCGCC GTGCGGAGGT TGAAGCGTAC	300
30	CTGCGGAGGT CGCACCAGG CGTGAGGAGG AGGAGGAAGG GCATGAGCCG AGCTTGAGGA	360
	ATCCGTGCTC CAAACTCTAC ACTCAAGGAT GCACTGCGCA ACTCTGGTGG CGATGGGCTG	420
35	GGCAGATGT CCTTGGAGTT CTACCAGAAG AAGAAGTCTC GCTGGCCATT CTCAGACGAG	480
	TGCATCCCAT GGAAGTGTG GACGGTCAAG GTGCATGTGG TAGCCCTGGC CACGGAGCAG	540
	GAGCGGCAGA TCTGCCGGGA GAAGTGGGT GAGAACTCT GCGAGAAGAT CATCAACATC	600
40	GTGGAGGTGA TGAATCGGCA TGAGTACTTG CCAAGATGC CCACACAGTC GGAGGTGGAT	660
	AACGTGTTTG ACACAGGCTT GCGGACGTG CAGCCCTACC TGTACAAGAT CTCCTTCCAG	720
45	ATCACTGATG CCTTGGGCAC CTCAGTCACC ACCACCATGC GCAGGCTCAT CAAAGACACC	780
	CTGCCCTCTG AGCGTGGCTG GATCTCTGGG AGCTCCTTGA TGGCTCCAG ACCTTGGCTT	840
	TTGGGAATTG CACTTTTGGG CCTTTGGGCT CTGGAACCTG CTCTGGGTCA TTGGTGAGAC	900
50	TTGGAAGGGG CAGCCCCCGC TGGCTTCTTG GTTTTGTGGT TGCCAGCTC AGGTCATCCT	960
	TTTAATCTTT GCTGACGTT CAGTCTGCC TCTACTGTCT CTCCATAGCC CTGGTGGGGT	1020
55	CCCCCTCTT TCTCCACTGT ACAGAAGAGC CACCACTGGG ATGGGGAATA AAGTTGAGAA	1080
	CATGAGTTTG GGCTGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	1140
	AAAAAAAAA AAA	1153
60		

(2) INFORMATION FOR SEQ ID NO: 42:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1983 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

GGCAAGAGAG GGGCCGAGCC GACAAGATGT TCTTGCTGCC TCTTCGGCT GCGGGGAG	60
15 TAGTGTCCG ACGTCTGGCC GTGAGACGTT TCGGAGCCG GAGTCTCTCC ACCGCAGACA	120
TGACGAAGG CCTGTGTTTA GGAATCTATT CCAAGAAAA AGAAGATGAT GTGCCACAGT	180
20 TCACAAGTC AGGAGAGAAT TTTGATAAAT TGTTAGCTGG AAAGCTGAGA GAGACTTTGA	240
ACATATCTGG ACCACCTCTG AAGGCAGGA AGACTCGAAC CTTTATGGT CTGCATCAGG	300
ACTTCCCCAG CGTGGTGCTA GTTGGCCTCG GCAAAAAGGC AGCTGGAATC GACGAACAGG	360
25 AAAACTGGCA TGAAGGCAAA GAAACATCA GAGCTGCTGT TGCAGCGGG TGCAGGCAGA	420
TTCAAGACCT GGAGCTCTCG TCTGTGGARG TGGATCCCTG TGGAGACGCT CAGGCTGCTG	480
CGAGGGAGC GGTGCTTGGT CTCTATGAAT ACGATGACCT AAAGCAAAAA AAGAAGATGG	540
30 CTGTGTCCG AAAGCTCTAT GGAAGTGGG ATCAGGAGGC CTGCCAGAAA GGAGTCTGT	600
TTGCTTCTGG GCAGAACTG GCACGCCAAT TGATGGAGAC GCCAGCCAAT GAGATGACGC	660
35 CAACCAGATT TGCGAAATT ATTGAGAAGA ATCTCAAAG TGCTAGTAGT AAAACCGAGG	720
TCCATATCAG ACCCAAGTCT TGGATTGAGG AACAGGCAAT GGGATCATT CTCACTGTGG	780
CCAAAGGATC TGACGAGCCC CCAGTCTTCT TGGAAATTCA CTACAAAGGC AGCCCCAATG	840
40 CAAACGAACC ACCCCTGGTG TTTGTTGGGA AAGGAATTAC CTTTGACAGT GGTGGTATCT	900
CCATCAAGGC TTCTGCAAT ATGGACCTCA TGAGGGCTGA CATGGGAGGA GCTGCAACTA	960
45 TATGCTCAGC CATCGTGTCT GCTGCAAGC TTAATTTGCC CATTAATATT ATAGGTCTGG	1020
CCCCCTTTG TGAAAATATG CCCAGCGCA AGGCCAACAA GCGGGGGAT GTTGTAGAG	1080
CCAAAAACGG GAAGACCATC CAGGTGATA AACTGATGC TGAGGGAGG CTCATACTGG	1140
50 CTGATGCGCT CTGTTAGCA CACACGTTA ACCCGAAGT CATCTCAAT GCCGCCACCT	1200
TAACAGGTGC CATGGATGTA GCTTTGGAT CAGGTGCCAC TGGGGTCTTT ACCAATTCAT	1260
55 CCTGGCTCTG GAACAACTC TTCGAGGCCA GCATTGAAAC AGGGGACCGT GTCTGGAGGA	1320
TGCCTCTCTT CGAACATTAT ACAAGACAGG TTGTAGATTG CCAGCTTGT GATGTTAACA	1380
60 ACATTGGAAA ATACAGATCT GCAGGAGCAT GTACAGCTGC AGCATTCCTG AAAGAATTGG	1440

	TAAGTCATCC TAAGTGGGCA CATTTAGACA TAGCAGGCGT GATGACCAAC AAAGATGAAG	1500
	TTCCCTATCT ACGGAAAGGC ATGACTGGGA GGCCCAACAG GACTCTCATT GAGTTCTTAC	1560
5	TTGGTTTCAG TCAAGACAAT GCTTAGTTCA GATACTCAAA AATGTCTTCA CTCTGTCTTA	1620
	AATGGACAG TTGAACCTAA AAGGTTTTTG AATAAATGA TGAAAATCTT TTAACGGAGA	1680
10	CAAAGGATGG TATTAAAAA TGTAGAACAC AATGAAATTT GTATGCCCTG ATTTTTTTTT	1740
	CATTTACAC AAAGATTTAT AAAGTAAAG TTAATATCTT ACTTGATAAG GATTTTTTAAG	1800
	ATACTCTATA AATGATTAAA ATTTTITAGAA CTTCCTAATC ACTTTTCAGA GTATATGTTT	1860
15	TTCAATTGAGA AGCAAAATG TAACTCAGAT TTGTGATGCT AGGAACATGA GCAAACTGAA	1920
	AATTACTATG CACTTGTGAG AAACAATAAA TGCAACTTGT TGTGCAAAAA AAAAAAAAAA	1980
20	AAA	1983

25 (2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1406 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

35	ATGATGATGA CTTTGAAGAC GATTTTATTC CTCTTCCTCC AGCTAAGCGC CTTGAGGTTA	60
	ATAGTTGGAA AAGACTCTAT AGATATTGAC ATTTCTTCAA GGAGAAGAGA AGATCAGTCT	120
	TTAAGGCTTA ATGCCTAAGC NCTTGGTCTT AACTTGACCT GGGATAACTA CTTTAAAGAA	180
40	ATAAAAAATT CCAGTCAATT ATTCTCAAC TGAAAGTTTA GTGGCAGCAC TTCTATTGTC	240
	CCTTCACTTA TCAGCATACT ATTGTAGAAA GTGTACAGCA TACTGACTCA ATTCCTAAGT	300
45	CTGATTTGTG CAAATTTTTA TCGTACTTTT TAAATAGCCT TCTTACGTGC AATTCTGAGT	360
	TAGAGGTAAA GCCCTGTTGT AAAATAAAGG CTCAAGCAA ATTGTACAGT GATAGCAACT	420
	TTCCACACAG GACGTTGAAA ACAGTAATGT GGCTACACAG TTTTITTTAAC TGTAAGAGCA	480
50	TCAGCTGGCT CTTTAATATA TGAATAACA ATAATTTAAA ACAAATCATA GTAGCAGCAT	540
	ATTAAGGGTT TCTAGTATGC TAATATCACC AGCAATGATC TTTGGCTTTT TGATTTATTT	600
55	GCTAGATGTT TCCCCTTGG AGTTTGTGCA GTTTCACACT GTTGTCTGGC CCAGGTGTAC	660
	TGTTTGTGGC CTTTGTAAAT ATCGCAAACC ATTGGTGGG AGTCAGATTG GTTTCTTAAA	720
	AAAAAAAAA AAAACGACAT ACGTGACAGC TCACTTTTCA GTTCATTATA TGTACCGAGG	780
60	GTAGCAGTGT GTGGGATGAG GTTCGATACA GNCGTATTTA TTGCTTGTCA TGTAATTAA	840

	AAACCTTGTA TTTAACTCTT TTCAATCCTT TTAGATAAAA TTGTTCTTTG CAAGAATGAT	900
5	TGGTGCTTAT TTTTCAAAA ATTTGCTGTG AACAACTGA TGACAACAAG CAACATTTAT	960
	CTAATGAAC ACAGCTATCT TAATTTGGTT CTCAAGTTT TCTGKTGCAC TTGTAAAATG	1020
	CTACAAGGAA TATTAAAAA ATCTATTCAC TTAACTTAT AATAGTTTAT GAAATAAAAA	1080
10	CATGAGTCAC AGCTTTTGTT CTGTGGTAAC CTATAAAAAA AGTTTGTTCTT TGAGATTCAA	1140
	TGTAAAGAAC TGAAAACAAT GTATATGTTG TAAATATTG TGTGTGTGA GAAATTTTGT	1200
15	TCATAAGAAA TTAAGAAGAC TTACCAGGAA GGTTTTAAAG TTAGAAATAT TCCATGCCAA	1260
	TAAATAGGA AATTATAAAT ATATAGTTTT AAGCTGCAT CAGTGGGAGT CTGGCTATG	1320
	TAGTTATGTA GTTATTATGN AACCACCAAG ATTTTGTGG CTATTACCG TAACCAAAGG	1380
20	GCCCGATTAA NTGGTTTGAA GNCTTG	1406

25 (2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 1391 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

35	GGGCTGAAG GCGGCRGCGC AGTCCCGAGC AGTGCTCGCT CCTGCTCGGG GCGCTGCGGC	60
	CCCGGGCGTC GCCATGACCA GTGAGCTGGA CATCTTCGTG GGAACACGA CCCTTATCGA	120
40	CGAGGACGTG TATCGCTCTT GGCTCGATGG TTAATCGGTG ACCGACGGG TGGCCCTGG	180
	GGTGGCTCG GGAATCCTGG AGCAGACTGG CGCCACGGCA GCGGTGCTGC AGAGCGACAC	240
	CATGGACCAT TACCGCACCT TCCATGCT CTGACGGCTG CTGCATGCGC CGCCCAAGCT	300
45	ACTGCACCAG CTCATCTTCC AGATTCCGCC CTCGCGGAG GCACTACTCA TCGAGAGGTA	360
	CTATGCCTTT GATGAGGCCT TTGTTGCGGA GGTGCTGGGC AAGAAGCTGT CCAAAGGCAC	420
50	CAAGAAAGAC CTGGATGACA TCAGACCAA AACAGGCATC ACCCTCAAGA GCTGCCGAG	480
	ACAGTTTGAC AACTTTAAAC GGTCTTCAA GGTGCTAGAG GAAATGCGG GCTCCCTGGT	540
	GGACAATATT CAGCAACACT TCCTCTCTC TGACCGGTTG GCCAGGACT ATGCAGCCAT	600
55	CGTCTTCTTT GCTAACAACC GCTTTGAGAC AGGGAAGAAA AACTGCAGT ATCTGAGCTT	660
	CGGTGACTTT GCCTTCTGG CTGAGTCAT GATCCAAAAC TGGACCCCTG GACCCGTCGA	720
60	CTCAGATG GATGACATGG ACATGGACTT AGACAGGAAT TTCTCCAGGA CTTGAAGGAG	780

	CTCAAGGTGC TAGTGGCTGA CAAGGACCTT CTGGACCTGC ACAAGAGCCT GGTGTGCACT	840
	GCTCTCCGGG AAAGCTGGGC GTCTTCTCTG AGATGGAAGC CAACTTCAAG AACCTGTCCC	900
5	GGGGGCTGGT GAACGTGCCG CCAAGCTGAC CCACAATAAA GATGTCAGAG ACCTGTTTGT	960
	GGACCTCGTG GAGAAGTTTG TGGAAACCCTG CCGCTCCGAC CACTGGCCAC TCAGCGACGT	1020
10	GGGTTCTTTC CTGAATCAGT ATTCAGGTC TGTCCAATCC CTCGATGGCT TCCGACACCA	1080
	GGCCCTCTGG GACCGCTACA TGGGCACCT CCGCGGCTGC CTCCTGGCC TGTATCATGA	1140
	CTGAGGTGCC TCCCAACGTC CGCCACGCT GACAATAAAG TTGCTCTGAG TTTGGAGACT	1200
15	GGTCTCGCT CGGGGAGCA AGTGGGGGGC GTGCAGATGT GCCTGTGTCT GTCTCTGAGC	1260
	ACCTGGTGTC CCGTACAAG GATGGATGTG TNCNGTGGCT CCTTGGGAAC TGAGACATAT	1320
20	CTCAGGGAAT GGTGTCTGTG CTCAGCCCAT CCACCAGAAG AGTCTGCTCA CAAAAAAAAA	1380
	AAAAAAAAA A	1391
25	(2) INFORMATION FOR SEQ ID NO: 45:	
	(i) SEQUENCE CHARACTERISTICS:	
30	(A) LENGTH: 1569 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
35	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:	
	GGCACCAGTG GAGATGGCTG CGGCCGTGGC GGGGATGCTG CGAGGGGGTC TCCTGCCCCA	60
	GGCGGGCCGG CTGCCTACCC TCCAGACTGT CCGCTATGGC TCCAAGGCTG TTACCCGCCA	120
40	CCGTGCTGTG ATGCACTTTC AGCGGCAGAA GCTGATGGCT GTGACTGAAT ATATCCCCCC	180
	GAAACCAGCC ATCCACCCAT CATGCCCTGCC ATCTCCTCCC AGCCCCCCAC AGGAGGAGAT	240
45	AGGCCTCATC AGGCTTCTCC GCGGGAGAT AGCAGCAGTT TTCCAGGACA ACCGAATGAT	300
	AGCCGTCTGC CAGAAATGCG CTCTGAGTGC AGAGGACAAG CTTCTTATTG CGACACCAGC	360
	TGCGGAAACA CAAGATCCTG ATGAAGTCT TCCCAACCA GGTCTGAAA GCCCTTCTCTG	420
50	GAGGATTCCA AGTACCAAAA TCTGCTGCCC CTMTTGTGGG GGCACAACAT GCTGCTGGTC	480
	AGTGAAGAGC CCAAGGTCAA GGAGATGGTA CGGATCTTAA GGGACTGTGC CATTCCTGCC	540
55	GCTGCTAGGT GGCTGCATTG ATGACACCAT CCTCAGCAGG CAGGGCTTAA TCAACTACTC	600
	CAAGCTCCCC AGCCTGCCCC TGGTGAGGG GGAGCTTGTA GGAGGCCTCA CCTGCCTCAC	660
	AGCCAGACC CACTCCCTGC TCCAGCACCA GCGCTCCAG CTGACCACCC TGTGAGACCA	720
60	GTACATCAGA GAGCAACGG AGRAAGGATT CTGTCATGTC GGCCAATGGG AAGCCAGATC	780

	CTGACACTGT TCCGACTCG TAGCCAGCCT GTTTAGCCAG CCTGCGCAT AAATACACTC	840
5	TGCGTTATTG GCTGTGCTCT CCTCAATGGG ACATGTGGAA GAACTTGGGG TCGGGGAGTG	900
	TGTTTGTAC TTGGTTTTC CTAGTAATGA TATTGTCAGG TATAGGGCCA CTTGGAGATG	960
	CAGAGGATTC CATTTTCAGAT GTCAGTCACC GGCTTCGTCC TTAGTTTTC CAACTTGGGA	1020
10	CGTGATAGGA GCAAAGTCTC TCCATTCTCC AGGTCCAAGG CAGAGATCCT GAAAAGATAG	1080
	GGCTATTGTC CCTGCGCTCC TTGGTCACTG CCTCTGCTG CACGGGCTCC TGAGCCCACC	1140
15	CCTTGGGGG ACAACCTGCC ACTGCCACAG TAGCTCAACC AAGCAGTTGT GCTGAGAATG	1200
	GCACCTGGTG AGAGCCTGCT GTGTGCCAGG CTTGTGCTG AGTGCTGTTA CATGTATTAG	1260
	TTCTTTACT GCTGACCACA TTGTACCCAT TTCACAGAGA AGGAGCAGAG AAATTAAGTG	1320
20	GCTTGCTCAA GGTATGCAG TTAGTAAGTG GCAGAACAGG GACTTGAACC AAGCCCTCTG	1380
	CTCTGAAGAC CGCGTCTGA ATTTCTTCAC TAGAGCTTCC TCATCAGGTT ACCCAGAAGT	1440
25	GGTCCCATC CACCATCCAG GTGTGCTTG ATGTTAGTTC TCCACCTCG AGGTGTACGC	1500
	TGTGAAAGT TTGGGAGCAC TGCTTTATAA TAAATGAAA TATATTCTAA AAAAAAAAAA	1560
	AAAAAAAAA	1569

30

(2) INFORMATION FOR SEQ ID NO: 46:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1924 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

	GGGCCCCCCC WCGWKTITTTT TTTTTTTTTT TTTAATTAGG ATAATGCCTT TATTAACGAG	60
45	AATGAAACGT TCAITCCTCC TTCCACTCCT TCTCGTTGGT TTTCTGGACA CAGCTCACCT	120
	GATCCTGCTA GAAAGSTTGT CAGTCTGCTT GTGGCTTCCC TCCTTGATG ACTCAGCTG	180
50	TGTGATGTCT TGAGAAGTAT CTATCCACTT CATGTGAATG AGCACTCCAA TATCAGCCAA	240
	CATCAATCAT TCTTACCTAA AGAATAATAA GAAAAAGTTA ATATAAAGA CAAGGGTATA	300
	AAATAAAGGT TTGAAAATGC TAGTCAACTT CAAAATTAA AGAGTAAAAA TCCAGAGATA	360
55	AAGATTGGGG GTAAGTTACA GCATAAAAAA ATAGGAAGAA ACTTCATGGT GGGGGGGAAA	420
	TCTAAATTA TTCTTACATA AAATAAGTAG ACACCTGAAT TAGAATGAAA ACTGTATTTT	480
60	CTTTAAATG TAAAAGCCTG ACTCTCAGTT TCACCACTCT GAGCACAGT TTGACTGCAA	540

	CCCCAAATAT ACTATCCCTT ATGTGAAGGT ATGTGACAAC GTTGACCTCA CCAAATGAGT	600
	TTTAACATCA GCTCTTTTTT CATATGAAAG CACATACCTT GCTCCCCATT CAAGTATGTC	660
5	TTCCATTGTC AGGCAGGCTG ACCACCTTCA GCAGGAGTCC TCCAAGAGTG CCCAACTCCC	720
	CTTCCACAG TACACAACGC TGTAGTTGTT GTCTTGCAAT CCTTTGTATT TACCTCATTC	780
10	TTTCCCATCT AAGTCTCAC TGAGTTTAA AGTTAGGGCT GGAAAAGCTA TGCCTTACTG	840
	GGACAGCAAG GAACCAATTT TTTTCTGAGG GAGAAGACAT TCACCTTCAC TATATGCTG	900
	GCAGGGCCAC AGTGCACAAA ACAAGATCA GCCTTCATTC AAGTTCCAGG TTTTCTTCC	960
15	TCCCTGAATG ATTACTGCAA AGGGTATATG AAGTAAGAGT TCCCTGTTGC ACATGTACCA	1020
	TCCATAAGGG ATACTATATC GTTTTGCATT CTTCOCCCA TTCTCCACAT TGTCTATCT	1080
20	TAAGTCCAAG CCTTTTTCAC TCTCAAAAAA AAAAAAAAAA TATTTTTTTC AGCACTGGTG	1140
	TTCAAAAGCA ACGTTTTTAT GGTAAATGGT TTACCAGCAA CTGTTGAGAT TTCCAGTTGA	1200
	GTCTTAAAAA TTGCCAATCA TTATCTAGCA GCAATGACAG ATGATTAGGA GCAGTCAAAT	1260
25	CCTCTGAATT CTTTCCCTAA TAGGCAGCCA TTTGAGAACT GCACTAGCTG ACATCACTAA	1320
	AACATTATCA GCTAAAGCCA AAACCAATA AAGGCCAGA CCAACATCCT GGCTCTCTAA	1380
30	AACCTGTCCA AAATCATTAA GTGAAAGCCA GTAAATGCAG GACTGTGGAT CATGTCCTG	1440
	CAGCTGACAA TGATTACAA TAGGAGACAT GCAACCCCA TTAAGGTTAA AAGTCCAAA	1500
	CTAGTCACAC GCATCTCTTT ATTGGGGAAA AGTGAGACTA TTATGCATTC TTGGTAGGTT	1560
35	TGCAACCTTG CATGAAGAGC ACCCATGCA TTTCTTTCAT CTTTCAGAAA GCACCGGTAT	1620
	CTGTTCCAAG GGCCTAACAG TACGAAATA CATTCTGGCA TCACACCTCT GAACCAAGA	1680
40	CTGTTCTCAT TAAAAATAAT TTTGGTTTGT AACAAAATA TGAAATACAA TGCAAGCACC	1740
	TGGTATAGC ATTATTACTG AAACCACTTA ATTCCAGCT TTTTGAGTTT TTTAAAAAAA	1800
	CCCACTGCAC TAAGATTAC AATTCATTC TACATACAAA TTAAGCTAG TAAGAACACA	1860
45	CTAACGTCAC AAGTTTCTCA TTCTAAAGTG CAAAAGCCTA ATCATCTGAA AGTGAACAGG	1920
	GTAA	1924

50

(2) INFORMATION FOR SEQ ID NO: 47:

55

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 475 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

TGGTGTGGGG CCCAGAAAMC AAGGGACCAG TGAAAACAMC CCCAGAGACT TGTATCCGCC 60
 5 AGGAAAGCCA TTGCCAMTYC TGAGCCCTTG AAGGGCAAGG AGGGAAACAG TGTACCAGA 120
 GCCCAGTAAG AACTGCTGTC ATGAAGGAGG GGCCACCTTG TAAGAGACAT CATTACTACC 180
 AGAACTGTGG TGCCAAATG CTGGTGTCTC TCTTTGGAGA AACCAACCAG ATACATCTGC 240
 10 TGGAGACCCA GGTGGGCACA GAGAAGGGTG GAGAGAGAAT CTGGGAAGAG AAATGGAGAA 300
 TAAGCAGCAC AGTGTATTTC ATTTCTGTAA ATTCTATGT AGAAGGCTCA GTGTTAGAAA 360
 15 TAAAGTTATT CTACTAGTTG CAAGTTAAGT GTTCTGTGTT GTTCTGCTTT CCTGTTAGCA 420
 TAAGTAACT CCCTTTGGAA CTACACAGGT ATGTCTCTCC TTCAACATGT GTGAA 475

20

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 346 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

30

AAGGGACAGA GACCTGGATT CAGATCTCAT TTTACAATGA AGACCCCAAT GCAGAAAGTC 60
 ATGTCTGAAA TTCTGAGCTT ACTCTCTGCG CTGCTGGGAC CTGCTCTGGA TGAGAGAAGG 120
 35 GAGGAAAAGG ACTAATCAGA GGAGCCAATG AAGTCACTCC ATGAGTTTCC TGAACCTGC 180
 CCAGCTAGAG ATTAACGTYT GACCCWCAAC GTAGGACACT GTGCAGATGG CTACTTGCTG 240
 40 GCGCACATGA AGACCAAAGC CAGGACCAAG CCCCMASCT GCTWAACAGC GCAGARTCTT 300
 GCCCAGCCMA CYTCTGTGAR AATCTGCTTC CCTCCACAGC TGACCC 346

45

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

50

- (A) LENGTH: 1366 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

55

TAGGTGTCAG CCGCCACCCC CCCCCATAT GCAGATTTAC TSGGCATGGT AGTGGCCAGC 60
 TTCTAACACA GCTGGTATTT CAAGTCTCCT GGGACCTCAC TCAGGAATGA TACCCCTCA 120
 60 GTAGAAGCAG CAGGTGATCT TAACTCCTTT CAAAGAGCAG GCCTGTCTGG GAAGCCATGT 180

	CCTCAGCAGG CACAGCAACC CCTCTGGAAA TGGATCACAA ACTCACTTCT CAGCCAGGCA	240
5	GGCCAAGCTT CTATTGTAAC AGTAGGCACA GTATAGTCGG ATCATCACAT CAGCTGGGTT	300
	TTTGGTTTAG TCATCTAGAG TCGTCTGGAC TAAAGGTCCT TCAGGTCCTC TTGCCCTGTG	360
	AGTGCCTGAA CCTCCCCACC CGAATTGCCT CAGTTGTCCT GAGCCTCATG TCTCTCCTGG	420
10	TGGTGGGCCA GGCCCTGCA TGGGAAGGGA GCCTGCTGCG GGGCAGGCCA GCTGGGGGTG	480
	CTCACCTATG CGCAATGANA GTTATTGAAG GACTGGTTGT TGATGTTGGT GAGCGTATCC	540
15	TTCATGGCCA GCGGAAGTC GGCCAGGTCA GCCAGGTGCT GCCAGCGCTC TCTCTGGAC	600
	TTGTCTTCCT GTGOCAGGG ACCGTGGAGA AAGTGTGAGG GGCCGCTCAC TGCAGCAGCC	660
	TGCTCTGCTG CCTTCCCTGG CAGTGTTCGT GGGGTGGATT CCTACAMCT AGATGTTCAA	720
20	GGCCTTACTT TTCTTCCAC AAAGGAGTCG CAGCCACGCT AGCTCTGACT TGCCACTGTG	780
	ACAAAGTTCA CGTAGCAGGT CTAGGCAAAG ACTGGGCAAT TGAGCAGAGG AGACGGACCT	840
25	GTGAGTCTGA CCRYGAGSCG GRCCCTTCA CCTTGGCTGG GCTGGTCTG GTCCTTAGGT	900
	TTTGTGAGT TGTCTTGTG TGGATCCTC AACTAGGTGA TAAGCACTGG AGGGGGATGA	960
	CCCGCCTTGG ACGTGTTCCT TTAACCTCAT CCATATAATA GGGCCGTGGG ATGTTGTAG	1020
30	AGGTAAAGCA GGATGATGGT GTTTTAAGAC CAGAGCTTGG GACCAGGGCT CCTACACCTA	1080
	ATTTTCTCTC CTGGTAGCTG AACAAAGTC TAAATTAGCT TAACAAAAGA ACAGGCTGCC	1140
35	GTCAGCCAGA GTTCTGAAGG CCATGCTTTC AGTTTCCCTT GTTGACAATT GCTCTCCAGT	1200
	TCCTATGAAA GCACAGAGCC TTAGGGGGCC TGGCCACAGA ACACAACCAT CTTAGGCCTG	1260
	AGCTGTGAAC AGCAGGGGGT TGTGTGTCTG TTCTGTTTCT CTGCTTGCCG AACTTTCTCA	1320
40	ATAAACCTTA TTTCTTATTT ATAAAAAAAA AAAAAAAAAA AAAAAA	1366

45 (2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 1405 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

55	GCAGTAATTC CTGTTAGCCA CTGCATCCAC CAAACTAGT TTATTTTTC CCTCAAAATC	60
	ATGATTTTTA CGTCTGTAC AAAGGGAATT TTGCTGATAG CTCTTTGGGT CCCACTGTTC	120
60	CATTTTATGC TAATAGATTC CATCTAGGG CCCAGCGTC TCTTGAAGA TGGTGTTCCT	180

	TTTAACCCCTT GGCATGTATA ATAGAATTTT GGTGAATGAA AGAACCCAAA TAGGCCAGAT	240
	AGTCCCCCCA GGCCCTGATA TCCATAAAAG GCTTGGGAAT GCATTATGTA ATTGTCCTTA	300
5	GTCTTTTGT TGTTTTAGAA AAAAAAACA AGATGGGCTC AGATGGATGC CTACGTAAAA	360
	ATGGTTCCTA GCTGTGTACT CATAACTTTT CTTTGAATTG AGTAGTGAAA GGAAGGAGGA	420
10	GGAAAGGAAA TTAAATGTCC TTCTAGTATT CTCGGGACTC AAGTCTGACA TATGAGATAA	480
	TAACCTATAT TGAAATGCCA AGAATTGTAT CTGAAACAAG AGAACAGTTT GACACATTTA	540
	TCATGCCTTC ATATTACATA TTAAGTGAAA CCAATTAATA AACATATGAA ATATCCATG	600
15	CACAAGGCAA AGGCACCTAA ACCTTTGTGT TCTTTTCTA CATAGCAGAA ATTGATTTTT	660
	TTTTTATTTT TTAGGGGAA CCTATATAAT TATGACCCAG TGATGTCTTT TGGTGACTTA	720
20	AGCTTATGAA TTCAGGTAC AATTGAGTTG ATTCTAGATG GTTACTACCT TGAAAAGGAT	780
	GTTGGTGCCT TATGTGACAC GAGCCAGAGC CTGCTGGGGA ATAAACAAG CAGGTTTCAT	840
	GCCAACACCA ACTCGTAGCT TTAGTGGGCA GATGGGGAGT GGTTCACAGA CTTCCCAAAA	900
25	TGTGGGGGCT TTGGGATTTT CCACACCATC CCAAGTGTGT TGTTCATTCT TCCTCTTTTC	960
	ACACTCTTGG ATGGATWATT TGRAAATGGT GRAAWYMCY YYKRAATTG CCCAATAGCC	1020
30	WTGRGCCACC ATTCTTWATG ACACCATAAC CAAATAGTTC CWTAAATGTG AAATATTAGA	1080
	AACCTGTAC CAGCCYKMA KIWACCCWA WTTTCCCAT GTTGTGGAA TTGATATTGA	1140
	AATAGCAGGG CTAAGGAATT ACTGGCAAGT TTTAGCCTGT GGGTAATACC TTAGGGTTAT	1200
35	TTAAATATTT GTAATTTTAT TTAAATGTTT ATGAATGTTT GAAAGGAACA AAATTATCAG	1260
	GGATGCTCTT TTGCCATGGG TCTTATTTTC ACCCTCTTTT CTGTAAGAAA AAAGAACAAT	1320
40	GTCTTAATGT ATTTTAAAG TTTTGGTAT AGTTTCTAAT TCCAATTTTA ATAAAAGTTT	1380
	TWRTAAAAA AAAAAAAAAA AAAA	1405

45

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:

50

- (A) LENGTH: 504 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

	CGGATTTTCT AGGACCCCAA AAAAAAAAAA AGGGNAAAAA AAACCCNCAA AACCANCCAA	60
	AACCCCAAAA AAAAAAAAAA TCCACAAAAA CAAAAAACT ATAAAAAGA AAGAATTAAA	120
60	AACPTTCAGA GAATTACTAT TTACTTTATT AACTTACGGA TTTATTATAT AAATATATAT	180

TCACCTAGCA ACATATCTCT GCGTCTCTC CTGCTCTCAT AATGAAGACA TAGCCGATTC 240
5 TCTGCCCGGG CCCCTTGCTG ATGCTCCTCC GGGTCTGGT CGGGCGTGGG TCTCTGGGGA 300
CCCTCCAGAG GTGGAGGTGG GCTGATGGCC TGGCTGCCTG GTGGTTGATG GTTTTGCTCC 360
CCCTACCTTT TTTTTTGTAG TTTATTCTGA TTGATTTTTT TTCTTGGTTT CTGGATAAAC 420
10 CACCTCTGCG GGACAGGATA ATAAACATG TAATATTTTT AAGAAGGAAA AAAAAAAAAA 480
AAAAAACTNG GGGGGGGCCC CGAA 504

15

(2) INFORMATION FOR SEQ ID NO: 52:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 777 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

NAAGTATCTT GGCCAGTTTA TTACAGAGGA CGATAAATGA TTCCATGTGG ATAGGGCATA 60
30 ACATACAGAG AATGAGACTA TGCCAGAAAT GGGAGGAGGC ATTTGAAACA ACATGAGTAT 120
CTCAGGGACA GATGGATTGA TTCTGCTATT GGTAGGCCTG GAAGCAANGG TCAGAAGTAG 180
CAAAAAATGG ATACCAAAAG CACTATTWGT CACCCAAGCT AAGTGGAAATA GCTGGCCCGAG 240
35 TAGGAGAAAT GCAGGTTTTG CTCTACACTA AGTTCTCCAA CTCTTGATAA GCCTCCAAA 300
ACAAATGTTA GGGGAAAAA ACCCAGCTGG TTATGAAAAG ATATATCTCA TTTCATTAAA 360
AAATCAATGT CAATGCTGTT AATAGAATCC TTTTATCTTC AGGACAGAGG CAATGCCCTA 420
40 AACAAACACC AGCTCAAGAG CCTCTGATGC CAACCTAGAG GGTACCCAAA CACAACTTA 480
GCATAGAGGT AAGAATCTCT ATGTCTTTTG GTGGAGGCAA AGCCATTGG TTGGTACTTC 540
45 ACAGGAACAT CTTCTACCA AGTCTTCATC ATATGGTATG TGCCACGAGT CTCCAGTTGT 600
TTGCACCACT GTGTCATAGC TGAGAATACG CTGAAAGGTT AGTTTGTATC CTGGAAACCT 660
ATTTACAATT GCCAGCTGAT GTCCCTGCTG CCACTTAAAA AAGGCTTGGG TCTGGCATAG 720
50 GCAGAMAGGC CTGTGGTCCC CTCGTGCCGA TTCTNGGCTC GAGGCCAATT NCCTTAT 777

55

(2) INFORMATION FOR SEQ ID NO: 53:

60 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 602 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

5
ATGACTACAG TGTATACCC TCCAATCTTT GCAGGTGGGC ATGGAACACT GCTTGTATCA 60
CTCTGTGCAC GGTATAAATC CATATATCCA CAAAAACACA CATCCATCCA TCAACATATA 120
10 CATGGTTTGG GATGAGCAGG TCAATAGTTT TGAGAGGGAG TTTGTTCCTT TTTTPTTCT 180
CATTATACTC TTAAATTGTT GTCAGTTATC AAACAAACAA ACAGAAAAAT TGTTTGGAAA 240
AACCTTGCAT ACGCCTTTTC TATCAAGTGC TTTAAAATAT AGACTAAATA CACACATCCT 300
15 GCCAGTTTTC TCTTACAGTG ACAGTATCCT TACCTGCCAT TTAATATTAG CCTCGTATTT 360
TTCTCACGTA TATTTACCTG TGAATGTAT TTTTATTTA AACAGGAAAA AAAACATTCA 420
20 AAAAAAGAAA AATTAAGTGT AGCGCTTCAT TATACTATTA TATTATTATT ATTATTGTGA 480
CATTTTGGAA TACTGTGGAA GTTTTATCTC TTGCATATAC TTTATACGGA AGTATTACGC 540
CTTAAAAATA CGAAAATAA TTTTACAAGG TTCCGGTTTT GGTGGTGGAA AGAGTAAATT 600
25 GA 602

30

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 1749 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

40
AGTCACTGAC TTGGAGCCGC TCGGGGAAG TCCCGCCAG ACAGGCGGTG GGTGGGAATG 60
CCTCACTTCA GTTTGAAGAG GGTCCGGATC CAAAGGGGT AAAACGAGCG AACCCGATC 120
45 CCGGACCACA CTTCOCGCT CCTTAAACG CACACCCGC TAGCCATGGG CAGCCGOGAC 180
CACCTGTCA AAGTGCTGT GGTGGGGAC GCCGAGTGG GCAAGACGTC GCTGGTGCAG 240
GATTATTCCT AGGACAGCTT CAGCAAACAC TACAAGTCCA CGGTGGGAGT GGATTTTGCT 300
50 CTGAAGGTTC TCCAGTGGTC TGACTACGAG ATAGTGGGC TTCAGCTGTG GGATATTGCA 360
GGGAGGAGC GCTTCACCTC TATGACACGA TTGTATTATC GGGATGCCTC TGCTGTGTT 420
55 ATTATGTTTG ACGTTACCAA TGCCACTACC TTCAGCAACA GCCAGAGGTG GAAACAGGAC 480
CTAGACAGCA AGCTCACACT ACCCAATGGA GAGCCGGTGC CCTGCCTGCT CTTGGCCAAC 540
AAGTGTGATC TGTCCCTTG GGCAGTGAGC CGGACCAGA TTGACCGGTT CAGTAAAGAG 600
60

	AACGGTTTCA CAGGTGGAC AGAAACATCA GTCAAGGAGA AAAAAATAT TAATGAGGCT	660
	ATGAGAGTCC TCATTGAAAA GATGATGAGA AATTOCACAG AAGATATCAT GTCTTTGTCC	720
5	ACCCAAGGGG ACTACATCAA TCTACAAACC AAGTCTCTCA GCTGGTCTG CTGCTAGTAG	780
	TGTTTGGCTT ATTTTCCATC CCAGTCTCTG GAGGTCTTTT AAGTCTCTTC CCTTTGGTTG	840
10	CCCACCTGAC CATTTTATTA AGTACATTG AATGTCTCC TGACTIONGT CCAGTAAGGA	900
	GGGCCCATTG TCACCTAGAA AAGACACCTG GAACCCATGT GCATTTCTGC ATCTCCTGGA	960
	TTAGCCTTTC ACATGTTGCT GCTCACATT AGTCCAGTT AGTGCCCTCG GTGTAAGATC	1020
15	TTCTCATCAG CCTCAATTT GTGATCGGA ATTTTGTGAG AAGGATTAGA AATCAGCACC	1080
	TGCGTTTTC AGATCATAAT TCTCACTAC TTCTGAGCTT ATTTTCCAT TTGATATTCA	1140
20	TTGATATCAT GACTTCCAAT TGAGAGGAAA ATGAGATCAA ATGTCATTTC CCAAATTTCT	1200
	TGTAGCCGT TGTTCAGAT TCTTTCTGTC TTGGAATGTA AACATCTGAT TCTGGAATGC	1260
	AGAAGGAGGG GTCTGGGCAT CTGTGGATT TTGGCTACTA GAAGTGTCCC AGAAGTCACT	1320
25	GTATTTTGA AACTTCTAAC GTCATAATTA AGTTTCTCTT GTCTTGGCAT CAAGAATAGT	1380
	CAAGTTTTTT GGCCGGGCAT GGTGGCTCAT GCKGTAATC CCAGCACTTG GGGAGGCCAA	1440
30	GGCAGGCGGA TCACATGAGG CCAGGAATTC GAGACCAACC TGGTCAGCAT GGCAAAACCC	1500
	CGTCTCTACT AAAAGTACAA AAATTAGCCA GCGGTGATGG CACGTGTCTG TAATCCCAGC	1560
	TACTCTGGAG ACTGAGGTGG GAGAATCGCT TGAGACTGGG AGGCAGAGGT TGCACTGAAC	1620
35	CGAGATCATG CCACCGCACT TCAGCCTGGG TGACAGAGAA GGACTCCGTC TCAAAAAAAA	1680
	AAAAAATAA AAAACTCGAG GGGGGGCGG GTACCCAAAT CGCCTGATA GTGATCGTAW	1740
40	ACAATCNAA	1749

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1896 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

55	AAAGAGATGG GCTCTTTATT TTCTGAAAA ACCAATTTGG AGTTACTCAT TTTTCATAA	60
	CATTAAATTT CTTACAGTGA ACTACATATT GTCCATAAGT GCTTCATCAG GACTCATCGC	120
	CCTCTGTCT ACTGGCTCCA AATAGACCAT GTCAGCTTCA CCCCCTGGCT TTGTGTCTAT	180
60	GGTGGGCTG TGGTATATGG AAAAGTAGCA GGTGGTTCAG GGTGGGAGAC ACAAGATGTT	240

	TTTATAGTCT AGAGCCTTTA AAAAACCCAG CAGAATGTAA TTCAGTATTT GTTTATTTGGC	300
5	TGTTTTTTGA CAGATTGTTG AAATTAAATG AATTGAAAGG GAAACTCAGA GTACTAGGAC	360
	GTTTATTAAA AGGAAAAAAA TGTCTTGCAA TGTGCTGTAA TCACAAGAGG AGAAAAATAAC	420
	TTGTTTCCTT GATCTGTGAG AGGTCACAGT AACCTGGGCC GAGCTGTTAT TATTTATTAT	480
10	ATAATAGTAG TAGGAAGTAA ATAACTGGTT CTCTGTGTTT CAAGCACAAT ATTACAACCT	540
	CTTTTGAACC GTAAATATCA GAATGAATCC TCTTCCAGG GGATTGAACA GAAGCTTAAT	600
15	GTTTACAAGT GTTTGAATTT GTGATCTGAA ATAACACAAA ATTAAAAACA TGATTCTCTCT	660
	AATTTTCCAA CTAGAGGAAG AGAACTTGT GGAAAAGTTC TTTTTTTTTC TTTTTTTTTT	720
	CTTAAAGAAG GGCAGCCAAG GTAGTAACCT AAAAATAGTG CCCAGGCATA TGAGAGTTGT	780
20	CCTACGAGGT TAAAGAACAC ACTGTTCCAC TGTATGGCTT TGGCCCTGAG TGGCCAGGGA	840
	GGTCAACTTG ACCCTGCCAT GTTGGTTTGA CTTACTAAGA CACAGGAATC ATTGTTTTTC	900
25	TTGACCAGG TCTCACACCC TGGAGGAATG TTAAGTAAGA GAAAGAACCT CTTTCTTGAA	960
	TATTGACATG TAAAGACCA AAGTAATTTT TCTGAACTTC TGCAATTCTG AGAACTCTCC	1020
	AAGGAATTTA CAGTGATTTT AGTGCTTGTG AGCATTTTTC CATGAGGACT TTCATACATT	1080
30	TGACTCTTTA GTTCACAGGT TCCCATGTAT TGTGAGCAAG ATATTTATCT CTTTAGCCCT	1140
	TGGGGATCCA GCTGAGAGCA ATCTCTTGCA TTTTTTACC CGTGATGTGA CAGATATCAT	1200
35	TTCTTGTTGA TGCCATGACT TGAAAAAGTT TGGGAAGCTC TTTAGCAATA TCAGCTAAAA	1260
	GGATATGAAA TCACAGGTGA TAGCAGTTGT CATTCACTAA TTTCTTACAA GCAGCACCCC	1320
	AAAGGAATA TAGTCTAAT CTTTACTATC CACTTCTAAA TTTAATGTGA ATTTTATACA	1380
40	TGTTATTAGT TGTTTTCTTT ATAATTTTAT AAAAATTATT CATCGGGAGT TTAACCTCCA	1440
	CTTCCATGCT ATCGGATGTG TGGGCTCCA TGCAAGAACT TGAAGAAAA ACAGGCAGGA	1500
45	ATGCATTGCG ATAATGACCC AGATCATCAT TTTCTGCAAC TGAGAATTAT ATTTTATCAT	1560
	TGCTTCTAGA AGTCTGCAAT TCTTTACTTT TCTTTGGTGC ATTATTATCT AGGTGCCATC	1620
	ACTGGATAAT GTGGAGTGAC TAGAGAAGTC AYATATCACT GTAAGGTACA GTTAGGGGTA	1680
50	ACACTTTAGA GGTTTATTAT TTTTAAAAAA CTTTCTTGA ACTCTGGGC CAACATGGGT	1740
	GAAACCCCGT CTTCTTACTT AAAAATACCC AAAATTAGGC CAGGGGCGTG GATGGGTGGG	1800
55	GTGCTGTGA ATCTTCAGCT ACTTNGGGGA GGCCTTGAAG CCAGGGAGGA ACTGCCCTGG	1860
	ANCCCCGGGG NGGGCCAGNA GGTTTGCCAG TTGAGT	1896

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:

5

- (A) LENGTH: 1753 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

10

TCCTTTTAAA ATAGACATTT GTGGGGCTCA CACAATATAT GAAATAGTAC CCTCTAAAAA 60
AGAGAAAAAA AAAATCAGGC GGTCAAACCT AGAGCAACAT TGTCTTATTA AAGCATAGTT 120
15 TATTTCATA GAAAAAATTT AATATCAAGG ACTATTACAT ACTTCATTAC TAGGAAGTTC 180
TTTTTAAAT GACACTTAAA ACAATCACTG AAAACTTGAT CCACATCACA CCCTGTTTAT 240
TTTCCTTAAA CATCTTGGA GCTTAAGCTT CTGAGAATCA TGTGGCAAGT GTGATGGGCA 300
20 GTAAATACC AGAGAAGATG TTTAGTAGCA ATTAAAGGCT GTTGCACCT TTAAGGACCA 360
GCTGGGCTGT AGTGATTCTT GGGCCAGAG TGGCATTATG TTTTACAAA ATAATGACAT 420
25 ATGTCACATG TTTGCATGTT TGTTTGCTTG TTGAATTTT GAACAGCCAG TTGACCAATC 480
ATAGAAAGTA TTACTTTCTT TCATATGGTT TTTGGTTCAC TGGCTTAAGA GGTTCCTCAG 540
AATATCTATG GCCACAGCAG CATAACAGTT TCCATCCTAA TAGGAATGAA ATTAATTTTG 600
30 TATCTACTGA TAACAGAATC TGGGTCACAT GAAAAAAAT CATTTTATCC GTCTTTTAAG 660
TATATGTTTA AAATAATAAT TTATGTGTCT GCATATTGCA GAACAGCTCT GAGAGCAACA 720
35 GTTCCCATTT AACTCTTCT GACCAATAGT GCTGGCACCG TTGCTTCTC TTTGGGAAGA 780
GGAAAGGGTG TGTGAACATG GCTAACAATC TTCAAATACC CAAATTGTGA TAGCATAAAT 840
AAAGTATTTA TTTTATGCCT CAGTATATTA TTATTTAATT TTTTAGGTAA TGCCTATCTC 900
40 TTGGTCTATT AAGGAAAGAA GCAATCAGTA GAGAATTCAG GATAGTTTGT TTTAAATTCT 960
TGCAGATTAC ATGTTTTTAC AGTGGCCTGC TATTGAGGAA AGGTATTCTT CYATACAACT 1020
45 TGTTTTAACC TTTGAGAACA TTGACAGAAA TTATGCAATG GTTTGTTGAG ATACGGACTT 1080
GATGGTGCTG TTTAATCAGT TTGCTTCCAA AGTGGCCTAC TCAAGAGGCC CTAAGACTGG 1140
TAGAAATTAA AAGGATTTCA AAACTTTCT ATTCTTTCT TAAACCTACC AGCAAACCTAG 1200
50 GATTGTGATA GCAATGAATG GTATGATGAA GAAAGTTTGA CCAAATTGT TTTTTGTTG 1260
TGTGTGTGT TTTGAATTG AAATCATTCT TATTCCTTT AAGAATGTTT ATGTATGAGT 1320
55 GTGAAGATGC TAGOGAACCT ATGCTCAGAT ATTCAATGTA AGTCTCCCTT CACCTGTTAC 1380
AGAGTTTCAG ATCGGTCAGT GATAGTATGT ATTCTTTAG TAAGAATGTG TTAAATTTAC 1440
AATGATCTTT TAAAAGATG ATGCAGTTCT GTATTATTG TGCTGTGTCT GGTCTAAGT 1500
60

	GGAGCCAATT AAACAAGTTT CATATGTATT TTCCAGTGT TGAATCTCAC AACTGTACT	1560
	TTGAAAATTT CCTTCCATCC TGAATAACGA ATAGAAGAGG CCATATATAT TGCCTCCTTA	1620
5	TCCTTGAGAT TTCACTACCT TTATGTTAAA AGTTGTGTAT AATTGTTAAA ATCTGTGAAA	1680
	GAATAAAAAG TGAATTTAAA TTAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	1740
10	AAAAAAAAAGG GGG	1753
15	(2) INFORMATION FOR SEQ ID NO: 57:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 1220 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
20	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:	
25	GCGGAAGTTA CTGCAGCCGC GGTGTGTGC TGTGGGAAG GGAGAAGGAT TTGTAAACCC	60
	CGGAGCGAGG TTCTGCTTAC CCGAGGCCGC TGCTGTGCGG AGACCCCGG GTGAAGCCAC	120
	CGTCATCATG TCTGACCAGG AGGCAAAACC TTCAACTGAG GACTTGGGGG ATAAGAAGGA	180
30	AGGTGAATAT ATTAACTCA AAGTCATTGG ACAGGATAGC AGTGAGATTC ACTTCAAAGT	240
	GAAAATGACA ACACATCTCA AGAACTCAA AGAATCATAC TGTCAAAGAC AGGGTGTTC	300
35	AATGAATCA CTCAGTTTC TCTTGAGGG TCAGAGAATT GCTGATAATC ATACTCCAAA	360
	AGAACTGGGA ATGGAGGAAG AAGATGTGAT TGAAGTTTAT CAGGAACAAA CGGGGGTCA	420
	TTCAACAGTT TAGATATTCT TTTTATTTT TTTCTTTTC CTCAATCCCT TTTTATTTT	480
40	AAAAATAGTT CTTTGTAAAT GTGGTGTCA AAACGGAATT GAAACTGGC ACCCATCTC	540
	TTTGAAACAT CTGTAATTT GAATCTAGT GCTCATTATT CATTATTGTT TGTTTTCATT	600
45	GTGCTGATTT TTGGTGATCA AGCCTCAGTC CCCTTCATAT TACCTCTCC TTTTAAAAA	660
	TTACGTGTGC ACAGAGAGGT CACCTTTTC AGGACATGTC ATTTTCAGGC TTGTGGTGAT	720
	AAATAAGATC GACCAATGCA AGTGTTCATA ATGACTTTC AATTGGCCCT GATGTTCTAG	780
50	CATGTGATTA CTTCACTCCT GGAATGTGAC TTTCAGTGGG AGATGGAAGT TTTTCAGAGA	840
	ACTGAACTGT GGAATAATGA CCTTCCCTTA ACTTGAAGCT ACTTTTAAAA TTTGAGGGTC	900
55	TGGACCAAAA GAAGAGGAAT ATCAGGTGTA AGTCAAGATC ACAGATAAGG TGAGAGTAAT	960
	GACTAACTCC AAAGATGGCT TCACTGAAGA AAAGGCATT TAAGATTTT TAAAAATCTT	1020
	GTCAGAAGAT CCCAGAAAAG TTCTAATTT CATTAGCAAT TAATAAGCT ATACATGCAG	1080
60	AAATGAATAC AACAGAACAC TGCTCTTTT GATTTTATT GTACTTTTG GCCTGGGATA	1140

5 TGGGTTTAA ATGGACATTG TCTGTACCAG CTTCAATAAA ATAAACAATA TTTGTAAAAA 1200
TCAAAAAAA AAAAAAAAAA 1220

10 (2) INFORMATION FOR SEQ ID NO: 58:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1049 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

20 TGGGCGCTGC AGACACAGCA TCTACTCAGC GTGGGTCACC TCTGTGAACA TCACTGACTG 60
CAAGCCTCCC TCAATTCTCG GTGCAGCCCA TCAGGGACCC ACAGCGCCTG GGAGGATGGT 120
GCGGATCTTG GCCAATGGGG AAATCGTGCA GGACGACGAC CCCCAGTGA GGACCACTAC 180
25 CCAGCCACCA AGAGGTAGCA TTCTCTGACA GAGCTTCTTC AATAGGGGCC ATGGTGCTCC 240
CCCAGGGGGT CCTGGCCCCC GCCAGCAGCA GGCAGGTGCC AGGCTGGGTG CTGCTCAGTC 300
CCCTTCAAT GACCTCAACC GGCAGCTGGT GAACATGGGC TTCCGCGAGT GGCATCTCGG 360
30 CAACCATGCT GTGGAGCCCG TGACCTCCAT CCTGCTCTC TTCTGCTCA TGATGCTTGG 420
TGTTCTGGC CTCTCTCTGG TTGGCCTTGT CTACCTGGTG TCCACCTGA GTCAGCGGTG 480
35 ACCTCTGAGG GCTGATAGG GTGGGTTTGT TGAGAGGGAC TTGCTGGGCC TTGGTGTGAG 540
AGCAGGCATA TTTGGAGGGG ATCTGGTGGT GCCTTGAAGG TATGATCAGA GAGGGGACCA 600
40 CAGGTGTGTG TTCCCCCTT GTGTTAAGG TGAGGCAGAG GGAGACGTTA GTCCCAGCAT 660
TTCCCAAAGT GTGGGTGGT CCGTTGGTTC CCGAGATACT TTTAGGTGGT ATGGGGCCTG 720
CATTAAGTGG CACAAATCA GAGCAAGAAA GCGATGCCCT TCCCAATTCT CTCAATCCTT 780
45 TTATGCCGAG AAGATCTCAG CTGGATGCCA ACATGTTCCG ATGCTGTGG AAGACATGCC 840
GACGTCTCCT CTGCCTAGGG AGCAGGACTT GGGCTTAGGG CAGGTGAAA AAATTCCAGA 900
50 CTTTTTTACG ACTGTTTTG TTTTAATGGT ATATTTTAT TGGCTACTTT ATTGTTTAGG 960
ACAAGTGGTA GTGGCATTCT ATTATTGTG ACCTTTTCAA TAAATAGATT TAAGTAAAAA 1020
AAAAAAAAA AAAACTCGAG GGGGGGCC 1049

55

(2) INFORMATION FOR SEQ ID NO: 59:

- 60 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1776 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

	AAAGAGGATG TGMAGCTAGA GGTCCCGAT GGCTGGTCGG ATGGGAAGCA CAAGGCTGAG	60
10	GGACTGGATT GTAAAGGCAC TAAGTCGTTT TCGGTGAGA ATCAGACATG GGGGACCTCT	120
	AGCTTCACAT CCTCTTTCCT TGCAGSTCTG GACATCCTGA GCCCAAGTCC CCCACACTCA	180
15	GTGCAGTGAT GAGTGGGAA GTGAAGGTGA CAGGGCAGAA CCAGGAGCAA TTTCTGCTCC	240
	TAGCCAAGTC GGGCAAGGGG GCAGCGCTGG CCACACTCAT CCATCAGGTG CTGGAGGCC	300
	CTGGTGTCTA CGTGTTTGGA GAACTGCTGG ACATGCCAA TGTAGAGAG CTGGCTGAGA	360
20	GTGACTTTGC CTCTACCTTC CGGCTGCTCA CAGTGTTC TTATGGGACA TACGCTGACT	420
	ACTTAGCTGA AGCCCGGAAT CTTCCTCCAC TAACAGAGGC TCAGAAGAAT AAGCTTCGAC	480
25	ACCTCTCAGT TGTACCCCTG GCTGCTAAAG TAAAGTGTAT CCCATATGCA GTGTGCTGG	540
	AGGCTCTTGC CCTGCGTAAT GTGCGGCAGC TGAAGACCT TGTGATTGAG GCTGTGTATG	600
	CTGACGTGCT TGTGGCTCC CTGGACCAGC GCAACCAGCG GCTCGAGGTT GACTACAGCA	660
30	TCGGCGGGGA CATCCAGCGC CAGGACCTCA GTGCCATTGC CGAACCCTK AANAAAAACC	720
	ATTAAAGTTA CGACGCGAGC AGCAGCGCA GCCACATCTC AGGACCTGA GCAACACCTG	780
35	ACTGAGCTGA GGAACCCAGC TCCTGGCACC AACGAGCGCC ASCCAGCAAG AAAGCCTCAA	840
	AGGGCAAGGG GCTCCGAGGG ANCGCCAAGA TTTGGTCCAA GTCGAATTGA AAGRACTGTC	900
	GTTTCCTCCC TGGGATGTG GGTGCCAGC TGCTTGCTG CCTCTTAGGA GTCTCAGAG	960
40	AGCCTTCTGT GCCCTGGCC AGCTGATAAT CCTAGGTTCA TGACCCCTCA CCTCCCCTAA	1020
	CCCCAACAT AGATCACACC TTCTCTAGGG AGGAGKCAA TGTAGGTCAT GTTTTGTG	1080
45	GTACTTTCTG TTTTGTGTA CTTCATGTGT TCCATTGCTC CCCGCTGCCA TGCTCTCTCC	1140
	CTGTCTTCTT TAAGAGCTCA GCATCTGTCC CTGTTCATTA CATGTCAITG AGTAGGTGGG	1200
	TAGCCCTGAT GGGGTGCGT CTGTCTGGAG CATAACCCAC AGGCGTTTTT TCTGCCACCC	1260
50	CATCCCTGCA TGCTGATCC CCAGTTCCTA TACCCCTACC CTGACCTATT GAGCAGCCTC	1320
	TGAAGAGCCA TAGGGCCCCC ACCTTTACTC ACACCCAGG AATTCTGGGA GCCAGTCTGC	1380
55	CATGCCAGGA GTCAGTGAC ATGTTCATCC TAGAATCCTG TCACACTACA GTCATTTCTT	1440
	TTCTCTCTC TGGCCCTGG GTCCCTGGGA TGCTGCTGCT TCAACCCAG AGCCTAAGAA	1500
	TGGCAGCCGT TTCTTAACAT GTTGAGAGAT GATTCTTTCT TGGCCCTGGC CATCTCGGA	1560
60	AGCTTGATGG CAATCCTGGA AGGGTTTAAT CTCCTTTTGT GAGTTTGGTG GGAAGGGAA	1620

	GGGTATATAG ATTGTATTAA AAAAAAAG GTATATATGC ATATATCTAT ATATAATATG	1680
5	ACGCAGAAAT AAATCTATGA GAAATCTATC TACAAAMWAA AAAAAAAAAA AAAAAAAAAA	1740
	AGGAATTCGA TNCAAGCTT ATCGATACCG TCNACC	1776
10	(2) INFORMATION FOR SEQ ID NO: 60:	
	(i) SEQUENCE CHARACTERISTICS:	
15	(A) LENGTH: 443 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
20	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:	
	ACAGATAAAT AAATAAATAA TAAATTAAAT TAAATAAAAA ATCTGAGCTA ATCTGAATAA	60
	ATTGAGAGAT TTCACATGAA AGCCAGGATT TCTGGCTTCC CAGGAACAGT CAGAAGAGCT	120
25	AGCTAGCAAC ACTGGTCTGC TTGGCTACCT TCTTTGGAAC AACATGAAAT CTAGCTCCCT	180
	TTTTTTTTTT TTTTGGGCC ACTTCATCCA TTCACATGAC CTGCTGGCC TCTGCAGGTA	240
30	AGTGAGTATG CAACAAAAT GTAGCACAGG TTTGTGCTG GAACTACGTG GTTTCAGGTC	300
	CAGCTCTGCC ACTTGCTAGC ATGACCTCGT GCCGAATTCC NGCAGGAAGT TTTTTTTTTT	360
	TTTTTCAGTG CTCCAGTCCC CCTATTGGAG AATCCTGCCC CCCCTGGGA CAGAATGTTT	420
35	ACCCTGGCCC CGCGANTCCC TGA	443
40	(2) INFORMATION FOR SEQ ID NO: 61:	
	(i) SEQUENCE CHARACTERISTICS:	
45	(A) LENGTH: 2888 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:	
50	TTAATGTTGT CAATAACCAC CAGCCAAAC AGAATTATA TGACCTGGAT GAAGATGATG	60
	ATGGTATAGC TTCCGTTCTT ACTAAACAGA TGAAGTTTG AGCCTCAGGC GNTTTCTCC	120
55	ACCACATGGC TGGGCTAAGC AGTTCCAAGC TTTCCATGTC CAAGGCCCTC CCTCTACCA	180
	AAGTGGTTCA GAATGATGCA TACACAGCTC CTGCTCTCCC TTCTCTATT CGAACAAAAG	240
	CCTTGACCAA CATGTCCCGG AACTGGTGA ACAAGGAAGA ACCCCCCAAA GAGCTGCCAG	300
60	CTGCTGAGCC TGTTCCTCAGC CCATTGGAAG GCACCAAGAT GACTGTGAAT AATCTGCACC	360

	CTCGAGTCAC TGAGGAGGAC ATTGTTGAGC TTTTCTGTGT GTGTGGGGCC CTCAAGCGAG	420
5	CTCGACTGGT CCATCCTGGG GTAGCGGAGG TGGTGTTTGT GAAAAAGGAC GATGCCATCA	480
	CCGCATATAA GAAGTACAAC AACCGGTGTC TGGACGGGCA GCOGATGAAG TGCAACCTTC	540
	ACATGAATGG GAATGTTATC ACCTCAGACC AGCCCATCCT GCTGCGGCTG AGTGACAGCC	600
10	CATCAATGAA AAAGGAGAGC GAGCTGCCTC GCAGGGTGAA CTCTGCCTCC TCCTCCAACC	660
	CCCTGCTGA AGTGGACCCCT GACACCATCC TGAAGGCACT CTTCAAGTCC TCAGGGGCTT	720
15	CTGTGACCAC GCAGCCACA GAATTCAAAA TCAAGCTTTG AGCAGGGGAG TGAGGCAGCC	780
	AGAAGTGGGG GCAGAGGAGG GTGGCTCTGT TTCCCAAGG CAAAGCTTAT GACCAATGGG	840
	CCATCGGACT GGAGACCCCT GATTGTGGGA AGGGTTGCCA GGGATAAAGA GCTTCCTCAC	900
20	TGGATGGGAC CCGCCTTTCT GTGTGTGTT CTGCCCTGTG CTCTTCTCTC TACGTTAACG	960
	TTTCTGTAG TATGTTTCTT CATCTCATCG CCAAGGTAGG CTGTGTTTT TCAGTGTGTG	1020
25	CCTCCCGAG CCTCAGCCCC AAGCTGATTT CTTATCTGGA AATGGTACAC TGAATTCTCT	1080
	GGGTGGCTTT CTTGTGGCCC CATGGGATGC AGCGTGGGG CTGTCTGAAG GACCTGCTT	1140
	TTTCCAGGG CCGAGGGGCT GCCTTTCTTT TGTGTGTATT AAGCTTTTCA AACAATGGAG	1200
30	GGGATGGAGA GCCCTGGTGT CCTGACGGGA GCCAGGTCGG CCTGAGAGCT GTGCCGCTCC	1260
	TCTGTCTGT CAGTGGAGGT GCCTGGGTGG GGAGCAGGTC TCAGGCCTCT TGTCTCTCC	1320
35	CCAGTGGCTC CAGGCCTCAC TAGTGGCAAG GGCAGGATGA GGCTGCACCG CTGGGAAGAG	1380
	TCTATCTAAG YTCITGGCTT GGAGTCCCGT GTCGTCTCCR CCCAGAGGAA GTTCTCCAGA	1440
	GTTACCTTT CCCTTTCTCT TGAGTGTGC TGAATGCCCC ACCCCAGCTC TCTTTCCCTT	1500
40	CTGGGTGTCT TTGCTGGGAG GGGCTGTGT TGTGAGCCCT CCCGTTCTC ACCTCGCCTG	1560
	GCACTTAACC ACACCTGGT TTTGTGTAGC CGCCAGCTCT CTTCTGGTTG GGCCTTTGAA	1620
45	AGGCTCAGCC TCCCATTTGT CAGTCTTGG GTTTGGAGCT TATTTGAATG GAAGAGGTCA	1680
	GTTTGTCTCT GGCTCTCCAT TTCTGGCTC AGTTGTCTAC AGGACAGTGG TCAGGGATGC	1740
	CTGGAGGCAT ATATCCAGCT GCCACCAAGG GGCAGTGT TTTCCACTT ATGTGAGTGA	1800
50	CCCCATCCAT CCATGACCAG AGGATTATTT TCCTGCCCTG GCAGAGGAGG AGGAGTCAAG	1860
	GGAGCAGGG AGCTCTACCA GGCAAGGTGT TTCCCCAGCA TAGGCGCAGA CAGTTGGGAC	1920
55	GAAACTTCAG AGCCAGGCA GTCCCTGAAT GACCAGGCCA GTGTGTCTAC TGAGTGGTCC	1980
	CCTGCTGGTT GGGAGTGAAG AGAATCCAGG CTGGCAGAGC TGGAGCCAGT TGGGGAGCAC	2040
	GTTCTGGGA GCTCTGCAA ATCAGTAGCA AGTGTGGAA AAGGCACATG CCGAAGATAC	2100
60	TCAAGAGCTC CCAAGATTTG CTTGAGGCTA GCCCAGTGAA RAAAACCAGA GACTCATGTT	2160

	TCCAGGGGTC AGTCTGTCAG GCAGGAAGGA CCCAGGATTT GAACCCAGCT TCAGTGTGCA	2220
5	GGCTCTGAGG CTGCCCAGGA CGGAAAGTC CAAGGAAGGG GCCTGGTGGT GCTCCACTTG	2280
	CAGTTCCTTA AAGAATGCTG CTTTITATTC TCCTAACCTT TTCAAGTGGG TGCAGACTTC	2340
	TCGTTAGCAG CTGGAAGACA TTCTCCAC ACTTTTCCCT TCCTGGCCCA AGAGAGCATC	2400
10	CAGAAGGCAG TAGGACCTGG TTTTTCAGGT ACTGGGAGCC GGGGGCTCAC TGCTTGCACT	2460
	GTGCTTAGGG TAGGGATGGT AAATATCTC OCTGCATGGC TTTATCTCTC CTCTCATCCC	2520
15	AAAGCAGSTA TCTTCTGGT GTACAGAGT TTCATTGAGT CCAGCTGCAG CCACGTGGCC	2580
	ATCTGGAGCT GGTCTATAG GTGACCATCT GGTACATTGA GGGGACCTGT TTGCTCTCTC	2640
	CACTCTATAA GCAGTCATCT TGGGAGACCG GGAGGAGAAG GTGGTGGGCT AGTCTGTGT	2700
20	CCTCTCCAC TTCCCATGCC TCTATGTTAC CCATCTGTGT CTCTGTGCA GAAGGAGAGG	2760
	AAGGGGCATT AAGAGATGAA GGTGATTAT GTATTACTTA TCCATTTCTG AATAAACATT	2820
25	TGTTATCTCT AAAAAAAAAA AAAAAAACT CGAGGGGGGG CCCGGWACCC AWATCGCCSK	2880
	AAAGTGAG	2888

30

(2) INFORMATION FOR SEQ ID NO: 62:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1851 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

40

CACTAGTATA ATTTATAATT ATAACCTATT CTGATTTCCT TTCAAATATT AGGTGTCTTA 60

GTGCTATG AAGGTTTGCC ACTTCATCTT GCACTGTTC CCAAATTTG GACTGAGCTA 120

45

TGCCAGACTC AGTCTGCTAT GTCAAAAAC TGCATCAAGC TTTGTGTGA AGATCCTGTT 180

TTCCGAGAAT ATATTAAATG TATCCTAATG GATGAAAGAA CTTTTTAAA CAACAACATT 240

50

GTCTACAGT TCATGACACA TTCTCTCTA AAGGTTCAA GTCAAGTGT TTCTGAAGCA 300

AACTGTGCCA ATTTGATCAG CACTCTTATT ACAAACCTGA TAAGCCAGTA TCAGAACCTA 360

CAGTCTGATT TCTCCAACCG AGTTGAAATT TCCAAAGCAA GTGCTTCTTT AAATGGGGAC 420

55

CTGAGGGCAC TCGCTTGCT CCTGTCACTA CAACTCCCA AACAGTTAAA CCCAGCTCTA 480

ATTCCAATC TGCAAGAGCT TTAAAGCAA TGCAGGACTT GTCTGCAACA GAGAACTCA 540

60

CTCCAAGAGC AAGAAGCCAA AGAAAGAAA ACTAAAGATG ATGAAGGAGC AACTCCCAT 600

AAAAGCGGC GTGTTAGCAG TGATGAGGAG CACACTGTAG ACAGCTGCAT CAGTGACATG 660
 AAAACAGAAA CCAGGGAGGT CCTGACCCCA ACGAGCACTT CTGACAATGA GACCAGAGAC 720
 5 TCCTCAATTA TTGATCCAGG AACTGAGCAA GATCTTCCTT CCCCTGAAAA TAGTTCTGTT 780
 AAAGAATACC GAATGGAAGT TCCATCTTCG TTTTCAGAAG ACATGTCAAA TATCAGGTCA 840
 10 CAGCATGCAG AAGAACAGTC CAACAATGGT AGATATGACG ATTGTAAAGA ATTTAAAGAC 900
 CTCCACTGTT CCAAGGATTC TACCCTAGCC GAGGAAGAAT CTGAGTTCCC TTCTACTTCT 960
 ATCTCTGCAG TTCTGTCTGA CTTAGCTGAC TTGAGAAGCT GTGATGGCCA AGCTTTGCCC 1020
 15 TCCCAGGACC CTGAGGTGTC TTTATCTCTC AGTTGTGGCC ATTCCAGAGG ACTCTTTAGT 1080
 CATATGCAGC AACATGACAT TTTAGATACC CTGTGTAGGA CCATTGAATC TACAATCCAT 1140
 GTCGTCACAA GGATATCTGG CAAAGGAAAC CAAGCTGCTT CTTGACATTA GGTGTAGCAT 1200
 20 GTCTACTTTT AAGTCCCTCA CCCCCAACCC CCATGCTGTT TGTATAAGTT TTGCTTATTT 1260
 GTTTTGTGTC TTCAGTTTGT CCAGTGCTCT CTGCTTGAAT GGCAAGATAG ATTTATAGGC 1320
 25 TTAATTCTTG GTCAGGCAGA ACTCCAGATG AAAAAAAGTT GCATCTTCAG TATACTTCCT 1380
 AAAGGGCAAT CAGATAATGG ATATGTTTTA TGTAAATTAAG AGTTCACTTT AGTGGCTTTC 1440
 ATTTAATATG GCTGTCTGGG AAGAACAGGG TTGCCTAGCC CTGTACAATG TAATTTAAAC 1500
 30 TTACAGCATT TTTACTGTGT ATGATATGGT GTCTCTGTG CCAGTTTGT ACCTTATAGA 1560
 GGCAGATTGC CTCOGATGC TGTGGTTCTT ATTATCAAAA TTAAGTTTAC TTGTATACGG 1620
 35 AACAACCACA AGAAATTGA TTCTGTAAAG AATCCTCTTT AGCTGTGGCC TGGCAGTATA 1680
 TAAATGGTGC TTTATTTAAC AGAATACCTG TGGAGGAAAT AAAGCACACT TGATGTAAAA 1740
 ATAATGTGTT TATTTTTATT GACATGACTG ATTGATTGCT ATTCTGTGCA CTTAATTAAA 1800
 40 CTGATTGTGA TGACTTWWAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA A 1851

45

(2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:

50

- (A) LENGTH: 3542 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

TCCAATGCTG ATGAGCGTCT TCGCTGGCAG GCCAGCTCCT TGCTGTCTGA TGACCTTTGC 60
 ACAGAAAATG CCATCATGCT GAAACGATTC AATAGGTATC CGCTGATCAT TGACCCCTCT 120
 60 GGACAGGCCA CAGAAITCAT TATGAATGAA TATAAGGWTG GTAAGATCAC ACGGACCAGC 180

	TTCTGGATG ACGCCTTCAG AAAGAACTTA GAGAGTGCAC TGAGATTGG TAACCCCTT	240
5	CTGGTCCAGG ATGTGGAAAG CTACGATCCA GTTTTGAACC CCGTGCTGAA CCGTGAAGTG	300
	CGGCGAACAG GGGGGAGAGT GCTGATCACT CTCGGGGACC AGGACATAGA CCTGTGCCA	360
	TGTTTGTCA TCTTCTGTC CACCCGGAT CCAACTGTG AGTTCACC AGATCTCTGT	420
10	TCCCGGGTTA CTTTGTAAA CTTACAGTT ACCCGTAGCA GTTTACAAAG CCAGTGTCTA	480
	AATGAAGTAC TTAAAGCAGA AAGACCTGAT GTGGACGAGA AACGATCTGA TCTCTTAAA	540
15	CTTCAAGGGG AATTTCAGCT CGTTTGGCT CAGCTGGAAA AATCTCTACT ACAAGCTCTG	600
	AACGAGGTGA AAGGGCGCAT TTGGATGAC GACACGATCA TAACCACTCT GGAGAACCTG	660
	AAGAGAGAGG CTGCAGAGGT CACCAGGAAA GTTGAGGAGA CGGACATTGT CATGCAGGAG	720
20	GTGGAGACCG TGTCACGCA GTACCTCCCG CTCTCCACCG CCTGCAGCAG CATCTACTTC	780
	ACCATGGAGT CCCTCAAGCA GATACACTTC TTGTACCACT ACTCCCTCCA GTTTTCTCTG	840
25	GACATTTATC ACAACGTCCT ATACGAGAAC CGGAACCTGA AGGGTGTAC CGACCACACA	900
	CAGCGCTGT CCATTATAAC AAAGGACCTC TTCCAGGTGG CGTTTAACCG AGTGGCTCGA	960
	GGCATGCTGC ATCAGGACCA CATTACCTTT GCCATGCTGC TGGCAAGAAT CAACTGAAG	1020
30	GGCACCGTGG GGGAGCCAC CTACGATGCA GAATTCCAGC ACTTCTTGAG AGGAAATGAG	1080
	ATTGTCTGA GTGCTGGCTC CACCCCGAGG ATCCAGGGCC TGACTGTGA GCAGCGGAG	1140
35	GCGGTGGTGA GGCTGAGCTG CCTTCCCGG TTAAAGGACT TGATTGCAA GGTTCAGGCA	1200
	GACGAGCAAT TTGGCATCTG GCTGGACAGC AGCTCCCGG AGCAGACTGT GCCCTACCTC	1260
	TGGAGTGAAG AAACACCTGC AACACCCATT GGCCAGGCCA TCCACCGCT GCTCTGATC	1320
40	CAGGCTTTCC GGCCCGATCG CCTGTGGCC ATGGCCACA TGTTTGTTC AACAAACCTT	1380
	GGGAGTCTT TCATGTCCAT CATGGAGCAG CCGCTCGACC TGACCCACAT TGTGGSCACA	1440
45	GAGGTGAAGC CCAACACTCC TGTCTTAATG TGCTCTGTGC CTGGTTATGA TGCCAGTGA	1500
	CATGTCGAGG ACCTTGACG CGAGCAGAAC ACGCAGATCA CTCAATTGC AATCGGCTCT	1560
	GCAGAAGGCT TTAACCAAGC AGATAAGGCA ATAAACACCG CTGTAAAGTC GGGCAGGTGG	1620
50	GTGATGCTGA AGAATGTGCA TCTGGCCCA GGGTGGCTGA TGCAGCTGA GAAGAAGTGA	1680
	CATTCCCTGC AGCCGATGC CTGCTCCGA CTCTCTCTCA CCATGGAGAT CAACCCCAAG	1740
55	GTGCTGTGA ATCTGCTCCG TGCGGGCCGC ATCTTTGTGT TCGAGCCACC GCCAGGRTG	1800
	AAGGCCAACA TGCTGAGGAC GTTCAGCAGC ATTCCCGTCT CACGATATG CAAGTCTCCC	1860
	AACGAGCGTG CCCGCTTGTA CTCTCTGCTG GCCTGGTTTC ATGCGATCAT CCAAGAACGC	1920
60	TTACGATACG CACCACTGGG GTGGTCAAAG AAGTATGAAT TTGGAGAGTC TGACCTGGG	1980

	TCANYTTGCG ATACGGTGGA CACGTGGCTG GATGACACGG CCAAGGGCAG GCAGAACATC	2040
5	TCACCGGATA AGATCCCGTG GTCTGCACTA AAGACCTTAA TGGCCCAGTC CATTATATGGC	2100
	GGGCGCGTGG ACAACGAGTT TGACCAGCGT CTGCTCAACA CCTTCCTGGA GCGCCTGTTC	2160
	ACAACCAGGA GTTTCGACAG TGAGTTTAAAG CTGGCATGCA AGGTCGACGG ACATAAAGAC	2220
10	ATTCAAATGC CAGATGGCAT GCAGGCGAGA GGAGTTTGTG CAGTGGGTGG AGTTGCTCCC	2280
	CGACACCCAG ACGCCCTCCT GGCTGGGCTT GCCCAACAAC GCGGAGAGAG TCCTCCTTAC	2340
15	CACACAGGGT GTGGACATGA TCAGTAAAAT GCTGAAGATG CAGATGTTGG AGGATGAGGA	2400
	CGACCTGGCC TACGAGAGA CTGAGAAGAA GACGAGGACA GACTCCACGT CCGACGGGCG	2460
	CCCTGCCTGG ATGCGGACAC TGCACACCCAC CGCGTCCAAC TGGCTGCACC TCATCCCCCA	2520
20	GACGCTGAGC CACCTCAAGC GCACCGTGGA GAATATCAAG GATCCTTTGT TCAGGTTCTT	2580
	TGAGAGAGAA GTGAAGATGG GCGCAAAGCT GCTTCAGGAC GTTCGCCAGG ACCTTGACAG	2640
25	TGTCGTCCAG GTGTGCGAAG GAAAGAAGAA GCAGACCAAC TACTTGCGCA CGCTGATCAA	2700
	CGAGCTAGTG AAAGGGATCT TGCCTCGGAG CTGGTCCAC TACACGGTGC CTGCCGGCAT	2760
	GACCGTCATC CAGTGGGTGT CCGACTTCAG CGAGAGGATC AAACAGCTGC AGAACATCTC	2820
30	ACTGGCAGCT GCATCTGGTG GCGCCAAGGA GCTAAAGAAC ATCCACGTGT GCCTGGGTGG	2880
	CCTGTTGCTG CCTGAGGGGT ACATCACTGC CACCAGGCAG TATGTGGCCC AGGCCAACAG	2940
35	CTGGTCCCTG GAGGAGCTCT GCCTGGAAGT CAACGTCACC ACCTCACAGG GCGCCACCCT	3000
	TGACGCTTGC AGCTTCGGAG TCACGGGTTT GAAACTTCAA GGGGCCACGT GCAACAACAA	3060
	CAAGCTGTCA CTGTCCAATG CCATCTCAAC CGCCCTTCCC CTGACGCAGC TGCGCTGGGT	3120
40	CAAGCAGACA AACACCGAGA AGAAGGCCAG TGTGGTAACC TTACCTGTCT ACCTGAACTT	3180
	CACCGTGCA GACCTCATCT TCACCGTGA CTTGAAATT GCTACAAAGG AGGATCCTCG	3240
45	CAGCTTCTAC GAGCGGGGTG TCGCAGTCTT GTGCACAGAG TAAACTTTTC TAGCTGCCCC	3300
	TTTCTGTAAT AGTGAAAGTT GGTATTTAAC ATTTATTCAT TTTTAAATA TTTGGAAGGT	3360
	CTGAGCTTGT GAAAAGAAAG TGGTTGGTCT GAGGTTGGAG GAAGCTGAAT GGAATCTGAC	3420
50	GGTTGGGAGT GGTGGAAATT GGAAGGATAC CAGGAGGTAT TTGGGAAGGC CAATGGCGTG	3480
	GCTCCTTTGA GGAAATAAAA CACTAAGCAT GAAAAAATAA AAAAACTTA CAANCCNCAA	3540
55	GG	3542

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 883 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

5
10
15
20
25
30
35
40

AGGTGATTTT AATGATAGGT GTCATATATA GGACGGATAA TCTGTTTACA TTCTGTTCTT 60
CTCGATGCAC TCACAAGCGG GTAAGTAGGT GACAAGAAAA CAAAGATCTT ATTCAAAGA 120
GGTCTTACAG CAACCCAACG TCTCATCTTC CCATAGTAAA GATGACGGCG CCTTGAGGTA 180
AGCTACAGGC AACACCATT CCAGCTTCTT CTTGGCCCTT GGTCCAAGAT GGCGGATGAA 240
GCCACGGGAC GTGTGTGTG TGAGATCCCG GTGCTGAAGA CTAACGCCGG ACCCCGAGAT 300
CGTGAGTTGT GGGTGCAGCG ACTGAAGGAG GAATATCAGT CCCTTATCCG GTATGTGGAG 360
AACAACAAGA ATGCTGACAA CGATTGGTTC CGACTGGAGT CCAACAAGGA AGGAACTCGG 420
TGGTTTGGA AATGCTGGTA TATCCATGAC CTCCTGAAAT ATGAGTTTGA CATCGAGTTT 480
GACATTCTTA TCACATATCC TACTACTGCC CCAGAAATTG CAGTTCTTGA GCTGGATGGA 540
AAGACAGCAA AGATGTACAG GGGTGGCAA ATATGCCTGA CGGATCATTT CAAACCTTTG 600
TGGGGCCAGG AATGTGCCA AATTGGACT AGCTCATCTC ATGGCTCTGG GGCTGGGTCC 660
ATGGSTGGCA GTGGAAATCC CTGATCTGAT TCAGAAGGGC GTCATCCAAC ACAAGAGAA 720
ATGCAACCAA TGAAGAATCA AGCCACTGAG GCAGGGCAGA GGGACCTTTG ATAGGCTACG 780
ATACTAWTTT CCTGTGCATC AACTTAACT CATCTAACTG TTCCCCGGAC ANCTCCACT 840
CTAGTTGTTA CTAAGTANTG CAGTAGCATT NTGGGAAGA ACA 883

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1541 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

50
55
60

GGCAGAGGT GGCTCTACC CTGGCTCAT CTGGCTACAC AGGACTCTA AACGCTTCCA 60
GATTCCTTGG AAACATGCCA CCCGGCATAG CCCTCAACAA GAAGAGGAAA ATACCATTTT 120
TAAGGCCTGG GCTGTAGAGA CAGGAAGTA CCAGGAAGGG GTGGATGACC CTGACCCAGC 180
TAAATGGAAG GCCAGCTGC GCTGTGCTCT CAATAAGAGC AGAGAATTCA ACCTGATGTA 240
TGATGGCACC AAGGAGGTGC CCATGAACCC AGTGAAGATA TATCAAGTGT GTGACATCCC 300

	TCAGCCCCAG GGCTCGATCA TTAACCCAGG ATCCACAGGG TCTGCTCCCT GGGATGAGAA	360
5	GGATAATGAT GTGGATGAAG AAGATGAGGA AGATGAGCTG GATCAGTCGC AGCACCATGT	420
	TCCCATCCAG GACACCTTCC CCTTCCTGAA CATCAATGGT TCTCCCATGG CGCCAGCCAG	480
	TGTGGGCAAT TGCAGTGTGG GCAACTGCAG CCCGGAGGCA GTGTGGCCCA AACTGAACC	540
10	CCTGGAGATG GAAGTACCCC AGGCACCTAT ACAGCCCTTC TATAGCTCTC CAGAACTGTG	600
	GATCAGCTCT CTCCCAATGA CTGACCTGGA CATCAAGTTT CAGTACCGTG GGAAGGAGTA	660
15	CGGCAGACC ATGACCGTGA GCAACCTCA GGGCTGCCGA CTCTTCTATG GGGACCTGGG	720
	TCCCATGCCCT GACCAGGAGG AGCTCTTTGG TCCCGTCAGN CTGGAGCAGG TCAAATTCCT	780
	AGGTCTGAG CATATTACCA ATGAGAAGCA GAAGCTGTTC ACTAGCAAGC TGCTGGACGT	840
20	CATGGACAGA GGAATGATCC TGGAGGTCAG CGGTCATGCC ATTTATGCCA TCAGGCTGTG	900
	CCAGTGCAAG GTGTACTGGT CTGGGCCATG TGCCCCATCA CTGTGTGCTC CCAACCTGAT	960
25	TGAGAGACAA AAGAAGGTCA AGCTATTTTG TCTGGAAACA TTCTTAGCG ATCTCATTGC	1020
	CCACCAGAAA GGACAGATAG AGAAGCAGCC ACCGTTTGAG ATCTACTTAT GCTTTGGGGA	1080
	AGAATGGCCA GATGGGAAAC CATTGGAAG GAAACTCATC TTGGTTCAGG TCATTCCAGT	1140
30	AGTGGCTCGG ATGATCTACG AGATGTTTTT TGGTGATTTT ACACGATCCT TTGATAGTGG	1200
	CAGTGTCGCG CTGCAGATCT CAACCCAGCA CATCAAGGAT AACATCGTTG CTCAGCTGAA	1260
35	GCAGCTGTAC CGCATCCTTC AAACCCAGGA GAGCTGGCAG CCCATGCAGC CCACCCCCAG	1320
	CATGCAACTG CCCCCTGCCC TGCCCTCCCCA GTAATTGTGA ATGCCATCTT CTTCTTCTC	1380
	TTTTTTATAA TATTGTACAT ATGGATTTTT TTATGTGTTA GATTTAACCA GCTTTTAAAT	1440
40	CTCTGTTTTC TGTGACAGTG TTAGAAGTTT GTGATTCTCC AAATATGCCT AGATTTAAAG	1500
	CTGATTTAAT TTATGGAAAA AAAAAAAAAA AAAAAAAAAA A	1541

45

(2) INFORMATION FOR SEQ ID NO: 66:

50

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 732 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

60

AGAAAAATGAA TGTTAGAAGG TGCCTGCCGA GCGGGGACAG AGTGTTTGCT CGCGCTGGAG	60
AAGGCTCTGC TCAGCCCTGA GAGTCCCTTC CTGCCCCACC GATACTGGCA CTTTAAAAAG	120

GAAGCTGACC GCACAGTGTC CAGACGAATT GGCCCCCAGA AGATGGGGAG TTCTGTCTCTG 180
CCCTTCTGTG TCTGGGTGAC CTCACCCAGC CTAGGAGGGA GGTGCATTCA GGGTAGATTT 240
5 GCCTCTCATT CAAAGTTCTG GGGCTTTGGG CGGAAAACAG CCAGCTTTGG CGCTGTGGG 300
GAGACTCTC CAGACCAGGA ACCCCAGAAG GAGACAGAGC CTGCCACATC CTCCCACGCC 360
10 AGGCCCTGGG CCAGGGTGAT TGGACTGAGA ATTGGCCAC AACCAAATG ATGCTGGCTG 420
GAACCAGAGG CCAGAAAGCC TGGCCTTGTC CCCATGTGGG AGCCCTGTCC TCAGCCCTCT 480
TGTCCCTTG AGCTCAGTGA ATTCCACCA GGTGCCACA GCTCTGGAC TTCAAATTCT 540
15 ATATATTGAG AGAGTTGGAG AGTATATCAG AGATATTTT GGAAAGGAGT TGGTCTATGC 600
AATGTCAGTT TGAATCTTC TTGAAAGTTT AATGTTTTTA TTAGGAGATT TAAAGAAAAT 660
20 AAAGGTCTAC AATATCAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 720
AAAAAAAAAA AA 732

25.

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:

30

- (A) LENGTH: 629 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

TTAAGGAATT CGGCMGATC CCGGCAAGTA ACATGACTAA AAAGAAGCGG GAGAATCTGG 60
GGGTGCTCT AGAGATCGAT GGGCTAGAGG AGAAGCTGTC CCAGTGTCCG AGAGACCTGG 120
40 AGGCCGTGAA CTCCAGACTC CACAGCCGGG AGCTGAGCCC AGAGGCCAGG AGGTCCCTGG 180
AGAAGGAGAA AACAGCCTA ATGAACAAAG CCTCCAATA CGAGAAGGAA CTGAAGTTTC 240
TTGGCAAGA GAACCGGAAG AACATGCTGC TCTCTGTGGC CATCTTTATC CTCCTGACGC 300
45 TCGTCTATGC CTACTGGACC ATGTGAGCCT GGCCTTCCC CACAACCAGC ACAGGCTTCC 360
ACTTGGCCCC TTGGTCAGGA TCAAGCAGGC ACTTCAAGCC TCAATAGGAC CAAGGTGCTG 420
50 GGGTGTTCCT CTCCTAACCT AGTGTCAAG CATGGCTTCC TGGCGGCCCA GGCCTTGCCT 480
CCTTGGCCTG CTGGGGGGTT CCGGTCTCC AGAAGGACAT GGTGCTGGTC CCTCCCTTAG 540
CCCAAGGGAG AGGCAATAAA GAACACAAAG CTGAAAAAA AAAAAAAAAA AACTCGTAGG 600
55 GGGGGCCCGT ACCCAATCGC CCTNTCGTG 629

60

(2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1751 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

10 CTGCTAGCCG GCCGGCGCAG GCTGCCGAGC GGGTGAGCGC GCAGGCCAGG CCAAAGCCCT 60
GGTACCCGCG CGGTGCGGGC CTCAGTCTGC GGCCATGGGG GCGTCCGCGC GGCTGCTGGG 120
15 AGCGGTGATC ATGGGGGCCC CGGGCTCGGG CAAGGGCACC GTGTGCTCGC GCATCACTAC 180
ACACTTCGAG CTGAAGCACC TCTCCAGCGG GGACCTGCTC CGGGACAACA TGCTGCGGGG 240
20 CACAGAAATT GCGGTGTTAG CCAAGGCTTT CATTGACCAA GGGAAACTCA TCCCAGATGA 300
TGTCATGACT CGGTGGGCC TTCTATGAGCT GAAAAATCTC ACCCAGTATA GCTGGCTGTT 360
GGATGGTTTT CCAAGGACAC TTCCACAGGC AGAAGCCCTA GATAGAGCTT ATCAGATCGA 420
25 CACAGTGATT AACCTGAATG TGCCCTTTGA GGTCAATAAA CAAGCCCTTA CTGCTCGCTG 480
GATTCATCCC GCCAGTGGCC GAGTCTATAA CATTGAATTC AACCTCCCA AACTGTGGG 540
30 CATTGATGAC CTGACTGGGG AGCCTCTCAT TCAGCGTGAG GATGATAAAC CAGAGACGGT 600
TATCAAGAGA CTAAAGGCTT ATGAAGACCA AACAAAGCCA GTCCTGGAAT ATTACCAGAA 660
AAAAGGGGTG CTGGAAACAT TCTCCGGAAC AGAAACCAAC AAGATTTGGC CCTATGTATA 720
35 TGCTTTCCCTA CAAACTAAAG TTCCACAAAG AAGCCAGAAA GCTTCAGTTA CTCCATGAGG 780
AGAAATGTGT GTAACATTA ATAGTAAGAT GGGCAAACCT CCTAGTCCTT GCATTTAGAA 840
40 GCTGCTTTTC CTAAGACTTC TAGTATGTAT GAATTCCTTG AAAATTATAT TACTTTTATT 900
TCTACTGATT TTATTTTGGG TACTAAGGAT GTGCCAAATG ATTGGGATAC TAAGATGCAT 960
CGTTTGAAAT CATCTAGTGT GTTGATGCA GTTATCCTCA AAAACATCAG CGATGTCTGA 1020
45 ACCTTTAAAA CATCTGTTAG AGCAAAATTA AAAGAGCATT TGGTAGTAAT CTAACCTTTT 1080
GTTCAAGTTA TAAGTGGTTG ATAAAGTTTC CATATTTTTC TGGAAAAGTT AAAAAAGTT 1140
50 ACATGTCATT TGGAGAAAAT ACGTAATCAG AAATTTGTGC ATAGATTGAT GCCAAAAAG 1200
ACATTTCCAG CATTGTGGAA CATGGTGAGA CACTATATAA AATTCAGAA AGAAAGCAAC 1260
TGGATTTACA GATTTATTGT GAGACACAAA TTCCTGCTG CCTTTACACT AAGAAATGTA 1320
55 TATGTTAACC ATATATGCTG TATTTATTTT GTCGTTAAGC ATACTTTCAG TTTACTCAGA 1380
ATTTTCAATT TGCTATAAAG ATGTATCAAT TAGCATATAG AAAATATTA CTTTAAGATG 1440
60 ACTTGTTCCT TTGAAAATA CCTGTGTAAT GAGGGTTATG ATTTGTGTCA AAAATTGACA 1500

TAAGTGCTTT TACAAGCACC AAAGTTGAAT GAATTTTCAA CAAAATGTAA TTAAAGTCTA 1560
TGTTTTTCAGT TATGACTCAG GTTAAGAAAT GTGTTTTAGG ATCTACTTGC TGGTTTTTCT 1620
5 TTTTGATCCA AATGTGTGAT CTGCCCTGAT AAATAACAAG TTATNGTACC ATCTCCCCCG 1680
CCAATAAAAA AAAAAAAAAA AAAAAAAAAAC TCGAGGGGGG GCCCGGTACC CAATTCTCCG 1740
NAATAGGNAG T 1751
10

(2) INFORMATION FOR SEQ ID NO: 69:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 508 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

20

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

GGCACGAGAT TATGTATTAA AATGTTTTTG AATGTGAAA TATTAGAATA TTGTTACTAT 60
25 TTGACCCAAC TCAAAATCTC CATGGGAAA TACCTGTGCA TACCCACAGT ATTGTTGAAA 120
ATAATCAGAT GCAGTATCAC AGCTGTGTCA GACTCTAGTA CCAGTTGGGC AATCAAGGCA 180
30 CAGCTAAAAA TTGAAAACAA AGATCTGGAC AACAAAACAG CCAAAGGTGG GGGTCAAGAA 240
GCTCTGACGT GTACCTAGCT GTAGAATGCT ATGCACACGT GCCAGGTGTA GTGTGCATAT 300
CCAGGAAAAA CTGCAGAGAG CCCAGTCTT CACCTCTGGT TGACCATGAG CTCTGTGTAA 360
35 GCAGGAAGTG AAGGCTAAGG CAGATTTAAG CTCTGAAAGC ATTCCACAAC ATACACACAA 420
ATCGTGCAAA GCATTAAGGA AATCTTGTTA CTGCTAAGTG TTGCTGACCC AGGAACAAC 480
40 CCTACTCAGC TGGACTTAAA AATAAAAA 508

45 (2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 245 base pairs

(B) TYPE: nucleic acid

50

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

TACATAGAGC AAAGAGAAAT TTCCAGAATT TCTARAATTC TGGAAAGAGA ATTTTCCTGA 60
GATGTCAGAT TTGCTTGTGT CCTCAGGTGA TGATGAGGGC TGTTTTCCCC TGTGTCTCTT 120
60 TCCTCACACT CATGCTTCCT CTCTAGAGT GTCTGGTTGG CATGATCATG TGCTACCTAG 180

GCATTTCCTT CACTGATACA AGGAAACTG CAGGGTTAAA AAAAAAAAAA AAAAAAAAAA 240

NCNCG 245

5

(2) INFORMATION FOR SEQ ID NO: 71:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 361 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

ATGTTCTCA TGAGGATGCA CTGTGCTTC TGCAAGTATT GCTGCAGCTT CATAGTGACT 60

20 CCCACCAGCA CCAGCAATAC AGCTAGCTAC CTGTGGCCTT GGATCTCAGC CAGCATGGCT 120

GGGAGAGGGA GCAGCTGGGC ATGTACCCTA AATGCTGTTA CCAGGGAAGG ACTCCAGAG 180

25 TGAAGACAAG TAGGGACTTC CTCAGAGGT GGTACATGTG CTCTCTGTAT CCATACTTTT 240

TTTTTTTTTT TTTTGAGATA GAGTTTCACC CTGTGTGCCC TGGCTGGAGT GCAATGGTGC 300

GATCTCAGCT CACTGCAACC TCTCTGCCTC CCGGGTTCAA GTGATTCTCC TGCCTCAGCC 360

30 T 361

35 (2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 713 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

45 AGGATCACAC AATAGAGAAC ACTGTAGTAA CATTTCCGTC TGCTCACAAG ACCCAGAACA 60

TTGATCAGTT TTGTTGTTG GTTTATTATT TTCTGTATA AAAATTGTGA AAAGTTTGTT 120

50 TTAGCTAGAT GATATTTTAA TAGCTGCGAG TGCTTTGGAA CTATAAGAT GTCACTACTT 180

AACACACATA CCTATGTTT TGTPTTGTTT TGTPTTACAC TCAGTATAAA TCAGGAGAAG 240

TTAGCCAACC ATCTAGCATT TAGAATCCTC TTTTATTATT TCTTCTAAGG ATATGGATGT 300

55 TCCCATACA GCAACAAAC AGCAACAAA ACATTTTATA AATATCACTT GATAGACTGT 360

AAGCACCTGC TTAACTTTGT GTCCCAAATA TTTAGTGTGT ATATATATAT ATATATATAC 420

60 ACACACACAC ACATATATAT TCAACAAATA AAGCAAATA TAACATGCAT TTCACATTTT 480

GTCTTTCCCT GTTACGATTT TAATAGCAGA ACTGTATGAC AAGTTTAGGT GATCCTAGCA 540
TATGTTAAAT TCAAATTAAT GTAAAACAGA TTAACAACAA CAAAGAACT GTCTATTGA 600
5 GTGAAGTCAT GCTTTCTATT ATAATAACTT GGCTTCGGTT ATCCATCAAA TGCACACTTA 660
TACTGTTATC TGATTGTTTA TAATAAGAA TACTGTACTT ATAAAAAAA AAA 713

10

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 862 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

GAAAGTCAGA GCTGTCCAAT CCCTCAGCAC CTTTITAGATT TGCTCCAAAT TAGAAACGTG 60
GGGACTATGT GTTCTGGGCA ATCAGAGGTC TGGAAAATGG CTCTGCAGGC TCTTGATAGT 120
25 GAGACAGTGG TCATCTTACC AGACATGCAT CTGATTTTAA GCCTCAGGCT AATCCACAAT 180
GCTCGGCCAT GCCTATGATT AACAAACAAA AGCAAAATCT GCTTTTATAG TTTAGGAAAC 240
30 CTGGATAGAA CAGTATTTTT CAGCATTTCTT GGATAAAGCA GTTCTGCATT TTAAATTGG 300
GACTGCAGAA GTGACTGTCT ATAGTTGTGA AATACAAAAA ATGGTATGTT TGATCAGAAA 360
AGGAAGCCCG TGCTGGCAC TTGGAAAGAT ACTGAGCATC ATAACCCTAA TGAGAAAATG 420
35 TAGGCTCTGT GAATGTTAAC TACAAATCAG GTTAGGAAAG CATATGACAC CCTTTGTCAA 480
ACTAAGCTTC ACTAGGAGGA CCTGTGCTCA TAGAAGAATA TGCTTTAAAA GTATCAATTT 540
40 TCCACAGTCG ATGATGGAGA AAAGTTCATT TGCACCAGAA TGCTGATAGT CACAATACAC 600
AGCCTGACAT ATATACAAT ACAGTTTCTT GTAAACAGAA GTTCTTCCTC TTCCAATTCA 660
GGAGTCAGTC AGAGCATAAA TATTGCATGT TTCACTTTAG AAAGTGATTC ATTTTAGAAA 720
45 GCAGATCTGG ATTATTTTGC AGGGTAGAAA TGAAGCTAT TTCTGGCATT CTGTCTCAA 780
AAGTCAATAT ATGTACATTA AGTATAAAAA AGGGTCTCTT TCACCTCTTT TGTTTCGTAG 840
50 CATGGCTAC ATAACCTGTG CC 862

55 (2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4602 base pairs
60 (B) TYPE: nucleic acid
(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

5	GCGAGGGGGC GKGGGGAGCA GCGCCGARGC CGCCGCCCTCC GCCTCCGCCG CCTAGGACTA	60
	GGGGGTGGGG GACGGACAAG CCGGATGCC GGGGGAACG GAAGAGCCGA GACCCCGGA	120
	GCAGCAGGAC CAGGAAGGGG GAGAGGGGCG CAAGGCGGCT CCGGAGGACC CGCAACAACG	180
10	GCCCCCTGAG GCGGTGCGG CGGCGCCTGC AGGGACCACT AGCAGCCGCG TGCTGAGGGG	240
	AGGTCCGGAC CGAGGCCGGG CCGCTGCGRC CGCCGCGCMG CAGCTGTGTC CCGCCGGAGA	300
15	AGGCCGAGTA TCCCCGCCG CGAGGAGCAG CCCCAGCGCC AGGCTCCCG ACGTCCCCGG	360
	GCAGCAGCCC AGGCCGGAA GTCCCGTCT CCAGTTCAGG GCAAGAAGAG TCCGCGACTC	420
	CTATGCATAG AAAAAGTAAC AACTGATAAA GATCCCAAGG AAGAAAAGA GGAAGAAGAC	480
20	GATTCTGCCC TCCTCAGGA AGTTTCCATT GCTGCATCTA GACCTAGCCG GGGCTGGCGT	540
	AGTAGTAGGA CATCTGTTTC TCGCATCGT GATACAGAGA ACACCCGAAG CTCTCGGTCC	600
25	AAGACCGGTT CATTCAGCT CATTTGCAAG TCAGAACCAA ATACAGACCA ACTTGATTAT	660
	GATGTTGGAG AAGAGCATCA GTCTCCAGGT GGCATTAGTA GTGAAGAGGA AGAGGAGGAG	720
	GAAGAAGAGA TGTTAATCAG TGAAGAGGAG ATACCATTCA AAGATGATCC AAGAGATGAG	780
30	ACCTACAAAC CCCACTTAGA AAGGGAACC CCAAGCCAC GGAGAAAATC AGGGAAGGTA	840
	AAAGAAGAGA AGGAGAAGAA GGAATTAAA GTGGAAGTAG AGGTGGAGGT GAAAGAAGAG	900
35	GAGAATGAAA TTAGAGAGGA TGAGGAACCT CCAAGGAAGA GAGGAAGAAG ACGAAAAGAT	960
	GACAAAAGTC CACGTTTACC CAAAAGGAGA AAAAAGCCTC CAATCCAGTA TGTCGGTTGT	1020
	GAGATGGAAG GATGTGAAC TGTCCTTGCC CATCTCGCT ATTTGCAGCA CCACATTAAA	1080
40	TACCAGCATT TGCTGAAGAA GAAATATGTA TGTCCCCATC CCTCTGTGG ACGACTCTTC	1140
	AGGCTTCAGA AGCAACTTCT GCGACATGCC AAACATCATA CAGATCAAAG GGATTATATC	1200
45	TGTGAATATT GTGCTCGGC CTTCAAGAGT TCCCACAATC TGGCAGTGCA CCGGATGATT	1260
	CACACTGGCG AGAAGCATTA CAATGTGAGA TCTGTGGATT TACTTGTGCA CAAAAGGCAT	1320
	CTCTTAATTG GCACATGAAG AAACATGATG CAGACTCCTT CTACCAGTTT TCTTGCAATA	1380
50	TCTGTGGCAA AAAATTGAG AAGAAGGACA GCGTAGTGGC ACACAAGGCA AAAAGCCACC	1440
	CTGAGGTGCT GATTGCAGAA GCTCTGGCTG CCAATGCAGG CGCCCTCATC ACCAGCACAG	1500
55	ATATCTTGGG CACTAACCCA GAGTCCCTGA CGCAGCCTTC AGATGGTCAG GGTCTTCCTC	1560
	TTCTTCCTGA GCCCTGGGA AACTCAACCT CTGGAGAGTG CCTACTGTTA GAAGCTGAAG	1620
60	GGATGTCAAA GTCATACTGC AGTGGGACGG AACGGGTGAG CCTGATGGCT GATGGGAAGA	1680

	TCTTTGTGGG AAGCGGCAGC AGTGGAGGCA CTGAAGGGCT GGTATGAAC TCAGATATAC	1740
	TCGGTGCTAC CACAGAGGTT CTGATTGAAG ATTCAGACTC TGCCGGACCT TAGTGGACAG	1800
5	GAAGACTTGG GGCATGGGAC AGCTCAGACT TTGTATTTTAA AAGTTAAAAA GGACAAAAAA	1860
	AAAATCTAAA GCATTTAAAA TCTAGTGAAA TAACTGAAGG GCCTGCTCTT TCCATTGTGG	1920
10	ATCACAGCAC ACACATACAT ACACCCCTCCA CCTCCCCATC CCTGTTCCTC CCTCTGTTCG	1980
	TCCCCTTATA AAATTGATGT TGTCTTTACC AGAAAGGTAG ACAAAAAAGA AGCAGCAGCA	2040
	GCTCTTAAAG TGAGGGTTAT TCTCATACTC GGTTCAGCC ATCAGCAGAC TTCTGCTCA	2100
15	TCGGCAGATC CCCCCTTCCA ACCGTAACT CTGATGTGCT CTGGATCAGC TTTTAACTTT	2160
	TAATCATATA TTAGTGTCTT CTAAATCCCT TCTCCTCCTC TACTGCTGCC CTATGGTTCT	2220
20	GGCTCCTACC CCTGGGGCA CACTTATCTT CAAATACCAT AGAATCTAA TCTCTGAAAT	2280
	CATAGCTCTC CAGTGGCTTT TAAAGAAAGC TGGTCTCAG CACTAACAAA ATCACTACAA	2340
	TAGCCTAGTG CTTTTTTGGA AGCCTTTTTA GGGAAAGAATG TTAGGTTTCAT GGTAAGTAGT	2400
25	ATGCTCTTTG AGATTTTTAC AGTGTGAAA CTTAAGAATT TTGAGAGGGT GAGGAGGGTT	2460
	GTTCAGAATC TAAATTACAG ATAGATGATT GTTCTTGTG AATTGTGTTT TTTTCCTTTT	2520
30	TTTTGTGCC TACCATTTC TTACATTTCC CTGGGGCCC ATCTCTGGCT CCTGTCTTTT	2580
	TGTTCTTGC TTGCTTTAT CAGTTCATTC CAGCTCCCTG TTAGTGAAGG ACACTGCTGT	2640
	TAGTGAAGGA ACAAAGTCTA TGAGTCTAA AATTTAAGT CAAAGAAAAC TGCTCTGTTT	2700
35	CCCCTTAGT AACACTTCTG AAGAGGAAAA ACTTCAATAG CCAAAGTTAA TAATCCTATA	2760
	TAATAATTGC TTTGGCTTTC ACCTAAAATT CTGGGCATCA CAATTTCTTT GGGATAGAGG	2820
40	TTGTGTGGG GAATAGATTG CTTATTGCTG TTCACTGGAG AGAAAAGGTA GTGTTTTTGT	2880
	ACAAGGTCAT ACCGCCAGAA GCCCCAAATC CTATTTTGGC TCATCTTCAG GTAAAGAGTA	2940
	ATTCCTATCC TGTGTGCTC AGAAGCTAGA ATCGAAGGCT TACCCTATTC ATTGTTTATT	3000
45	GTCAGAAATG CATGATGGCT CTTGGAAAGA ATGACGTTTT GCTGGAAAAA AAAAAAARAA	3060
	CMGTTTGTGT TTCACAAACA TGGCTTATCA ATTTTTTCAA AGAATTCCTT TTTCCAAAA	3120
50	AGAGGAGTAA CAAATGTCA TTTCTGAAAG AGGCTTACTT TATACCAACT AGTGTGAGCA	3180
	TTTGGGATGC CAGGGAACAG AGAGTGAGAC ACCTACAATC ACCAGTCTCA AATGCGCTAT	3240
	TGTTTCTTTT CAGAGTGTG CAGATTGOC ATTTCTCCAT AATATGGGGA TAGAAAATGG	3300
55	AATAAGATA GAAGGGATGT AGAATATGCT TTCTTGCCAA CATGGTTTGG AGTCGACTTT	3360
	GGTATATTGA CTAGATTGA AAATACAAGA TTGATTAGAT GAATCTACAA AAAAGTTGTC	3420
60	CTCCTCTCAG GTCCCTTTTA CACTTTTTGA CTAAGTAGCA TCTATATTCC ACACTTAGCT	3480

	TTTTTGTAC ACTTATCCIT TGTCTCCGTA AATTTCATTT GCAGTGGTTA GTCAICAGAT	3540
	ATTTTAGCCA CCTACACAAA AGCAAAGTGC ATTTTAAAA ATCTTTCTGA GATGGGAGAA	3600
5	AATGTATTCT CCTTCCTAT ACCGCTCTCC CAACAAAAA ACAACTAGTT AGTTCTACTA	3660
	ATTAGAACT TGCTGFACTT TTCTTTTCT TTTAGGGGTC AAGGACCCCTC TTTATAGCTA	3720
10	CCATTTGCCT ACAATAAAT ATGTCAGCAG TTGCAATAC TAAAAATATT TTTATAGACT	3780
	TTATATTTTT CCTTTTGATA AAGGGATGCT GCATAGTAGA GTTGGTGTA TTAAGTATC	3840
	TCAGCCGTTT CCTGCTTTC CCTTCTGCTC CATATGCCCTC ATTGTCTTC CAGGGAGCTC	3900
15	TTTTAATCTT AAAGTCTAC ATTTATGCT CTTAGTCAA TTCTGTTACC TTTTAAATA	3960
	CTCTCCAC TGCATATTC CATCTGAAT TGGTGGTCT AAATCTGAA ACTGTAGTTG	4020
20	AGATACAGCT ATTTAATATT TCTGGGAGAT GTGCATCCCT CTCTTTGTG GTTGCCCAAG	4080
	GTGTTTTC GTAAGTAGA CTCTTGATA TGCTTCAGAG AATTAGGCA AACACTGGCC	4140
	ATGGCCGTGG GAGTACTGG AGTAAATAA AAATATCGAG GTATAGACTA GCATCCACAT	4200
25	AGAGCACTG AACCTCCTTT GTACCTGTTT GGGGAAAAAG TATAATGAGT GACTACCAA	4260
	TCTAACTAAG ATTATTATAG TCTGTTGTT TGAATACCA TTTTCTCTC CTTTGTGTT	4320
30	TTTCCACTT TCCAATGTAC TCAAGAAAT TGAACAAATG TAATGGATCA ATTTAAATA	4380
	TTTTATTCT TAAAGCCTT TTTGCTGT TGTAATGTG AGGACCCTC TCCTTTCATG	4440
	GGAGAGACAG GTAGTTACCT GAATATAGT TGAAGAGTT ATGTAAAAAG AAATTATAAT	4500
35	AAAAGGATA CTMGCTTTT CAAATCTTG TTTCTCTTA TTCTAGGTAA GGCATATTAA	4560
	AAATAAATAT GTAAAGAAGA AAAATAAAG TTGTCTTCAT GG	4602

40

(2) INFORMATION FOR SEQ ID NO: 75:

45

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1255 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

	CGCGCCCCGG GCCGGCGGGT TTCTCTAACA AATAACAGA ACCCGCACTG CCCAGGCGAG	60
55	CGTTGCCACT TTCAAAGTGG TCCCTGGGG GAGCTCAGCC TCATCCTGAT GATGCTGCCA	120
	AGGCGCACTT TTTATTTTTA TTTATTTTT ATTTTTTTTT TAGCATCCTT TTGGGGCTTC	180
	ACTCTCAGAG CCAGTTTTTA AGGGACACCA GAGCCGAGC CTGCTCTGAT TCTATGGCTT	240
60	GGTGTACT ATAAGAGTAA TTGCCTAACT TGATTTTCA TCTCTTTAAC CAAACTTGTG	300

5 GCCAAAAGAT ATTTGACCGT TTCCAAAATT CAGATTCTGC CTCTGCCGAT AAATATTTGC 360
 CACGAATGAG TAACTCCTGT CACCACTCTG AAGGTCCAGA CAGAAGGTTT TGACACATTC 420
 TTAGCACTGA ACTCCTCTGT GATCTAGGAT GATCTGTTC CCTCTGGAT GAACATCCTC 480
 TGATGATCAA GGCTCCAGC AGGCTACTTT GAAGGAACA ATCAGATGCA AAAGCTCTTG 540
 10 GGTGTTTATT TAAATACTA GTGTCACTTT CTGAGTACCC GCGCTTCAC AGGCTGAGTC 600
 CAGGCCCTGTG TGCTTTGTAG AGCCAGCTGC TTGCTCACAG CCACATTTCC ATTTGCATCA 660
 TTACTGCCTT CACCTGCATA GTCACCTTTT TGATGCTGGG GAACCAAAAT GGTGATGATA 720
 15 TATAGACTTT ATGTATAGCC ACAGTTCATC CCCAACCCCTA GTCTTCGAAA TGTTAATATT 780
 TGATAAATCT AGAAAATGCA TTCATACAAT TACAGAATTC AAATATTGCA AAAGGATGTG 840
 20 TGTCTTTCTC CCCGAGCTCC CTGTTCCTCC TTCATTGAAA ACCACCACGG TGCCATCTCT 900
 TGTGTATGCA GGGCTATGCA CCTGCAGGCA CGTGTGTATG CACTCCCCGC TTGTGTTTAC 960
 ACAAGCTGTG GGGTGTACG CATGCTGCT TTTTTCACCT AATAATACAG CTTGGAGAGA 1020
 25 TTTTGTATC ACATTATAAA TCCCACTGCT TCTTTTGTAT GGCCACATAA TAACTACTGC 1080
 ATAATATGGA TACGCCTTAT TTGATTTAAC TAGTTCCTTA ATGATGGACT TTTAAGTTGT 1140
 30 TTCCTTTTTT TTCTTTTTT GCTACTGCAA ACGATGCTAT AATAAATGTC CTTATCAAAA 1200
 AAAAAAAAAA AAAAAAAAAA AAAAAANCCC NGGGGGGGGG CCCC GGGAAC NCAAT 1255

35

(2) INFORMATION FOR SEQ ID NO: 76:

40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 475 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

GGCACGAGAG AAATGTTTGA TTCTCTTCC TATTTTAAGG GATCTTCTCT CTGTTGATG 60
 TTGAAACTT ACCTTAGTGA AGATGTGTTT CAACATGCTG TTGTCCTTTA CCTGCATAAT 120
 50 CACAGCTATG CATCTATTCA AAGTGATGAT CTGTGGGATA GTTTTAATGA GGTCAAAAC 180
 CAAACACTAG ATGTAAAGAG AATGATGAAA ACCTGGACCC TGCAGAAAGG ATTTCTTTTA 240
 55 GTGACTGTTT AAAAGAAAGG AAAGGAAGT TTTATACAAC AAGAGAGATT CTTTTTAAAT 300
 ATGAAGCCTG AAATTCAGCC TTCAGATACA AGGTACATGC CCTCTTCTT TTCATGCCAT 360
 60 CTCTTTTGCA CTCTCAGGTG GAAATATTTT GAAGTGTTT ATAATCATAA GTTCTTGTTA 420

AACCTAACAA GATTATCCCT TCCTAAGAAT ACTTAACCTT CCTACCAAAT TAAAA

475

5

(2) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:

10

- (A) LENGTH: 465 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

15

TTCTCTCTGC TCCTCGACTG CACCGCACTC GCGCGTGACC CTGACTCCCC CTAGTCAGCT 60
CAGCGGTGCT GCCATGGCGT GCGGCGGCG CGAACCRGCG TCGGGGCTCG CGGCGTGTG 120
20 GCTCTGGCGT TGCTCGCCCT GGCCCTGTGC GTGCCCGGGG CCGGGGGCGG GGCTCTCGAG 180
TGGTTCTCGG CCGTGGTAAA CATCGAGTAC GTGGACCCGC AGACCAACCT GACGGTGTGG 240
AGCGTCTCGG AGAGTGGCCG CTTCGGGAC AGCTCGCCCA AGGAGGGCGC GCATGGCCTG 300
25 GTGGGCGTCC CGTGGGGGCC CGGGGAGAM CTCGARGGCT KCGGCGCCGA CACGCGCTTC 360
TTCGTGCCCG AGCCCGGCGG CCGAGGGGCC GCGCCCTGGG TCGCCCTGGT GGTCTGGGG 420
30 GCTGCACCTT TCAAGGACAA AGTGCTGGTG GCGGCGCNGA ANGAA 465

35

(2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:

40

- (A) LENGTH: 1907 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

45

ACATGCAGCC CAACTACAGA TTCTTATGGA ATTCTCAAG GTTGAAGAA GAAATAAGAG 60
AGAGCAACTG GAACAGATCC AGAAGGAGCT AAGTGTTTTG GAAGAGGATA TTAAGAGAGT 120
GGAAGAAATG AGTGGCTTAT ACTCTCTGT CAGTGAGGAT AGCACAGTGC CTCAATTGTA 180
50 AGCTCCTTCT CCATCACACA GTAGTATTAT TGATTCCACA GAATACAGCC AACCTCCAGG 240
TTTCAGTGGC AGTTCTCAGA CAAAGAAACA GCCTTGGTAT AATAGCACGT TAGCATCAAG 300
ACGAAAACGA CTTACTGCTC ATTTTGAAGA CTTGGAGCAG TGTTACTTTT CTACAAGGAT 360
GTCTCGTATC TCAGATGACA GTCGAAGTGC AAGCCAGTTG GATGAATTTT AGGAATGCTT 420
GTCCAAGTTT ACTCGATATA ATTCAGTACG ACCTTTAGCC ACATTGTCAT ATGCTAGTGA 480
60

	TCTCTATAAT GGTTCAGTA TAGTCTCTAG TATTGAATTT GACCGGGATT GTGACTATTT	540
	TGCGATTGCT GGAGTTACAA AGAAGATTAA AGTCTATGAA TATGACACTG TCATCCAGGA	600
5	TGCAGTGGAT ATTCAATTACC CTGAGAATGA AATGACCTGC AATTGAAAA TCAGCTGTAT	660
	CAGTTGGAGT AGTTACCATA AGAACCTGTT AGCTAGCAGT GATTATGAAG GCACTGTTAT	720
10	TTTATGGGAT GGATTCACAG GACAGAGGTC AAAGGTCTAT CAGGAGCATG AGAAGAGGTG	780
	TTGGAGTGTT GACTTTAATT TGATGGATCC TAAACTCTTG GCTTCAGGTT CTGATGATGC	840
	AAAAGTGAAG CTGTGGTCTA CCAATCTAGA CAACTCAGTG GCAAGCATTG AGGCAAAGGC	900
15	TAATGTGTGC TGTGTAAAT TCAGCCCCTC TTCCAGATAC CATTGGCCTT TCGGCTGTGC	960
	AGATCACTGT GTCCACTACT ATGATCTTCG TAACACTAAA CAGCCAATCA TGGTATTCAA	1020
20	AGGACACCGT AAAGCAGTCT CTTATGCAAA GTTTGTGAGT GGTGAGGAAA TTGTCTCTGC	1080
	CTCAACAGAC AGTCAGCTAA AACTGTGGAA TGTAGGGAAA CCATACTGCC TACGTTCCCT	1140
	CAAGGGTCAT ATCAATGAAA AAAACTTTGT AGGCCTGGCT TCCAATGGAG ATTATATAGC	1200
25	TTGTGGAAGT GAAAATAACT CTCTCTACCT GTACTATAAA GGACTTTCTA AGACTTTGCT	1260
	AACTTTTAAG TTTGATACAG TCAAAAGTGT TCTGACAAA GACCGAAAAG AAGATGATAC	1320
30	AAATGAATTT GTTAGTGCTG TGTGCTGGAG GGCACCTACCA GATGGGGAGT CCAATGTGCT	1380
	GATTGCTGCT AACAGTCAGG GTACAATTAA GGTGCTAGAA TTGGTATGAA GGGTTAACTC	1440
	AAGTCAAATT GTACTTGATC CTGCTGAAAT ACATCTGCAG CTGACAATGA GAGAAGAAAC	1500
35	AGAAATGTC ATGTGATGTC TCTCCCCAAA GTCATCATGG GTTTTGGATT TGTTTTGAAT	1560
	ATTTTTTTCT TTTTTTCTTT TCCCTCCTTT ATGACCTTTG GGACATTGGG AATACCCAGC	1620
40	CAACTCTCCA CCATCAATGT AACTCCATGG ACATTGCTGC TCTTGGTGGT GTTATCTAAT	1680
	TTTTGTGATA GGGAAACAAA TTCTTTTGAA TAAAAATAAA TAACAAAACA ATAAAAGTTT	1740
	ATTGAGCCAC AGTTGAGCTT GGAAAGTTT TGTCAAATGC NGCAAGAGAT AACTCTTTTT	1800
45	ANGAAGTAGC ATATGTGAAC TATAATGTAA CAGTGAATAA TTTGTAAAGT TCGTATTTCC	1860
	CAACCTCTTT GGAATTACA CATATCAATA TAAACAAAAT ATAAAGT	1907

50

(2) INFORMATION FOR SEQ ID NO: 79:

55

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1168 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

	GCTGGGGTGT CCCCKCSGCC ACCATCGTCA TCGCTTACTT GATGAAGCAC ACTCGGATGA	60
5	CCCATGACTG ATGCTTATAA ATTTGTCAAA GGCAAACGAC CAATTATCTC CCCAAACCTT	120
	AACTTCATGG GGCAGTTGCT AGAGTTGAG GAAGACCTAA ACAACGGTGT GACACCGAGA	180
	ATCCTTACAC CAAAGCTGAT GGGCGTGGAG ACGGTTGTGT GACAATGGTC TGGATGGAAA	240
10	GGATTGCTGC TCTCCATTAG GAGACAATGA GGAAGGAGGA TGGATTCTGG TTTTITTTCT	300
	TTCTTTTTTT TTTTGTAGTT GGGAGTAAGT TTGTGAATGG AAACAAACTT GTTTAAACAC	360
15	TTTATTTTTA ACAAGTGTA GAAGACTATA ACTTTTGATG CCATTGAGAT TCACCTCCCA	420
	CAAACTGACA AATTAAGGAG GTTAAAGAAG TAATTTTTTT AAGCCAACAA TAAAAATATA	480
	ATACAACTTG TTTCTCCCCC TTTTCTTTT AAGCTATTTG TAGAGTTTAT GACTAAATAG	540
20	TCTGTGCAGG TTCATAGACC GAAGATACTA CACACTTTAA ACCAATTAAA AAGAACCAAA	600
	AGTAAATAGA AAAGACATTG AATCACCAAG GCCTGGGATC AACCTGGGCT GTCCACACAG	660
25	AAAACAAAAA CCCAACCAAA CCAAGCCCTG TTGTGCTCAC TGGTGCAAAG AGAAGATCAG	720
	GGCAGCTTAA GTGGTCTAAG RATCCTTCAG GCATTCTTTA AGGAGAAAAA GGATACCTTT	780
	GATTTTGTGT GTTTCATGCT CTGGATTTTT TTTTITTTTC CTCTCTGGG TTTAAGAGAT	840
30	TTTTTTTGAA ATAGTGAGGA ACTGACCATT ATATGCCCTC ACTGGCTTCT TGTGCAATAA	900
	TATGATGTTT TAAGTGTGCA AACAAGTTAG AGCTGGCAGC TGAATGATAG ACAAATAGTG	960
35	CAAATTTGCC AGCTTGAGGA TAGAAAGGAA TTCAACAATA TATCAAATAC TTTCTTTCCC	1020
	ACCTTTTICC TTTTTTTTTT TTTTITCTGA TTTGATTCTG GTTACAGTGC CATAAACCTT	1080
	GTACATATG TATATCAGAA TGTAAGAAAA AAAAATTTAT TTAATAATAT TTTTCGCAAA	1140
40	AAAAAANNA AAAAATCGA GGGGGGCC	1168

45 (2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 1285 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

55	AGAAAATCAC ATCCTAACAA AGAAGTCTGT CTAAGACAGT ACATCTCCTG TTGAACCTGC	60
	ATCTTTCCAC AGGACTTTCT GTTTTATAGG ATGAGACTAT TCTCTGCTTC ATCAAGGAAA	120
60	GAGAAATGTT CAGGGTTGTA GGGATGGCAC ACTTATTAGT TCTGCCTGTC TGAAAGGTTT	180

	CTGCAGGACA GTTTGGTCAG AGCTGCAATT CTTAGTCCAT GGTCTAATGC TTGAGTATCT	240
	CTTCTTTCCC TTCTCTGTCT CAGGAATCAG CTGAGAATTC ATTGATTGT CATGCCTCTA	300
5	GGCCCTTACT GTGATTGTGT GGTGCACTT TCATTGCTT TAGTTCTAGA ATCACCTGTT	360
	GACTCTCAG ACTTCACCTA ACTTTGGAAA CTCTCTTTTG GAGGCTTCTC ATTTCCCCCT	420
10	AATTCTGTGC TGCCTGAGCC CTAGAATTTT CCCACCAACG AATTATTCCA GGTAGATCCT	480
	AAGTGTCTGG ATCTAGTTGA TATTTAAACA ATATCTAGTT GATATTTCTC ATTCAGTTGG	540
	ATCCAGAAAC CAGTATCTCT NAAAAACAAC CTCTCATACC TTGTGGACCT AATTTTGTGT	600
15	GCGTGTGTGT GTGCGGCGCAT ATGTATATAG ACAGGCACAT CTTTTTACT TTTGTAAAAG	660
	CTTATGCTC TTTGGTATCT ATATCTGTGA AAGTTTAAAT GATCTGCCAT AATGTCTTGG	720
20	GGACCTTGT CTCTGTGTA AATGGTACTA GAGAAAACAC CTATATTATG AGTCAATCTA	780
	GTGTGTTTTA TTCGACATGA AGGAAATTTT CAGATAACAA CACTAACAAA CTCTCCCTTG	840
	ACTAGGGGA CAAAGAAAAG CAAACTGAC CATAAAAAAC AATTACCTGG TGAGAAGTTG	900
25	CATAACAGA ATTAGGTAGT ATATTGAAGA CAGCATCATT AAACAGTTAT GTTGTCTCC	960
	TTGCAAAAAA CATGTACTGA CTTCCTGTTG AGTAATGCCA AGTTGTTTTT TTTATTATAA	1020
30	AACTTGCCCT TCATTACATG TTTCAAAGTG GTGTGGTGGG CCAAAATATT GAAATGATGG	1080
	AACTGACTGA TAAAGCTGTA CAAATAAGCA GTGTGCCTAA CAAGCAACAC AGTAATGTTG	1140
	ACATGCTTAA TTCACAAATG CTAATTTTAT TATAAATTGT TTTGCTAAAA TACACTTTGA	1200
35	AACTATTTTT CTGTATTCCA AGAGCTGAGA TCTTAGATT TATGTAGTAT TAAGTGAAAA	1260
	AATACGAAAA TAATAACAT TGAAG	1285

40

(2) INFORMATION FOR SEQ ID NO: 81:

45

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1290 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

	TCTCCAGCCC CAATTCTAC GCGCACCGGA AGACGGAGGT CCTCTTTCCT TGCCTAACGC	60
	AGCCATGGCT CGTGGTCCCA AGAAGCATCT GAAGCGGGTG GCAGCTCCAA AGCATGGAT	120
55	GCTGGATAAA TTGACGGTG TGTTGTCTCC TCGTCCATCC ACCGGTCCCC ACAAGTTGAG	180
	AGAGTGCTC CCCCTCATCA TTTTCTGAG GAACAGACTT AAGTATGCCC TGACAGGAGA	240
60	TGAAGTAAAG AAGATTTGCA TGCAGCGGTT CATTAAAATC GATGGCAAGG TCCGAAGTGA	300

	TATAACCTAC CCTGCTGGAT TCATGGATGT CATCAGCAITT GACAAGACGG GAGAGAATTT	360
5	CCGTCTGATC TATGACACCA AGGGTCGCTT TGCTGTACAT CGTATTACAC CTGAGGAGGC	420
	CAAGTACAAG TTGTGCAAAG TGAGAAAGAT CTTTGTGGGC ACAAAGGAA TCCCTCATCT	480
	GGTGACTCAT GATGCCCCGA CCATCCGCTA CCCOGATCCC CTCATCAAGG TGAATGATAC	540
10	CATTTCAGATT GATTTAGAGA CTGGCAAGAT TACTGATTTC ATCAAGTTCC ATTACCCAG	600
	CCAGGTGGTC TCGTCACCTC AGAGGCTCCG CAGACTCCTG CCCAGGCCAG GACTGAGGCA	660
15	AGCCTCAAGG CACTTCTAGG ACCTGCCTCT TCTCACCAAG ATGAACTCAC TGGTTTCTTG	720
	GCAGCTACTG CTTTTCCTCT GTGCCAOCOA CTTTGGGGAG CCATTAGAAA AGGTGGCCTC	780
	TGTGGGGAAT TCTAGACCCA CAGGCCAGCA GCTAGAATCC CTGGGCCCTCC TGGCCCCSGG	840
20	GGAGCAGAGC CTGCCGTGCA CCGAGAGGAA GCCAGCTGCT ACTGCCAGGC TGAGCCGTCC	900
	GGGGACCTCG CTGTCCCCGC CCCCAGAGAG CTCGGGAGC CCCAGCAGC CGGGCCTGTC	960
25	CGCCCCCAC AGCCGCCAGA TCCCGCACC CCAGGGCGCG GTGCTGGTGC AGCGGGAGAA	1020
	GGACCTGCCG AACTACAAC TGAACCTCTT CGGCTGCGC TTGGCAAGC GGGAGGCGGC	1080
	ACCAGGGAAC CACGGCAGAA GCGCTGGCG GGGCTGAGGG CGCAGGTGCG GGGCAGTGAA	1140
30	CTTCAGACCC CAAAGGAGTC AGAOCATCG GGGCGGGGC GGGGGCGGG GACGTAGGC	1200
	TAAGGAGGG GCGCTGGAG CTTCCAACCC GAGGCAATAA AAGAAATGTT GCGTAACTCA	1260
35	AAAAAAAAA AAAAAAANC TCGGGGGGG	1290

40 (2) INFORMATION FOR SEQ ID NO: 82:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 684 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:

50	TTTATTGTAT TCTGTAACTA TAGAACTTCT ATTTWATTCT TTTTGGACT TGCTAAGTTG	60
	TCTTTWATGG TTTTWAGTTC CATGCTGAAG TTTTCAGTAT TGAATTATCC CCTTGAACAT	120
	GAGTTGTTTT ATAGACTCTR ATGATTCAAA AATCTTACAT CTTTGGTAG TCTCTTTCAT	180
55	TTGTCTACTG TTTCTGTGTA TTCTWACTCA TGGTATTTTA ATTCTTCGTT WTTTTTTTTC	240
	TGTTWAGAWA CATTCCTTGA AAAATAATTT GGAGGAATAT TTGATTCTTA TGAACAAGGC	300
60	ATTACTCACC AGAGAAGATT TTTTGTGTYT ACCARGTGCC TARGAATGCT AACAGTCTGG	360

	GAMCACATAG AMCACCAGGT GATGAGACAA TCCTGGGART CCTGTTTTAC TTTGGSOCAT	420
	CTTTTCTCCC AACCTGTGG GAATARTCAT YCATATCCTA RCTGCAGGCT ARAAGGTGGT	480
5	TTATCAGAGC CCAACTTCGA GGGCTCTGGG CTTTAGCTAC TGTCACCCCA TCATAACTGA	540
	GCTTCATGGA TTGATTCTCT TTTTATCTTT CAGATTTTCT TTTAAAAATC TTTGTTTTTT	600
10	TTTTTCTTCC GAAAGATTCC CCCAACATTA CCATTCCCCA CCTTCGGTTG AATTTTTTTG	660
	GCTCTCATTT TGAATTTTTC AAGA	684
15	(2) INFORMATION FOR SEQ ID NO: 83:	
	(i) SEQUENCE CHARACTERISTICS:	
20	(A) LENGTH: 2024 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
25	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:	
	CTGCAGGAAT TCGGCACAGC TGCCTGGAG GCTTCATCTT TGCCGCCGCT GCCGTGGCCT	60
	TCCTGGGATT GGAGTCTCGA GCTTCTTCG TTCGTTGCGC GCGGGGTTG CGCCCTTCTC	120
30	GCGCTCGGG GCTGCGAGGC TGGGGAAGGG GTTGGAGGGG GCTGTTGATC GCCGCGTTTA	180
	AGTTGCGCTC GGGGCGGCCA TGTGGGCGG CGAGGTCGAG CGCCTAGTGT CGGAGCTGAG	240
35	CGGCGGGACC GGAGGGGATG AGGAGGAAGA GTGGCTCTAT GCGGATGAAA ATGAAGTTGA	300
	AAGGCCAGAA GAAGAAAATC CCAGTGCTAA TCCTCCATCT GGAATTGAAG ATGAAACTGC	360
	TGAAAATGGT GTACCAAAAC CGAAAGTGAC TGAGACCGAA GATGATAGTG ATAGTGACAG	420
40	CGATGATGAT GAAGATGATG TTCATGTCAC TATAGGAGAC ATTAAAACGG GAGCACCACA	480
	GTATGGGAGT TATGTTACAG CACCTGTAAA TCTTAACATC AAGACAGGGG GAAGAGTTTA	540
45	TGGAATACA GGGACAAAAG TCAAAGGAGT AGACCTTGAT GCACCTGGAA GCATTAATGG	600
	AGTTCCACTC TTAGAGGTAG ATTTGGATTC TTTTGAAGAT AAACCATGGC GTAAACCTGG	660
	TGCTGATCTT TCTGATTATT TTAATTATGG GTTTAATGAA GATACCTGGA AAGCTTACTG	720
50	TGAAAAACAA AAGAGGATAC GAATGGGACT TGAAGTTATA CCAGTAACCT CTAATAACAA	780
	TAAAAATTAC GTACAGCAGG GAAGAACTGG AACTCAGAG AAAGAACTG CCCTTCCATC	840
55	TACAAAAGCT GAGTTTACTT CTCCTCCTTC TTTGTTCAAG ACTGGGCTTC CACCGAGCAG	900
	GAGATTACCT GGGGCAATG ATGTTATCGG TCAGACTATA ACTATCAGCC GAGTAGAAGG	960
	CAGGCGACGG GCAAATGAGA ACAGCAACAT ACAGGTCCTT TCTGAAAGAT CTGCTACTGA	1020
60	AGTAGACAAC AATTTTAGCA AACCACCTCC GTTTTCCCT CCAGGAGCTC CTCCCCTCA	1080

	CCTTCCACCT CCTCCATTTC TTCCACCTCC TCCGACTGTC AGCACTGCTC CACCTCTGAT	1140
5	TCCACCACCG GGTTTTCCTC CTCCACCAGG CGCTCCACCT CCATCTCTTA TACCAACAAT	1200
	AGAAAGTGA CATTCCTCTG GTTATGATAG TCGTTCTGCA CGTGCAATTTC CATATGGCAA	1260
	TGTTGCCTTT CCCCATCTTC CTGGTTCTGC TCCTTCGTGG CCTAGTCTTG TGGACACCAG	1320
10	CAAGCAGTGG GACTATTATG CCAGAAGAGA GAAAGACCGA GATAGAGAGA GAGACAGAGA	1380
	CAGAGAGCGA GACCGTGATC GGGACAGAGA AAGAGAACGC ACCAGAGAGA GAGAGAGGGA	1440
15	GCGTGATCAC AGTCTACAC CAAGTGTITT CAACAGCGAT GAAGAACGAT ACAGATACAG	1500
	GGAATATGCA GAAAGAGGTT ATGAGCGTCA CAGAGCAAGT CGAGAAAAAG AAGAACGACA	1560
	TAGAGAAAGA CGACACAGGG AGAAAGAGGA AACCAGACAT AAGTCTTCTC GAAGTAATAG	1620
20	TAGACGTGCG CATGAAGTG AAGAAGGAGA TAGTCACAGG AGACACAAAC ACAAAAAATC	1680
	TAAAAGAAGC AAAGAAGGAA AAGAAGCGGG CAGTGAGCCT GCCCCTGAAC AGGAGAGCAC	1740
25	CGAAGCTACA CCTGCAGAAT AGGCATGGTT TTGGCCTTTT GTGTATATTA GTACCAGAAG	1800
	TAGATACTAT AAATCTTGTT ATTTTCTGG ATAATGTTTA AGAAATTAC CTTAAATCTT	1860
	GTCTGTGTTG TTAGTATGAA AAGTTAACTT TTTTCCAAA ATAAAGAGT GAATTTTCA	1920
30	TGTTAAGTTA AAAATCTTTG TCTTGTAATA TTTCAAAAAT AAAAAGACAG CAATGACTTT	1980
	ATATCCAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAGGC GGCC	2024

35

(2) INFORMATION FOR SEQ ID NO: 84:

- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 931 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:

	CGCGCCMATA GCGGACGGG GATCTGAGCT GGCAGGATGA ATGTGGGGGT GGCACACAGC	60
50	GAAGTAAACC CCAACACCG AGTGATGAAT AGCGAGGCA TCTGGCTGGC CTACATCATC	120
	TTGGTAGGAT TGCTGCATAT GGTCTACTC AGCATCCCTT TCTTCAGCAT TCCTGTTGTC	180
	TGGACCTGA CCAACGTCAT CCATAACCTG GCTACGTATG TCTTCCTTCA TACGGTGAAA	240
55	GGGACACCTT TTGAGACTCC TGACCAAGGA AAGGCTCGGC TACTGACACA CTGGGAGCAA	300
	ATGGAATATG GGCTCCAGTT TACCTCTTCC CGCAAGTTCC TCAGCATCTC TCCTATTGTG	360
60	CTCTATCTCC TGGCCAGCTT CTATACCAAG TATGATGCTG CGCACTTCCT CATCAACACA	420

GCCTCATTGC TAAGTGTACT GCTGCCGAAG TTGCCCCAGT TCCATGGGGT TCGTGTCTTT 480
GGCATCAACA AATACTGAGG GATGGGTTTT GGCACAGCTC CATGGGCATG GGAAGGCAC 540
5 TGAAACAGAG GACTATAAAA CATCCTTCTC TTATTCTCCA TACTGTCTTC TACACCTTTA 600
AAGCCTGAGA ACTATACAAC CTTTCCCAGA CTCCCAAGAA GAGAAGAGAT TGGCAAATGG 660
GGCTCCTGGG CCCAGTCTG CTAGTGGCAA GTTCTTTTGA ATCAGGAAGG CAGGTGAGGT 720
10 AAGGCCAAA TCACTCTCCT CCATAGCAGG AAGCCATTG GGCAGCTCCT TTGTGATTA 780
CATCTTTCCA TATCTTTTAC ACTTACCACC TTCCAGCTCT GTTTTGCTGT GTATTTTCT 840
15 TACAATAATT TTTTTCAGCT ATAGCTGCAG TTTAATCAGG ATGGGTAGAG AGCTGTCTCT 900
ATAAGGCTGG GGGTGGGAAG ATGGAATACT G 931

20

(2) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERISTICS:
25 (A) LENGTH: 825 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85:

CGGGGCGGC GGGTCTTCA GGTACCGG CTGGTTACAG CAGCTCTACC CCTCAGACG 60
CAAACATGGC AGCGCAGAAG GACCAGCAGA AAGATGCCA GCGGAAGGG CTGAGCGGCA 120
35 CGACCTGCT GCGAAGCTG ATTCCCTCCG GTGCAGGCCG GGAGTGGCTG GAGCGGCGCC 180
GCGCGACCAT CCGGCCCTGG AGCACCTTCG TGGACCAGCA GCGCTTCTCA CGGCCCGCA 240
40 ACCTGGGAGA GCTGTGCCAG CGCCTCGTAC GCAACGTGGA GTACTACCAG AGCAACTATG 300
TGTTCGTGTT CTTGGGCTC ATCCTGTACT GTGTGGTGAC GTCCCTATG TTGCTGGTGG 360
CTCTGGCTGT CTTTTTCGGC GCCTGTACA TTCTCTATCT GCGCACCTTG GAGTCCAAGC 420
45 TTGTGCTCTT TGGCCGAGAG GTGAGCCCAG CGCATCAGTA TGCTCTGGCT GGAGGCATCT 480
CCTTCCCCTT CTCTGGCTG GCTGGTGGG GCTCGGCCGT CTTCTGGGTG CTGGGAGCCA 540
50 CCTGGTGGT CATCGGCTCC CACGCTGCCT TCACCAGAT TGAGGCTGTG GACGGGGAGG 600
AGCTGCAGAT GGAACCCGTG TGAGGTGTCT TCTGGGACCT GCGGCCCTCC CGGGCCAGCT 660
GCCCCACCCC TGCCCATGCC TGTCTGCAC GGCTCTGCTG CTCGGGCCCA CAGCGCCGTC 720
55 CCATCACAAG CCGGGGAGG GATCCCGCT TTGAAAATAA AGCTGTTATG GGTGTCATTC 780
AGGAAAAAAA AAAAAAAGG GGGGCCCTC TAGGGGTCAA AGTTA 825

60

(2) INFORMATION FOR SEQ ID NO: 86:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1238 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86:

CATGTAAAAG GATGAAATGT GACTTCTGGT GTTTTTTTAT TTCTATGGAG GGACTTTCCTG	60
GGGACGGTTT CTGGCTCTCA GGCTCTGAGA AGCTGCAGTT TATGAGTGGC TCTGTGTGTG	120
CTGCCACCTA CTGGAGAAGC CATAAGCTGC AGCTTTAGGA AAAGGGAACC CGGGGCAGAG	180
TGTGGGAAG TGGGATGGCA GCATGGCAGG GCTTTGGAAA ATGAGAGGTG AGAGTGTCTC	240
CAGGAAGGGT GTAAGGAGAG GATGGATCCT GATACATGGA TTCAGGATCA TTAGGGTCCT	300
GTCTGGGACA CTGGCCCTCC TGCTTACCTG CTCTTTCTCT CCTCTTGGT CGGAGGAGGG	360
GCTGGCTCAC TGCTCTGGCT TCAITTTTCCA GAGCTGCCTG CTGCAGTCAC ACTTAGGTCA	420
TCTTCTCTCA CTTTTCTCCT TTTGCCGATT AGTGGACGTG ACAGAGATGT GAATGGGGCA	480
GGGATGTCTT TTGATGGCAT CAAGACTTTA GCTTCTGGTG CGCTGTGTCC CAGCTCTGAT	540
TTCACTTGCA GCGTGATGG AMAGTTNGCA TGAAGCTGA GACTCTCACT GACAGTGAAA	600
CCCTCAAATG AACACAATCC CTGCTTTCTT GCCAAGGATC CTTGTAGGGT NCCCCAGCT	660
TCCCCACTTT TTTTCTGTGT CTTGACAAAG AAACACAGAG TAACTTGATT GCCCTGTGAC	720
CTGGCCAGTT GCATTTCCTC TGCAGGCTTG AGCCCAAGCC AGAGCCTTGA AAAGGTATTC	780
AGGTGTGTGC CCAAAACACT GAAAAAACT GCCCTGGCCC TGAACCAAAT ACCTTGAACC	840
CTCGTAAACT CCATACCTTG ACCCCCTTGT TTTGGATATA CCCAGGTAGA ACAACTCTCT	900
CTCACTGTCT GTTGTGAGGA TACGCTGTAG CCCACTCATT AAGTACATTC TCCTAATAAA	960
TGCTTTGGAC TGATCACCCCT GCCAGTCTTT TGTCCTTGGC AATCTATACT TTTNCTCAGA	1020
GGTCCCAAG GCCTACTGAA GGGACTTAAC ATACTCTTAA TGGCTTTCCT CTCTCTTGTT	1080
TTACCTTATG CCTCACTTC CTGAGTTAAC CTCCCAAATA CAGGATTCAC CTGTACCCAA	1140
GCCCTTAGCT TCAAGAATAC AGGATCACCT GTACCCAAGC CCTTAGCTCA AGCTCTGCTT	1200
TGGAAGAACC CAAACTAAGA CAGTGCTCCT GGTGCCCT	1238

55

(2) INFORMATION FOR SEQ ID NO: 87:

60

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1460 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87:

	ATTGCCCTTCT GGTCCTTGGT GACACTGGGG TCATCCTTCA TCCCCGGAGA GCATTTCCTGG	60
10	CTGCTCCTCC TGACCCGGGG CCTGGTGGGG GTCGGGGAGG CCAGTTATTC CACCATCGCG	120
	CCCACTCTCA TTGCGGACCT CTTTGTGGCC GACCAGCGCG ACCGGATGCT CAGCATCTTC	180
15	TACTTTGCCA TTCCGGTGGG CAGTGGTCTG GGCTACATTG CAGGCTCCAA AGTGAAGGAT	240
	ATGGCTGGAG ACTGGCACTG GGCTCTGAGG GTGACACCGG GTCTAGGAGT GGTGGCGGTT	300
	CTGCTGCTGT TCCTGGTAGT GCGGGAGCCG CCAAGGGGAG CCGTGGAGCG CCACTCAGAT	360
20	TTGCCACCCC TGAACCCAC CTCGTGGTGG GCAGATCTGA GGGCTCTGGC AAGAAATCCT	420
	AGTTTCGTCC TGTCCTCCCT GGGCTTCACT GCTGTGGCCT TTGTACGGG CTCCTGGCT	480
25	CTGTGGGCTC CGGCATTCTT GCTGCGTTCC CGCGTGTCC TTGGGGAGAC CCCACCCTGC	540
	CTTCCCGGAG ACTCCTGCTC TTCTCTGAC AGTCTCATCT TTGGACTCAT CACCTGCCTG	600
	ACCGGAGTCC TGGGTGTGGG CCTGGGTGTG GAGATCAGCC GCGGGCTCCG CCACTCCAAC	660
30	CCCCGGGCTG ATCCCTTGGT CTGTGCCACT GGCCTCCTGG GCTCTGCACC CTTCCTCTTC	720
	CTGTCCCTTG CCTGCGCCCG TGCTAGCATC GTGGCCACTT ATATTTTCAT CTTCATTGGA	780
35	GAGACCCCTC TGTCATGAA CTGGGCCATC GTGGCCGACA TTCTGCTGTA CGTGGTGATC	840
	CCTACCGGAC GCTCCACCGC CGAGGCCTTC CAGATCGTGC TGTCCACCT GCTGGGTGAT	900
	GCTGGGAGCC CCTACCTCAT TGGCTGATC TCTGACCGCC TCGCCCGGAA CTGGCCCCCC	960
40	TCCTTCTTGT CCGAGTCCG GGCTCTGCAG TTCTCGCTCA TGCTCTGGC GTTTGTGGG	1020
	GCACTGGGCG GCGCACTTCC TGGGCACCGC CATCTTCATT GAGGCCGACC GCCGGCGGGC	1080
45	ACAGCTGCAC GTGCAGGGCC TGCTGCACGA AGCAGGGTCC ACAGACGACC GGATTGTGGT	1140
	GCCCCAGCGG GGCCGCTCCA CCGCGTGCC CGTGGCCAGT GTGCTCATCT GGAGAGGCTG	1200
	CGCTCACCT ACCTGCACAT CTGCCACAGC TGGCCCTGGG CCCACCCAC GAAGGGCCTG	1260
50	GGCCTAAACC CCTTGGCCTG GCCAGCTTC CAGAGGGACC CTGGGCGGTG TGCCAGCTCC	1320
	CAGACACTAC ATGGGTAGCT CAGGGGAGGA GGTGGGGTTC CAGGAGGGG ATCCCTCTCC	1380
55	AACAGGGGCA GCCCAAGGG CTCGGTGCTA TTTGTAACGG GATTAAAATT TGTAGCCAGA	1440
	AAAAAAAAA AAAAAAAAAA	1460

60

(2) INFORMATION FOR SEQ ID NO: 88:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1395 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88:

10 CAGGTGCAAA GTGGGAAGTG TGAGTCTCA GTCTTGGGCT ATTCGGCCAC GTGCCTGCCG 60
GACATGGGAC GCTGGAGGT CAGCAGGTG GAGTCTGGC CTTTTCGTC CACGGGTGGG 120
15 AAATGGCCA TTGCCACGGC GGAAGTGGG ACTCAGGCTG CCCCCGGCC GTTCTCATC 180
CGTCCACCGG AYTCTGGGC GCTCGCACTG GCGCTGATGT AGTTTCTGA CCTCTGACCC 240
20 GTATTGTCTC CAGATTAAAG GTACGACATT TGGAGGCCCC AGCGAGAAAC GTCACCGGGA 300
GAAAGTCAC CGGCGAGAG CGGKCCGCT GTGTGCTCCC CGGAAGGAC AGCCAGCTTG 360
TAGGGGGGAG TGCCACCTGA AAAAAAATT TCCAGGTCCC CAAAGGGTGA CCGTCTTCCG 420
25 GAGACAGCGG ATCGACTACC ATGTGGGTGC CCACAAAAAT TYCACCTYTG AGTCTCAAC 480
TGCTGACCCC GGGTCACTT CCAGAGAGAA GGACTCCCTC CTGCTTGGA GAGACCTCAC 540
30 ACCGTATCA CGATGCCAAC GGCTCTGAAG GTGGATGGCA TTCTTGCGTG GATTCATCAC 600
TCCCGCATCA AAAAGGCCAA CRGAGCCCAA CTAGAACAT GGTCCCCAG GGCTGGGTCA 660
GGCCCCCTAA AACTGCACCT AAGTTGGGTG AAGCCATTAG ATTAATTCTT TTTCTTAATT 720
35 TTGTAAACA ATGCATAGCT TCTGTCACT TATGTATCTT AAGACTCAAT ATAACCCCT 780
TGTTATACT GAGGGAATCA ATGATTGAT TCCCCAAAA CACAAGTGG GAATGTAGTG 840
40 TCCAACCTGG TTTTACTAA CCGTGTMTT AGACTYTCCC TTTCCTTTAA TCACTCAGCC 900
TTGTTCCAC CTGAATTGAC TCTCCCTTAG CTAAGAGCG CAGATGGACT CCATCTTGGC 960
TCTTCTNACT GGCAGCGCT TCCTYCAAG ACTTAACTTG TGCAAGCTGA CTCCAGCAC 1020
45 ATCCAAGAAT GCAATTAACT GATAAGATAC TGTGCAAGC TATATCGCA GTTCCAGGA 1080
ATTCGTCAA TTGATTACAC CMAAGCCC CGGTCTATC ACCTTGTAAT AATCTTAAAG 1140
CCCCTGACC TGAAGTATT AAGTTCTG TAACCATTTA TCCTTTTAAC TTTTTCCT 1200
50 ACTTTATTC TGTAAGATTG TTTTAACTAG ACCCCCCCTC TCCTTTCTAA ACCAAAGTAT 1260
AAAAGCAAAT CTAGCCCCCT CTCAGGCCG AGAGAATTTC GAGCGTTAGC CGTCTCTGG 1320
55 CCACCAGCTA AATAAACGGA TTCTTCATGT GTAAAAAAA AAAAAAAA CTGGAGGGG 1380
GGCCCCGTA CCCAA 1395

(2) INFORMATION FOR SEQ ID NO: 89:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1186 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89:

10 GGCAAGGCC GGCAAGCCGA GCTAGGGTGA AAAGTGGGG CGCACCAGGA TGTNNACAG 60
AAAAGCAGAA GATGAGACTC TGTTCATTCA CTTTTCCTAG GCCATCTCTG TGGTCATCTT 120
15 TCCCCCTCCC ATCATACCTC CTCCTTCTCG GAGCCTCTGC CGGCTGGCT GTAATGGTGG 180
CACTTACCTG GATATTTCAG TGGGAGGATG AAAGGCGAGA CTCACCTAC GCGTGGGAC 240
20 AGATGGGGAG AGGAAAAAGG CAGAGATGCC CAGGAGAGGG GTGCAGGACA AACCAGAGAG 300
GTGGGTGAG GGGAAAAGG TGGGAGAGAA GAGGGGTGCA GGCCCTGCAG GCCGGTTAGC 360
CAGCAGCTGC GGCCCTCCCG GGCCCTGGC ATCCAACCTC GCAGACAGGG TACCAGCCTC 420
25 CTGGTGTGTA TCATAGGATT TGTTCACATA GTGTTATGCA TGATCTTCGT AAGGTTAAGA 480
AGCCGTGGTG GTGCACCATG ACATCCAACC CGTATATATA AAGATAAATA TATATATATA 540
30 TGTATGTAAA TTATGGCAG AGAAATTATA GCACTGAGGG CCCTGCTGCC CTGCTGGACC 600
AAGCAAACT AAGCCTTTTG GTTGGGTAT TATGTTTCGT TTTGTTATTT GTTTGTTTTT 660
GTGGCTGTG TTATGTCGTG ATAGCACAAG TGCCAGTCGG ATTGCTCTGT ATTACAGAAT 720
35 AGTGTTTTTA ATTCATCAAT GTTCTAGTTA ATGTCTACCT CAGCACCTCC TCTTAGCCTA 780
ATTTTAGGAG GTTGCCCAAT TTTGTTCTT CAATTTTACT GGTACTTTT TTGTACAAAT 840
40 CAATCTCTTT CTCTCTTCT CTCTCCCCA CCTCTCACC TTGCCCTCTC CATCTCCCTC 900
TCCCGCCCTC CCTCTCTCC TCTGGCTCCC CGTCTCATTT CTGTCCACTC CATCTCTCT 960
CCTCTCTCC TGCCCTCTGC TGCCCCCTCC CCAGCCCACT TCCCCGAGTT GTGCTTGCCG 1020
45 CTCTTATCT GTTCTAGTTC CGAAGCAGTT TCACTCGAAG TTGTGCAGTC CTGGTTGCAG 1080
CTTCCGCAT CTGCCTTCGT TTCGTGTAGA TTGACGCGTT TCTTTGTAAT TTCAGTGTTT 1140
50 CTGACAAGAT TTAAAAAAA AAAAAGGAAA AAAAAAATA AAAAAA 1186

(2) INFORMATION FOR SEQ ID NO: 90:

(i) SEQUENCE CHARACTERISTICS:

- 55 (A) LENGTH: 1821 base pairs
60 (B) TYPE: nucleic acid
(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90:

5	AAAACATGCT TTCAGGGCGT CCCCTATGTA TTCGGGGGGC CCACGGACAC TCAGGCTGGA	60
	KATCGGTCCT CACTGCGCTC AAGATGGCCT CAGCAGACAC CAGTTACCCA GCTGAAAGTC	120
10	ACAATCCCTC CCAGAAGTCT CCCAACACTA GTGCTGACCA GAGGTGGGGC TCTCAGGCTA	180
	GGAGTTTCAC ACACAATGAC AGGCTGCTGG GGGACATTGC AGGACCCCTT TTCTCTCTCT	240
	CTCCATGCTA GAAGCCAGCC CTAGGMAGCT GCAGTTACTC CCTGTGACTC AGCAGCAGGC	300
15	TGATTCACCA CAGCTGCCCA CACAAAGCCA GTGGTAATAC ATCTGTTTAC CTTCCTCTAT	360
	CACCCAGACA CAAGCCCTT TCCAGGTCA AACCACAGGC CGATGCATCT CCAGTTTGAC	420
20	AGTCAAAATCA CTACTTCCAT TGCTACTTTA GATCAGCCAA AGTGGTGACT GCTGCAGTGT	480
	GTGGCTATCC CTACAAGGCC CACCCAAGGG ATGCCCAAAG CCAACCTTC TCCAGGGCTG	540
	CAGCAGNAGC AACCCACCA GCCTAAGTCC AGCAGAGGAC CTCCACCCA ATGTCCTTGT	600
25	CTAATTAGAA GGGGAAGTTA GCCACAGAAA ATCAACTTAT CTATAATTAC AAAATTCCT	660
	TGACTCACCT TAAAGTTCCT ATGACATCT ACTGCTTTTA AACCTATTTG AAAACTCTGA	720
30	TACTAAAACA AATGACACTC TAAGAAAGTT TGGGAGCCCC ATGCTGAGAA CCATTTCTGT	780
	GCAGTGAGGA TGTTTCCAGA AGCTACTTAC CTACATGTGA ATGTGCCATT TTCTTTCTCT	840
	TTGTAGAGAA AATCCCTTT ACTTTTGGGA ACAGTAATGG CAGCTTCTAG TACAGCCATT	900
35	ACAGTTTCAT ATGAGAAAAA TTAAGAATAA CTATAAATT GTTAAATAT CCAATAATGG	960
	ATAATGATGG CCAGAAGATT TAACATACAA AGTAATCTC AATGTAAAGC TATTCAGCTC	1020
40	TTCCAGGTG ATGCCCCTGT AACCCACCT GACCTTCCAC ATCATCTTCA AAAAGCAGTT	1080
	TCTCTGTCC CCATGATTCT CCTATAAGGT AACTCTTTAG TCCTCCATT AGCACATTTT	1140
	AAATCCTCCA AAGAATAAGT ATCATGTGAT TATTTTAGCT TTACAAAAAA AAAGTTGAAT	1200
45	GGCGTTTAT TTTCATGGCC TATAAGCAGG TACCTTAGTA GGCAGATAT AGGAAAAACA	1260
	AATTAGAGCA AAACAAATCC TCTACAAATC CAAGGCAGGA AAAGTGGTGG CAGAGTGAAT	1320
50	CATTCTCTG TCCCTCCCAT CAGGTCAAAT CAGGAGGCTG CAGTGAATGC CTGTTCTTTG	1380
	AATGTGTAGC AGTGTCTCT GTAACCTTT AAAACTTGGC TATAGGCTGT TTAGCACAGT	1440
	ACAGATTAAA GATACAGTTA CGTAAACAGC AAAGTAATTT TATAGTGCTT CATCCATTTA	1500
55	TCATGCTTTG GTTGTCTAAT TTTTTCACAT ACCTTTTCT ATCACAGTCT GTTGCTTTTG	1560
	TACACATTTT TCATATTGGG GTTCGACAGG TAAACACAAA CTGCTATTTC AGTAGAAAAA	1620
60	GTTATTGTTA TGAATATTA AACCCAATAA ATGTATATAA GGTAAAAAA AAAAAAAAAA	1680

AAAAAAAAA AAAAAAAAAA AAAAAATTC CTGCGGGCCG CANGCTTTT CCCTTGGGT 1740
 GAGGGTTAT TTINGGCTTG GGCACGGGC CCTTCGTTT TACAACGTCG TGANGGGGG 1800
 5 AACCGGGGG GGGTTTCCCC C 1821

10 (2) INFORMATION FOR SEQ ID NO: 91:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 862 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:

20 TGCCCTTTT CCCACGATT CGGGGCTGG TGAAGGTGG AGATGTGAAC TCCAATTAAG 60
 GGA CTGGAGA GAGGTGAAGA ATTTG CAGG TGGGAGATT GGATTGAAT GTGGA CTGTG 120
 25 AAATGACTTG ACCTTGCCAT CTGTGTTCAA GGTACGGTT TGCTGTGGG TTCCTGGGAG 180
 AGCTTACTCA CCGCGAGTC TTTCCTTCT CTGCTCCAA GAAGAGCCCT GTTGGTGCTT 240
 TACCACCGCT TGGAGTCTCC CGAGGACACA AACAGGCAGA GAGGACGTG TAGGGAGAGT 300
 30 TCCTTCTGT TTCTGTGCT TTCCTTTTA CAGGACTCCC GGAAGGCCAC TCATGGCCAT 360
 GCCAGGAGCT TTCTCAGAAA CAGTCATAAA CGATCTCTTG AGTCTCTTC TTGTCCTCCC 420
 35 AGCTGAGCTT TCCTATCCA CCCTTCTGG TGTCTATAGG AATGCATGAG AAGACCTGG 480
 GACGTTTTTC TGCTCTCTC TGGCCCTCCA TGGAGCCATG GGCCTCGGC TCGGCGGCTC 540
 CTCACCTCA CAATTTATTT CCTCCTCCG TGCCAGCCCT TCTTTTGTG CTGAAACCG 600
 40 TTTTAAATG TGACTCTCC AGAGAAGAAG CCGCTGGCTG TATGAACTT GACGGCGCTT 660
 TTGTAAGGTG CCACCCCAA ACTTTAAGGT AGCTAAACCA ATTTTAAAA GATTCAATGG 720
 45 CTGTTCATC CTCCAGATGT AGCTATTGAT GTACACTTCG CAACGGAGTG TCTGAAATG 780
 TGGTGGTCTT GATTATAGG ATTTCATAAT TAAATGTCT GCTGAATAA AAAAAAAAAA 840
 AAAAACTGA GGGGGGCCG GT 862

50

(2) INFORMATION FOR SEQ ID NO: 92:

55 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 696 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 60 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92:

CTGAGGGGAG TGAAGTGGAC TCTGAGGGCT ACCGCTACCG CCACTGCTGC GGCAGGGGCG 60
 5 TGGAGGGCAG AGGGCCGCGG AGGCCGCGAGT TGCAAACATG GCTCAGAGCA GAGACGGCGG 120
 AAACCCGTTT GCGAGGCCA GCGAGCTTGA CAACCCCTTT CAGGACCCAG CTGTGATCCA 180
 10 GCACCGACCC AGCCGGCAGT ATGCCACGCT TGAOGTCTAC AACCCCTTTG AGACCCGGGA 240
 GCCACCACCA GCGTATGAGC CTCCAGCCCC TGCCCCATTG CCTCCACCCCT CAGCTCCCTC 300
 CTTGCAGCCC TCGAGAAAGC TCAGCCCCAC AGAACCTAAG AACTATGGCT CATAAGCAC 360
 15 TCAGGCTCA GCTGCAGCAG CCACAGCTGA GCTGCTGAAG AACAGGAGG AGCTCAACCG 420
 GAAGGCAGAG GAGTTGGACC GAAGGAGCGA GAGCTGCAGC ATGCTGCCCT GGGGGCACA 480
 GCTACTCGAC AGAACAATTG GCGCCCTCTA CCTTCTTTT GTCCAGTTCA GCCCTGCTTT 540
 20 TTCCAGGACA TCTCCATGGA GATCCCOCAA GAATTTCAGA AGACTGTATC CACCATGTAC 600
 TACCTCTGGA TGTGCAGCAC GSTGGTCTT CTCTGAAYT TCMTCGSCTG CCTGGCCAGT 660
 25 TCTGTGTGGA AACCAACAAT GCGAGGCTT TGGGTT 696

30 (2) INFORMATION FOR SEQ ID NO: 93:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1886 base pairs
 (B) TYPE: nucleic acid
 35 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93:

40 CAGGCCACTG ACGTCTCTTT GCGAGGGATG CAGGAGGTCC TACAGAGAAA GCGCTTCTTT 60
 GCATKTCAGA GGGCCACAG CCTGTCAACC ACAGATCACC AAGCAGCTTT CTACCTGGCT 120
 CTGCAGCTTG CCATCTCCAG ACAGATCCCA GAGGCTCTGG GGTATGTCOS CCAAGCTCTT 180
 45 CAGCTTCAAG GTGACGATGC CAACTCCCTG CACCTCCTTG CCTCCTGCT GTCAGCACAG 240
 AAGCATTACC ATGACGCTCT GAACATCATC GACATGGCCC TGAGTGAATA CCCAGAAAAT 300
 50 TTCATACTAC TGTTTTCCAA AGTGAAGTTG CAGTCACTCT GCGAGGGCCC GGACGARGCA 360
 CTGCTGACTT GTAAGCACAT GCTGCAGATA TGGAAATCCT GCTACAACCT CACCAACCCC 420
 AGTGATTCTG GACGTGGGAG CAGCCTCTTA GATAGAACCA TTGCTGACAG ACGACAGCTT 480
 55 AATACAATTA CTTTGCCAGA CTTTCAGGAT CCGAGACAG GCTCCGTCCA TGCCACATCG 540
 GTAGCAGCCT CAAGAGTGA GCAGGCACTG TCGGAAGTGG CTTCGTCTCT GCAGAGCATG 600
 60 CCCCTAAGCA GGGCCCGCTG CACCCCTGGA TGACGCTGGC ACAGATCTGG CTCCATGCAG 660

	CTGAAGTCTA TATCGGCATC GGAAGCCTG CAGAAGCCAC AGCCTGTACC CAAGAAGCTG	720
5	CCAACCTCTT CCCAATGTCC CACAATGTCC TCTACATGCG CGGCCAGATT GCTGAGCTCC	780
	GGGAAGCAT GGACGAGGCG CGGCGGTGGT ATGAAGAGGC CTTAGCCANT CAGCCCCACC	840
	CACGTGAAGA GCATGCAGCG ACTTGGCCCT GATCCTTCAC CAGYTAGGCC GYTACAGTCT	900
10	GGCGGAGAAG ATCCTCCGGG ACGCGGTGCA GGTGAAGTCG ACAGCCCACG AGGTCTGGAA	960
	CGGCTGGGC GAGGTCTCC AAGCTCAGG CAAAGATGCG GCGGCTACGG AGTGCTTCT	1020
15	GACGCCTTG GAGCTGGAGG CCAGCAGCCC GCGCGTCCC TTCACCATCA TCCCCCGGT	1080
	GCTCTGAGCA GCGCCCTGCC AGCCTCACCT GCGCTCAGC CTNCAGAGGC CCTGCCGGGC	1140
	ACCAGGGCTT GTGCCATCGC CCAAGGGGA TGAATCTGCC GCACTGAGGC CAGGACGAG	1200
20	TGTTCACTGG GCCACAGTGA ACCAACC AAA CCAACCCGA ATCATGCTC TCGCCATGTG	1260
	CGTTCTCTT GTTTTTTTTG CCAGCCCAAT GGTAGTTTCT GAACCTATTG ACATTGTTC	1320
25	AAATGGATCA TGTCCATAT TTTGTTAGT GACATCTGAG TTTTCAGTAA AATGATTATG	1380
	GAATTAATCA GCAAATGTAG AAGATATAT TCAAAGTTAA AATTCAGTG CAGCACAGAT	1440
	TATTTTATC AGAGCTGTAA AGAAAACAAC TGTCCTTTTC TCCCCACCAC CCTCCTGCC	1500
30	CCACTTTGGC CCAGAAACCA AATGTGAAT TCTGTCTCC CACCTCAGCA CTAGTCCATG	1560
	CCAGGACACC AGCTGACAAT TTCTTGGTTT TACTGTCAAT AATGTACCA TGTGATCAAT	1620
35	TACTGTCTC ACTTGAACA AAGCCTGAGT CCGAGAATAT TTATATTTTA CCAATATATG	1680
	CCTGTTACAA GAGAAGGAAA TATGAGTTAT TTAAGTTTAA CTTTTTTATG TGAATTCAGA	1740
	GTTTATTTAT CGAGGGAAT ATGTACAAAG AAGCTTCAAA TGAATATTT ACCGACATC	1800
40	CTTATACATG ACAGACACTT GGCTACATGG GAAGATGATG TTAATAATAA AATGATTTT	1860
	AAATGGAAA AAAAAAAAAA AAAAN	1886

45

(2) INFORMATION FOR SEQ ID NO: 94:

50

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1774 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94:

	CTCAGCTACC GTATACAGTA GGACATAACC CCATTTTACA TGCACTACAC TGAGACTTGC	60
60	CTCCTCTCCC CCCACATTGA AGATGTTCTT TTTTCATAAC TATATACTAT TCCATTGCAT	120

	GAATATCTG TAATTTATTT AATCCCTAT GGATTGATAA TTAGGTTTCAT TATAGATAGA	180
	AGTGTAATTA ACATTCCCTGT ACATGTATTT TGCTACTTGT GTGGGTATTT CTGTAGGATG	240
5	AATAACTAGA AATTTATTTG ATCAGGTTTC ACATTTGCAG TTTTGAAAAC TACTACCAA	300
	AAGATTTCAC CAATTTACAA CTCCATCATT AGTAAGAAATG CCTGTTTGCC TATAGTCTGC	360
10	CAACCOCTGAA TCCTTAAAAA TTTTGGCAA TCTGGTAGGC AAAATTCTTT TCTTTCTTT	420
	GAATATTAAT GAGGAGGAAC ATCTTTTCAT GTTCTTGGC CATTTGCATT TCCTATTATG	480
	AATGCTTTT GCCCATTTTC CTTTTTTAA TTATGAAAGT CTAATGACTA CCTTCTCATT	540
15	GTATAAAAAA CACAGTTCTT TGAATAGAGA GACCTTTTC TCCAATGCTA CCAATCACAT	600
	TCCACTTACC ACAGTTTAAAC ATACATCTTC TAGTCACCTT TCCGTACGAA TATACATACA	660
20	CATAAAACA CTTTTTACAT AAATAGGATC TCATATTCTG TAGCTTTTAA AAATTTGGT	720
	CTCAAAAAA GATAACAGGT CTTTAAATTT CTTTAATGGT TGAATATGAT TAAATACTAT	780
	GAAAATGCCA TTATTTATTC CCTTAATTTT TTTCTCTCG CTATTACATT GCCAAAGTAA	840
25	ACATCCTATT CAGATGCTT TGTGCATGTG TGTGAATATT TCTTAGTCT GGAGTCCAGT	900
	AAGGTGGATT TTTGGATCAA AGGGTTTGT CTCGTCCAC CTTCAGTCTT CCCAAAGGCC	960
30	TTCATAACTG TATTTTCACC AAGTGTATGG AGAATGTTC TTTCCCCATA TAACCATACC	1020
	TACACTIGAT AGTTTTATC TGTGGGCGA AAAAGAACCT TTTCTTATTT TGCATTTCCC	1080
	TGATTATAAA AAAAAATGGT GAGATTGGGG TTATTTTCAT GTTATTTGGC CATTTATAGT	1140
35	TTACTGTGGA TTGTTGTAT CCCTACCTG CTTTCTATTG GGTTATGTGT GGATATATTG	1200
	TTTTTATTG TTCAGCATCT CCTTCCCAT CTTCTGGTAA CACAACCTTT ATTTATTTGT	1260
40	GGGAACCTA TTCCCTGTGG CTTAGGTGAG CATGTGACCA GGCCTGGCCT CCTGAGTCCC	1320
	ACAGCTTCCT AGCCACAGTG ATAAAAGAAT GGGTATATAA CTTAAGCCAG GCTAAGGAAA	1380
	GCCCTTAACA GAACTTCTGC TGGAACTACT GGAAGAAGG CTTTATGGAG ATCCCAGGAA	1440
45	CCAAGGACCA TGTAAGCCTG AATTTGTGCC ATGTGGAGAG AGTCTGTCTG AGGAGAACT	1500
	CGGATGCTAG CAGAAATGGA AAGAGAACTA AGTTCTGATG TCAITTTTCT GGAGGCCCTA	1560
50	GATCCAGCTG TGCCTAAAGC CTGCCCTACT CCGGACTTTA AAGTTTGTG AGCCAATAAA	1620
	GTCCCTTCT TGTTAAGAT AATTGAATTG AGTTTCTGTT CTGATTAATA TAGGTTATTT	1680
	GTATTTCTT ATTGATTTGT AGAAAACCTT TGTAATTTA AATCTAGAC TTTATGCACT	1740
55	ATATAAGTTA ATAAAATTAG CATGGCCTTC CATG	1774

60 (2) INFORMATION FOR SEQ ID NO: 95:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 2503 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95:

10	GGCAGGAGCG AAGGCAAGGG GGCACCAGCT CAGGACTGCA TCTGCCCTGCC ATTTCCCTTC	60
	CACTCCTCCT TTCTGGAGTC TGACATTAGA AAGCCAGCGA GAAGGAAGAT TCAAACAACC	120
15	AACCCGTGATT TOCTGCTTCT CCTTTTCATG AGTGTTCCTG TGGTCTCTGC ACCTCCTTTC	180
	TGTCCCCCGG CAGAGGGCAG TAGAGATGGC OGGCCCAAGG CCTCRGTGGC GCGACCAGCT	240
	GCTGTTCATG AGCATCATAG TOCTCGTGAT TGTGGTCATC TGCCGTGATGT TATACGCTCT	300
20	TCTCTGGGAG GCTGGCAACC TCACTGACCT GCCCAACCTG AGAATCGGCT TCTATAACTT	360
	CTGCCTGTGG AATGAGGACA CCAGCACCTT ACAGTGTAC CAGTTCCTG AGCTGGAAGC	420
25	CCTGGGGGTG CCTCGGPTG GCCTGGGCCT GGCCAGGCTT GCGGTGTACG GGTCCCTGGT	480
	CCTCACCTTC TTGCCCCCCC AGCCTCTCCT CTAGCCAG TGCAACARTG ATGAGAGAGC	540
	GTGGCGSCTG GCAGTGGGCT TOCTGGCTGT KTOCTCTGTG CTGCTGGCAG GCGGCCTGGG	600
30	CCTCTTCCTC TOCTATGTGT GGAATGGGTC ARGCTCTCCC TCCCGGGGCC TGGGTTTCTA	660
	GCTCTGGGCA GCGCCAGSC CTTACTCATC CTCTTGCTTA TAGCCATGGC TGTGTTCCCT	720
35	CTGAGGGCTG AGAGGGCTGA GAGCAAGCTT GAGAGCTGCT AAAGGCTTAC GTGATTGCAA	780
	GGGTTGAGTT CCAACCATGG TCAGAGGTGG CACATCTGCT CAGCCATCTC ATTTTACAGC	840
	TAACGCTGAT CTCCAGCTCC AGCGATGGAA CCCACTACAG AGGAGGTGGG GCCCCGTGCT	900
40	CAAAGAGGCC GAGGGGCAGC AAGGGCAGMC AGGGCACCTG TGACTTCTTA GTACAAGATT	960
	GTCTGTCTTT CAGGACTTCC AAGGCTCCCA AAGACTCCCT AAACCATGCA GCTCATGTTC	1020
45	ACACCAATTC CTGCTTTAAT TAATGGATCT GAGCAAATCT TOCTCTAGCT TCAGGAGGGT	1080
	GGGAGGGGAG TGATTGCTGT CATGGGGCCA GACTTCCAGG CTGATTTGCC AAATGCCAAA	1140
	ATGAAACCTA GCAAAGAACT TACGGCAACA AACGAGGACA TTAAAAGAGC GAGCACCTCA	1200
50	GTGTCTCTGG GGACATGGTT AAGGAGCTTC CACTCAGCCC ACCATAGTGA GTGGGCGGCC	1260
	ATAAGCCATC ACTGGAATC CAACCCAGA GGTCCAGGAG TGATCTCTGA GTGACTCAAC	1320
55	AAAGACAGGA CACATGGGGT ACAAAGACAA GGCTTGACTG CTTCAAAGCT TCCCTGGACC	1380
	TGAAGCCAGA CAGGGCAGAG GGTCCGCTG ACAAATCACT CCCATGATGA GACCCCTGGAG	1440
	GACTCCAAAT CCTCGCTGTG AACAGGACTG GACGGTTGCG CACAAACAAA CGCTGCCACC	1500
60	CTCCACTTCC CAACCCAGAA CTTGGAAAGA CATTAGCACA ACTTACGCAT TGGGAATTG	1560

	TGTGTATTTT CTAGCACTTG TGTATTGGAA AACCTGTATG GCAGTGATTT ATTCAATATAT	1620
5	TCCTGTCCAA AGCCCACTG AAAACAGAGG CAGAGACATG TACTCTGGTG TGATCTCTTG	1680
	TCCTCAGTGT CTCTTCTGGG CTCTGTCCC TCTTGCTTTA TAGCTAGCTG CCCGGGGACC	1740
	AAGGTACAGG TGAAAGCAAG GTAGCAGCTT GCGGGAGGAG GCCTGTCTGG CTTACCAGTC	1800
10	TATACACTGT GGCTCAACC TCCAGACAG GGCAGAGAAC TGTGGGCAGC TCGTTTGCTT	1860
	TCTAGGCTGG CTGGAGAGGT GGGAGCTCAT TGATAGACTC ATGATGGAAA CTATTTTGA	1920
15	AACAGGCTTC CTCTTCAGG AGAGATCATG CGGACTAAAC TGTAGCAATT CCACTGCACC	1980
	TGGCAGTGAT CCTTTTCTTT GCAAAGTACT GTCTCTTTGG TTCCAGTAAG TTGGACCACC	2040
	ACATGACATY ATTTTCCCTG GAACCTGGTC ACTGACTAAC ACAGACAATT GGGACTCCAG	2100
20	AGCCTCAAGA GCCAGGAGAG GGCACAGTAC ATACAGAGGG AGTCAAATGG GATCTCATTT	2160
	TGAGTCTGTC CTTCGCCACA CTCAGAACGG CANCCCCAAG GCCCCGAGTG TCCAGGGCTT	2220
25	CTGGCCTGAG GTGAATCTGC CAGGCCCAAG AAGGCACAAA GGTAGGAGCA CAGAGAGCCC	2280
	CATTCGCCACA GCGGKGGC CCAGCAGCAC CAGTGGAAGC TCAGCTGTCC TCCAGCTGCT	2340
	CTCGGCAGAC AGTTAGTGC ACAGTTTATG CCCTAGCTGA AAAAGATCTC CCGGACGTAT	2400
30	TTCAGCACAT CCTCTTCTC CTCTCTCTCA GGGCTCTGTC TACAGGCAGA GCTGGAACCC	2460
	CCCGGCTCTT GGAAGGGCT GAGGCTGGA GYCACTGCCT GTC	2503

35

(2) INFORMATION FOR SEQ ID NO: 96:

- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 2801 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96:

	CTGGAAGCC GAGGGTAGCC GAGCGGGCG GCGCTCTGG AGCGGCGGT GCTCGGCTG	60
50	CGTCCGCTC CGCCAGAAGC ACCGAGCAGC CGAGCCGGG CCGCCGCC TCCTCTCCA	120
	TGAGCCCCGA GTGAGGCGG GCGCTATAG CCGACCGCG GCGCTTCCC CCGCGTCTT	180
	ATCGCGAGCG CACGACMAGC GGCCCTGGA GGAGGAGCG GAGGAGGAG AGCATGTGG	240
55	ACGGTTTGA TCGGGCCCCA GTGCTGCTC GGGCCCGAR CCGGGGCTG GGCCGCGGAG	300
	GGGGGGGCC TRAGGGCGG GTTPTYCGA AMGGARCGR GCCTGCTGAG CGGRCGGGC	360
60	ACCAGCCGCC GCAACCCAAA GCGCGGGCT TYCTGCARCC AMCGCGCTG CGCCARCCA	420

	GGACGACCCC GCGGCCAGGG GCCCAGTGGC AGGTCCCCGC CAGCCCCCAG CGGCCCTCCC	480
	GCCCCGGGGC GCTCCAGAG CAAACGAGGC CCTGAGAGC TCCACCTAGT TCACAGGATA	540
5	AAATCCACA GCAGAATCG GAGTCAGCAA TGGCTAAGCC CCAGGTGGTT GTAGCTCCTG	600
	TATTAATGTC TAAGCTGTCT GTGAATGCCC CTGAATTTTA CCTTCAGGT TATTCCTCCA	660
10	GTTACACAGA ATCCTATGAG GATGGTTGTG AGGATTATCC TACTCTATCA GAATATGTTT	720
	AGGATTTTTT GAATCATCTT ACAGAGCAGC CTGGCAGTTT TGAACTGAA ATTGAACAGT	780
	TTGCAGAGAC CCTGAATGGT TGTGTTACAA CAGATGATGC TTGCAAGAA CTTGTGGAAC	840
15	TCATCTATCA ACAGGCCACA TCTATCCAA ATTTCTCTTA TATGGGAGCT CGCCTGTGTA	900
	ATTACCTGTC CCATCATCTG ACAATTAGCC CACAGAGTGG CAACTTCCGC CAATTGCTAC	960
20	TTCAAAGATG TCGGACTGAA TATGAAGTTA AAGATCAAGC TGCAAAAGGG GATGAAGTTA	1020
	CTCGAAAACG ATTTTCATGCA TTGTACTCTT TTCTGGGAGA ACTTTATCTT AACCTGGAGA	1080
	TCAAGGGAAC AAATGGACAG GTTACAAGAG CAGATATTCT TCAGGTGGT CTTGAGAAT	1140
25	TGCTGAATGC CCTGTTTTCT AATCCTATGG ATGACAATTT AATTGTGCA GTAAAATTGT	1200
	TAAAGTTCAG AGGATCAGTT TTGGAAGATG CTTGGAAGGA AAAAGGAAAG ATGGATATGG	1260
30	AAGAAATTAT TCAGAGAATT GAAAACGTTG TCCTAGATGC AACTGCAGT AGAGATGTAA	1320
	AACAGATGCT CTTGAAGCTT GTAGAACTCC GGTCAAGTAA CTGGGGCAGA GTCCATGCAA	1380
	CTTCAACATA TAGAGAAGCA ACACCAGAAA ATGATCCTAA CTACTTTATG AATGAACCAA	1440
35	CATTTTATAC ATCTGATGGT GTTCTTTTCA CTGCAGCTGA TCCAGATTAC CAAGAGAAAT	1500
	ACCAAGAATT ACTTGAAAGA GAGGACTTTT TTCCAGATTA TGAAGAAAAT GGAACAGATT	1560
40	TATCCGGGGC TGGTGATCCA TACTTGATG ATATTGATGA TGAGATGGAC CCAGAGATAG	1620
	AAGAAGCTTA TGAAAAGTTT TGTTTGAAT CAGAGCGTAA GCGAAAACAG TAAAGTTAAA	1680
	TTTCAGCATA TCAGTTTAT AAAGCAGTTT AGGTATGGTG ATTTAGCAGA ACACAAGAGA	1740
45	GCAAGAAAAT GTGTCACATC TATACCAAAT TRAGGATGTT GAGTTATGTT ACTAATGTAT	1800
	GCAACTTTAA TTTTGTTTAA CACTATCTGC CAAAATAAAC TTTATCCCT ATAACCTAAA	1860
50	ATGTTATAT ATATATAATA GTTTATTATG TACAGTTAAT TCTACTGTTT TGGCTGCAAT	1920
	AAAATCGATT TTGAAATAAA TGAAATGTTG AAAATTTTGC TAGTTGGTTA GATGCTTATC	1980
	CTTTAAATTC TACTTTCTT GAGGGGAAAA AGTCTTCGTC TGGAAATACA TATTACTGCA	2040
55	AAAATGTAGC ATCCTTTTTT AGGTAGGAGT ATTATAGCTT YCATTTTAGT TKGACATTTA	2100
	GTGTCCCAAT GAATTGAATT TCAAATATGA ATCATAATCT TGAAAATCTT TAGCACTAAA	2160
60	GTCTTGGGAA TATATCAACA ACTGATTTAC ATATGCAGAT GCTATTTGNA TACCAAGGGC	2220

	TTTTTAAATG TCATGGGGGG GAAAAACCCA ACTTGGTGGA ACTCCCAGCT AAACAACCAA	2280
	GACTTCACTG GAAGATTAT TCCAATTCTA GGAATTGTC TTTTATTATTT TTATTTTTC	2340
5	AACTGRCTAA CTTCATTACC TTAAAGCCTA GAACATTATT CTGCTTTATT TATATGGCCT	2400
	TCTCACTTTT ATTTTGTAGC AKGGGTGCA TCGACTTTT TACTAGAGAA TTTTACTAGA	2460
10	TATTGTTCAT TCAAGTTTC ATCTGCTTTA TAATTGATAC ACCTTGAGGG TCACTTTTCT	2520
	AATACTTTTA CTATAATGTG GTACCACCTC AGCCCTAATA AATAATATTT TTACCTAATG	2580
	TCAAATCTTT TTCCAGCTAA CTAAAACTG TGTACAAAAG GATTGCTTGT AAATATGCAT	2640
15	GTAAATAGTT CTGTTAATAA CCCACTGTTT TACATTGGT ACATCTGTGT CTGCTAATAC	2700
	AGTTAGCTTT CTCACTTTC TGCTTGTTG TTCAGTCTGA ATTAAATTA GACTTTGAAA	2760
20	ATAAAGCTTA AAAAAAAAAA AAAAAAAAAA AAAAAGCTGA G	2801
25	(2) INFORMATION FOR SEQ ID NO: 97:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 1631 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
30	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97:	
35	ATGGAGCCAA AGACAATCAC TGATGCTTTG GCTTCTAGTA TAATTAAGAG TGTGCTGCCT	60
	AATTTCTTC CATAAATGT CATGCTCTAC AGTGATGCTC CAGTGAGTGA ACTGTCOCTC	120
	GAGCTGCTTC TGCTTCAGGT TGTCTGCCA GCATTACTCG AACAGGGACA CACGAGGCAG	180
40	TGGCTGAAGG GGCTGGTGG AGCGTGGACT GTGACCGCCG GATACTTGCT GGATCTTCAT	240
	TCTTATTAT TGGGAGACCA GGAAGAAAT GAAAACAGTG CAAATCAACA AGTTAACAAT	300
45	AATCAGCATG CTCGAAATAA CAACGCTATT CCTGTGGTGG GAGAAGGCCT TCATGCAGCC	360
	CACCAAGCCA TACTCCAGCA GGGAGGGCCT GTTGGYTTTC AGCYTTACCG CCGACCTTTA	420
	AATTTTCCAC TCAGGATATT TCTGTGATT GTCTTCATGT GTATAACATT ACTGATGCCC	480
50	AGCCTCATCT GCCTTACTTT ACCAGTATTT GCTGGCCGTT GGTAAATGTC GTTTTGAGC	540
	GGGACTGCCA AAATCCATGA GCTCTACACA GCTGCTGTG GTCTCTATGT TTGCTGGCTA	600
55	ACCATAAGGG CTGTGACGT GATGGTGGCA TGGATGCCTC AGGGACGCAG AGTGATCTTC	660
	CAGAAGGTTA AAGAGTGGTC TCTCATGATC ATGAAGACTT TGATAGTTGC GGTGCTGTTG	720
	GCTGGAGTTG TCCCTCTCCT TCTGGGGCTC CTGTTTGAGC TGGTCATGT GGCTCCCTG	780
60	AGGGTTCCT TGGATCAGAC TCCTCTTTT TATCCATGGC AGGACTGGG ACTTGAGTC	840

	CTGCATGCCA AAATCATTGC AGCTATAACA TTGATGGGTC CTCAGTGGTG GTTGAAAAC	900
5	GTAATTGAAC AGGTTTACGC AAATGGCATC CGGAACATTG ACCTTCACTA TATTGTTTGGT	960
	AAACTGGCAG CTCCCGTGAT CTCTGTGCTG TTGCTTTCCC TGTGTGTACC TTATGTCATA	1020
	GCTTCTGGTG TTGTTCTTTT ACTAGGTGTT ACTGCGGAAA TGCAAAACTT AGTCCATCGG	1080
10	CGGATTTATC CATTTTTACT GATGGTGGTG GTATTGATGG CAATTTTGTG CTTCCAAGTC	1140
	CGCCAGTTTA AGCGCCTTTA TGAACATATT AAAAATGACA AGTACCTTGT GGGTCAACGA	1200
15	CTCGTGAAC ACGAACGGAA ATCTGGCAAA CAAGGCTCAT CTCACCACC TCCACAGTCA	1260
	TCCCAAGAAT AAAGTAGTTG TCTCAACAAC TTGACCTTCC CCTTTACATG TCCTTTTGTG	1320
	TGGACTTCTC TCTTTGGAGA TTTTCCCAG TGATCTCTCA GCGTTGTTTT TAAGTTAAAT	1380
20	GTATTGACT TGTGTCTCA GCATTCAGAG AGCAGCGGTG TAAGATTCTG CTGTTCTCCC	1440
	TGGATCTTCT GACATTACTG CTGTCTGAGA TTTGTATATG TGTAAATACA AGTTCCTTGA	1500
25	TACCTTAAAA CCTTGGATTA AACAGATGT GCATTGTACA TCTTTAAACA AAATGTATAT	1560
	TAATTTATTA AATCTAGTTG TCACTTTAAA AAAAAAAAAA AAAAACTCG AGGGGGGCCC	1620
30	GGTACCCAAA T	1631

(2) INFORMATION FOR SEQ ID NO: 98:

- 35 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 504 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - 40 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98:

	CGAGCTGGG CGAGAAGTAG GGGAGGGCAC GAGCCGCCGC GGTGGCGGTT GCTATCGCTT	60
45	CGCAGAACCT ACTCAGGCAG CCAGCTGAGA AGAGTTGAGG GAAAGTGCTG CTGCTGGGTC	120
	TGCAGACGCG ATGGATAACG TGCAGCCGAA AATAAAACAT CGCCCTTCT GCTTCAGTGT	180
50	GAAAGGCCAC GIGAAGATGC TCGGCTGGA TATTATCAAC TCACTGGTAA CAACAGTATT	240
	CATGCTCATC GTATCTGTGT TGGCACTGAT ACCAGAAACC ACAACATTGA CAGTTGGTGG	300
	AGGGGTGTTT GCACTTGTGA CAGCAGTATG CTGTCTTGCC GACGGGGCCC TTATTTACCG	360
55	GAAGCTTCTG TTCAATCCCA GCGTCTTA CCAGAAAAG CCTGTGCATG AAAAAAAGA	420
	AGTTTGTGAA TTTTATATTA CTTTTAGTT TGATACTAAG TATTAAACAT ATTTCTGTAT	480
60	TCTTCCAAA AAAAAAAAAA AAAA	504

(2) INFORMATION FOR SEQ ID NO: 99:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1416 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99:

5	GGCAGGAGG AGGAGCCCT CTCGTTGGG TGA	60
10	CTCTCTTGT GTGCCCTTA GACAGGCTGG	
	CCTGCCGGT CCACAGGTA CAGTAGGAC TTGAGTC	120
	TTTCTCTGT TTTGAGTTGG	
	TGAGTGAGTG ATAGGTAAC ATGGGCCTC AGGATG	180
	ACCC CTGGAAC TGCCGAGTTC	
20	CTTAAATCTC AGCTGGGATC CTGGACCTGG	240
	GAGGCCCTG TGAGGGCCAG CTCTGGAAAA	
	ACCTGGGAGT TGATGCCGA GCTGTGAAG AACTCTG	300
	CTC GAGGGCAGG TGCCCTGGAA	
25	CACTGGTAGT TCTGGGGCTG GGAGGGAGAG	360
	GGGCTCCGGC TTTCTCTGAA ATGAACACTG	
	CTCTTCAGCA GTTCAAGTAC TTGTCTCAA	420
	AACATTTTCT AATTGATTGG TAGGTTTCA	
	TAAGCAATTG TTCTTTAAG CATGAAAGG	480
	GAAGAATGCT CAAGCAAGTC ATGTTTGT	
30	TTT TCACTGGAT GGGCCCGCT TCTCACTGCT	540
	GGGGCTTCC CTTTCATGTG GCACCTTTGT	
	GCAGGGGCCA CCAGGCAGAC TCTTCCACC	600
	TTCTCCACT GAAGCACCA GGGCTTGA	
35	ACCGTAATT GGCTAATCAG AGGCATTTT	660
	TTTGTCTTAG TATCTTTCAC ACTTGTCCAA	
	CGTCTTATT TTTTAAAG TTCTGTGCT	720
	TGTATTAACA CGAACTAGA GAGAAATAGT	
	TTCTGAAGCC AGTTTATTGT GAAGATCCC	780
	AAGGGAGGT TCGGTAGAGA AAAATAGTAA	
40	GCTGGTTTAG AACTGACGA GGSCAACAG	840
	CCAGGACGCA TTGGAGAGGA ATTTGCCAAA	
	GATCTACCT GAGATAACGC CTGTCCAGTG	900
	TCTTCACCAC GTGAATAACC AGCGCTCCAA	
45	AGTGTTTTC TGCTTTGAAA AAAAAAATC	960
	CACAAGCTTT TAAAGGTGCA TTTAAGAATC	
	CATGTGACTT TAGAATGGAA CTGCCGGCC	1020
	TGGCAACTGT CACGTGTGCT AGAAGGTTCG	
	ATGCCTCTGG AATGCATGTG ATACTCATCT	1080
	CCATTTTGTT TCCTTGATTG CATTTTGT	
50	CTTTTAGCAG ATCTGTCCCT GTGGTGCTG	1140
	TCTAAGAAGT CGGACACCTT GGTTTTGTG	
	TTAGATTGAG CTGGGCAGCT GCAATCAGCT	1200
	TCTTTATATG CAAATTAGGC ACGACCCATC	
55	TGTGGTTCCT GGTGGTGGC TAATGAAGTG	1260
	AGGGGAGGGA GGGATGTAC CCCAAAAGTA	
	GGCCCTCCA TTGGCTTTGG CCAGGCCAGA	1320
	CATTACAT CGTTTACATG GTTCTGTGTA	
	ATTTTAAAGT TTATGTGTAT AAAGCGAAGC	1380
60	TGTTCTGTG AACTGTATA TTTGTAAAT	
	AAATATATTG CTAATTGAAA AAAAAAAAAA	1416

5 (2) INFORMATION FOR SEQ ID NO: 100:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 2847 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100:

15 GGCTAGGACA ATTTTGGTGC TTTACCTATC TCTGCAAAGA CTGGAGAATT TGGCATACCA 60
TTAATTACAA CCACCAATCA TATCCAACAA AAGTACCCCTA AAAGAAGGAC CAGTGGCCAC 120
20 TCTCGAAAAA ATTAAAGTAT CAGAAGATTAA AAAAGATTTT AGGATTTGGA AGCTTGTTATT 180
GTCTTTCCCC AATAATCATT GTTTGATCTC CAAATAGTAG CCTTATATTA GCAATRGACA 240
GATCATTTGGT TCTCCATATC TGATCATATG TTACTACTTT GGAATCAGTA TTTGGGCAAA 300
25 TTCAAGCATT TATGCAGTGG ATATAAATGG AAATATAAAA ATATTTGCCA ACCTGTCTCA 360
GTAACCTATC ATATCTCTGT GNATCCTCAA GGAAAGCACT TTTGCTTTTA CTTAGAAAGC 420
30 GTTTCAGATT TGCTTTATAG ACTCTGCTG TCTTCAGTAC CTGATAAAAC TTTAACCAGG 480
GAAGCATTAA ACACAGTGCA GCAGCTTTTG CCCAGGCTTC TAAGTTCTTG CCGGCAGCAT 540
TTATCAATGT AAGAACTAGG ATGCTTCCTG CAGTGGCACT ACCTTCCCCT AGAGCTGGAG 600
35 CATGCTGCTT GGCCTTAAGC CCCAGCATGA TGAGGCTTCC CTCTGCCAG GTCAGTAAAA 660
GTTAGAGAGC TCAGAATTGG GTCTTGCCTG GGTGCAGGTG GCAGGGTTTG CTGAAACCCC 720
TAAAGAGAAG TCACCAAGGG AGGCAGGTAA TGAATGTTTC CAGAATCAGT CRGATACTCA 780
40 TAGCAATTTC TGGCTATCTT TCAAATGTTG AATTTCTGGA TGCTGAGAGG GACTTTGATT 840
TGATATCATT AAATCCAGGA CAGTCCCAAG AAGTGCTTGG AGTCTGGGCT CTGACAGCCC 900
45 AAGAAGGGAA ATAACCTGTA TTAAGGAACA ACTATGAGCC AGGCCCTGAG CTGTCTCTTA 960
GATAATAAAA CAGATGGGGA GTGGAAGAGT CATTTGCTTC AAGTTATACA GCTAGGAAAT 1020
ACTCAAGCCA AATCTTGAAC GCAGCTCCCC CTAATTCCTG GGACAGGCAC TTTGTACCAC 1080
50 ACACCATGGT CCACCTAAAA ACAGAAGGAT AAAAAGACTT CAGGTTTTCC CACTGTGTGC 1140
TGACCATCCC AATTTATGAA TCTTCTTCAA AATGACATTT CACAGTTATA GTTAGGGCTC 1200
55 AGAAATGGCA TTGAGGTAGC CTTATTCTC CCCTTTAGCA GATGCTTTAA GTACACATTG 1260
CTGACTTGAG CCCACCCCA GGAGTTAGGA GAACATTTC TTTTTCATGC CATCTTCCAT 1320
60 AAATAAGGTG TTTCTTGGCC TTCAAAGATA TAGAACTTTG CAGCAGTAGT AAAAGTGAAG 1380

	GGTGTCTGCG TCTCTACTCA ACTTTATTTG AAAATGCTCG CAGCTTCACT CCTGTAGAAA	1440
	AGGAAATCTT CATATTTTAG TAAACTTAGC CGCCAGTGTA CTCTGTGAGG ATGTGGCAAT	1500
5	TCAAAGTCCA GTGAATCTGG CTCTCTTACT GATTCCTGGT TTTAGTGTGT GTGTGGGGG	1560
	AGTGTGTACC TATATATAAA GGACAAGTGT GATATGTGTG TATATGTATA TACATACATA	1620
10	CATGTCCACA CACACACACA CAATATTTGA GAGCTAAGGA AAACCTCAAAG CAGCCCCCTC	1680
	ATTATCTTGC GTACTACTTC AAAGATTCTT GTCAGCCCTA ATTACAAGTG TCACCATATA	1740
	GTTGGGGCTT AGGTACTTGC TTACAGGAAG AGCAATTCCC TAGCAAAGGT CATTAGCTCC	1800
15	TAAGGCACTG AGTCAAAGTG ACAGCCCTGA AGGAAATTGC ACTCCAGCCC TCCTCCAGGA	1860
	TGTCTAATAA GATGGGAAAC TTGGATGCCC AGCCATTTTG GTGACCTGAG AGTCTAACTA	1920
20	CTCCAGTTAG ACCTAAGGGC ACAAATGCAG AATTCATGAC CTGTAGTTG TGGCAGGGTC	1980
	TAGGAAGTCC TCTCTCCCA AGTAGAAAAT ATTCTCTTGC CATTCTGAA ATTCCACATT	2040
	CATATAATGG CTGTGCAATA CATGCTTCTC AATAAGAAAA TTAACATCAT GTTACTGTG	2100
25	TGCTGATCAC ATCAGATTTT TATGTTTAAA AAAATCTCAT TATGGNTTGA GTCCAGCCCA	2160
	GCTCTAAGAG AAAAGAAGG CCCATATGGG AGACTTCAGT CTCATTATTA TTGCCTTTAT	2220
30	CCAGCAGTGC TTATRAAGCC CCTACCCCTG TCCCATTCCA GAAACCATAA GACTCAGGCA	2280
	GTCTTGATT CTGGAGGCTT GCCTGGTAAG ATAAGATAGT ATAATTTGGA ACTGAGAACA	2340
	TACCAGAAAC AGCAGAACGA GGGCCAGAGC AGAAAAATGA AAATAAGTGG AGACACTTAT	2400
35	GGATACATTG GTGCAAAAAA AGCCACGGGS CCCATACTGG GCTTGATATG ACTTTGAGGG	2460
	GACAGCAGAT TAATACTTAA TGAGGGTTAA ACCTGACCAG TCTTTCTACA GTGACAGGCC	2520
40	AACTGCATG AATGGGGAGA ACCAATGAAT CCATTGTCCT CTGCCTATTT TCCTGTGCAC	2580
	AGTCACATTC CCTCCTTAGG AATCTTCCCC TTCCACCCCT TACATTAAAC AAGGGAACAC	2640
	TGAATCTTTC AAGGGAATTA CACGTTTGGG TTAATGTTTC AGTATATCAT TTTCATACTG	2700
45	TAAATTATTT TGTAAGAGAG ATTTACTGCT ATCCCAGGAT GPTCGGACTT GGTGCCCCTG	2760
	TGCATTTGGA AATCAATAAA CTATTACTGG AAATGCCAAA AAAAAAAAAA AAAAAAAAAAN	2820
50	NAAAAAATC GAGGGGGGCC CGTACCC	2847

55 (2) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1394 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101:

5	GAGATTGGTG GAGGAGAGTA AATAATCTAG AGGCAAGAGT TCAGTGAGGG CCAAGGGGGA	60
	CCCCCAGAAA AAGGTATGGA GCTAACTCAT CTCITTTTACA AGGGGTGGCC ATGACTTACT	120
	GTGCAAAAGT ACTCAGTGTA TATTTAATGT TGATTGTGTA ATTTTAGTTA CGAGAGGGAA	180
10	GAACAATTTT ACTTCTGTCC TTATTTCACT TGCTGAAAAG CTGTGGGACA AAATGTATGG	240
	AATAGACAAG GCCACTTTCT TTGTGATTTC TGCTTTTCAT GCATATTATT TTATTTACCC	300
15	ATAATTICCA AGAGGTTTGG CGTTCGGCTC TCCTGCTTTT TTCTTTTCATC CACCCCTTTC	360
	CTTTTTTTGG AAGGGGGTTA TATATGAGAG TTCATTGAAG AAGTCCAGTG AGGCTGAAGT	420
	AAAGGGGCAA GATAGGGCAG TTAATAAAG AGCACTTTAT TTCTTTGAAG CCTTTCTAAG	480
20	AAAGAAATGG GGGTCCGAGT GGCTGAATC TCCCATGATG TTGGAGGGCA CTTAGTGGGG	540
	TTGAAGTATG ACATAATATT TCCCATGGG GAAAGGAGAA TTTCTCTTAG AGGGTGGCAA	600
	AATGCCTTTG CCCAGTGTCC CTATTTTAGG CATCTTTTCC TTCCTTATTC CTTCCAGTCA	660
25	GGGTGTGTCC TATACAAAAC TTCCCATCAG TTCTCTCAA TATTCCTCAT TTGTAAATGA	720
	TCACTTCTCT TTTCTAAACC CTTTTCCTGT TCAGATCCAT ACAGGATTTG CAAGGGTAGG	780
30	ATCATACATG CAAATGCCCC TTGTTCATCT GTGTCTTCTG CAACTAGTC TCATGAAGAA	840
	TTCTGGCGTG CAGCAGGTA GCTGAAGTTT GGGTCTGGGA CTGGAGATTG GCCATTAGGC	900
	NTCNCCTGAGA TTCCAGCTCC CTTCACCAA GCCAGTCTT GCTACGTGGC ACAGGGCAAA	960
35	CCTGACTCCC TTTGGGCCTC AGTTTCCCCCT CCCCTTCATG AAATGAAAAG AATACTACTT	1020
	TTTCTTGTG GTCTAGCATT GCTGGACACA AAGTGTAGTC ATTATGTGTG TATTGGGTGA	1080
40	TGTGTGCAAA ACTGCAGAAG CTCACTGCCT ATAAGAGGAA ATAAGAGAGA AAGTGGAGGA	1140
	GAGGGACAAA AGGAGTAATT ATTTGGTATA GATCCACCCA TCCCAACCTT TCTCTCTCA	1200
45	GTCCCTGCTC CTCATGTTTC TGGTTTGGTG AGTCCTTTGT GCCACCACCC ATAATGCTTT	1260
	GCATGTCTGC ATCCTGGGAA GGGGTATAT GGTCTCACA GTTGTGTGCA TTGTTTTTTT	1320
	GCATGCTTTC TTAATAAAAA AAAAAAAAAA ATGTTTANAG TTTTATCTTA AAAAAAAAAA	1380
50	AAAAAAAAAA ACCC	1394

55 (2) INFORMATION FOR SEQ ID NO: 102:

(i) SEQUENCE CHARACTERISTICS:

- 60 (A) LENGTH: 794 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102:

5	GGMROGAGGC GGAGTAAAG GACTTGAGCG AGCCAGTGC CGGATTATTC TATTTCCCTC	60
	CCCTCTCTCC CGCCCGTAT CTCTTTTCAC CCTTCTCCCA CCCTGCTCG CGTACCATGG	120
10	CGGAGCGTCG GGGGCCACTC AGTCCCATTC CATCTCTCG TCGTCTTCG GAGCCGAGCC	180
	GTCCGCGCCC GGGCGGGCG GGAGCCAGG AGCCTGCCCC GGCCTGGGA CGAAGAGCTG	240
	CAGCTCCTCC TGTGCGGTGC ACGATCTGAT TTTCTGGAGA GATGTGAAGA AGACTGGGTT	300
15	TGTTCTTGA CACGCTGATC ATGCTGCTTT CCTGGCAGC TTTCAGTGC ATCARTGTGG	360
	GTTTCTTAMC TCATCCTGGC TCTTCTCTCT GTCAACATCA RCTTCAGGAT CTACAAGTCC	420
20	GTATCCAAG CTGTWCAGAA RTCAGAARAA GGCCATCCAW TCCAAAGCCT ACCTGGACGT	480
	AGACATTACT CTGTCTCAG AAGCTTTCCA TAATTACATG AATGCTGCCA TGGTGCACAT	540
	CAACAGGGCC CTGAAACTCA TTATTCGTCT CTTCTGGTA GAAGATCTGG TTGACTCCTT	600
25	GAAGCTGGCT GTCTTCATGT GGCTGATGAC CTATGTTGGT GCTGTTTTTA ACGGAATCAC	660
	CCTTCTAATT CTGTCTGAAC TGCTCATTTT CAGTGTCCCG ATTGTCTATG AGAAGTACAA	720
30	GACCCAGATT GATCACTATG TTGGCATCGC CCGAGATCAG ACCAAGTCAA TTGTTGAAAA	780
	GATCCCAAGC AAAA	794

35

(2) INFORMATION FOR SEQ ID NO: 103:

(i) SEQUENCE CHARACTERISTICS:

40	(A) LENGTH: 1544 base pairs
	(B) TYPE: nucleic acid
	(C) STRANDEDNESS: double
	(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103:

45	TTTGCTTGCT AGTCTGAACC AAAGAGTTGT TTGGGCATTT GCTGTGTTGG CCATTTCTGG	60
	AGCAAGAGGG TCTTCTTCCT CCTTCCCCCA GCCAGCCAGC TGTCTGGGG CCAGGCTTTC	120
50	CTGGGTGGAA AGAAGTATAC CTTTCCCTGG GGCCCTAGGA TAGCAAAGTG AGCCATAGTG	180
	GGCCAGGCTG CCTCCATGC TGGGCCCCAG CCCAGGTCTG CACTCGCCTG GATCACCTTC	240
55	TTTGAGCCTT AGCCATCTCC TGTCAGGTAG GAATGAACTT GCCAGCCTTC AGGYTCGTTC	300
	AGCTATGACC ATCTGTGCGG TCAGGGTACA CTCAGCTCTC CTCCCCAACT CCAGCAGCCT	360
	TTAAGAAGTG TCCCTTTGGC GCCCCCTGGA GGCAGAGCAC TGAGCTGGAC CCTGGGTAGA	420
60	CTCCACAGG GAGGACGGAG CTGGCCTCAG GAGTGGGACA CCCAGACTTG GCAGGGCCTT	480

5 CAAGAGGCCT GTGTGGGGGC CCCAGGAATC CTTAGCTGAA GCGGGGAGAC TCACTCTCCA 540
 TCTCAGGAAA TTCTAGCCCT TGCCCTCAGG GAGCCACGGT TGAGGGTGAG GCCCAACACC 600
 TGCCTTAGGG CCCTGGGTGG GCAAGTCTGG GCCCTGGGGT AGGGAGGGAG ACTCAGGGCC 660
 ACACCTGGGT ATTTTCTAAT TTCAGACAAA CACACACTCA GCGGCGACTC ACTGATTCTT 720
 10 ACACATTGCC AAGATTTCAC ACATGTGACC AGGGGCCACC AAAGTCCTG TGACCTTTGT 780
 GACTAGGATC CTAATTCTC TATTTTCTCC TGGGTGCCTG GGTCTGTGTC ACCTGGGGCA 840
 15 GTGTGGATAA TGTTTAGTTC TGTGACACTG TTTTGTGGG GTGGCACCTG GTTCTCCGAT 900
 GCCTGGGCTG GTGTACGGCC CAGGACTGTA GTGCTGGGAG CAGTAAAGCT CAGCTCTGTG 960
 TAATGAGTGA TGCTATGGCT TGCTGTGTC TTATGATCCA ATCCTTTTCT ACATCAGCCC 1020
 20 TTGTTTGTG TTATGGCTAG TCTTATCTGG CCTGGTTATT TCCTTCCGGG GAGGAGAGGG 1080
 TTTGCTAATC TGCTCCGAGC CCAACCTATT ACCACCCAC CTCGCTGGGA CCTACTGCTC 1140
 25 GGGAGGCAGC AGACAGGGAG CCACCAGCAG TGGCTTCTG GCCCTGTGCT GGGGGTGGG 1200
 GGAAGCTGGG GGCACATGTG GCCCTTGCCT TCTGAGCAGC TCCAGTGCC AGGGCTTTGA 1260
 GACTTTCCCA CATGATAAAA GAAAAGGGAG GTACAGAAGT TCCAATTCCC TTTTATTTT 1320
 30 GCTGGTTGGT ATCTGTAAAT GTTAATAAA TATCTGAGCA TGTATCTATC AACGCCAAGA 1380
 ATTTCAAAGT CTCCTTCAAC AATATGAGGC TTTTAGGATG TTTATATPCC TTCATCCCTC 1440
 35 TTGTTTCCCA GGTPTTGCAG GGAATAAAG TCTGGAATTA TAGATACAGC TTATTATTAA 1500
 ATTTGTCTCT GCATAAAAAA AAAAAAAAAA AACNCNNGGG GGGG 1544

40

(2) INFORMATION FOR SEQ ID NO: 104:

45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 871 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104:

ACCACGCGT CCGNCTGTG CACCCGGGGG CGTGGGAGTG AGGTACCAGA TTCAGCCCAT 60
 TTGGCCCCGA CGCCTCTGTT CTCGGAATCC GGGTGTGCG GATGAGGTC CCGGTTCTTA 120
 55 AGGTGGGTCT CTGTCCACCC GGGGCGTGG GAGTGAGGTA CCAGATTCAG CCCATTGGC 180
 CCCGACGCT CTGTCTCGG AATCCGGGTG CTGCGGATTG AGGTCCCGGT TCCTAACGGA 240
 60 CTGCAAGATG GAGGAAGCG GGAACCTAGG AGGCCGTGATT AAGATGGTCC ATCTACTGGT 300

CTTGTCAGGT GCCTGGGGCA TGCAAAATGTG GGTGACCTTC GTCTCAGGCT TTCCTGCTTT 360
 TCCGAAGCCT TCCCCGACAT ACCTTCGGAC TAGTGCAGAG CAAACTCTTC CCCTTCTACT 420
 5 TCCACATCTC CATGGGCTGT GCCTTCATCA ACCTCTGCAT CTGGGCTTCA CAGCATGCTT 480
 GGGCTCAGCT CACATTCTGG GAGGCCAGCC AGCTTTACCT GCTGTTCTTG AGCCTTACGC 540
 10 TGGCCACTGT CAACGCCCCG TGGCTGGAAC CCCGCACCAC AGCTGCCATG TGGGCCCTGC 600
 AAACCGTGGG AGAAGGAGCG AGGCCTGGGT GGGGAGGTAC CAGGCAGCCA ACAGGTTCOC 660
 GATCCTTAAC GCCAGNITCG AGAGAAGGAC CCCAAGTACA GTGCTCTCCG CCAGAATTTC 720
 15 TTCCGCTACC ATGGGCTGTC CTCCTTTTGC AATCTGGGCT GCGTCTGAG CAATGGGCTC 780
 TGCTCGCTG GCCTTGCCCT GGAAATAAGG AGCCTCTAGC ATGGGCCCTG CATGCTAATA 840
 20 AATGCTTCTT CAGAAAAAAA AAAAAAAAAA A 871

25 (2) INFORMATION FOR SEQ ID NO: 105:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 404 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105:

35 GGCACGAGTT ATAGCATGGC ATTCATACTT TTGTTTATT GCCTCATGAC TTTTITGAST 60
 TTAGAACAAA ACAGTGCAAC CGTAGAGCCT TCTTCCCATG AAATTTTGCA TCTGCTCCAA 120
 AACTGCTTTG AGTTACTCAG AACTTCAACC TCCCAATGCA CTGAAGGCAT TCCTTGTCOA 180
 40 AGATACCAGA ATGGGTACA CATTTAACCT GGCAACATT GAAGAACTCT TAATGTTTTC 240
 TTTTAAATAA GAATGACGCC CCACTTTGGG GACTAAAATT GTGCTATTGC CGAGAAGCAG 300
 45 TCTAAATTT ATTTTITTA AAAGAGAAAC TGCCCATTA TTTTGGTGGG GTTGGTTTTT 360
 AATTINTAAT NTGAAAAATT TTTTGGGGT TTTTGGGGCC ATGG 404

50

(2) INFORMATION FOR SEQ ID NO: 106:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1542 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106:

60

	GTGAGACAGG TGGAGCCGCC GGGGCAGGAG TCTCAAAGAG CCAGGCTCCA GGAGAGGAAG	60
	GGCTCTROGA GAGGAGAGAG GAGAGCGCTG GAGAGGAGAG GCTGGAGAGT CCTTAGCCAG	120
5	GATGGAGGCT GTTGTGAAC TGTACCAAGA GGTGATGAAG CACGCAGATC CCCGGATCCA	180
	GGGCTACCCT CTGATGGGGT CCCCCTTGCT AATGACCTCC ATTCTCCTGA CCTACGTGTA	240
10	CTTCGTTCTC TCACTTGGGC CTGCGATCAT GGCTAATCGG AAGCCCTTCC AGCTCCGTGG	300
	CTTCATGATT GTCTACAAC TCTCACTGGT GGCACCTTCC CTCTACATTG TCTATGAGTT	360
	CCTGATGTGG GGCCTGGCTGA GCACCTATAC CTGGCGCTGT GACCCGTGGG ACTATTCCAA	420
15	CAGCCCTGAG GCACTTAGGA TGGTTCCGGT GGCCTGGCTC TTCTCTTCT CCAAGTTTAT	480
	TGAGCTGATG GACACAGTGA TCTTTATTCT CCGAAAGAAA GACGGGCAGG TGACCTTCCT	540
20	ACATGTCTTC CATCACTCTG TGCTTCCCTG GAGCTGGTGG TGGGGGGTAA AGATTGCCCC	600
	GGGAGGAATG GGCTCTTTC ATGCCATGAT AAACCTCTTC GTGCATGTCA TAATGTACCT	660
	GTAACAGGA TTATCTGCCT TTGGCCCTGT GGCACAACCC TACCTTTGGT GGAAAAAGCA	720
25	CATGACAGCC ATTCAGCTGA TCCAGTTTGT CCTGGTCTCA CTGCACATCT CCCAGTACTA	780
	CTTTATGTCC AGCTGTAACT ACCAGTACCC AGTCATTATT CACCTCATCT GGATGTATGG	840
30	CACCATCTTC TTATGCTGT TCTCCAACTT CTGGTATCAC TCTTATACCA AGGGCAAGCG	900
	GCTGCCCCGT GCACCTCAGC AAAATGGAGC TCCAGGTATT GCCAAGGTCA AGGCCAACTG	960
	AGAAGCATGG CCTAGATAGG CGCCCACTA AGTGCCTCAG GACTGCACCT TAGGGCAGTG	1020
35	TCCGTCACTG CCTCTCCAC CTACACCTGT GACCAAGGCT TATGTGGTCA GGAAGTGA	1080
	GGGACTGGC CCTCCCTCC CCACAGCTGC TCTACAGGA CCACGGCTTT GGTTCCTCAC	1140
40	CCACTTCCCC CGGGCAGCTC CAGGGATGTG GCCTCATTCG TGTCTGCCAC TCCAGAGCTG	1200
	GGGGCTAAAA GGCTGTACA GTTATTTCCT CCTCCCTGCC TTAAAACTTG GGAGAGGAGC	1260
	ACTCAGGGCT GGCCCCACAA AGGGTCTCGT GGCTTTTTC CTCACACAGA AGAGGTGAGC	1320
45	AATAATGTCA CTGTGGACCC AGTCTCACTC CTCCACCCCA CACACTGAAG CAGTAGCTTC	1380
	TGGGCCAAAG GTCAGGGTGG GCGGGGGCT GGAATACAG CCTGTGGAGG CTGCTTACTC	1440
50	AACTTGTGTC TTAATTAAAA GTGACAGAGG AAACCANAAA AAAAAAAAAA AAAAACTCGA	1500
	GGGGGGCCCC TACCCAAATC GCCCGTATGA TCGTAAACAA TC	1542

55

(2) INFORMATION FOR SEQ ID NO: 107:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2327 base pairs

(B) TYPE: nucleic acid

60

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107:

5	GGTAGCTCAN TGCAGTGAAA TAGTCTTACT GGAAACAAAG CCCTTTATCA AGAATAATTA	60
	ACTCTTCCCT TTTCTTTTGG GAGAGGTGCT TTGTTTCTGA TCGGACCATT TCACTGCAGC	120
10	AAGCAACACA GTATTCTRAG CAGAAGATCG GGACTTGAGG CCATGTTGGG GAGGGCCAGT	180
	RACATTATCT GGACTCTGGA GTGTGAGGAA TATGGACTCC ACTCTTCACT ATATTCACAR	240
15	CGATTTCAGAC TTGAGCAACA ATAGCAGTTT TAGCCCTGAT GAGGAAAGGA GAACTAAAGT	300
	ACAAGATGTT GTACCTCAGG CGTTGTTAGA TCAGTATTTA TCTATGACTG ACCCTTCTCG	360
	TGCACAGACG GTTGACACTG AAATTGCTAA GCACTGTGCA TATAGCCTCC CTGGTGTGGC	420
20	CTTGACACTC GGAAGACAGA ATTGGCACTG CCTGAGAGAG ACGTATGRGA CTYTGCCCTC	480
	AGACATGCAG TGGAAAGTTC GACGGAATC TAGCATTCTC CATCCACGRG CTGTCAGTTA	540
25	TTCTTGGAGA TCAATGACA GCTGCAGATC TGGTCCAAT TTTTAATGGA TTTTAAAG	600
	ACCTCGATGA AGTCAGGATA GGTGTTCTTA AACACTTGCA TGATTTTCTG AAGCTTCTTC	660
	ATATTGACAA AAGAAGAGAA TATCTTTATC AACCTCAGGA GTTTTGGTG ACAGATAATA	720
30	GTAGAAATTG GCGGTTTCGA GCTGAACCTG CTGAACAGCT GATTTTACTT CTAGAGTTAT	780
	ATAGTCCCAG AGATGTTTAT GACTATTTAC GTCCCATGTC TCTGAATCTG TGTGCAGACA	840
35	AAGTTTCTTC TGTTCTGTTG ATTTCTTACA AGTTGGTCAG CGAGATGGTG AAGAAGCTGC	900
	ACGCGGCAAC ACCACCAACG TTCGGAGTGG ACCTCATCAA TGAGCTTGIG GAGAACTTTG	960
	GCAGATGTCC CAAGTGGTCT GTTCGGCAAG CCTTTGTCTT TGTCTGCCAG ACTGTCAATTG	1020
40	AGGATGACTG CCTTCCCATG GACCAGTTTG CTGTGCATCT CATGCCGCAT CTGCTAACCT	1080
	TAGCAAATGA CAGGGTTCCT AACGTCCGAG TGCTGCTTGC AAAGACATTA AGACAAACTC	1140
45	TACTAGAAAA AGACTATTTT TTGGCCTCTG CCAGCTGCCA CCAGGAGGCT GTGGAGCAGA	1200
	CCATCATGGC TCTTCAGATG GACCGTGACA GCGATGTCAA GTATTTTGCA AGCATCCACC	1260
	CTGCCAGTAC CAAAATCTCC GAAGATGCCA TGAGCACAGC GTCCTCAACC TACTAGAAGG	1320
50	CTTGAATCTC GGTGTCTTTC CTGCTTCCAT GAGAGCCGAG GTTCAGTGGG CATTCGCCAC	1380
	GCATGTGACC TGGGATAGCT TTGGGGGAG GAGAGACCTT CCTCTCCTGC GGACTTCATT	1440
55	GCAGGTGCAA GTTGCCCTACA CCCAATACCA GGGATTTCAA GAGTCAAGAG AAAGTACAGT	1500
	AAACACTATT ATCTTATCTT GACTTTAARG KKWAWKMMWW KCTCAGMSRA TTATAMITSW	1560
	CWMRARGSM WYMAAWSCTK SWGCTCYWCC KSRSTGRMKG MMRCTCTAGA AYTRGYRGAK	1620
60	CMYYYKSGCT KMWGAARKS GGCASGAGCC AGAGACCTGC ATTGCTTTCT CCTGGTTTTA	1680

	TTTAACAATC GACAAATGAA ATTCTTACAG CCTGAAGGCA GACGTGTGCC CAGATGTGAA	1740
5	AGAGACCTTC AGTATCAGCC CTAACCTTC TCTCCAGGA AGGACTTGCT GGGCTCTGTG	1800
	GCCAGCTGTC CAGCCAGCC CTGTGTGTGA ATCGTTTGTG ACGTGTGCAA ATGGGAAAGG	1860
	AGGGGTTTTT ACATCTCCTA AAGGACCTGA TGCCAACACA AGTAGGATTG ACTTAAACTC	1920
10	TTAAGCGCAG CATATTGCTG TACACATTTA CAGAATGGTT GCTGAGTGTG TGTGTCTGAT	1980
	TTTTTCATGC TGGTCATGAC CTGAAGGAAA TTTATTAGAC GTATAATGTA TGTCTGGTGT	2040
15	TTTAACTTG ATCATGATCA GCTCTGAGGT GCAACTTCTT CACATACTGT ACATACCTGT	2100
	GACCACTCTT GGGAGTGCTG CAGTCTTTAA TCATGCTGTT TAACTGTTG TGGCACAAGT	2160
	TCTCTGTCC AAATAAAATT TAITAATAAG ATCTATAGAG AGAGATATAT ACACTTTTGA	2220
20	TTGTTTCTA GATGTCTACC AATAAATGCA ATTTGTGACC TGTAAAAAA AAATAAAAAA	2280
	ACTCGAGGGG GGCCCGGTAC CCAAATCGCC GATATGATCT AANCATC	2327

25

(2) INFORMATION FOR SEQ ID NO: 108:

30

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1062 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:

	GGCCGCGAG GCGCAACAGC CGTCTGTCA GCTCTGGGTC CAACCGGACT AGCGAANATC	60
40	TTCTCATCC TCATCATCGT CTCTCTCATC CCGATCTCGG TCCAGGTCCC TCTCCCCCCC	120
	ACACAAGAGG TGGCGAAGGT CCAGCTGTAG TTCTCTGGA CGTCTCGAA GATGCTCTTC	180
	CTCTCTCTCG TCATCATCTT CCTCTCTGTC TTCTCATCC TCATCATCCA GTTCTCGAAG	240
45	CGCTCACGA ATCCCCATCC CCCC GCCGA GRAAGTGACA GGAGGCGCG GTACAGCTCT	300
	TATCGTTCAC ATGACCATTA CCAAAGGCAA AGAGTGCTAC AAAAGGAGCG TGCAATAGAA	360
50	GAAAGAAGGG TGGTCTTCAT TGGAAAGATA CCTGGCCGCA TGACTCGATC AGAGCTGAAA	420
	CAGAGTTCTT CCGTTTTTGG AGAGATTGAG GAGTGCACCA TCCACTTCCG TGTCCAAGGG	480
	GACAACTACG GCTTCGTAC TTATCGCTAT GCTGAGGAGG CATTTCAGC CATTGAGAGT	540
55	GGCCACAAGC TCGGCCAGGC AGATGAGCAG CCCTTTGATC TCTGCTTTGG GGGCCGAAGG	600
	SWGTTCTGCA AGAGGAGCTA TTCTGATCTT GACTCCAACC GGGAAGACTT TGACCCAGCA	660
60	CCTGTAAAGA GCAAATTTGA TTCTCTTGAC TTTGACACAT TGTGAAACA GGCCGAGAAG	720

	AACCTCAGGA GGTAACCTTG GGCCTTCCC TGCTATCCTT TTTCTCCTTT GGAGGTGCCC	780
	AACCTCCTCC ACCCCCTTCC CCTACTCTAG GGGAGAGAGC TGCTAGTGAG ATGACTGTTT	840
5	TATAAAGAAA TGGAAAAAG TGAAATAAAA AATATGTTGA ATCAGATTTT TTAAAAGGGG	900
	TATTTGTTTT TTTATAACAG GTATTGAAAC AAGTTAACTT GCATTCTAT GTAAGATAGG	960
10	AGGGGCTGAG GGGATCCCCA GTGTTTGGA CATAAGTCAC TATGCAGACT AATAAACATC	1020
	AACTAGAGAG NAAAAA AAAAATAAAA ATTTAAAAA CT	1062
15	(2) INFORMATION FOR SEQ ID NO: 109:	
	(i) SEQUENCE CHARACTERISTICS:	
20	(A) LENGTH: 2539 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
25	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:	
	GAGAGACTCA CACTTCTTTT CCATTATCAC TGACGATGTA GTGGACATAG CAGGGGAAGA	60
	GCACCTACCT GTGTTGGTGA GGTGTTGTTGA TGAATCTCAT AACCTAAGAG AGGAATTTAT	120
30	AGGCTTCCTG CCTTATGAAG CCGATGCAGA AATTTTGGCT GTGAAATTTT AACTATGAT	180
	AACTGAGAAG TGGGGATTAA ATATGGAGTA TTGTGCTGGC CAGGCTTACA TTGWCTCTAG	240
35	TGGATTTTCT TCCAAAATGA AAGTTGTTGC TTCTAGACTT TYAAGMKMRA TWKCCCCMAK	300
	YWAWCKGAAC AMAMKCTGSW CYTCCWSYGC SKTRRMKRYC GYKSTATRRC WARWKSAYM	360
	CCYGKMTGS RRGTAWYTSK TGCAYKAGGG AACAAITGAG GAAGTTTGTT CTTTTTTCCA	420
40	TOGATCACCA CAACTGCTTT TAGAACTTGA CAACGTAATT TCTGTTCTTT TTCAGAACAG	480
	TAAAGAAAGG GGTAAGAAC TGAAGGAAAT CTGCCATTCT CAGTGGACAG GCAGGCATGA	540
45	TGCTTTTGAA ATTTTAGTGG AACTCCTGCA AGCACTTGTT TTATGTTTAG ATGGTATAAA	600
	TAGTGACACA AATATTAGAT GGAATAACTA TATAGCTGGC CGAGCATTIG TACTCTGAGT	660
	GCAGTGTGAG ATTTTGATTT CATGTTTACT ATTGTTGTTT TAAAAATGT CCTATCTTTT	720
50	ACAAGAGCCT TTGGGAAAAA CYYCMAGGGG CAAACCTCTG ATGTCCTCTT TGCKKMSRT	780
	ARMTTTTGAY ATRMARYACT RMTKSAITY AAYGRNGTGA CWSGAWAATA TTRAASTYTA	840
55	TACAATKAAT YWTRRYTSM KRMAGMYAAT CCGAAAYTGT GGMAAMYAAA CTTGATATTC	900
	AAATGAAACT CCCTGGGAAA TTCCGCAGAG CTCACCAGGG TAACCTGGAA TCTCAGCTAA	960
	CCTCTGAGAG TTACTATAAA GAAACCCTAA GTGTCCCAAC AGTGGAGCAC ATTATTCAGG	1020
60	AACTTAAAGA TATATTCTCA GAACAGCACC TCAAAGCTCT TAAATGCTTA TCTCTGGTAC	1080

	CCTCAGTCAT GGGACAACCTC AAATCAATA CGTOGGAGGA ACACCATGCT GACATGTATA	1140
5	GAAGTGACTT ACCCAATCCT GACACGCTGT CAGCTGAGCT TCATTGTTGG AGAATCAAAT	1200
	GGAAACACAG GGGGAAAGAT ATAGAGCTTC CGTCCACCAT CTATGAAGCC CTCCACCTGC	1260
	CTGACATCAA GTTTTTTCCT AATGTGTATG CATTGCTGAA GGTCTGTGT ATTCTTCCTG	1320
10	TGATGAAGGT TGAGAATGAG CGGTATGAAA ATGGACGAAA GCGTCTTAAA GCATATTGTA	1380
	GGAACACTTT GACAGACCAA AGGTCAAGTA ACTTGGCTTT GCTTAACATA AATTTTGATA	1440
15	TAAACACGA CTGGATTTA ATGGTGGACA CATATATTAA ACTCTATACR AKTAMGTCAG	1500
	MGCTYYCTAC AKAYRAYTCM SWAMTGTGG AAARYWSSTA MGMSWGCWKK TAMMRRTMCG	1560
	GMWWTYYMYK RRTYGAYMYW YGCGWMCAG AAAAAGCCGT AAGGTGTATG TAGACCACTT	1620
20	AATCACTAAA TATCTTTGCC TATAGGACTC CATTGAATAC ATTAGCCATT GATAATCTAC	1680
	CTGTTTAAAT GGGCCCTGTT TGAACCTCA AGCTTTGAAG ACCTACCTGT TCTTCCAGAA	1740
25	GAGAACGTTG AAAGTGCCAT GTTTCCTTTT GCGTGATCTC TGTGTATGGC ACTCTGGAAT	1800
	TGTTTCCAGT TTAATCATT TTAGACATAG CATTTATTAT CACTGTGGAT CTCTACTTGT	1860
	TGGTGTATT GAATTCCTTG AAGAATATAT TTTGAAGAGG TGTGGGAGGA AGGAATACAT	1920
30	TTTATAAAAT GTGTAGTGA AGCCCACAAT TGACCTTKGA CTAATAGGAG TTTAAGTAT	1980
	GTAAAAATC TATACTGGAC AGTTACAAGA AATTACCGGA GAAAAGCTTG TGAGCTCACC	2040
35	AAACAAGGAT TTCAGTGTAG ATTTTGTCTT TCTTGAACCT AAAGAAACAA ATGACAAAGT	2100
	TTGAATGGAA AAGCCTGCTG TTGTCCACA TCTCGTGTCT GTTTACATC CTTTGTGGAG	2160
	CCTACATCTT CTAAGCTTT TTAGCAGGTA TATGTTGAAC ACTTCTGTTT CATGGTTGAG	2220
40	ACAGAATCAG AGCCATGGA TACTGACAAC TGATTGTCT GTTTTPTTTC TCTGTCTTTT	2280
	TCCATGACTC TTATATACTG CCTCATCTTG AATTATAAGC AAAACCTGGA AAACCTACAA	2340
45	AATAAGTGT GTGGTTTATC TAGAAAAATA TGGAAATAT TGCTGTTATT TTTGGTGAAG	2400
	AAAATCAATT TTGTATAGTT TATTCAATC TAAATAAAAT GTGAATTTTG TTWATTAAA	2460
	AATTWGSAC AAABTBHGG GGGDTCCAAA CHWVTCGHG KAAMTCTCT WAARMATYTK	2520
50	ATAAACMSCT TCACAATTC	2539

55 (2) INFORMATION FOR SEQ ID NO: 110:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1751 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

60

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110:

5	AGCATGAAGC CGATGGCCGT GGTGGCCAGT ACCGTCTTGG GCCTGGTGCA AAACATGCGT	60
	GGGTTTGGCG GGATCCTGGT GGTGGTCTAC TACGTATTTG CCATCATTGG GATCAACTTG	120
10	TTTAGAGGCG TCATTGTGGC TCTTCCTGGA AACAGCAGCC TGGCCCTGCG CAATGGCTCG	180
	GCGCCCTGTG GGAGCTTCGA GCAGCTGGAG TACTGGGCCA ACAACTTCGA TGACTTTGCG	240
	GCTGCCCTGG TCACTCTGTG GAACTTGATG GTGGTGAACA ACTGGCAGGT GTTCTTGAT	300
15	GCATATCGGC GCTACTCAGG CCCGTGGTCC AAGATCTATT TTGTATTGTG GTGGCTGGTG	360
	TCGTCTGTCA TCTGGGTCAA CCTGTCTCTG GCCCTGATTC TGGAGAACTT CCTTCACAAG	420
20	TGGGACCCCC GCAGCCACCT GCAGCCCTTT GCTGGGACCC CAGAGGCCAC CTACCAGATG	480
	ACTGTGGAGC TCCTGTTCAG GGATATTCTG GAGGAGCCCG GGGAGGATGA GCTCACAGAG	540
	AGGCTGAGCC AGCACCCGCA CCTGTGGCTG TGCAGGTGAC GTCCGGGCTG CCATCCCAGC	600
25	AGGGGCGGCA GGAGAGAGAG GCTGGCCTAA CACAGGTGCC CATCATGGAA GAGGCGGCCA	660
	TGCTGTGGCC AGCCAGGCAG GAAGAGACCT TTCTCTGAC GGACCACTAA GCTGGGGACA	720
30	GGAACCAAGT CCTTTGCGTG TGGCCCAACA ACCATCTACA GAACAGCTGC TGGTGCTTCA	780
	GGGAGGCGCC GTGCCCTCCG CTTTCTTTTA TAGCTGCTTC AGTGAGAATT CCCTCGTCGA	840
	CTCCACAGGG ACCTTTTACA CAAAAATGCA AGAAGCAGCG GCCTCCCCTG TCCCCTGCAG	900
35	CTTCGGTGGT GCCTTTGCTG CCGGCAGCCC TTGGGGACCA CAGGCCTGAC CAGGGCCTGC	960
	ACAGGTAAAC CGTGAGTCTG TCTCATCTAT TCACAGCTGG GAATGATACT AATACCTCCG	1020
40	ATTTTAGCCC AGCACCACAG GGTACGTTC AGTTTTTCTC TCTTTCCATA GCTGTAAGGC	1080
	CCTTCTGCGG AATGGTCTC ATTCTCCTTA ATCTATTATT GGGTCAGTTT TCCTGCATGT	1140
	CCCCAGCCTC CCATCACTGC CACCCACTCC CCACAGAGAT GCCCTGCTCA TCCGACTGGG	1200
45	GCTTTGACTC CCACACTGTG TACCCTCTTT GTGTGGACGC CCGCTGCCA AAACCTTCAG	1260
	CAACAGCTT TCCAAATGGA AGTTGTCACT GTCAGGCCTT TACAATCAGC AACAGCAAAA	1320
50	TCTACATGCT GCTGAGGGTC CTGCCTCATT AAGATGCAAT AAATATGTAA GTACATAAAA	1380
	ACAGCAATAG AAGAAACGTA ATGCTTTATT CTCAAATATG ATGTCTACAT AGAAAAGCCA	1440
	AAATTATTAA GAATAGTAAG AATTCAACCA GCACCTTTGGG AGGCCGAGGC GGGTGGATCA	1500
55	TGAGGTCAGG AGATCGAGAC CATCCTGGCT AACAGGGTGA AACCCCGTCT CTAATAAAAA	1560
	TACAAAAAAT TGGCCGGGCG CAGTGGCGGG CGCCTGTGGT CCCAGCTACT GGGGAGGCTG	1620
60	AGGCAGGAGA ATGGCGTGAA CCCGGGAAGC GGAGCTTGCA GTGAGCCGAG ATTGCGCCAC	1680

TGCAGTCCGC AGTCCAGCCT GGGCGACAGA GCGAGACTCC GTCTCAAAAA AAAAAAAAAA 1740
 AAAAAAAAAA A 1751

5

(2) INFORMATION FOR SEQ ID NO: 111:

10

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1117 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111:

AATGTTGTGG TGGTAGCATT TGGGTTAATT CTRATTATAG AGTCTCTTGG AGAGCAATGT 60
 20 CCATAAACTA ATCCCAAACA ACATTGTCTT TTTRATGTTG TAGTGAACAG CAGAGAATTT 120
 CAAAGGACCT TGCTAATATC TGTAAGACGG CAGCTACAGC AGGCATCATT GGCTGGGTGT 180
 25 ATGGGGGAAT ACCAGCTTTT ATTCATGCTA AACACAATA CATTGAGCAG AGCCAGGCAG 240
 AAATTTATCA TAACCGGTTT GATGCTGTGC AATCTGCACA TCGTGCTGCC ACACGAGGCT 300
 TCATTGTTA TGGCTGGGCG TGGGGTTGGA GAACTGCAGT GTTGTGACT ATATTCAACA 360
 30 CAGTGAACAC TAGTCTGAAT GTATACCGAA ATAAAGATGC CTTAAGCCAT TTTGTAAITG 420
 CAGGAGCTGT CACGGGAAGT CTTTTTAGGA TAAACGTAGG CCTGCCGTGGC CTGGTGGCTG 480
 GTGGCATAAT TGGAGCCTTG CTGGGCACTC CTGTAGGAGG CCTGCTGATG GCATTTCAGA 540
 35 AGTACTCTGG TGAGACTGTT CAGGAAAGAA AACAGAAGGA TCGAAAGGCA CTCCATGAGC 600
 TAAAACTGGA AGAGTGGAAA GGCAGACTAC AAGTTACTGA GCACCTCCCT GAGAAAATG 660
 40 AAAGTAGITT ACAGGAAGAT GAACCTGAGA ATGATGCTAA GAAAATGAA GCACCTGCTAA 720
 ACCCTCCTAG AAACCTTCA GTAATAGATA AACAGACAA GGACTGAAAG TGCTCTGAAC 780
 TTGAACTCA CTGGAGAGCT GAAGGGAGCT GCCATGTCCG ATGAATGCCA ACAGACAGGC 840
 45 CACTCTTGG TCAGCCTGCT GACAAATTTA AGTGCTGGTA CCTGTGGTGG CAGTGGCTTG 900
 CTCTGTCTT TTTCTTTTCT TTTTAACTAA GAATGGGGCT GTGTACTCT CACTTTACTT 960
 50 ATCCTTAAAT TTAAATACAT ACTTATGTTT GTATTAACTT ATCAATATAT GCATACATGA 1020
 ATATATCCAC CCACCTAGAT TTTAAGCAGT AAATAAAACA TTTGCGAAAA GATTAAAGTT 1080
 55 GAATTTTACA GTTAAAAAAA AAAAAAAAAA AAAAAA 1117

60

(2) INFORMATION FOR SEQ ID NO: 112:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1313 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112:

GGCAGAGGTT TTCTTATATT TTAAGTAAAT TTAAAGTGGC TATCAGAATA TTTATTCTTG 60
TTTGAGACTA CCAACATAAC TACGTGTTGA AGGTGCTTCA CAGAGAATAT ATTGCCTTTA 120
ATGTGAAATA ATTTTCACCA ATGTTGCTAA CTTTAATAAA GTATAAAATT TGTAGAATAT 180
15 TCAGTTAAGT AGTTGGTAAC CCTTTTCTAT TTTAGTAAAA CTTAATGCAT GTTTACTTTT 240
TTTTGAAGA TGCAGACAAT CTCTTTGAAC ATGAATTGGG GGCTCTCAAT ATGGCTGCAT 300
TACTACGAAA AGAAGAAAGA GCAAGTCTTC TTAGTAATCT TGGCCCATGT TGTAAAGCGT 360
20 TGTGCTTCAG ACGGATTCT GCAATTCGAA AGCAGCTTGT TAAAAATGAG AAGGGCACCA 420
TAAACAAGC TTACACGAGT GCTCCAATGG TAGACAATGA ATTACTTCGA TTGAGTCTTC 480
25 GGTATTTTAA GCGGAAGACT ACTTGCCATG CTCCAGGACA TGAAAAGACT GAAGATAATA 540
AACTTTCACA GTCCAGTATC CAACAGGAAC TGTGTGTGTC TTAAGACCGA AGTTACAATA 600
TGGTATTTTT GGTACTGTCT TCCTTCAGCA GTGCATATTC TTTTGCAAAG TTCTTTGGTT 660
30 TGACAAGCAT TAGTGACAAA GGCAGAAAAG ATTTATCAGC CATGCTAAAA GAGTGAAGAA 720
TTTGATCTT TAGAGACACT AGTTTGGCC AACTTAAGAT TTTACGTTAA TTTTACATA 780
35 GTATTTGACA CTCATGCAA ATAATGTGAA AACATCTAGA TTTAGTAGTT TATTCTGCGC 840
CTTTGTGTTAA AACTGAAGAT TTTGGAAAT GGTGTCACT GCTCTCCAG CCTATGAATA 900
TTTTGTGAA ATGGAACCAT GGATTATGT CTGGATCATC CATAAGAAC CAACAATTTT 960
40 ATTCAAAAAC AATGTGTCA TCAAAGTAAT TGCTCATT GTGCAGTACT ATGTTGTACA 1020
GACCACGTGA AAGGAATGC TGGTCTAGCT GCGTGGTAT GTTTATAGGC GAATTCAGC 1080
45 AGAAGGAAGC CAAATAGTT TTTTCTTTT GAAAGTTTT TAAAAATTAT TTCATGGGTC 1140
TTTTTTTTAA TTAATATGTG TGCATTGTTA CAATGTATGT TGGGATGTCT TTTGACCCTA 1200
AATGCTTTTT TTGTTATCAG AGATTGTGTA CTATTTTAT TTTAATAAA TGTATCTTCC 1260
50 CTTTMAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAA 1313

55

(2) INFORMATION FOR SEQ ID NO: 113:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1654 base pairs
(B) TYPE: nucleic acid

60

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113:

5	ACAGGGACAG AATACTTTCT TTCTTCCTT CAAGTACAAG AAGGCTTTCT CTACCATTTG	60
	CGTCTACACT TTATTTTAAA AGCTATCCCTT TTCTAGTAGT ATTTTATCAT GGCAATGGCA	120
10	TGATGACAAC AACAGTCTTT CATTCACAGAC TGAAGGGAAG CATGTCCTTA CTTAAAATAG	180
	TTCTGCTACT TTCCCTCCTA TTATAAGGAA ATTTTACAGA TTCTAAAAAT ACCTTAATTT	240
	TTCTTTGATT TTTATTTTAC CAAGTCACAA ATGTCCTTTT GATGTTTTGA GAATGTTCT	300
15	CATAGAATCA CAAATACTGA CATTTCAATTA GATGATTATT TTCTAGAAT CCCCAGAG	360
	CAGTGGCAGT CCATGGCTTG GTTGAAGCTA GAAATTTTCC TGGCCCTGGT GACCTGGTAA	420
20	GCCTCCTGCT CGGAACCGTG TGAGTGGGTG AGGAAGATGA GAGATGGTCA GATGGAAGAG	480
	AGRAATACAT GAACTGCTCT GGCTCTCTG GTTCTGTTCT TGGCCAGAG TTTTGA AAA	540
	GCAGCGGANA TNGACTGACT TCACATGCTC AGCTTTCTCA GCCTTTTGTT TATTTGTTG	600
25	TCCTTAGATT TCCCTGTTGT AAAAGGGGCA AGAAAAGTAA CTCATCATCT CTAACACACC	660
	ATGGCAGCTT AGCCAGGTAG TCTTAGTGGT GGTGTTTAGG CATAAGATAT GCTGATCATC	720
30	AGTCTCAGGC CACAGTTTCC TTCACTAATC GTCCAGCTTG AGTGTCTGT TCTCTCCTG	780
	CCCATTTCTT TGAACCTCCT GCTCTAGCCT TGGCGGAGGG AGAGTGCTAT TTGCTTTTGT	840
	TCTCCCTCTG TCTTAGGAAA AGCCATCTTT AATATAGTTC TTCACCACTG TTGGGGTTGT	900
35	TTTGIGATTT TTTTCTCTT CCGAAGAACT CCTGGTTGTT ATTGATTTT GTATTTTAAT	960
	ACAAATATT GAATTTTATA AGCTTGTA CAATATTTAA TTAGTGTA AGGAAACAAA	1020
40	GAATGCAGGA AAAATAATTT AATATCAACC TCAGTTGACA AGGTGCTCAG ATTATTCAT	1080
	TGGGATCCT CCTTTGTTA GGTTTTGTAG ACAACCCCTAG ACCTAAACTG TGTACAGAC	1140
	TTCTGAATGT TTAGGCAGTG CTAGTAATTT CCTCGTAATG ATTCTGTTAT TACTTTCTTA	1200
45	TTCTTTATTC CTCCTTCTTC TGAAGATTAA TGAAGTTGAA AATTGAGGTG GATAAATACA	1260
	AAAAGGTAGT GTGATAGTAT AAGTATCTAA GTGCAGATGA AAGTGTGTTA TATACATCCA	1320
50	TTCAAAATTA TGCAAGTTAG TAATTACTCA GGGTTAACTA AATTACTTTA ATATGCTGTT	1380
	GAAYCTACTC TGTTCCTTGG CTAGAAAAA TTATAAACAG GACTTTGTAG TTTGGGAAGC	1440
	CAAATGATA ATATCTATG TTCTAAAAGT TGGGCTATAC ATAAATATT AAGAAATATG	1500
55	GATTTTTATT CCCAGGATAT GGTGTTCAAT TTATGATATT ACGCAGGATG ATGTATTGAG	1560
	TAAATCAGT TTTGTAAATA TGTAATATG TCATAAATAA ACAATGCTTT GACTTATTTT	1620
60	CAAAAAAAA AAAAAATAAA NTTCGAGGGG GGGC	1654

5 (2) INFORMATION FOR SEQ ID NO: 114:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 1171 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114:

15 GGCAAACTTT CCCCCAANGC TTCGAAACTT GCAAGCCGAA ACCTTGAATC GTTAAAAGTT 60
GGGTTGCGNC GGGGCCCTGG CCCGAAGAAG CGCAATTGGC GTTCCGGGAA CGTTGGCCCT 120
CAACGGCTCG GCAGCCAGCC ATGTCTGCA CCCAGGACAG GGGCCCTGGG CTACAAGGAC 180
20 CTGGMCCTCA TCTTCTGCG CCGACCTGCG CGGGTAAGG GGWAGTTTCA GACTGTGAAG 240
GACGTCGTGC TGGACTGCCT GTTGACTTTC TTACCCGAGG GGTGAACAA AGAGAAGATC 300
25 ACACCACTCA CGCTCAAGGA AGCTTATGTG CAGAAAATGG TTAAGTGTG CAATGACTCT 360
GACCGATGGA GTCTTATATC CCTGTCAAAC AACAGTGGCA AAAATGTGGA ACTGAAATTT 420
GTGGATTCCC TCCGAGGCA GTTTGAATTC AGTGTAGATT CTTTTCAAAT CAAATTAGAC 480
30 TCTCTCTGCG TCTTTTATGA ATGTTCAAGAG AACCCAATGA CTGAGACATT TCACCCACA 540
ATAATCGGG AGAGCGTCTA TGGCGATTTC CAGGAAGCCT TTGATCACCT TTGTAACAAG 600
35 ATCATTGCCA CCAGGAACCC AGAGGAAATC CGAGGGGGAG GCCTGCTTAA GTACTGCAAC 660
CTCTTGGTGA GGGGCTTTAG GCGCGCTCT GATGAAATCA AGACCCCTCA AAGGTATATG 720
TGTTCCAGGT TTTTCATCGA CTTCTCAGAC ATTGGAGAGC AGCAGAGAAA ACTGGAGTCC 780
40 TATTTGCAGA ACCACTTTGT GGAATTGGA AGACCGCAAG TATGAGTATC TCATGACCCCT 840
TCATGGAGTG GTAAATGAGA GCACAGTGTG CCTGATGGGA CATGAAAGAA GACAGACTTT 900
45 AAACCTTATC ACCATGCTGG CTATCGGGT GTTAGCTGAC CAAAATGTCA TTCCTAATGT 960
GGCTAATGTC ACTTGCTATT ACCAGCCAGC CCCCTATGTA GCAGATGCCA ACTTTAGCAA 1020
TTACTACATT GCACAGGTC AGCCAGTATT CACGTGCCAG CAACAGACCT ACTCCACTTG 1080
50 GCTACCCCTG AATTAAGAAT CATTTAAAAA TGTCTGTGG GGAAGCCATT TCAGACAAGA 1140
CAGGAGAGAA AAAAAAAAAA AAAAAAAAAA A 1171

55

(2) INFORMATION FOR SEQ ID NO: 115:

- 60 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 842 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115:

GGTCTGCGCC GGAAGTGCAT GAGCTGCCGA TGTGGTGCTT AGTGATTGCG GTTTCGGTCC 60
10 CTCTCCCGTG TTTCCCGGGC TGGGTATTMG CCTGCACCA TGGGCCCCAA GGGCAAAGTG 120
GGCAGGAGAG GGAAGAAGCA GATATTTGAA GAGAACAGAG AGACTCTGAA GTTCTACCTG 180
CGGATCATAC TGGGGGCCAA TGCCATTTC TGCCTTGTA CGTTGGTCTT CTTTACTCA 240
15 TCTGCCCTCAT TTTGGGCTG GTTGGGCTG GGCTTTAGTC TGGCAGTGA TGGGGCCAGC 300
TACCACTCTA TGAGCTCGAT GGCACGAGCA GCGTTCTCTG AGGATGGGGC CCTGATGGAT 360
20 GGTGGCATGG ACCTCAACAT GGAGCAGGGC ATGGCAGAGC ACCTTAAGGA TGTGATCCTA 420
CTGACAGCCA TCGTCAGGT GCTCAGCTGC TTCTCTCTCT ATGTCTGGTC CTTCTGGCTT 480
CTGGCTCCAG GCCGGGCCCT TTACCTCTCTG TGGGTGAATG TGCTGGGGCC CTGTTTCACT 540
25 GCAGACAGTG GCACCCAGC ACCAGAGCAC AATGAGAAAC GGCAGCGCCG ACAGGAGCGG 600
CGGCAGATGA AGCGTTTATA GCCATTGACA TTGTGGCCAC AGGCCACTGG CCTTGGGTGG 660
30 CTCTGTCAAG GTGCACAGCC CCTCATGCCT GGAGCAATGA GGGTCTAGTC CAGGGGCCAA 720
AAGCAGTCTG AGGTATTGGG TATACTTATA CTCTATAGGG TCGTTGAATA AATGGCTTAG 780
AATGTGAAAA AAAAAAAAAA AAAAACTCG AGGGGGGCC GGTACCCAAT TTCNCCTANA 840
35 AT 842

40

(2) INFORMATION FOR SEQ ID NO: 116:

(i) SEQUENCE CHARACTERISTICS:

45

- (A) LENGTH: 1640 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116:

GGCAGGAGGC GCGGCAGCG GTGGCGGCGG CGCCCCCGG CGGAGCCGT TCCCTTTCCC 60
GTCGGGAGC GCGGGYCGG GGCCAGGGG ACCCGGGCC ACGGAGAGCG GGAAGAGGAT 120
55 GGATTGCCCG GCCCTCCCC CGGATGGAA GAAGGAGGAA GTGATCGAA AATCTGGGCT 180
AAGTGCTGGC AAGAGCGATG TCTACTACTT CAGTCCAAGT GGTAGAAGT TCAGAAGCAA 240
GCCTCAGTTG GCAAGGTACC TGGGAAATAC TGTGATCTC AGCAGTTTTC ACTTCAGAAC 300
60

	TGGAAAGATG ATGCCTAGTA AATTACAGAA GAACAAACAG AGACTGCGAA ACGATCCTCT	360
	CAATCAAAAT AAGGGTAAAC CAGACTTGAA ATACAACATT GCCAATTAGA CAAACAGCAT	420
5	CAATTTTCAA ACAACCGTA ACCCAAAGTC ACAATCATC CTAGTAATAA AGTGAAATCA	480
	GACCCACAAC GAATGAATGA ACAGCCACGT CAGCTTTTCT GGGAGAAGAG GCTACAAGGA	540
10	CTTTAGTGCA TCAGATGTAA CAGAACAAAT TATAAAAACC ATGGAACACT CCAAAGGTCT	600
	TCAAGGAGTT GGTCCAGTAG CAATGATGAG ACCCTTTTAT CTGCTGTTGC CAGTGCTTTG	660
	CACACAAGCT CTGCGCCAAT CACAGGGCAA GTCTCCGCTG CTGTGGAAAA GAACTGCTG	720
15	TTTGGCTTAA CACATCTCAA CCCCTCTGCA AAGCTTTTAT TGTACAGAT GAAGACTCAG	780
	GAAACAGAAG AGCGAGTACA GCAAGTACGC AAGAAATTGG AAGAAGCACT GATGGCAGAC	840
20	ATCTTGTCGC GAGCTGCTGA TACAGAAGAG ATGGATATTG AAATGGACAG TGGAGATGAA	900
	GCCTAAGAAT ATGATCAGGT AACTTTGAC CGACTTTCCC CAAGAGAAAA TTCCTAGGAA	960
	ATTGAACAAA AATGTTTCCA CTGGCTTTTG CCTGTAAGAA AAAAAATGTA CCCGAGCACA	1020
25	TAGAGCTTTT TAATAGCACT AACCAATGCC TTTTATAGTG TATTTTGTAT GTATATATCT	1080
	ATTATTCAAA AAATCATGTT TATTTTGAGT CCTAGGACTT AAAATTAGTC TTTTGTAATA	1140
30	TCAAGCAGGA CCTAAGATG AAGCTGAGCT TTTGATGCCA GGTGCAATCT ACTGGAAATG	1200
	TAGCACTTAC GTAAACATT TGTTTCCCC ACAGTTTAA TAAGAACAGA TCAGGAATTC	1260
	TAAATAAATT TCCAGTTAA AGATTATTGT GACTTCACTG TATATAAACA TATTTTATA	1320
35	CTTTATTGAA AGGGGACACC TGTACATTCT TCCATCGTCA CTGTAAAGAC AAATAAATGA	1380
	TTATATTCCA CAGAAAAAA AAAAAAAAW MWSTYGARRR GSRGCMCRSW AYMMARWCC	1440
40	CCWMRTWRGS MKTCSMTKA YTTACATTCA ACTCTGATCC CGGGGCCTTA GGTTTGACAT	1500
	GGGAGGTGGG AGGAAGATAG CGCATATATT TGCAGTATGA ACTATTGCCT CTGGGACGTT	1560
	GTGAGGAATT GTGCTTTCAC CAGAATTCT AAGGATTTCT GGCTTAAATA TCACCTAGCC	1620
45	TGIGGTAATT TTTTTCCT	1640

50 (2) INFORMATION FOR SEQ ID NO: 117:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 952 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117:

60 TGAATTTAGN AAACACTTTG GAAACTCAT AACCTCATCA GAACTGCCT TTAGCCACAC 60

	TCCTGACCTT CTAGATGAGT AACAAAAAA TGAAATAAGT TCTTGGAAAT TAAGCCATTT	120
5	ATTTTAATTT GCTATTTTTT TCAATGTTCT AGGTATCTTT AAATTTGTTA TTGTGGAATC	180
	ATTTTCCTGC CAGATACCTT TATCAAAATT ATTGGCCTCA TGAGAGCTGA AGTAAGTCAG	240
	CTTTTGGTG AACTTTAGTG GACTTCTGTG AGATTGTAGT TGTACTTTGT ATCTCTAAAT	300
10	CTAAAGATAG TTTTAAATA CTCCCAAAGA AAATCTGCTC TCCTTTCTGA TCTAAAACT	360
	CATCTTTGGG GTAAAGAGTT AAGTGTCCAA AGGTTGTCAC AGTTCATGAG GTCAGAGGGA	420
15	GCTAGCCTGG CACCTGGACT CTGCCATCC ACAGCTGACA GATTCCAACA GAAGTGTATT	480
	TAAATTCTCC AGTAGACAAT GCTGGGTAAG GGAGGGGTA GGGCTGGGTT ATTAAGATAC	540
	AGGCTGCTGT ATTTTACATT GGTGTGGGG GAAGGGGAGC CTGGAGAAAA CAAAGTCACT	600
20	ATTCCCTTTT TTGAAACAGG AAAAAAATT ATTTTGTGT CAGTAAAAAT GGTAGAGAAT	660
	TCCAATGTCC CTAGCCACAA GGGACCAATT CCACTGAGAA GTGAACAGTG GGAAGTCAAA	720
25	ATTCAGAAA CATGGGGGA AGGGAAAATT GGCTTCTCT TAATTGGCAG ATGTTCCAGT	780
	GGGSGGGG GGCTCTGTTT TTGTTGGAT GTGTTATGTT GTATGTACGC ATATATGGAC	840
	CGGAGTCTGC TGAGTTTATA AGGTTCCAAA AATATGGTAA AATCTGGTT TTTGTTAATT	900
30	TATCTCAATA AAAGCCCACT GGRACCTCAA AAAAAAAGA AAAAAAAGA NN	952

35 (2) INFORMATION FOR SEQ ID NO: 118:

(i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 1256 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118:

45	GACGTCATAG GTAAACAGGC TCTGTATCCG TGGCAGCGGC CGTGGCAGGC TGGCTGGGTA	60
	CCGGCTGTGC CTGACCCAGG AGAAGCTGCC TGTCTACATC AGCCTGGGCT GCAGCCGGCT	120
50	GCCGCCGCCG GCGCCGCAGC TGAAGTATGT GCTCTTCAGG GCGGGCACCG TGTTCATTTC	180
	ATCTTTGTAC CCCCAGCATC TAGCAGTGTT GGCATGTAGT AGGCACTCAA GAAATGTGTG	240
	TTGAATGAAC GATGCCTGTG ACAAGCAAGC GGACTTTATT CTTCCTGAC CCTTGCTCCT	300
55	ATGACACACC TCCTCCTGAC TGCCACTGTC ACTCCTTCAG AGCAGAACTC CTCTAGGGAA	360
	CCTGGATGGG AAACAGCCAT GGCCAAGGAC ATCCTGGGTG AAGCAGGGCT ACACTTTGAT	420
60	GAAGTGAACA AGCTGAGGGT GTTGGACCCA GAGGTTACCC AGCAGACCAT AGAGCTGAAG	480

	GAAGAGTGCA AAGACTTTGT GGACAAAATT GGCCAGTTTC AGAAAATAGT TGGTGGTTTA	540
	ATTGAGCTTG TTGATCAACT TGCAAAAGAA GCAGAAAATG AAAAGATGAA GGCCATCGGT	600
5	GCTCGGAAC TGTCTAAATC TATAGCAAAG CAGAGAGAAG CTCAACAGCA GCAACTTCAA	660
	GCCCTAATAG CAGAAAAGAA AATGCAGCTA GAAAGGTATC GGGTTGAATA TGAAGCTTTG	720
10	TGTAAAGTAG AAGCAGAACA AAATGAATTT ATTGACCAAT TTATTTTTC GAAATGAACT	780
	GAAAATTTG CTTTATAGT AGGAAGGCAA AACAAAAAA AGCCTCTCAA AACCAAAAAA	840
	ACCTCTGTAG CATTCAGCG GCTTGACCAA TGACCTATGT CACAAGAGGT GGCGTGTAG	900
15	GAATGCAGCC CCCTGAAGAC AGCACTACAA GTCTGGGGGA GCCAGTTTTA ACATCAGTGC	960
	ACAGCTGCTG CTGGTGGCCC TGCAGGTAC GTTCTCACCT CTTATGCTTA GTTGGAAC TA	1020
	AGCAGTTTGT AAACCTTTCAT CCTTTT TTTT GTAAATTCAC AAAGCTTTGG AAGGAGAAGC	1080
20	AATAAATTTT TGTTTTCAAA TGGCTTGATG TACCTTTT TTTT CCTGTGCTC TTGAAATATG	1140
	TTTAACTCCT CATGAGAGAA CCTGGATTC TCTATCCCT AGTCCACAAA ACAAAACCAGG	1200
25	CAGTGGTCAG CAGCTACCTT TNATTTGGAT CACACACGTG AGTCAGACAG TACCAC	1256

30 (2) INFORMATION FOR SEQ ID NO: 119:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1143 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119:

40	GGCCGTAGCA GCCGGGCTGG TCCTGCTGCG AGCCGGGGC CCGGAGTGGG GCGGCGGCAT	60
	GTACCTTCCA CATGAGTAT TCAGAAAGAA GTGATCTGAA CTCTGACCAT TCTTTATGGA	120
	TACATTAAGT CAATATAAG AGTCTGACTA CTTGACACAC TGGCTCGAGC AAACATGAAC	180
45	GTGGAGTTG CCCACAGTGA AGTGAATCCA AATACCCGTG TCATGAACAG CCGGGGTATG	240
	TGGCTGACAT ATGCATTGGG AGTTGGCTTG CTTTATATG TCTTACTCAG CATTCCTTC	300
50	TTCAGTGTTC CTGTGCTTG GACTTTAACA AATATTATAC ATAATCTGGG GATGTACGTA	360
	TTTTTGATG CAGTGAAAGG AACACCTTTC GAAACTCCTG ACCAGGGTAA AGCAAGGCTC	420
	CTAACTCATT GGAACAACCT GGACTATGGA GTACAGTTTA CATCTTCACG GAAGTTTTTC	480
55	ACAATTTCTC CAATAATTCT ATATTTTCTG GCAAGTTTCT ATACGAAGTA TGATCCAAC T	540
	CACCTCATCC TAAACACAGC TTCTCTCTG AGTGACTAA TTCCCAAAAT GCCACAAC TA	600
60	CATGGTGTTC GGATCTTTGG AATTAATAAG TATTGAAATG TTTTGAACT GAAAAAAAT	660

	TTTACAGCTA CTGAATTTCT TATAAGGAAG GAGTGGTTAG TAAACTGCAC TGTTTCTSTG	720
	ATAATGTGAA ATGAGAAGTA TTTACATTGG AGGGCCAATG GCTGGTCCTT CAAGTGCTGT	780
5	TTTGAAGTGC AGATTTCCAT TAAATGATGC CTCTGTTTAA TACACCTGGT ACATTTCTGA	840
	AGAGGGGCTT TATAAGCAGG CTGGGCAGGC CCAGCTTATA AGTTAAAGGG CATCACAGTG	900
10	AGGGTGTAGT AGATAAATTC AAGGAAATAA GAGATTTGTA AGAACTAGG ACCAGCTTAA	960
	CTTATAATGA ATGGGCATTG TGTTAAGAAA AGAACATTTC CAGTCATTCA GCTGTGGTTA	1020
	TTTAAAGCAG ACTTACATGT AAACCGGAAT CCTCTCTATA CAAGTTTATT AAAGATTATT	1080
15	TTTATTACCG TAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	1140
	GAN	1143

20

(2) INFORMATION FOR SEQ ID NO: 120:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1782 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120:

	CAGGCCCCCG CCCCCACCC ACGTCTGCGT TGCTGCCCG CCTGGGCCRG GCCCCAAGG	60
35	CAAGGACAAA GCAGCTGTCA GGGAACTCC GCCGGAGTCG AATTTACGTG CAGCTGCCG	120
	CAACCACAGG TTCCAAGATG GTTTGCGGGG GCTTCGGGTG TTCCAAGAAC TGCCTGTGCG	180
40	CCCTCAACCT GCTTTACACC TTGGTTAGTC TGCTGCTAAT TGGAATTGCT GCGTGGGGCA	240
	TTGGCTTCGG GCTGATTTCC AGTCTCCGAG TGGTCGGCGT GGTCAITGCA GTGGGCATCT	300
	TCTTGTTCCT GATTGCTTTA GTGGGTCTGA TTGGAGCTGT AAAACATCAT CAGGTGTTGC	360
45	TATTTTITTA TATGATTATT CTGTTACTTG TATTTATGT TCAGTTTCT GTATCTTGG	420
	CTTGTTTAGC CCTGAACCAG GAGCAACAGG GTCAGCTTCT GGAGTTGGT TGAACAATA	480
50	CGGCAAGTGC TCGAAATGAC ATCCAGAGAA ATCTAACTG CTGTGGGTTC CGAAGTGTTA	540
	ACCCAAATGA CACCTGTCTG GCTAGCTGTG TTAAGTGA CCACTCGTGC TCGCCATGTG	600
	CTCCAATCAT AGGAGAATAT GCTGGAGAGG TTTTGAGATT TGTGGTGGC ATTGGCCTGT	660
55	TCTTCAGTTT TACAGAGATC CTGGGTGTTT GGCTGACCTA CAGATACAGG AACCAGAAAG	720
	ACCCCGCGC RAATCCTAGT GCATTCCTTT GATGAGAAA CAAGGAAGAT TTCTTTTCGT	780
60	ATTATGATCT TGTTCACTTT CTGTAATTTT CTGTTAAGCT CCATTTGCCA GTTTAAGGAA	840

	GGAAACACTA TCTGAAAAG TACCTTATTG ATAGTGAAT TATATATTTT TACTCTATGT	900
	TTCTCTACAT GTTTTTTCT TICCGTIGCT GAAAAATATT TGAAACTTGT GGTCCTGAA	960
5	GCTCGGTGGC ACCTGGGAAT TTACTGTATT CATGTGGG CACTGTCCAC TGTGGCCTTT	1020
	CTTAGCATTT TTACCTGCAG AAAAAGTTG TATGGTACCA CTGTGTGGT TATATGGTGA	1080
10	ATCTGAACGT ACATCTCACT GGTATAATTA TATGTAGCAC TGTGCTGTGT AGATAGTTCC	1140
	TACTGGAAAA AGAGTGGRAA TTTATTAAAA TCAGAAAGTA TGAGATCCTG TTATGTTAAG	1200
	GGAAATCCAA ATTCCCAATT TTTTGTGGT TTTTATAGAA AGATGTGTG TGGTAAAAAG	1260
15	TGTTAGTATA AAAATGATAA TTWACTKGTA GTCTTTTATG ATWACACCAA TGTATTCTAG	1320
	AAATAGTTAT GYCYTAGGAA ATTGTGGTTT AATTTTGTGAC TTTTACAGGT AAGTGCAAG	1380
20	GAGAAGTGGT TTCATGAAAT GTTCTAATGT ATAATAACAT TTACCTTCAG CCTCCATCAG	1440
	AATGGAACGA GTTTTGAGTA ATCAGGAAGT ATATCTATAT GATCTTGATA TTGTTTATA	1500
	ATAATTTGAA GTCTAAAAGA CTGCATTTT AAACAAGTTA GTATTAAATGC GTTGGCCAC	1560
25	GTAGCAAAAA GATATTTGAT TATCTTAAAA ATGTTTAAAT ACCGTTTTC TGAAGTTCT	1620
	CAGTATTGTA ACAGCAACTT GTYAAACCTA AGCATATTTG AATATGATCT CCCATAATTT	1680
30	GAAATGAAA TCGTATTGTG TGGCTCTGTA TATTCTGTTA AAAAATTAAA GGACAGAAAC	1740
	CTTCTTTGT GTATGCATGT TTGAATTAAA AGAAAGTAAT GG	1782

35

(2) INFORMATION FOR SEQ ID NO: 121:

(i) SEQUENCE CHARACTERISTICS:

40

- (A) LENGTH: 610 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 121:

45

	GTGGCTGCA GATTGTGGT GCGTCTGAG CCGTCTGCC TGGCCAAGA TGCTCAAAG	60
	TATTATTAAA AACATATGGA TCCCATGAA GCCCTACTAC ACCAAAGTTT ACCAGGAGAT	120
50	TTGGATAGGA ATGGGGCTGA TGGGCTTCAT CGTTTATAAA ATCCGGGCTG CTGATAAAAG	180
	AAGTAAGGCT TTGAAAGCTT CAGCGCTGC TCCTGGTCAT CACAACCAGA TTTACTTGA	240
55	GTACATGTGA AAGAAAACGT CAGTCTGCCT GTAAATTTCA GCAAGCCGTG TTAGATGGG	300
	AGCGTGAAC GTCACGTGAC ACTTGTATAA GTACCGTTTA CTTTCATGGCA TGAATAAATG	360
	GATCTGTGAG ATGCACTGCT ACCTGGTACT GCTTTCAGTG TGTTCCTCCCT CAGCCCTCCG	420
60	GCGTGTCAAG CATACTCTGA GTAGATAATT TGTATGCAG CGCATGCAAT CAGAATCTCA	480

CTGAGCCACC CATCATTGTG AAATAATTAC CTCAGTTGTA CAGGACTTGG TGATCAGGAT 540
5 CCAGGCACTC ACTTGTAATC TACTGCTCAA TAAACGTTTA TTAAACTTGA AAAAAAAAAA 600
AAAAAAAAAA 610

10

(2) INFORMATION FOR SEQ ID NO: 122:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 526 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122:

20

GGTAGCCCTG CAGGTACCGG TCCGGAATTC CGGGTCGCCC ACGCGTCNGG CCACGCGTCC 60
ACCCACGCGT CCGSCCAGCG GTCCGAGCCG AGCCGGACTG GTCAGGATGA TCACGGACGT 120
25 GCAGCTCGCC ATCTTCGCCA ACATGCTGGG CGTGTGCTC TTCTTGCTTG TCGTTCTCTA 180
TCACTACGTG GCCGTCAACA ATCCCAAGAA GCAGGAATGA AAGTGGCGCT TTCTCCGCCC 240
CAGGGTTCCA GGACATAGTC TGAGGCAAGA TGGAGGGTAT GAGGGGCCCT CACACTTCAC 300
30 TTCATCCCTT CTACCCATCA CAACATACAA AGCAACTACA CCTGGATTTT TCCAAACAAC 360
TTTATTTC TCAGAGTCTT CCTTAATCCT ATGGAACAAG AAGCTGCCAC TGAATAGGGC 420
35 CCACTATAGG GGCTTGCTTT TCTACTCCCT CCCCCAATA TAAAAATATA GACTTTTAA 480
AAAAAAAAA AAAAANITCG NGGGGGGCC GGTACCCATC CCCCTA 526

40

(2) INFORMATION FOR SEQ ID NO: 123:

(i) SEQUENCE CHARACTERISTICS:

45

- (A) LENGTH: 2081 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 123:

TGTACCGGTC CGGAAATTC CGGGTCGACC CACGTCGTCS GGGGAACATG GCGGCTKCGG 60
AGCCGGCGGT CCTTGCGCTC CCCAACAGCG GCGCCGGGGG CGCGGGGGCG CCGTCGGGCA 120
55 CAGTCCCGGT GCTCTTCTGT TTCTCAGTCT TCGCGCGACC CTCGTGGGTG CCACACGGGG 180
CGGGCTACGA GCTGCTCATC CAGAAGTTCC TCAGCCTGTA CGGCGACCAG ATCGACATGC 240
60 ACCGCAAATT CGTGGTGCG CTGTTCGCGG AGGAGTGGGG CCAGTACGTG GACTTGCCCA 300

	AGGGCTTCGC GGTRAGCGAG CGCTGCAAGG TGGGCTCGT GCGYTGACAG ATCCAGCTCA	360
	CTACCOCTGGG AAATCTTACA CCTTCAAGCA CTGTGTTTTT CTGCTGTGAT ATGCAGGAAA	420
5	GGTTCAGACC AGCCATCAAG TATTTTGGGG ATATTATTAG CGTGGGACAG AGATTGTTGC	480
	AAGGGGCCCC GATTTTAGGA ATTCCTGTTA TTGTAACAGA ACAATACCCT AAAGGTCTTG	540
10	GGAGCAGGT TCAAGAAAT TATTTAACAG GTGTAAACT GGTACTTCCA AAGACCAAGT	600
	TTTCAATGGT ATTACCAGAA GTAGAAGCGG CATTAGCAGA GATTCCCGGA GTCAGGAGTG	660
15	TTGTATTATT TGGAGTAGAA ACTCATGTGT GCATCCAACA AACTGCCCTG GAGCTAGTTG	720
	GCCGAGGAGT CGAGGTTTAC ATGTGTGCTG ATGCCACCTC ATCAAGAAGC ATGATGGACA	780
	GGATGTTTGC CCTCGAGCGT CTCGCTCRAR CCGGGATCAT AGTGACCACG AGTGAGGCTG	840
20	TTCTGCTTCA GCTGGTAGCT GATAAGGACC ATCCAAAATT CAAGGAAATT CAGAATCTAA	900
	TTAAGGCGAG TGCTCCAGAG TCGGCTCTGC TTTCCAAAGT ATAGGACATT TGAAGAACTG	960
25	GTATGCTACT CACTGGTGAA GGACAGTCAG GTGAAGGACT GTAAGCCAC ACAAGCTCTT	1020
	CTTATCTCTA CTAGAATTAA AATGTTAAGT CAAAAACGGC TCCTTTTTTG CGCCTCTAG	1080
	TGAACTTAA CCAGCTAGAC CATTTGAGTA CCAGCATTTA GTTACAAACG TCAAAGGCTT	1140
30	CCGGTCTGTC TTACCTTCCT TTTTGTAA TGTGCTTTTA TTTATTAAAA AAAATTACAA	1200
	TGAAGATGCC TGTMTTGTCT CACTGTGTA CTCTGATCGT ATCTTTCCAA AGTGCAGACT	1260
35	CTGTGAAGT TTTCTTAAAT TGTTCACCTT AAAGAAAATG ACGTACCAAC AATGATTTGG	1320
	CTTTATATT ACTGTAAGAT GTTATAATGT TAATGTGGAT GTAGTGCTTT TACTTTACAG	1380
	ATTGATTGGA ATAAGATTAT TGCATATGAA TTTACCCACA GGACTCTGAA TCATGTTACC	1440
40	CACTCCCCC ACAATGTTGT CCACTTAGTG AGTTGCATTG ATCTATCCGT ACCAAATGAT	1500
	GTGAATAAT TACATATCTT TCTGACTAT ACTGATTCT TATTTTGGTC ACTATTACTA	1560
45	AATCTCTGTT AATATTCTCT CTTTAACTG AAAAGGGATG GGATAGAAGG GTTTGCAATG	1620
	CCATATTATT GGTGGAGGGC TGTTTTAAACA TCTTTGAAGT ATGGCTTGCT GAATATCTTT	1680
	ACCAACATCT TGAATATATA TTCTAGTGTC CACAAGATT AGCAAAAAGA TAAAGCTTGG	1740
50	GTGGAATATC ATTTTAAAA GTTCATGTTT GTTCTATAT TTTCTTCACC TACTCTCCAA	1800
	ATATTGTAAT GCAAAAAGTC TCAGTAATGA TTTGGTAGTA TTAATTTTGT GGTCAATTGTT	1860
55	TCCTCTGAT AAATTTATTT TCATTAAATA CTTRTTAGAG GGTTTTGAAA TGTTTTCAA	1920
	ATATGTGAAA TGTGAACTG CTGTCTTTTA TATTAAAGTA ATTAAAGAAA ATGTATTGTG	1980
	ATTGAAATTA TTTTGNCTC CACAAGATGG CTCTATGAGT ATTCTTCCAG GGATCTAAT	2040
60	ATTATTATA GGINATAAAA TCTTGACATT TATAATCTTT C	2081

5 (2) INFORMATION FOR SEQ ID NO: 124:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 1717 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124:

15 CCCCCGCGGA GCTGGACCCG CGGTGGGCTA GGGGCAGGGC CGGAGCCGCG GCGGCGGAGC 60
TGTGGATCCT TCATGATGAG AGATTGTTGGG ACACTTCTCT CTCTGTGTG TAGTTGATAG 120
TTTGGTGGTG AAGAGATGGC TGACAGTGTC AAAACCTTTC TCCAGGACCT TGCCAGAGGA 180
20 ATCAAAGACT CCATCTGGGG TATTGTGACC ATCTCAAAGC TAGATGCTCG AATCCAGCAA 240
AAGAGAGAGG AGCAGCGTCG AAGAAGGGCA AGTAGTGTCT TGGCACAGAG AAGAGCCGAG 300
25 AGTATAGAGC GGAAGCAAGA GAGTGAGCCA CGTATGTGTA GTAGAATTTT CCAGTGTGTG 360
GCTTGAATG GTGGAGTGT CTGGTTCAGT CTCTCTTGT TTTATCGAGT ATTTATTCCT 420
GTGCTTCAGT CGTAACAGC CCGAATTATC GGTGACCCAT CACTACATGG AGATGTTTGG 480
30 TCGTGGCTGG AATTCTTCCT CACGTCAATT TTCAGTGCTC TTTGGGTGCT CCCCTGTGTT 540
GTGCTTAGCA AAGTGGTGAA TGCCATTGCG TTTCAGGATA TAGCTGACCT GGCATTGAG 600
35 GTATCAGGGA GGAAGCCTCA CCCATTCCCT AGTGTGAGCA AAATAATTGC TGACATGCTC 660
TTCAACCTTT TGCTGCAGGC TCTTTTCCCTC ATTCAGGGAA TGTTGTGAG TCTCTTTCCC 720
ATCCATCTTG TCGGTGAGCT GGTAGTCTC CTGCATATGT CCCTTCTCTA CTCACGTAC 780
40 TGCTTTGAAT ATCGTTGGTT CAATAAAGGA ATTGAAATGC ACCAGCGGTT GTCTAACATA 840
GAAAGGAATT GGCCTTACTA CTTTGGGTTT GGTTCGCCCT TGGCTTTTCT CACAGCAATG 900
45 CAGTCTCAT ATATTATCAG TGGCTGCCTT TTCTCTATCC TCTTCCCTTT ATTCATTATC 960
AGCGCCAATG AAGCAAAGAC CCCTGGCAAA GCRTATCTCT TCCAGTTGCG CCTCTTCTCC 1020
TTGGTGGTCT TCTTAAGCAA CAGACTCTTC CACAAGACAG TCTACCTGCA GTCGGCCCTG 1080
50 AGCAGCTCTA CTTCTGAGA GAAGTTCCT TCACCGCATC CGTCGCCCTGC CAAACTGAAG 1140
GCTACTGCAG GTCAGTGTG TGCTGCCAT CCAAGGGGA TGGCGGGAT TGAAGAAGC 1200
55 TGTGGCAGCT CTTTCCCTG TTCACCTCCC GCTGCCAGG GAAGGCAGGA CCCGCTCTGC 1260
CAAGGGCCCT CTGCGTATTC CCTTCTCTCT GAGGAATTGA AATTTTGTG TCTGGTGCAC 1320
60 GTAAGGCAGA ATGTTCCCTG ACACCAAGT GTGGATTTT AACATCACCG TGAGTCTGAA 1380

AGGACCACAG GTTTTCTGC AGCTATTTTC TAGCATTTGC CAGTCCCTGT GCCTGGACTG 1440
ATTGGAACAC TTGTPTTTC TCCCTGTGCC ATTTACCCCT CCACCTTTCC ATCCTGCTT 1500
5 CTACCACCCT TGGATGAATG GATTTTGTA TTTCTAGCTGT TGTATTTTGT GAATTGTGA 1560
ATTTTGTGTG TTTTCTGTGA AACACATACA TTGGATATGG GAGGTAAAGG AGTGTCCAG 1620
TTGCTCCTGG TCACTCCCTT TATAGCCATT ACTGTCTGT TTCTGTAAAC TCAGGTAGG 1680
10 TTTTGGTCTC TCTTGCTCCA CTGCAAAAAA AAAAAA 1717

15

(2) INFORMATION FOR SEQ ID NO: 125:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 804 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 125:

25

CCACGCGTCC GGTCACTATG TAGTGGAGGG GCAGACACCC TCCCGCAAAT TCTGGAAGGT 60
TCTTAGTCTC GACTAGGGCA GTAGCCCCAG GACTCCTAGT CGCGGCTTC AGGTCACTGC 120
30 CGGCTGAACG GAGCTGCGGT CGCCATGTTT GGCTGCTTGG TGGCGGGGAG GCTGGTGCAA 180
ACAGCTGCAC AGCAAGTGGC AGAGGATAAA TTGTPTTTTG ACTTACCTGA TTATGAAAGT 240
ATCAACCATG TTGTGGTTTT TATGCTGGGA ACAATCCCAT TTCCTGAGGG AATGGGAGGA 300
35 TCTGTCTACT TTTCTTATCC TGATTCAAAT GGAATGCCAG TATGGCAACT CCTAGGATTT 360
GTCACGAATG GGAAGCCAAG TGCCATCTTC AAAATTTTCA GTCTTAAATC TGGAGAAGGA 420
40 AGCCAACATC CTTTGGAGC CATGAATATT GTCCGAATC CATCTGTTGC TCAGATTGGA 480
ATTTCACTGG AATTATTAGA CAGTATGGCT CAGCAGACTC CTGTAGGTAA TGCTGCTGTA 540
TCCTCAGTTG ACTCAITCAC TCAGTTCACA CAAAAGATGT TGGACAATTT CTACAATTTT 600
45 GCTTCATCAT TTGCTGTCTC TCAGGCCAG ATGACACCAA GCCCATCTGA AATGTTTATT 660
COGCGAAATG TGGTCTGAA ATGGTATGAA AACTTTCAAA GACGACTAGC ACAGAACCCT 720
50 NINTTTTGGN AAACATAATT TGAATAAAAT AATTTTAAAT GGATTNIGNA AAAAAAAAAA 780
AAAAAAAAA AAAAAAAAAA AAAA 804

55

(2) INFORMATION FOR SEQ ID NO: 126:

(i) SEQUENCE CHARACTERISTICS:

60

(A) LENGTH: 431 base pairs

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126:

	GGCAGAGCCC AGGGCCTTGA AGCCAGCTGG CCCTGGAGAG GGGCTGCTGT GCCAGCTTGG	60
	GGAGGGTCTG GGATGGGGCT GCCCCTGATG GCCCTGATGT GGAGTACCTT GCCAGCATCT	120
10	GCTGGGGTGA ACTTTATTTT AGCCCTTCCC TTGTTGCTCT TATGGAAGAA CAGAGGAGGG	180
	GTGGGCAGGT CAGTGATGTC AGCAGTGGAG TGATTCCAG CACAGCGGCT TCTGGGAAGA	240
15	GGGCATGGAG GCATTTCTTT CAGGGAAATG GTCCATNATT TCAGCCAGAA GGCATTGCAT	300
	TAAGTTAAGT CCNGGACTTT TGTGGCCAG CTCTGTGTTA TTAAGGGCCC TTGGCGAAGA	360
	CTTCAAGGAG GGGGCAAAAN GACCTTTAAG TTTTATAGTT TAACACAGGG AACCCNCAA	420
20	GGGTTATTTT G	431

25

(2) INFORMATION FOR SEQ ID NO: 127:

(i) SEQUENCE CHARACTERISTICS:

30	(A) LENGTH: 3752 base pairs
	(B) TYPE: nucleic acid
	(C) STRANDEDNESS: double
	(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127:

35	NGGCAGGAG AGAGTCACCT GGACTCAGAA CTAGAGATAT CCAATGACCC AGACAAAATT	60
	AAACTTCAGC TTTCTAAGCA TAAGGATTT CAGAAGACTC TTGGTGGCAA GCAGCCTGTG	120
40	TATGATACCA CAATTAGAAC TGGCAGAGCA CTGAAAGAAA AGACTTTGCT TCCCGAAGAT	180
	ASTCAGAAAC TTGACAATTT CCTAGGAGAA GTCAGAGACA AATGGGATAC TGTTTGTGGC	240
45	AAGTCTGTGG AGCGGCAGCA CAAGTTGGAG GAAGCCCTGC TCTTTTCGGG TCAGTTCATG	300
	GATGCTTTGC AGGCATTGGT TGA CTGGTTA TACAAGGTGG AGCCACAGCT GGCTGAGGAC	360
	CAGCCCGTGC ACGGGGGACC TTGACCTCGT CATGAACCTC ATGGATGCAC ACAAGGTTTT	420
50	CCAGAAGGAA CTGGNGAAAG CGAACAGGAA CCGTTCAGGT CCTGAAGCGG TCAGGCOGAG	480
	AGCTGATTGA GAATAGTCGA GATGACACCA CTTGGGTAAA AGGACAGCTC CAGGAAC TGA	540
55	GCACTCGCTG GGACACTGTC TGTAACTCT CTGTTTCCAA ACAAAGCCGG CTTGAGCAGG	600
	CCTTAAACA AGCGGAAGTG TTTGAGACA CAGTCCACAT GCTGTGGAG TGGCTTTCTG	660
	AAGCAGAGCA AACGCTTCGC TTTGGGGAG CACTTCCTGG ATGACACAGA GGCCCTGCAG	720
60	TCTCTCATTG ACACCCATAA GGAATTCATG AAGAAAGTAG AAGAAAAGCG AGTGGACGTT	780

	AACTCAGCAG TAGCCATGGG AGAAGTCATC CTGGCTGTCT GCCACCCCGA TTGCATCACA	840
5	ACCATCAAAC ACTGGATCAC CATCATCCGA GCTCGCTTCG AGGAGGTCTT GACATGGGCT	900
	AAGCAGCACC AGCAGCGTCT TGAAACGGCC TTGTCAGAAC TGGTGGCTAA TGCTGAGCTC	960
	CTGGAAGAAC TTCTGGCATG GATCCAGTGG GCTGAGACCA CCCTCATTCA GCGGGATCAG	1020
10	GAGCCAATCC CGCAGAACAT TGACCGAGTT AAAGCCCTTA TCGCTGAGCA TCAGACATTT	1080
	ATGGAGGAGA TGA CTCGCAA ACAGCCTGAC GTGGACCGG TCACCAAGAC ATACAAAAGG	1140
15	AAAAACATAG AGCCTACTCA CGCGCTTTC ATAGAGAAAT CCGCAGCGG AGGCAGGAAA	1200
	TCCCTAAGTC AGCCAACCCC TCCTCCCATG CCAATCCTTT CACAGTCTGA AGCAAAAAAC	1260
	CCACGGATCA ACCAGCTTTC TGCCCGCTGG CAGCAGGTGT GGCTGTTAGC ACTGGAGCGG	1320
20	CAAAGGAAAC TGAATGATGC CTTGGATCGG CTGGAGGAGT TGAAAGAATT TGCCAACTTT	1380
	GACTTTGATG TCTGGAGGAA AAAGTATATG CGTTGGATGA ATCACA AAAA GTCTCGAGTG	1440
25	ATGGATTCTT TCCGGCGCAT TGATAAGGAC CAGGATGGGA AGATAACACG TCAGGAGTTT	1500
	ATCGATGGCA TTTTAGCATC CAAGTCCCC ACCACCAAGT TAGAGATGAC TGCTGTGGCT	1560
	GACATTTTCG ACCGAGATGG GGATGGTTAC ATTGATTATT ATGAATTTGT GGCTGCTCTT	1620
30	CATCCCAACA AGGATGCGTA TCGACCAACA ACGGATGCAG ATAAAATCGA AGATGAGGTT	1680
	ACAAGACAAG TGGCTCAGTG CAAATGTGCA AAAAGTTTC AGGTGGAGCA GATCGGAGAG	1740
35	AATAAATACC GGTCTCTCTT CGGCAATCAG TTTGGGGATT CTCAGCAGTT GCGGCTGGTC	1800
	CGTATTCTGC GCAACCGTGA TGGTTCGGT TGGTGGAGGA TGGATGGCCT TGGATGAATT	1860
	TTTAGTGAAA AATGATCCCT GCCGAGCAG AGGTAGAACT AACATTGAAC TTAGAGAGAA	1920
40	ATTTCATCTA CCAGAGGGAG CATCCAGGG AATGACCCCC TTCCGCTCAC GGGGTGGAAG	1980
	GTCCAAACCA TCTTCCGGG CAGCTTCCOC TACTCGTTC AGCTCCAGTG CTAGTCAGAG	2040
45	TAACCACAGC TGTACATCCA TGCCATCTTC TCCAGCCACC CCAGCCAGTG GAACCAAGGT	2100
	TATCCCATCA TCAGGTAGCA AGTTGAAACG ACCAACACCA ACTTTTCATT CTAGTCGGAC	2160
	ATCCCTTGCT GGTGATACCA GCAATNAGTT CTCCCGGC CTCCACAGGT GCCAAACTA	2220
50	ATCGGCAGCA CCTTAAAAAG TCTGCCAGTC GCCCTGGGAG TCGGGCTGGG AGTCGAGCCG	2280
	GGAGTCGAGC CAGCAGCCGG CGAGGAAGTG ACGCTTCTGA CTTTGACCTC TTAGAGACGC	2340
55	ATTGCTTGTT CCGACACTTC AGAAAGCAGC GCTGCAGGGG GCCAAGGCAA CTCCAGGAGA	2400
	GGGCTAAACA AACCTTCCAA AATCCCAACC ATGTCTAAGA AGACCACCAC TGCTCCCCC	2460
	AGGACTCCAG GTCCCAAGCG ATAACACTGT CTAAGCACCC CCAAGCCACT ATCCACTTTG	2520
60	AATCCTGCTC CATACATTGG GTGTATATTT ATTCTGAACG GGAGAAGTTA TATTGTTAAA	2580

	AGTGTAAAAG AATAATTGTG TTATGAAGCT GCCTTATTTT TTTTCTTTTT GTAAGTTACT	2640
5	ATTTTCATGT GAATATTTAT GTAGATAAAA TTTGCCTCCT GGTAAACCTG TAATGGATGG	2700
	GGCCCGAGAA TGAAATATTT GAGAAAAACA AGTGAAAAGG TCAAGATACA AATGTGTATT	2760
	AAAAAAAAA AAGCCTATTA ATAGGGTTTC TGGCGGGTGC AGGGTTGTAA ACCTGCTTTA	2820
10	TCTTTTAGGA TTATTCCTAA ATGCATCTTC TTTATAAACT TGACTIONCTA TCTCAGCAAG	2880
	ATAAATTATA TTAAAAAAT AAGAATCCTG CAGTGTATAA GGAATCTTT TTTGTAAAT	2940
15	CACGGACACC TCAATTAGCA AGAACTGAGG GGAGGGCTTT TTCCATTGTT TAATGTTTTG	3000
	TGATTTTATG CTAAAGAGAG GGAACCTCAT CTAAGTAACA TTTGCACATG ATACAGCAAA	3060
	AGGAGTTCAT TGCAATACTG TCTTTGGATA TTGTTTCAGT ACTGGGTGTT TAAAGGACAA	3120
20	ATAGCTGCTA GAATTCAGGG GTAAATGTAA GTGTTTCAGAA AACGTCAGAA CATTTGGGGT	3180
	TTTAAACTGA TTTGTTGCTC CCTATCCAGC CTAGACACCA GTAATCTCTG TGTTCACCAG	3240
25	GACCCAGACC CTTGGCAAGG GATAGGCTCG TTGGTGACAT TGTGAATTTT AGATTTGTTT	3300
	TATCCACTTT TTTTGCTATT TATTTAAATG GTCGATCAAC TTCCACAAA CTGAGGAATG	3360
	AATTCCACGA GCTGTCTCG AAAATGTGGA CGTAAGACAA ACACGTGCTC GTCCTTTAAT	3420
30	GGAGTTCACC AGCACACTTG TTAACCACTC CTGTTTGCTT TCGTCTTTTT TTGTGCGTAA	3480
	TAAAGTCAAC TGACCAAGTG ACCATGAAAA GGGGCTGTCT GGGGCTCCTG TTTTTTAGCT	3540
35	GCTGTCTTTC AGCTCCGACC ATGTGCTGTT GTGATTATCT CAATTGGTTT TAATTGAGGC	3600
	AGAACTGAA GCTCTACCAA TGAATGTTT AGAAACAAGA CACACTTTTG TATTAAATT	3660
	GCTTGCACTA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAATCGAGG GGGGCCCCGT	3720
40	ACCCAATTCG CCGTATATGA TCGTAAACAA TC	3752

45 (2) INFORMATION FOR SEQ ID NO: 128:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 1144 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128:

55	TGACCTCTG CCGCCGGGC TCAGTGCTGG ACGCTTCTG TTTGTGCA GTCCGTCTC	60
	GGTAACACCA GGGGCTGTG GTCCACCACT CCATTCAGCA GCTCCATTG GTCCAGCAAC	120
60	CTTAGCAGCG CTTCCCTTC ACCACTCCAG CAAACAGCT GGCAAGCATC GGCTCATGG	180

	GCACAGAAAA CTCCCCTGCT CCTCAGCTC CCTCCACCTC CAGTCCAGCT GACGACTTGG	240
	GACAGACCTA CAACCCGTGG CGGATATGGA GCCCCACGAT TGGAGAAGA AGCTCGGACC	300
5	CTTGGTCTAA TTGCGACTTT CCTCAGGAGA ATTAAATTAA GCAAAAAACA AACAAACATA	360
	GTGGGCCCTC GTCTAGATCA TGATGTGCCA GTTCTTGAGA CATCTTTTTA AGGCTCTTAC	420
10	TGCAGCTCCC CTCCCCACCC TCCTCTTCTT TGCAAAACAG ACCCAAGCAG GGCAGGCTCA	480
	GACCACTCGC TTCTTTTCTA TCTTTCTTGC AATTATGATA ACATGAGATT TGCTGTTGTG	540
	CTTTTAGAGA AAAGTCTGGA CTCAGCCACA AACTCTAATA AGAOCCTGTAC ATCTGAGAAC	600
15	CTTCCCGTT ACTGCGTTT CACCACCTGT CTTCCTCATG CTTTATTTAT CTGTATGAAC	660
	ACAGATTGTA CATTACAGCT AAGGAAATAA TTTGAGTTGA TTCAGAAATC CTGGCATGTG	720
20	ACAATTTTGT TAAATTACCA AGTTTGGTTT TTAATAATTT CTCAATATTA TCGCCCAAGA	780
	TCTAATTTTA AAACGTATG AGGACTTTGT GCTGAAAATA GAGTATTTT TTAAGTAAG	840
	GCTGTCTTGG TTTAAAAGCA GATTACAGAA ATGTAAGTCA ACTTAAGAAC RGTGAATGAA	900
25	TGTAAAAACA TTCAGTYGAG ACCATATGCA TTTTCTGTGC TGTPTGTACT TGAGGTATGT	960
	AACATTTGTA TACCTGAACT TATTTTAAAG ATGAACTGAA ATGCACATAG CCAAGTCTTG	1020
30	AGATACAAGA TTGAATGTGT ATTTCTTAAA AATACAACCT TGTGTTGTAC TTTGAAATAA	1080
	ATGATGCTTT TTTCAAAAAA AAAAAAAAAA AAAAAAAAC TCGAGGGGGG GCCCGGTACC	1140
	CAAT	1144

35

(2) INFORMATION FOR SEQ ID NO: 129:

40

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1830 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129:

	GCATGCAGAG GAGCACCTG AGCGTGTGCC TGGAGCAGGC GGCCATSTTG GCACGGAGCC	60
50	ACGGGTGCT GCCCAAGTGC ATCATGCAGG CCACGGACAT CATGCGGAAC AGGGCCCAAG	120
	GGTGGAGATT CTGGCCAAA ACCTGCGAGT CAAGGACCAG ATGCCCCAGG GTGCTCCGG	180
55	CCTCTACCGC CTCTGCCAGC CGCCGGTGA TGGGGACCTC TGAACACCA AATGCCCCAC	240
	GCTGGGCCGC GGCTCTGGA GCTGGGATTT GGGAGGACAC AGCAGGCAGC GCTGGCCTTC	300
	TCCAGGGATG GCCCAANGCT TCCGCARCCG CCCGTTCCGG GACCTGCCCA GCGTCCCTCC	360
60	TGCCTCTTC CGGACAAGC CTGGCCACCC TCGCTGTGAT GACGAGCTGG CTGATTGGCC	420

	CTGGGCCGGC CCATTCTTCA CACGCTGCC AGAAGCTGGA GGGGTGCTGG AGACCCATAG	480
5	AGCTGATGGG AGCAGCTGGT GCCTGGCCTT CGGCTCCTGC GTCCCCAGAA CCCAAGGGAA	540
	CGTCATGGAG GCCACATGGG GCCACCCGGC TCCCTCGGGA TGGCTCCGCT GCACCTTTTGA	600
	AACCCCGGTT TCCTTCAACG TCCACATTCC AGGTGACCAC ACGTGTCTCC TCCTCCTCAT	660
10	CTTAGCTTCC AGGTTCACCC TAACCTGTGA CTAACCTGCT TGGTGGACTT GGAAAAGACT	720
	TGGCTCTGTC GGGAAAGGAG AGACGGGGCC TCCATCACGC CTGTTACCAG AGGATCCCCG	780
15	AGAGCCACAC CAGCTCTGGA CATCACGCC CCTGGAAGTG GGGCCACCAG CCCTGGGCAC	840
	GAGATTTGCT CTGACTTTAT TTATATGGCA TGAAATCTCT GGTTTATTTT GGGATTTTTT	900
	GTGTGTGGTG TTGTCAAAGT TTGTTTTTTC TAAAGTTGTG TGATTATATA TTTGACATTT	960
20	TACATTTCAA AGAAAGGTAT GTGTCTTAAC AGGGGACCAA CAGAAGGTAG TATTGACAAC	1020
	TGTTCTGCT TCTACTAAAA AAAAAAGAGC ACAAAGAAA AACTAAATTA TTGAAAAAT	1080
25	AAAAAATGTC ATTGTTTCCT GTTGTGTAAT ATTAGGGTTG TAAGGTGTCG TTTTGAGGTA	1140
	TCGACTGTGA TTCTTCCCC CACCTCCAT TCTCCAGCGG TTGGCCGGTG TTAGAACTCG	1200
	CTCTCTTTGA GTGACTGGCT ACAAGGGCCT GAGAGGTGGC CAGCCAGGGT TGGAGCTGGA	1260
30	GGGGATGGAG CCCACCTGA GGTGCCGTGT CACACGGGTT AGAGGGTCAC TGGGAAACAC	1320
	CGGGCGGTGG CTTCTGTGAT TTATTTTCTT GATGGTAACT TCTCAGAGCA GGGCRATTGG	1380
35	GACATCACCA GCCAGAGCAC AGGAAGCCAC CCTGCTGCT GGGGAGGAGG GACCCACACA	1440
	AGCCCCCTCG GCAGTTTGTG CCCCCAGCTT CGGTATGCCT TCAGGGAAAG GTCACAGCTG	1500
	GGGAGGAAGC GGGGGGACGC CTGTACCCCC TGGCAGGTGG TGAGTTCAGG TGGGGGCTCC	1560
40	CTGCTKCCCC CAGGCTGGG AGCTTGAAGC CCTCCCGGCA TCTGGCATCC GAGCCTCCCG	1620
	CCCTCCAGGG TCGCTTCCC TCTCTTGCCG CAGCATACAC GAGGGCAGGC AGTGGCCTTG	1680
45	TCACTGTATC TTGCATCAGA GACAAAGGAG GACCCGCTTT AGCCCTGCTG CGGGAAATGG	1740
	GGGATGGCCC AGGGCCAGCG CATGTGCAC TGGTTTACTT TAAAATGTAC AGATTCTTCT	1800
	CGTTAAATTC TTGATAGATT TTTTATTATT	1830

50

(2) INFORMATION FOR SEQ ID NO: 130:

55

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1864 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 130:

	GGCCGCCCGG ATGGGACCC CAGCCTGGC CCCAGACACA CGGGCTCTGG TGGCAGACTT	60
5	TGTAGGTTAT AAGCTGAGGC AGAAGGGTTA TGTCTGTGGA GCTGGCCCCG GGGAGGGCCC	120
	AGCAGCTGAC CCGCTGCACC AAGCCATGCG GGCAGCKGGA GATGAGTTG AGACCCGCTT	180
10	COGGGACACC TTCTCTGATC TGGCGGCTCA GCTGCATGTG ACCCCAGGCT CAGCCCAACA	240
	ACGCTTCACC CAGGTCTCCG ATGAACTTTT TCAAGGGGGC CCCAACTGGG GCCGCCTTGT	300
	AGCCTTCTTT GTCTTTGGGG CTGCACTGTG TGCTGAGAGT GTCAACAAGG AGATGGAACC	360
15	ACTGGTGGGA CAAGTGACAG AGTGGATGGT GGCTTAOCCTG GAGACGGGCG TGGCTGACTG	420
	GATCCACAGC AGTGGGGGCT GGTATATCCA GATCACTGAA GCTGAGATGG CTGATGAAGT	480
20	AATTTCAGT GAAATTTTAA GCGACTGTGA CTCTGCTGCA AGTTCCCCAG ATCTTGAGGA	540
	GCTGGAAGCT ATCAAAGCTC GAGTCAGGGA GATGGAGGAA GAAGCTGAGA AGCTAAAGGA	600
	GCTACAGAAC GAGGTAGAGA AGCAGATGAA TATGAGTCCA CCTCCAGGCA ATGCTGGCCC	660
25	GGTGATCATG TCCATTGAGG AGAAGATGGA GGCTGATGCC CGTTCCATCT ATGTTGGCAA	720
	TGTGGACTAT GGTGCAACAG CAGAAGAGCT GGAAGCTCAC TTTTCATGGCT GTGGTTCAGT	780
30	CAACCGTGTT ACCATACTGT GTGACAAATT TAGTGGCCAT CCCAAAGGGT TTGCGTATAT	840
	AGAGTTCTCA GACAAAGAGT CAGTGAGGAC TTCCTTGGCC TTAGATGAGT CCCTATTTAG	900
	AGGAAGGCAA ATCAAGGTGA TCCCAAAACG AACCAACAGA CCAGGCATCA GCACAACAGA	960
35	CCGGGGTTTT CCAOGAGCCC GCTACCGCGC CCGGACCACC AACTACAACA GCTCCCGCTC	1020
	TCGATTCTAC AGTGGTTTTA ACAGCAGGCC CCGGGGTGCG GTCTACAGGG GCCGGGCTAG	1080
40	AGCGACATCA TGGTATTCCC CTACTAAAA AAAGTGTGTA TTAGGAGGAG AGAGAGGAAA	1140
	AAAAGAGGAA AGAAGGAAAA AAAAAAGAA TAAAAAATA AAAAAAATA ACAGAAGWTG	1200
	MCCTTGATGG AAAAAAATA TTTTAAATA AAAAGATATA CTGTGGAAGG GGGGAGAATC	1260
45	CCATAACTAA CTGCTGAGGA GGGACCTGCT TTGGGGAGTA GGGGAAGGCC CAGGGARTGG	1320
	GGCAGGGGGC TGCTTATTCA CTCTGGGGAT TCGCCATGGA CACGTCTCAA CTGCGCAACT	1380
50	GCTTGCCCAT GTTCCCTGC CCCACCCAC CCCTCTCTC CGGCTCCCTG CCCCTCCAGA	1440
	TGCGCTGGTG ATCTATTTTG TTTCCTTTTG TGTTCTTTT TCTGTTTGA GTGTCTTTCT	1500
	TTGCAGGTTT CTGTAGCCCG AAGATCTCCG TTCCGCTCCC AGCGGCTCCA GTGTAAATTC	1560
55	CCCTTCCCCC TGGGGAAATG CACTACCTTG TTTTGGGGGG TTAGGGGTG TTTTGTGTTT	1620
	TCAGTGTGTT TGTTTTTTTG TTTTTTNTT TTTCTTTGC CTTTTTCCC TTTTATTTGG	1680
60	AGGGAATGGG AGGAAGTGGG AACAGGGAGG TGGGAGGTGG ATTTTGTTTA TTTTATTAGC	1740

TCATTTCAG GGGTGGGAAT TTTTTTTTAA TATGTGTCAT GAATAAAGTT GTTTTGGAAA 1800
 AKAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1860
 5 AAAA 1864

10 (2) INFORMATION FOR SEQ ID NO: 131:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2041 base pairs
 (B) TYPE: nucleic acid
 15 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 131:

20 GGCACGAGCG CGCGGCAGGG CCTTGGACCC GCGCGGCTCC CGGGGATGGT GAGCAAGGCG 60
 CTGCTGGGCC TCGTGTCTGC CGTCAACCGC AGGAGGATGA AGCTGCTGCT GGGCATCGCC 120
 25 TTGCTGGCCT ACGTCGCCTC TGTTTGGGGC AACTTCGTTA ATATGAGGTC TATCCAGGAA 180
 AATGGTGAAC TAAAAATTGA AAGCAAGATT GAAGAGATGG TTGAACCACT AAGAGAGAAA 240
 ATCAGAGATT TAGAAAAAAG CTTTACCCAG AAATACCCAC CAGTAAAGTT TTTATCAGAA 300
 30 AAGGATCGGA AAAGAATTTT GATAACAGGA GCGCGAGGGT TCGTGGGCTC CCATCTAACT 360
 GACAACTCA TGATGGACGG CCACGAGGTG ACCGTGGTGG ACAATTTCCT CACGGGCAGG 420
 AAGAGAAACG TGGAGCACTG GATCGGACAT GAGAACTTCG AGTTGATTAA CCACGACGTG 480
 35 TGGAGCCCCT CTACATCGAG GTTGACCAGA TATACCATCT GGCATCTCCA GCCTCCCTC 540
 CAACTACAT GTATAATCCT ATCAAGACAT TAAAGACCAA TACGATTGGG ACATTAAACA 600
 40 TGTTGGGGCT GGCAAAACGA GTCGGTGCCG GTCTGCTCCT GGCTCCACA TCGGAGGTGT 660
 ATGAGATCC TGAAGTCCAC CCTCAAAGTG AGGATTACTG GGGCCACGTG AATCCAATAG 720
 GACCTCGGGC CTGCTACGAT GAAGGCAAAC GTGTTGCAGA GACCATGTGC TATGCCTACA 780
 45 TGAAGCAGGA AGCGGTGGAA GTGCGAGTGG CCAGAATCTT CAACACCTTT GGGCCACGCA 840
 TGCACATGAA CGATGGGCGA GTAGTCAGCA ACTTCATCCT GCAGGCGCTC CAGGGGGAGC 900
 50 CACTCACGGT ATACGGATCC GGTCTCAGA CAAGGGCGTT CCAGTACGTC AGCGATCTAG 960
 TGAATGGCCT CGTGGCTCTC ATGAACAGCA ACGTCAGCAG CCGGTCAAC CTGGGGAACC 1020
 CAGAAGAACA CACAATCCTA GAATTTGCTC AGTTAATTAA AAACCTTGTT GGTAGCGGAA 1080
 55 GTGAAATTCA GTTCTCTCC GAAGCCAGG ATGACCCACA GAAAAGAAAA CCAGACATCA 1140
 AAAAGCAAA GCTGATGCTG GGTGGGAGC CCGTGGTCCC GCTGGAGGAA GGTTTAAACA 1200
 60 AAGCAATTCA CTACTCCGT AAAGAACTCG AGTACCAGGC AAATAATCAG TACATCCCA 1260

	AACCAAAGCC TGCCAGAATA AAGAAAGGAC GGACTGCGCA CAGCTGAACT CCTCACTTTT	1320
5	AGGACACAAG ACTACCATTG TACACTTGAT GGGATGTATT TTTGGCTTTT TTTTGTGTC	1380
	GTTTAAAGAA AGACTTTAAC AGGTGTCATG AAGAACAAC TGGAAATTCA TTCTGAAGCT	1440
	TGCTTTAATG AAATGGATGT GCCTAAAAGC TCCCCTCAA AACTGCAGA TTTTGCCCTG	1500
10	CACTTTTGA ATCTCTCTT TTATGTAAAA TAGCGTAGAT GCATCTCTGC GTATTTTCAA	1560
	GTTTTTTTAT CTGTCTGTGA GAGCATATGT TGTGACTGTC GTTGACAGTT TTATTTACTG	1620
15	GTTTCTTTGT GAAGCTGAAA AGGAACATTA AGCGGGACAA AAAATGCCGA TTTTATTTAT	1680
	AAAAGTGGT ACTTAATAAA TGAGTCGTTA TACTATGCAT AAAGAAAAAT OCTAGCAGTA	1740
	TTGTCAGGTG GTGGTGGCC GCATTGATT TTAGGGCAGA TAAAGAATT CTGTGTGAGA	1800
20	GCTTTATGTT TCTCTTTTAA TTCAGAGTTT TTCCAAGGTC TACTTTTGAG TTGCAACTT	1860
	GACTTTGAAA TATTCCTGTT GGTCATGATC AAGGATATTT GAAATCACTA CTGTGTTTG	1920
25	CTGCGTATCT GGGCGGGGG CAGGTGGGG GGCACAAAGT TAACATATTC TTGGTTAACC	1980
	ATGGTTAAAT ATGCTATTTT AATAAAATAT TGAAACTCAC CAAAAAAAAA AAAAAAAAAA	2040
	A	2041

30

(2) INFORMATION FOR SEQ ID NO: 132:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2012 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 132:

	TACCAAGCTG CAAGAATCTA CTATATCATG GCAGAAGAAG TAGAGTGGGA CTATGCCCCT	60
45	GACCGGAGCT GGGAACGGGA ATGGCACAAC CAGTCTGAGA AGGACAGTTA TGGTTACATT	120
	TTCTGAGCA ACAAGGATGG GCTCCTGGGT TCCAGATACA AGAAAGCTGT AITCAGGGAA	180
50	TACACTGATG GTACATTCAG GATCCCTCGG CCAAGGACTG GACCAGAAGA ACACTTGGGA	240
	ATCTTGGGTC CACTTATCAA AGGTGAAGTT GGTGATATCC TGACTGTGGT AITCAAGAAT	300
	AATGCCAGCC GCCCCTACTC TGTGCATGCT CATGGAGTGC TAGAATCTAC TACTGTCTGG	360
55	CCACTGGCTG CTGAGCCTGG TGAGGTGGTC ACTTATCAGT GGAACATCCC AGAGAGGTCT	420
	GGCCCTGGG CAATGACTCT GCTTGTGTTT CCTGGATCTA TTATTCTGCA GTGGATCCCA	480
60	TCAAGGACAT GTATAGTGGC CTGGTGGGG CCTTGGCTAT CTGCCAAAAG GGCATCCTGG	540

	NAGCCCCATG GAGGACGGAN TGACATGGAT CGGGAATTG CATTGTTGTT CTTGATTTT	600
	GATGAAAATA AGTCTTGGA TTTGGAGGAA AATGTGGCAA CCCATGGGTC CCAGGATCCA	660
5	GGCAGTAITA ACCTACAGGA TGAACTTTC TTGGAGAGCA ATAAAATGCA TGCAATCAAT	720
	GGGAAACTCT ATGCCAACCT TAGGGGTCTT ACCATGTACC AAGGAGAAG AGTGGCCTGG	780
10	TACATGCTGG CCATGGGCCA AGATGTGGAT CTACACACCA TCCACTTTCA TGCAGAGAGC	840
	TTCTCTATC GGAATGGCGA GAACTACCGG GCAGATGTGG TGGATCTGTT CCCAGGGACT	900
	TTTGAGGTTG TGGAGATGGT GGCCAGCAAC CCTGGGACAT GGCTGATGCA CTGCCATGTG	960
15	ACTGACCATG TCCATGCTGG CATGGAGACC CTCCTCACTG TTTTCTCTG AACAGAACAC	1020
	TTAAGCCCTC TCACCGTCAT CACCAAGAG ACTGAAAAAG CAGTGCCCCC CAGAGACATT	1080
20	GAAGAAGGCA ATGTGAAGAT GCTGGGCATG CAGATCCCCA TAAAGAATGT TGAGATGCTG	1140
	GCCTCTGTTT TGGTTGCCAT TAGTGTCAAC CTCTGCTCG TTGTTCTGGC TCTTGGTGGA	1200
	GTGGTTTGGT ACCAACATCG ACAGAGAAAG CTACGACGCA ATAGGAGGTC CATCTGGAT	1260
25	GACAGCTTCA AGCTTCTGTC TTTCAAACAG TAACATCTGG AGCCTGGAGA TATCCTCAGG	1320
	AAGCACATCT GTAGTCACT CCCAGCAGGC CATGGACTAG TCACTAACCC CACACTCAA	1380
30	GGGCATGGG TGGTGGAGAA GCAGAAGGAG CAATCAAGCT TATCTGGATA TTTCTTTCTT	1440
	TATTTATTTT ACATGGAAAT AATATGATTT CACTTTTCTT TTAGTTTCTT TGCTCTACGT	1500
	GGGCACCTGG CACTAAGGGA GTACCTTATT ATCCTACATC GCAAATTICA ACAGCTACAT	1560
35	TATATTTCTT TCTGACACTT GGAAGGTATT GAAATTTCTA GAAATGTATC CTCTCACA	1620
	AGTAGAGACC AAGAGAAAAA CTCATTGATT GGGTTTCTAC TTCTTTCAAG GACTCAGGAA	1680
40	ATTTCACTTT GAACTGAGGC CAAGTGAGCT GTTAAGATAA CCCCACTTA AACTAAAGGC	1740
	TAAGAATATA GGCTTGATGG GAAATGAAG GTAGGCTGAG TATTGGGAAT CCAAATTGAA	1800
	TTTTGATTCT CCTTGGCAGT GAACTACTTT GAAGAAGTGG TCAATGGGTT GTCCTGCCA	1860
45	TGAGCATGTA CAACCTCTGG AGCTAGAAGC TCCTCAGGAA AGCCAGTTCT CCAAGTTCTT	1920
	AACCTGTGGC ACTGAAAGGA ATGTTGAGTT ACCTCTTCAT GTTTTAGACA GCAAACCCTA	1980
50	TCCATTAAAG TACTTGTTAG AACACTGAAA AA	2012

55 (2) INFORMATION FOR SEQ ID NO: 133:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1669 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

60 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133:

5	GAGCAGTATT TTAACCAACT TGTATTACAG ATGTTACAGT TCATGTTAGG AAGTCAGAAA	60
	AGACTTTGTT TGTCTTTGTT CTGCTGATGT GAGTCATGTT TTGTGGGGTC TTCCATGGCA	120
	CATTTACCTG TTGCTCCGTC CAGATGTTGA GGGCCAGTCT AGGCTGACAC ATCCTACCCG	180
10	AGGACAAGCC TGTCTCCAT TTCTTCACTC TCCCTCCCC ATATAGCAAC TCTCCCAGGT	240
	TTAGATTACC GTTTTCGACG ACAGATTAAC CAAAAATGCC CCACACAGGT TTTATTACTG	300
	TTATATACTA TACTTTTAAC AGTACAGACC CTAAATTTTA TTATTTGTG CTCCCCCAAT	360
15	CTGATACCAA ATGTTTAAAG TTGTTGAAA TCCAAACATG GTAGTGTTC TGGGTAAATA	420
	TTTTCTAGGC TATGTAAGAG TTAGCAGCCC ATAGCATAGA AGTAATCAAG TAGCATCTGA	480
20	GACTGTTGGA GGCAC TAGGG CCTCTCTGGG CCTAACAGCC TCACTTCCCC AGCCTCACCT	540
	TGCTGTCTC TGACACTGCC ATCAGGGCTG TTAGTGGCAC CTGTATGAGG CCAAGTGTGC	600
	GTCCAGGGGA ACAGCACAGG TTAATGCGTC TCCCTAGAAC TCATGAAGTC AGTTTAATTC	660
25	ATGCATGAAC ATGAGTTCAT TTTATGTTTT ATATAGCTTT CTTAGACATA CCAAACCATC	720
	ATTCATAAAT CAGATAAATT ATTCAGTTTT TGTGTTTAGA AAGCTAAGTA TGTGTAGCTG	780
30	GAAACAAAA TGAGCGTGT TTCTCTCTG TTAATCTAGA GTGTGCAGTT ACACATGTGT	840
	GGATAAATTC ATGTTCCAGG GCGCTTGGC ATCTCCCATG GACTGATTCC CAGGAAGAAA	900
	AGCCCAAAGG GAAACCCACG ATTCTTTTCG AGTAGATGTG GGAAGAGCC CATTGGAGGA	960
35	TATGAGGTCC TGTGAAATC AGTTGTGTGT GTGGCTCCTT GTTAGCAGTC ATGTTGACAT	1020
	GGTGTAGGA GGCTCCCAT CCACCTTTA CATGATGTAG GGACCACTGT CTTGTGAGAT	1080
40	TAACCTTGGG ACACAGTGGG TTAGCCTGGA GAAATGAGA GGCCCTGCCT GGACCCAGGG	1140
	AGAGGAGCCA GTGACACAGG CAGAGCGGTG CAGCCCTCCT TCCCTCCAT TTGGAGGAGG	1200
	TGGTGCCAGG AGCCTGCCCG CTTACCTCTG CTGAAGCATA AGTGGACTTT GCTTTTGGGG	1260
45	CTTATCTCTG ATACATGCTG GAGCCCTGCC TCTCCACTGC TAGATGGAAC CTGGAATCTC	1320
	TCATCTACCT CTTAGTCTGT CAGTTTCTAC GTGTGAGAAG CAAGCTTGTG GGCCAGTGTG	1380
50	CTGTACATG CTGTAGCACT TAAAAATAA TTCCAGGGTT CCCTGGAAAA CCAGTCCCAG	1440
	GGTTCCTATG ATCTGTAGTT TCTACCTGGA TTATAACTGG TTTTGGGTAC CTGAATTTTG	1500
	ATTGGTTAGC CTTAATTTATA GTCTGGCGTG ATCATGTAGA ATCTTTTCTG GTGAACAGAT	1560
55	CATAAAGTTC TATCAAGGAG TTCTATCAAG GCATCCATGT CAGTGGTGCT ATGCTGGTTA	1620
	CAACTTGAGA TTTTGAAT AAAAAATTG TCATAAAAA AAAAAAAA	1669
60		

(2) INFORMATION FOR SEQ ID NO: 134:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1565 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134:

	CACTTTTGCT ATATAACCTA AGTGATAACC CTCTTTTAGT TACCTGCCAA ACTCTGGNCT	60
15	TGGTTTATAT TGCAGTTAAC ACAGTTACAA AGCTGTAATG GTGTCCTTTT TTCCTTTGTA	120
	ACGGAATGTG TAAATCAAAG TATATACATT GTGTGGTGTT CCTGTTTCTG GAGTTTCATG	180
20	AGGATTTACA CATGGCATTG AGTGTCTGT ATAGATCTGC CTACCTTTGT GAATTCATCT	240
	GTTAACCCCT CTTCCTTTGA GAGAGCACCG GCGATGGTGG TTAACCTCTT GTGTTTCTC	300
	TCTCTCTAC TGGTTATTCT TGAATTAAGC ACAGACTCGT CAGCTCGGTT GCTTTATCAT	360
25	GAATAATGTG TGTGACCTTG CAGTTCTTCC ACAGTTCAGC AAACAAGTGC TAGCTTCACT	420
	GACCAAAAAT TAAGGAAGGA AAACACAGTT TTTAAAACGA TCCATCTTTT AACAGCCGAA	480
30	ACCGATGTGT CTATGGTGCT GCACCTTGCT GTTGACTTTC TGAAATCAGA CGTGTGTGAA	540
	CGATCATTTT TGACTTAACC GTGAGATGCT CACGAGTACC CTTCCTGTTG TTTTGTTAGC	600
	ATTGAAATCG AGACTATTTA TTTGGAATAT ATACAACAGT GTTTTTCCAC TGTATTTTCA	660
35	TTGCAAAAGT TGAGAACTGC TTTCTCTACC TTTTGCAAAA TAATTGATAT TCCATATTGG	720
	ATTCTCAAAG ACTTCGATAT GGTGAACCTA TTAAACCTAG AAATTGTATT CATCCTTTCA	780
40	TGACTGTGGC CTGAGTTCCC CAGCCCCCTC CTTCTTTT TTTAGATGAG ATTTAGCACA	840
	CTCTCAGTTA TTTAAACATG CAACATTTCT TGAGTATGTA TGTGTAGGCC ATCTGAGCTC	900
	ATAGCTGATT CAGTAACCAG TTTATGCTG TGTCAITTCAC ACTCACTACT TAATACTGCC	960
45	ATGGTGAAAA TGTGGAGGAA AAATGTATCC ATGTGTGTCT GCGAAGCATA TACACTTGTA	1020
	CATTTTTTAA TACTCTGATT CTGTAACATT TCTGAGTTT GTTTTGTMTT ACAGNAAAAA	1080
50	AAAAAAAAGT GATAAAGCAA TCAGAAGACC AAGAGGTTTA CTATTGATGC TTAGGTCGT	1140
	CTGACCTTGG CTGGCCAATA GACCTACACG GCCAAATTAA TTTACGAGAG TAATAATTTT	1200
	TCAAAAGCCA ATTTTTTTTC TGTATTTTCT GTATGAACT GCCAATATCA TGAATAGAAA	1260
55	GGGAGAACCA TAAAGGAGAA AGAACGTGAT GTTCTGTTAT GTTCATGTAA ACCTAAAGAA	1320
	ACAGTGTGGA GGCAGGCGCG ATCAGCCGAA CTCTAGGGAC TTGGTGTGTC TTGGAAGGCA	1380
60	TCCATACCTG CATTTTGCAT TCTTCGTATG TAATCATATT GCCAAAGACA AACTATTTCA	1440

TCATTTATTG TAAATAACAC TTTTCCCCAG ACCTACCATA AAGTTTCTGT GATGTATTGT 1500
 CTTCAGTTG CAATAAAAT TACTGAGTTG CATCAATTGA AGAAAAAAA AAAAAAAA 1560
 5 CTCGA 1565

10 (2) INFORMATION FOR SEQ ID NO: 135:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2007 base pairs
 (B) TYPE: nucleic acid
 15 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135:

20 TCTAAAAGCC CCCTTATACC CCACTTTGTG CAGCAAAGAT CCCCCTGCAG GTCACAGCCT 60
 GATTGTGGC CAGGCTGGAC AAATTCCTGA GGCACAACCT GGCTTCAGTT CAGATTTCAA 120
 25 GCTGTGTTGG TGTGGGACC AGCAGAAGC AAACGTCCAG CCAACACACA GGAAGTAAAG 180
 AGGACTCTGA GCTACGTGCC CTGTGAAGAC CCCCAGGCTT TGTATAGGA GGTCGTTTCA 240
 CTTCCCCAAA GTCAGAGGTG ATTTGATTGG GGAAGACTG AATATTCACA CCTAAGTCGT 300
 30 GAGCATATCC TGAGTTTAC TTCCTTATGG CTGGCCCTCC AAGTCTCTC TCTCATACAC 360
 ACACACACCC TTGCTCCAGA ATCACCAGAC ACCTCCATGG CTCAGCTAT GGAACAGCT 420
 35 GCATGGGGC TGCTTCTCTG TTTGGCTTAG GAATCTCTGT GCTTCTGTG GCTCCACTCG 480
 CGAGGCAGCT CGAGGTGTG GACTCCGATT GGGCTGCAGG CAGCTCTGGG ACGGCACAGG 540
 GGGGCGCTC TGATCAGCTC GTGTAAACA CACCGTCTTC TTGGCCTCCT GGCAGTTCTT 600
 40 TCTGCGAATA GTCTCTCCC TGGCCAGTTG AATGGGGGAA GCTGCTGCA CAGGAAGGAG 660
 AGGCGATCCC GGCTGAGGCT TAGGAAATTG CTGGAGCCGG CTCGAAGCAG ATAATTCACT 720
 GGGGAGGTTT TCAGAGTCAA ACATCATCTC GCCTGTCTTG GGGGCCAGGT GTGTCACACA 780
 45 AGCATCTCAA AGTCAAAAGC CATCTGGGCG TGCTGCTTCT CTTTCTCAGG CTCTGGGGAA 840
 AGGAATCTCC CTCTCTCTC ACTTGATCC AAGTGTGGT GAATTGTCTG GAGCACTGGG 900
 50 ACTTTTTC TCTTTCTCT GATGGACCAA CAGTGCAAAT GCAATCTCC CATTTAACTT 960
 TCAGGTGAT TTCCTTCTCT GATCAGACAT CTTTGTGCCC CCTTTAGGAA GGAAAAGAAT 1020
 ACACCTACGA TGTGCCAGGC ACTGTGTAG GCGCTTTTAT ATAGATCTC GTTAGGATGA 1080
 55 GACTAAGGGA TGAGGACATC TCTTTATAAA AGGCCCTAA GTAATGGATA AACAGAAACA 1140
 CTTAGAGGTG AGAAGGTCTG TCTCAAGAT CCAAGGTAAG ATTGCCCTCA GTCTGATGTT 1200
 60 TGTCTCAAG GACTTATCCC CTACAATATT CTCCCACTCC ATACTCTCC TTCTACCCCA 1260

CCATGTGCTC CCGTGCACCTC CTCAGATGGT CAGAGGGGTA ACCCAAGTCC TTAGAGAATT 1320
 TGGGGACCAA TAGAATATGT GATGTGTGAA TTTCTTTAA AAAACTTAAG GAGTCTTTGC 1380
 5 TACCTTCTGC TTGTTGAGTT GTTTTGCCAT TCATATTAAA AGCCAGCATC TCACTATTTA 1440
 TTGACAGGTT GGGCTGTGTG TGTCGCATG TGTGTATACA TTTCCAGGCG TGCCGTGTGC 1500
 10 CTGTAGCTTT TTAAGAGGAA ACCCAGTCAT OCCACTATGA ATCTGGCATC TTCTTATGCT 1560
 TCTAGTGTTC TGGCCATACA TCAACCAAGG GGTTTAATTT ATCCAATGCT TGACGACATG 1620
 TTCAGGAGGG GCTGGATCAA ATTTTGAGAG GGTATGGA AAGGGAGGGG GAGAAGAAAT 1680
 15 TGACATTTAT TTTATTATTT ATTTTAAATG TTTACATCTT CTTTATGTTG TATCAAGCCT 1740
 GAATAGAAAC TGATAGCAAT AAAATACTCC GTTCTCTCT CTCTTCTCGC TTCCTTTTTT 1800
 20 TTTTTTTTAA AATTAGGAT AACACATTTT TGTTTCTAAA GTGATTGTG ATTTGTGCTG 1860
 TATAAAGTGT ATAAAGGTT CTGTTTAA AGGTGGATT TCATTCTCT GGGACAGTG 1920
 GTCGCCAAGA CATCTACATT GTAAGAGAAC ACAGTGAAG ATCTGTCTT GATTCTCAA 1980
 25 AATTATTTTC TCTGTATGAT TAAAGT 2007

30

(2) INFORMATION FOR SEQ ID NO: 136:

(i) SEQUENCE CHARACTERISTICS:

35

- (A) LENGTH: 1291 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 136:

40

CTTTAAACC TCCCCCTCA CACACATACA TATCAGGTTG TTTCTAGTT AAAAACCCAA 60
 GTAGCTCAGA TTCTACTTTA ATGTCAGTGC AGATTGTCAT TGAATCATGC CATATGTTT 120
 45 TTTCTCATTT TTATGCTGTT GGGTCTTAGT TTTTAAATG ATATAAGAA CTCAGCAATG 180
 GTTTTATTTT CTAATCATAC TTAGGTTTAA GGAAACACTA CCACTAGTTA TCATTTAATC 240
 AACTTCAATG GTCTACTGAA ACAAAAATGG TAACTTTTCA TTAGTGGATT ATTTAGAGTT 300
 50 ATAGTAGTTG TTTCCAGAAA ACATTCCTC ACAATTGTAC TTCCAATCA AATCATGTGA 360
 TCATACAGTT ATCCCATGA AAGGCAGAAT GTTTGTTTCA AAATTAATCT AGTTTCTGT 420
 55 ACATTTAAAT TTGAGAAGGT GACAACTGGC TCTTTTCCAG TCTTCCTTCA TGTCAATTT 480
 CTGATAGACC ACTATTGGCA AACAGTATCT GTCAACTACC AAATGTGTAA AATTTCTGT 540
 ATTTCACTTT GTCTTATTTG TAAATAGTGA ACTAAACTT TTGGCAGATC AGCAACATTT 600
 60

	GCTGAGCCTG TTTTAAAGC TAATGTGTAT TCTTACTAAT GTTCCTATCA AGAATGGATT	660
	TGTAATATAT GCTGTCTATT TCTAATGTTC ACATTCATAT TTTGAGGTTT TATCTTATTT	720
5	TAATAGAGAA CAGACTTCTC AAAAAATCTT CAGAAGCAGC TTATTATTGA AATATCGAAA	780
	TATTGAAATA AACCCGGTGG GTTAGATTAC TCATCTGTCC ACCAAGTGGG ACATTTGCAT	840
10	GGACTGGGGG CTTAAAGGAC TTAGAAGAGA CCTGTAAGTA AATCCTGAAA ATGAGCCAAT	900
	CCCCACTTGA ATGGTTACTG GAGTAAACCC ACCTTTACCA CCCCATTAC AGCACCOGAG	960
	GCCGATAAAC CAACTTGGCT CTGGTTCATT TTTCTTTTCT TCAITTTGTGA TGCTCAGATT	1020
15	CAAAATGTGT GTTCTACACT GTTACAGGCT TCTCTTTTGT TTGATTAAAG ATTTTAGTCC	1080
	TACTTTTGTA TGGACACATT AGAATATTCA GAGACCAAAA TAGAAGAATT TGCTGTTAGA	1140
20	TATTTTTCAG AAGTCAGCAG ATTTGTGGCA AATCATTTAT TTGCCTTTTT AAAAATTCAT	1200
	TTAAGCAGTT CAGAGAGTAG ACTACTCAGA AAATTATTTT ACGTAATTGT CTAAGAGGTC	1260
	AATATTTTTT AATGCATATT GAATCAAATA A	1291

25

(2) INFORMATION FOR SEQ ID NO: 137:

30

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1906 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137:

	GGCAGGAGGA CCTACTTTTG TAACAGACCA TGGTTGTGTC CAAGGTAAAA CCACAGTGAT	60
40	ATTTTGGGAT GCTTTGTCTG CAATCTTGAC TTGTTTTTGC AGTATCAITTA TTCAGACTTC	120
	AAATGTGAA TCTTTTAAAC ATCTTGATAA TTGTGTGTG AGAGCTGTTT ATTCTAAAAT	180
45	GTAATGAAAT TCAGTCTAGT TCTGCTGATA AAGATCATCA GPTTTGAAAG GTTACTGATT	240
	TTCTCTTCC CTCTTAGTTT TTTACCCAAT ATATGGAGAA GAGTAATGGT CAATCTTAAC	300
	ATTTGTGTTT AATTGTTTAA TAAAGCTGCT GGGCAGTGGT GCAGCATTC CACCTAGTGT	360
50	CATAAAAGCA AAATACTTAC ATAGCTTTCT TAAAAATATAG GAATGACATT ACATTTTTAG	420
	GAGAAAGTAA GTTGCTTTGC ACCGCCTACT TAATTCCTTT CCATATATTG TGATACAAAC	480
55	TTTTGAATAT GGAATCTTAC TATTTGAATA GAAATGTGTA TGTATAATAT ACATACATAC	540
	ATAAGCATAT ATGTGTGTGT GTGTGTGTAT ATATATATAT ATGCATGCTG TGAAACTTGA	600
	CTACACAACA TAAATCACTT TTTAAATTC AGGAACGGT AGTCTGACAC GGTGATTATC	660
60	CTTTTGAGGC TGAATCCGTT ATTAACCTGT TATTTAGGTT TTACTCCAG TAGCAAGGGA	720

	TTCTAAGTTA GTTGCACCTTA CATGATTATT GTGATTTAAA ACTAAGAATA AAGGCTGCAT	780
5	TTTCAAAGAT AAATTGGAAT TGCTGTTGGT GAAATAACAA CCAAAATACT GAATCTGATG	840
	TACATACAGG TTTCTACAGG AAGAGATGGT ATAATTTACA ATTTGGAGAT TTAATAACCA	900
	GGGCTACCCA GAAAAAGTGA CTTGATAACA TGGTACCAAT AAGTAAGGGA TGCTCTCTCG	960
10	GTTTGCTTTT GCCACTTTCA AGATTTTAAAC TTCTCAGGTT ATTAATCAAA ATTATTGTAT	1020
	AAGTTAGCCA ATAGAATTTT TAGGTTAAAA CAACAGATGG GGGGTTTGTG GAGTGTTTAA	1080
15	TGTCATGGGC ATTTTGTAGTA GCATAGACCC TTTGTCTGTC ATTTGAATGT TTCGTATATT	1140
	TTTGTTCAC AGTTAATCTT CCTTCCCAA GTTTGCTATT CAAATCAACT GCCTGAATGA	1200
	CATTCTAGT AGTCTGATGT ATTTTCTGA GGAATAGTTT GTGATTCCAA TGCAGGTGTC	1260
20	TTCATTACCA TTACCTCTAC ACTGCAGAAG AAGCAAACT CCTTTATTAG AATTACTGCA	1320
	CATGTGTATG GGGAAAATAG TTCTGAAAGG CTAGAATGAT ACAAGTGAGC AAAAGTTGGT	1380
25	CAGCTTGCT ATGGAGTGGT GGCAATAATC TCTAAACATT CCAAAGACC ATGAGCTGAA	1440
	CCTAACTCC CTTGGGAATC TGAACAAAG GAATATGAAA ATTGCCATTT GAAAACGAC	1500
	CAGCTAATCT GGACCTCAGA GATAGATCAG CCAGTGGCCC AAAGCCATTT CAAGTACAGA	1560
30	AATTATAGAG ACTACAGCTA AATAAATTTG AACATTAAAT ATAATTTTAC CACTTTTGT	1620
	CTTTATAAGC ATATTTGTAA ACTCAGAACT GAGCAGAAGT GACTTTACTT TCTCAAGTTT	1680
35	GATACTGAGT TGACTGTCC CTTATCCCTC ACCCTTCCCC TTCCCTTCC TAAGGCAATA	1740
	GTGCACAACT TAGGTTATTT TTGCTCCGA ATTTGAATGA AAAACTTAAT GCCATGGATT	1800
	TTTTCTTTT GCAAGACACC TGTTTATCAT CTTGTTTAAA TGTAAATGTC CCCTTATGCT	1860
40	TTTGAAATAA ATTTCCCTTT GTAAAAAAA AAAAAAAA AAAAAA	1906

45 (2) INFORMATION FOR SEQ ID NO: 138:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 1935 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138:

55	TCTGAACTAA TGCTAACAGA TCCCTTGAG GGATTCCTGA TGGGCTGAGC AGCTGGCTGG	60
	AGCTAGTACT GACTGACATT CATTGTGATG AGGCAGCTT TCTGGTACAG GATTCTAAGC	120
60	TCTATGTTTT ATATACATTT TCATCTGTAC TTGCACCTCA CTTTACACAA GAGGAACTA	180

	TGCAAAAGTTA GCTGGATCGC TCAAGGTCAC TTAGGTAAGT TGGCAAGTCC ATGCTTCCCA	240
	CTCAGCTCCT CAGGTCAGCA AGTCTACTTC TCTGCCTATT TTGTATACTC TCTTTAATAT	300
5	GTGCCTAGCT TTGGAAAGTC TAGAATGGGT CCTGGTGCY TTTTACTTT GAAGAAATCA	360
	GTTTCTGCCT CTTTTTGAA AAGAAAACAA AGTGCAATTG TTTTTTACTG GAAAGTTACC	420
10	CAATAGCATG AGGTGAACAG GACGTAGTTN AGGCCCTCCT GTAAACAGAA AATCATATCA	480
	AAACACTATC TTCCCATCTG TTTCTCAATG CCTGCTACTT CTGTAGATA TTTCATTTCA	540
	GGAGAGCAGC AGTTAAACCC GTGGATTTTG TAGTTAGGAA CCTGGGRTCA AACCCCTCTC	600
15	CACTAATTGG CTATGTCTCT GGACAAGTTT TTTTTTTTTT TTTTTTTTAA ACCCTTCTG	660
	AACTTTCACT TTCTATGTCT ACCTCAAAGA ATTGTTGTGA GGCTTGAGAT AATGCATTTG	720
20	TAAAGGTCT GCCAGATAGG AAGATGCTAG TTATGGATT TACAAGTTGT TAAGGCTGTA	780
	AGAGTCTAAA ACCTACAGTG AATCACAATG CATTTACCCC CACTGACTTG GACATAAGTG	840
	AAAAGTAGCC AGAAGTCTCT TTTTCAAAT ACTTACAGGT TATTCAATAT AAAATTTTGT	900
25	TAATGGATAA TCTTATTTAT CTAAACTAAA GCTTCTGTT TATACACACT CCTGTTATTC	960
	TGGGATAAGA TAAATGACCA CAGTACCTTA ATTTCTAGGT GGGTGCTGT GATGGTTCAT	1020
30	TGTAGGTAAG GACATTTTCT YTTTTTCAGC AGCTGTGTAG GTCCAGAGCC TCTGGGAGAG	1080
	GAGGGGGTA GCATGCACCC AGCAGGGGAC TGAAGTGGGA AACTCAAGGT TCTTTTACT	1140
	GTGGGGTAGT GAGCTGCCTT TCTGTGATCG GTTTCCTAG GGATGTTGCT GTTCCCTCC	1200
35	TTGCTATTCG CAGCTACATA CAACGTGGCC AACCCAGTA GGCTGATCCT ATATATGATC	1260
	AGTGCTGGTG CTGACTCTCA ATAGCCCCAC CCAAGCTGGC TATAGGTTTA CAGATACATT	1320
40	AATTAGGCAA CCTAAAATAT TGATGCTGGT GTTGGTGTGA CATAATGCTA TGGCCAGAAC	1380
	TGAAACTTAG AGTTATAATT CATGTATTAG GGTCTCCAG AGGGACAGAA TTAGTAGGAT	1440
	ATATGTATAT ATGAAAGGGA GGTATTAGG GAGAACTGGC TCCCACAGTT AGAAGGCGAA	1500
45	GTGCACAAT AGGCCGTCTG CAAGCTGGGT TAGAGAGAAG CCAGTAGTGG CTCAGCCTGA	1560
	GTTCAAAAAC CTCAAAACG GGAAGCTGA CAGTGCAGCC AGCCTTCAGT CTGTGGCCAA	1620
50	AGGCCAAGAG CCCCTGGCAA CCAACCACT GGTGCAAGTC CTAGATTCCA AAGGCTGAAG	1680
	AACCTGGAGT CTGATGTCCA AGAGCAGGAA GAGTGAAGA AAGCCAGAAG ACTCAGCAA	1740
	CAAGGTAGAC AGTGTCTACC ACCAYAGTGG CCATACCAA GAGGCTACCG ATTCTTCT	1800
55	GCTACCTGGA TCCCTGAAGT TGCCCTGGTC TCTGCACCTT CTAAACCTAG TTCTTAAGAG	1860
	CTTTCCATTA CATGAGCTGT CTCAAAGCCC TCCAATWAAT TCTCAGTGA AGYTTCAAAA	1920
60	AAAAAAAAA AAAAA	1935

(2) INFORMATION FOR SEQ ID NO: 139:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1446 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

10

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139:

15 NGCCCCCTTG GCACAAGTCA GATGAAGCAC GTTCTGCGG GGAGGCCCTC AMCTTCCAGA 60
 GAGGACAGAC ACAGATTTC TGCTGGGGGA GGGAGGAGTC CACGCATCCT GATGCTGCCT 120
 GGAAGCTTAT TTTCCCGTGG CCAGGATGCA TTTCTCTGAG TGGAAACAGG TTCTTGCAATG 180
 20 TGGATGTGTG TTTCCCCAGG CAGACGGCCC CTCCTTTCCC AGCACTTCCC TGCTTCCCC 240
 AGGCTCAGG CCAGCACCCA GTTCTCTCTC ACATGGCAGG TGAGCACAGA CTCTAGTTG 300
 GCAGGAGCTG AGGAGGGTGA ACAAAACCCG AGGGAGGCCG GGCCCTTGCT CCCGAGTTGG 360
 25 GGGGAGGGG TGTGGCAACG TGCCCCCGC AGAGGCCACG CATGTTTGAC CAAAGCCCTC 420
 ATTGTGGTCC GAGGACAGCC TTTTCCCCAG GCCTCARAGC ATTGCTCATC CGTGCCAAAC 480
 30 TGGGTAGGTG GATTTGAGCG GAAAGACTCC CAAAATGTGC CAAGAATTTC CCRGTCCAG 540
 GCAGGCAGG GGAAACTAAG GGCAAGCAGG ATACAGGGCG AGGGATGTGG CAGGTGAGGG 600
 GGCTCCCGCC TGTGCCCTT CTCTCACCA TGTCTCCCC ACCCTGCCCTC AGTTCTCCGT 660
 35 TCCCCTTCAT CTCGTCCTCC CTCTTTGAAG CTGTCCCAT CTCAGTGTC GACCAGCCTT 720
 CTCTCAKCT GACCACCTC CTCTGACCSA CGCCCCCTCC TTGTCTGAAA AAAGGAGCCT 780
 40 TGAATGGTGG AGGGAGGCAG TGGGAGAAA GGTCTCACCG GACAGGTGG GAGAATGAGG 840
 TCAGCGGTGC TGGGAACAG ATGGAGGGG CAGTGGGGAC AGGCTTGGG CAGACACCAG 900
 CAGGAATAAT TTGAAATGTG TGAGGTGACT CCCCAGAGG CTTGGGCTTG GCATTTGGG 960
 45 AAAAGAATGA TGTCTGGAAG GGCTTAAGG ACACAGTGA CGAGGGGAGA GTCCTCATCT 1020
 GCTGGCATTT TGTGGGTGT TAGTGCCAAA CTTGAATAGG GGCTGGGGTG CTGTCTTCCA 1080
 50 CTGACACCCA AATCCAGAAT CCTGGTCTT GAGTCCCCAG AACTTTGCCT CTTGACTGTC 1140
 CCTCTCTTC CTACCTCCAT CCATGGAAAA TTAGTTATTT TCTGATCCTT TCCCCTGCCT 1200
 GGTCTAGCTC CTCTCCAAAC AGCCATGCCC TCCAAATGCT AGAGACCTGG GCCCTGAACC 1260
 55 CTGTAGACAG ATGCCCTCAG AATTGGGGCA TGGAGGGGG GSTGGGGGAC CCCATGATTC 1320
 AGCCACGGAC TCCAATGCC AGCTCCTCTC CCAAAAACAA TCCGACAAT CCTTATCCC 1380
 60 TACCCCAACC CTTTGGCGCT CTGTACACAT TTTTAAACCT GGCAAAAGAT GAAGAGAATA 1440

TTGTAA

1446

5

(2) INFORMATION FOR SEQ ID NO: 140:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1109 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 140:

TTTTTTTTTT TTTGATATGA AATTGTCCTT CTCCATTGCA GAAATAAGCT AGGGAAACAC	60
TAACCCAAAA ACTTCTGTGA GAGCTGTTCC TTTGGAGGCA GCATCACTTA TTGGCAGTAA	120
AGACTCAGTA TAAAGCACC AGCATCCCTA CTTGGGTGAT GGGGATTAAT TTTATAGCAT	180
TCCATTTTCC TAGTGCCACA TGTGAAATTG GATTTTGATG ATCTTAATCT ATATTCTACC	240
CTTATAATAA AAGATCAAAA GATATATCTC CTATGAACAG ATTGGAGATA GGAGATGAAA	300
AGTTGGGAGG ATGTCCTTAT TCTAATGTGA GGGTAGGGAA AATGTGGATA ACATTACTGG	360
GGTGARGGAG GCATGTCTCT TTAGTTGGAG TTCTCATTTT TATTCTCCAG TACTGACTTG	420
TGGGAAAGC ATACTTTTTC ACTGCCAGGT ACTGAATGCA GAGGCTCAGT GAAGTATATA	480
TGTGGGAAGT GCATGCATTT CGTTTATTAG CAAACATAGC TGGATTAAGA CAAAGTTGTT	540
GGTTTGAAA GGGTTAAAG CCTTAAGTGA ACAAATCTAG CTAACAGTGA ATGAACTAGG	600
TAATATAACT TGCATATTTT TAATTCCTT TGGTTAAAGG TCCCCATAC TTCTCTGTTT	660
GGAGACATGA GAAGTATGAT TACTTCAGTG TTAGTTTCT TAATTTTTTT TTTCCTCTAT	720
TTGTCCCTTG TCACTTTGT GCAAGCTAGA AATCTGTGGG TTATACATAG GGCAGCTCTT	780
TGTGAAAGTG GTTTATTCCA CTGGAGAAAG GGGATTGAAA ATCAGTTAGA ACCAATGTAT	840
TTCTTGCCCC ACGGAACACT ATTCTATAA GATAGCTGAA AGAAGCTGCT GTGAGGAGCT	900
CAGCTCCAAA CACAGGATCA GCACCTTGTA TAGGAATTCC CATGAATTAT GACTTCTCAT	960
TCGTGTTTAT CAGAGTGCAT ATATGTCCTA CTTCAGGAAA AGTAAAACAG TCATTTACGA	1020
AAGAAAGTCA ATCTGTATCC TAAGCATTTT AATAAAAAGT TAAAACAAAA AATTAAAAGG	1080
GACACTCGAG GGGGGGCCCC AAACCCAAT	1109

55

(2) INFORMATION FOR SEQ ID NO: 141:

60

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 497 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 141:

TAGGACTAAC TTAAATTCCTT TTATTCATCT TTTATTTATT AAAAAATTTT ATTTCTTTGA 60
10 ATTTTCCTGT AATTTCCCTTA RGCTCTTCTA TAAAAATGTTA TATTCATGTG AACCATACCT 120
CATTATCCTT AACATTTACT CTCAAAAAGC TTTTATTTTT TATTTTTTTG AAGGTAGTTT 180
15 TTCTGTGTGT ACTCTGTAAAC ATGATTTTGC TTTCAAATCA TTGTGTGCC CCCATACAAA 240
ATGCCTTTTA TTTTGTAGGA TCGTGGACTT TTTAGTATGG CATGAGTGTG CTAAAAGCCA 300
GATATCTTTC CACATTCACT GGTGGCTTTG ACACCTAGTT TTTAATCTCC CATCCTTACT 360
20 TTAAACCCCTG ACAGTGCAGT CCTCAGTCAG GGCCAGGACC GGGCTGAGGC CCTTTGTGGA 420
GATGCTGCAC CACCAGCAGA AGGCTGAGAC CTGGTTACCT GTACCTGTTT ACTTGTAAATA 480
25 AAAAGAATTA TCTAAAA 497

30

(2) INFORMATION FOR SEQ ID NO: 142:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 269 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 142:

ATGAGGCAGA GGCAAGCTGC CTGCCAACC CCTCCCTCAA GGAATGGCCT TGCCCAGGAA 60
40 TGCCCACCAC ACATACCCCTC TTCTTTTTTT CTAGTCAAAC TCTGTATTAT TCCTTGGCTT 120
GCCTCCCTCC TTTCTCCCC TCTCAACCTT TACTTCTGG TTTCTATTTC ATGGGATTTG 180
45 GGGTTGAAGT TAAACTTACA ACAGTGGCGC CAACACCAAG TCTTGCAGGA AAAAAATACA 240
AAGAAATTTA ACAAAAAAAA AAAAAAAA 269

50

(2) INFORMATION FOR SEQ ID NO: 143:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1269 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

55

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 143:

	TTGATTGACT ATGGTCTCTC CGGCTACCAG GAAGAGTCTG CCGAAGTGAA GGCCATGGAC	60
5	TTCATCACCT CCACAGCCAT CCTGCCCTG CTGTTGGGCT GCCTGGGGGT CTTGGGCTC	120
	TTCCGGCTGC TGCAGTGGGT GCGCGGAAG GCCTACCTGC GGAATGCTGT GGTGGTGATC	180
	ACAGGCGCCA CCTCAGGGCT GGGCAAAGAA TGTGCAAAG TCTTCTATGC TCGGGTGCT	240
10	AAACTGGTGC TCTGTGGCCG GAATGGTGGG GCCCTAGAAG AGCTCATCAG AGAACTCACC	300
	GCTTCTCATG CCACCAAGGT GCAGACACAC AAGCCTTACT TGGTGACCTT CGACCTCACA	360
15	GACTCTGGGG CCATAGTTGC AGCAGCAGCT GAGATCCTGC AGTGCTTTGG CTATGTGAC	420
	ATACTGTGCA ACAATGCTGG GATCAGCTAC CGTGGTACCA TCATGGACAC CACAGTGGAT	480
	GTGGACAAGA GGGTCATGGA GACAACTAC TTTGGCCAG TTGCTCTAAC GAAAGCACTC	540
20	CTGCCCTCCA TGATCAAGAG GAGGCAAGGC CACATGTGCG CCATCAGCAG CATCCAGGGC	600
	AAGATGAGCA TTCCTTTTCG ATCAGCATAT GCAGCCTCCA AGCACGCAAC CCAGGCTTTC	660
25	TTTGACTGTC TCCGTGCCGA GATGGAACAG TATGAAATTG AGGTGACCGT CATCAGCCCC	720
	GGCTACATCC ACACCAACCT CTCTGTAAAT GCCATCACCG CGGATGGATC TAGGTATGGA	780
	GTTATGGACA CCACCACAGC CCAGGGCCGA AGCCCTGTGG AGGTGGCCCA GGATGTTCTT	840
30	GCTGCTGTGG GGAAGAAGAA GAAAGATGTG ATCCTGGCTG ACTTACTGCC TTCCTTGGCT	900
	GTTTATCTTC GAACTCTGGC TCCTGGGCTC TTCTTCAGCC TCATGCCCTCC AGGGCCAGAA	960
35	AAGAGCGGAA ATCCAAGAAC TCCTAGTACT CTGACCAGCC AGGGCCAGGG CAGAGAAGCA	1020
	GCACTCTTAG GCTTGCTTAC TCTACAAGGG ACAGTTGCAT TTGTTGAGAC TTTAATGGAG	1080
	ATTGTCTCA CAAGTGGGAA AGACTGAAGA AACACATCTC GTGCAGATCT GCTGGCAGAG	1140
40	GACAATCAAA AACGACAACA AGCTTCTTCC CAGGGTGAGG GGAAACACTT AAGGAATAAA	1200
	TATGGAGCTG GGGTTTAACA CTAAAACTA GAAATAAACA TCTCAAACAG TAAAAAATAA	1260
45	AAAAAAAC	1269

(2) INFORMATION FOR SEQ ID NO: 144:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1944 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 144:

AAAAGGCAAA CTATAGGATA ACACAGAGCC CTTTTTGAAA ATAAATTGGC ATTGAGTGT 60

	TTTACCCCTCT AGCTGTTTTTA CTTAGAATGT AACATATGCT GCCTACCCAC CTCAAAATGT	120
	CTGTACTGCA AGAGGGCCCT GGGCCTCTGC TTTCCATATT CACGTTTGGC CAGAGTTGTA	180
5	GTCCCAAAGA AGAGCATGGG TGGCAGATGG TAGGGAATG AACTGGCCTG TGCAATGGGC	240
	ATGGAGCACA AGGGGTCACA GCATGCCTCC TGCCTTACCG TGGCAGTACG GAGACAGTCC	300
10	AGAACATGGT CTTCTTGCCA CGGGTGTGTG TTGTCTCTGG TGGTGCTGCA TGTCTGTGGC	360
	TCACCTTTAT TCTTGAAACT GAGGTTTACC TGGATCTGGC TACTGAGGCT AGAGCCCACA	420
	GCAGATGGG GTTGGGCCTG TGGCCCCCAA ACTAGGGGGT GTGGGTTTCAT CACAGTGTGTG	480
15	CCTTTTGTCT CCTAAAGATA GGGATCTACT TTTGAAGGA ATGTMTCTC CCAAATAAAT	540
	TTGCTTTACC TTGTCTCTT CTTTGTGTGCC AGTATTCAAG TGGTATAGCT CTGAGCAGGG	600
20	TCACATTTGG CCAAACCTGA CACTGTCTTG CTGCATTCTC CTTTGGCAA CATCAGGGTC	660
	AGAATTCAGG ATAGCCCTTC CTAGGGCACT GGACTTTCTG GCATGGGGGC TGTGTTTGCA	720
	CAAGTTATTT TCATGTTACC TGGAGAGTGT CCAGAGGCTG CTCTGAGGCT GAGGTGTGTT	780
25	CCCCCTTGCC TGGTTCCAGC TGTGAGAGG ATACCATCCT AGGGTCTGGG AATCCAAGGC	840
	CACGAGACTC CTTGGTTTGT GGTCCGAGAT CCTGTACTAA GGAGGGTCTG GCCAGAGGAA	900
30	CAGACCAGCT TTTGCACAAT GAAGCGCAAG GGAACAAGTG GTTGCCCTGG TGTCTTACCT	960
	GTCTGAACC TGGTCTGTG GGCCATTGAA AAGTTAGATC TGTGATCTCT GGGGTTTTTG	1020
	TGGCTTTGTT CAATGCTTCC ACTCTAGGGC AGGCAGAGCA GTCTATACTC TCCCAAGCCT	1080
35	GCTTGACCTC CAAGTAGAGC TGATACAGAG ATCTGTGAAT ATGTGTATAG AAATCTTTG	1140
	GTATTCATAC ATTTTCAGCTG CAAGTCAGCA ATTTCCAGG TACCATGTAA GCTATAAAAC	1200
40	AGTCATTCTT AAAGACAGAG GATAGCTGTG ACTCATGGGA TCATGAGGTC CATGGCTGTT	1260
	TGCAGGTTCC CTTTTCCTT CCTCAGGTTT TGTCTCTTCC TGTGTGTGCC CCAGCAAGGG	1320
	AGAGACTGTG GGGTGGATTG GGAGAACAGA TTAGGAGTAT AGCAAATGAA CCCAGAATGG	1380
45	AACAGTGGG AGCTAACTGT GAATGAGGAG AGTACCTGCT GCAGGACCTG GAGGTCAGGT	1440
	GTGAATGCTG TATTGGCACA GGAATAAAT ATCCTGGCGT CTGGAGCCTT CACCTCTCCG	1500
50	TCAAGTCCTT CCTGTGATAC TGCCATGGCA CAGGATCTGA GTTGCAGCTC TGCACCCATA	1560
	ATCACACCTT GGGCATTGTC TGGGCTGCAG GGCTGCCAGG TTCTGTACTT GTGTCCAGCT	1620
	GTGGCCCTGG ATGCTGGAGC TGGAGGGTTT TCTGTGCTCA GACTGTAGCC TGTAGCTCTT	1680
55	GGCCTGTGTA GAGCCCCCTC CTGTGCCCTC AGTGGCTGTC GTTGTGTAAC ATCATCAGGA	1740
	AGATGGGAAA GGTGAGGCAG AATTTTCTG CCTACAAAG GGTGGAAGAG AAAGGACACA	1800
60	GTATTTTCAT GAATTTACCA TATATCTTTG TTTTCTTCA ACGAAAAAGT TAATTGAGGC	1860

AATGTCATCT GCTCAAAGTT GAGTGGTTTA TTCACAATAA ACTGTAAGTT TCTGATTATA 1920
AAAAAAAAAA AAAAAAAAAA AAAG 1944

5

(2) INFORMATION FOR SEQ ID NO: 145:

10

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1021 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 145:

TGCACCCACG CGTCCGGGGT GCGCAACGGG GAGTTCGGC TGGAGACCCG TGCTCTGGGC 60
CGGCGCCTTC ACCATGGCCT CGGCAGAGCT GGACTACACC ATCGAGATCC CGGATCAGCC 120
CTGCTGGAGC CAGAAGAACA GCCCAGCCCC AGGTGGGAAG GAGGCAGAAA CTCGGCAGCC 180
TGTTGGTATT CTYTTGGGCT GGGGTGGCTG CAAGGACAAG AACCTTGCCA AGTACAGTGC 240
CATCTACCAC AAAAGGGGCT GCATCGTAAT CCGATACACA GCCCGTGGC ACATGGTCTT 300
CTTCTCCGAG TCACTGGGTA TCCCTTCACT TCGTGTMTTG GCCCAGAAGC TGCTCGAGCT 360
GCTCTTTGAT TATGAGATTG AGAAGGAGCC CCTGCTCTTC CATGTCTTCA GCAACGGTGG 420
CGTCATGCTG TACCGCTACG TGCTGGAGCT CCTGCAGACC CGTCGCTTCT GCCGCTGCG 480
TGTGGTGGGC ACCATCTTTG ACAGCGCTCC TGGTGACAGC AACCTGGTAG GGGCTCTGCG 540
GGCCCTGGCA GCCATCCTGG AGCGCCGGGC CGCCATGCTG CGCCTGTTGC TGCTGGTGGC 600
CTTTGCCCTG GTGGTCGTCC TGTTCACGT CCTGCTTGCT CCCATCACAG CCNICTTCCA 660
CACCCACTTC TATGACAGGC TACAGGACGC GGGCTCTGCG TGGCCGAGC TCTACCTCTA 720
CTCGAGGGCT GACGAAGTAG TCCTGGCCAG AGACATAGAA CGCATGGTGG AGGCACGCCT 780
GGCACGCCGG GTCTGGGCG GTTCTGTGGA TTTGCTGTCA TCTGCACAG TCAGCCACCT 840
CCGTGACTAC CCTACTTACT ACACAAGCCT CTGTGTGAC TTCATGGCA ACTGGGTCCG 900
CTGCTGAGGC CATGTCTCCA TCTACCTCT GCTCCAGAAA TAAATGCCTG ACACCTCCCC 960
50 ACAAAAAAAAA AAAAAAAAAA ACTCGAGGGG GGGCCCGTA CCCAATTCGC CCTATAAAGG 1020
T 1021

55

(2) INFORMATION FOR SEQ ID NO: 146:

60

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1285 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146:

	GGCAGGAGGA GGGCCACGGC AGCCATGCGG CTTTGCAAGT CCGTCTCCTG GTGTACGGCC	60
	AACGCCAAGT AGGGGATTGC GTTCCCTCCA GTCGCAGACC CTATCAGATT TGGATATGTC	120
10	CTTCATATTT GATTGGATT ACAGTGGTTT CAGCAGTGTG CTACAGTTTT TAGGATTATA	180
	TAAGAAACT GGTAACTGG TATTTCTTGG ATTGGATAAT GCAGGAAAA CAACATTGCT	240
15	ACACATGCTA AAAGATGACA GACTTGGACA ACATGTCCCA ACATTACATC CCACTTCCGA	300
	AGAACTGACC ATTGCTGGCA TGACGTTTAC AACTTTTGAT CTGGGTGGAC ATGTTCAAGC	360
	TCGAAGAGTG TGGAAAACT ACCTTCTGTC TATCAATGGC ATGTATTTT TGGTGGATTG	420
20	TGCAGACCAC GAAAGGCTGT TAGAGTCAAA AGAAGAACTT GATTCACTAA TGACAGATGA	480
	AACCATTGCT AATGTGCCTA TACTGATTCT TGGGAATAAG ATCGACAGAC CTGAAGCCAT	540
25	CAGTGAAGAG AGGTTCGGAG AGATGTTTGG TTTATATGGT CAGACAACAG GAAAGGGGAG	600
	TATATCTCTG AAAGAACTGA ATGCCCGACC CTTAGAAGTT TTCATGTGTA GTGTGCTCAA	660
	AAGACAAGGT TACGGAGAAG GCTTCCGCTG GATGGCACAG TACATTGATT AACACAACT	720
30	CACATTGGTT CCAGGTCTCA ACGTTCAGGC TTAATCAGAG ATTTGATTGC TCAACATGCA	780
	TAACTTGAAT TCAATAGACT TTGCTGGTT ATAAAACAGA TGTTTTTTAG ATTATTAATA	840
35	TTAAATCAAC TTAATTTGAA TGAGAATTGA AAAGTATTC AAGTAAGTTT GAGTATCACA	900
	AATGTTAGCTT TCTAATTCCA TAAAAGTACT TGGTTTTTAC AGTTTATAAT CTGACATCAC	960
	CCCAGCGCCA TTTGTAAAGA GCAACTTTCC AGCAGTACAT TTGAAGCACT TTTTAAACAAC	1020
40	ATGAAACTAT AAACCATATT TAAAAGCTCA TCATGTTAAA TTTTTTATGT ACTTTTCTGG	1080
	AACTAGTTTT TAAATTTTAG ATTATATGTC CACCTATCRT AAGTGACAG TTAATAATTA	1140
45	GCTTATCAA TGATGCAATG ATGCCTTACA GTTTCAATA ACTTTTTTTC TTATGCAAAC	1200
	GTCATGCAAT AAAACAACT CTAATGTTTG GCAAAAAAAA AAAAAAAA NTCGAGGGGG	1260
50	GGCCCGTACC CAATTCGCCC TAAAG	1285

55 (2) INFORMATION FOR SEQ ID NO: 147:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1386 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
60 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 147:

5	GGCAGGAGGT GCGCAGGGG TCAGTGGTTC TCTCGGGTCT CGGGACAGGT GAGCACCTG	60
	ATGAAGGCCA CGGTCTGAT GCGGCACCTG GCGGGGTGCA GGAGATCGTG GCGCCCTCC	120
	GCAAGGGCGS CGGAGACCGG TTACAGGTGA TTTCTGATTT TRACATGACC TTGAGCAGGT	180
10	TTGCATATAA TGGAAAGCGA TGCCCTTCTT CTTACAATAT TCTGGATAAT AGCAAGATCA	240
	TCAGTGAGGA GTGTGCGAAA GAGCTCACAG CGCTCCTTCA CCACTATTAC CCAATTGAGA	300
	TGACCCACA CCGGACCGTC AAGGAGAAGC TACCTCATAT GGTGGAATGG TGGACCAAAG	360
15	CGCACAACTT CCTATGTCAG CAGAAGATTC AGAAGTTTCA GATAGCCCAG GTGGTTAGAG	420
	AGTCCAATGC AATGCTCAGG GAGGGATATA AGACCTTCTT CAACACACTC TACCATAACA	480
20	ACATTCCCCT TTTCACTTTT TCTGCGGGCA TTGGTGATAT CCTGGAAGAA ATTATCGAC	540
	AGATGAAAGT GTTCCACCCC AACATCCACA TCGTGTCTAA CTACATGGAT TTTAATGAAG	600
	ATGGTTTCTT CCAGGGATTT AAGGGCCAGC TGATACACAC ATACAACAAG AACAGCTCTG	660
25	TGTGTAGAA CTSTGGTTAC TTCCAGCAAC TTGAGGGCAA AACCAATGTC ATCCTGCTGG	720
	GAGACTCTAT CGGGGACCTC ACCATGGCCG ATGGGGTTCC TGGTGTGAG AACATTCTCA	780
30	AAATTGGCTT CCTGAATGAC AAGGTGGAGG AGCGGCGGGA NCGCTACATG GACTCCTATG	840
	ACATCGTGCT GGAGAAGGAC GAGACTCTGG ATGTGGTCAA CGGGCTACTG CAGCACATCC	900
	TGTGCCAGGG GGTCCAGCTG GAGATGCAAG GCGGCTGAAG GCGCAGGCTN CCAGNCCGCC	960
35	TGCAGGCCGT GGTGAGGAGG GCGCCCTCCC CAGAGTCTGC TCCCCCGTGA ACACAGAGCA	1020
	GANGCCAGGG TGGCCAGCAG TGGCTGGGTC CTTCCGCGCC CTTCCGTCCT CCTTTCCCTG	1080
40	AGCACCTTCA TCACCAGAGG CTTGAAGGAA CCCCGCCATG TGGCAGGGCA CAGGCACTGT	1140
	TCCTGGTGAA CCTTGGACCA CAGCATGTCA GTGCTCTAGG GATTGTCTAC TCCAGGGATT	1200
	TTCTTCAAAA TTTTAAACA TGGGAAGTTC AAACAAATAT AATGTGTGAA ACAGATCAAA	1260
45	ATTTTAAAAA TGAAAAAAA GCTGCTCTGA TTCAGGGGAT GTGGGTCCGG GTAGAACCTG	1320
	GACCTCTTGG CCTGGGGGCA CATGGGATGC TTCTAGGAAC ACAGTTTGAG AACCACCAAA	1380
50	AAAAAA	1386

55 (2) INFORMATION FOR SEQ ID NO: 148:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2098 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

60

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 148:

5	AGCCCTTCTC CCCGCGCTTG GGACTCTGAC ATCTTAAGGC TGCACGGTCG TGTCCTTGTC	60
	TGGGTGAGGC CATGTCTGTG ATCCAAGGTT CCTGGAAGTG ACACAGGAAG GGGCTGTGAA	120
	CCCTAAGTGG GTGTMATCTC CTCRACCGA GGCTTCTMAC CCTGGAGATG GCAGTTACTC	180
10	CTGGCCATGG TTGCTGAGCA TGGGCAGACC AGTGGAGGCC ACCCTACTGT GTTATCTGCG	240
	CCTTCRATGA AGTGAGACCC TTGGGGAGAA CGGGCTGTGG ATGAAGGAGT GGACTGCAGC	300
15	CTTGGCCTAG CCACTGGGCT GGGATCTTCT GGGTCATGTG ACTGTGTATC CAGGAGCAGA	360
	AACTTGTAAT CTCAGGATTC AGGATCTACC CAGCACCAAA GATGTATTTT CAGGAGAACA	420
	GACCTAGAAA TGGGCCTGTC TGCCATTTCA GAGTCAGGCA AAGCAGGCAG GGCCAGGGAG	480
20	CTTCTGTGGG TCTACACAAG AAGGTTCCTG TGAGGGCTAT CAGTTGTTGC CTCTAGCTT	540
	GCTGGTAACT TTGGCGCCTC CGCCAAGCCC TGCCAGACTC CCTGGCTGT GATGGCATTC	600
25	TGTGCCATCC TGCCCTGTCC CCAGCCTCTG CAGGATGCCC TCCCTACCCA MCTYTYCCTG	660
	GGCCTTCCTT GTCCACTGGG CTGGATTTCAT GTTCAAACCA CTGGACTGGC AGGGCAACGA	720
	CTTCTTCCCA CCTCAAGATG AGGTCCCTCG CCCCTTGTCT TGGCATAAAA ACACCTTTAA	780
30	AGCATGAGCC ATGTGCTTCT TTGCCCTTCT CTGTCTGTGT CCAATCTTCT GCCTCCCACT	840
	CACTCCCTGG GGACTATGGG ATCACTGTCC CCCCACCTGT GTGGCCACAC CATGTGTCTT	900
35	GTCAATCCAG AACTGCCTCT GAGCTCCAGG CTGACCACAG ATCAGCCACA GCCTGATGCC	960
	TGCAGCCCCA CTTTGCTCAC CCTTCCCTC CCTTCTCTT TCCTTCCACA CAGCAAGCCT	1020
	ACCTTTTCTC ATCCATGCTC ACCATAGCCC CCTTCTTGT GACCTGGACC CTCCATTGTA	1080
40	CCTGGCTGAG ACTGTACAGC TCCTGGAGGA GTGGGTCCA CCTTCTTCTT GCCCTATGCA	1140
	GTGCAAGCTT CACTTCTCAC CCAGCAAGGT TGACTCATCT GCCTCCATGT CTCTGGGGCT	1200
45	TTGCTGTTCG CCTGAAACCT AGCTGGGCTG GTCTTGCTCC CAGCTTGCTT CCCCTCCTC	1260
	GGATGTCCCT TTGCAGGCC CTGTGCTCC TCCGGCACCA GTGTCTTGG CTGCCATGGC	1320
	AAGCTCATCA GGGCTTTGTA CCTGGTCAC CAAGCATGGT AGCAGCTGCC TGCAATGTAT	1380
50	CTCCATCTGG TCACTGCAGG TGCCAACCTT TCATCCCCCA TGTTTTCCTG GGCCATGGAG	1440
	GGCTGACCTC CGTTTCTGGG GAATGTGGCT GAGCTGTGGT AACCAGCTAC ACCCCAGGTG	1500
55	CTCTTTCCAT GGTGGTGCCT GCTCATCTTG CTGATGCAA CTAGGAAGTT AGGCTGCATC	1560
	TCCGAGTGGC TTTCGCTGGA GAGGTGCTTT GCTGTCTCTC AGACTCAGTC ACTGTGTTC	1620
60	CTCCCCGCTT CTCTTATCTC CATGGCTGTT TGCAGCTCTC CCAGGTACTT TGGGGTCTGA	1680

GCTGGAATTC CTTTGTGGTT TGCTCTTCTG CTTCTCACTC TTGTATTAAG AAGGATTCCA 1740
 CAAAGGGAGA GTGGCATCCC TGCTGCTGCT GTGCCAGACC AGAGTTTCTT GAGGGGCCCT 1800
 5 GACCCTAACC CTCCAGCTCA GCCCTGTACA CCTGACCCCTG TAAATGAGTG GGGTTTGCTG 1860
 ACTGTAATCC CTGACACCAG TAAACCAAAA AGGACTCTTG GGGGCTCAGT GTGAGAGCCA 1920
 GGGTTACCTA CTCTGCCAAG TGAGGACAAA CTGCTAGGCT GTATCCCATATA ATTTTCAGGAT 1980
 10 GAGAAACATT AACATAAAAA ATTTGTAGTA AACATAACCT CATGANGACT AAAAAAAAAA 2040
 AAAAACTYGG GGGGGGGCCC GTAACCCATT GGGCCCTTNG GGGGGGNGTT TTAAAATT 2098

15

(2) INFORMATION FOR SEQ ID NO: 149:

20

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1847 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149:

TCGACCCACG CGTCCGAAGT GAGGCGGCGG CGGGAGCCCG TTGGKGTCTG GTCITCGCGT 60
 30 CGGCCCCCGG GACCAGACGC TGCCCCCGGC GCGGGGAGAA GATGGTGCKK AGCGGCTCG 120
 GGGCCGCCAC GGGCCGCCAC GAGTGAGCCC AGCGGACCG CGGGCGTCCG CCGAGCAGCT 180
 GGGCCGGCTG GGGCCGGGCG GCGCANTGCC CGCCGGGGCG GGTGGAGCT GATCAGAATA 240
 35 ATGTTTACGA TCAACCCCTT GGAGAACCTG AAGGTGTACA TCAGCAGTCG GCCTCCCTTG 300
 GTGGTCTTCA TGATCAGCGT AANGCCCATG GCCATAGCTT TCCTGACCTT GGGCTACTTC 360
 40 TTCAAATCA AGGAGATTAA ATCCCCAGAA ATGGCAGAGG ATTGGAATAC TTTTCTGCTA 420
 CGGTTCATG ATTTGGACTT GTGTGTATCA GAGAATGAAA CCTCAAGCA TCTCAGAAC 480
 GACACCACAA CTCCGGAAAG TACAATGACC AGCGGGCAGG CCGGAGCTTC CACCCAGTCC 540
 45 CCCCAGGCCC TGGAGGACTC GGGCCCGGTG AATATCTCAG TCTCAATCAC CCTAACCTG 600
 GACCCACTGA AACCCCTTCG AGGTATTTCC CGCAACGTCA CCCATCTGTA CTCAACCATC 660
 50 TTAGGGCATC AGATTGGACT TTCAGGCAGG GAAGCCACG AGGAGATAAA CATCACCTTC 720
 ACCCTGCCTA CAGCGTGAGG CTCAGATGAC TGCGCCCTCC ACGGTCACTG TGAGCAGGTG 780
 GTATTTCAGC CTGCAATGAC CCTCAGGCC AGCCCTGGGG TGTCCCCGT CACTGTACAG 840
 55 CCACCGCACT GTGTTCTTGA CACGTACAGC AACGCCACG TCTGGTACAA GATCTTCACA 900
 ACTGCCAGAG ATGCCAACAC AAAATACGCC CAAGATTACA ATCCTTTCTG GTGTTATAAG 960
 60 GGGCCCATG GAAAAGTCTA TCATGCTTTA AATCCCAAGC TTACAGTGAT TGTTCAGAT 1020

5 GATGACCGTT CATTAAATAAA TTGTCATCTC ATGCACACCA GTTACTTCCT CTTTGTGATG 1080
 GTGATAACAA TGTMTTGCTA TGCTGTTATC AAGGGCAGAC CTAGCAAATT GCGTCAGAGC 1140
 AATCCTGAAT TTGTCCCGA GAAGGTGGCT TTGGCTGAAG CCTAATTCCA CAGCTCCTTG 1200
 TTTTTTGAGA GAGACTGAGA GAACCATAAT CCTTGCCCTGC TGAACCCAGC CTGGGCCTGG 1260
 10 ATGCTCTGTG AATACATTAT CTTCGGATGT TGGGTTATTC CAGCCAAAGA CATTTCAAGT 1320
 GCCTGTAAC TATTGTGACA TATTTATAAA AATCTATTCA GAAATTGGTC CAATAATGCA 1380
 CGTGCTTTGC CCTGGGTACA GCCAGAGCCC TTCAACCCCA CCTTGGACTT GAGGACCTAC 1440
 15 CTGATGGGAC GTTTCACCGT GTCTCTAGAG AAGGATTCCT GGATCTAGCT GGTACAGACG 1500
 ATGTTTTCAC CAAGGTCACA GGAGCATTGC GTGCTGATG GGGTTGAAGT TTGGTTTGGT 1560
 20 TCTTGTTTCA GCCCAATATG TAGAGAACAT TTGAAACAGT CTGCACCTTT GATACGGTAT 1620
 TGCATTTCCA AAGCCACCAA TCCATTTTGT GGATTTTATG TGTCTGTGGC TTAATAATCA 1680
 TAGTAACAAC AATAATACCT TTTTCTCCAT TTGCTTGCA GGAAACATAC CTTAAGTTTT 1740
 25 TTTTGTTTTG TTTTGTTTT TTTGTTTTT GTTTTCCTTT ATGAAGAAAA AATAAATAG 1800
 TCACATTTTA ATACTACCAA AAAATGGACA AAAAAAGTCG AGGGGGG 1847

30

(2) INFORMATION FOR SEQ ID NO: 150:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1569 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 150:

GACGCTGACG AGAGAAGGCC TCTTCCTTGA GGGTTGGTGC TGTGTTGCAG TGACCGTGGC 60
 45 GGATTACGCC AACTCGGATC CGGCGTCTGT GAGGTCTGGA CGAGTCAAGA AAGCCGTAGC 120
 CAACGCTGTT CAGCAGGAAG TAAATCTCTT TTGTGGCTTG GAAGCCTCTC AGGTTCTTGC 180
 50 AGAGGAAGCT CTTTCTGGGG CTGGTGAGCC CTGTGACATC ATCGACAGCA GTGATGAGAT 240
 GGATGCCCGAG GAGGAAAGCA TCCATGAGAG AACTGTCTCC AGAAAAAGA AAAGCAAGAG 300
 ACACAAAGAA GAACTGGACG GGGCTGGAGG AGAAGAGTAT CCCATGGATA TTTGGCTATT 360
 55 GCTGGCCTCC TATATCCGTC CTGAGGACAT TGTGAATTTT TCCCTGATTT GTAAGAATGC 420
 CTGGACTGTC ACTTGCACCTG CTGCCTTTTC GACCAGGTTG TACCGAAGCA CTACACGCTG 480
 60 GATGCTTCCC TGCCTTTTCG TCTGCGACCA GAGTCAATGG AGAAGCTGCG CTGTCTCCGG 540

	GCTTGTGTGA TCCGATCTCT GTACCATAATG TATGAGCCAT TTGCTGCTCG AATCTCCAAG	600
	AATCCAGCCA TTCCAGAAAG CACCCCCAGC ACATTAAAGA ATTCCAAATG CTTACTTTTC	660
5	TGGTCAGAA AGATTGTTGG GAACAGACAG GAACCAATGT GGAATTCAA CTTCAAGTTC	720
	AAAAACAGT CCCCTAGGTT AAAGAGCAAG TGTACAGGAG GATTGCAGCC TCCCCTTCAG	780
10	TACGAAGATG TTCATACCAA TCCAGACCAG GACTGCTGCC TACTGCAGGT CACCACCTC	840
	AATTTCATCT TTATTCCGAT TGTATGGGA ATGATATTTA CTCGTTTTAC TATCAATGTG	900
	AGCACGGACA TCGGCATCA TCGAGTGAGA CTGGTGTTC AAGATTCCCC TGTCCATGGT	960
15	GGTCGAAAC TCGCAGTGA ACAGGCTGTG CAAGTCATCC TGGACCCAGT GCACAGCGTT	1020
	CGGCTCTTTG ACTGGTGGCA TCCTCAGTAC CCATTCTCCC TGAGAGCGTA GTTACTGCTT	1080
20	CCCATCCCTT GGGGCGAGC TCGAGTGTAG TCCATTAGTA ATCAGATTCC AGTTTGGACA	1140
	GGGTGGCTGG ATTGTATATC TCGTTAGTAA TGTACATGCT CTTCAAGTTC TAGGGCTCCT	1200
	GTTAGGGGAG GGAGAAATGT TGAATCAAGA GGGAAAACAA CTACTATGAT TTATAACAT	1260
25	ATTTTAATGT AAAAATTGTC ATTTAAAAGG AGTGGCCCTG TTTTCTGTGT TAAAACCCCA	1320
	TTTGGTGCTA TTGAGTTTGT TCTTTATCT TTTATCCCAG TGAAAATGT TGATCTTGCT	1380
30	GTAGGGAAAA ATTAACTCT TTGAATCTCC AAACAAGGAA GTTTCAGCAT TCCCTTATGG	1440
	ATCAGAGGAA CCTTAGAGGC CTGAAATGT TGCTTCCAGT TTAGCTGCCC CTCAAATTCA	1500
	AGTGAATATT TTCCCTTCTC CCTTTACCCT TCTCCAGAAA TAAAGCAGGT GACAGGGTTT	1560
35	CAGAATCTT	1569

40 (2) INFORMATION FOR SEQ ID NO: 151:

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 1540 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 151:

50	CCCACGCGTC CGGAAGGATT GACCAGTTAA CCAACATCTT AGCCCCCATG GCTGTTGGCC	60
	AGATTATGAC ATTTGGCTCC CCAGTCATCG GCTGTGGCTT TATTTCCGGA TGGAAGTTGG	120
55	TATCCATGTG CGTGGAGTAC GTCTGCTCT GGAAGTTTA CCAGAAAACC CCAGCTCTAG	180
	CTGTGAAAGC TGGTCTTAA GAAGAGGAAA CTGAATTGAA ACAGCTGAAT TTACACAAAG	240
	ATACTGAGCC AAAACCCCTG GAGGGAATC ATCTAATGGG TGTGAAAGAC TCTAACATCC	300
60	ATGAGCTTGA ACATGAGCAA GAGCCTACTT GTGCTTCCCA GATGGCTGAG CCTTCCGTA	360

5 CCTTCCGAGA TGGATGGGTC TCCTACTACA ACCAGCCTGT GTTCTGGCT GGCATGGGTC 420
TTGCTTTTCCT TTATATGACT GTCCTGGGCT TTGACTGCAT CACCACAGGG TACGCCTACA 480
CTCAGGGACT GAGTGGGTTT CATCTCAGT ATTTTGATGG GAGCATCAGC TATAACTGGA 540
ATAATGGGAA CTGTAGCTTT TACTTGGCTA CGTCGAAAAT GTGGTTTGGT TCGGCAGGTC 600
10 TGATCTCAGG ATTGGCACAG CTTTCTGTG TGATCTGTG TGTGATCTCT GTATTCATGC 660
CTGGAAGCCC CCTGGACTTG TCCGTTTCTC CTTTGAAGA TATCCGATCA AGGTTTCATT 720
AAGGAGAGTC AATTACACCT ACCAAGATAC CTGAAATTAC AACTGAAATA TACATGTCTA 780
15 ATGGGTCTAA TTCTGCTAAT ATTGTCCCGG AGACAAGTCC TGAATCTGTG CCCATAATCT 840
CTGTCAGTCT GCTGTTTGCA GGCCTCATG CTGCTAGAAT CGGTCTTTGG TCCTTTGATT 900
20 TAACTGTGAC ACAGTTGCTG CAAGAAAATG TAATTGAATC TGAAAGAGGC ATTATAAATG 960
GTGTACAGAA CTCCATGAAC TATCTCTTG ATCTTCTGCA TTTTCATCATG GTCATCCTGG 1020
CTCCAAATCC TGAAGCTTTT GGCTTGCTCG TATTGATTTT AGTCTCCTTT GTGGCAATGG 1080
25 GCCACATTAT GTATTTCCGA TTTGCCCAAA ATACTCTGGG AAACAAGCTC TTTGCTTGGC 1140
GTCTGATGC AAAAGAAGTT AGGAAGGAAA ATCAAGCAA TACATCTGTT GTTTGAGACA 1200
30 GTTTAACTGT TGCTATCCTG TTACTAGATT ATATAGAGCA CATGTGCTTA TTTTGTACTG 1260
CAGAATTCCA ATAAATGGCT GGGTGTTTTG CTCTGTTTTT ACCACAGCTG TCCCTTGAGA 1320
ACTAAAAGCT GTTTAGGAAA CCTAAGTCAG CAGAAATTAA CTGGATTAAAT TTCCCTTATG 1380
35 TTGAGGGCCA TGGRAAAAAA ATTGGGAAAA GGAAAACTC AGTTTAAAT ACGGGAGACT 1440
ATAATGGATA ACACTGRAIT CCCCTATTTC TCATGAGTAG ATACAATCTT ACGTAAAAGA 1500
40 GTGGTTAGTC ACGTGAATTC AGTTATCAAT TGACAGATTC 1540

45 (2) INFORMATION FOR SEQ ID NO: 152:

(i) SEQUENCE CHARACTERISTICS:
50 (A) LENGTH: 1719 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 152:

55 TACTTATGAG GTCAATTGGA AATAAGAACA CCATTTTACT GGGTCTAGGA TTTCAAATAT 60
TACAGTTGGC ATGGTATGGC TTTGGTTCAG AACCTTGGAT GATGTGGGCT GCTGGGGCAG 120
60 TAGCAGCCAT GTCTAGCATC ACCTTTCTGT CTGTCAGTGC ACTTGTTTCA CGAACTGCTG 180

	ATGCTGATCA ACAGGGTGTG GTTCAAGGAA TGATAACAGG AATTCGAGGA TTATGCAATG	240
	GTCTGGGACC GGCCTCTAT GGATTCATTT TCTACATATT CCATGTGGAA CTTAAAGAAC	300
5	TGCCAATAAC AGGAACAGAC TTGGGAACAA ACACAAGCCC TCAGCACCAC TTTGAACAGA	360
	ATTCCATCAT CCTTGGCCTT CCTTCCTAT TTGGAGCCTG TTCAGTACTG CTGGCTCTGC	420
10	TTGTTCCTTT GTTTATTCGG GAACATACCA ATTTAAGCTT AAGGTCCAGC AGTTGGAGAA	480
	AGCACTGTGG CAGTCACAGC CATCCTCATA ATACACAAGC GCCAGGAGAG GCCAAAGAAC	540
	CTTTACTCCA GGACACAAAT GTGTGACGAC TGAATCAGG AAGATTTTTC TATCAGCACC	600
15	CAGGCTTAG TTTTCAOCTC TAGTCTGGA TGTACATTCC ATTTCCATCC ACAGTGTACT	660
	TTAAGATTGT CTTAAGAAAT GTATCTGCAT GAACTCOGTG GGAECTAAAG GAAGTGGGAA	720
20	CTTAGAACCA GACAGTTTTC CAAAGATGTT ACAATTTCTT TTGAAAAACC TTTTGTATTAT	780
	TAGCACCAAT TTCTYGCCAC TAAGCTATTT GTTTTATTAT ACATCCTTTA ATTAAAACT	840
	ATATATGTAA CTCTTAGAT ATTAGCAAAT GTCTCTGCTA CCATTTCTCTT AAGGTGTGA	900
25	GCTTTAATC TATGCTGACT CAGTGAGACA CAGTAGGTAG TATGGTTGTG GACCTATTTG	960
	TTTTAACATT GTAAAATTTT GAGTCAGATT TTAATATTGT AAAATCTTGG GTCAAATAAT	1020
30	TCAAAGCCTT AATGCAGATG CACTAAAACA AAGAAATGGT AAATGAATTG TTTGCATTTA	1080
	AAAAAAAAAA CTCTTAAGAA AACTGTACTA AATCTGAATC ATGTTTTGAG CTTGTTTGCA	1140
	GTACTTTTAA ACATTATTCA CTACTGTTTT TGAAGTGAGA AAGTATCAGC CATTTAGCAT	1200
35	TTAAGTTGGG GTATTTAGAG CCTGTAATCT AAATGCTGGC TCAAATTTAT TCCCCAGCTA	1260
	CTTCTTATAC CACTATTCTT TTAATGTTTG CATAATCATA AGCACCTCAA CACTTGAATA	1320
40	CATAATCTAA AAATTATATA GTAAAGCTGG TAGCCTTGAA AATGTCAGTG TGATATCTAT	1380
	TATGTAGATA AATATATATA GTGGCCTTTC AGGACTGTCA CAGTAACACT TTATTTACAG	1440
	AGCTAATGTT TGTCCTAAAT TTTCAGGACC CTAGAGGAGA GCTTTATACA ATTACCGATG	1500
45	TGAATTTCTC TAAAGTGTAT ATTTTGTGT CCAGTTATAT TATTTAAAAA AGTGTACTT	1560
	TGTAAAAATT GTATATAAAG AACTGTATAG TTTACACTGT TTTTCATCTG TGTGTGGTTA	1620
50	TTGCTTAATG CTTTTTAAAC TTGGAACACT CACTATGGTT AATAAGGTC TTAAAGAAA	1680
	TGTAAATATT YGTTAATAA AGTTAAATAT TTTAATGAT	1719

55

(2) INFORMATION FOR SEQ ID NO: 153:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 863 base pairs

(B) TYPE: nucleic acid

60

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 153:

5
 GCCACGAGGG AAGCCGGGAC GATGTCCGCA TGACAACCGA CGTTGGAGTT TGGAGGTGCT 60
 TGCCTTAGAG CAAGGGAAAC AGCTCTCATT CAAAGGAAGT AGAAGCCTCT CCCTCAGTGG 120
 10 TAGGGAGACA GCCAGGAGCG GTTTCCTGGG AACTGTGGGA TGTGCCCTTG GGGGCCCAG 180
 AAAACAGAAG GAAGATGCTC CAGACCACTA ACTACAGCCT GGTGCTCTCT CTGCAGTTCC 240
 TGCTGTGTC CTATGACCTC TTTGTCAATT CCTTCTCAGA ACTGCTCAA AAGACTCCTG 300
 15 TCATCCAGCT TGTGCTCTTC ATCATCCAGG ATATTGCAGT CCTCTTCAAC ATCATCATCA 360
 TTTCTCTCAT GTTCTTCAAC ACCTTCGTCT TCCAGGCTGG CCTGGTCAAC CTCCTATTCC 420
 20 ATAAGTTCAA AGGACCATC ATCCTGACAG CTGTGTACTT TGCCCTCAGC ATCTCCCTTC 480
 ATGTCTGGGT CATGAACCTA CGCTGGAAAA ACTCCAACAG CTTCATATGG ACAGATGGAC 540
 TTCAAATGCT GTTTGTATTC CAGAGACTAG CAGCAGTGTG TACTGCTAC TTCTATAAAC 600
 25 GGACAGCCGT AAGACTAGGC GATCCTCACT TCTACCAGGA CTCTTTGTGG CTGCGCAAGG 660
 AGTTCATGCA AGTTCGAAGG TGACCTCTTG TCACACTGAT GGATACTTTT CCTTCCTGGA 720
 30 TAGRAGGCCA CATTTGCTGC TTTGCAGGGG AGAGTTGGGC CCTATGCATG GGGCAAAACA 780
 GGTGGGATTT TCCAAGGGAA GGGTTCAGAA TTAGGCNTGT TGTTTCAGCC ATTTCCAAGG 840
 AAGGGGAAGG GTTCCCTTNC CCT 863
 35

(2) INFORMATION FOR SEQ ID NO: 154:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1101 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

45

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154:

50 AACAGCAAAA AAGAATGATT TCTTCTGAAA TTGTGGAACA TGAGGATTCA AGTTTTTATT 60
 TTGTACTAG GTGCTGGAGG AACATCCAG TTCACAAAGC CCCCATCTCT TCCTCTGGAG 120
 CCAGAGCCTG CGGTGAATC AAGTCCAAGT GAAACATCAG AACAAATAAG AGAGAAATAA 180
 55 GAATAGAATG AATGACCCCA AAATARGGTT TTCTTGGGCG AGGATGTGCT GGATTAGGAA 240
 AGGTGACATG ACACAGGCAG AGCAGAGTGG CACCCACCAC AGAATACAGT GTGTGTTATT 300
 ACCAGGAGCC AGCAGTTGAG CCTAAGGTCC TTCTACCTAC CTGGTATTGG CATTTGAGGT 360
 60

	CGGAAACCCCT CTAAGCCCC ATAAGCCAGG AAAAGTGAAA AGAGAACACA GTTCCTTTTAA	420
	GAAGTGGCAG CAAGGCTTGA GGCCTTATGT ATGTAGCTGA GTCAGCAAGG TACATGATGC	480
5	TGTCCTGCTT CAAAAGGACT TTTCTCTCCT AGCTGACTGA CTCCTTCCTT AGTTCAAGGA	540
	ACAGCTGAGA CAGACCTCTG CTGAGTAGCT CTGTGATGAC AAAGCCTTGG TTAACTGAG	600
	GTGATCCTCA GGTGTGAGG TTTATTAGTC CCCAAGGCAA ACACAAATAT TAGATTAAATA	660
10	ATCCAACCTT AATAGTATAC ATTAAAAAGA AAAAAAACAA AAGCCCTGGA AGTTTGAGGC	720
	CAAGCCTGCT GAGTATTGCA GCTGCATTG CCCAAGGGA ATCCAGAACA AGTCCCTCCC	780
15	TGTATTTTGT TCTTGAGAGG GGTCACTCTA GAAGCTAGAT CCTATCAGGA TGAGGAGCAG	840
	CAGCCAGGG CTGTCTGGA TCAGCACCA CGATTTTAAA GAAAAAGGA AGAGTTCTT	900
	AGATGAGTAA TTGTTATTGA AGATAGTCAG TGATAACCAC TGACCAGATG CTATCAATAC	960
20	ACTATGTGTC CTTTTAGAA TAAAGATTAC ATATCATCAT TCCTTTGGGG AAAATGTGA	1020
	TTCAAGTATA AAAACAAGAG ATTATAATAA AAAANTAAAA GAACCCTAAA AAAAAAAAC	1080
25	CTGTGCGCA ATTCCCTGCA G	1101

30 (2) INFORMATION FOR SEQ ID NO: 155:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 2031 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 155:

40	CAATTAACCC GTTTGAGGCC TAGGTGTTT GGCAAGCCCC NGGCCTAAAG TTTTAATTCG	60
	GCAGAGCCAA GGGCTGAAA GGAAGGGAAA GGGGAGGTA GCGGAGGGT AGCAGGTGAG	120
	TTCTAGGGC TGAAGGTTT AGCAGCAGCC TGGTGAGTG CCTGTGATC AAGACAAACC	180
45	CACGGTCTC CTGGGTGCTT ACCAAGCTTG GTTTGTACAA AAGCAAGGTG GGAGTCTATT	240
	TTTGATACG AGATACATCA CACTTACCTG TGGGCCAGTA TTGTGAAGTG AGTCTGAGTT	300
50	GTTTACACTG ATGCCTTCCC TGCCACCAC AAATGTGTGA CATAGTCTTC AGAATGATAC	360
	CACCCCTTTC CCCAGCTCCC AACCAAGAGC TGGTTCTAGG CCTGTGTTAT ATGTCATATT	420
	TAGCGTTTTT ATATATGACC TTGATTCTT GTTGTGTGTA TTTAGCACA GTGTATGCAC	480
55	CTTCATTAA ATACATCTGT GTGCATACAG ATACGCATAT ATGTGTGTGC GTATGCATAT	540
	ATCTCTCATC TGTAGTTTCC AAGAGTTCAG CTGAAGCAGA TGGAGTCTG CAGCCAGGA	600
60	GACACCTGTC ATCCTGCTA ATAGTGTTG CCACAAGTAT TAGTGAGTCT TCCTTATTAA	660

TATTTTCATT TCAGAAGACT GAAGCAAAGC TGATAGTGT TGCTGTTTCT TTGGCAGCTA 720
5 AGTGAGGGTC TTGGGATGAC TTGCTGTGTT CCTCAAGCTG CACTTTGGGG CCATCTCTGC 780
AGTATTAAGC CCCCTTTTGT CTGGGTGGTA CTCTGTCTGT GCTGTGTGT GTGTGTGATA 840
GTCACTCTTG CATGGCTTCC ATGTCTGGTT TGIGGCATT GGGGATAAGT GCTGAACCAG 900
10 AGCATTTGCA GTTTGTTTGA GGCCTCGTTG CCAATGATAG ATCACTCCTG TTGACCTGGT 960
ATGTCTGCTT GCTTGTGCT TTTCCTTGCT TTCTCTTGA AGAGGAAAGG ACTCTGGTCA 1020
GGCCCAGGCT GAGTGAGATG AGCTGCAGCT GGCTCATGGC CTCTTAGAG CAGAGAGAGG 1080
15 AGTATGTCAT TTTACTAAGT TCCTAAACAA ACATTTATGC AGGCAACACT CCTTGCAGAT 1140
CCAGAACTG AGGCACAATA GGGTTATGAC TTGCTCAAGA ATATGTAGCT GCTAGGGGGT 1200
20 AAATCAAGGC ATCACAATT CTGTTCAAGC GGCAGGAATA GGCTGTGAAT TGCTAGCACT 1260
TTTTTTTAA GCAATTACTT TTGACTTGT TCCTCTGAAA GTGCAAGAGG CGTACACCTT 1320
TCCCAAATGT AGACTAGAAT CTGCAGGATG CCACCCACTG TATAGTTCTG CTTTCCAGA 1380
25 GAGGAAGAAC TTTTAGAAAC CAAATGATCT TAATTGTTAT TGCCACCCC TGGCTTTTCC 1440
GGGTAGAAAA TTCACAGTAG GAATGATTGT TAAGAGAGAG TGCTTGGAAC CATGGGTTAA 1500
30 CAGGAAAGGC TACCTAACTT CACATATCTG CAACCAGAGC AGCCACCAAG CATTACTTAG 1560
CAGCAGGAAA ATGATTGTAT TTGAGTTCCT GTGTGTCCAA AACTGAGGCA CCATGTTCTT 1620
TGAAAACATG CCACCTCAAG GCTGGGCGCG GTGGCTCACA CCTGTTAATC CCAGCACTTT 1680
35 GGGAGGCCGA GCGGGCGGA TCACCGGAGT CGGGGAGTTT GAGACCAGCC TGGACCAACA 1740
TGGGAGAAAC CCCATCTCTA CCTAAAAATA CAAAATTAGC CGGGCGTGGT GGCATGCGCC 1800
40 TATAATCTCA GCTACTTGGG AGGGYTGAGG CAGGRGAATT GCTTGAACCC RGGANGGCGG 1860
AGGTTTGCGG TTGAGTTGAG GATCGTGCCA TTGCACTTCC GGGCCTTGGG GCAACAACAG 1920
CAAAAAYTCC GTCTTCAAMW MRTGCCGAAT TCGATATCAA GCTTATCGAT ACCGTGACC 1980
45 TCGAGGGGGG GCGCGGTACC CAATCGCCC TATAGNATC GTATTACAAT C 2031

50

(2) INFORMATION FOR SEQ ID NO: 156:

(i) SEQUENCE CHARACTERISTICS:

55

- (A) LENGTH: 1981 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 156:

	CCTGCACCCCT GAGCCCTTCA CCCCTCCGAG TTCCCCCAG GTTGGCTTCC TTCGATTCTCT	60
	TTTCTTGGTA TCAACGTTTG ATTGGAAGAA CAACCCCTC TTTGTCAACC TCAATAATGA	120
5	GCTCACTGTG GAGGAGCAGC TCGGGCACAG CTCMCCGTYA TGGTCATTGT TACCCCCCAA	180
	GACCGCAAAA ACTCTGTGTG GACACAGGAT GGACCCCTCAG CCCAGATCCT GCAGCAGCTT	240
10	GTGGTCTTGG CAGCTGAAGC CCTGCCCATG TTAGAGAAGC AGCTCATGGA TCCCCGGGGA	300
	CCTGGGGACA TCAGGACAGT GTTCCGGCCG CCCTTGGACA TTTACGACGT GCTGATTCCG	360
	CTGTYTCTC GCCATATCCC GGGGCACCGC AGGCTTGTGG ACTGCCAGY TGCTCTCTC	420
15	TGCCGGGGCC TGCTCAGCCA GCCGGGGCCC TCATCCCTGA TGCCCGTGCT GGGTNATGAT	480
	CCTNCTCAGC TCTATCTGAC GCAGCTCAGG GAGGCCCTTG GGGATCTGGC CCTTTTCTTC	540
20	TATGACCAGC ATGGTGGAGA GGTGATTGGT GTCTCTGGA AGCCACCAG CTTCAGCCG	600
	CAGCCCTTCA AGGCCTCCAG CACAAAGGG CGCATGGTGA TGTCTCGAGG TGGGGAGCTA	660
	GTAATGGTGC CCAATGTTGA AGCAATCTG GAGGACTTTG CTGTGCTGGG TGAAGGCCTG	720
25	GTGCAGACTG TGGAGGCCCG AAGTGAGAGG TGGACTGTGT GATCCAGCT CTGGAGCAAG	780
	CTGTAGACGG ACAGCAGGAC ATTGGACCTC TAGAGCAAGA TGTCAGTAGG ATGACCTCCA	840
30	CCCTCCTTGG ACATGAATCC TCCATGGAGG GCCTGCTGGC TGAACATGCT GAATCATCTC	900
	CAACAAAACC CAGCCCCAAC TTTCTCTCTG ATGCTCCAGC ATTGGGGCAG GGGCATGGTG	960
	GCCCCATGTAG TCTCCTGGG CTCACCATCC CAGAAGAGGA GTGGGAGCCA GCTCAGAGAA	1020
35	GGAAGTGAAC CCAGGAGATC CATCCACCTA TTAGCCCTGG GCCTGGACCT CCCTGCGATT	1080
	TCCCACTCCT TTCTTAGTCT TCTTCCAGAA ACAGAGAAGG GGATGTGTGC CTGGGAGAGG	1140
40	CTCTGTCTCC TTCTGCTGC CAGGACCTGT GCCTAGACTT AGCATGCCCT TCACTGCAGT	1200
	GTCAGGCCCT TAGATGGGAC CCAGCGAAAA TGTGGCCCTT CTGAGTCACA TCACCGACAC	1260
	TGAGCAGTGG AAAGGGGCTA TATGTGTATG AATAGACCAC ATTGAAGGAG CACAATGCCC	1320
45	TCCTGTGTG ATGCCACTTC CCAGGGTGA GACAGTGA AAGAACCAG GACAGGAAAG	1380
	GATTGGGTAG GTGAAGGGGT CAGGGGACTG GTAGTCACCC AATCTTGGAG AGGTGCAAAA	1440
50	AGCACTGGG GCTACCCGTT AGCTGCATCT GCCCTGGCTG TTTGCCCGTT CATGTCACAA	1500
	ACTGCCACTA CTATGTACCT GCAGTGGGT TGCAGAGATG GGGGAGACTC AAGTCTTACT	1560
	CCCCAGGAGC TCCAGGGCC CAAGGAGGAG AATGCTGCCT CCTTTCAGTC TGGTCTACAC	1620
55	CCACTTCTG GTAGCCTCTC TGCTTCTGT AATCTGGCT GTTTTCCAG ACTCAGCTCA	1680
	AATAGTCCC CTCTTAAGC CCATCCCTCG CCCCCAGCCT GAGGTGATCT TTCCCTCTC	1740
60	TGAACATTA GAGCAGTTAC TGTCTGTCA GTTGTGTTGG CAGGCACACA CAGTGGCATA	1800

AATTCTATTG TTTGAACTC TGATTAAAA TTAAATTGCA GCTGGGGGTG GTGGCTCATG 1860
CTTGTAATCC CAACACTTAG GGAGTMAGGR GAATCACTTG ASCYCAGGAG TYCTAGACCA 1920
5 ATCTGGGCAA MAGAGAGACC CCATCTCTTT TAAATAAAAA GTTAAATTGC TTAAAAAAA 1980
A 1981

10

(2) INFORMATION FOR SEQ ID NO: 157:

(i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 915 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 157:

GAATTCGGCA CGAGCGCGGC CATGGCGCTC CTGCTTTCCG TGCTGCGTGT ACTGCTGGGC 60
GGCTTCTTCG CGCTCGTGGG GTTGGCCAAG CTCCTGGAGG AGATCTCGGC TCCAGTTTCG 120
25 GAGCGGATGA ATGCCCTGTT CGTGCAGTTT GCTGAGGTGT TCCCGCTGAA GGTATTGGC 180
TACCAGCCAG ATCCCTGAA CTACCAAATA GCTGTGGGCT TTCTGGAAGT GCTGGCTGGG 240
30 TTGCTGCTGG TCATGGGCC ACCGATGCTG CAAGAGATCA GTAACTTGT CTGATTTCTG 300
CTCATGATGG GGGCTATCTT CACCTTGCA GCTCTGAAAG AGTCACTAAG CACCTGTATC 360
CCAGCCATG TCTGCCTGGG GTTCTGCTG CTGCTGAATG TCGGCCAGCT CTTAGCCAG 420
35 ACTAAGAAGG TGGTCAGACC CACTAGGAAG AAGACTCTAA GTACATTCAA GGAATCCTGG 480
AAGTAGAGCA TCTCTGTCTC TTTATGCCAT GCAGCTGTCA CAGCAGGAAC ATGGTAGAAC 540
40 ACAGAGTCTA TCATCTTGT ACCAGTATAA TATCCAGGT CAGCCAGTGT TGAAAGAGAC 600
ATTTTGTCTA CCTGGCACTG CTTTCTCTTT TTAGCTTTAC TACTCTTTTG TGAGGAGTAC 660
ATGTTATGCA TATTAACATT CCTCATGTCA TATGAAAATA CAAAATAAGC AGAAAAGAAA 720
45 TTAAATCAA CCAAAATTCT GATGCCCAA ATAACCACTT TTAATGCCTT GGTGTAAGTA 780
TACCTCTGAA CTTTTTCTG TGCCTTTAAA CAGATATATA TTTTTTTTAA ATGAAAATAA 840
50 AACCATATAT CCTATTTTAT TTCTCCTTT TAAACCTTA TAACTATAA MAAAAAAA 900
AAAAAAA CTCGA 915

55

(2) INFORMATION FOR SEQ ID NO: 158:

(i) SEQUENCE CHARACTERISTICS:
60 (A) LENGTH: 2117 base pairs

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

5	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 158:	
	AGAGCGAAGC GAGGGTGGCG CGGGTCCGGG CATGAAGCTG GGCCGGGGCCG TGCTGGGCCCT	60
	GCTGCTGCTG GCGCCGTCCG TGGTGCAGGC GGTGGAGCCC ATCAGCCTGG GACTGGCCCT	120
10	GGCCGGCGTC CTCACGGCT ACATCTACCC GGTCTCTAC TGCTCTTCG CCGAGTGCTG	180
	CGGCAGAAG CGGAGCCTTA GCCGGGAGGC ACTGCAGAAG GATCTGGACG ACAACCTCTT	240
15	TGGACAGCAT CTTGCAAAGA AAATCATCTT AAATGCCGTG TTTGGTTTCA TAAACAACCC	300
	AAAGCCCAAG AAACCTCTCA CGCTCTCCCT GCACGGGTGG ACAGGCACCG GCAAAAATT	360
	CGTCAGCAAG ATCATCGCAG AGAATATTTA CGAGGGTGGT CTGAACAGTG ACTATGTCCA	420
20	CCTGTTTG TGCCACATTG ACCTTCCACA TGCTTCAAAC ATCACCTTGT ACAAGGATCA	480
	GTTACAGTTG TGGATTGAG GCAACGTGAG TGCCGTGCG AGGTCCATCT TCATATTTGA	540
25	TGAAATGGAT AAGATGCATG CAGGCCTCAT AGATGCCATC AAGCCTTTCC TCGACTATTA	600
	TGACCTGGTG GATGGGTCT CCTACCAGAA AGCCATGTTT ATATTTCTCA GCAATGCTGG	660
	AGCAGAAAGG ATCAGAGATG TGCTTTGGA TTTCTGGAGG AGTGGAAAGC AGAGGAAGA	720
30	CATCAAGCTC AAAGACATTG AACACGCGTT GTCTGTGTCG GTTTTCAATA ACAAGAACAG	780
	TGGCTTCTGG CACAGCAGCT TAATTGACCG GAACCTCATT GATTATTTTG TTCCCTTCCT	840
35	CCCCCTGGAA TACAAACACC TAAAAATGTG TATCCGAGTG GAAATGCAGT CCCGAGGCTA	900
	TGAAATGAT GAAGACATTG TAAGCAGAGT GGCTGAGGAG ATGACATTTT TCCCCAAGA	960
	GGAGAGAGTT TTCTCAGATA AAGGCTGCAA AACGGTGTTC ACCAAGTTAG ATTATTACTA	1020
40	CGATGATTGA CAGTCATGAT TGGCAGCCGG AGTCACTGCC TGGAGTTGGA AAAGAAACAA	1080
	CACTCAGTCC TTCCACACTT CCACCCOCAG CTCCTTTCCC TGAAGAGGA ATCCAGTGAA	1140
45	TGTTCCGTGT TGATGTGACA GGAATTCTCC CTGGCATTGT TTCCACCCC TGGTGCCTGC	1200
	AGGCCACCCA GGGACCACGG GCGAGGACGT GAAGCCTCCC GAACACGCAC AGAAGGAAGG	1260
	AGCCAGCTCC CAGCCCACTC ATCGCAGGGC TCATGATTTT TTACAAATTA TGTTTTAATT	1320
50	CCAAGTGT TTCTTTCAAG GAAGGATGAA TAAGTTTAT TGAAATGTG GTAACCTTAT	1380
	TTAAATGAT TTTTAACATT ATGAGAGACT GCTCAGATTC TAAGTTGTTG GCCTTGTTG	1440
55	TGTTTTTTTT TTTAAGTTCT CATCAATTAT ACATAGACTG TGATGTATCT TTAAGTGAAA	1500
	TGAGCCCAAG CACACATGCA TGGCATTTGT TCCACAGGAG GGATCCCTG GGGATGTGGC	1560
60	TGGAGCATGA GCCAGCTCTG TCCAGGATG GTCCAGCGG ATGCTGCCAG GGGCARTGAA	1620

GTGTTTAGGT GAAGGACAAG TAGGTAAGAG GACGCCTTCA GGCACCACAG ATAAGCCTGA 1680
 AACAGCCTCT CCAAGGGTTT TCACCTTAGC AACAAATGGGA GCTGTGGGAG TGATTTTGGC 1740
 5 CACACTGTCA ACATTTGTTA GAACCACTCT TTTGAAAGAA AAGTATTTCC AACTTGTAC 1800
 TTGCCAGTCA CTCGGTTTGG CAAAAGGTGG CCCTTCACTG TCCATTCCAA ATAGCCCACA 1860
 CGTGCTCTCT GCTGGATTCT AAATTATGTG AATTTTGCCA TATTAAATCT TCCTCATTTA 1920
 10 TACTATTATT TGTTACGTTT AATCAGAATC CCCGAAACCT CCTATAAAGC TTAGCTGCCC 1980
 CTTCTGAGGA TGCTGAGAAC GGTGTCTTTC TTTATAAATG CAAATGGCTA CCGTTTAC 2040
 15 ATAAATTTT GCATGTGCAA AAAAAAAAAA ANAAAAAAAA AAAATCCCGG GGGGGGGCCG 2100
 GTAACCAATT TGNCCCC 2117

20

(2) INFORMATION FOR SEQ ID NO: 159:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2395 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 159:

TGTTCCTTAA TCCTTTTCT AAAAAGGGG GAAATCCGG ATGGATTTTA GGGATTGGTC 60
 TGGTGTGAGC TGTGTTTAT TGCACACCTA AATCCTGATT ATAGGCTTTT CATTTCTCCG 120
 35 CAAAGCCTTT ATTTTGGCAG TTAAGCCAAA TGTGTTTCC AGAAAGTTAG TTATTTTCTC 180
 CTCCTTCTTT CCTTCTTTC CTCCTTTTTC CCCGCTGAC CCCAAACGTT ATTGTCCAAA 240
 40 CATGACTGGA CAGCAGCTTT TGTTCCTTGA CCCTGTAATA TGACAGTCTG CTAATATTGA 300
 CAGAAGGTGC AGTTTTTGGG TTATAGTCGT GATTTTGGCT AATCAATCAT ATTAGCAGGA 360
 AAAAAAAGA CTGTTTCTG TTGTACTTGA GTCTTAAGAA AAAGTGGCCC ATAGTTTAGT 420
 45 GGACAATTTC CAAAGGCTTT AGTACCACCT GTATTTCAAA ATGGGGGACC CAAACTCCCG 480
 GAAGAAACAA GCTCTGAACA GACTACGTGC TCAGCTTAGA AAGAAAAAAG AATCTCTAGC 540
 50 TGACCAAGTT GACTTCAAGA TGTATATTGC CTTTGTATT AAGGAGAAGA AGAAAAAGTC 600
 AGCACTTTT GAAGTGCTG AGGTATATAC AGTCATGACA AATAATTATG AAGAAAATAT 660
 CCTGAAAGGT GTGCGAGATT CCAGCTATTC CTGGGAAAGT TCCCTAGAGC TTTTACAGAA 720
 55 GGATGTGGTA CAGCTCCATG CTCCTCGATA TCAGTCTATG AGAAGGGATG TAATTGGCTG 780
 TACTCAGGAG ATGGATTCA TTCTTGGCC TCGGAATGAT ATTGAAAAAA TCGTCTGTCT 840
 60 CCTGTTTCT AGGTGGAAG AATCTGATGA GCCTTTTAGG CTTGTTTCAAG CAAATTGAG 900

	TTTCATCATG GTGACTATGA AAAACAGTTT CTGCATGTAC TGAGCCGCAA GGACAAGACT	960
5	GGATCGTTG TCAACAATCC TAACCACTCA GTGTTTCTCT TCATTGACAG ACAGCACTTG	1020
	CAGACTCCAA AAAACAAAGC TACAATCTTC AAGTTATGCA GCATCTGCCT CTACCTGCCA	1080
	CAGGAACAGC TCACCCACTG GGGCAGTTGG CACCATAGAG GRTCAOCTCC GTCCTTATAT	1140
10	GCCAGAGTAG AGTACTGACC AGCAAAATGG AGAAGATCAG AGAATGCAGC AGCAGTTTTT	1200
	TTTCTGTGTT TCTTACCACT TTATTCTTTC AGAGTTTAAA GAAAATGGAC TCATGCACAG	1260
15	AACACTATGC ATTTTGAAAC TTGTTCAATC TGGATTTTTT TAAATCAITTT TTATCTCAGA	1320
	ACTTAAACAA AAATTAGATG TCGTGCACGG ACTGTGTGAA AGAAGATGCT TTGCATATTT	1380
	GCTGCACTGC ATCAGTATCT TACTAAAAAT GTGAAATGAA AGGACTATIG TACACTGAAA	1440
20	TGCTTAAATG TATCTGAAAG CACAAGGTGA TACTCATTTT TATGGTCTTC CCATTTGTGC	1500
	TGGTTTTTGC CTCTTTGACA TCTGTCAATC GTATTTTAGAG GGTGAGAAGT GAATGTAACA	1560
25	GGTATAAATA ACATTTTAA AAACAATAAC TTGCTATAA TCACAGTTGT TCCAGAGCAC	1620
	TGTCAGATAC ATTCTAATGA CCAGAACTGG TTTAAAAAAA GAAAATACAA CCATGGGAAA	1680
	GAAATCTTAA ATGAAAAACG CATCTCAITG TAGGCATTTT TGCCTCATAT TTTACTGGGC	1740
30	CATGTTTGTT TCCTGGTACT CATGTATTTT TTTTTCCAG ATCTCTTTCC CCAAGTTGCT	1800
	ATTGTAAGAG TATTCTGCTG CGTGTGGATG CAGTTATACA CATTAAGCA GATCTGGAGT	1860
35	CTGAAGTAGC TATAAAGCAG CTATAAACA GAAATACATG CATAGCTGCA GAAACCATGA	1920
	TAGGTAGAGG ACTTTTCTTT TGGTTTGTGTT TTGTTTGTGTT TTGTTTGTGTT TTTGGTTTAA	1980
	CAGAGAAGAG ATTTTATTAA CAAAGAAAAA AATTCCAGTG AATTGTGCAG AAATGCTGGT	2040
40	TTTTACACCA TCCTAAAGAA AAACCTTACA AGGGTGTGTT GGAGTAGAAA AAAGTTTATA	2100
	AAGTTGGAAT CTAAATTGT AAAATTAACC ATTGAGTGTC AAAGTTCTAA AAGCAGAACT	2160
45	CATTTGTGTC AATGAACATA AGGAAAGACT ACTGTATAGG TTTTTTTTTT TTCTCCTTTT	2220
	AAATGAAGAA AAGCTTTGCT TAAGGGTGC ATACTTTTAT TGGAGTAAAT CTGAATGATC	2280
	CTACTCCTTT GGAGTAAAC TAGTGCTTAC CAGTTTCCAA TTGTATTTAG CTTCTGGTTG	2340
50	GAATTTGAAA AAAAAAGAAA AAAAGAAAAA GAAAACCTAA ATAAAATAGG TGAAA	2395

55 (2) INFORMATION FOR SEQ ID NO: 160:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2120 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

60

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160:

5	CCCCGGATAC CGCCTGACGT AGTGCCAATC ACACCTCTCG CGTCTCGGCG CCTCGGAGGC	60
	TAATGAGGAC GCCTGGCGAA ACGCAGTAAC GGATTTCCGG GTGGACCTTC GCTTTAOGGC	120
10	TGCTGAGTTC TTCCGCCCAA CCCAGAGGAA GCGGGAGAGC AGTTTACGAC AGCGCCGGTC	180
	GTGTTTACGG CGGCGCCGCG TGCGCGCGCA TGTTCCTCTT TTCTCTGGTT TCTCAAGAGT	240
	GCTGCTGCTA ACGCGGTCCC CGGCACGCAC CATCTGTTGC CATCCCGGCC GGCCGAGGCA	300
15	TTGCAGATTT TGGAAGATGG CAAAGTTTCAT GACACCCGTG ATCCAGGACA ACCCCTCAGG	360
	CTGGGGTCCC TGTGCGGTTT CCGAGCAGTT TCGGGATATG CCCTACCAGC CGTTCAGCAA	420
20	AGGAGATCGG CTAGGAAAGG TTGCAGACTG GACAGGAGCC ACATACCAAG ATAAGAGGTA	480
	CACAAATAAG TACTCTCTCT AGTTTGGTGG TGGAAGTCAA TATGCTTATT TCCATGAGGA	540
	GGATGAAAGT AGCTTCCAGC TGGTGGATAC AGCGCGCACA CAGAAGACGG CCTACCAGCG	600
25	GAATCGAATG AGATTTGCCC AGAGGAACCT CCGCAGAGAC AAAGATCGTC GGAACATGTT	660
	GCAGTTCAAC CTGCAGATCC TGCTTAAGAG TGCCAAACAG AAAGAGAGAG AACGCATTGC	720
30	ACTGCAGAAA AAGTTCCAGA AACAATTGGG GGTTAGGCAG AAATGGGATC AGAAATCACA	780
	GAAACCCCGA GACTCTTCAG TTGAAGTTCG TAGTGATTGG GAAGTGAAAG AGGAAATGGA	840
	TTTCTCTCAG TTGATGAAGA TGGCTACTTT GGAAGTATCA GAGCCACAGG ACATTGAGTG	900
35	TTGTGGGGCC CTAGAATACT ACGACAAAGC CTTTGACCGC ATCACCACGA GGAGTGAGAA	960
	GCCACTGCGG ASATNCAAGC GCATCTTCCA CACTGTCACC ACCACAGACG ACCCTGTCAT	1020
40	CCGCAAGCTG GCAAAAATC AGGGGAATGT GTTTGCCACT GATGCCATCC TGGCCACGCT	1080
	GATGAGCTGT ACCCGCTCAG TGTATTCTCG GGATATTGTC GTCCAGAGAG TTGGGTCCAA	1140
	ACTCTTCTTT GACAAGAGAG ACAACTCTGA CTTTGACCTC CTGACAGTGA GTGAGACTGC	1200
45	CAATGAGCCC CCTCAAGATG AAGGTAATTC CTTCAATTCA CCCCAGCAACC TGGCCATGGA	1260
	GGCAACCTAC ATCAACCACA ATTCTCTCCA GCAGTGCTTG AGAATGGGGA AGGAAAGATA	1320
50	CAACTTCCCC AACCCAAACC CGTTTGTTGA GGACGACATG GATAAGAATG AAATCGCCTC	1380
	TGTTGCGTAC CGTTACCGCA GTGGNAAGCT TGGAGATGAT ATTGACCTTA TTGTCCGTTG	1440
	TGAGCACCAT GCGTTCATGA CTGGAGCCAA CGGGGAAGTG TCCTTCATCA ACATCAAGAC	1500
55	ACTCAATGAG TGGGATTCCA GGCAGTGTAA TGGCGTTGAC TGGCGTCAGA AGCTGGACTC	1560
	TCAGCGAGGG GCTGTCAATT CCACGGAGCT GAAGAACAAC AGCTACAAGT TGGCCCGGTG	1620
60	GACCTGCTGT GCTTTGCTGG CTGGATCTGA GTACCTCAAG CTGGTTATG TGTCTCGGTA	1680

CCACGTGAAA GACTCCTCAC GCCACGTCAT CCTAGGCACC CAGCAGTTCA AGCCTAATGA 1740
 GTTTGCCAGC CAGATCAACC TGAGCGTGGA GAATGCCTGG GGCATTTTAC GCTGCGTCAT 1800
 5 TGACATCTGC ATGAAGCTGG AGGAGGGCAA ATACCTCATC CTCAGGACC CCAACAAGCA 1860
 GGTATCCGT GTCTACAGCC TCCCTGATGG CACCTTCAGC TCTGATGAAG ATGAGGAGGA 1920
 AGAGGAGGAG GAAGAAGAGG AAGAAGAAGA GGAAGAACT TAAACCAAGTG ATGTGGAGCT 1980
 10 GGAGTTGTG CTTCACCGA GACTACGAGG GCCTTTGATG CTTAGTGGAA TGTGTGCTA 2040
 ACTTGCTCTC TGACATTTAG CAGATGAAAT AAAATATATA TCTGTTTAGT CTTAAAAAAA 2100
 15 AAAAAAAAAA AAAAAAAAAAN 2120

20 (2) INFORMATION FOR SEQ ID NO: 161:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 900 base pairs

(B) TYPE: nucleic acid

25 (C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 161:

30 GGAAGCTGAA GTCCTTCCAG ACCAGGGACA ACCAGGGCAT TCTCTATGAA GCTGCACCCA 60
 CCTCCACCTT CACCTGTAC TACGACCAC AGAAGCAAAA GTTCTCACTC AAAGTGGATG 120
 CCAAGGATGG GCGCTGTTC AATGAGCAGA ACTTCTTCCA GCGGGCCGCC AAGCCTCTGC 180
 35 AAGTCAACAA GTGAAGAAG CTGTACTCGA CCCCACTGCT GGCCATCCCT ACCTGCATGG 240
 GTTTGGTGTG TCACCAGGAC AAATACAGGT TCTTGGTGTG ACCCAGCCTG GGGAGGAGCC 300
 40 TTCAGTGGC CCTGGATGTC AGCCCAAAGC ATGTGCTGTG CAGAGAGGTC TGTGCTGCAG 360
 GTGGCTGCC GGCTGCTGGA TGCCCTGGAG TTCCTCCATG AGAATGAGTA TGTTCATGGA 420
 AATGTGACAG CTGAAAATAT CTTGTGGAT CCAGAGGACC AGAGTCAGGT GACTTTGGCA 480
 45 GGCTATGGCT TCGCTTCCG CTATTGCCA AGTGCCAAAC ACGTGGCCTA CGTGAAGGC 540
 AGCAGGAGCC CTCACGAGG GGACCTTGAG TTCATTAGCA TGGACCTGCA CAAGGGATGC 600
 50 GGGCCCTCCC GCGCGCGCA CTCCAGAGC CTGGGCTACT GCATGCTGAA GTGGCTCTAC 660
 GGGTTTCTGC CATGGACAAA TTGCCTTCCC AAMAMTGAG ACATCATGAA GCAAAAACAG 720
 AAGTTTGTG ATAAGCCGGG GCCCTTCGTG GGACCCTGCG GTCACCTGGAT CAGGCCCTCA 780
 55 GAGACCTGCG AGAAGTACCT GAAGGTGGTG ATGGCCCTCA CGTATGAGGA GAAGCCGCC 840
 TACGCCATGC TGAGGAACAA CTTAGAAGCT TTGCTGCAGG ATCTGCGTGT GTCTCCATAT 900

60

(2) INFORMATION FOR SEQ ID NO: 162:

5

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1003 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 162:

GGCACGAGAT GAGGGGCACC CAGTGCTTCT AGGGCAGGCT GGGTGGTGGT CCCCTAGGTA 60
15 TCAGCCTCTC TTA CTGTACT CTCCGGGAAT GTTAACCTTT CTATTTTCAG CCTGTGCCAC 120
CTGTCTAGGC AAGCTGGCTT CCCCATTTGGC CCTGTGGGT CCACAGCAGC GTGGCTGCCC 180
20 CCCAGGGCCA CCGCTTCTTT CTGTATCCTC TTTCCTTAAC AGTGACTTGG GCTTGAGTCT 240
GGCAAGGAAC CTGTCTTTTA GCTTCACCAC CAAGGAGAGA GGTGACATG ACCTCCCCGC 300
CCCCTACCA AGGCTGGGAA CAGAGGGGAT GTGGTGAGAG CCAGGTTCTT CTGGCCCTCT 360
25 CCAGGGTGTT TTCCACTAGT CACTACTGTC TTCTCCTTGT AGCTAATCAA TCAATATTCT 420
TCCCTTGCTT GTGGGCAGTG GAGAGGCTGC TGGGTGTACG CTGCACCTGC CCACTGAGTT 480
GGGAAAGAG GATAATCAGT GAGCACTGTT CTGCTCAGAG CTCCTGATCT ACCCCACCCC 540
30 CTAGGATCCA GGA CTGGGTC AAAGCTGCAT GAAACCAGGC CCTGGCAGCA AACCTGGGAA 600
TGGCTGGAGG TGGGAGAGAA CCTGAACCTC TCTTTCCCTC TCCCTCCTCC AACATTACTG 660
35 GAACTCTATC CTGTTAGGAT CTTCTGAGCT TGTTCCTCTG CTGGGTGGGA CAGAGGACAA 720
AGGAGAAGGG AGGGTCTAGA AGAGGCAGCC CTTCTTTGTC CTCTGGGGTA AATGAGCTTG 780
ACCTAGAGTA AATGGAGAGA CCAAAAGCCT CTGATTTTTA ATTTCCATAA AATGTTAGAA 840
40 GTATATATAT ACATATATAT ATTCTTTTAA ATTTTGTAGT CTTTGATATG TCTAAAAATC 900
CATTCCTCTT GCCCTGAAGC CTGAGTGAGA CACATGAAGA AAAGTGTGTT TCATTTAAG 960
45 ATGTTAATTA AATGATTGAA ACTTGAAAAA AAAAAAAAAA AAA 1003

50

(2) INFORMATION FOR SEQ ID NO: 163:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2196 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163:

60 AAGAAGCGGC ACACGGATGT GCAGTTCTAC ACAGAAGTGG GAGAGATAAC CACGGACTTG 60

	GGGAAACATC AGCATATGCA TGACCGAGAT GACCTCTATG CTGAGCAGAT GGAACGAGAA	120
5	ATGAGGCACA AACTGAAAAC AGCCTTTAAA AATTTTCATTG AGAAAGTAGA GGCTCTAACT	180
	AAGGAGGAAC TGGAAATTGA AGTGCCCTTTT AGGGACTTGG GATTTAACGG AGCTCCCTAT	240
	AGGAGTACCT GCCTCCTTCA GCCCCTAGT AGTGCGCTGG TAAATGCTAC GGAATGGCCA	300
10	CCTTTTGTGG TGACATGGGA TGAGGTAGAG CTGATCCACT TTRAGCGGGT CCAGTTTCAC	360
	CTGAAGAACT TTGATATGGT AATCGTCTAC AAGGACTACA GCAAGAAAGT GACCATGATC	420
15	AACGCCATTG CTGTAGCCTC TCTTGACCCC ATCAAGGAAT GGTGAATTG CTGCGACCTG	480
	AAATACACAG AAGGAGTACA GTCCCTCAAC TGGACTAAAA TCATGAAGAC CATTTGTGAT	540
	GACCTTGAGG GCTTCTTCGA ACAAGGTGGC TGGTCTTTCC TGGAGCCTGA GGGTGAGGGG	600
20	AGTGATGCTG AAGAAGGGGA TTCAGAGTCT GAAATTGAAG ATGAGACTTT TAATCCTTCA	660
	GAAGATGACT ATGAAGAGGA AGAGGAGGAC AGTGATGAAG ATTATTTCATC AGAAGCAGAA	720
25	GAGTCAGACT ATTCTAAGGA GTCATTGGGT AGTGAAGAAG AGAGTGGAAG GGATTGGGAT	780
	GAAGTGAGG AAGAAGCCCG AAAAGCGGAC CGAGAAAGTC GTTACGAGGA AGAAGAAGAA	840
	CAAAGTCGAA GTATGAGCCG GAAGAGGAAG GCATCTGTGC ACAGTTGGGG CCGTGGCTCT	900
30	AACCGTGGTT CCAGACACAG CTCTGCACCC CCCAAGAAAA AGAGGAAGTA ACTTCTGAAC	960
	TTTGGCCCTG AGCTCCATTG TTCTCCAGC CAACCCCTGA AAATTTTACA TGACATAGAA	1020
35	ACTGTATTTT TCCTTTCTGT TTCAATTGAA GTTTTGCCAT TTGTGTTTAT GGGTTTAGGG	1080
	GGCCATTGTG GTGGACCAAT CFACTCGGG AATTCCAGG CCACCAGGAC ACGTGCCAAT	1140
	GGCCCATTC AGATGGCAAG GGAGGAGGTG TTCTTGAAGA CAGGAGGAGG CTCCCGCTGT	1200
40	TAATAAATAT TGTTTTCATC TTCTCTCTC CTGTACCTT CTGCCAAGAC ATTGATGGCT	1260
	TCGACATCT TATTGTGGT CTCAAAGCTG TATTCCAAG ACAGTGGTAC AAGGTGACCC	1320
45	TTAATTACCC GTATCATGGT TCTTGACCAG CACATTCAAT CCTCCAACCT ACCCTACTGC	1380
	CATGACCTTC CGCACATCTC TAAGTTTAT CTTTGCAATA CTCAAGGTTT TCGGAAATTT	1440
	GCTAATGGTT GTGATAAACC ATACAGCTTG AGCCAGTGAG GCAGATTGGG CTGGTGCCCT	1500
50	CGTCTGAGTT TTCTGCTTT CCTGCCTCGT GCAGATTCTG AGGTATATCT GCTGCCTTGG	1560
	AAGACATAAG AAGCAGTGAT ACTCCCTGGC TCGGTTATTT TCTCCATACA ATGCACACAT	1620
55	GGTACAATGA TAGAAGGCAA AATTGCCACT GTCTTCTTTT TTTTCTCATA TATCTAAGGA	1680
	AGATATATCA GGTGTGCTT CATGTACCGC TTCTAGTGAA ATGTAGAGGA AGGCTCAAAG	1740
	GAGTCAACAT TTAGATCTGG AAGGGACAAG TCATGCCTTG GGCCTAGAAT ACCCTGATGA	1800
60	GAAAAGAGAA GAGGAAGGGA GGCCATATCT ACAACANCAN CCTCTGGCA CTGCTGCTCC	1860

TTATTTTAAC TTGTCTTGC ATTGTCCTGT ATTTATCACA GTTCTGTGTG AACAGCTTTT 1920
 CAAGTATTTG GGGAGTTTAT CTTGCCATCC TCCCTTCTG GTTCTCTGCA CCCACCTGTC 1980
 5 CCACTGCAGT TCCTCCGTG CTCGTGACT TTAAGAGAAG AAGGGGGAG GGTCCCGGA 2040
 TTTTATGTTT GTTGTTTTTT TCTCCTTAGC AGTAGGACTT GATATTTTCA ATTTTGGAAG 2100
 10 AACTAAAAGA TGAATAAACT GGGTTTTTTT TGTGTGTGT TTTGTAAAA AAAAAAAAAA 2160
 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAA 2196

15

(2) INFORMATION FOR SEQ ID NO: 164:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1945 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 164:

GCACAGAGTC GGGCGGACGG ACAGGGAGAG GAGGAGAGGG GGTCTGCGCG CGGCCGCTAC 60
 CCAGAAGCCA GCGGACGGCA GCACGGAGTG GGCTGTCCCC GAGCCAGCC CCGAGCGAGC 120
 30 CCCCCCCCCG CCCCCGAGG ACGGCCTTC CAGCCAGCCC GACTYCTAGG AGGAGGGGAG 180
 GCGGGAAGC AGCTCAAGCC TCACCCACCG CCCTGCCCCC AGCCCCGCCA CTCCCAGGCT 240
 35 CCTCGGGACT CGGGGGTCC TCCTGGGAGT CTCGGAGGGG ACCGGCTGTG CAGACGCCAT 300
 GGAGTTGGTG CTGCTCTTCC TCTGCAGCCT GCTGGCCCCC ATGGTCTCTG CCAGTGCAGC 360
 TGAAAAGGAG AAGGAAATGG ACCCTTTTCA TTATGATTAC CAGACCCCTGA GGATTGGGGG 420
 40 ACTGGTGTTC GCTGTGGTCC TCTCTCGGT TGGGATCCTC CTTATCTTAA GTCGCAGGTG 480
 CAAGTGCAGT TTCAATCAGA AGCCCCGGGC CCCAGGAGAT GAGGAAGCCC AGGTGGAGAA 540
 45 CCTCATCACC GCCAATGCAA CAGAGCCCCA GAAAGCAGAG AACTGAAGTG CAGCCATCAG 600
 GTGGAAGCCT CTGGAACCTG AGGGGGCTGC TTGAACCTTT GGATGCAAAT GTCGATGCTT 660
 AAGAAAACCG GCACTTCAG CAACAGCCCT TTCCCCAGGA GAAGCCAAGA ACTTGTGTGT 720
 50 CCCCCACCTT ATCCCTCTA ACACCATTC TCCACCTGAT GATGCAACTA AACTTGCCTT 780
 CCCCAGTCCA GCCTGCGGTC CTGCCCACCT CCCGTGATGT GTGTGTGTGT GTGTGTGTGT 840
 55 GTGACTGTGT GTGTTTGCTA ACTGTGGTCT TTGTGGCTAC TTGTTGTGTG ATGGTATGT 900
 GTTTGTTAGT GAACTGTGGA CTCGCTTTC CAGGCAGGGG CTGAGCCACA TGGCCATCTG 960
 CTCCTCCCTG CCCCCGTGGC CCTCCATCAC CTCTGCTCC TAGGAGGCTG CTTGTTGCCC 1020
 60

	GAGACCAGCC CCTCCCCCTG ATTTAGGGAT GCGTAGGGTA AGAGCACGGG CAGTGGTCTT	1080
	CAGTCGTCTT GGGACCTGGG AAGGTTTGCA GCACCTTTGTC ATCATTTCTC ATGGACTCCT	1140
5	TTCACTCCTT TAACAAAAAC CTTCCTTCCT TATCCACCT GATCCAGTC TGAAGTCTC	1200
	TTAGCAACTG GAGATACAAA GCAAGGAGCT GGTGAGCCCA GCGTTGACGT CAGGCAGGCT	1260
10	ATGCCCTTCC GTGGTTAATT TCTTCCAGG GGCTTCCACG AGGAGTCCC ATCTGCCCG	1320
	CCCCCTCACA GAGCGCCCGG GGATTCCAGG CCCAGGGCTT CTACTCTGCC CCTGGGGAAT	1380
	GTGTCCCCTG CATATCTTCT CAGCAATAAC TCCATGGGCT CTGGGACCCT ACCCCTTCCA	1440
15	ACCTTCCCCTG CTCTGAGAC TTCAATCTAC AGCCAGCTC ATCCAGATC AGACTACAGT	1500
	CCCTGCAATT GGGTCTCTGG CAGGCAATAG TTGAAGGACT CCTGTTCCGT TGGGGCCAGC	1560
20	ACACCGGGAT GGATGGAGGG AGAGCAGAGG CCTTTGCTTC TCTGCCTACG TCCCCTTAGA	1620
	TGGGCAGCAG AGGCAACTCC CGCATCCTTT GCTCTGCCTG TCRGTGGTCA GAGCGGTGAG	1680
	CGAGGTGGGT TGGAGACTCA GCAGGCTCCG TGCAGCCCTT GGAACAGTG AGAGGTGAA	1740
25	GGTCATAACG AGAGTGGGAA CTCAACCCAG ATCCCGCCCC TCCTGTCTC TGTGTTCCCG	1800
	CGGAAACCAA CCAAACCGTG CGCTGTGACC CATGTCTGTT CTCTGTATCG TGATCTATCC	1860
30	TCAACAACAA CAGAAAAAG GAATAAATA TCCTTTGTTT CCTAGTGAAA AAAAAAAAAA	1920
	AAAAAAAAA AAAAAAAAAA CTCGA	1945

35

(2) INFORMATION FOR SEQ ID NO: 165:

(i) SEQUENCE CHARACTERISTICS:

40

- (A) LENGTH: 2933 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 165:

45

	GGGTGACCC ACGGTCCGG CAGCCGTGCT TTGAGTGTGT GCTGCCGCTG CCCCCTCCCG	60
	GATCAGGAGC CAGTGTATAC CGCCGCCCA CGCCCTGGT GCCGCTAGAG GAAACGAGAA	120
50	GGAGCCCGCC TGGGTTTGT CGCCGCAGCT CGCCCMYGY CYGGRAGAGC CGAGCCCGG	180
	CCAGTGGGT CGCTGCCAC CSCTGCTAGC CGTTACCCG GGGCCGCCAC AGCCGCGGC	240
55	CGGGAGAGGC GCGCGCCATG GCTCTGGAG CCGATTCAA AGGTGATGAC CTATCAACAG	300
	CCATTCTCAA ACAGAAGAAC CGTCCCAATC GGTAAATTGT TGATGAAGCC ATCAATCAGG	360
	ACAACAGTGT GGTGTCTTG TCCAGCCCA AGATGGATGA ATTGCAGTTG TTCCGAGGTG	420
60	ACACAGTGT GCTGAAAGGA AAGAAGAGAC GAGAAGCTGT TTGCATCGTC CTTTCTGATG	480

	ATACTTGTTC TGATGAGAAG ATTGGGATGA ATAGAGTTGT TCGGAATAAC CTTCGTGTAC	540
	GCCTAGGGGA TGTATCAGC ATCCAGCCAT GCCCTGATGT GAAGTACGGC AAACGTATCC	600
5	ATGTGCTGCC CATTGATGAC ACAGTGAAG GCATTACTGG TAATCTCTTC GAGGTATAAC	660
	TTAAGCCGTA CTTCCTGGAA GCGTATCGAC CCATCCGGAA AGGAGACATT TTTCTTGTCC	720
10	GTGGTGGGAT GCGTCTGTG GAGTTCAAAG TGGTGGAAAC AGATCCTAGC CCTTATTGCA	780
	TTGTTGCTCC AGACACAGTG ATCCACTGCG AAGGGGAGCC TATCAAACGA GAGGATGAGG	840
	AAGAGTCCTT GAATGAAGTA GGGTATGATG ACATTGGTGG CTGCAGGAAG CAGCTAGCTC	900
15	AGATAAAGGA GATGGTGGAA CTGCCCCTGA GACATCCTGC CCTCTTTAAG GCAATTGGTG	960
	TGAAGCCTCC TAGAGGAATC CTGCTTTACG GACCTCCTGG AACAGGAAAG ACCCTGATTG	1020
20	CTCGAGCTGT AGCAAATGAG ACTGGAGCCT TCTTCTTCTT GATCAATGGT CCTGAGATCA	1080
	TGAGCAAATT GGCTGGTGAG TCTGAGAGCA ACCTTCGTAA AGCCTTTGAG GAGGCTGAGA	1140
	AGAATGCTCC TGCCATCATC TTCATTGATG AGCTAGATGC CATCGCTCCC AAAAGAGAGA	1200
25	AAACTCATGG CGAGGTGGAG CGGCGCATTG TATCACAGTT GTTGACCCTC ATGGATGGCC	1260
	TAAAGCAGAG GGCACATGTG ATTGTTATGG CAGCAACCAA CAGACCCAAC AGCAATTGACC	1320
30	CAGCTCTACG GCGATTTGGT CGCTTTGACA GGGAGGTAGA TATTGGAATT CCTGATGCTA	1380
	CAGGACGCTT AGAGATTCTT CAGATCCATA CCAAGAACAT GAAGCTGGCA GATGATGTGG	1440
	ACCTGGAACA GTAGCCAATG AGACTCACGG GCATGTGGGT GCTGACTTAG CAGCCCTGTG	1500
35	CTCAGAGGCT GCTCTGCAAG CCATCCGCAA GAAGATGGAT CTCATTGACC TAGAGGATGA	1560
	GACCAITGAT GCCGAGGTCA TGAAGTCTCT AGCAGTTACT ATGGATGACT TCCGGTGGGC	1620
40	CTTGAGCCAG AGTAACCCAT CAGCACTGCG GGAAACGCTG GTAGAGGTGC CACAGGTAAC	1680
	CTGGGAAGAC ATCGGGGGCC TAGAGGATGT CAAACGTGAG CTACAGGAGC TGGTCCAGTA	1740
	TCCTGTGGAG CACCCAGACA AATTCCTGAA GTTTGGCATG ACACCTTCCA AGGGAGTTCT	1800
45	GTTCATATGA CCTCTGGCT GTGGGAAAAC TTTGTGGCC AAAGCCATTG CTAATGAATG	1860
	CCAGGCCAAC TTCATCTCCA TCAAGGGTCC TGAGCTGCTC ACCATGTGGT TTGGGGAGTC	1920
50	TGAGGCCAAT GTCAGAGAAA TCTTTGACAA GGCCCGCCAA GCTGCCCCCT GTGTGCTATT	1980
	CTTTGATGAG CTGGATTGCA TTGCCAAGGC TCGTGGAGGT AACATTGGAG ATGGTGGTGG	2040
	GGCTGCTGAC CGAGTCATCA ACCAGATCCT GACAGAAATG GATGGCATGT CCACAAAAA	2100
55	AAATGTGTTT ATCATTTGGC CTACCAACCG GCCTGACATC ATTGATCCTG CCATCCTCAG	2160
	ACCTGGCCGT CTTGATCAGC TCATCTACAT CCCACTTCCT GATGAGAAGT CCCGTGTTGC	2220
60	CATCCTCAAG GCTAACCTGC GCAAGTCCCC AGTTGCCAAG GATGTGGACT TGGAGTTCCT	2280

5 GGCTAAAATG ACTAATGGCT TCTCTGGAGC TGACCTGACA GAGATTTGCC AGCGTGCTTG 2340
 CAAGCTGGCC ATCCGTGAAT CCATCGAGAG TGAGATTAGG CGAGAACGAG AGAGGCAGAC 2400
 AAACCCATCA GCCATGGAGG TAGAAGAGGA TGATCCAGTG CCTGAGATCC GTCGAGATCA 2460
 CTTTGAAGAA GCCATGGCTT TTGCGCGCCG TTCTGTCACT GACAATGACA TTCGGAAGTA 2520
 10 TGAGATGTTT GCCCAGACCC TTCAGCAGAG TCGGGGCTTT GGCAGCTTCA GATTCCCTTC 2580
 AGGGAACCAG GGTGGAGCTG GCGCCAGTCA GGCAGTGA GCGGCACAG GTGGCAGTGT 2640
 ATACACAGAA GACAATGATG ATGACCTGTA TGGCTAAGTG GTGGTGGCCA GCGTGCAGTG 2700
 15 AGCTGGCCTG CCTGGACCTT GTTCCCTGGG GGTGGGGGCG CTTGCCCAGG AGAGGGACCA 2760
 GGGGTGCGCC CACAGCCTGC TCCATTCTCC AGTCTGAACA GTTCAGCTAC AGTCTGACTC 2820
 20 TGGACAGGGG GTTCTGTGTG CAAAATACA AAACAAAAGC GATAAAATAA AAGCGATTTT 2880
 CATTGTGTAA AAAAAAAAAA AAAAAAAAAAT CCGGGGGGGG GCCCGAACCA TTT 2933

25

(2) INFORMATION FOR SEQ ID NO: 166:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2243 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166:

TCGGAGAGCC GCGGGGCGNG CGCCTCTGG CCAGGAAGCG CCTCTTGGAC GCGTGTNACC 60
 40 GATGCCCAGA AGTGGCCTTG GGCTGGGGAT CACCATAGCT TTTCTAGCTA CGCTGATCAC 120
 GCAGTTTCTC GTGTATAATG GTGTCTATCA GTATACATCC CCAGATTTC TCTATATTCC 180
 TTCTTGCTC CCTTGTATAT TTTTCTCAGG AGCGTTCAG GTGGGAACA TAGGACGACA 240
 45 GTTAGCTATG GGTGTTCCTG AAAAGCCCCA TAGTGATTGA GTCTTCAAAA CCACCGATT 300
 TGAGAGCAAG GAAGATTTTG GAAGAAAATC TGAATGTGGA TTATGACAAA GATTATCTTT 360
 50 TTTCTTAAGT AATCTATTTA GATGGGCTG ACTGTACAAA TGAATCCTGG AAAAACTCT 420
 TCACCTAGTC TAGAATAGG AGGTGGAGAA TGATGACTTA CCTGAAGTC TTCCCTTGAC 480
 TGCCCGCACT GCGCCTGTC TGTGCCCTGG AGCATCTGTC CCAGGCTACG TGGGTTCAGG 540
 55 CAGGTGGCAG CTTCCCAAGT ATTGATTTT ATTCAATGTA TTAAACAAG TTGCCATATT 600
 TCAAAGCCTT GAATAAGAC TCAATTACCA ACCCGCAGTT TTGTGTCACT GCCCAAAGGA 660
 60 GGTAGGTGTA TGGTGCTTAA CAAACATGAA GTATGGTGTA ATAGGAATAA TATTTATCCA 720

	AAAGATTTTT AAAAATAGGG CTGTGTTTAA AAAAAAAAC AAAACARGAA AAGCAGCAGT	780
	GATTATAGAG AGGTCACACT CTAAGTGGGG TCGCGGGTG GCCACGCTTC ACGGTCACGC	840
5	TCGTCCGTCC TGCAGTGGCG TGTTTACATG GTCACACGTG TGTGTATCAC CAGTGGGTCA	900
	ACTGCTTGTC ATTCTCCCG TGGCAGTTTG TGTAGACAAT CTTACTGAGC AAAAGGCAAT	960
10	GAAAAGTCTT GGTCCCACA CTGCGATATA TTGGAATTTT CACCTCAGTT TATGAAGTTT	1020
	ATTTGAAAT CCATAGTCAT CTAAGAATGA ATACCTGTCT GCCATGTATT TCAATCTTAG	1080
	TGAGCCAAA TTGTTTGT TTACTACAG AATAGAGATG ACTGTTTTTT GCCACAGCCC	1140
15	TATGGRATTT GCAATCTGTG ATTGCCTTGT AAAAAGGAGA GTGCATATGG CACTGCATTA	1200
	AACGTGTGGT GTTCTAGTC AATGATATTG GTGAGCACAA TGTATTCAAT TAATGGCATA	1260
20	GACCATACCA GACCTAATTT GCAAGTATIG GGTCTTAAAC TTCAAGTCA ATGTATATGA	1320
	AAACCAATCT GAGCCTTGTA TCTCTTAAAT ATTTATTTTT TTTAACGTGT GAGATGTTG	1380
	AGAGAAGTT CTCCATTCAT TTCAGTGCTG CCTGGAGGAA ACTCGGCAAT GATTCTTTTC	1440
25	AGTTGTGAAG TTCCTTTCGT GTTACACCTT CACTGAACC CTCAACCTTC GAAATACTCC	1500
	AGTTTTGTGG GTTTGGTCAT TTTACTTAT AAATTTACCT TTTTGTATTT TGCAATTTAC	1560
30	ATGTGTTTGG TTTGTTTAA ATTCTGTGAA AGTGGCTTGA TTTAAAGACT CCTTTTAAAT	1620
	GGAAGCCACC AGTCAGCAGA ATGGAAGCTT AGAGGAACTT GCCTGTGAGC GCTGGTCTTT	1680
	GTGTTTGGTT TTGTGATGTA ACGATCTTIG CTGGGGTTTT TTGCTTTGTT TTGAGGGAAA	1740
35	TGCTCTGGAG TAAATTTTAA GTTCTGGAG TTAATTTGTT TTACAGGAAT TTTGTTTTTT	1800
	AAAAAATAG GATCATCTCG AACTTTGGAA TGACCCCTT ATATATTTTC TGAAAATGAA	1860
40	AACAGTTACA TGAAAAAAT TTCCAATGAA GATGTCAGCA TTTTATGAAA AACCAGAAGT	1920
	TATTAGATGA AAGCAGCGAG TGAATCTTTA AACAGACTT GATCACGCAC ACACAATAAG	1980
	CTTTCTCTC CGAAACCGGA AGTAAATCTA TATCTGTTAG AAATAATGTA GCCAAAAGAA	2040
45	TGTAAATTTG AGGATTTTTT TGCCAATAGT TTATAGAAA TATATGAACC AAAGTGATTT	2100
	GAGTTTGTA AAATGTAAAA TAGTATGAAC AAAATTTGCA CTCTACCAGA TTTGAACATC	2160
50	TAGTGAGGTT CACATTCATA CTAAGTTTTT AACATTGTGT TCTTTTGTGA TTCAITTTTT	2220
	ACTTTTATTA AAGGTTCAAA ACC	2243

55

(2) INFORMATION FOR SEQ ID NO: 167:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1816 base pairs

(B) TYPE: nucleic acid

60

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 167:

5	GGTGGGNAGC TTINAATTTC CCCTTACWGG GCGCTNTAA GGGGAAACCT TCCCGGAATT	60
	TTCGGGTGCA CCCACGGTC CGGCCAGCCT AGGAGAAGAA GTTGTAGTTC CCAGAGGTGA	120
10	GGCAGGAGGC GGCAGTTTCT GCGGGTGAG GCGGGAGCTG AAGTGACAGC GGAGGCGGAA	180
	GCAACGGTCG GTGGGGCGGA GAAGGGGGCT GCGCCAGGA GGAGGAGGAA ACCCTTCCGA	240
	GAAAACAGCA ACAAGCTGAG CTGCTGTGAC AGAGGGGAAC AAGATGGCGG CGCCGAAGGG	300
15	GAGCCTCTGG GTGAGGACCC AACTGGGGCT CCGCGCGCTG CTGCTGCTGA CCATGGCCTT	360
	GGCGGAGGT TCGGGGACCG CTTGGGCTGA AGCATTTGAC TCGGTCTTGG GTGATACGGC	420
20	GTCTTGCCAC CGGGCCTGTC AGTTGACCTA CCCCTTGCAC ACCTACCCTA AGGAAGAAGA	480
	GTTGTACGCA TGTACAGAGG GTTGCAGGCT GTTTTCAATT TGTACAGTTG TGGATGATGG	540
	AATGACTTAA AATCGAACTA AATTGAATG TGAATCTGCA TGTACAGAAG CATATTCCCA	600
25	ATCTGATGAG CAATATGCTT GCCATCTTGG RTGCCAGAAT CAGCTGCCAT TCGCTGAACT	660
	GAGACAAGAA CAACTTATGT CCCTGATGCC AAAAATGCAC CTACTCTTTC CTCTAACTCT	720
30	GGTGAGGTCA TTCTGGAGTG ACATGATGGA CTCCGCACAG AGCTTCATAA CCTCTTCATG	780
	GACTTTTAT CTTCAGCCG ATGACGGAAA AATAGTTATA TTCCRGTTA AGCCAGRAA	840
	TCCCAGGTAC GCACCACATT TGGAGCCAGG AGCCCTACCA AATTTGRRG RAWCMTCTCT	900
35	AAGCAAAATG TCCNTCAKMT CGSMAATGAG AAATTCACAA GCGCACAGGA ATTTTCTTGA	960
	AGATGGAGAA AGTGATGGCT TTTTAAGATG CCTCTCTCTT AACTCTGGGT GGATTTTAAC	1020
40	TACAACCTTT GTCTCTCGG TGATGGTATT GCTTTGGATT TGTGTGCAA CTGTGTGCTA	1080
	CACGCTGTG GACGCAGTAT AGTTTCCCTC TGAGAAGCTG AGTATCTATG GTGACTTGGA	1140
	GTTTATGAAT GAACAAAAGC TAAACAGATA TCCAGCTTCT TCTCTGTGG TTGTTAGATC	1200
45	TAAACTGAA GATCATGAAG AAGCAGGGCC TCTACCTACA AAAGTGAATC TTGCTCATTC	1260
	TGAAATTTAA GCATTTTCT TTTAAAAGAC AAGTGTAATA GACATCTAAA ATTCCACTCC	1320
50	TCATAGAGCT TTTAAATGG TTTCATTGGA TATAGGCCTT AAGAAATCAC TATAAAATGC	1380
	AAATAAGTT ACTCAAATCT GTGAAAAAAA AAAAAAAAC TCGAGGGGGG	1440
	GCCCGTTACC AARTCGCCCT ATWGTGADTB GTATTMTAT TTTACTAATA TCTGTAGCTA	1500
55	TTTTGTTTTT KGCTTKGGTT ATKGTTTTTY TCCCTTYTCT WAGCTATRAG CTGATCATKG	1560
	CYSCTTCTCA CCTCCTGCCA TGATACTGTC AGTTACCTTA GTTAACAAGC TGAATATTTA	1620
60	GTAGAAATGA TGCTTCTGCT CAGGAATGGC CCACAAATCT GTAATTTGAA ATTTAGCAGG	1680

AAATGACCTT TAATGACACT ACATTTTCAG GAACTGAAAT CATTAAAATT TTATTTGAAT 1740
AATTATGTGC TGAAAAAAAA AAAAAAAAAA AMWMRARASK RRMWACTCGA GGGGGGGCCC 1800
5 GGTACCCNAT TCGCCG 1816

10

(2) INFORMATION FOR SEQ ID NO: 168:

(i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 945 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 168:

AGAAACCGTT GATGGGACTG AGAAACCAGA GTTAAACCT CTTTGGAGCT TCTGAGGACT 60
CAGCTGGAAC CAAGGGGCAC AGTTGGCAAC ACCATCAACT TCTCCCAAGC AGAGAAACCC 120
25 GAACCCACCA ACCAGGGGCA GGATAGCCTG AAGAAACATC TACACGCAGA AATCAAAGTT 180
ATTGGGACTA TCCAGATCTT GTGTGGCATG ATGGTATIGA GCTTGGGGAT CATTTTGGCA 240
TCTGCTTCCT TCTCTCCAA TTTTACCCAA GTGACTTCTA CACTGTTGAA CTCTGCTTAC 300
30 CCATTCATAG GACCCCTTTT TTTTATCATC TCTGGCTCTC TATCAATCGC CACAGAGAAA 360
AGGTTRACCA AGCTTTTGGT GCATAGCAGC CTGGTTGGAA GCATTCTGAG TGCTCTGTCT 420
35 GCCCTGGTGG GTTTCATTAT CCTGTCTGTC AAACAGGCCA CCTTAAATCC TGCTCACTG 480
CAGTGTGAGT TGGACAAAA TAATATACCA ACAAGAAGTT ATGTTTCTTA CTTTATCAT 540
GATTCACTTT ATACCAOGGA CTGCTATACA GCCAAAGCCA GTCTGGCTGG AWCTCTCTCT 600
40 CTGATGCTGA TTGCACTCT GCTGGAATC TGCCTAGCTG TGCTCACTGC TGTGCTGCGG 660
TGAAACAGG CTTACTCTGA CTTCCCTGGG AGTGTACTTT TCCTGCCTCA CAGTTACATT 720
45 GGTAATTCTG GCATGTCTC AAAAATGACT CATGACTGTG GATATGAAGA ACTATTGACT 780
TCTTAAGAAA AAAGGGAGAA ATATTAATCA GAAAGTTGAT TCTTATGATA ATATGGAAAA 840
GTTAACCATT ATAGAAAAGC AAAGCTTGAG TTTCTTAAAT GTAAGCTTTT AAAGTAATGA 900
50 ACATTAAGAAA AAACCATTTAT TTCACGTGCA TTAAAGATA ATGTG 945

55

(2) INFORMATION FOR SEQ ID NO: 169:

(i) SEQUENCE CHARACTERISTICS:
60 (A) LENGTH: 902 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 169:

5	GGCAGAGCCA CAGGAAGGAT GAGGAAGACC AGGCTCTGGG GGCTGCTGTG GATGCTCTTT	60
	GTCTCAGAAC TCCGAGCTGC AACTAAATTA ACTGAGGAAA AGTATGAACT GAAAGAGGGG	120
10	CAGACCCCTGG ATGTGAAATG TGA CTACACG CTAGAGAAGT TTGCCAGCAG CCAGAAAGCT	180
	TGGCAGATAA TAAGGGACGG AGAGATGCCC AAGACCCCTGG CATGCACAGA GAGGCCTTCA	240
15	AAGAATTCCTC ATCCAGTCCA AGTGGGGAGG ATCATACTAG AAGACTACCA TGATCATGGT	300
	TTACTGCGCG TCCGAATGGT CAACCTTCAA GTGGAAGATT CTGGACTGTA TCAGTGTGTG	360
	ATCTACCAGC CTCCCAAGGA GCCTCACATG CTGTTTCGATC GCATCCGCTT GGTGGTGACC	420
20	AAGGGTTTTT CAGGGACCCC TGGCTCCAAT GAGAATTCTA CCCAGAATGT GTATAAGATT	480
	CCTCCTACCA CCACTAAGGC CTTGTGCCCA CTCTATACCA GCCCCAGAAC TGTGACCCAA	540
25	GCTCCACCCA AGTCAACTGC CGATGTCTCC ACTCCTGACT CTGAAATCAA CCTTACAAAT	600
	GTGACAGATA TCATCAGGGT TCCGGTGTTC AACATTGTCA TTCTCCTGGC TGGTGGATTC	660
	CTGAGTAAGA GCCTGGTCTT CTCTGTCTCG TTTGCTGTCA CGCTGAGGTC ATTTGTACCC	720
30	TAGGCCACAG AACCCACGAG AATGTCTCTT GACTTCCAGC CACATCCATC TGGCAGTTGT	780
	GCCAAGGGAG GAGGGAGGAG GTAAAAGGCA GGGAGTTAAT AACATGAATT AAATCTGTAA	840
35	TCACCRGCTA AAAAAAAAAA AAAAAAACN CGANCCTNGG TTTTCAGCTC CATCAGCTCC	900
	TT	902

40

(2) INFORMATION FOR SEQ ID NO: 170:

(i) SEQUENCE CHARACTERISTICS:

45	(A) LENGTH: 1883 base pairs
	(B) TYPE: nucleic acid
	(C) STRANDEDNESS: double
	(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 170:

50	AGAAAACAAC TGAAAAACCA CATTTTCTTA CATACAGCTG GGGAGGTAGC TGAGAACTTG	60
	GCACTGCGCA CACATACTAG GTTGAAAGAG AGTTGAGGAA ACCAGAAGGC CAAGTGGATC	120
55	TGCTGGCAAA CCCTGAACCT GTCTCCTGCG CTGTCTCTAC AGTTCTGAAG TTGAAAATCC	180
	TTTTCATGCC TAGCATCTGC TTGAGTTATA AACCCCAAGG CAGCCATGTC ATAGACTAGT	240
60	GTTTACTCTT GTTTTGACTT TGTTTTAATG CTTCCTAAGA CCCAAGTGCC TCCTGCTGTT	300

	TCCTCCTTTG TGGTAGCCTC TGGCCATCTG GGACCTCAAT CCCCAGCTTT CCCACTTTCA	360
	GCAGTCCTTT GCTCTCTTTG CTTCTACCTC AAATAGCCCC AGGAGTGGGC TTTAGTCTCC	420
5	AATATGGAGC ATYTCAAGCT TCTCCTGGGG GATGGGGATT GGGATGGGCA GAATCTGTTT	480
	TGGWCTCCG GGTATTTCC AGTGGGTGTA AAAGCAGAGC TGGGCCTTTC CCTCTCTTAT	540
10	CCCTGAGGGT GGGTAAGAAG GACTGTATCT ACACCTGTTT TCCCTACCT TCTCTTTTGT	600
	TAGGGAGGCC TCATTCTAAG TTCTCAAGA GAGTCCTTGG CTAAAGCTG TAGCAAGGGT	660
	GTGCTAGGTG GGGGATTGG AGCAAAACCG TCGAGTAGGC ATGATACTGG TATGGAGTGG	720
15	GCCTGCAAAA TCAGACAGAA ATGGCTTGAG AAGCCGCAGG GGAGCATGCC TGTCTCTCAG	780
	TGATAGAGTA TGGGAGGGAC CTCCTAGCT TGGAAATGA GAATTGAAGG GGTATGAAC	840
20	AAATAGGATG CCTAGTTGAG GATGTTCCCA AAGTTTGTG CAATCTTATC ATTAGTAGAT	900
	TTTATAAGCC ACAGAGACAA ACCAGAAACG GAATAATGTT ACTTTGGATG CTTTATTTTT	960
	TTGTTCTAGG TGTGGCTTTG TACATGCAGA AGAATGCTAT ATGCTGCACA TTTTGCCCTT	1020
25	AAAGTCTTAC GACTTTCCCC ATTTTAGTCT AATGGGAAGA TACAGATGTG CAAGTCTGCT	1080
	TTTTTGTTTT TTGTTATTAT TTTTTTTTTT TTGCTCTGTG TTATGGACAT TTTCAGACAT	1140
30	GCACAGAAGT GGAGAGGATG GTCCTTGGAC CCCATGTGTC CATCACCTAG CTGCATCACT	1200
	TATCAGCTAT GGTCAACCTG GTTTCATCTG TATCTCTCTC TTTTCACCTG TATTGTTTAT	1260
	TGAAATCCA AGACACTATG CCAATGCAAC CGTGACTACT TTGGGAGATT GGTAGTCTCT	1320
35	TTTGATGGTG ATAGTGATGG GGTGCACTAT CATAATCACA TCAGGTCTGC TTTTGTCTTT	1380
	TAATGTTAAC TAATGAAGTT CCAGAGATGG GCCTTAGAAA TGTGTTTTAA GAATTAACAA	1440
40	GGAGTCTCAA AAAGAAATGA GAGGGATGCT TCCTTTCCCC TTGCATCTAC AAAACAAGAG	1500
	AGAGACTGTT CTGTTGTAAA ACTCTTTCAA AAATTCCTGAT ATGGTAAGGT ACTTGAGACC	1560
	CTTCACCAGA ATGTCAATCT TTTTCTCTGT GTAACATGGA AACTTGTTGT ACCATTAGCA	1620
45	TTGTTATCAG CTTGTACTGG TCTCATAACT CTGGTTTGG AAGAATAATT TGGAAATGTT	1680
	TGCTGTGTTT TGTGAAATA ACCTCCCCAA AATAATTAGT AACTGGTTGT TCTACTTGGT	1740
50	AATTTGACAC CCTGTTAATA ACGCAATTAT TTCTGTGTTT TTAACAGTA TAAATAGTTG	1800
	TAAGTTTGCA TGCATGATGG AAAAAATAAA ACCTGTATCT CTGTTAAAAA AAAAAAAAAA	1860
	AAAAAAAAA AAAAAAAAAA AAA	1883
55		

(2) INFORMATION FOR SEQ ID NO: 171:

60

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2100 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 171:

	TACTTTTAGA TTTACTGCCT TCAAAAAGTG CCTATTCTGA GCAACATAAA CGTTATTCCT	60
10	TACATATGTA TGTACACACG GTACCCAGAG TCGTACTGTG GCAGCCTTCA AAAACATACC	120
	ATCAGAAAGA GTAGGTGCTG AGATAAGGNA ACTTTGCCAA ATGNAAGAAA GTCACCTACT	180
	TCCAATATCC CCTCTTCAAG CGGCTACCGT GRAASGGGCT GCAAACACAT TCCCTGAGCA	240
15	TCCCTTGCTG ATACAGCTTC TTTATATTTA TATCCTACTG GATGGTAGCA TATTGCTAAG	300
	GTTTCTGTGA CTCTGCTTCA AGGGAATGTA AGYTTTATGG CATTGAAACA TTTAGGAAAA	360
20	AAAAAGATGT TTAAGAGAAT TAATAGAGCC GTAGTCTGTA TTAGGATGTG TGTATATGT	420
	GTGTTCTATA AACTAAGCAT CGGTGGGTTT AGAGTGTAA AGTGTACGCA CATTCCTTCT	480
	CCTTTTGTCT CTCAGGCTAA CATGAGAGAA AATAGAAAAG TCTTGCTGTG GGGGATTGGA	540
25	AGCTCAGGGG GCCAAATGTC CTTGCCAGAT CCTTAGAGCA TTACTTTGAC TCCTAAAAAT	600
	AGTAGTGTAT GTTATTGTAT GGCTTTTGT TCCATAGTTC CATCACTGAC AAAACTGTCA	660
30	ATACTGTGTA TGGAGCAGCA GCATAGCCTA GAGTGATGCA TTCTTACCCA GAGGTGGCAA	720
	TAGGAGAGGG TCCATGTAAA TAGGACGAGG TAGACAGTGC ATGATTGTAG GAGAAGGGTT	780
	GAAGGGAGGA CATGATTCCA AAAAAGATCG TTCTCAATGT GTCGTCTGAC TCAACCAGCT	840
35	GGCAGATTAC ACTTGCCAAG TCGTCCCTT TCCTTCTAAG TCAGTTGGCT CCATATTCAC	900
	TTGAATATGC CTCTGTTTGG GCAAAGCAAG ATACCTCCAC TTAACCTTTA TCCAAGGAAG	960
40	CTCTTGGTGT CCTCTTGGTC ATAAAGTTGT CTCCTACCTA ACCCAGTTTT ACCAAATGGA	1020
	AGTAAAAGGG GACAACTAT GGAAGATGGA CTCCATGCCA TTGCAGTCAG CCACCATTCT	1080
	CTTTTCCATA TAAGGAGCCC CATTACATAA GCTACGGGTG AGGTTGGAAC AGCTATGTTT	1140
45	CATAATTTCA AGAGTGTGAC CACCCTGCTC TAGTCATCAT CATTTGGATGA ATCCAGTTGA	1200
	CTCTTTGGCA AAAGGGTGAT ACTTTTCACT AAAAATGCCT ACTCTTCCTG TTGATGTTCC	1260
50	TTTTCTGTTT TTACCTTGTC CAATTTCCAC ACTAGTCATT TTTTATTATT TTTAGAGGAT	1320
	CAGATTTTAG CGCTGGAATA TGAGTTCAAA AATTTCAAGT TAATGTCATA AGGATGTTGG	1380
	GATACAGAGA TTTTTTTTTT CCTTGGAAC AAATGGACTG GGAAGAAACA CAGCATGGCT	1440
55	TTGCTCTGAG TTTCAATCTG ATGATTATGA CCATGGAAGA TAGTCTTATG TAAAGGTTAA	1500
	ATGGTGTTTA CAGTGGATA GATAAGGCGG AGATGGTGAG AAGCCGGGTT TTCTCTATGC	1560
60	TAAATGTGTC TACTAAGAGC AGCACTTCCT ACTAGCTAAG CACAATCATA GCCCCACCGT	1620

5 GATGAGCTGC TAGTCTGAAT AACATTCCCT GACTTAGGGA AAGGCACACA AAAACATATA 1680
 AAGAATATGT CTATTTTCAT ATGTGTGATA CTGACAGAGC CATGGTATTC CTAAAATATA 1740
 GGTTCCTCTT TTTCTTGTA TTCTTAGCAA ATTGCATTTA TTCCTACAT TACAAACCAT 1800
 CACTGATGTA TOCAAAATAG CACACATAGT TCAGTATGAA AATAAGAGAA TAAAATCTGT 1860
 10 TATAAGCAAG TGATTTAGGT ATTTCTTTT GTGTTTATGC ATTATCTGAC TATATTAAAA 1920
 CCTGTTTTTC TATTTACCTT CTATCAGTTT TCTCTACCAA TTATGTTTTT TCAATGCTCT 1980
 ATAAGAATGA ATATGGAAAT TATATTTCTT TTTTCTGTAA AAGAGTTGCA ACTACTTTAT 2040
 15 TATATTTAGA AATCCAATAA ACTTCTTATT ACATTTAAAA AAAAAAAAAA AAAACTCGAA 2100

20

(2) INFORMATION FOR SEQ ID NO: 172:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 1930 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 172:

35

40

45

50

55

60

CCTTTGANTG TGGTCCCGGG TGCNGATGG CAGCGCCTCC GCCGCGGCTC GTGGTTGTCC 60
 CGCCATGGCA CTGTGCGGGG GGCTGCCCGG GGAGCTGGCT GAGGCGGTGG CCGGGGGCCG 120
 GGTGCTGGTG GTGGGGGCGG GCGGCATCGG CTGCGAGCTC CTCAGAATC TCGTGCTCAC 180
 CGGTTTCTCC CACATCGACC TGATTGATCT GGATACTATT GATGTAAGCA ACCTCAACAG 240
 ACAGTTTTTG TTTCAAAGA AACATGTTGG AAGATCAAAG GCACAGTTG CCAAGGAAAG 300
 TGTACTGCAG TTTTACCCGA AAGCTAATAT CGTTGCCTAC CATGACAGCA TCATGAACCC 360
 TGACTATAAT GTGGAATTTT TCCGACAGTT TATACTGGTT ATGAATGCTT TAGATAACAG 420
 AGCTGCCCGA AACCATGTTA ATAGAATGTG CCTGGCAGCT GATGTTCTCT TTATTGAAAG 480
 TGGAACAGCT GGGTATCTTG GACAAGTAAC TACTATCAAA AAGGGTGTGA CCGAGTGTTA 540
 TGAGTGTGAT CCTAAGCCGA CCCAGAGAAC CTTTCTGGC TGTACAATTC GTAACACACC 600
 TTCAGAACCT ATACATGCA TCGTTTGGGC AAAGTACTTG TTCAACCACT TGTTTGGGGA 660
 AGAAGATGCT GATCAAGAAG TATCTCTGA CAGAGCTGAC CCTGAAGCTG CCTGGGAACC 720
 AACCGAAGCC GAAGCCAGAG CTAGAGCATC TAATGAAGAT GGTGACATTA AACGTATTTT 780
 TACTAAGGAA TGGGCTAAAT CAACTGGATA TGATCCAGTT AAACCTTTTTA CCAAGCTTTT 840
 TAAAGATGAC ATCAGGTATC TGTGACAAT GGACAACTA TGGCGGAAAA GGAAACCTCC 900

	AGTTCGGTTG GACTGGGCTG AAGTACAAAG TCAAGGAGAA GAAACGAATG CATCAGATCA	960
	ACAGAATGAA CCCCAGTTAG GCCTGAAAGA CCAGCAGGTT CTAGATGTAA AGAGCTATGC	1020
5	ACGTCTTTTT TCAAAGAGCA TCGAGACTTT GAGAGTTCAT TTAGCAGAAA AGGGGGATGG	1080
	AGCTGAGCTC ATATGGGATA AGGATGACCC ATCTGCAATG GATTTTGTCA CCTCTGCTGC	1140
10	AAACCTCAGG ATGCATATTT TCAGTATGAA TATGAAGAGT AGATTTGATA TCAAATCAAT	1200
	GGCAGGGAAC ATTATTCTCG CTATTGCTAC TACTAATGCA GTAATTGCTG GGTTGATAGT	1260
	ATTGGAAGGA TTGAAGATTT TATCAGGAAA AATAGACCAG TGCAGAACAA TTTTMTTGAA	1320
15	TAAACAACCA AACCCAAGAA AGAAGCTTCT TGTGCCTTGT GCACTGGATC CTCCAACCC	1380
	CAATTGTTAT GTATGTGCCA GCAAGCCAGA GGTGACTGTG CGGCTGAATG TCCATAAAGT	1440
20	GACTGTTCTC ACCTTACAAG ACAAGATAGT GAAAGAAAAA TTGCTATGG TAGCACCAGA	1500
	TGTCCAAATT GAAGATGGGA AAGGAACAAT CCTAATATCT TCCGAAGAGG GAGAGACGGA	1560
	AGCTAATAAT CACAAGAAGT TGTGCAATT TGGAAATTAGA AATGGCAGCC GGCTTCAAGC	1620
25	AGATGACTTC CTCCAGGACT ATACTTTATT GATCAACATC CTTCATAGTG AAGACCTAGG	1680
	AAAGGACGTT GAATTTGAAG TTGTTGGTGA TGCCCCGGAA AAAGTGGGGS CCAAACAAGC	1740
30	TGAAGATGCT GCCAAAAGCA TAACCAATGG GCAGTGATGA TGGGAGCTTC AGCCCTCCAC	1800
	CTYCACAGCT TCAAGGAGGC AAGATGGACG TYTCYCATAG TTGATYCGGR TGAAGAAGRT	1860
	TCTCCAATAA TTGCCCGACG TTCATTGAAG GAAGGAGGAG GAGGCCCGCC AAGAGGGGAA	1920
35	TTTAGGNTTG	1930

40 (2) INFORMATION FOR SEQ ID NO: 173:

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 1509 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 173:

50	GGCCCTGGCC TCTGGGCTGA GGCTTGCTAG GGA CTGGGG TGGCTCTAAG GGCAGGGAT	60
	AGGGCTGGGG AGCGCCGGCC TGTGGCCCTG ACCAGCCCTT TCTCGTGCRC GTTCCACCCC	120
	GATGCAGGTG GTCACGTGCT TGACGCGGGA CAGCTACCTG ACGCACTGCT TCCTCCAGCA	180
55	CCTCATGGTC GTGCTGTCTT CTCTGGAACG CACGCCCTCG CCGGAGCCTG TTGACAAGGA	240
	CTTCTACTCC GAGTTTGGGA ACAAGACCAC AGGGAAGATG GAGAACTACG AGCTGATCCA	300
60	CTCTAGTCGC GTCAAGTTTA CCTACCCAG TGAGGAGGAG ATTGGGGACC TGACGTTTAC	360

	TGTGGCCCAA AAGATGGCTG AGCCAGAGAA GGGCCAGCC CTCAGCATCC TGCTGTACGT	420
5	GCAGGCCCTC CAGGTGGGCA TGCCACCCCC TGGGTGCTGC AGGGGCCCCC TGCGCCCCAA	480
	GACACTCTG CTCACCAGCT CCGAGATCTT CCTCTGGAT GAGGACTGTG TCCACTACCC	540
	ACTGCCCGAG TTTGCCAAAG AGCCGCGCA GAGAGACAGG TACCGGCTGG ACGATGGCCG	600
10	CCGCTGCCG GACCTGGACC GAGTGCTCAT GGGCTACCAG ACCTACCCGC AGCCCTCACC	660
	CTCGTCTCG ATGACGTGCA AGGTATGAC CTCATGGCA GTGTACCCCT GGACCACTTT	720
15	GGGAGGTGC CAGGTGGCCC GGCTAGAGCC AGCCAGGGCC GTGAAGTCCA GTGGCAGGTG	780
	TTTGTCCCA GTGCTGAGAG CAGAGAGAAG CTCATCTCG TGTGGCTCG CCAGTGGGAG	840
	GGCTGTGTG GCGTGAGCT GCGTGTGAG CTCACCGCT AGCCAGGCC ACAGCCAGCC	900
20	TGTCGTGCC AGCCTGACGC CTACTGGGGC AGGGCAGCAG GCTTTTGTGT TCTCTAAAAA	960
	TGTTTATCC TCCCTTTGGT ACCTTAATTT GACTGTCTC GCAGAGAATG TGAACATGTG	1020
25	TGTGTGTGT GTTAATCTT TCTCATGTTG GGAGTGAGAA TGCCGGGCC CTCAGGGCTG	1080
	TCGGTGTGCT GTCAGCCTCC CACAGGTGGT ACAGCCGTGC ACACCACTGT CGTGTCTGCT	1140
	GTTGTGGAC CGTGTTAAC ACGTGACACT GTGGGTCTGA CTTTCTCTC TACACGTCTT	1200
30	TTCTGAAGT GTCCAGTCCA GTCCTTTGT GCTGTGCTG TTGCTGTTGC TGTGTCTGTT	1260
	GGCATCTGC TGCTAATCT GAGGCTGGTA GCAGAATGCA CATTGGAAGC TCCCACCCCA	1320
35	TATTGTCTT CAAAGTGGAG GTCTCCCTG ATCCAGACAA GTGGGAGAGC CCGTGGGGC	1380
	AGGGGACCTG GAGCTGCCAG CACCAAGCGT GATTCTCTG GCTGTATTC TCTATTCCAA	1440
	TAAAGCAGAG TTTGACCCG TCAAAAAA AAAAAAAAAA AAAAAAAAAA ATTNCTGCGG	1500
40	CCTCAAGGG	1509

45 (2) INFORMATION FOR SEQ ID NO: 174:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 3173 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174:

55	TGACCCAS GCGTCCGTGC TTTCCACAG AAGGTTAGAC CCTGAAAGAG ATGGCTCAGC	60
	ACCACCTATG GATCTTGCTC CTTGCCTGC AAACCTGGCC GGAAGCAGCT GGAAAGACT	120
60	CAGAAATCTT CACAGTGAAT GGGATTCTGG GAGAGTCAGT CACTTTCCCT GTAAATATCC	180

	AAGAACCACG GCAAGTTAAA ATCATTTGCTT GGACTTCTAA AACATCTGTT GCTTATGTAA	240
	CACCAGGAGA CTCAGAAACA GCACCCGTAG TTACTGTGAC CCACAGAAAT TATTATGAAC	300
5	GGATACATGC CTTAGGTCGG AACTACAATC TGGTCATTAG CGATCTGAGG ATGGAAGACG	360
	CAGGAGACTA CAAAGCAGAC ATAAATACAC AGGCTGATCC CTACACCACC ACCAAGOGCT	420
10	ACAACCTGCA AATCTATCGT CGGCTTGGGA AACCAAAAAT TACACAGAGT TTAATGGCAT	480
	CTGTGAACAG CACCTGTAAT GTCACACTGA CATGCTCTGT AGAGAAAGAA GAAAAGAATG	540
	TGACATACAA TTGGAGTCCC CTGGGAGAAG AGGGTAATGT CCTTCAAATC TTCCAGACTC	600
15	CTGAGGACCA AGAGCTGACT TACACGTGTA CAGCCCAGAA CCCTGTCAGC AACAAITCTG	660
	ACTCCATCTC TGCCCGGCAG CTCTGTGCAG ACATCGCAAT GGGCTTCCGT ACTCACCACA	720
20	CCGGGTGCT GAGCGTGCTG GCTATGTTCT TTCTGCTGT TCTCATCTG TCTTCAGTGT	780
	TTTGTTCGG TTTGTTCAG AGAAGACAAG ATGCTGCCTC AAAGAAAACC ATATACACAT	840
	ATATCATGGC TTCAAGGAAC ACCCAGCCAG CAGAGTCCAG AATCTATGAT GAAATCCTGC	900
25	AGTCCAAGGT GCTTCCCTCC AAGGAAGAC CAGTGAACAC AGTTTATTC GAAGTGCAGT	960
	TTGCTGATAA GATGGGGAAA GCCAGCACAC AGGACAGTAA ACCTCCTGGG ACTTCAAGCT	1020
30	ATGAAATGT GATCTAGGCT GCTGGGCTGA ATTCTCCCTC TGGAACTGA GTTACAACCA	1080
	CCAATACTGG CAGGTTCCTT GGATCCAGAT CTCTCTGCC CAACTCTTAC TGGGAGATTG	1140
	CAAACTGCCA CATCTCAGCC TGTAAGCAAA GCAGGAAACC TTCTGCTGGG CATAGCTTGT	1200
35	GCCTAAATGG ACAAAATGGAT GCATACCCCTT CCTGAAATGA CTCCCTTCTG AATGAATGAC	1260
	AAAGCAGGTT ACCTAGTATA GTTTTCCCAA ACTTCTTCCC ATCATAGCAC ATGTAGAAAA	1320
40	TAATATTTT ATGGCACACT GGGATAAACA AGCAAGATTG CTCACTTCTG GAAGCTGCAT	1380
	ATGACTAGAG GCCTCTTGTG ACTGGAGGTA ACAACCTGC CCAGTAACTG TGGGAGAAGG	1440
	GGATCAATAT TTTGCACACC TGTAATAGGC CATGGCACAC CAGCCAAGAT GCTCTGCTCA	1500
45	CAGTCAGTAT GTGTGAAGAT CCTTGGTGG TGGCCTTAC CAGGCATCTT GAGCAAATTA	1560
	GGAAAATGTA CCCTTCGCTT GAGGCAGATG CAGCCCTTCC CCGAGTGCA TGGCTTGGAG	1620
50	AGCAGAATGT GGGCTGCATA TAAGCACACT CATCCCTTTG TCTGGGAATC TTTGTGCAGG	1680
	GCATAACAGG CTTAGTAAGT CCAAACACAG ATGACAGTGC TGTGTGGGTC TCTGTCAGAG	1740
	TTGTGGCTCT CAGCCATGTA GACACACTCT CCAAATGGAG TGTGGGAAA TGTTCCTTCT	1800
55	GCAGGGCTA GAGACTGCTG GGACACTTTT CTGGAGTGC TACTTCAGAA GCCTTATAGG	1860
	ATTTTCTTTC TGGCCAAGAT TTCTTCTGT ATCACTCCAA GCAGCCTCAG CAGAAGAAGC	1920
60	AGCCATGCCC AGTATTCCTA CTCTCCAAA GGAAGTACC AGCTTATATT TCTCACACTT	1980

	CTGGGGAAC T GGTATAATC CAACCATCAA AATAGAAGAC CTTGCAAGAA GCAGAGTCAT	2040
	TCTCCAGAAG GAACTTGGGA GATGATGGTG CAGATGATGA AACTGGGTTC ATCCCAGTTC	2100
5	CAAAGACTCA GAGAACTAGA GTTTAAGCTG AGGCAGAGTG CCGCCACCTT GGCATGCCCC	2160
	ACAAACAGAT CACCAGCCAG CTTACACAGG CATTAACTCT CCTCAATGAG GAAGAATCAT	2220
10	TCACAACTGA GCAAGACATT CATATGATCA TTTAAGGAAG TGTTCCTCTT ATGTGTTAGC	2280
	AAGTATAATC GGCTAACTCC TAAATCCCAA TGAATAGTCC TAGGCTGGAC AGCAATGGGC	2340
	TGCAATTAGG CAGATAAAGA CATCAGTCCC AGTAAATGAA TCCATAGACT CATCTAGCAC	2400
15	CAACTACCAT TAGCACTATG TTAGGAGCTG CAAGGCCCCA AAGTAGAAGA TGTGCATAAT	2460
	GTCTGCTCTT GTGTAGCTCA GGAGACAATT CCAGCACAGA CACTACAGTT AACCGTGAAC	2520
20	TGCAGCTGCA AGTAATAGCA TGAACAGTCA GAAAAATACC TTATGAGGGG GCAGGGCTGA	2580
	AGCTGGGCCT TGAAGGATGG ATGAAATTG GATAGAGAAT GAGGAAGACA GAGGGCCTCC	2640
	AAGTGAGAGA AGCATGAAAA ATGAGCAGGG GCCTGGATCA GTGGGGTGTA TTCAGAGCAC	2700
25	CTCTCCAGAT GCACCATGCA TGCTCACAGT CCCTTGCTTA TGTGTGGCAG AGTGTCCAG	2760
	CCAGATGTGT GCCCCACCC CATGTCCATT TACATGTCTT TCAATGCCCA CCTCAAAAGG	2820
30	TACCTCTTCT GTAAAGCTTT CCCTGGTATC AGGAATCAAA ATTAATCAGG GATCTTTTCA	2880
	CACTGCTGTT TTTTCTCTTT TGGTCTTCT ATCACTAAAA CTCATCTCAT TCAGCCTTAC	2940
	AGCATAACTA ATTATTTGTT TTCTCTACTA CATTGTACAT GTGGGAATTA CAGATAAACG	3000
35	GAAGCCKGCT GGGGTGGTGG CTCACGCCTG TAATCCCAAC ACTTTGGGAG GCCAAGGCAG	3060
	GCGGATCACC TGAGGTACAG ARTTCGAGAT TARTCTGGCC AACATGGTGA AACCCCATNT	3120
40	NTACTAAAAA TACGAAATTA GCCAGGTGTG GTGGCACACA TCTGTAGTCC CAG	3173

45 (2) INFORMATION FOR SEQ ID NO: 175:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 991 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 175:

55	AAATTCGGCA CAGCTGAGAG GAGACACAAG GAGCAGCCCG CAAGCACCAA GTGAGAGGCA	60
	TGAAGTTACA GTGTGTTTCC CTTTGGCTCC TGGGTACAAT ACTGATATTG TGCTCAGTAG	120
	ACAACCACGG TCTCAGGAGA TGTCTGATTT CCACAGACAT GCACCATATA GAAGAGAGTT	180
60	TCCAAGAAAT CAAAAGAGCC ATCCAAGCTA AGGACACCTT CCCAAATGTC ACTATCCTGT	240

	CCACATGGA GACTCTGCAG ATCATTAAGC CCTAGATGT GTGCTGOGTG ACCAAGAACC	300
5	TOCTGGCGTT CTAOGTGGAC AGGGTGTTC AAGGATCATCA GGAGCCAAAC CCCAAAATCT	360
	TGAGAAAAAT CAGCAGCATT GCCAACTCTT TCCTCTACAT GCAGAAAACT CTGGGGCAAT	420
	GTCAGGAACA GAGGCAGTGT CACTGCAGGC AGGAAGCCAC CAATGCCACC AGAGTCATCC	480
10	ATGACAACTA TGATCAGCTG GAGGTCCACG CTGCTGCCAT TAAATCCCTG GGAGAGCTCG	540
	ACGTCTTTCT AGCCTGGATT AATAAGAATC ATGAAGTAAT GTCCTCAGCT TGATGACAAG	600
15	GAACCTGTAT AGTGATCCAG GGATGAACAC CCCCTGTGCG GTTTACTGTG GGAGACAGCC	660
	CACCTTGAAG GGAAGGAGA TGGGAAGGC CCCTTGCAGC TGAAAGTCCC ACTGGCTGGC	720
	CTCAGGCTGT CTTATTCCGC TTGAAAATAG CCAAAAAGTC TACTGTGGTA TTTGTAATAA	780
20	ACTCTATCTG CTGAAAGGGC CTGCAGGCCA TCCTGGGAGT AAAGGGCTGC CTTCCCATCT	840
	AATTTATTGT GAAGTCATAT AGTCCATGTC TGTGATGTGA GCCAAGTGAT ATCCTGTAGT	900
25	ACACATTGTA CTGAGTGGTT TTTCTGAATA AATTCATAT TTTACCTAAA AAAAAAAAAA	960
	AAAAACTCGA GGGGGGCCC GTACCCAATT T	991

30

(2) INFORMATION FOR SEQ ID NO: 176:

(i) SEQUENCE CHARACTERISTICS:

35

- (A) LENGTH: 1290 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 176:

40

	ACAGCCCTCT TCGGAGCCTG AGCCCGGCTC TCCTCACTCA CCTCAACCCC CAGGCGGCCC	60
	CTCCACAGGG CCCCTCTCCT GCCTGGACGG CTCTGCTGGT CTCCCCGTCC CCTGGAGAAG	120
45	AACAAGGCCA TGGGTGGGCC CCGCTGCTG CCCCCTCTGC YCTGCTGCW GCCGCCAGCA	180
	TTTCTGCAGC CTRGTGGCTC CACAGGATCT GGTCCAAGCT ACCTTTATGG GGTCACTCAA	240
50	CCAAAACACC TCTCAGCCTC CATGGGTGGC TCTGTGGAAA TCCCCTTCTC CTTCTATTAC	300
	CCCTGGGAGT TAGCCAYAGY TCCCRACGTG AGAATATCCT GGAGACGGGG CCACTTCCAC	360
	GGGCAGTCCT TCTACAGCAC AAGGCCGCTT TCCATTCA CAAGGATATGT GAACCGGCTC	420
55	TTTCTGAACT GGACAGAGGG TCAGGAGAGC GGCTTCCTCA GGATCTCAA CCTGCGGAAG	480
	GAGGACCACT CTGTGTATTT CTGCCGAGTC GAGCTGGACA CCGGAGATC AGGGAGGCAG	540
60	CAGTTGCAGT CCATCAAGGG GACCAAACTC ACCATCACCC AGGCTGTCAC AACCACCACC	600

	ACCTGGAGGC CCAGCAGCAC AACCACCATA GCCGGCCTCA GGGTCACAGA AAGCAAAGGG	660
	CACTCAGAAT CATGGCACCT AAGTCTGGAC ACTGCCATCA GGGTTGCATT GGCTGTGGCT	720
5	GTGCTCAAAA CTGTCATTTT GGGACTGCTG TGCCCTCTCC TCTGTGGTGG AGGAGAAGGA	780
	AAGGTAGCAG GGGCCAAGC AGTGACTTCT GACCAACAGA GTGTGGGGAG AAGGGATGTG	840
10	TATTAGCCCC GGAGGACGTG ATGTGAGACC CGCTGTGAG TCCTCCACAC TCGTTCCTCA	900
	TTGGCAAGAT ACATGGAGAG CACCCTGAGG ACCTTTAAAA GGCAAAGCCG CAAGGCAGAA	960
	GGAGGCTGGG TCCCTGAATC ACCGACTGGA GGAGAGTTAC CTACAAGAGC CTTTCATCCAG	1020
15	GAGCATCCAC ACTGCAATGA TATAGGAATG AGGTCTGAAC TCCACTGAAT TAAACCACTG	1080
	GCATTTGGGG GCTGTTYATT ATAGCAGTGC AAAGAGTTC TTTATCTCTCC CCAAGGATGG	1140
20	AAAATACAAT TTATTTTGCT TACCATACAC CCCTTTTCTC CTCGTCCACA TTTTCCAATC	1200
	TGTATGGTGG CTGTCTTCTA TGGCAGAAGG TTTTGGGGAA TAAATAGCGT GANATGVTNC	1260
	TGACTNAAAA AAAAAAAAAA AAAAAGTCGA	1290
25		

(2) INFORMATION FOR SEQ ID NO: 177:

- 30 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 2290 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 177:

	TGGGGCCCCCT TTTGGATGCT CTGGGTGTTT TTGCCAAGAG TTACAGGATG TCAAGTGTGG	60
40	GGAGCTCAGC ACCCTTGCTG TGGACCAGTG AAGGCTGTTT CAGACCAGGT GCTTCCAGAC	120
	ATTTCCAGGC TCCAGGAGAG AGGCTGGGAG CCCCCACAGA AAGCACAGGA AAATGCAAAA	180
45	AAAAAACAGT CTTTTTTTTT TTTTGTCTTT TTATTATGAA AACAAAACAA ATGCCCCAGG	240
	AGAAGGTCC ATGATTACCA GAAACATCAA AGAGTACTTT CTACCATTTT TATTCTGTG	300
	TGTTGAGGCC AGCATTGCAA TAAACAAGCT AACTACTTA CATTGGACTC ATTTTCAGTA	360
50	ACTGACATTT ACAGGAATAT ACTAGAAACG GCACTAAAAA GTTTAAGAAA AGTTACGGTA	420
	AACTTGCATG CACATCATAC AGAAAAGTAA CATTTTAAAT ATAAAAAGA AAAACTTCCT	480
55	GGAAGCATTG TGCCAGTATT AAGGAACAGT GCTACTCTGG ATGTGACAAA TTCTGTATGT	540
	GGGTGTTACT CTTTCCCAAA AGACTGTCAG AGGCGTGAGT GCTGCAAAAG AACAAACA	600
	AAAACAACA CACAAAAAAA TGTGTCTTAC AGTTTGTAAAG CAAGATGACA CTGCCCAACA	660
60	CAAAGAGGGG TCTGGAGTTC AGTTCACGCC CGAAGCCTGC CCCCTGGGCC TCCAGGGGTC	720

	ATTCAGAGTG TTCTCAAATC CAATTCGGAC ACACGACTTG TCACTACTCC TCTCCCTTG	780
5	AAAAAAGCAT GTTAGAAGCT GCCCTACAGG TCTCAGCAGT GGGACAATCT AATTGAATCA	840
	CCGCAGCCTT CTAATACAGA AGAAACGGAC GTGACTGTCA CCTCAGCCC GCCAGCAAGG	900
	GCGCTGAGGA AGTCATTAAT CCTTCGAAAC TCTGAAAAGA AACCAGTGTT GAAGTCTGGA	960
10	CAGAAAGCCT TAAAAAAGTG ACAGCACCAA TGCAGCTGCT CAGTGTACCC NCCGTGGGT	1020
	GTCAGGGTCA GTGGCTTCTT TCTAGATGAA AGGAGCAGAG GCGAGCCGAC GCCACCGTCA	1080
15	CAGAGAACCA GCCGAGAAGG AAAGGCCCCA CGATGCTCCC TGTGCGCTGC CCCACAGCC	1140
	GGCCGCTCCC CCGACGGCTC ACACAGGCAG CACCTCACTG CCTGTGGCT GGAGGGGCAT	1200
	TGCAAGGAGC GCGCCCGAGC CCCAGGCACC CCGGCTTAG GGTGTACGTA TCACCCAGCC	1260
20	CTGTGCTGGC AGCAGGTTAC CAACCAGCCT GCGTGAAGAC CTGTCAACTG TCGTGTGTGA	1320
	ATTCCCTTAA TTCCGTTTAA ATAGTCCATT AAAGATCTGT TTAGAAAATA CCTTTGAAAA	1380
25	CGAGGGTAAC TTTAAAAAAT GGAACTTTC AAATCCATTT ATATTTTAT TATAAACAAA	1440
	ACTTAATTAA AAGTTTAACA AACTGGCTGA AAATCACCA AGTGTGAGC TCACCAGCAA	1500
	TTTAAAAAAT GATAATTTAC CAGCATCTCC TCATCAGAGT TCCCTCTCCA GTAAGGGTAT	1560
30	ACCTACATCT GTAAGGGTCA GTGGACTCTG AATCAATTTT ATGGTTGTTT TAAAATCACC	1620
	GTGTATTAGG ATACTAATGA TAGTCCCTAT ATCCATCCAG AAATGCTGGC AGAAAGCACT	1680
35	GGCCACCATA CAGGACAGAC CACACCACAG CTCATACCC AGCGTCTGCC TGGAGGCTCC	1740
	CCCACGCTGA GGTCCGGGAG AATGCCTGGT TTCAGTCATT TCCGGACTAA CTGTGACAAC	1800
	GCGTGAGCAG GGAGCACCGT GCGAGTCTCC GGGAGGGAAT CCTCTGGGG CCCAGAGACT	1860
40	CCTCCACCCC TGGGGAGGGC AGACAGGCTC GGGARGGCCT GGCCAGGCCA CTGGAGGCTG	1920
	GCAGGGAGCA GGCATGTCCA CCCGCAAGCC TGGGAGGCTA ACTCTGGCAT TCCTGGCCGG	1980
45	AGCCGCCATG CTCATTGGTG GGCCAGTTTG GGACATCCCC GTACTCAAAG ACCATATGGC	2040
	AGCCTCTGGG AAAACAAAAC CAAAACATCA CCTTCTATTA AACTCTGTAT ATTATTATTT	2100
	TTTACAATAG AAAGTTAAAA ATCAAGACTT AGATTTACTA TACATTTTTT CTCTCAGATT	2160
50	ACAAAGTTTA TATTATATAA CTGGGGTTCC CTAAATGAT TTCTTTTAAA ACAGTCTTAA	2220
	AGAGACCAGA AGTGAATACA AAAGAACTAA ACAAATAAAA AAATTAGAAT GTGCTGTAGC	2280
55	TGAAAGCTGT	2290

60 (2) INFORMATION FOR SEQ ID NO: 178:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 549 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 178:

10 GGCACGAGCC ATGCCTGGCC TCTCCTTGAT TCTTACAGTC ACTTTGTTGG CTGTTTCTGA 60
 CTCAGCAGCT ACCTGCATTG TGGCCAAAGG ATGACCTATT CCTTCTCAGG AGGGCAAAAA 120
 TGTGGAATAG TGTCTGTCCA TGCCCTCTCT CATGGGCTAC CACCTCTGCC ACCGTGGTTA 180
 15 ATCAGTAACA ACCAGGAGAG AAGCTGCTGG AACTGACCTC TGGGAACTCC CTGGGATGGT 240
 TTGGTGCAGG AATGTAGTAG GCATACACGT GGTTCGCTGG ATCTGGGCCC TCCTGATGTG 300
 AGTAGAGAGG TAAAAGGCCA CCATCTCCTT GACCTCTGGG GAACTCATCC ACAAGAAGA 360
 20 TGTTCCTCAAG ATGCTTCTGA AGATTGCCTA AAAATAGCCG GTTCCACCC CCGTGAATGC 420
 ATCCATTCTA GAATGCTCCT TCACCAGGAC CAGAGAACTG ATTTACAGAA GTGACATGAA 480
 25 AACATTCCAT CCCAGAAATT GCAGTAGCTC AAATTAAGTT TCTAGCTATT AAAAAGAAAA 540
 AAAAAAAAAA 549

30

(2) INFORMATION FOR SEQ ID NO: 179:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1509 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 179:

40

GGCACGAGGG CTCATTCAAT CCGCCCGGG CCTGCCAGAC ACCTGCCGCC TTCTGCAGCC 60
 GCCCCCGCA TCCGCCCGG CAGCCCCAG CATGTCGGC CCAGACGTG AGACGCCGTC 120
 45 CGCCATCCAG ATCTGCCGA TCATGCCGCC AGATGATGCC AACGTGGCCG GCAATGTCCA 180
 CGGGGGACC ATCCTGAAGA TGATCGAGGA GGCAGGCGCC ATCATCAGCA CCGGCATTG 240
 50 CAACAGCCAG AACGGGGAGC GCTGTGTGGC CGCCCTGGCT CGTGTGAGC GCACCGACTT 300
 CCTGTCTCCC ATGTGCATCG GTGAGGTGGC GCATGTCAGC GCGGAGATCA CCTACACCTC 360
 CAAGCACTCT GTGGAGGTGC AGGTCAACGT GATGTCCGAA AACATCCTCA CAGGTGCCAA 420
 55 AAAGCTGACC AATAAGGCCA CCCTGTGGTA TGTGCCCTG TCGCTGAAGA ATGTGGACAA 480
 GGTCTCGAG GTGCCTCTG TTGTGTATTC CCGGCANGAG CAGGAGGAG AGGGCCGGAA 540
 60 GCGGTATGAA GCCCAGAAGC TGGAGCGCAT GGAGACCAAG TGGAGGAACG GGGACATCGT 600

	CCAGCCAGTC CTCAACCCAG AGCCGAACAC TGTCAGCTAC AGCCAGTCCA GCTTGATCCA	660
5	CCTGGTGGGG CCTTCAGACT GCACCCCTGCA CGGCTTTGTG CACGGAGGTG TGACCATGAA	720
	GCTCATGGAT GAGGTGCGCG GGATCGTGGC TGCACGCCAC TGCAAGACCA ACATCGTCAC	780
	AGCTTCGGTG GACGCCATTA ATTTTCATGA CAAGATCAGA AAAGGCTGCG TCATCACCAT	840
10	CTCGGGACGC ATGACCTTCA CGAGCAATAA GTCCATGGAG ATCGAGGTGT TGGTGGACGC	900
	CGACCCGTGT GTGGACAGCT CTCAGAAGCG CTACCGGGCC GCCAGTGCCT TCTTCACCTA	960
15	CGTGTGCTG AGCCAGGAAG GCAGGTGCT GCCTGTGCCC CAGCTGGTGC CCGAGACCGA	1020
	GGACGAGAAG AAGCGCTTTG AGGAAGGCAA AGGGCGGTAC CTGCAGATGA AGGCGAAGCR	1080
	ACAGGGCCAC GCGGASCYTC AGCCCTAGAC TCCTCTCTCC TGCCACTGGT GCCTCGAGTA	1140
20	GCCATGGCAA CGGGCCAGT GTCCAGTCAC TTAGAAGTTC CCCCCTTGGC CAAAAACCCA	1200
	ATTACATG AGAGCTGGTG TTGTCTGAAG TTTCGTATC ACAGTGTAA CCTGTACTCT	1260
25	CTCCTGCAAA CCTACACACC AAAGCTTTAT TTATATCAIT CCAGTATCAA TGCTACACAG	1320
	TGTTGTCCCG AGCGCCGGGA GCGTGTGGC AGAAACCTC GGAATGCTT CCGAGCACGC	1380
	TGTAGGTAT GGAAGAACC CAGCACCCT AATAAGCTG CTGCTTGGCT GGAAAAA	1440
30	AAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	1500
	AGAAAAAAN	1509

35

(2) INFORMATION FOR SEQ ID NO: 180:

- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1316 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 180:

	AGCTGTATCA TAGGAAAGAT GGCCACACCG GCGGTACCAG TAAGTGCTCC TCCGGCCACG	60
50	CCAACCCAG TCCCGGCGGC GGCCCCAGCC TCAGTTCCAG CGCCAACGCC AGCACCGGCT	120
	GCGGCTCCGG TTCCCGCTGC GGCTCCAGCC TGCATCCTCA GACCTGCGG CAGCAGCGGC	180
	TGCAACTGCG GCTCCTGGCC AGACCCCGGC CTCAGCGCAA NTCCAGCGCA GACCCAGCG	240
55	CCCGCTCTGC CTGGTCTGC TCTCCAGGG CCTTCCCCG GCGGCCGCGT GGTGAGGCTG	300
	CACCCAGTCA TTTTGGCCTC CATGTGTGAC AGCTACGAGA GACGCAACGA GGGTGTGCC	360
60	CGAGTTATCG GGACCTGTT GGAAGTGTG GACAAACACT CAGTGGAGGT CACCAATTGC	420

	TTTTCASTGC CGCACAATGA GTCAGAAGAT GAAGTGGCTG TTGACATGGA ATTTGCTAAG	480
	AATATGTATG AACTGCATAA AAAAGTTTCT CCAAATGAGC TCATCCTGGG CTGGTACGCT	540
5	ACGGGCCATG ACATCACAGA GCACTCTGTG CTGNATCCAT GAGTACTACA GCGAGAGGC	600
	CCCCAACCCC ATCCACCTCA CTGTGGACAC AAGTCTCCAG AACGGCCGCA TGAGCATCAA	660
10	AGCCTACGTC AGCACTTTAA TGGGAGTCCC TGGGAGGACC ATGGGAGTGA TGTTCACGCC	720
	TCTGACAGTG AAATACGGT ACTACGACAC TGAACGCATC GGAGTTGACC TGATCATGAA	780
	GACCTGCTTT AGCCCCAACA GAGTGATTGG ACTCTCAAGT GACTTGCAGC AAGTAGGAGG	840
15	GGCATCAGCT CGCATCCAGG ATGCCCTGAG TACAGTGTG CAATATGCAG AGGATGTACT	900
	GTCTGGAAAG GTGTCACTG ACAATACTGT GGGCCGCTTC CTGATGAGCC TGGTTAACCA	960
20	AGTACCGAAA ATAGTTCCCG ATGACTTTGA GACCATGCTC AACAGCAACA TCAATGACCT	1020
	TTTGATGGTG ACCTACCTGG CCAACCTCAC ACAGTCACAG ATTGCACTCA ATGAAAACT	1080
	TGTAAACCTG TGAATGGACC CCAAGCAGTA CACTTGCTGG TCTAGGTATT AACCCAGGA	1140
25	CTCAGAAGTG AAGGAGAAAT GGGTTTTTTG TGGTCTTGAG TCACACTGAG ATAGTCAGTT	1200
	GTGTGTGACT CTAATAAACG GAGCCTACCT TTTGTAAATT AAAAAAAAAA AAAAAAACCN	1260
30	SGRGGGGGGG CCGGTCCCA TTSSCCCTTT NGTAATTCGT NTTACAATCC CCNGGC	1316

(2) INFORMATION FOR SEQ ID NO: 181:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 777 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 181:

45	GGCATGWKCA GACATGACTT CTATTGCCAG GCTGGTCAAG TGGCAGGGTC ATGAGGGAGA	60
	CATCGATAAG GGTGCTCCTT ATGCTCCCTG CTCTGGAATC CACCAGCGGG CTATCTGCGT	120
	TTATGGGGCT GGGGACTAGA ATTGGATGCT TCAAAACCAT CACCTGTTGG CCAACAAGTT	180
50	TGACCCAAAG GTAGATGATA ATGCTCTTCA GTGCTTAGAA GAATACCTAC GTTATAAGGG	240
	CCATTCTATT GGGACCTGAA CTTTGAAGAC CACAMTATTG AAGAGGCGTT GCTTACCYGT	300
55	TGGGGGCCAA GAGGCATGTT ACCAAACATG GYYCARGAAM YTTGGYKGGG AMCARKKKKG	360
	GKKGGGARRM CMRGGGYTTG SCAAWTTC SK KGGCMWCCYT TTAGGGTAAR RRGGGCKGTW	420
	ATTAGATTGT GGGTAAAGTA GGATCTTTTG CCCTTGCAAA TTTGCTGCCT GGGTGAATGY	480
60	TGCTTGTTCC TTCTCMACCC CTAACCTAG TAGTTCCTCC ACTAACTTTC TCACTAAGTG	540

AGAATGAGAA CTGCTGTGAT AGGGAGAGTG AAGGAGGGAT ATGTGGTAGA GCACTTGATT 600
TCAGTTGAAT GCCTGCTGGT AGCTTTTCCA TTCTGTGGAG CTGCCGTTCC TAATAATTCC 660
AGGTTTGGTA GCGTGGAGGA GAACTTTGAT GGAAAGAGAA CCTTCCCTTC TGTA CTGTTA 720
ACTTAAAAAT AAATAGCTCC TGATTCAAAG TAAAAA AAAA AAAAAA 777

10

(2) INFORMATION FOR SEQ ID NO: 182:

15

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 791 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 182:

GGCACAGATA ACTATGTACA TGTATTCCTT AAATGTTTTT TTAAGTTTTA TATTCCTGGC 60
ACTGGTCTTC AAATGTGTAC ATGTGTGCCA GGGAGCAAAT GCCTTCTTGT TTCTGAAATT 120
GGTCTTTTAG ACTGTTCTTT TTCCCATCT TCTCACCTCC TGCCCTCCT TCAGGGTACT 180
TCCGTGGCCA GAACCCCTCC AGGTCAGAGG CAGAAGAGAA GCCTCATGGG TCACAGCAGC 240
AGATGTGGGC TGGAGATCTA TTCATTGGT TTTGGCTTGA ATTTTCTGRA TGGTTTACTT 300
GATCYTGGGA AAGANATATC TTGCCAGGAA AAATGATAGN CCTTGACAAT GTTGAATGAT 360
CCTGCACCAC CTTGAAAGAC ATTTCTAATA TGGTTTGTC GGCAAAGTGG TTAGTAGTCA 420
TTTGTGGCCT GAGGTAGAAG TCCTCAGAAA TCAGCAGACT TCACTGATAA AATGCTGACT 480
TGCCCTGGA CTGGGCTCTG TGAGAGTGGC CTCTGCACT GTGCACAGTA GGTGTGAACA 540
CACCACACCT ACAGGGACCA CGTGGTGGGC TGTGGACTAG CGGCCAAGCT CCTGCAGGC 600
CCACTAATAG AATTCAGCTT TTAGCATGGG CTGTTTCATA CTGTTCTGAT GAAACTGATT 660
TGGTTTCTTT CCTCCATACC CCTTCTGCAT TTCAGTGT TTGTTTAGTT TTCTGGTTT 720
TTAATPATAA CTACAAAATA AAATCTTTAG GCTATTCACC TTAGCTTAGT AAAAAAAAAA 780
AAAAAAACT C 791

50

(2) INFORMATION FOR SEQ ID NO: 183:

55

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1405 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 183:

5	AAATTGATTA ACAGCTTGAA AGAAGGCTCT GGTTTTGAAG GCCTAGATAG CAGCACTGCC	60
	AGTAGCATGG AGCTGGAAGA ACTTCGGCAT GAGAAAGAGA TGCAGAGGGA GGAAATACAG	120
	AAGCTGATGG GCCAGATACA TCAGCTCAGA TCCGAATTAC AGGATATGGA GGCACAGCAA	180
10	GTTAATGAAG CAGAAATCAGC AAGAGAACAG TTACAGGWTG TGCATGACCA AATAGCTGGG	240
	CAGAAAGCAT CCAACAAGA ACTAGAGACA GAACTGGAGC GACTGAAGCA GGAGTTCCAC	300
15	TATATAGAAG AAGATCTTTA TCGAACAAAG AACACATTGC AAAGCAGAAT TAAAGATCGA	360
	GACGAAGAAA TTCAAAAAC T CAGGAATCAG CTTACCAATA AACTTTTAAG CAATAGCAGT	420
	CAGTCTGAGT TAGAAAATCG ACTCCATCAG CTAACAGAGA CTCTCATCCA GAAACAGACC	480
20	ATGCTGGAGA GTCTCAGCAC AGAAAAGAAC TCCCTGGTCT TTCAACTGGA GCGCCTCGAA	540
	CAGCAGATGA ACTCCGCCTC TGGAAAGTAGT AGTAATGGGT CTTGATTAA TATGTCTGGA	600
25	ATTGACAATG GTGAAGGCAC TGGTCTGCGA AATGTTCTTG TTCTTTTAA TGACACAGAA	660
	ACTAATCTGG CAGGAATGTA CGGAAAAGTT CGCAAAGCTG CTAGTTCAAT TGATCAGTTT	720
	AGTATTCGCC TGGGAATTTT TCTCCGAAGA TACCCCATAG CCGAGTTTTT TGTAAITATA	780
30	TATATGGCTT TGCTTCACCT CTGGGTCATG ATTGTTCTGT TGACTTACAC ACCAGAAATG	840
	CACCACGACC AACCATATGG CAAATGAACC AAGCCCAGTT GTTGCACTGA TTGGTTGTCT	900
35	TTTTCTAGAC TTGGGATCTG CAAGAAGGCC AATTGCCTAA AATTCTGAG AACAGTGCAC	960
	AAGATTATTT TATCACTACA AGCTTTTAAC TTTTAAAGTT ATTGTACAAG TATICTACCT	1020
	AAATCTTCCA ATTTCCTTTA AATGGTAAGA GTTCTTAAAA CAGACAATAA TTTAACAAGC	1080
40	TCAGCTCTGC TTTATCTGAG TTTAGTGGTC CTAATATATA TGTAGAGAAA GATGGTGGGG	1140
	TTGTTACCTT CTGTACAGAC CATCTGTATG TTAGGTGACA TTGATTATGG GTTATAATCA	1200
45	GGGAAACTAA TTGTATTTAG TGACAAAAAT AAAAAGTTTT TTTTATATA TTCAGTCTGC	1260
	TTTTGGATTT TCATATATTT AACTTTGCAA AAAGATTTAC TTTGTACATG TTACAGGCTT	1320
	GATTGGTGTA AATCTTTTTA TAAATACATA AATAAAAGNA AAATATGCAT TTTTCTTTTC	1380
50	TAAAAAATAA AAAAAAATAA CTCGA	1405

55 (2) INFORMATION FOR SEQ ID NO: 184:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1596 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

60

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 184:

5	GTCATGCACT GCGOOGGAGA ACTGTGCTCT TTGAGGCCGA CGCTAGGGGC CCGGAAGGGA	60
	AACTGCGAGG CGAAGGTGAC CGGGGACCGA GCATTTTCAGA TCTGCTGGGT AGACCTGGTG	120
	CACCACCACC ATGTTGGCTG CAAGGCTGGT GTGTCTCCGG AACTACCTT CTAGGGTTTT	180
10	CCACCCAGCT TTCACCAAGG CCTCCCCTGT TGTGAAGAAT TCCATCACGA AGAATCAATG	240
	GCTGTTAACA CCTAGCAGGG AATATGCCAC CAAAACAAGA ATTGGGATCC GCGTGGGAG	300
15	AACTGGCCAA GAACTCAAAG AGGCAGCATT GGAACCATCG ATGGAAAAA TATTTAAAAT	360
	TGATCAGATG GGAAGATGGT TTGTTGCTGG AGGGGCTGCT GTTGGTCTTG GAGCATTGTG	420
	CTACTATGGC TTGGGACTGT CTAATGAGAT TGGAGCTATT GAAAAGGCTG TAATTTGGCC	480
20	TCAGTATGTC AAGGATAGAA TTCATTCCAC CTATATGTAC TTAGCAGGGA GTATGGTMTT	540
	AACAGCTTTG TCTGCCATAG CAATCAGCAG AACGCCTGTT CTCATGAACT TCATGATGAG	600
25	AGGCTCTTGG GTGACAATG GTGTGACCTT TGCAGCCATG GTTGGAGCTG GAATGCTGGT	660
	ACGATCAATA CCATATGACC AGAGCCGAGG CCCAAAGCAT CTGCTTGGT TGCTACATTC	720
	TGGTGTGATG GGTGCAGTGG TGGCTCCTCT GACAATATTA GGGGGTCTC TTCTCATCAG	780
30	AGCTGCATGG TACACAGCTG GCATTGTGGG AGGCCTCTCC ACTGTGGCCA TGTGTGCGCC	840
	CAGTGAAGAAG TTTCTGAACA TGGGTGCACC CCTGGGAGTG GGCTGGGTC TCGTCTTTGT	900
35	GTCTCATATG GGATCTATGT TTCTTCCACC TACCACCGTG GCTGGTGCCA CTCITTACTC	960
	AGTGGCAATG TACGGTGGAT TAGTTCTTTT CAGCATGTTT CTCTGTATG ATACCCAGAA	1020
	AGTAATCAAG CGTGCGAAG TATCACC AAT GTATGGAGTT CAAAAATATG ATCCCATTA	1080
40	CTCGATGCTG AGTATCTACA TGGATACATT AAATATATTT ATGCGAGTTG CAACTATGCT	1140
	GGCAACTGGA GGCAACAGAA AGAAATGAAG TGAATCAGCT TCTGGCTTCT CTGCTACATC	1200
45	AAATATCTTG TTTAATGGGG CAGATATGCA TTAATAGTT TGTACAAGCA GCTTTGGTTG	1260
	AAGTTTAGAA GATAAGAAAC ATGTATCAT ATTTAAATGT TCCGGTAATG TGATGCCTCA	1320
	GGTCTGCCTT TTTTCTGGA GAATAAATGC AGTAATCCTC TCCCAAATAA GCACACACAT	1380
50	TTTCAATCT CATGTTGAG TGATTTTAAA ATGTTTGGT GAATGTGAAA ACTAAAGTTT	1440
	GTGTATGAG AATGTAAGTC TTTTCTTAC TTAAATTTT AGTAGGTCA CTGAGTAACT	1500
55	AAAATTTAGC AAACCTGTGT TTGCATATTT TTTGGAGTG CAGMATAWTG TAATTARAGC	1560
	ATTCCAGTAA NAGTGTNTTT AAGTTGNTC TATATN	1596
60		

(2) INFORMATION FOR SEQ ID NO: 185:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 2293 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 185:

10 GGCAGAGCC CGYACGAGCA GGACGACGAC GACAAGGGCG ACTCCAAGGA AACGCGGCTG 60
 ACCCTGATGG AGGAAGTGCT CCTGCTGGGC CTCAAGGACC GCGARGGTTA CACATCATTT 120
 15 TGGAACTGACT GTATATCATC TGGATTACGT GGCTGTATGT TAATTGAATT AGCATTGAGA 180
 GGAAGGTTAC AACTAGAGGC TTGTGGAATG AGACGTAAAA GTCTATTAAAC AAGAAAGGTA 240
 20 ATCTGTAACT CAGATGCTCC AACAGGGGAT GTCTCTCTTG ATGAAGCTCT GAAGCATGTT 300
 AAGGAAATC AGCCTCCAGA AACGGTCCAG AACTGGATTG AATTACTTAG TGGTGAGACA 360
 TGGAAATCCAT TAAAATTGCA TTATCAGTTA AGAAATGTAC GGGAACGATT AGCTAAAAAC 420
 25 CTGGTGGAAA AGGGTGTAAT GACAACAGAG AAACAGAACT TCCTACTTTT TGACATGACA 480
 ACACATCCCC TCACCAATAA CAACATTAAG CAGCGCCTCA TCAAGAAAGT ACAGGAAGCC 540
 30 GTTCTTGACA AATGGGTGAA TGACCTCAC CGCATGGACA GCGCTTGCT GGCCCTCATT 600
 TACCTGGCTC ATGCTCGGA CGTCTGGAG AATGCTTTTG CTCTCTCTT GGACGAGCAG 660
 TATGATTTGG CTACCAAGAG AGTGGCGCAG CTTCTCGACT TAGACCTGA AGTGAATGT 720
 35 CTGAAGCCA ACACCAATGA GGTCTGTGG GCGGTGGTG GCGCGTCAC CAAGTAACTC 780
 TGCTCGGGGT GAACCATCT CTTTCTCTC AAGTAAACCA GTAGTTTTC TTCTGTGAC 840
 40 TTCTGGTTT CTGTAATTTG TACTTTCCCA CACTATAATT GGCTTCTGTT TTACAAAATG 900
 GTGGGTGGCT TTTTCTTTT TGTACGTGA CAGGATTCTG CTGGTACGAG AGGCCTTCCT 960
 CTTTCTGTT TTAaaaaaag TTTTACTGCC ATATTGGCAT TCCATTCCCT GTTGCCATCC 1020
 45 TCACTGTTAC CTGTTTGGG TTTCTGGTCT ACTTTGACTT TCAAAGTACC TCCAGCCTCC 1080
 TCATACGCAC AGCTTTTGGG TGACCTCAGC TTGAGTTTCT CCATATGTGC ATGTACATCT 1140
 50 AGCATTCTGC CTACAGTTCA GACAGAAGTC AAAAAAGGC CTTCAACTCA CCAAAGGTAA 1200
 ATATCTGTAT CTATTAGGAC ATTTTTTACA TAGACTTCAG TTGAGATGTA TACTTAGCAA 1260
 AATTATTTT AAATTGAAAC AGCACAGTAA ATACTTAATA TAAATGTCC CTTGGATTTT 1320
 55 GCTTCCCATG TAAATCTATT GTATTATTAC ACTTGTATA ATTTTAACTA TAAAGGTCCA 1380
 ATTGTTTCAC AGAGCCAGTT TGGGATGGG TGCAATCCAT TTATGCTGTA TATAGTTTGA 1440
 60 ATTATATATA AATTACCCCT TCTTCTGGCC ACCCTGCTC CCATCTTAGT ATTTTGCAAG 1500

ATCTAATCAG TTGTACACCT GGTGCCCTC GCTTGCTTCA ATCATGGTTA TTTGATGGCA 1560
 5 AAATCGACCT CTTGTGCTG AAGGAGAGAG AAAAGATGTG TGTCTGATTG GTCTGGGAT 1620
 TTTTGTAGCT GTGCCATTTA TGGTACTCTT TGCCTATGCA TCCCCTTTT AGATTTTTTT 1680
 TAAATTTTAT CTTACTGTTT TTATAATTTT TATTGGGAAG AGGCTTGTGA CCAGTACCAA 1740
 10 TCTTGAGTTT CTTTTTCTGT CCACAAGTAA ATTAATATCT GCTCTGAAAT GTCATTTATC 1800
 TACTCACACA TTCTTGGGA AAAAAATCAA ATGTCAGTCC TAGCAGATGT TGCATGTAAA 1860
 15 TTGGTAGCAA GTAATGATTA CAACCCAGAG GATTAAGAAT TTTGTAACAG AAAGCTCTAT 1920
 GTTTTAATTT TTTATATACA ATTAGGATAA TTAGCATGT CAGACTATAA ACCTTTGCTT 1980
 TTAAAGTTT ATTTTACTA TTCTTTATC ACTTTATGT ATCATCACC A TTGGTTTCAT 2040
 20 AATGTAAATA CTATATGTTG AACAAATTAA ATGTCAAAAT TTTTATTAC CATAGTCCAT 2100
 GTTAATAGTG GGGCTTTCAG GTGTTTAGAG ATTTTTTTTG TTGTGTAA CATTCATTGC 2160
 AAAAGTACTA GATGGTGTAT AACTCTAGAG TTGAATTTA AGGGATTCCC TAATATGTAT 2220
 25 ACTATCTTTT TATCTGAAGT AATAAATAA CAATGATCTT GAAAGTGCCY RAAAMAAAAA 2280
 AAAAAAAAA AAA 2293

30

(2) INFORMATION FOR SEQ ID NO: 186:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1212 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 186:

GGCAAGAGGC GAGCCGGGC ACCGTACGCT GGGACGTGTG GTTTCAGCTC GTGCGCCTCC 60
 45 CCGTGGGTTT GCGACGTTTA GCGACTATTG CGCCTGCGCC ACCCGGCTG CGAGACTGGG 120
 GCGTGGCTG CTGGTCCGG GTGATGCTAG GCGGCTCCCT GGGCTCCAGG CTGTTGCGG 180
 50 GTGTAGGTGG GAGTCACGA CGGTCGGGG CCCGAGGTGT CCGGAAGGT GGCGCACATG 240
 GGCGGCAGGG GAGAGCATGG CTCAGCGGAT GGTCTGGGTG GACCTGGAGA TGACAGGATT 300
 GGACATGTAG AAGGACCAGA TTATTGAGAT GGCCTGTCTG ATAACCTGACT CTGATCTCAA 360
 55 CATTTTGGCT GAAGGTCTTA ACCTGATTAT AAAACAACCA GATGAGTTGC TGGACAGCAT 420
 GTCAGATTGG TGTAAGGAGC ATCACGGGAA GTCTGGCCTT ACCAAGGCAG TGAAGGAGAG 480
 TACAATTACA TTGACGAGG CAGAGTATGA ATTTCTGTCC TTTGTACGAC AGCAGACTCC 540
 60

	TCCAGGGCTC TGTCCACTTG CAGGAAATTC AGTTCATGAA GATAAGAAGT TTCTTGACAA	600
	ATACATGCCC CAGTTCATGA AACATCTTCA TTATAGAATA ATTGATGTGA GCACGTGTAA	660
5	AGAACTGTGC AGACGCTGGT ATCCAGAAGA ATATGAATTT GCACCAAAGA AGGCTGCTTC	720
	TCATAGGGCA CTTGATGACA TTAGTGAAAG CATCAAAGAG CTTCACTTTT ACCGAAATAA	780
10	CATCTTCAAG AAAAAAATAG ATGAAAAGAA GAGGAAAATT ATAGAAAATG GGGAAAATGA	840
	GAAGACCGTG AGTTGATGCC AGTTATCATG CTGCCACTAC ATCGTTATCT GGAGGCAACT	900
	TCTGGTGGTT TTTTTCCTC ACGCTGATGG CTTGGCAGAG CACCTTCGGT TAACTTGTCAT	960
15	CTCCAGATTG ATTACTCAAG CAGACAGCAC ACGAAATACT ATTTTCTCC TAATATGCTG	1020
	TTTCCATTAT GACACAGCAG CTCCTTGTGA AGTACCAGGT CATGTCCATC CCTTGGTACA	1080
20	TATATGCATT TGCTTTTAAA CCATTTCTTT TGTTTAAATA AATAAATAAG TAAATAAAGC	1140
	TAGTTCTATT GAAATGCAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	1200
	AAAAAAAAAA AN	1212

25

(2) INFORMATION FOR SEQ ID NO: 187:

30

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1605 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 187:

	GCTTCCGGAA GTTGCTTTTG TCCAAACATC CGGGCTTCTC CTTTGTGTGT TCCGGCCGAT	60
40	CCCACCTCTC CTCGACCCTG GACGTCTACC TTCCGGAGGC CCACATCTTG CCCACTCCGC	120
	GCGCGGGGCT AGCGCGGGTT TCAGCGACGG GAGCCCTCAA GGGACATGGC AACTACAGCG	180
45	GCGCCGGCGG GCGGCGCCCG AAATGGAGCT GCGCCGAAT GGGGAGGGTT CGAAGAAAAC	240
	ATCCAGGGCG GAGGCTCAGC TGTGATTGAC ATGGAGAACA TGGATGATAC CTCAGGCTCT	300
	AGCTTCGAGG ATATGGGTGA GCTGCATCAG CGCCTGCGCG AGGAAGAAGT AGACGCTGAT	360
50	GCAGCTGATG CAGCTGCTGC TGAAGAGGAG GATGGAGAGT TCCTGGGCAT GAAGGGCTTT	420
	AAGGGACAGC TGAGCCGGCA GGTGGCAGAT CAGATGTGGC AGGCTGGGAA AAGACAAGCC	480
55	TCCAGGGCCT TCAGCTTGTA CGCCAACATC GACATCCTCA GACCTACTTT TGATGTGGAG	540
	CCTGCTCAGG TCGAACAGG GTCCTGGAG TCCATGATCC CTATCAAGAT GGTCAACTTC	600
	CCCCAGAAA TTGCAGGTGA ACTCTATGGA CCTCTCATGC TGGTCTTCAC TCTGGTTGCT	660
60	ATCCTACTCC ATGGGATGAA GACGTCTGAC ACTATTATCC GGGAGGGCAC CCTGATGGGC	720

	ACAGCCATTG GCACCTGCTT CGGCTACTGG CTGGGAGTCT CATCCTTCAT TTA CTTCCTT	780
5	GCCTACCTGT GCAACGCCCA GATCACCATG CTGCAGATGT TGGCACTGCT GGGCTATGGC	840
	CTCTTTGGGC ATTGCATTGT CCTGTTTCATC ACCTATAATA TCACCTCCA CGCCCTCTTC	900
	TACCTCTTCT GGCTGTGGT GGGTGGACTG TCCACACTGC GCATGGTAGC AGTGTGGTG	960
10	TCTCGGACCG TGGGCCCCAC ACAGCGGCTG CTCCTCTGTG GCACCCCTGGC TGCCCTACAC	1020
	ATGCTCTTCC TGCTCTATCT GCATTTTGCC TACCACAAAG TGGTAGAGGG GATCCTGGAC	1080
15	ACACTGGAGG GCCCAACAT CCGGCCCATC CAGAGGGTCC CCAGAGACAT CCTGCCATG	1140
	CTCCCTGCTG CTCGGCTTCC CACCACGTC CTCAACGCCA CAGCCAAAGC TGTTCGGTG	1200
	ACCTTGCACT CACTTGACC CCACCTGAAA TTCTTGGCCA GTCTCTTTC CCGCAGCTGC	1260
20	AGAGAGGAGG AAGACTATTA AAGGACAGTC CTGATGACAT GTTTCGTAGA TGGGGTTTGC	1320
	AGCTGCCACT GAGCTGTAGC TGCCTAAGTA CCTCTTGAT GCTGTGGC ACTTCTGAAA	1380
25	GGCACAAGGC CAAGAACTCC TGGCCAGGAC TGCAAGGCTC TGCAGCCAAT GCAGAAAATG	1440
	GGTCAGCTCC TTTGAGAAC CCTCCACC TACCCCTTCC TTCTCTTTA TCTCTCCAC	1500
	ATTGTCTTGC TAAATATAGA CTGTGTAAT AAAATGTTGA TTGAAGTCTG GAAAAAATA	1560
30	AAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAC TCGAG	1605

35 (2) INFORMATION FOR SEQ ID NO: 188:

(i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 1516 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 188:

45	ATTCGGCATG AAGGGGTAC GTGGTGGCTG GCGGGGGAA ATGGCGGCTT CAGGAGAGAG	60
	CGGGACTTCA GCGGGCGGAG GCAGCACCGA GGAAGCATTT ATGACCTTCT ACAGTGAGGT	120
50	GAAACAAATA GAGAAGAGAG ACTCGGTCTT AACTTCGAAA AATCAGATTG AAAGACTGAC	180
	CGTCTCTGGT TCCTCTTACT TCAATTTGAA CCCATTGAG GTTCTTCAGA TAGATCCTGA	240
	AGTTACAGAT GAAGAAATAA AAAAGAGGTT TCGGCAGTTA TCCATCTTGG TGCATCTGA	300
55	CAAAAATCAA GATGATGCTG ACAGAGCACA AAAGGCTTTT GAAGCTGTGG ACAAGCTTA	360
	CAAGTTGCTA CTGGATCAGG AGCAAAAGAA GAGGGCCCTG GATGTAATTC AGGCAGGAAA	420
60	AGAATACGTG GAACACACTG TGAAAGAGCG AAAAAACAA TTAAAGAAGG AAGGAAAACC	480

	TACAATTGTA GAGGAGGATG ATCTGAGCT GTTCAAACAA GCTGTATATA AACAGACAAT	540
	GAAACTCTTT GCAGAGCTGG AAATTAAAG GAAAGAGAGA GAAGCCAAAG AGATGCATGA	600
5	AAGGAAACGA CAAAGGGAAG AAGAGATTGA AGCTCAAGAA AAAGCCAAAC GGGAAAGAGA	660
	GTGGCAGAAA AACTTTGAGG AAAGTCGAGA TGGTCGTGTG GACAGCTGGC GAAACTTCCA	720
10	AGCCAATACG AAGGGGAAGA AAGAGAAGAA AAATCGGACC TTCTGAGAC CACOGAAAGT	780
	AAAAATGGAG CAACGTGAGT GACCGCCCAA GGTACAGGC ACAGAACCTT TCCCTGCTA	840
	TCTCCCTTCC TGCTTCGAAG GACTCATTTCT TTCTCCAC TTCCACCCCA ACATAGAGTA	900
15	GTATTTGCTT TTTAGTCCAT TTGTGTTTCA ATACGATTTA ATATCGATCA GAGTAATTCT	960
	TTGTACATT GAAATGAGG GCTTGGTTTA AAAAAAGACC TTCCCTCTC CCTGCCCCCTA	1020
20	GAACAACCAG TATTAGAAGG TGCCACCATT GGTGCTGCCT TCTCTTCCCA CAGCCTGTAA	1080
	CTCAGTGTG TGTACTTCAC TGAATTGTGA TGGTTAGAAA CTTCGTGGAT AGTTTGTGA	1140
	AATCATCCAA TTAACATAC TGCTTAAAC AGTGTGCTG TGAATTCAGA GACAAGCCTG	1200
25	GAAGGGGCAC CTTAGGAAGC CCCTTCGCTT CAGTTGCTCG CTCTGGGTG TGCTCCCTTC	1260
	GAAGGCCAG ATAAGACAGG GAACACTTGT GAGCACACAG AGCAGCATCT GATGCCCTGT	1320
30	GGTGTPIGGC ATGTGCCCCC TGTCTACTGA CCAATCAGTG TGGCATGAGG CCCACGCCAC	1380
	CCAAACCTTT CACTTTCCAA AGAGCTAGCC GTCTCCACC CAGTACCATG TCCTAGCCTG	1440
	TCTGCATTTG TTAGTGGTAA TATTCTTTAT GTATAATAAA TTTTATACC CAAAAAAAAA	1500
35	AAAAAAAAA ACTCGA	1516

40 (2) INFORMATION FOR SEQ ID NO: 189:

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 681 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 189:

50	GCTCCCATGT TGCTGGCTGT CCGTACATCA CCTGTCCCC TGCAGGAGGG GGCTACAGGC	60
	CATCTCCCTC CTGTAGGCCT CTGACTCCCC TCCACTTTTG GGCCCTCAGC TTATCTGGG	120
55	CAGGGGACCA TTGCAGCATC CTCCCTCCT CNGGACTCAA GGTGCTGAGG TATAAGCCCT	180
	GGGCCCCAGA TCCTGRTKA CACCTTCCTG GAGAAGACTC TCAAAAGTGA CTGTATATTT	240
	GAGTTCACCA GCAATAACTC CCCACACTCG AAGCAGGTCC AAACCCMAGG ATCCCAGGT	300
60	CCTTGGGCTC TGTTGGCACTG TCTTCCCAAG ATCCTTCCTG TTGCACAATG GGAAACCTAA	360

5 GAGGAAAAAG ACAGGGGCGT GCTTGCCCAG CCATGCGAGG GATTCCATGC CCACCTGCCC 420
 TCTGYCTGCC TCGCTGGAAT GTGGGCCCCCT GCTCCCCGTC AGGTTGTGCT GTCTCTGACC 480
 TATGTTTACA TCCCCGAGGG GTTCTTGCTT CCTCCCCACC CAGGTCAGGG TGTGGTCCAG 540
 CAGCTTGCTG TGGGGTGCTG ACATGTGTCA CCACTGCCCC CCTTGCCCCC GGGGGGGTCA 600
 10 TGGTCTCTC CTGGATGCTG CTCCTTGAAT YTTTTTYYT GAWAAACCYT TTAMAATTAA 660
 AAAAAAAAAA AAAAACTCG A 681

15

(2) INFORMATION FOR SEQ ID NO: 190:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1014 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 190:

GCCTCAAGCC ACGCATATGA TAATTTTCTG GAACATTCAA ATTCAGTGTT TCTACAGCCA 60
 30 GTTAGTCTAC AAACCATGTC AGCAGCACCA TCAAACCAGA GTCTGCCACT TTTTGTCTATC 120
 GCTGGATGAT TGCTGGGCAA AGGTGGCCTT TTAGAGCTCT TAAAAGCCCA CAAAAGGCT 180
 ATTCGTAGAG CCACAGTCAA CACATTTGGT TATATTGCAA AGGCCATTGG CCTCATGATG 240
 35 TATTGGCTAC ACTTCTGAAC AACCTCAAAG TTCAAGAAAG GCAGAACAGA GTTGTGTACCA 300
 CTGTAGCAAT AGCTATTGTT GCAGAACAT GTTCACCTT TACAGTACTC CCTGCCTTAA 360
 40 TGAATGAATA CAGAGTTCTT GAACTGAATG TTCAAAATGG AGTGTTAAAA TCGCTTTCTT 420
 TCTTGTTTGA ATATATTGGT GAAATGGGAA AAGACTACAT TTATGCCGTA ACACCGTTAC 480
 TTGAAGATGC TTTAATGGAT AGAGACCTTG TACACAGACA GACGGCTAGT GCAGTGGTAC 540
 45 AGCACATGTC ACTTGGGGTT TATGGATTG GTTGTGAAGA TTCGCTGAAT CACTTGTGTA 600
 ACTATGTATG GCCCAATGTR TTTGAGACAT CTCCTCATGT AATTCAGGCA GTTATGGGAG 660
 CCTAGAGGG CTGAGAGTT GCTATTGGAC CATGTAGAAT GTTGCAATAT TGTTTACAGG 720
 50 GTCTGTTTCA CCCAGCCCGG AAAGTCAGAG ATGTATATTG GAAAATTTAC AACTCCATCT 780
 ACATTGGTTC CCAGGACGCT CTCATAGCAC ATTACCCAAG AATCTACCAA CGATGATAAG 840
 55 RACACCTATA TTCGTTATGA ACTTGACTAT ATCTTATAAT TTTATTGTTW ATTTKGIGKT 900
 TAATGCACAS TACTTCACAC CTTAACTTG CTTTGATTG GTGATGTAAA CTTTAAACA 960
 60 TTGCAGATCA GTGTAGGACT GGTCCATAGG GGAAGAGCTA GGAANTCCAT AGGC 1014

(2) INFORMATION FOR SEQ ID NO: 191:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2779 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 191:

TCGCAGCAGG GTGTGTCCAG ATGGTCAGTC TCTGGTGGCT AGCCTGTCTT GACAGGGGAG 60
AGTTAAGCTC CCGTCTCCA CCGTCCCGC TGGCCAGGTG GGCTGAGGGT GACCGAGAGA 120
CCAGAACCTG CTGTCTGGAG CTGTAGTCTC AGAGCTGGGG AGGGAGGTTC CGCCGCTCCT 180
CTGCTGTGAG CGCCGCGAGC CCTTCCCGC TTCACTTCTT CCCGACGCCC CTGCTACTGA 240
GAAGCTCCGG GATCCACAGC GCGCCACGC CCTGGCTTCA GCCTGGGGGG CTCCAGTCAG 300
GCCAACACCG ACGCGCANTG GGAGGAAGAC AGGACCCCTG ACATCTCCAT CTGCACAGAG 360
GTCTTGCTG GACCGAGCAG CCTCTCTCTC CTAGGATGAC CTCACCTCC AGCTCTCCAG 420
TTTTCAGGTT GGAGACATTA GATGGAGGCC AAGAAGATGG CTCTGAGGCG GACAGAGGAA 480
AGCTGGATTT TGGGAGCGGG CTGCCCTCCA TGGAGTCACA GTTCCAGGGC GAGGACCGGA 540
AATTCGCCCC TCAGATAAGA GTCAACCTCA ACTACCGAAA GGAACAGGT GCCAGTCAGC 600
CGGATCCAAA CCGATTGAC CGAGATCGGC TCTTCAATGC GGTCTCCCGG GGTGTCCCGG 660
AGGATCTGGC TGGACTTCCA GAGTACCTGA GCAAGACCAG CAAGTACCTC ACCGACTCGG 720
AATACACAGA GGGCTCCACA GGTAAGACGT GCCTGATGAA GGCTGTGCTG AACCTTAAGG 780
ACGGGGTCAA TGCTGCATT CTGCCACTGC TGCAGATCGA CCGGACTCTT GGCAATCCTC 840
AGCCCTGGT AAATGCCAG TGCACAGATG ACTATTACCG AGGCCACAGC GCTCTGCACA 900
TGCCATTGA GAAGAGGAGW CTGCAGTGTG TGAAGCTCCT GGTGGAGAAT GGGGCCAATG 960
TGCATGCCCC GGTCTGGGC GCTTCTTCCA GAAGGGCCAA GGGACTTGCT TTTATTTCCG 1020
TGAGCTACCC CTCTYTTTGG CCGCTTGAC CAAGCAGTGG GATGTGGTAA GCTACCTCCT 1080
GGAGAACCCA CACCAGCCCG CCAGCCTGCA GGCAGTACT CCCAGGGCAA CACAGTCTTG 1140
CATGCCCTAG TGATGATCTC GGACAACTCA GCTGAGAACA TTGCACTGGT GACCAGCATG 1200
TATGATGGG TCCTCCAAGC TGGGGCCCGC CTCTGCCCTA CCGTGACGCT TGAGGACATC 1260
CGCAACCTGC AGGATCTCAC GCCTCTGAAG CTGGCCGCCA AGGAGGGCAA GATCGAGATT 1320
TTCAGGCACA TCCTGCAGCG GGAGTTTCA GGACTGAGCC ACCTTTCCCG AAAGTTCACC 1380
GAGTGGTGCT ATGGGCTGT CCGGTGTCTG CTGTATGACC TGGCTTCTGT GGACAGCTGT 1440

	GAGGAGAACT CAGTGCTGGA GATCATTGCC TTTCATTGCA AGAGCCCGCA CCGACACCGA	1500
5	ATGGTCGTTT TGGAGCCCCCT GAACAAACTG CTGCAGGCCA AATGGGATCT GCTCATCCCC	1560
	AAGTTCTTCT TAAACTTCCT GTGTAATCTG ATCTACATGT TCATCTTCAC CGCTGTTGCC	1620
	TACCATCAGC CTACCCTGAA GAAGCAGGCC GCCCTCACC TGAAAGCGGA GGTGGAAC	1680
10	TCCATGCTGC TGACGGGCCA CATCCTTATC CTGCTAGGGG GGATCTACCT CCTGTGGGC	1740
	CAGCTGTGGT ACTTCTGGCG GCGCCAGTG TTCACTGGA TCTGTTCAT AGACAGCTAC	1800
15	TTTGAAATCC TCTTCTGTT CCARGCCCTG CTCACAGTGG TGTCCARGT GCTGTGTTT	1860
	CTGGSCATCG AGTGGTACCT GCCCTGCTT GTGTCTGCGC TGGTGCTGGG CTGGCTGAAC	1920
	CTGCTTTACT ATACACGTGG CTCCAGCAC ACAGGCATCT ACAGTGTCTAT GATCCAGAAG	1980
20	CCCTGGTGAG CCTGAGCCAG GANNITGGCG CCCCGAAGCT CCTACAGGCC CCAATGCCAC	2040
	AGAGTCAGTG CAGCCCATGG AGGGACAGGA KGACGARGGC AACGGGGCCC AGTACAGGGG	2100
25	TATCCTGGAA GCCTCCTTGG AGCTCTTCAA ATTCAACATC GGCATGGCG AGCTGGCCTT	2160
	CCAGGARCAG CTGCACTTCC GCGGCATGGT GCTGCTGCTG CTGCTGGSCT ACGTGTGCT	2220
	CACCTACATC CTGCTGCTCA ACATGCTCAT CGCCCTCATG AGCGAGACCG TCAACAGTGT	2280
30	CGCCACTGAC AGCTGGAGCA TCTGGAAGCT GCAGAAAGCC ATCTCTGTCC TGGAGATGGA	2340
	GAATGCTAT TGGTGGTGCA GGAAGAAGCA GCGGGCAGGT GTGATGCTGA CCGTTGGCAC	2400
35	TAAGCCAGAT GGCAGCCCSG ATGAGCGCTG GTGCTTCAGG GTGGAGGAGG TGAAGTGGC	2460
	TTTCATGGGAG CAGACGCTGC CTACGCTGTG TGAGGACCCG TCAGGGGCAG GTGTCCCTCG	2520
	AACTCTCGAG AACCTGTCC TGGCTTCCC TCCCAAGGAG GATGAGGATG GTGCCTCTGA	2580
40	GGAAACTAT GTGCCCCGCC AGCTCCTCCA GTCCAACTGA TGGCCAGAT GCAGCAGGAG	2640
	GCCAGAGGAC AGAGCAGAGG ATCTTTCCAA CCACATCTGC TGGCTCTGGG GTCCCACTGA	2700
45	ATTCTGGTGG CAAATATATA TTTTCACTAA CTCAAAAAAA AAAAAAAAAA AAAAAAAAAA	2760
	AAAAAAAAA AAAAAAGGC	2779

50

(2) INFORMATION FOR SEQ ID NO: 192:

(i) SEQUENCE CHARACTERISTICS:

55

- (A) LENGTH: 1923 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 192:

	ACCCGCTCCG CTCCGCTCCG CTCCGCCCCG CGCCGCCCCG CAACATGATC CGCTGGGGCC	60
	TGGCCTGCGA GCGCTGCCG TGGATCCTGC CCTGCTCCT ACTCAGCGCC ATCGCCTTCG	120
5	ACATCATCGC GCTGGCCGGC CGCGGCTGGT TGCAGTCTAG CGACCACGGC CAGACGTCTT	180
	CGCTGTGGTG GAAATGCTCC CAAGAGGGCG GCGGCAGCGG GTCCTACGAG GAGGGCTGTC	240
10	AGAGCCTCAT GGAGTACGG TGGGGTAGAG CAGCGGCTGC CATGCTCTTC TGTGGCTTCA	300
	TCATCCTGGT GATCTGTTTC ATCCTCTCCT TCTTCGCCCT CTGTGGACCC CAGATGCTTG	360
	TCTTCCTGAG AGTGATTGGA GGTCTCCTTG CCTTGGCTGC TGTGTTCCAG ATCATCTCCC	420
15	TGTAATTTA CCCCGTGAAG TACACCCAGA CCTTCAACCCT TCATGCCAAC CSTGCTGTCA	480
	CTTACATCTA TAACTGGGCC TACGGCTTTG GGTGGGCAGC CAGGATTATC CTGATYGGCT	540
20	GTGCCCTCTT CTTCCTGCTG CTCCCCAACT ACGAAGATGA CCTTCTGGGC AATGCCAAGC	600
	CCAGGTACTT CTACACATCT GCCTAACTTG GGAATGAATG TGGGAGAAAA TCGCTGCTGC	660
	TGAGATGGAC TCCAGAAGAA GAACTGTTT TCCAGGCGA CTTTGAACCC ATTTTMTGGC	720
25	AGTGTTCATA TTATTAACT AGTCAAAAAT GCTAAAATAA TTTGGGAGAA AATAATTTTTT	780
	AAGTAGTGT ATAGTTTCAT GTTATCTTT TATTATGTTT TGTGAAGTTG TGTCTTTTCA	840
30	CTAATTACCT ATACTATGCC AATATTTCTT TATATCTATC CATAACATTT ATACTACATT	900
	TGTAAGAGAA TATGCACGTG AAACCTAACA CTTTATAAGG TAAAAATGAG GTTTCCAAGA	960
	TTTAATAATC TGATCAAGTT CTGTATTATT CCAATAGAA TGGACTCGGT CTGTAAAGGG	1020
35	CTAAGGAGAA GAGGAAGATA AGGTAAAAG TTGTTAATGA CCAAACATTC TAAAAGAAAT	1080
	GCAAAAAAAA AGTTTATTTT CAAGCCTTCG AACTATTTAA GGAAAGCAA ATCATTTCCT	1140
40	AAATGCATAT CATTTGTGAG AATTTCTCAT TAATATCCTG AATCATTCAT TTCAGCTAAG	1200
	GCTTCATGTT GACTCGATAT GTCATCTAGG AAAGTACTAT TTCATGGTCC AAACCTGTTG	1260
	CCATAGTTGG TAAGGCTTTC CTTAAGTGT GAAATATTTA GATGAAATTT TCTCTTTTAA	1320
45	AGTTCTTTAT AGGGTTAGGG TGTGGGAAAA TGCTATATTA ATAAATCTGT AGTGTMTTGT	1380
	GTTTATATGT TCAGAACCAG AGTAGACTGG ATTGAAAGAT GGACTGGGTC TAAITTTATCA	1440
50	TGACTGATAG ATCTGGTTAA GTTGTGTAGT AAAGCATTAG GAGGGTCATT CTTGTCACAA	1500
	AAGTGCCACT AAAACAGCCT CAGGAGAATA AATGACTTGC TTTTCTAAAT CTCAGGTTTA	1560
	TCTGGGCTCT ATCATATAGA CAGGCTTCTG ATAGTTTGCA ACTGTAAGCA GAAACCTACA	1620
55	TATAGTTAAA ATCCTGGTCT TTCTTGGTAA ACAGATTTTA AATGTCTGAT ATAAAACATG	1680
	CCACAGGAGA ATTCGGGAT TTGAGTTTCT CTGAATAGCA TATATATGAT GCATCGGATA	1740
60	GGTCATTATG ATTTTATACC AATTGACTT ACATAATGAA AACCATTCA TTTTAAATAT	1800

CAGATTATTA TTTTGTAGT TGtGGAAAA GCTAATTGTA GTTTTCATTA TGAAGTTTTC 1860
 CCAATAAACC AGGTATTCTA AAAAAAAAAA AAAAAAACTN GAGGGGGGGC CCGGTACCCA 1920
 5 ATT 1923

10 (2) INFORMATION FOR SEQ ID NO: 193:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2346 base pairs
 (B) TYPE: nucleic acid
 15 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 193:

20 AGGCTCAGGG GGACACTCTC AAAATTACAC AGCTTTTAAC AGGTGGCAGA ATtGGGGTTC 60
 AGACCCAGAT CTGGGTCAA GTCACTCATG GTGTGATTGC GGCATTCTT CCCGCATCTG 120
 GGCTTGCCA TCTCTCTCTC OGAGTGGACA TGGAGAGGAC GGGGGCCCAG CAGCTGGATG 180
 25 GCTGCAGGGG ATCAAGTCTT CTCTGGGGCT GGGCACGTAN AAGAGCATGT GGCTGGTGA 240
 CGGCATGCTT GGCTCTCAC CTGGCAGTCT GCCTGCCCTG CTAACCGGCT GTCTCTTGTT 300
 30 CCCCTAGTGC CCTGGGCTAG CATGACCCGC CTGATGCGWT SCCGCACAGC CTCTGGTTCC 360
 AGCGTCATTTC TCTGGATGGC ACCCGCAGCC GCTCCACAC CAGCGAGGGC ACCCGAAGCC 420
 GCTCCACAC CAGCGAGGGC ACCCGCAGCC GCTCCACAC CAGCGAGGGG GCCCACCTGG 480
 35 ACATCACCCC CAACTCGGGT GCTGCTGGGA ACAGNGCCGG GCCCAAGTCC ATGGAGGTCT 540
 CCTGCTAGGC GGCTGCCCC GCTGCCGCC CCGGACTCTG ATCTCTGTAG TGGCCCCCTC 600
 40 CTCCCCGGCC CCTTTTGCC CCCTGCCTGC CATACTGCC CTAACCGGT ATTAAATCAA 660
 AGCTTATTTT GTAAGAGTGA GCTCTGGTGG AGACAAATGA GGTCTATTAC GTGGGTGCCC 720
 TCTCCAAAGG CGGGGTGGCG GTGGACCAA GGAAGGAAGC AAGCATCTCC GCATCGCATC 780
 45 CTCTTCCATT AACCAGTGGC CGGTGCCCAC TCTCTCCCC TCCCTCAGAG ACACCAAAT 840
 GCCAAAACA AGACCGGTAC AGCACAACT TCACAAAGCC AAGCCTAGGC CGCCCTGAGC 900
 50 ATCCTGGTTC AAACGGGTGC CTGGTCAGAA GGCCAGCCGC CCACTTCCCG TTTCTCTTT 960
 AACTGAGGAG AAGCTGATCC AGTTTCCGGA AACAAAATCC TTTTCTCATT TGGGGAGGGG 1020
 GGTAATAGTG ACATGCAGGC ACCTCTTTTA AACAGGCAA ACAGGAAGGG GGAAGAGGTG 1080
 55 GGATTCATGT CGAGGCTAGA GGCATTTGGA ACAACAAATC TACGTAGTTA ACTTGAAGAA 1140
 ACCGATTTTT AAAGTTGGTG CATCTAGAAA GCTTTGAATG CAGAAGCAA CAAGCTTGAT 1200
 60 TTTTCTAGCA TCCTCTAAT GTGCAGCAA AGCAGGCRAC AAAATCTCCT GGCTTTACAG 1260

	ACAAAAATAT TTCAGCAAAC GTTGGGCATC ATGGTTTTTG AAGGCTTTAG TTCTGCTTTC	1320
5	TGCTCTCTCT CCACAGCCCC AACCTCCAC CCCTGATACA TGAGCCAGTG ATTATTCTTG	1380
	TTCAGGGAGA AGATCATTTA GATTTGTTTT GCATTCCTTA GAATGGAGGG CAACATTCCA	1440
	CAGCTGCCCT GGCTGTGATG AGTGTCTTG CAGGGGCCGG AGTAGGAGCA CTGGGGTGGG	1500
10	GGCGGAATTG GGGTACTCG ATGTAAGGGA TTCCTTGTG TTGTGTGAG ATCCAGTGCA	1560
	GTGTGATTT CTGTGGATCC CAGCTTGGTT CCAGGAATTT TGTGTGATG GCTTAAATCC	1620
15	AGTTTTCAAT CTTGACAGC TGGGCTGGAA CGTGAATCA GTAGCTGAAC CTGTCTGACC	1680
	CGTCAAGTT CTTGGATCCT CAGAACTCTT TGCTCTGTG GGGGTGGGG TGGGAATCA	1740
	CGTGGGAGC GGTGGCTGAG AAAATGTAAG GATTCGTGA TACATATTCC ATGGGACTTT	1800
20	CCTTCCCTCT CCGCTTCTT CTTTCTCTG TCCTAACCT TTCGCCAAT GGGCAGCAC	1860
	CACTGACGTT TCTGGGCGC CAGTCCGCT GCCAGGTTCC TGTACTACTG CCTTGTACTT	1920
25	TTCAATTTGG CTCACCGTGG ATTTCTCAT AGGAAGTTG GTCAGAGTGA ATTGAATATT	1980
	GTAAGTCAGC CACTGGGACC CGAGGATTTC TGGACCCCG CAGTTGGGAG GAGGAAGTAG	2040
	TCCAGCCTTC CAGGTGGGT GAGAGGCAAT GACTCGTTAC CTGCCGCCA TCACCTTGGA	2100
30	GGCCTTCCCT GGCCTTGAGT AGAAAAGTCG GGGATCGGG CAAGAGAGGC TGAGTACGGA	2160
	TGGGAACTA TTGTGCACAA GTCTTCCAG AGGAGTTCT TAATGAGATA TTTGTATTTA	2220
35	TTTCCAGACC AATAAATTTG TAACTTTGCA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	2280
	AAAAAAAAA AAAAAAACT CGAGGGGGC CCGTACCCAA TTCGCCGTAT ATGATCGTAA	2340
	ACAATC	2346

40

(2) INFORMATION FOR SEQ ID NO: 194:

45

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3054 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 194:

	TATCTGAACC ACCCTTTATT CTACATATGA TAGGCAGCAC TGAAATATCC TAACCCCTA	60
55	AGCTCMAGGT GCCCTGTGGN ACGAGCAACT GGACTATAGC AGGGCTGGG TCTGTCTTCC	120
	TGGTCATAGG CTCACTCTTT CCCCCAAATC TTCTCTGGA GCTTTCAGC CAAGGTGCTA	180
60	AAAGGAATAG GTAGGAGACC TCTCTATCT AATCCTTAAA AGCATAATGT TGAACATCA	240

	TTCAACAGCT GATGCCCTAT AACCCCTGCC TGGATTCTT CCTATTAGGC TATAAGAAGT	300
	AGCAAGATCT TTACATAATT CAGAGTGGTT TCATTGCCCTT CCTACCCCTCT CTAATGGCCC	360
5	CTCCATTAT TTGACTAAAG CATCACACAG TGGCACTAGC ATTATACCAA GAGTATGAGA	420
	AATACAGTGC TTTATGGCTC TAACATTACT GCCTTCAGTA TCAAGGCTGC CTGGAGAAAG	480
10	GATGGCAGCC TCAGGCTTC CTTATGTCT CCACCACAAG AGCTCCTTGA TGAAGGTCAT	540
	CTTTTCCCC TATCTGTTC TTCCCTCCC CGCTCCTAAT GGTACGTGGG TACCCAGGCT	600
	GGTCTTGGG CTAGGTAGTG GGGACCAAGT TCATTACCTC CCTATCAGTT CTAGCATAGT	660
15	AAACTACGT ACCAGTGTTA GTGGGAAGAG CTGGGTTTTC CTAGTATACC CACTGCATCC	720
	TACTCTTACC TGGTCAACCC GCTGCTTCCA GGTATGGGAC CTGCTAAGTG TGAATTACC	780
20	TGATAAGGA GAGGAAATA CAAGGAGGGC CTCTGGTGT CTGGGCTCA GCCAGCTGCC	840
	CACAAGCCAT AAACCAATAA AACAAGAATA CTGAGTCAGT TTTTATCTG GGTCTCTTC	900
	ATTCCCACTG CACTTGGTGC TGCTTTGGCT GACTGGGAAC ACCCCATAAC TACAGAGTCT	960
25	GACAGGAAGA CTGGAGACTG*TCACCTTCTA GCTCGGAAGT TACTGTGTAA ATAACTTTC	1020
	AGAACTGCTA CCATGAAGTG AAAATGCCAC ATTTTGTCTT ATAATTCTA CCCATGTGG	1080
30	GAAAACTGG CTTTTCCTCA GOCCTTCCA GGGCATAAAA CTCAACCCCT TCGATAGCAA	1140
	GTCCCATCAG CCTATTATTT TTTTAAAGAA AACTTGCACT TGTTTTCTT TTTACAGTTA	1200
	CTTCTTCTT GCCCAAAAT TATAACTCT AAGTGTAAAA AAAAGTCTTA ACAACAGCTT	1260
35	CTTGCTGTGA AAAATATGTA TTATACATCT GTATTTTAA ATTCTGCTCC TGAAAAATGA	1320
	CTGTCCATT CTCCACTCAC TGCAATTGGG GCCTTTCCTA TTGGTCTGCA TGTCTTTTAT	1380
40	CATTGCAGGC CAGTGGACAG AGGGAGAAGG GAGAACAGGG GTCCCAACA CTGTGTGTC	1440
	TTTCTGACTG ATCTGAACA AGAAAGAGTA AACTGAGGC GCTCGCTCCC ATGCACAACT	1500
	CTCCAAAACA CTTATCTCTC TGCAAGAGTG GGCTTTCAG GGTCTTACT GGAAGCAGT	1560
45	TAAGCCCCCT CTCACCCCT TCCTTTTTC TTTCTTACT CTTTGGCTT CAAAGGATTT	1620
	TGGAAAAGAA ACAATATGCT TTACTCTCAT TTTCAATTTC TAAATTGCA GGGGACTG	1680
50	AAAAATACGG CAGGTGGCTT AAGGCTGCTG TAAAGTTGAG GGGAGAGGAA ATCTTAAGAT	1740
	TACAAGATAA AAAACGAATC CCTAAACAA AAAGAACAAT AGAACTGGTC TTCCATTTTG	1800
	CCACCTTTC TGTTCATGAC AGCTACTAAC CTGGAGACAG TAACATTTCA TTAACCAAAG	1860
55	AAAGTGGGTC ACCTGACCTC TGAAGAGCTG AGTACTCAGG CCACTCCAAT CACCTACAA	1920
	GATGCCAAGG AGGTCCAGG AAGTCCAGCT CCTTAAACTG ACGCTAGNCA ATAAACCTGG	1980
60	GCAAGTGAGG CAAGAGAAAT GAGGAAGAAT CCATCTGTGA GGTGACAGGC AAGGATGAAA	2040

	GACAAAGAAG GAAAAGAGTA TCAAAGGCAG AAAGGAGATC ATTTAGTTGG GTCTGAAAGG	2100
	AAAAGTCTTT GCTATCOGAC ATGTACTGCT AGTACCTGTA AGCATTTTAG GTCCCAGAAT	2160
5	GGAAAAAAA ATCAGCTATT GGTAATATAA TAATGTCCTT TCCCTGGAGT CAGTTTMTTT	2220
	AAAAAGTTAA CTCTTAGTTT TTA CTGTGTTT AATTCTAAAA GAGAAGGGAG CTGAGGCCAT	2280
10	TCCCTGTAGG AGTAAAGATA AAAGGATAGG AAAAGATTCA AAGCTCTAAT AGAGTCACAG	2340
	CTTTOCCAGG TATAAAACCT AAAATTAAAG AGTACAATAA GCAGAGGTGG AAAATGATCT	2400
	AGTTCTTGAT AGCTACCCAC AGAGCAAGTG ATTTATAAAT TTGAAATCCA AACTACTTTC	2460
15	TTAATATCAC TTGGTCTCC ATTTTCCCA GGACAGGAAA TATGTCCCCC CCTAACTTTC	2520
	TTGCTTCAAA AATTAAAATC CAGCATCCA AGATCAITCT ACAAGTAATT TTGCACAGAC	2580
20	ATCTCTCAC CCCAGTGCCT GTCTGGAGCT CACCCAAGGT CACCAAACAA CTGGTTGTG	2640
	AACCNAACTG CCTTAACCTT CTGGGGGAGG GGGATTAGCT AGACTAGGAG ACCAGAAGTG	2700
	AATGGGAAAG GGTGAGGACT TCACAATGTT GGCCTGTGAG AGCTTGATTA GAAGCCAAGA	2760
25	CAGTGGCAGC AAAGGAAGAC TTGGCCAGG AAAACCTGT GGGTTGTGCT AATTCTGTC	2820
	CAGAAATAG GGTGGACAGA AGCTTGTGGG GTGCATGGAG GAATTGGGAC CTGGTTATGT	2880
30	TGTTATTCTC GGACTGTGAA TTTTGGTGAT GTAAAACAGA ATATTCTGTA AACCTAATGT	2940
	CTGTATAAAT AATGAGCGTT AACACAGTAA AATATTCAAT AAGAAGTCAA AAAAAAAAAA	3000
35	AAAAAACTCG AGGGGGGGCC CGGTACCCAA TTINCCAAAT AGAGATNGTA TTAC	3054

(2) INFORMATION FOR SEQ ID NO: 195:

- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 907 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 195:

	GGCAGAGCTC GTGGCCGNAA CTTTCTCTGC TCCTGGCTGC CACCTACTGG CTGGCCGCCG	60
50	CCCTGGCCTG GGCTGCACC AGCCTGCGNG CGGGCTCCA CAGCAGCCCC CTTCCAAGCA	120
	GGTCCCCAC ACCGCGCACC TTCTGCGGGA ACGTGCTCGC CGTGCCGGGG ACCATATGGA	180
55	CGGAAGGCTT TGTGCTCACC TACAAGCTGG GTGAGCAGG TGCCAGCAGC CTGTTGATCC	240
	TCCTGGCTCC TGCTGGAGCA CGAGCGGCGT TTCTGCTCCC GAGTTGGGAC TGTGGAATGG	300
	TGTGGGTGCT GTGGTCTGCT CCATGCTGG CTCTCCCTG GGTGGGACCT TGCTGGCCAA	360
60	GCACTGGAAA CTGCTGCCTC TGTGAGGTGG GTGCTGCGCT TCCGCTCGG GGGCCTAGCC	420

TGTGAGACTG CCTTGGTCTT CCACCTTGGG CACCTTGGGG GCCAGCATGG ACGCTGGCAC 480
 AATCTTGAGA GGGTCAGCCT TGCTGAGCCT ATGTCTGCAG CACTTCTTGG GARGCCTGGT 540
 CACCACAGTC ACCTTCACTG GGAATGATGC GCTGCAGCCA GCTGGCCCCC AGGGCCTTGC 600
 AGGCCACACA CTACAGCCTT CTGGCCACGC TGGAGCTGCT GGGGAAGCTG CTGCTGGGCA 660
 CTYTGSGCG AGGGCCTGGC TGATGGGTG GGGCCACATC CCTGCTTCTT GCTCCTGCTC 720
 ATCCTCTCTG CCTTCCCGT TCTGTACCTG GACCTAGCAC CCAGCACCTT TCTCTGAGCT 780
 GAGTGGCTGG AGTGGTCAAT AAAGCCACAT GTGCTGTGG CCAAAAAA AAAAAAAA 840
 AAAAAAAA AAAAAACTG GAGGGGGGC CCGGTACCCA AATGCCGGA TATGATCGTA 900
 AACAATC 907

20

(2) INFORMATION FOR SEQ ID NO: 196:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1290 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 196:

GGCACGAGGA GGGACAGGGA GTGGGCAAGG GGAAGAAGCA GCTTATTTGA CTAACCAGCC 60
 CCTCTGTGGT CCACCAGCGT CTTGGCTTGG TGGGAGGGCT CTCATCAGC AGGGCCOCAG 120
 KAGGCAAGA AGAAGTGGG CAAAGCCTGG CGCTCGCCG CGGTGCGGC AGCTTTGCM 180
 TCTGGAGCCA CGCTCCTCC AGGCCATGCT CCTTGAAGTT GGAAATGTCA ACCGGAGCCC 240
 TTAACACCAG CCTCCAGCA TCTAATAGAC TTGAATCTAC TCTAAACGAA TATTTAATCC 300
 AACCTCAACT ACATTGTAGC TCAGTCCAAC GACTAACCTT GAAATGGGG TGTTCAGCC 360
 TTCAGCGAGA TGGCCAAGCG GTCCCTGGG GGCTGTGGCA GCGGGCTTAT CCTTCTCTGT 420
 TGCCAACTT GCCGTCCGAC CTCCTCCGCC CCCATGCGGT GACCCCGTCC GTGTCTGTGT 480
 CTGTCCATAC GTGTGAGTCC AGCTAAAAG ACAAACAGA ACCCGTGGGC CCAGCTCGGA 540
 AGGTGCGTGG AGAAGGCTCC GACGTCTCCG AAGTGCAGCC CTTGGGATGG CATTCGTTG 600
 TGTGCTTAT TCCTGGAGAA TCTGTATACG GCTGCGCTAT AAGAAATATA GCCTCTTCAT 660
 GCTGTATTAA AAGGACTTTT AAAAGCAAAA AAAAAAAA AAAAACTCGA GGGGGGGCCC 720
 GGTACCCAAT TCGCCAATA GTGAGTCGTA TTACAATCA CTGGGCGTC STTTAACAA 780
 CGTCGTGAAC TGGGAAAACC CTGGCGTTTA CCAACTTAA TCGCCTTGCA GCACATCCCC 840

60

CTTTCGCCAG CTGGCGTTAA TAGCGAAAAA NGCCCGCACC CGAATCGCCC TTCCCAACAG 900
 TTTCGCAGC CCTGAATGGC GAAATGGCAA ATTGTAAGCG TTTAATATTT TKKTAAAAAT 960
 5 TCNCGTTWA AWTTTTTGT TAAATCARCT CAATTTTTTT AACCCAATAA GSCCGAAATC 1020
 CGGCAATCC CCYTTATTAA TTCCAAAAAA ATAAACCSAA AAWGGGTTTG AATTTTTTCT 1080
 10 TTCCCAATT TTGGAACAA AWTYCCCCCT TTTTAAAAAA GTTGAACCC CCAMCCYTCC 1140
 AAAGGGGAAA AAACSYTTTT YTGCGGGGNA ANGGGGCCCC CNTACTTTNA ACAYCCCCCC 1200
 CCAAWCAATT TTTTGGGGG GTCCCNAAAG GTCCCCCTAA AANCTTTTTT CGGAACCCNA 1260
 15 AGGGGANCCC CCCATTTAAA ATTTTNGGIN 1290

20 (2) INFORMATION FOR SEQ ID NO: 197:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1020 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 197:

30 GGTTGCCCTG GATGGTCGTG TAGGTGAGTT TTACCAAGGA TTATGGTAAC AAATGAGTGA 60
 GACCTCTATG GAGAAAATAT TGAAGNNCAT TAAAGAAGAC CTCATANTAG GAGAGAATGT 120
 SCTTTGGAGG ATTTGTATTG AGCTTTTACA GTATTCAATT TTCAACTCAA GGCAATGGCT 180
 35 TTCTACACCA ACTCTAATCC ATAAACGGGT CTTATGACAT CTATGAAGTA GTAGCAAGAC 240
 ATGCTTAGTG TGTATTCTC TCTTTGAGAC ACTGTAATTT CTACCAGAAA TTTCCAGAGC 300
 40 ATTATGTAGG TAGAAAAAAA TGCAAGCAAG CTGTTAAAGA TCTTGATCC CATTATATAG 360
 TATGTATAGC TGAAATCTGT AATTCAATCA CTTTTCTCT TTTATCCTCT AACCAAAAAA 420
 TGTTTAATT TTGCATCCCA AATGTTTTTA ATCTTTGTAT ATTTTTTAAA AAYCCTTTTC 480
 45 TCCTCATCAT TGCTTTTTT GTGGTTGTAA ATAGACTTAC TTGCACCTTG AAGATGAGTT 540
 ACTCCTTGT ATCTTACAAA TATGTGATAT GGTAAATTTT ATAACAGATG TCAGTTTGA 600
 50 ACCAAGAATT GGTGATTGT TTATAAGAAA AAAACTGGCT TCATTTCTGT GAAATTGCTC 660
 TTTGAAAATT TCTTTTTACA CGTGAAGCC AACTGAGATA CCGTGATGTT GTTGATTCT 720
 TTCAATGATG CTTACCATCT ATTTTAGCCA CTGAGCCTTT TATTATTGT CTATTGTAA 780
 55 AGTTTATTG TCTTAACTCA TTTAATAAAT ATACTGTTA TCTGTTTCTG AATGGGGACT 840
 GAACTTTTG GATATTGATA TTGATTGAA AATATTTTGG AATTTTTCT ACTTGAAATT 900
 60 TTAGAAATCT AATKGAAAT TCTATAATGT ACTGAAAGTA WGGTTGTGTA CAGTGAKCAC 960

TCTCTAATAA TATGATGNET TGCCCTAAAN GAGGNGGAC ATGTCCCACT TTCCACCACG 1020

5

(2) INFORMATION FOR SEQ ID NO: 198:

- 10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 524 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 198:

AATTCOCGAA GCTGAGGGTT GTGTGCCNVC GGGCGAGCCA AGTCTTTTGA CCGGACCCCTT 60
CCCGGCGCAG AAGANCTGAA GTTGATTGA GAGCCTGTGT TTGGGGTTTA GCCGAGCTGC 120
20 TGCGGGCTTY GTCCGCGGCC AGGACACAAG YTACTTGCAA CGGGCGCGCG CCTGGCTTAT 180
GATGTTCCCTC AACCCAGGGG CGGCCTCTGC CCTCTACTCG TGCCAGGCCC ACTTGCCAGG 240
25 CAGGAGCCCT CCCAAGCCT TCAGGGCTGC TCGGAGTCAC CTGTTGGAAT GGAATAAAG 300
GACCCCTGTG TGGGAACAGG TGCTCCAAAC ACCCTGCTGC TGGCTGCCAG GCAGGCCCTC 360
TGAAGGGAA GGGCAGGAC TCATCAGGAC CTCCCTGGAC CCGCAGGCG AGGCAGTTGG 420
30 CCCGAGCCCA AGCATTTGGC TCTGCTTGCC CCAAGGGGAC AGGAAGCCTC TTGGGCCTCT 480
TCCCTTCCTG GACAAGGCC CCGCCTTTG CCTCACATAA ACTG 524

35

(2) INFORMATION FOR SEQ ID NO: 199:

- 40 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 332 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 199:

GTGATACAAG GAAGGGTGAT CATCATCTGT CACCATGCAA TTCCTGCTCA CAGCCTTTCT 60
50 GTTGGTGCCA CTCTGGCTC TTTGTGATGT CCCCATATCC CTAGGCTTCT CCCCCTCCTA 120
GAAGGCTTC TTGATAGATT AGAAAATAAG AATGAGTGAC ATTTCCCTATG TGCATATAAG 180
AAGGAGCCAC AAGACATGTC TTTTAAATAA AAGGACAGTG TCCATCCTTT TAGCTGCCGA 240
55 ATAGAACCTT GGTCTCATCC TCCTGGAGCT AGGSCITAAA ACAGCTTCTG TGTTCCTSAT 300
TKGTCTCART GTTTTGCCAA GGTTCCTATC GG 332

60

(2) INFORMATION FOR SEQ ID NO: 200:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 376 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 200:

CCAGGGAAGC CCCARGCCTG TCCTGAATTG ACATCAGTGC TTCCCTGAAC TGCCTCCCCC	60
15 ACCCCTGGGC ATTATCCCAG GAAACTTATG TTTTCTAGAA GCTAAGCAGC TGCTGGGACT	120
CAGGGACTGG TGCAGGTAGG CTGAGTGGCA GCTCAGTCCT AGAAGGTCTC TGAAGATCTG	180
GACTGAGGAC CYTGCTACTC CCCAAGCCAG AGCCCATCAG CCAGGCCTGC TGTGAGCCAC	240
20 CTGCCTGTGG AGTGCTGAGC TCAACCAAAG GCTGGCAAGC TCTGGGCCTC ATTAAAGGGA	300
TTCTGATGAG CCGATGGGCC CTGGAGGCAG CCCATTAAAG CATCTGGCTC GTTTTGGAA	360
25 AAAAAAAAAA AAAAAG	376

30

(2) INFORMATION FOR SEQ ID NO: 201:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1192 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 201:

40 CCCAGTATAT TTCTATAACA TTTATTTTAG TGAAC TTATA ATGTTTCTTT GTATTAAATT	60
ATTAGATTAT ATCTTTAGAT AATATTGTTA CTNAATTAGT AGGTAATATA TATTTTATTC	120
AAAAATAAAT TGTGCATCTA ATGCTACCA ATTAATGTAC TTGTAGATGT ATCTTATCTT	180
45 AACTTGAGTC TTTGCTGCCC CTAATGAGGT GTGAAGGACT CTTCTCCCT GGGGAAGTTT	240
TTCTTTTTC AAGAGGAGGA GGGCTTTCCC AGGTAATGTG TCTAGAGTGT TGGGCAGAAR	300
50 AATCTGGGAC CACACCACAC CAGTTCTCTC CTTAATCCAC GTCAATTGCC TTCTATCCCA	360
GCTATGTTTC CAGTGTCTC TGGGTGTTTC CAAGAGCAAC AAGAAAYGAA TAAATCTCTG	420
KTGAGTTGTT TATTTGTCT TCACTTTGTT TTACACTGTA WTTTCTGAGT TTATGGGTGT	480
55 CTGTGAATTA AAAAGGAAAA GTTGAAATAA GTAAACTCA GGTGAAGGA AATATACATA	540
AATAAGATAA AGCTGACCTG TAGATATARR CAGTTTATAA RAGCTTAGAG TTGCTAAGT	600
60 TGRGTGCAAA KTTTCTCTG ATCTTCTGA TGCCGARACA AAAAAGGCAG TCATGTTTGT	660

5 WATGTGATTG GAATGGAACC CGARAAGAGA GCAYGCTGTG TTCTTGGGGA CAGGAAAGCT 720
TGYGTGCACC AAGTCTKAAC CACCACCTTC ATGGGACATA GRTTATGTGC TGGAACATAT 780
TTCACACCGG CCTGGCAGTA AACACTTGTG GTGTTGTGCA GTGGAAACGG TCATCTTCCG 840
CTAAAGCACG GCGTGTGTG CAGCGGAAAT GGTTCATCTGC TGCTAAAACA CAGCTTCCAT 900
10 CGTAATGTAT GCTCCTTACT CAAAGAGTGT GGTCCCAAAC AGCCTTTGGG AGGTCTCTCT 960
TGATTCATGG ATGAAACCTG GAACATCTTG AGGACTGAGT TAACCATAGG TCCTTAAATA 1020
ACTCTCCACA CGTTTTTCTT AGTTTATCTC TACATGCAGG GTGTGCAGCA GCCTGTTCAA 1080
15 AGTCATATTT TCTGGGAAAT ATTTCCAGTG TTTATTTGCA CTTTAGOCCA CTCTGTGTAG 1140
CCTTATTTCT TCTAAACTCA CCATTAATCT GAATAATAGT CAAATTTAGG GG 1192
20

(2) INFORMATION FOR SEQ ID NO: 202:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 589 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
30 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 202:

ATCTTGGGCT ATCTTTGACA GGGGATTCTT GCAAGTTGAT GCTTCTACA AGTGAATATA 60
35 GTCAGTCCCC AAAGATGGAG AGCTTGAGTT CTCACAGAAT TGATGAAGAT GGAGAAAACA 120
CACAGATTGA GGATACGGAA CCCATGTCTC CAGTTCTCAA TTCTAAATTT GTTCCTGCTG 180
AAAATGATAG TATCCTGATG AATCCAGCAC AGGATGGTGA AGTACAACTG AGTCAGAATG 240
40 ATGACAAAAC AAAGGGAGAT GATACAGACA CCMGGGATGA CATTAGTATT TTAGCCACTG 300
GTTGCAAGGG CAGAGAAGAA ACGGTAGCAG AAGATGTTTG TATTGATCTC ACTTGTGATT 360
45 CGGGGAGTCA GGCAGTTCCG TCACCAGCTA CTCGATCTGA GGCACTTTCT AGTGTGTTAG 420
ATCAGGAGGA AGCTATGGAA ATTAAAGAAC ACCATCCAGA GGAGGGGTCT TCAGGGTCTG 480
AGGTGAAGA AATCCCTGAG ACACCTTGTG AAAGTCAAGG AGAGGAACTC AAAGAAGAAA 540
50 ATATGGAGAG TGTTCGGTTG CACCTTCTC TGA CTGAAAC TCAGTCCCA 589

55

(2) INFORMATION FOR SEQ ID NO: 203:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 847 base pairs
60 (B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 203:

5
GGCACGAGCG CAAGCTGCTG GCCGCCATCA ACGCGTTCCG CCAGGTGCGG CTGAAACACC 60
GGAAGCTCCG GGAACAAGTG AACTCCATGG TGGACATCTC CAAGATGCAC ATGATCCTGT 120
10 ATGACCTGCA GCAGAATCTG AGCAGCTCAC ACCGGGCCCT GGAGAAACAG ATTGACACGC 180
TGGCGGGGAA GCTGGATGCC CTGACTGAGC TGCTTAGCAC TGCCCTGGGG CCGAGCAGCT 240
TCCAGAACCC AGCCAGCAGT CCAAGTAGCT GGACCCACGA GGAGGAACCA GGCTACTTTC 300
15 CCCAGTACTG AGTGGTGGAC ATCGTCTCTG CCACTCCTGA CCAGCCTGAA CAAAGCACCT 360
CAAGTGCAAG GACCAAAGGG GGCCTGGCTT GGATGGGTG GCTTGCTGAT GGCTGCTGGA 420
20 GGGGACGCTG GCTAAAGTGG GGAGGCCTTG GCCCACCTGA GGCCCCAGGT GGAACATGG 480
TCACCCCCAC TCTGCATACC CTCATCAAAA ACACTCTCAC TATGCTGCTA TGGACGACCT 540
CCAGCTCTCA GTTACAAGTG CAGGCGACTG GAGGCAGGAC TCTTGGGTCC CTGGGAAAGA 600
25 GGGTACTAGG GGCCCGGATC CAGGATTCTG GGAGGCTTCA GTTACCGCTG GCCGAGCTGA 660
AGAACTGGGT ATGAGGCTGG GCGGGGGCTG GAGGTGGCGC CCCCTGGTGG GACAACAAAG 720
30 AGGACACCAT TTTTCCAGAG CTGCAGAGAG CACCTGGTGG GGAGGAAGAA GTGTAAGTCA 780
CCAGCCTCTG CTCTTATCTT TGTAATAAAT GTTAAAGCCA GAAAAAAAAA AAAAAAAAAA 840
AAAAAAAA 847
35

(2) INFORMATION FOR SEQ ID NO: 204:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 852 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

45

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 204:

50 ACAAACATAC TCGCAGGAAG GAGTCTCATG CTGCCCGCAG CATCAGCGCA ACNCTGGCC 60
GCCATCAACG CGTTCCGCCA GGTGCGGCTG AAACACCGGA AGCTCCGGGA ACAAGTGAAC 120
TCCATGGTGG ACATCTCCAA GATGCACATG ATCCTGTATG ACCTGCAGCA GAATCTGAGC 180
55 AGCTCACACC GGGCCCTGGA GAAACAGATT GACACGCTGG CGGGGAAGCT GGATGCCCTG 240
ACTGAGCTGC TTAGCACTGC CCTGGGGCCG AGGCAGCTTC CAGAACCAG CCAGCAGTCC 300
AAGTAGCTGG ACCCAGNAG GAGGAACCAG GCTACTTTCC CCAGTACTGA GGTGGTGGAC 360
60

ATNCGTCTCT TGCCACTCCN TGNACCCAGC CCTGAACAAA GCACCTCAAG TGCAAGGACC 420
 AAAGGGGGCC CTGGCTTGGG GTGGGTGGC TTGCTGATGG CTGCTGGAGG GGACGCTGGC 480
 5 TAAAGTGGGK AGGCCTTGGC CCACCTGAGG CCCCAGGTGG GAACATGGTC ACCCCCACTC 540
 TGCATACCCCT CATCAAAAAC ACTCTCACTA TGCTGCTATG GACGACCTCC AGCTCTCAGT 600
 10 TACAAGTGCA GGCAGCTGGA GGCAGGACTC CTGGGTCCCT GGGAAAGAGG GTACTAGGGG 660
 CCCGATCCA GGATTCTGGG AGGCTTCAGT TACCGCTGGC CGAGCTGAAG AACTGGGTAT 720
 GAGGCTGGG CGGGCYGGA GGTGGCGCCC CCTGGTGGGA CAACAAAGAG GACACCATTT 780
 15 TTCCAGAGCT GCAGAGAGCA CCTGGTGGG AGGAAGAAGT GTAACTCACC AGCCTCTGCT 840
 CTTATCTTTG TA 852

20

(2) INFORMATION FOR SEQ ID NO: 205:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1354 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 205:

GATTGGGCAC GAGGCTTGCT GGAGCAGGAG AAGTCTCTRG CCGGCTGGGC ACTGGTGCTG 60
 GCASGARCTG GCATTGGACT CATGGTGCTG CATGCAGAGA TGCTGTGGTT CGGGGGGTGC 120
 35 TGGCTGTCA ATGCCACTGG GCACCTTTCA GACACACTTT GGCTGATCCC CATCACATTC 180
 CTGACCATCG GCTATGGTGA CGTGGTGCCG GGCACCATGT GGGCAAGAT CGTYTGCTG 240
 40 TGCCTGGAG TCATGGGTGT CTGCTGCACA GCCCTGCTGG TGGCGTGGT GGCCCGGAAG 300
 CTGGAGTTTA ACAAGGCAGA GAAGCACGTG CACAACCTCA TGATGGATAT CCAGTATACC 360
 AAAGAGATGA AGGAGTCCG TGCCCGAGTG CTACAAGAAG CCTGGATGTT CTACAAACAT 420
 45 ACTCGCAGGA AGGAGTCTCA TGCTGCCCGC AGGCATCAGC GCAANCTGCT GGCCGCCATC 480
 AACGGTTCC GCCAGGTGCG GCTGAAACAC CGGAAGCTCC GGAACAAGT GAACTCCATG 540
 50 GTGGACATCT CCAAGATGCA CATGATCCTG TATGACCTGC AGCAGAATCT GAGCAGCTCA 600
 CACCGGGCCC TGGAGAAACA GATTGACACG CTGGCGGGGA AGCTGGATGC CTTGACTGAG 660
 CTGCTTAGCA CTGCCCTGGG GCCGAGGCAG CTTCCAGAAC CCAGCCAGCA GTCCAAGTAG 720
 55 CTGGACCCAC GAGGAGGAAC CAGGCTACTT TCCCCAGTAC TGAGGTGGTG GACATCGTCT 780
 CTGCCACTCC TGANCCAGC CCTGAACAAA GCACCTCAAG TGCAAGGACC AAAGGGGGCC 840
 60 CTGGCTTGA GTGGGTGGC TTGCTGATGG CTGCTGGAGG GGACGCTGGC TAAAGTGGGK 900

5 AGGCCTTGGC CCACTGAGG CCCAGGTGG GAACATGGTC ACCCCACTC TGCATACCCT 960
 CATCAAAAAC ACTCTCACTA TGCTGCTATG GACGACCTCC AGCTCTCAGT TACAAGTGCA 1020
 GCGGACTGGA GGCAGGACTC YTGGGTCCCT GGGAAAGAGG GYACTAGGGG CCCGGATCCA 1080
 GGATTCTGGG AGGCTTCAGT TACCGCTGGC CGAGCTGAAG AACTGGGTAT GAGGCTGGGG 1140
 10 CGGGGCTGGA GGTGGCGCCC CCTGGTGGGA CAACAAAGAG GACACCATT TCCAGAGCT 1200
 GCAGAGAGCA CCTGGTGGGG AGGAAGAAGT GTAACCTACC AGCCTCTGCT CTTATCTTTG 1260
 TAATAATGT TAAAGCCAGA AAAAAATAAA AAAAAAAAAA AAAAACTCG AGGGGGGGCC 1320
 15 AGACCCAATC TCCCTATAGT AAGNCGCCNN ANAN 1354

20

(2) INFORMATION FOR SEQ ID NO: 206:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 1378 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 206:

30 TCCCCAGGTG CACAGCCAGG GCCCTCCTGT CTGCAGGAGA ATTCACAGCT GGTGTGGGAC 60
 TCAGCCCCTA GNCCATTCAA AGCCTTAATG TTGTAATCAT ATCTTACGTG TTGAAGACCT 120
 35 GACTGGAGAA ACAAATGTG CAATAACGYG AATTTTATCT TAGAGATCTG TGCAGCCTAT 180
 TTCTGTGACA AAAGTTATAT TGTCTAATAA GAGAAGTCTT AATGGCCTCT GTGAATAATG 240
 TAACTCCAGT TACACGGTGA CTTTAAATAG CATACAGTGA TTTGATGAAA GGACGTCAAA 300
 40 CAATGTGGCG ATGTGCTGGA AAGTTATCTT TCCCGCTCTT TGCTGTGGTC ATTGTGTCTT 360
 GCAGAAAGGA TGGCCCTGAT GCAGCAGCAG CGCCAGCTGT ANATAAAAAA TAATTACAC 420
 45 TATCAGACTA GCAAGGCACT AGAACTGGAA AAGACCACAG AAAACAAAGA ATCCAACCTT 480
 TTCATCTTAC AGGTGAACAA ACTGTGATGA TGCACATGTA TGTGTTTTGT AAGCTGTGAG 540
 CACCGTAACA AAATGTAAAT TTGCCATTAT TAGGAAGTGC TGGTGGCAGT GAAGAAGCAC 600
 50 CCAGGCCACT TGACTCCAG TCTGGTGCCC TGTCTACACC AGACAACACA GGAGCTGGGT 660
 CAGATTCCCC TCAGTGCTT AACAAAGTTC CTCGAACAGA AAGTGCTTAC AAAGCTGCCT 720
 55 TCTCGGATAC TGAAAGGTG AGTTTCTGTA ACTGCACTGA TTTTATTGCA GTTGAAAAAA 780
 AAAAAAGCT ATTCCAAGA TTTCAAGCTG TTTGAGACA TCTTCTGATG GCTTTACTTC 840
 60 CTGAGAGGCA ATGTTTTTAC TTTATGCATA ATTCATTGTT GCCAAGGAAT AAAGTGAAGA 900

AACAGCACCT TTTAATATAT AGGTCTCTCT GGAAGAGACC TAAATTAGAA AGAGAAAAC 960
 GTGACAATTT TCATATCTC ATTCTTAAAA AACACTAATC TTAAC TAACA AAAGTCTTT 1020
 5 TGAGAATAAG TTACACACAA TGGCACAGC AGTTTGTCTT TAATAGTATA GTGCCTATAC 1080
 TCATGTAATC GGT TACTCAC TACTGCCTTT AAAAAAAAA ACCAGCATAT TTATTGAAAA 1140
 CATGAGACAG GATTATAGTG CCTTAACCGA TATATTTTGT GACTTAAAA ATACATTTAA 1200
 10 AACTGCTCTT CTGCTCTAGT ACCATGCTTA GTGCAAATGA TTATTTCTAT GTACAACTGA 1260
 TGCTTGTCTT TATTTTAATA AATTTATCAG AGTGAAAAA AAAAAAAAAA AAAAAAAAAA 1320
 15 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAGAA NAAAAANA 1378

20 (2) INFORMATION FOR SEQ ID NO: 207:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1166 base pairs

(B) TYPE: nucleic acid

25 (C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 207:

30 AANCCACTGC ANTTTAAACC CCTCCCTC CAAGAAAGTT CACAACCGGC CATGGATGAC 60
 CCTCATTTTA GATGGCCNC AATATTAAAG ATGGACTGRG GCCCCARAG ACTGACCTT 120
 GAAAGGGGA CTCAGAAGAA AGATCCTTGA CATTGCCMAA CATGCTGGGC TTGTCCAACA 180
 35 CAGTGATGCG GCTCATGAG AARCGGCTT TCCMAGGACA AGTACTTTAT GATAGGTGGG 240
 ATGCTGCTGA CCTGTGTGGT CATGTCCTC GTGGTGCAGT ACCTGACATG AGCCAGCCAC 300
 40 GCTCAGTGGC TGAACAGCAT TCCCACAGCC TGCAAGTGTG TGTGTGTGTG AAAGAGAGAG 360
 GGGGCCAGA GCGCGCTT TGAAATGTTT GCCTGTCTGA ACTGTGAAGA CACTTGGGAG 420
 TGATTGTGGT CTAATTTCCA ACCTGCTCTG TTTTCTGTGA CATCTTGGAG GGGGAGCTAG 480
 45 TGCCAMCACC ATGCGGGTG CTTAGGAAAT GAAAGAAGTC CCGGTCTGT CTCTCTCACT 540
 CTCGCTCTCA MTGGGGGAG GAAAGAATGG CTTTGGTGGC TTGTTCACA CAGCTGATGC 600
 50 GTGSCCTGGG AAGGTGTCCA CAGTGAGCCC TGTGTGCAGG ACTGTCCACN ACGGTTTACA 660
 CCTGTGACC ATCAGGCCTT TCTGGCTCTT GATAGGTGG AGCAAAAGTG GAAAGGAAAG 720
 GAAAGAGGCY TTTTCTCACA GCCATTATAT TAAATAGTAG GTCGATTCAC ATCTCGTGC 780
 55 TCTTGGCCAC CCTCCCTGT GCCTCAGTGA CATGTAGATG ACTGACTGCC AATACTTGTG 840
 ACCATTCCCT GGAAGCAGCT ACCTAGGGGA AACAAGATGT AGTGCTATTG CCGATAACAA 900
 60 GTAAGATTTT CCACACTACA GCTGGGTGTT TCTCTTTTCT AAAGTGAGGC CAGTGTATT 960

5 TCCCGGGAGT GTTCAGTCTT GACCCTAGTC ACTGATTTTT TCTAGTTGTT AATAGAGTGG 1020
TTGGGCTTTT AAGGTTTCAGA GACTGTGGGC TTGGGCACCT GCGCCCAGGG STTTTGTGGG 1080
GGCCTTTGCC CCTTAGRAAA GTAGCTTTTA GGGGCAAAGA TTTGTTGATT TTCCCCATTA 1140
CAGTCTTCAG CTCNAGGGTT TTA AAAA 1166

10

(2) INFORMATION FOR SEQ ID NO: 208:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 697 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 208:

TACTTCTAGG ATTATAAGGA ATTAACATTG AGATGACATT TCCATTTGAG AAGGAAAATA 60
25 GTTGCTTTCA GTGCCTTTTA TTTGATTCTT GGAGAGAGCA GACTCGCACS AACATTCAAC 120
CCCAGCGCTG ATATGACAGT AATCCTCAGA GGCAGAGCCC AGCACAAAAC AGCAATGCTA 180
GAAAGTTACA ATTGGAAAGT TTCCTGCCAG CTTCGGGAAT GACACTGCAA AGCTGATGCC 240
30 AGAAACTGCC AGRGTAATTC TCCTCATTAC TGCTCTACCC ACCCACTTTC AGCTCCCCAA 300
ATTAAGTAGT GCAGTTGACT AATTCTCTTT ACCTTTATCA TTTARGGTGA RGCAITGCAC 360
35 AAAAACTCTC GACTTTGCCA TATAAGGGCT GTGGTTCTCT GTGGTCCCCT GGATAAGAGG 420
CATCACCATT ATCTGGAAAC ATGCAGTAAA TGCAGATTNT TCATCTTCTC CCCAGACCTC 480
CTGAGTTAGA AATTCACAAG TTCTCCAGGT GATCTCATA C ATGCTAAAGT TTGAGAACCA 540
40 TTGAGTAAAG TTAATGCATT AAGAAGAGAT TAGATAGGGA TGGTGGGTA TCTTCCTACA 600
GTTCCCTGT TAACAAGAAA GTCAGAGGTC AGTTGATCAG ACATTAGATT ATTTATTGCT 660
45 AAAACTAAAA AAAATTAAAA AAACTGGAG GGGGGCC 697

50

(2) INFORMATION FOR SEQ ID NO: 209:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 932 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 209:

60 CGTGAGTCAC CTCTCTATAG TGGCGTGGC CGAGGCGGG GTGACCTGC CGAAGCCTCC 60

	GCTGCCAGAA ACCATGTTCA AGGTAATTAA AAGGTCGGTG GGGCCAGCCA GCCTGAGCTT	120
5	GCTCACCTTC AAAGTCTATG CAGCACCAAA AAAGGACTCA CCTCCCAAAA ATTCCGTGAA	180
	GGTTGATGAG CTTTCACTCT ACTCAGTTCC TGAGGGTCAA TCGAAGTATG TGGAGGAGGC	240
	AAGGAGOCAG CTTGAAGAAA GCATCTCACA GCTCCGACAC TATTGCGAGC CATACACAAC	300
10	CTGGTGTGAG GAAACGTACT CCCAACTAA GCCCAAGATG CAAAGTTTGG TTCAATGGGG	360
	GTTAGACAGC TATGACTATC TCCAAAATGC ACCTCCTGGA TTTTTCCTCGA GACTTGGTGT	420
15	TATTGGTTTT GCTGGCCTTA TTGGACTCCT TTTGGCTAGA GGTTCAAAA TAAAGAAGCT	480
	AGTGATCCG CCTGGTTTCA TGGGATTAGC TGCTTCCCTC TATTATCCAC AACAAGCCAT	540
	CGTGTTCGCC CAGGTCAGTG GGGAGAGATT ATATGACTGG GGTTCACGAG GATATATAGT	600
20	CATAGAAGAT TTGTGGAAGG AGAACTTTCA AAAGCCAGGA AATGTGAAGA ATTACCTGG	660
	AACTAAGTAG AAAACTYCAT GYTCTGCCAT CTTAATCAGT TATRGTTAAA CATTGGAAAC	720
25	TCCATAGAAT AAATCAGTAT TTCTACAGAA AAATGGCATA GAAGTCAGTA TTGAATGTAT	780
	TAAATGGCT TTCTTCTTCA GGAAAACTA GACCAGACCT CTGTTATCTT CTGTGAAATC	840
	ATCCTACAAG CAAACTAACC TGGAATCCCT TCACCTAGAG ATAATGTACA AGCCTTAGAA	900
30	CTCCTCATTC TCATGTTGCT ATTTATGTAC CT	932

35 (2) INFORMATION FOR SEQ ID NO: 210:

(i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 661 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 210:

45	GTCATTCTTT AAATAAAAGC TTTCTGTTT AAAGCTTTT AAAGGAGCAG ACCACCTTGA	60
	AGATTCCCC TAGGGTTGAT ATGTGTCTAA TTCATTTTAT AAAAATTATT CTGTCTTCA	120
50	TTTAAAGCT TTGGCTATAT AGTCAGAAAT GTCCTAAATA ACAAACTATT TTGTATTTAA	180
	TTTAGGGAAG ACTAAAGGGA AGAAAAATGA AAACCTAGTC TTTATGTAAG CTCCAAGGAT	240
	ATTAGGGCTT AAAGGGCTTT TCTAGTTTTA TGAGAATTG TACTACTGAT TTTTATATAT	300
55	TCCTGTTTTT GAGATGAACA GATCTCTGGG GAAATTGTTG AGTTACAATG GCATTTCACT	360
	GTGATCCCTC TCAAGCTCAG ATCAGTTCTA TAACCCAATG ACAACCTGTC TCTTTGGTTT	420
60	ACTGTCTGT GAAATGTCAG CTCAAGTTTC CCAGAAGTCG TGTGTTTATG ATGAGTCAGA	480

GTGCTTTTCC TCGGTGGGAC AGTTGCTGGC CCTCTTAATT TTGGTGTATG TGCTTCCAAG 540
TATCTAAACC TCCAGTCTGA TCTGTATATG CTATCCTAAC TGTTAATTGT ATTATTGATT 600
5 ATGTTGATTA TCTTGCTTGA AGGTTTCATAC TTTTCAATTT GATAGAAATA AAGTTTTTTT 660
C 661

10

(2) INFORMATION FOR SEQ ID NO: 211:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 592 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 211:

GAAACTGACA TTGTTAAACA CACTAAAACA GAAGTACTTA CCTCTTGAAG ATTTAATATA 60
TAATGGTTGA CATGATACAT GTACATGAAT GGAATGACCA GATGCTTATG GTCTACATTT 120
25 TCCTTTATCC TGTTAGTATT ACCTTCTTTA ATCTTTGTTC CTTAACATGC TAAATTCCTC 180
TTCAGTGTIT ATTTTCTAGT GACAGAATGC TAAACATTTCT TACACCCTGG CAGAAGGGAG 240
30 AGAAATGTGT TTGGGGTGG GTAACATAAT TTTTGAGTGA AATATCATAA GATGAGAATG 300
GAAAGAGGGA GACACAAAGA GTTATAACAA AAAACAATG GTTTTTTTAG CCATTTGACT 360
GGCTCTTTAA ATAGTCTACA AGACATTAC GTTNAACATC ACTTTTAGTG AAATAAAATG 420
35 TGCCATACTA GTATGTGCTT CAAAAGGGCA AATGTGCTTT AGTGCCCTAA GGCTAAATTT 480
TGGTCATTTG ACATCAGAGA TGTTGTAAGT ATTGCACTTA ATACGCACCT ATTTCTCAAT 540
40 AGTGNATTTT TTTTGCTAG CATTTNCTTT ACCACTAACC TTGTTGGATA GC 592

45 (2) INFORMATION FOR SEQ ID NO: 212:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 938 base pairs
(B) TYPE: nucleic acid
50 (C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 212:

55 TGGAGTGGCT TTCCAGCTGA ATGAATCCTA TGTTCTCGGT GCAGGTGGTT GGTTTTCAAT 60
GTTCTTSC TAATTTTTTCC TAFTGGCTCT TGGGAGTTN CTTTGTTTGC TCCTGTGTTT 120
60 GCCCAGCTTT AATAAAACCA GCGCAAACA AAAACCATAG CATTC TGAAA CAATAGGGGG 180

	CCCACATTGG ACCCAGTATG TCACTTTAAT GGACTTCAAG AAAAAATCTG AATGGGAAAA	240
	TGACACTAGG AATGTATACT CCACACATTT TATGCCATAT AATGGTGTGT TTCTTTAATT	300
5	TTGTTTCTTG TGGCGAAATG TGGCTTTCAA ATTAAATGM CCTTTTCTTC TTKGAACTT	360
	TTTGTTTKGA CTKGATAAT TAAGGGTTTG GAAAGATTCA TAATTMTGAG AGAGGTTTGC	420
10	AACCAGGAGA TACAAAGAAG TCTCAGTAGT AATCTTGTC ATGTGCTTTT ACAGCCAGCT	480
	ACATTTAAGR ATGTATTAGT TACAGAAATT ATATGTCTGT GTATGTGTCT CTACTCAATA	540
	AAGTACATGC CTCCACATAA TGCGGTGCTG TCCATCTCGG CAAATACTGG CCAAGTCCCT	600
15	TTATGACAGG CACACAGAAA CCATAGCATG GTCTGGCTTT CAGAAATGC CTCTCATCTT	660
	TCCTGGAACC TTATTTTGCT AAATGTCTGT TTTCTTGTA TTGTGTGTAC CTCACAGCAC	720
20	CATTGTGACC ATGGTGATGC CTCATTGCA TGATATGTAC CTTGTGTTTA ATGTGAAATA	780
	CATTTTCATT GAAGAGTCTG ATGACTTGCT AGCGTTTAT TTTTCTGTA AGCTCAATGT	840
	GCTGAAACCA AACCAGGCTT TTA AAAACCT GTGTAGAAGA AAACCAAAAA ATCCTGTGTG	900
25	GGTGTCTTT CCCTGTCAA CTCAATAAAA ATTCTTT	938

30 (2) INFORMATION FOR SEQ ID NO: 213:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 1079 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 213:

40	AGCCTGCCGG GAGAGTGGTG GCATCTRARA GGCTGGTCTG GGACTGTGGT TGGGGGAGGT	60
	GGGAGCTGTT TTAACCGTGT GCGCCCTCTC CTGTGCKGK GTGGGCATCC CCGGGGCAG	120
45	TGGAACGCGG GCGCTCTCC AGCTTCCGAG TCCAGCCAGC CTGGGCGCGG GCGCGCCCC	180
	CGAGACACCC GAGGAGTCCG TTCCTCCCTG GTTACGTGGA CTGTGGAGCT GGTCTCTGT	240
	GGCTCAGCGC CGTGCGGAGG TTGAAGCGTA CCTGCCGAGG TCGCACCAGG GCGGTGAGGA	300
50	GGAGGAGGAA GGCATGAGC CGAGCTTGAG GAATCCGTGY TCCAACTCT AACTCAAGG	360
	RTGCMCTGCG CAACTCTGGT GCGATGGGC TGGGCGAGAT GTCCTTGAG TTCTACCAGA	420
55	AGAAGAAGTC TCGCTGGCCA TTCTCAGACG AGTGATCCC ATGGGAAGTG TGGACGTCA	480
	AGGTGCATGT GGTAGCCCTG GCCACGGAGC AGGAGCGCA GATCTGCCG GAGAAGGTGG	540
	GTGAGAACT CTGCGAGAAG ATCATCAACA TCGTGAGGT GATGAATCG CATGAGTACT	600
60	TGCCCAAGAT GCGCACACAG TCGGAGGTG ATAACGTGTT TGACACAGC TTGCGGGACG	660

TGCAGCCCTA CCTGTACAAG ATCTCCTTCC AGATCACTGA TGCCCTGGGC ACCTCAGTCA 720
 5 CCACCACCAT GCGCAGGCTC ATCAAAGACA CCCTTGCCCT CTGAGGTCG CTGGATCTCT 780
 GGGAGCTCCT TGATGGCTCC CAGACCTTGG CTTTGGGAA TTGCACTTTT GGGCCTTTGG 840
 GCTCTGGAAC CTGCTCTGGG TCATTGGTGA GACTTGGAAG GGGCAGCCCC CGCTGGCTTC 900
 10 TTGGTTTGT GGTGCCAGC CTCAGGTCAT CCTTTTAATC TTTGCTGACG GTTCAGTCTT 960
 GCCTCTACTG TCTCTCCATA GCCCTGGTGG GGTCCCCCTT CTTTCTCCAC TGTACAGAAG 1020
 15 AGCCACCACT GGGATGGGGA ATAAAGTTGA GAACATGAGT TTGGGCTGAA AAAAAAAAAA 1079

20 (2) INFORMATION FOR SEQ ID NO: 214:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3791 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 214:

TGAAGCAGGC GCTCTTGCT CGGCGCGGCC CGCTGCAATC CGTGGAGGAA CGGCGCGCCG 60
 30 AGCCACCATC ATGCTTGGC ACTTACAGGA AGGCTTGGC TGGTGGTCA CCAACCGATT 120
 CGACCAGTTA TTTGACGACG AATCGGACCC CTTGAGGTG CTGAAGGCAG CAGAGAACAA 180
 35 GAAAAAGAA GCGGCGGGG GCGCGTTGG GGGCCCTGGG GCCAAGAGCG CATCAGGGCC 240
 GCGGCCAGA CCAACTCCAA CGCGCAGGC AAACAGCTGC GCAAGGAGTC CCAGAAAGAC 300
 CGCAAGAACC CGTGCCCCC CAGCGTTGGC GTGGTTGACA AGAAAGAGGA GACGAGCCG 360
 40 CCCGTGGCGC TTTAAGAAAG AAGGAATAAG ACGAGTTGA AGAAGACCTG ATCAACAACT 420
 TCAGGTGAA GGGAAAATAA TTGATAGAAG ACCAGAAAGG CGACCACCTC GTGAACGAAG 480
 45 ATTCGAAAAG CCACTTGAAG AAAAGGTGA AGGAGGCGAA TTTTCAGTTG ATAGACCGAT 540
 TATTGACCGA CCTATTGAG GTCTGGTGG TCTTGAAGA GGTGAGGGG GCGTGGACG 600
 TGGAATGGC CGAGGAGATG GATTGATTC TCGTGGCAA CGTGAATTG ATAGGCATAG 660
 50 TGGAAGTGAT AGATCTTCTT TTTACATTA CAGTGGCTG AAGCACGAGG ACAAACGTGG 720
 AGGTAGCGGA TCTCACAAC GGGGAACGT CAAAGACGAA TTAACGACT TGGATCAATC 780
 55 AAATGTGACT GAGGAAACAC CTGAAGGTGA AGAACATCAT CCACTGGCAG AACTGAAAA 840
 TAAGGAGAT GAAGTTGAAG AGGTAAAGA GGAGGGTCCA AAAGAGATGA CTTTGATGA 900
 60 GTGAAGGCT ATTCAAAATA AGGACCGGGC AAAAGTAGAA TTTAATATCC GAAAACCAA 960

	TGAAGGTGCT GATGGGCAGT GGAAGAAGGG ATTTGTTCTT CATAAATCAA AGAGTGAAGA	1020
	GGCTCATGCT GAAGATTGGG TTATGGACCA TCATTTCCGG AAGCCAGCAA ATGATATAAC	1080
5	GTCTCAGCTG GAGATCAATT TTGGAGACCT TGGCCGCCCA GGACGTGGCG GCAGGGGAGG	1140
	ACGAGGTGGA CGTGGGGGTG GTGGGCGCCC AAACCGTGGC AGCAGGACCG ACAAGTCAAG	1200
10	TGCTTCTGCT CCTGATGTGG ATGACCCAGA GGCATTCCCA GCTCTGGCTT AACTGGATGC	1260
	CATAAGACAA CCTGGTTCC TTTGTGAACC CTTCTGTTCA AAGCTTTTGC ATGCTTAAGG	1320
	ATTCCAAACG ACTAAGAAAT TAAAAAATAA AAGACTGTCA TTCATACCAT TCACACCTAA	1380
15	AGACTGAATT TTATCTGTTT TAAAAATGAA CTTCTCCCGC TACACAGAAG TAACAAATAT	1440
	GGTAGTCAGT TTTGTATTTA GAAATGTATT GGTAGCAGGG ATGTTTTCAT AATTTTCAGA	1500
	GATTATGCAT TCTTCATGAA TACTTTTGTA TTGCTGCTTG CAAATATGCA TTTCCAAACT	1560
20	TGAAATATAG GTGTGAACAG TGTGTACCAG TTAAAGCTT TCACTTCATT TGTGTTTTTT	1620
	AATTAAGGAT TTAGAAGTTC CCCCATTAC AAACGTGTTT TAAATATTGG ACATACTGGT	1680
25	TTTAATACCT GCTTTGCATA TTCACACATG GTCAACTGGG ACATGTTAAA CTTTGATTG	1740
	TCAAATTTTA TGCTGTGTGG AATACTAACT ATATGTATTT TAACCTAGTT TTAATATTTT	1800
30	CATTTTTGGG GAAAAATCTT TTTTCACTTC TCATGATAGC TGTTATATAT ATATGCTAAA	1860
	TCTTTATATA CAGAAATATC AGTACTTGAA CAAATTCAAA GCACATTTGG TTTATTAACC	1920
	CTTGCTCCTT GCATGGCTCA TTAGGTTCAA ATTATAACTG ATTTACATTT TCAGCTATAT	1980
35	TTACTTTTTA AATGCTTGAG TTTCCCATTT TAAATCTAA ACTAGACATC TTAATTGGTG	2040
	AAAGTTGTTT AAACCTACTT TTGTTGGTAG GCACATCGTG TCAAGTGAAG TAGTTTTATA	2100
40	GGTATGGGTT TTTTCTCCCC CTTCAACCAG GTGGGTGGAA TAAGTTGATT TGGCCAATGT	2160
	GTAATATTTA AACTGTTCTG TAAATAAGT GTCTGCCCAT TTGGTATGAT TTCTGTGTGT	2220
	GAAAGGTCCC AAAATCAAAA TGGTACATCC ATAATCAGCC ACCATTTAAC CCTTCCTTGT	2280
45	TCTAAACAA AAACCAAGG GCGCTGGTGT GTAGGGTGAG GTGGGGGAGT ATTTTAATTT	2340
	TTGGAATTTG GGAAGCAGAC AGCTTTACTT TGTAAGGTG GAACAGCAGC ACTATACATG	2400
50	AAATATAAAC CAAAAACCTT TACTGTTTCT AAATTTCTTA GATTGCTATT ATTTGGTTGT	2460
	AAGTTGAGTA TTCCACAGAA AGTGGTAATT ATCTCTCTC TCTTCTCCA TTAGAAAATT	2520
	AGGTAAATAA TGGATTCTTA TAATGGGAGC ATCACCATT ATTAACACAC ACATAGAATG	2580
55	ATGAATTAAA AAAGTTTCTT AGGATTGTCT TTTATCTG CACATTTATT GATAAACAGT	2640
	GAAGGAATTT TTAATAAATT TTTAAGAATT GTTTGTCAG TCATTTTATG AAATGTTCTA	2700
60	CCTGTATATG GTAATGTCCA GTTTTAAAA TATTGGACAT CTTCAATCTT AAACATTTCT	2760

	ATTAGCTGA TTGGTCTCA CATATACTTC TAAAAGAAAC TTTTATGTTA TAAGAGTTAC	2820
	TTTTTGATA AGATTATTA ATCTCAGTTA CCTACTATTC TGACATTTTA GGAAGGAGGT	2880
5	AATGTGTTTT AATGATGGAT AAACCTGTGC TGGTGTGTTG GATCTTATGA TGCTGAGCAT	2940
	GTCTGCACT GGTGCTAATG TCTAATATAA TTTTATATTT ACACACATAC GTGCTACCCA	3000
10	GAGATTAATT TAGTCCATAT GAACTATTGA CCCATTGTTC ATTGAGACAG CAACATACGC	3060
	ACTCCTAAAT CAGTGTGTTT AGACTTTTCA AGTATCTAAC TCATTTCCAA ACATGTACCA	3120
	TGTTTTATAA ACCTCTTGAT TTCCAGCAAC ATACTATAGA AAACACCTGC TACTCAAAAC	3180
15	ACAACCTCTC AGTGTCAATC ATTGCTGTGC TGAGAGACAA CATAGCAATA TCTGGTATGT	3240
	TGCAAGCTTT CAAGATAGCC TGAACCTAAA AAGTTGGTGC ATTAGTTGTA TCTGATGGAT	3300
20	ATAAATTTGC CTCCTAGTTC ACTTTGTGTC AAGAGCTAAA ACTGTGAACC TAACTTTCTC	3360
	TTATTGGTGG GTAATAACTG AAAATAAAGA TTTATTTTCA TGCTCACTTC TTAAAAGTCA	3420
	TAAAAACAAT CAAATAGGRT CATGTTTATT GTCATGTGTT TCCTGGKTTT TGACCTGTGT	3480
25	GCACACCCCT GTGTGTTTAT AATTTTAAAT TTGAATTTTA TATGGGGTTT TTATTTGCTA	3540
	AAAACCAGGC TGTGAATCA CATTTGGGAA GGTACTTAT CTTAATGACT AATGACTTAA	3600
30	TTGGGAAAGT TGAATCTTG TAAATACAA AATCCAAGGA CTTCTTGGGA TTAAATCTAA	3660
	TTGTCACTTC NTTAGGCAGA TNCACCTTTT TGGATAATGG AAAGTTAAGC ATACCGAATG	3720
	CTACTTTTGG TTGACAAACG GGCCTAATAG TCCGGGGGGA AATCCCTAAC NGGTAAGGNT	3780
35	CCCAAGTATG G	3791

40 (2) INFORMATION FOR SEQ ID NO: 215:

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 1334 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 215:

50	CAGTGCTGCG TCCTGCTGGG GCGCTGCGG CCCCAGGCGT CGCCATGACC AGTGAGCTGG	60
	ACATCTTCGT GGGGAACAGA CCTTATCGA CGAGGACGTG TATCGCTCTT GGCTCGATGG	120
55	TTACTCGGTG ACCGACGCGG TGGCCCTGCG GGTGCGCTCG GGAATCCTGG AGCAGACTGG	180
	CGCCACGGCA GCGGTGCTNC AGAGCGACAC CATGGACCAT TACCGCACCT TCCACATGCT	240
	CGAGCGGCTG CTGCATGCGC CGCCAAGCT ACTGCACCAG YTCATCTTCC AGATTCCGCC	300
60	CTCCCGGCAG GCACTACTCA TCGAGAGGTA CTATGCCCTT RATGAGGCCT TTGTTCCGGA	360

	GGTGCTGGGC AAGAAGCTGT CCAAAGGCAC CAAGAAAGAC CTGGATGACA TCAGCACCAA	420
5	AACAGGCATC ACCCTCAAGA GCTGCCGGAG ACAGTTTGAC AACTTTAAAC GGGTCTTCAA	480
	GGTGGTAGAG GAAATGCGGG GCTCCCTGGT GGACAATATT CAGCAACACT TCCTCCTCTC	540
	TGACCGGTTG GCCAGGGACT ATGCAGCCAT CGTCTTCTTT GCTAACAACC GCTTTGAGAC	600
10	AGGGAAGAAA AAATGCACT ATCTGAGCTT CGGTGACTTT GCCTTCTGCG CTGAGCTCAT	660
	GATCCAAAAC TGGACCCCTG GAGCCGTCGA CTCACAGATG GATGACATGG ACATGGACTT	720
15	AGACAAGGAA TTTCTCCAGG ACTTGAAGGA GCTCAAGGTG CTAGTGGCTG ACAAGGACCT	780
	TCTGGACCTG CACAAGAGCC TGGTGTGCAC TGCTCTCCGG GGAAAGCTGG GCGTCTTCTC	840
	TGAGATGGAA GCCAACTTCA AGAACCTGTC CCGGGGGCTG GTGAACGTGG CCGCCAAGCT	900
20	GACCCACAAT AAAGATGTCA GAGACCTGTT TGTGGACCTC GTGGAGAAGT TTGTGGAACC	960
	CTGCCGCTCC GACCACTGGC CACTCAGCGA CGTGCGGTTT TTCTGAATC AGTATTCAGC	1020
25	GTCTGTCCAC TCCTCGATG GCTTCOGACA CCAGGCCCTCT GGGACCGCTA CATGGGCACC	1080
	CTCCGCGGCT GCCTCCTGCG CCTGTATCAT GACTGAGGTG CCTCCCAACG CTCCGCCAC	1140
	GCTGACAATA AAGTTGCTCT GAGTTTGGAG ACTGGTCTC GCTCCGGGA GCAAGTGGGG	1200
30	GGCGTGCGA TGTGCCGTG TCTGTCTCTG AGCACCTGGT GTCCGTGTAC AAGGATGGAT	1260
	GTGTNCNGTG GCTCCTTGGG AACTGAGACA TATCTCAGGG AATGGTGTCT GTGCTCAGCC	1320
35	CATCCACCAG AAGA	1334

(2) INFORMATION FOR SEQ ID NO: 216:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1511 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

45

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 216:

50	GTGGCGGGGA TGCTGCGAGG GGGTCTCTCTG CCCAGGCGG GCCGGCTGCC TACCTCCAG	60
	ACTGTCCGCT ATGGCTCCAA GGCTGTTACC CGCCACCGTC GTGTGATGCA CTTTCAGCGG	120
	CAGAAGCTGA TGGCTGTGAC TGAATATATC CCCCCGAAAC CAGCCATCCA CCCATCATGC	180
55	CTGCCATCTC CTCCAGCCC CCACAGGAG GAGATAGGCC TCATCAGGCT TCTCCGCCGG	240
	GAGATAGCAG CAGTTTTCOA GGACAACCGA ATGATAGCCG TCTGCCAGAA TGTGGCTCTG	300
60	AGTGACAGAG ACAAGCTTCT TATGCGACAC CAGCTGCGGA AACACAAGAT CCTGATGAAG	360

	RTCTTCCCCA ACCAGGTCTT GAAGCCCTTC CTGGAGGATT CCAAGTACCA AAATCTGCTG	420
	CCCCTTTTTC TGGGGCACAA CATGCTGCTG GTCAGTGAAG AGCCCAAGGT CAAGGAGATG	480
5	GTACGGATCT TAAGGACTGT GCCATTCTCG CGCTGCTAG GTGGCTGCAT TGATGACACC	540
	ATCCTCAGCA GGCAGGGCTT TATCAACTAC TCCAAGCTCC CCAGCCTGCC CCTGGTGCAG	600
10	GGGAGCTTG TAGGAGGCCT CACCTGCTC ACAGCCAGA CCCACTCCCT GCTCCAGCAC	660
	CAGCCCTCC AGCTGACCAC CTGTGTGGAC CAGTACATCA GAGAGCAACG CGAGAAGGAT	720
	TCTGTCAATG CGGCCAATGG GAAGCCAGAT CCTGACACTG TTCCGGACTC GTAGCCAGCC	780
15	TGTTTAGCCA GCCCTGGCCA TAAATACACT CTGGCTTATT GGCTGTGCTC TCCTCAATGG	840
	GACATGTGGA AGAACTTGGG GTCGGGGAGT GTGTTTGTC CTTGGTTTTC ACTAGTAATG	900
20	ATATTGTCAG GTATAGGGCC ACTTGAGAT GCAGAGGATT CCATTTCAGA TGTCACTCAC	960
	CGGCTTCGTC CTTAGTTTTC CCAACTTGGG ACGTGATAGG AGCAAAGTCT CTCCATTCTC	1020
	CAGGTCCAAG GCAGAGATCC TGAAAAGATA GGGCTATTGT CCCCTGCCCT CTTGGTCACT	1080
25	GCCTCTTGCT GCACGGGCTC CTGAGCCACC CCCTTGGGGC ACAACCTGCC ACTGCCACAG	1140
	TAGCTCAACC AAGCAGTTGT GCTGAGAATG GCACCTGGTG AGAGCCTGCT GTGTGCCAGG	1200
30	CTTTGTGCTG AGTGCTGTAC ATGTATTAGT TCCTTTACTG CTGACCACAT TGTACCCATT	1260
	TCACAGAGAA GGACGAGAGA AATTAAAGTG CTTGCTCAAG GTCATGCAGT TAGTAAGTGG	1320
	CAGAACAGGG ACTTGAACCA AGCCCTCTGC TCTGAAGACC GCGTCTGAA TTTCTTCACT	1380
35	AGAGCTTCCT CATCAGGITA CCCAGAAGTG GGTCCCATCC ACCATCCAGG TGTGCTTGGA	1440
	TGTTAGTTCT CCACCTCGA GGTGTACGCT GTGAAAAGTT TGGGAGCACT GCTTTATAAT	1500
40	AAAATGAAAT A	1511

45 (2) INFORMATION FOR SEQ ID NO: 217:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 642 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 217:

55	AGGCCTTACT TTTCCTOCCA CAAAGGAGTC GCAGCCACGC TAGCTCTGAC TTGCCACTGT	60
	GACAAAGTTC ACGTAGCAGG TCTAGGCAAA GACTGGGCAA TTGAGCAGAG GAGACGGACC	120
	TGTGAGTCTG ACCRYGAGSC GGRCCCTTTC ACCTTGGCTG GGCTGGTCTT GGTCTTAGG	180
60	TTTTGTCAAG TTGTCTTGT TTGGATCCCT CAACTAGGTG ATAAGCACTG GAGGGGGATG	240

5
10
15

ACCCGCTTG GACGTGTTTC TTAACTCA TCCATATAAT AGGGCGTGG GATGGTTGTA 300
GAGGTAAAGC AGGATGATGG TGTTTAAGA CCAGAGCTTG GGACCAGGGC TCCTACACCT 360
AATTTTCTCT CCTGGTAGCT GAACAAAGGT CTAAATTAGC TTAACAAAAG AACAGGCTGC 420
CGTCAGCCAG AGTTCTGAAG GCCATGCTTT CAGTTTCCT TGTGACAAT TGCTCTCCAG 480
TTCTATGAA AGCACAGAGC CTTAGGGGGC CTGCCACAG AACACAACCA TCTTAGGCCT 540
GAGCTGTGAA CAGCAGGGG TTGTGTGCT GTTCTGTTT TCTGCTTGC GAACTTTCTC 600
AATAAACCTT ATTTCTTATT TTATATTAC GINGGTGCTG GG 642

20 (2) INFORMATION FOR SEQ ID NO: 218:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1241 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 218:

30
35
40
45
50
55
60

GGTCCACTG TTCCATTTTA TGCTAATAGA TTCCATTCTA GGGCCAGCC GTCTCTTGAC 60
TGATGGTGT CCCTTTAACC CTTGGCATGT ATAATAGAAT TTTGGTGAAT GAAAGAACCC 120
AAATAGGCCA GATAGTCCCC CCAGGCCCTG ATATCCATAA AAGGCTTGGG AATGCATTAT 180
GTAATTGTCC TAGTCTTTT TGTGTTTTA GAAAAAACA ACAAGATGGG CTCAGATGGA 240
TGCTACGTA AAAATGGTTC CTAGCTGTGT ACTCATAACT TTTCTTTGAA TTGAGTAGTG 300
AAAGGAAGGA GGAGGAAAGG AAATTAAATG TCCTTCTAGT ATTCTCTGGA CTCAAGTCTG 360
ACATATGRGA TAATAACCTA TATGAAATG CCAAGAATTG TATCTGAAAC AAGRGACAG 420
TTTGACACAT TTATCATGCC TTCATATTAC ATATTAACTG AAACCAATTA ATAAACATAT 480
GAAATATCCA TTGCACAAGG CAAAGGCACC TAAACCTTTT GTTCTTTTTT CTACATAGCA 540
GAAATTGAIT TTTTTTTTAT TTTTITAGGG GAACCTATAT AATTATGACC CAGTGATGTC 600
TTTTGGTGAC TTAAGCTTAT GAATTCAGGT TACAATTGAG TTGATTCTAG ATGGTTACTA 660
CCTTGAAAAG GATGTTGGTG CCTTATGTGA CAGAGCCAG AGCCTGCTGG GAATAAACAA 720
AGCAGATTCA TGCCAACACC AACTCGTAGC TTTAGTGGCA GATGGGAGTG GTCACAGACT 780
CCCAAAATGT GGGGCTTTGG ATTTCCACAC CATCCACGT GTGTGTCATC TTCTCTTTT 840
ACACTCTTGA TGATAATTTG AAAATGRTGA AATCACTCT GAATTTGCCT ATAGCATGAG 900
CACATTCTTA TGACAACATA ACAAATAGTT CATAATGTGA ATATTAGAAA CTGTTACAGC 960

CTGCAGTTAC CATAATTTTC CATGTTTGTG GAATTGATAT TGAAATAGCA GGGCTAAGGA 1020
ATTACTGGCA AGTTTTAGCC TGTGGGTAAT ACCTTAGGGT TATTAAATA TTTGTAATTT 1080
5 TATTAAATG TTCATGAATG TTTGAAAGGA ACAAATTTAT CAGGGATGGC TCTTTGCCAT 1140
GGGTCTTATT TTCACCTCT TTTCTGTAAG AAAAAAGAAC AATGCTTAA TGTATTTTAA 1200
AAGTTTTTGG TATAGTTTCT AATCCAATT TTAATAAAG T 1241
10

(2) INFORMATION FOR SEQ ID NO: 219:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1080 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 219:

TGTTATGTG ACCTAAACA TACACACATG CACACACACA TACATATCCA TTCATTCATT 60
25 CATTCAGTG GTGTTCCAG TGTCTGTGTG TCACTGTTTA TGCAGTTTCC ATTTCCCACT 120
GAATTATGAG TGGAGGGCAA CTTTTCTAAC CAGATTGTCT TTTCAGAACA AAGACCKGGG 180
30 RAITGAGGAA GAGTTTGGAA AGAGGGGAGAG GCAAGGAAAG AGAGCTTTAA ATTGAAAGGT 240
TAATTTCTTA AGAGGAACCT GGGCTGAATG ACTACAGTGT TATACCTCC AATCTTTGCA 300
GGTGGGCATG GAACACTGCT TGTATCACTC TGTGCACGGT ATAAATCCAT ATATCCACAA 360
35 AAACACACAT CCATCCATCA ACATATACAT GGTTTGGGAT GAGCAGGTCA ATAGTTTGA 420
GAGGGAGTTT GTTCTTTT TTTTCTCATT ATACTCTTAA ATTGTTGTCA GTTATCAAAC 480
40 AAACAACAG AAAAATTGTT TGGGAAAAAC CTGCATACG CCTTTTCTAT CMAGTGCTTT 540
AAAATATAGA CTAAATACAC ACATCCTGCC AGTTTTTTCT TACAGTGACA GTATCCTTAC 600
CTGCCATTTA ATATTAGCCT CGTATTTTTC TCACGTATAT TTACCTGTGA CTTGTATTIG 660
45 TTATTTAAAC AGGAAAAAA ACATTCAAAA AAAGAAAAAT TAACTGTAGC GCTTCATTAT 720
ACTATTATAT TATTATTATT ATTGTGACAT TTTGGAATAC TGTGAAGTTT TATCTCTTGC 780
50 ATATACITTA TACGGAAGTA TTACGCCTTA AAAATACGAA AATAAATTTT ACAAGGTTTC 840
TGTTTTGTGT GGAAGAGTAA TTGATGTTGC TAAGAATGAT GTTTGTTTTT TTGGGGTTTT 900
TGTTGTTTTT TTTTAAATG TTACCAACAC TTTTTTGTGA AGTTTCACTT TCCGAGGTAT 960
55 TGTACAAGTT CACACTGTTT GTGAAGTTTG AATATGAAGG AATAATTAAA AAAAAAAAAA 1020
AAACCNCGGG GGGGGCCCGG TCCCATTGGN CCCAAGGGGG CGTTACGGG GTCACGGCCG 1080
60

(2) INFORMATION FOR SEQ ID NO: 220:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1258 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 220:

TGAATTGAGG GCTTAAAGAT AAACATATGG GRTTGGAGTT GTGTGTCCAT AGGGTTTCAC 60

15 TGCCTATTTG ATTGAGTTT ATCCCTATTA ATTTTTTACA GTGAAATTTT ATTAAAGTAT 120

AATGTACATA TATTTTCAGT GGATTTTGCT CTGAAGGTTT TCCAGTGGTC TGAAGACGAG 180

20 ATAGTGGGGC TTCAGCTGTG GGATATTGCA GGGCAGGAGC GCTTCACCTC TATGACACGA 240

TGTATTATC GGGATGCTC TGCTGTGTT ATATGTTTG ACGTTACCAA TGCCACTACC 300

TTCAGCAACA GCCAGAGGTG GAAACAGGAC CTAGACAGCA AGCTCACACT ACCCAATGGA 360

25 GAGCCGGTGC CCTGCCCTGCT CTTGGCCAAC AAGTGTGATC TGTCCCCTTG GGCAGTGAGC 420

CGGGASCAGA TTGACCGTT CAGTAAAGAG AACGGTTTCA CAGGTTGGAC AGAAACATCA 480

30 GTCAAGGAGA AAAAAATAT TAATGAGGCT ATGAGAGTCC TCATTGAAAA GATGATGAGA 540

AATTCACAG AAGATATCAT GTCTTTGTCC ACCCAAGGGG ACTACATCAA TCTACAAACC 600

AAGTCTCCA GCTGGTCTG CTGCTAGTAG TGTGTGGYTT ATTTTCCATC CCAGTTCTGG 660

35 GAGGTCTTTT AAGTCTCTTC CCTTGGTTG CCCACCTGAC MATTTTATTA AGTACATTTG 720

AATGTCTCC TGACTACTGT CAGTAAGGA GGCCCATTTG CACTTAGAAA AGACACCTGG 780

40 AACCCKAGTG CATTTCTGCA TCTCTGGAT TAGCCTTSTA CATGTTGCTG RCTCACATTA 840

GTGCCAGTTA GTGCTTCGG TGTAAGATCT TCTCATCAGC CCTCAATTG TGATCCGGAA 900

TTTTGTGAGA AGGATKAGAA ATCAGCACCT GCGTTTTAGA GATCATAATT CTCACCTACT 960

45 TCTGAGCTTA TTTTCCATT TGATATTCAT TGATATCATG ACTTCCAATT GAGAGGAAAA 1020

TGAGATCAAA TGTATTTCC CAAATTTCTT GTAGGCCGTT GTTTCAGATT CTTTCTGTCT 1080

50 TGGAAATGTA ACATCTGATT CTGGAATGCA GAAGGAGGGG TCTGGGCATC TGTGGATTTT 1140

TGGCTACTAG AAGTGTCCA GAAGTCACTG TATTTTIGAA ACTTCTAACG TCATAATTAA 1200

GTTCCTCTTG TCTTGGCAT CAAGANTAGT TCCAATTTTT TGGGCCGGG CAGGGTGG 1258

55

(2) INFORMATION FOR SEQ ID NO: 221:

60

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1693 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 221:

	CACAATATAT GAAATAGTAC CCTCTAAAAA AGAGAAAAAA AAAATCAGGC GGTCAAACCT	60
10	AGAGCAACAT TGTCTTATTA AAGCATAGTT TATTTCACTA GAAAAAATTT AATATCAAGG	120
	ACTATTACAT ACTTCATTAC TAGGAAGTTC TTTTAAAT GACACTTAAA ACAATCACTG	180
15	AAAACCTGAT CCACATCACA CCTGTATTAT TTTCCTTAAA CATCTTGGA GCCTAAGCTT	240
	CTGAGAATCA TGTGGCAAGT GTGATGGGCA GTAAAATACC AGAGAAGATG TTTAGTAGCA	300
	ATTAAAGGCT GTTGCACCT TTAAGGACCA GCTGGGCTGT AGTGATTCTT GGGGCCAGAG	360
20	TGGCATTATG TTTTACAAA ATAATGACAT ATGTCACATG TTTGCATGTT TGTTTGCTTG	420
	TTGAATTTT GAACAGCCAG TTGACCAATC ATAGAAAGTA TTACTTTCTT TCATATGGTT	480
25	TTTGGTTCAC TGGCTTAAGA GGTTCCTCAG AATATCTATG GCCACAGCAG CATACCAGTT	540
	TCCATCCTAA TAGGAATGAA ATTAATTTTG TATCTACTGA TAACAGAATC TGGGTCACAT	600
	GAAAAAAAT CATTTTATCC GTCTTTTAAG TATATGTTTA AAATAATAAT TTATGTGTCT	660
30	GCATATTGCA GAACAGCTCT GAGAGCAACA GTTCCCATTT AACTCTTTCT GACCAATAGT	720
	GCTGGCACCG TTGCTTCCTC TTGGGAAGA GGAAAGGGTG TGTGAACATG GCTAACAATC	780
35	TTCAAATACC CAAATTGTGA TAGCATAAAT AAAGTATTTA TTTTATGCCT CAGTATATTA	840
	TTATTTAATT TTTTAGGTAA TGCTATCTC TTGGTCTATT AAGGAAAGAA GCAATCAGTA	900
	GAGAATTCAG GATAGTTTGT TTAAATTCT TGCAGATTAC ATGTTTTTAC AGTGGCCTGC	960
40	TATTGAGGAA AGGTATTCTT CYATACAACT TGTTTTAACC TTTGAGAACA TTGACAGAAA	1020
	TTATGCAATG GTTGTGTGAG ATACCGACTT GATGGTGCTG TTTAATCAGT TTGCTTCCAA	1080
45	AGTGGCTAC TCAAGAGGCC CTAAGACTGG TAGAAATTAA AAGGATTTC AAAACTTTCT	1140
	ATTCCTTTCT TAAACCTACC AGCAAACTAG GATTGTGATA GCAATGAATG GTATGATGAA	1200
	GAAAGTTTGA CCAATTTGT TTTTGTGTG TTGTGTGTG TTTGAATTTG AAATCATTCT	1260
50	TATTCCTTTT AAGAATGTTT ATGTATGAGT GTGAAGATGC TAGOGAACCT ATGCTCAGAT	1320
	ATTCAATGTA AGTCTCCCTT CACCTGTTAC AGAGTTTCAG ATCGGTCACCT GATAGTATGT	1380
55	ATTTCTTTAG TAAGAAATGT TTAATAATTAC AATGATCTTT TAAAAAGATG ATGCAGTTCT	1440
	GTATTTATTG TGCTGTGTCT GGTCTAAGT GGAGCCAATT AAACAAGTTT CATATGTATT	1500
	TTCCAGTGT TGAATCTCAC ACACGTACT TTGAAAATTT CCTTCCATCC TGAATAACGA	1560
60	ATAGAAGAGG CCATATATAT TGCCTCCTTA TCCTTGAGAT TTCACTACCT TTATGTTAAA	1620

AGTGTGTAT AATTGTTAAA ATCTGTGAAA GAATAAAAAG TGGATTTAAA TTAACAAAAA 1680

AAAAAAAAAA AAA 1693

5

(2) INFORMATION FOR SEQ ID NO: 222:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1196 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

15

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 222:

ACGCGTGGGT CGACCCACGC GTCCGGGACN TGGCGTGGTG GGAAGGGAG AAGGATTGT 60

20

AAACCCCGGA GCGAGTTCT GCTTACCCGA GGCGCTGCT GTGCGGAGAC CCGCGGTGA 120

AGCCACGTC ATCATGTCTG ACCAGGAGGC AAAACCTTCA ACTGAGGACT TGGGGGATAA 180

25

GAAGGAAGGT GAATATATTA AACTCAAAGT CATTGGACAG GATAGCAGTG AGATTCACCT 240

CAAAGTGAAA ATGACAACAC ATCTCAAGAA ACTCAAAGAA TCATCTGTG AAAGACAGGG 300

30

TGTTCCAATG AATTCACCTCA GGTTCCTCTT TGAGGGTCAG AGAATTGCTG ATAATCATA 360

TCCAAAGAA CTGGGAATGG AGGAAGAAGA TGTGATTGAA GTTTATCAGG AACAAACGGG 420

GGGTCACTCA ACAGTTTAGA TATTCTTTTT ATTTTTTTTC TTTTCCCTCA ATCCTTTTTT 480

35

ATTTTAAAA ATAGTTCTTT TGTAATGTGG TGTTCAAAC GGAATTGAAA ACTGGCACCC 540

CATCTCTTTG AAACATCTGG TAATTGAAT TCTAGTGCTC ATTATTCATT ATTGTTTGT 600

40

TTCATTGTGC TGATTTTGG TGATCAAGCC TCAGTCCCT TCATATTACC CTCTCCTTT 660

TAAAAATTAC GTGTGCACAG AGAGGTCACC TTTTTCAGGA CATGCAATT TCAGGCTTGT 720

GGTGATAAAT AAGATCGACC AATGCAAGTG TTCATAATGA CTTTCCAATT GGCCCTGATG 780

45

TTCTAGCATG TGATTACTTC ACTCCTGGAC TGTGACTTTC AGTGGGAGAT GGAAGTTTTT 840

CAGAGAACTG AACTGTGGAA AAATGACCTT TCCTTAACTT GAAGCTACTT TTAATAATTG 900

50

AGGGTCTGGA CCAAAGAAG AGGAATATCA GGTGGAAGTC AAGATGACAG ATAAGGTGAG 960

AGTAATGACT AACTCCAAAG ATGGCTTCAC TGAAGAAAAG GCATTTTAAG ATTTTAAAA 1020

AATCTGTGCA GAAGATCCCA GAAAAGTTCT AATTTTCATT AGCAATTAAT AAAGCTATAC 1080

55

ATGCAGAAAT GAATACAACA GAACACTGCT CTTTTTGATT TTATTGTAC TTTTGGCCT 1140

GGGATATGGG TTTTAAATGG ACATGTCTG TACCAGCTTC ATTAATAATA ACAATA 1196

60

(2) INFORMATION FOR SEQ ID NO: 223:

(i) SEQUENCE CHARACTERISTICS:

5

- (A) LENGTH: 1791 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 223:

TCAGGGAGGT GGCAGGAAAG GCTTGAACA GCTGCCGGAG TGACGGAGCG GCGGCCCCGC	60
CCGGTTGCCG TGGAGGTGCA AGCTTCCAGG TAGGGGCCCC CAGAGCCTGA CCCAGGCTCT	120
GGACATCCTG AGCCCCAGTC CCCCACTC AGTGCACTGA TGAGTGCGGA AGTGAAGGTG	180
ACAGGGCAGA ACCAGGAGCA ATTCTGTCTC CTAGCCAAGT CGGCCAAGGG GGCAGCGCTG	240
GCCCACTCA TCCATCAGGT GCTGGAGGCC CCTGGTGTCT ACGTGTTTGG AGAACTGCTG	300
GACATGCCCA ATGTTAGAGA GCTGGCTGAG AGTGACTTTG CCTCTACCTT CCGGCTGCTC	360
ACAGTGTTCG CTATGGGAC ATACGCTGAC TACTTAGCTG AAGCCCGGAA TCTTCCTCCA	420
CTAACAGAGG CTCAGAAGAA TAAGCTTCGA CACCTCTCAG TTGTCACCTT GGCTGCTAAA	480
GTAAAGTGTA TCCCATATGC AGTGTGTCTG GAGGTCTTGC CTTGCGTAAT GTGCGGCAGC	540
TGGAAGACCT TGTGATTGAG GCTGTGTATG CTGAAGTGCT TCGTGGCTCC CTGGACCAGC	600
GCAACCAGCG GCTGAGGTT GACTACAGCA TCGGGCGGGA CATCCAGCGC CAGGACCTCA	660
GTGCCATTGC CCGAACCTTG CAGGAATGGT GTGTGGGCTG TRAGGTGCTG CTGTCAAGCA	720
TTGAGGAGCA GGTGAGCCGT GCCAACCAAC ACAAGGAGCA GCAGCTGGGC CTGAAGCAGC	780
AGATTGAGAG TGAGGTTGCC AACCTTAAAA AAACCATTAA AGTTACGACG GCAGCAGCAG	840
CCGAGCCAC ATCTCAGGAC CCTGAGCAAC ACCTGACTGA GCTGAGGGAA CCAGCTCCTG	900
GCACCAACCA GCGCCASCCA GCAAGAAAGC CTCAAAGGCG AAGGGGCTCC GAGGGAGGCG	960
CAAGATTTCG TCCAAGTCGA ATGAAAGRA CTGTGTTTC CTCCCTGGGG ATGTGGGGTC	1020
CCAGCTGCCT GCCTGCCTCT TAGGAGTCCT CAGAGAGCCT TCTGTGCCCC TGGCCAGCTG	1080
ATAATCCTAG GTTCATGACC CTTCACTCC CCTAACCCCA AACATAGATC ACACCTTCTC	1140
TAGGGAGGAG KCAAATGTAG GTCATGTTTT TGTGGTACT TTCTGTTTTT TGTGACTTCA	1200
TGTGTTCCAT TGCTCCCCGC TGCCATGCTC TCTCCCTTGT TTCTTAAGA GCTCAGCATC	1260
TGTCCCTGTT CATTACATGT CATTGAGTAG GTGGGTAGCC CTGATGGGGG TCGCTCTGTC	1320
TGGAGCATAA CCCACAGGCG TTTTTTCTGC CACCCCATCC CTGCATGCCT GATCCCCAGT	1380
TCCTATACCC TACCCCTGAC CTATTGAGCA GCCTCTGAAG AGCCATAGGG CCCCCACCTT	1440
TACTCACACC CTGAGAAATC TGGGAGCCAG TCTGCCATGC CAGGAGTCAC TGGACATGTT	1500

CATCCTAGAA TCCTGTACACA CTACAGTCAT TTCTTTTCCT CTCTCTGGCC CTGGGGTCCT 1560
 5 GCGAATGCTG CTGCTTCAAC CCCAGAGCCT AAGAATGGCA GCCGTTTCTT AACATGTTGA 1620
 GAGATGATTC TTTCTTGGCC CTGGCCATCT CGGGAAGCTT GATGGCAATC CTGGAAGGGT 1680
 TTAATCTCCT TTTGTGAGTT TGGTGGGAA GCGAAGGGTA TATAGATTGT ATTAAAAAAA 1740
 10 AAAAGGTATA TATGCATATA TCTATATATA ATATGACGCA GAAATAAATC T 1791

15 (2) INFORMATION FOR SEQ ID NO: 224:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2517 base pairs
 (B) TYPE: nucleic acid
 20 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 224:

25 ACACTAGTGG ATCCAAAGAA TTCGGCACAG CGGCACAGCA TTGTTGAGCT TTTCTGTGTG 60
 TGTGGGGCCC TCAAGCGAGC TCGACTGGTC CATCTGGGG TAGCGASGTG GTGTTTGTGA 120
 AAAAGGACGA TGCCATCACC GCATAYAAGA AGTACAACAA CCGGTGTCTG GACGGGCAGC 180
 30 CGATGAAGTG CAACCTTCAC ATGAATGGGA ATGTTATCAC CTCAGACCAG CCCATCCTGC 240
 TGCGGCTGAG TGACAGCCCA TCAATGAAAA AGGAGAGCGA GCTGCCCTGC AGGGTGAAC 300
 35 CTGCCCTCCTC CTCCAACCCC CCTGCCGAAG TGGACCCTGA CACCATCCTG AAGGCACTCT 360
 TCAAGTCTC AGGGGCTCT KITGACCACGC AGCCACAGA WITCAAAATC AAGCTTTGAG 420
 CAGGGGAGTR AGGCAGCCAG AAGTGGGGC AGAGGAGGGT GGCTCTGTTT CCCCAGGCA 480
 40 AAGCTTATGA CCAATGGGCC ATCGGACTGG AGACCCCTGA TTGTGGGAAG GGTGCCAGG 540
 GATAAAGAGC TTCTCACTG GATGGGACCC GCCTTTCTGT GTGTGTCTT GCCCTGTGCT 600
 45 CTCTCTCTA CGTTAAGGTT TCCTGTAGTA TGTTCCTTCA TCTCATGCC AAGGTAGGCT 660
 TGTGTTTTT AGTGTGTGCC TCCCCGAGCC TCAGCCCCAA GCTGATTTCT TATCTGGAAA 720
 TGGTACACTG AATTCTCTGG GTGGCTTTCT TGTGGCCCCA TGGATGCAG CGTGGGGCT 780
 50 GTCTGAAGGA CCTGCTTTT TCCAGGGGCC GAGGGGCTGC CTTTCCTTTG TGTGTATTAA 840
 GCTTTTCAAA CAATGGAGGG GATGGAGAGC CCTGGTGTCC TGACGGGAGC CAGGTCCGCC 900
 55 TGAGAGCTGT GCGCTCCTC TGTCTGTCA GTGGAGGTGC CTGGGTGGG AGCAGGTCTC 960
 AGGCTCTCTG TCCTCTCCCC AGTGGCTCCA GGCCTCACTA GTGGCAAGGG CAGGATGAGG 1020
 CTGCACCGCT GGAAGAGTC TATCTAAGCT CTGGCTTGG AGTCCCGTGT CGTCTCCRC 1080
 60

CAGAGGAAGT TCTCCAGAGT TCACCTTTCC CTTTTCCTTG AGTTGTGCTG AATGCCCCAC 1140
 CCCAGCTCTC TTCCCTTCT GGGTGTCTTT GCTGGGAGGG GGCTGTGTTG TGAGCCCTCC 1200
 5 CGGTCTCAC CTCGCCCTGGC ACTTAACCAC ACCCTGGTTT TGTGTAGCCG CCAGCTCTCT 1260
 TCTGGTTGGG CCTTGAAAG GCTCAGCCTC CCATTGTGCA GTGCTTGGGT TTGGAGCTTA 1320
 10 TTTGAATGGA AGAGGTCAGT TTGTTCCTGG CTCTCCATTT CTGGCCTCAG TTGTCTACAG 1380
 GACAGTGGTC AGGGATGCC T GGAGGCATAT ATCCAGCTGC CACCAAGGGG CACTGTTTGT 1440
 TCCCCTTAT GTGAGTGACC CCATCCATCC ATGACCAGAG GATTATTTTC CTGCCCTGGC 1500
 15 AGAGGAGGAG GAGTCAAGGG AGCAGGGCAG CTCTACCAGG CAAGGTGTTT CCCCAGCATA 1560
 GGCGCAGACA GTTGGGACGA AACTTCAGAG CCCAGGCAGT CCCTGAATGA CCAGGCCAGT 1620
 GTTGTCACTG AGTGGTCCCC TGCTGGTTGG GAGTGAAGAG AATCCAGGCT GGCAGAGCTG 1680
 20 GAGCCAGTTG GGGAGCACGG TTCTGGGAGC TCTGCAAAAT CAGTAGCAAG TGCTGAAAA 1740
 GGCACATGCC GAAGATACTC AAGAGCTCCC AAGATTGCT TGAGGCTAGC CCAGTGAAAA 1800
 25 AAACCAGAGA CTCATGTTTC CAGGGGTCAG TCTGTCAGGC AGGAAGGACC CAGGATTGA 1860
 ACCCAGCTTC AGTGTGCAGG CTCTGAGGCT GCCCAGGACG GGAAAGTCCA AGGAAGGGGC 1920
 CTGGTGGTGC TCCACTTGCA GTTCTTTAAA GAATGCTGCT TTTTATTCTC CTAACCCCTT 1980
 30 CAAGTGGGTG CAGACTTCTC GTTAGCAGCT GGAAGACATT CCTCCACAC TTTTCCCTTC 2040
 CTGGCCCAAG AGAGCATCCA GAAGGCAGTA GGACCTGGTT TTTAGGTAC TGGGAGCCGG 2100
 35 GGGCTCACTG CTTGCACTGT GCTTAGGTA GGGATGGTAA ATATCCTCCC TGCATGGCTT 2160
 TATCCTCCCT CTCATCCCAA AGCAGGTATC TTCTGGTTGT CACAGAGTTT CATGAGTCC 2220
 AGCTGCAGCC ACGTGGCCAT CTGGAGCTGG TGCTATAGGT GACCATCTGG TACATTGAGG 2280
 40 GGACCTGTTT GCTCCTCCA CTCTATAAGC AGTCATCTTG GGAGACCGG AGGAGAAGGT 2340
 GGTGGGCTAG TCCTGTGTCC TCCTCCACTT CCCATGCCTC TATGTTACCC ATCTGTGTCT 2400
 45 CCTGTGCAGA AGGAGAGGAA GGGGCATTAA GAGATGAAGG GTGATTATGT ATTACTTATC 2460
 CATTTCTGAA TAAACATTG TTATTCTTAA AAAAAAAAAA AAAAAACTCG AGGGGGG 2517

50

(2) INFORMATION FOR SEQ ID NO: 225:

55 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2424 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 225:

	TTGTANCTAA TCGAGGATTG ATTCTAATGA CAGAGTCTTT CAACACTTTG CACATGATGT	60
5	ATCAOAGAAGC TACAGCTTGC CATGTGACTG GAGATTTAGT AGAACTTCTG TCAATATTTC	120
	TTTCGGTTTT GAAGTCTACA CGCCCTTATC TTCAGAGAAA AGATGTGAAA CAAGCATTAA	180
	TCCAGTGGCA GGAGCGAATT GAATTGCCCC ATAAACTGTT AACTCTTCTT AATTCCTATA	240
10	GTCTCCAGA ACTTAGAAAT GCCTGTATAG ATGTCTCAA GGAAGTTGTA CTTTGTAGTC	300
	CCCATGATTT TTTTCATACT CTGGTCCCT TTCTACAACA CAACCATTGT ACTTACCATC	360
15	ACAGTAATAT ACCAATGTCT CTGGACCTT ATTTCCCTTG TCRAGAAAAT ATCAAGCTAA	420
	TAGGAGGGAA AAGCAATATT CGCCCTCCGC GCCCTGAACT CAATATGTGC CTCTTGCCCA	480
	CAATGGTGA AACCAAGTAAG GGCAAGATG ACGTTTATGA TCGTATGCTG CTAGACTACT	540
20	TCTTTTCTTA TCATCAGTTC ATCCATCTAT TATGCCGAGT TGCAATCAAC TGTGAAAAAT	600
	TTACTGAAAC ATTAGTTAAG CTGAGTGTCC TAGTTGCCTA TGAAGGTTTG CCACTTCATC	660
25	TTGCACTGTT CCCCAACTT TGGACTGAGC TATGCCAGAC TCAGTCTGCT ATGTCAAAAA	720
	ACTGCATCAA GCTTTTGTGT GAAGATCCTG TTTTCGAGA ATATATTAAA TGTATCCTAA	780
	TGGATGAAAG AACTTTTTTA AACACAACA TTGTCTACAC GTTCATGACA CATTTCTCTC	840
30	TAAAGGTTCA AAGTCAAGTG TTTTCTGAAG CAAACTGTGC CAATTTGATC AGCACTCTTA	900
	TTACAACTT GATAAGCCAG TATCAGAACC TACAGTCTGA TTTCTCCAAC CGAGTTGAAA	960
35	TTTCCAAAGC AAGTGCTTCT TTAAATGGGG ACCTGAGGGC ACTGGCTTTG CTCTGTCTAG	1020
	TACACACTCC CAAACAGTTA AACCCAGCTC TAATTCCAAC TCTGCAAGAG CTTTAAAGCA	1080
	AATGCAGGAC TTGTCTGCAA CAGAGAACT CACTCCAAGA GCAAGAAGCC AAAGAAAGAA	1140
40	AAACTAAAGA TGATGAAGGA GCAACTCCA TTAAAGGCG GCGTGTAGC AGTGATGAGG	1200
	AGCACACTGT AGACAGCTGC ATCAGTGACA TGAAACAGA AACCAGGGAG GTCTGACCC	1260
45	CAACGAGCAC TTCTGACAAT GAGACCAGAG ACTCCTCAAT TATTGATCCA GGAAGTGAAC	1320
	AAGATCTTCC TTCCCCTGAA AATAGTTCTG TTAAAGAATA CCGAATGGAA GTTCCATCTT	1380
	CGTTTTCAGA AGACATGTCA AATATCAGGT CACAGCATGC AGAAGAACAG TCCAACAATG	1440
50	GTAGATATGA CGATTGTAAA GAATTTAAAG ACCTCCACTG TTCCAAGGAT TCTACCCTAG	1500
	CCGAGGAAGA ATCTGAGTTC CCTTCTACTT CTATCTCTGC AGTCTGTCT GACTTAGCTG	1560
55	ACTTGAGAAG CTGTGATGGC CAAGCTTTGC CCTCCAGGA CCCTGAGGTT GCTTTATCTC	1620
	TCAGTTGTGG CCATTCCAGA GGACTCTTTA GTCATATGCA GCAACATGAC ATTTTAGATA	1680
	CCCTGTGTAG GACCATTGAA TCTACAATCC ATGTCTGTC AAGGGATATC TGGCAAAGGA	1740
60	AACCAAGCTG CTTCTTGACA TTAGGTGTAG CATGTCTACT TTTAAGTCCC TCACCCCAAA	1800

5 CCCCCATGCT GTTGTATATA GTTTTGCTTA TTTGTTTTTG TGCTTCAGTT TGTCCAGTGC 1860
 TCTCTGCTTG AATGGCAAGA TAGATTTATA GGCTTAATTC TTGGTCAGGC AGAACTCCAG 1920
 ATGAAAAAAA CTTCATCTT CAGTATACTT CCTAAAGGGC AATCAGATAA TGGATATGTT 1980
 TTATGTAATT AAGAGTTCAC TTTAGTGGCT TTCATTTAAT ATGGCTGTCT GGAAGAACA 2040
 10 GGGTGCCTA GCCCTGTACA ATGTAATTTA AACTTACAGC ATTTTACTG TGTATGATAT 2100
 GGTGTCTCT GTCCAGTTT TGTACCTTAT AGAGGCAGAT TGCCTCOGAT CGCTGTGGTT 2160
 CTTATTATCA AAATTAAGTT TACTTGTATA CGGAACAACC ACAAGAAATT TGATTCTGTA 2220
 15 AAGAATCCTC TTTAGCTGTG GCCTGGCAGT ATATAAATGG TGCTTTATTT AACAGAATAC 2280
 CTGTGGAGGA AATAAGCAC ACTTGATGTA AAAATAATTG TTTTATTTT ATGACATGA 2340
 20 CTGATTGATT GCTATTCTGT GCACTNAATT AACTGATTG TGATGACTTA AAAAAAAAAA 2400
 AAAAAAAAAA AAAAAAAAAA AAAA 2424

25

(2) INFORMATION FOR SEQ ID NO: 226:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1080 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 226:

ATATAGGACG GATAATCTGT TTACATTCTG TTCTTCTCGA TGCACTCACA AGCGGGTAAC 60
 TAGGTGACAA GAAACAAAG ATCTTATTCA AAAGAGGTCT TACAGCAACC CAAAGTCTCA 120
 40 TCTTCCATA GTAAAGATGA CGGCGCTTG AGGTAAGCTA CAGGCAACAC CACTTCCGG 180
 TTTCTCTGC GCCCTGGTCC AAGATGGCGG ATGAAGCCAC GCGACGTGTT GTGTCTGAGA 240
 45 TCCCGGTGCT GAAGACTAAC GCCGACCCC GAGATCGTGA GTTGTGGGTG CAGCGACTGA 300
 AGGAGGAATA TCAGTCCCTT ATCCGGTATG TGGAGAACA CAAGAATGCT GACAACGATT 360
 GGTTCCGACT GGAGTCCAAC AAGGAAGGAA CTCGGTGGTT TGGAAAATGC TGGTATATCC 420
 50 ATGACCTCCT GAAATATGAG TTTGACATCG AGTTTGACAT TCCTATCACA TATCCTACTA 480
 CTGCCCCAGA AATGTCAGTT CCTGAGCTGG ATGGAAGAC AGCAAAGATG TACAGGGGTG 540
 55 GCAAAATATG CCTGACGGAT CATTTCAAAC CTTTGTGGGC CAGGAATGTG CCCAAATTTG 600
 GACTAGCTCA TCTCATGGCT CTGGGGCTGG GTCCATGGCT GGCAGTGGAA ATCCCTGATC 660
 TGATTCAGAA GGGCGTCATC CAACACAAAG AGAAATGCAA CCAATGAAGA ATCAAGCCAC 720
 60

	TGAGGCAGGG CAGAGGGACC TTTGATAGGC TACGATACTA TTTTCCTGTG CATCACACTT	780
	AACTCATCTA ACTGCTTCCC CGGACACCCCT CCACCTCTAG TTGTTACTAA GTAGCTGCAG	840
5	TAGGCATTGC TGGGGAAGAA ACAAACACAC ACCAAACAGT ACTGCTACTT AGTTTCTAAG	900
	GCTGCACAGG GAAGGGAAG ACTGGGCTTT GGACAATCTA GAGGTAATTT ATATCCGCCC	960
10	CCAGGTGGAG CAACATGCCA TTCTGGAGGC ACGGGGTAA CTGAAAGTGA GTACATATAG	1020
	TCTTTCTGGT TTCTGGAGAT AACCCATCAA TAAAGCTGC TTCTCTGGG TAAAAAAAG	1080
15	(2) INFORMATION FOR SEQ ID NO: 227:	
	(i) SEQUENCE CHARACTERISTICS:	
20	(A) LENGTH: 1336 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
25	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 227:	
	TTGCATTAC AATTACTGGG AGGCAGGCAG GGGCAGTTGC ATGCTGGGGG TGGCTGCATG	60
	GSCTGCCASC TCTCTGGGT TTGAAGGATG CGGTACASCT GCTTCAGCTG AGCAACGATG	120
30	TTATCCTTGA TGTCGGGGT TGAGATCTGC AGGCGGACAC TGCCACTATC AAAGGATCGT	180
	GTGAAATCAC CAGAAAACAT CTCGTAGATC ATCCGAGCCA CTACTGGAAT GACCTGAACC	240
35	AAGATGAGTT TCCTTTCCAA TGGTTTCCCA TCTGGCCATT CTTCGCCAAA GCATAAGTAG	300
	ATCTCAAACG GTGGCTGCTT CTCTATCTGT CCTTTCTGGT GGGCAATGAG ATCGCTAAGG	360
	AATGTTTCCA GACAAAATAG CTTGACCTTC TTTTGTCTCT CAATCAGGTT GGGAGCAACA	420
40	AGTGATGGGG CACATGGCCC AGACCAGTAC ACCTTGCACT GGCACAGYCT GATGGCATAA	480
	ATGGCATGAC CGCTGACCTC CAGGATCAGT CCTCTGTCCA TGACGTCCAG CAGCTTGCTA	540
45	GTGAACAGCT TCTGCTTCTC ATTGGTAATA TGCTCAGGAC CTGGGAATTT GACCTGCTCC	600
	AGNCTGACGG GACCAAAGAG CTCCTCCTGG TCAGGCATGG GACCCAGGTC CCCATAGAAG	660
	AGTCGGCAGC CCTGAGGGTT GCTCACGGTC ATGGTCTGTC CCGTACTCCT TCCCACGGTA	720
50	CTGAAACTTG ATGTCCAGGT CAGTCATTGG GAGAGAGCTG ATCCACAGTT CTGGAGAGCT	780
	ATAGAAGGRC TGTATAGGTG CCTGGGGWAC TTCCATCTCC AGGGGTTTCTG TTTTGGGCCA	840
55	CACTGCTTCC GGSCTGCAGT TGCCCACT GCAATTGCCC AACTGGCTG GCGCCATGGG	900
	AGAACCATTG ATGTTTCAAG AGGGGAAGGT GTCTGGATG GGAACATGGT GCTGCGACTG	960
	ATCCAGCTCA TCTTCTCAT CTCTTCTATC CACATCATTA TCCTTCTCAT CCCAGGGAGC	1020
60	AGACCCTGTG GATCTGGGT TAATGATCGA SCCCTGGGGC TGAGGGATGT CACACACTTG	1080

5 ATATATCTTC ACTGGGTTC TGGGCACCTC CCTTGGTGCC ATCCATACAT CCAGGTIGAA 1140
 TTCTCTGCTC TTATTGAGAG CACAGCGCAG CTGGGCCTTC CATTTAGCTG GGTCAGGGTC 1200
 ATCCACCCCT TCCTGGTACT TCCCTGTCTC TACAGCCCAG GCCTTAAAAA TGGTATTTTC 1260
 CTCTTCTTGT TGAGGGCTAT GCCGGGTGGC ATGTTTCCAG GGAATCTGGA AGCGTTTAGA 1320
 10 GTCCCTGTGT AGCCAG 1336

15 (2) INFORMATION FOR SEQ ID NO: 228:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 2043 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 228:

25 TCAGCTGGTC CCTTCCTTGT GTCCTGGGGG ACCTGCTGGC GGCTCTTCC TGGGAGCCAT 60
 GACCTCAGAC CCCACCCACA CTCCAGATCG AGACCCCTGC CTCCCCCCGG CAAATGTCTT 120
 CCCGCTGCCT TGCAGCCTGC ACTTTGCACA TGCTCACCCC CAGCACAGTC CCACTGGCCC 180
 30 CTCAMCTCCC CTTCCTGAG CTCCCTCCCA AGGACTCCTG GTCACTGCCT GCTGTGCART 240
 CAGAGGCCCC GGTCCAGCA GCCCGGSGGG AACGGGTGCT GCCTSTTCTT CCAGTTAGCT 300
 35 CCAGYTCAGG TCTGAGACCC GTGYTGAGTA AAGGTCTGAG CAMOGACCGT GCCCTCTGCC 360
 CAGGCTGGG TCCTGAGCAG CTGGTTTTC TGCAGGAAGG TTGGAGCAAG CAAAGTCCTT 420
 CTCTGCCCTC AGGGTCAGCT GCCCAGACTG GGGCGGATGC AGAGAGGCAG GTGGGCTGTG 480
 40 GCTGGACTGG TCCGGAGCTG GCTTCCTTAC CAGAAAAGCC TCAGCCTTCC TCTGGAAGCA 540
 TCCCCCGTTC TGGCAAGGG GGAAGGGCTC CTTTAAGGGG TGTGCTTTCC CAGTGGGGAG 600
 45 CAGTCTGGCC CTGCCCCCTA CTAAAGCCTC TGCTCTCAGC ACTTCCCCC AAGTCCTTGT 660
 AACTTGCTTG AAGGTGGGTT CTGGCTGCCA GCCAGTCCCT GGACAAACTC TCCTGCCCCCT 720
 TTTAAATTTC ACTCATTTTG TATAAACCCA GCAGGCTGGT GTTTACTTAG CCCTGTAGCT 780
 50 TTTTTCATTT TTTCTTTCCG TCTTTCTTCT TGAGTTCACG GTTCAATATT GCCTCCTCGC 840
 CCTGGTGAGG GGAGGTGCTG CTTTCTTGCC CCACCTGCCG GCTGGTTCCA GCAGCGCTGG 900
 55 NGCCCAGCTG GGGGGCCGGG ATGGGGCTT CTCTCTCTGG GAGGGGTGCA GGTGCCCTCC 960
 CCAGGCTGGG AGGGTTCTTT CCCTAGCTCC CCATCTGCCC CCGCTGGTGA GAGTTGGGCT 1020
 60 TCTTGGTCTT GGAACCTCCT GCATTTGGGA ACAGAGCATT TCCAGCATTT GTTGTGTGTG 1080

	TTTTACTCAC CTAACCCCTTA GAAAATGAAT GTTAGAAGGT GCCTGCCGAG GCGGGACAGA	1140
	GTGTTTGCTC GCGCTGGAGA AGGCTCTGCT CAGCCCTGAG AGTCCCTTCC TGCCCCACCG	1200
5	ATACTGGCAC TTTAAAAAGG AAGCTGACCG CACAGTGTC AGACGAATTG GCCCCCAGAA	1260
	GATGGGGAGT TCTGTCTGTC CCTTCTGTGT CTGGGTGACC TCACCCAGCC TAGGAGGGAG	1320
10	GTGCATTTCAG GGTAGATTTC CCTCTCATTC AAAGTTCTGG GGCTTTGGGY GGAAAACAGC	1380
	CAGCTTTGGC GCTGTTGGGG AGACTCCTCC AGACCAGGAA CCCCAGAAGG AGACAGAGCC	1440
	TGCCACATCC TCCACGCCA GGCCTGGGC CAGGGTGATT GGA CTGAGAA TTTGGCCACA	1500
15	ACCAAATTGA TGCTGGCTGG AACCAGAGGC CAGAAAGCCT GGCTTTGTCC CCATGTGGGA	1560
	GCCCTGTCTT CAGCCCTCTT GTCCCTTGA GCTCAGTGAA TTCCCACCAG GTGCCACAG	1620
20	CTCCTGGACT TCAAAATTCTA TATATTGAGA GAGTTGGAGA GTATATCAGA GATATTTTTC	1680
	GAAAGGAGTT GGTCTATGCA ATGTCAGTTT GGAATCTTCT TGAAAGTTTA ATGTTTTTAT	1740
	TAGGAGATTT AAAGAAAATA AAGGTCTACA ATATCTTTAG GTTTTTTTTT TTCTCTGTTT	1800
25	ACCGCACAAA CTGACCACAT GGCATGTCTA TCAGGATGGA GGGTGTCAT GTTCTCTCT	1860
	GTCTTTAGGG AGGTGATAAG GAGATGGSCG RAGGGGTGTT TTTTCTTTG ACTCCCTCC	1920
30	TTTCTAACAG AATGTTGCCA CCACTGCTTG AGTGGGCTGT GTTGTTCCT CTGTCCCAGC	1980
	TTCTGTTGTA GAAAATAACA TTGTTAGGGG AACTCAGGCT AGTGTACAGC TCTTGGTTTG	2040
	GGG	2043
35		

(2) INFORMATION FOR SEQ ID NO: 229:

- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 540 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 229:

	TAAAAAGAAG CGGAGAAATC TGGGCGTCG TCTAGAGATC GATGGGCTAG AGGAGAAGCT	60
50	GTCCCACTGT CGGAGAGACC TGGAGGCCGT GAACTCCAGA CTCCACAGCC GGGAGCTGAG	120
	CCCAGAGGCC AGGAGGTCCC TGGAGAAGGA GAAAAACAGC CTAATGAACA AAGCCTCCAA	180
55	CTACGAGAAG GAACTGAAGT TTCTTCGGCA AGAGAACCGG AAGAACATGC TGCTCTCTGT	240
	GGCCATCTTT ATCCTCCTGA CGCTGCTCTA TGCTACTGG ACCATGTGAG CCTGGCACTT	300
	CCCCACAACC AGCACAGGCT TCCACTTGGC CCCTTGGTCA GGATCAAGCA GGCACCTCAA	360
60	GCCTCAATAG GACCAAGGTG CTGGGGTGTT CCCCTCCCAA CCTAGTGTTT AAGCATGGCT	420

5 TCCTGGCGGC CCAGGCCTTG CCTCCCTGGC CTGCTGGGGG GTTCCGGGTC TCCAGAAGGA 480
CATGGTGCTG GTCCTCCCT TAGCCCAAGG GAGAGGCAWT AAAGACACAA AGCTGGAAAT 540

10 (2) INFORMATION FOR SEQ ID NO: 230:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 448 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 230:
20 AATTGTGAAA TATTAGAATA TTGTTACTAT TTGACCCAAC TCAAAATCTC CATGGGAAAA 60
TACCTGTGCA TACCCACAGT ATTGTGAAA ATAATCAGAT GCAGTATCAC AGCTGTGTCA 120
GACTCTAGTA CCAGTTGGGC AATCAAGGCA CAGCTAAAAA TTGAAAACAA AGATCTGGAC 180
25 AACAAAACAG CCAAAGGTGG GGGTCAAGAA GCTCTGACGT GTACCTAGCT GTAGAATGCT 240
ATGCACACGT GCCAGGTGTA GTGTGCATAT CCAGGAAAAA CTGCAGAGAG CCCAGTCTT 300
CAMCTCTGGT TGACCATGAG CTCTGTGTAA GCAGGAAGTG AAGGCTAAGG CAGATTTAAG 360
30 CTCTGAAAGC ATTCCACAAC ATACACACAA ATCGTGCAA GCATTAAGGA AATCTTGTTA 420
CTGCTAAGTG TTGCTGACCC AGGAACAA 448
35

(2) INFORMATION FOR SEQ ID NO: 231:

- 40 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 407 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
45 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 231:
GTATGCTGCC CCAAACCAAT ATGTGTGGCT GCCTTWACC TGACTTCTCC AACATGTAGC 60
50 CCCAAGAGGA GGCTCTAGA CTRAGGGAGG GGCTGGTGAC CCAGGTGTGG TGGGGCTGCA 120
TGARACTACC AGAGAGACAG ACATTCTGGA ACTCACCTG GGGGATCCAG TGGATCTGCC 180
TATGGTCTGG TCCACCCAG ACCTGTGAGA TGTTCCTCAT GAGGATGCAC TTGTGCTTCT 240
55 GCAAGTATTG CTGCAGCTTC ATAGTGACTC CCACCAGCAC CAGCAATACA GYTAGCTACC 300
TGTGGCCTTG GATCTCAGCC AGCATGGCTG GGAGAGGGAG CARCTGGGCA TGTACCCTAA 360
60 ATGCTGTTAC CAGGGAAGGA CTCCAGAGT GAAGACAAGT AGGGACT 407

5 (2) INFORMATION FOR SEQ ID NO: 232:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 830 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 232:

15 GTATTGATT TCAGGCTGCT AAATGGGCTC ATTTAGCATT CATTCCTTGA TGTAGACATT 60
AAAAAAAAA CTGAATAGCA TTCTTTCCAG GNTAACTAAT AAAGCAGACA TGCTAAGCCT 120
ATAAATACAT CAGCACTGCA GCACACGTTT AAGGTTGCCA CGGACAAGGA TCACACAATA 180
20 GAGAACACTG TAGTTCGGTC TGCTCACAAG ACCCAGAACA TTGATCAGTT TTTGTTGTTG 240
GTTTATTATT TTTCTGTAA AAAATTGIGA AAAGTTTGT TTAGCTAGAT GATATTTTAA 300
25 TAGCTGCGAG TGCTTTGGAA CTATAAGAT GTCACTACTT AACACACATA CCTTATGTTT 360
TGTTTGTGTT TGTTTACAC TCAGTATAAA TCAGGAGAAG TTAGCCAACC ATCTAGCATT 420
TAGAATCCTC TTTTATTATG TCTCTAAGG ATATGGATGT TCCCATAACA GCAACAAAAC 480
30 AGCAACAAA ACATTTTATA AATATCACTT GATAGACTGT AAGCACCTGC TTAACTTTGT 540
GTNCCAAATA TTTAGTGTGT ATATATATAT ATATATACAC ACACACACAC ATATATATTC 600
35 AACAAATAAA GCAAAATATA ACATGCATTT CACATTTTGT CTTTCCCTGT TACGATTTTA 660
ATAGCAGAAC TGTATGACAA GTTTAGGTGA TCCTAGCATA TGTTAAATTC AAATTAATGT 720
AAAACAGATT AACACAACA AAGAACTGT CTATTGAGT GAAGTCATGC TTTCTATTAT 780
40 AATAACTTGG CTTGGTTAT CCATCAAATG CACACTTATA CTGTTATCTG 830

45

(2) INFORMATION FOR SEQ ID NO: 233:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 932 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 233:

55 CCAGAAGAAA GACCAATCTA GAATATGGAA CTCTAATCAC TTCTAGTATT TCAACTTCCT 60
AGCAGAAATG AACTTGGCCC TAGACCTAGG GGATAAGCAA TGTTCTTTAT GTAGCCAATG 120
60 CTACGGAAAC AAAAGAGGTG AAAGAGACCC TTTTITTATA CTTAATGTAC ATATATTGAC 180

TTTTGTGACGA AGAATGCCAG AAATAGCCTT CATTCTTACC CTGCAAATA ATCCAGATCT 240
 5 GCTTCTAAA ATGRANTCAG TTTCTAAAGT GAAACATGCA ATATTTATGC TCTGACTGAC 300
 TCCTGAATTG GARGAGGAAG RACTTCTGTT TACAGAAAAC YGTATTGTA TATATGTCAG 360
 GCTGTGTATT GTGACTATCA GCATTCTGGT GCAAATGAAC TTTTCTCCAT CATOGACTGT 420
 10 GGAAAAATGA TACTTTTAAA GCATATTCTT CTATGAGCAC AGGTCTCTCT AGTGAAACTT 480
 AATTTGACAA AGGTGTGCAT ATGCTTTCTT AACCTGAWTT GTATTAACAT TCACAGAGCC 540
 TACATTTTCT CATTAGGGTT RTGATGCTCA GTATCTTTCC AAGTGCCAGG CAGRGCTTNC 600
 15 CTTTCTGAT CAAACATACC ATTTTGTGTA TTTCACTACT ATAGACAGTC ACTTCTGCAG 660
 TCCCAATTTA AAAATGCAGA ACTGCTTTAT CCAAGATGC TGAAAAATAC TGTCTATCC 720
 20 AGGTTTCCTA AACTATAAAA GCAGATTTTG CTTTGTGTTG TTAATCATAG GCATGGCCGA 780
 GCATGTGGA TTAGCCTGAG GCTTAAATC AGATGCATGT CTGGTAAGAT GACCACTGTC 840
 TCACTATCAA GAGCCTGCAG AGCCATTTTC CAGACCTGTG ATTGCCAGA ACACATAGTC 900
 25 CCCACGTTTC TAATTGGAG CAAATCTAAA AG 932

30

(2) INFORMATION FOR SEQ ID NO: 234:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2786 base pairs
 35 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 234:

TTAGCAGGT GAGCTGTAA AACAGCACAC ATCTCTCATC CCTCTTCTT TATTTCCCC 60
 CTGGGTTTCA GAAAGGAAG ATATATGGG ACCACCTCCC CCTTCTTTGA TCCCAGCATC 120
 45 TCAGTCCCC TCCCAACCT CCATATGGCT CTCAATGGTG CTCCTTGCT TGGAAGCAGG 180
 CTCCAATAG GGAGGGGCT GCGCTCTACA GTCTCTTTGA CTGTAAGACA GGGCTCTGTA 240
 TCAGTGAGAC GATGAGAAA GTCCAGGCT AATGGCAGAA ATTTGCACTT TGAACATGTG 300
 50 TGTMTTGTG TTGTGGAACC TGAGATTCCT TATTATTAA CAGGAAGTCT GATTTTTTTT 360
 TTTTGGAGTC TTTGTGCTA TATTTGTGG GGCTGGAGA GAGAGATTAG ATTATTTTGA 420
 55 CATGGGATCC CTTCCATAAC AGGTACTTTG AAGGAAGAC ATAGGGTTGA AGAAGCACA 480
 CCAGCCTCTG AAATCATAGC TCTCCAGTGG CTTTAAAGA AAGCTGGTCC TCAGCACTAA 540
 60 CAAAATCACT ACAATAGCCT AGTGCTTTTT TGGAAGCCTT TTAGGGAAG AATGTTAGGT 600

	TCATGGTAAC TAGTATGCTC TTTGAGATTT TTACAGTGT GAAACTTAAG AATTTTGAGA	660
	GGGTGAGGAG GGTGTTCAG AATCTAAATT ACAGATAGAT GATTGTTTCT TGTGAATTG	720
5	TTTCTTTCC TTTTTTTTG TCCCTACCAT TTCCTTACAT TTCCCTGGG GCCCATCTCT	780
	GGCTCCTGC TTTTGTTC TIGCTTGTCT TTATCAGTTC ATTCCAGCTC CCTGTTAGTG	840
10	AAGGACACTG CTGTTAGTGA AGGAACAAAG TCTATGAGTC CTAAAATTTT AAGTCAAAGA	900
	AAACTGCTCT GTTCCCTT TAGTAACACT TCTGAAGAGG AAAAATTCA ATAGCCAAAG	960
	TTAATAATCC TATATAATAA TTGCTTGGC TTTCACCTAA AATCTGGGC ATCACAATTT	1020
15	CCTTGGGATA GAGGTGTGT TGGGAATAG ATTGCTTATT GCTGTTCACT GGAGAGAAAA	1080
	GGTAGTGTTF TTGTACAAGG TCATACCGCC AGAAGCCCCA AATCCTATTT TGGCTCATCT	1140
20	TCAGGTAAAG AGTAATTCCT ATCCGTGTG CCTCAGAAGC TAGAATCGAA GGCTTACCT	1200
	ATTCAITGTT TATGTGTCAGA AATGCATGAT GGCTCTTGA AAGATGACG TTTTGTGGA	1260
	AAAAAAAAA AGAACAGTTT GTGTTTACA AACATGGCTT ATCAATTTTT TCAAAGAATT	1320
25	CTTTTTCCT AAAAAGAGGA GTAACAAAT GTCATTCTG AAAGAGGCTT ACTTTATACC	1380
	AACTAGTGT AGCATTTGGG ATGCCAGGA ACAGAGAGTG AGACACCTAC AATCACCAGT	1440
30	CTCAATGCG CTATTGTTT TTTTCAGAGT GTTGCAGATT TGCCATTCT CCATAATATG	1500
	GGGATAGAAA ATGGAATAA GATAGAAGG ATGTAGAATA TGCTTTCCTG CCAACATGGT	1560
	TTGGAGTCGA CTTGGTATA TTGACTAGAT TTGAAAATAC AAGATTGATT AGATGAATCT	1620
35	ACAAAAAGT TGCTCTCTC TCAGGTCCCT TTTACACTTT TTGACTAACT AGCATCTATA	1680
	TTCCACACTT AGCTTTTTTG TCACACTTAT CCTTGTCTC CGTAAATTC ATTTGCACTG	1740
40	GTTAGTCATC AGATATTTTA GCCACCTACA CAAAAGCAA CTGCATTTTT AAAAATCTTT	1800
	CTGAGATGG AGAAAATGTA TTCTCCTTC CTATACCGCT CTCCAACAA AAAACAAC	1860
	AGTTAGTTCT ACTAATTAGA AACTTGCTGT ACTTTTCTT TTCTTTTAGG GGTCAAGGAC	1920
45	CCTCTTTATA GCTACCATTT GCCTACAATA AATTATGCA GCAGTTTGCA ATACTAAAAT	1980
	ATTTTTTATA GACTTTATAT TTTTCTTTT GATAAAGGA TGCTGCATAG TAGAGTTGGT	2040
50	GTAATTAAAC TATCTCAGCC GTTCCCTGC TTTCCCTCT GCTCCATATG CCTCATGTG	2100
	CTTCCAGGA GCTCTTTTAA TCTTAAAGTT CTACATTTCA TGCTCTTAGT CAAATCTGT	2160
	TACCTTTTTA ATAACCTTC CCACTGCATA TTCCATCTT GAATGGTGG TTCTAAATTC	2220
55	TGAACTGTA GTTGAGATAC AGCTATTTAA TATTTCTGGG AGATGTGCAT CCTCTTCTT	2280
	KGTGGTGGC CAAGGTGTG TTGGTAACT GAGACTCCTT GATATGCTTC AGAGAATTTA	2340
60	GGCAAACT GGCCATGGC GTGGGAGTAC TGGGAGTAAA ATAAAAATAT CGAGGTATAG	2400

ACTAGCATCC ACATAGAGCA CTTGAACCTC CTTTGTACCT GTTTGGGGAA AAAGTATAAT 2460
 GAGTGTACTA CCAATCTAAC TAAGATTATT ATAGTCTGGT TGTGTGAAAT ACCATTTTIT 2520
 5 TCTCCTTTTG TGTPTTTCCTC ACTTTCCAAT GACTCAAGA AAATTGAACA AATGTAATGG 2580
 ATCAATTTAA AATATTTTAT TTCTTAAAAG CCTPTTTTGC CTGTTGTAAT GTGCAGGACC 2640
 10 CTCTCCTTT CATGGGAGAG ACAGGTAGTT ACCTGAATAT AGGTGAAAA GGTATGTAA 2700
 AAAGAAATTA TAATAAAGG GATACTTTGC TTTTCAAATC TTTGTTTTCT CTTATTCTAG 2760
 GTAAGGCATA TTAATAATTA ATATGT 2786

15

(2) INFORMATION FOR SEQ ID NO: 235:

20

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 458 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 235:

GGGTGCAGGA ATTCGGCAGC AGAGAATGTT TGATTTTCTT TCCTATTTTA AGGATCTTCT 60
 30 CTCTGTGTA TGTGAAAAC TTACCTTAGT GAAGATGTT TTCAACATGC TGTGTCTT 120
 TACCTGCATA ATCAGCTA TGCATCTATT CAAAGTGATG ATCTGTGGGA TAGTTTTAAT 180
 35 GAGGTACAA ACCAAACACT AGATGTAAAG AGAATGATGA AAACCTGGAC CCTGCAGAAA 240
 GGATTTCTT TAGTGACTGT TCAAAAGAAA GGAAAGGAAC TTTTATACA ACAAGAGAGA 300
 TTCTMTTAA ATATGAAGCC TGAAATTCAG CCTTCAGATA CAAGGTACAT GCCCTCTTC 360
 40 TTTTCATGCC ATCTCTTTTG CACTCTCAGG TGAAATATT TTTAAGTGT TTATAATCAT 420
 AAGTCTTGT GAAACCTAAC AAGATTATCC CTTCCTAA 458

45

(2) INFORMATION FOR SEQ ID NO: 236:

50

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 591 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 236:

AGGATGAAGA GGAAATTATC TCTGGATTG CTCTCCAGGA AATCCTTCTC TATACTTTAA 60
 60 AAGCTCTGT TCTTTCTAG GATCCAATG TGCTGATTGC TGCTAACAGT CAGGGTACAA 120

TTAAGGTGCT AGAATTGGTA TGAAGGGTTA ACTCAAGTCA AATTGTACTT GATCCTGCTG 180
 AAATACATCT GCAGCTGACA ATGAGAGARG AAACAGAAAA TGTCATGTGA TGTCCTCTCC 240
 5 CAAAGTCATC ATGGGTTTGG GATTTGTTTT GAATATTTTT TCTTTTTTTC TTKTCCCTCC 300
 TTTATGAGCC TTTGGGACAT TGGGAATACC CAGCCAACTC TCCACCATCA ATGTAACCTC 360
 ATGGACATTC CTGCTCTTGG TGGTGTATC TAATTTTTGT GATAGGGAAA CAAATCTTT 420
 10 TGAATAAAAA TAAATAACWA AACAATAAAA GTTTATTGAG CCACAGTTGA GCTTGGAAAG 480
 TTTTGTCAA ATGCGCAAG AGATAACTCT TTTTANGAAG TAGCATATGT GAACTATAAT 540
 15 GTAACAGTGA ATAATTTGTA AAGTTCGTAT TTCCCAACCT CTTTGGGAAT T 591

20 (2) INFORMATION FOR SEQ ID NO: 237:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1286 base pairs
 (B) TYPE: nucleic acid
 25 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 237:

30 TCTTTTAAAG GTACAGCAGG GAAGAACTGG AACTCAGAG AAAGAACTG CCCTTCCATC 60
 TACAAAAGCT GAGTTTACTT CTCCTCCTTC TTGTTCAGG ACTGGGCTTC CACCGAGCAG 120
 GAGATTACCT GGGCAATTG ATGTTATCGG TCAGACTATA ACTATCAGCC GAGTAGAAGG 180
 35 CAGGCGACGG GCAAATGAGA ACAGCAACAT ACAGGTCTT TCTGAAAGAT CTGCTACTGA 240
 AGTAGACAAC AATTTTAGCA AACCACCTCC GTTTTCCCT CCAGGAGCTC CTCCACTCA 300
 40 CCTTCCACCT CCTCCATTTC TTCCACCTCC TCCGACTGTC AGCACTGCTC CACCTCTGAT 360
 TCCACCACCG GGTTTTCTC CTCCACCAGG CGCTCCACCT CCATCTCTTA TACCAACAAT 420
 AGAAAGTGA CATTCCTCTG GTTATGATAG TSGTTCTGCA CGTGCAATTC CATATGGCAA 480
 45 TGCGATGAAG AACGATACAG ATACAGGGAA TATGCAGAAA GAGGTTATGA GCGTCACAGA 540
 GCAAGTCGAG AAAANGAAGA ACGACATAGA GAAAGACGAC ACAGGGAGAA AGAGGAAACC 600
 50 AGACATAAGT CTTCCTGAAG TAATAGTAGA CGTCGCCATG AAAGTGAAGA AGGAGATAGT 660
 CACAGGAGAC ACAAACACAA AAAATCTAAA AGAAGCAAAG AAGGAAAAGA AGCGGGCAGT 720
 GAGCCTGCCC CTGAACAGGA GAGCACCGAA GCTACACCTG CAGAATAGGC ATGGTTTTGG 780
 55 CCTTTGTGT ATATTAGTAC CAGAAGTAGA TACTATAAAT CTTGTTATTT TTCTGGATAA 840
 TGTTTAAGAA ATTTACCTTA AATCTGTTC TGTTGTAG TATGAAAAGT TAACTTTTTT 900
 60 TCCAAAATAA AAGAGTGAAT TTTTCATGTT AAGTTAAAAA TCTTGTCTT GTACTATTTT 960

AAAAATAAAA AGACAGCAAT GACTTTATAT CCAAGAAAGG AATGTGAATG AGTCACTTAA 1020
5 CAGGGAATCT AAAGAGCTGT GTTAGCTGTG TACATACACA GATTATCTGA GAAAAGGTCA 1080
AGGGTTCCAC TTGGGCCACA GTTTTTTGT TAATCAAACA CCACTCTCTT AAGRGGCTGC 1140
ATCACAARG GCAACCAARG GGGCCCTCTT ARGGCTTTGA GGATTAAAC TAGTCTTTAT 1200
10 CCATTACTGC TGTGGACACT CTTGGCTTRG TATWTTTAGG GGGGNTCCTT ACCTTTTTTTT 1260
GGTTTCCNC ACCTTTTTGG TTGGC 1286

15

(2) INFORMATION FOR SEQ ID NO: 238:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 734 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 238:

ATGGCAGCGC AGAAGGACCA GCAGAAAGAT GCCGAGGCGG AAGGGCTGAG CGGCACGACC 60
30 CTGCTGCCGA AGCTGATTCC CTCCGGTGCA GGCCGGGAGT GGCTGGAGCG GCGCCGCGCG 120
ACCATCCGGC CCTGGAGCAC CTTCTGTGGAC CAGCAGCGCT TCTCAGGCGC CCGCAACCTG 180
GGAGAGCTGT GCCAGCGCCT CGTACGCAAC GTGGAGTACT ACCAGAGCAA CTATGTGTTC 240
35 GTGTTCCTGG GCCTCATCCT GTACTGTGTG GTGACGTCCC CTATGTGTCT GGTGGCTCTG 300
GCTGTCTTTT TCGGCGCCTG TTAACATTCT CTATCTGCGC ACCTTGGAGT CCAAGCTTGT 360
40 CCTCTTTGGC CGAAAGGTGA GCCCAGCGCA TCATATGCTC TGGCTGGAGG CATCTCCTTC 420
CCCTCTTCTT GGCTGGCTGG TGCGGGCTCG GCCGTCTTCT GGGTGTCTGG AGCCACCCTG 480
GTGGTCATCG GCTCCACGCG TGCCCTCCAC CAGATTGAGG CTGTGGACGG GGAGGAGCTG 540
45 CAGATGGAAC CCGTGTGAGG TGTCTTCTGG GACCTGCGCG CCTCCCGGGC CAGCTGCCCC 600
ACCCCTGCCC ATGCTGTGCC TGCACGGTCT GCTGCTCGGG CCCACAGCGC CGTCCCATCA 660
50 CAAGCCCGGG GAGGGATCCC GCCTTTGAAA ATAAAGCTGT TATGGGTGTC ATTCAAAAAA 720
AAAAAAAAA AAAA 734

55

(2) INFORMATION FOR SEQ ID NO: 239:

60 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 809 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 239:

5
 CGGGGTCTTC AGGGTACCGG GCTGGTTACA GCAGCTCTAC CCCTCACGAC GCARACATGG 60
 CAGCGCAGAA GGACCAGCAG AAAGATGCCG AGGCGGAAGG GCTGAGCGGC ACGACCCCTGC 120
 10 TGCCGAAGCT GATTCCCTCC GGTGCAGGCC GGGAGTGGCT GGAGCGGCGC CGCGCGACCA 180
 TCCGGCCCTG GAGCACTTC GTGGACCAGC AGCGCTTCTC ACGGCCCCGC AACCTGGGAG 240
 AGCTGTGCCA GCGCCTCGTA CGCAACGTGG AGTACTACCA GAGCAACTAT GTGTTCGTGT 300
 15 TCCTGGGCCT CATCTGTAC TGTGTGGTGA CGTCCCTAT GTTGCTGGTG GCTCTGGCTG 360
 TCTTTTTCGG CGCCTGTAC ATTCTCTATC TGCGCACCTT GGAGTCCAAG CTTGTGCTCT 420
 20 TTGGCCGAGA GGTGAGCCCA GCGCATCAGT ATGCTCTGGC TGGAGGCATC TCCTTCCCCT 480
 TCTTCTGGCT GGCTGGTGG GGTTCGGCCG TCTTCTGGGT GCTGGGAGCC ACCCTGGTGG 540
 TCATGGGCTC CCACGCTGCC TTCCACCAGA TTGAGGCTGT GGACGGGGAG GAGCTGCAGA 600
 25 TGGAACCCGT GTGAGGTGTC TTCTGGGACC TGCCGGCCTC CCGGGCCAGC TGCCCCACCC 660
 CTGCCCATGC CTGTCTGCA CGCTCTGCT GCTCGGGCCC ACAGCGCCGT CCCATCACAA 720
 30 GCGCGGGGAG GGATCCCGCC TTGAAAATA AAGCTGTTAT GGGTGTCAAT CAGGAAAAAA 780
 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 809

35

(2) INFORMATION FOR SEQ ID NO: 240:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2201 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 240:

TGACCCACG CGTCGGCAA CATGGCGGCT GCCGTGGTGC AGCGCCCGGG CTGAGCGACA 60
 GCAAGTGCAG CGGGCTCCTA CCGCGGTGA GGGGTGGCCT CCGCGTGGGA TCGTGCCCTC 120
 50 TTCAGCCCGC TCCTGTCCC GACATCACGT GTATTCCGCA CGTCCCTCC GCGCTGTGTG 180
 TCTACTGAGA CCGGGAGGCG TGACAGGGCC CGGGTCCCTT CTCAGTGGTG CTCTGTGCTT 240
 55 CAGGGCAAGC TCCCGTCTC CGGGCGCACT TCCCTCGCCT GTGTTCGGTC CATCCTCCTT 300
 TCTCCAGCCT CCTCCCTCG CAGGCGGATG AMCGGACGA CCGGCCAGTG CCTGGCACCC 360
 CCGGGTTGCC ARGGTCCAMG GGAACCCGA AGTCCGAGGA GCGCGARGTC CCGAACCAGG 420
 60

	ARGGGCTGCA GCGCATCAME GGCCTGTCTC CCGGCCGTTC GGCTCTCATA GTGGCGGTGC	480
	TGTGCTACAT CAATCTOCTG AACTACATGG ACCGCTTCAC CGTGGCTGGC GTCCCTCCCG	540
5	ACATCGAGCA GTTCTTCAAC ATCGGGGACA GTAGCTCTGG GCTCATCCAG ACCGTGTTCA	600
	TCTCCAGTTA CATGGTGTG GCACCTGTGT TTGGCTACCT GGGTGACAGG TACAATCGGA	660
10	AGTATCTCAT GTGCGGGGGC ATTGCCTTCT GGTCCCTGGT GACACTGGGG TCATCCTTCA	720
	TCCCCGGAGA GCATTCTTGG CTGCTCCTCC TGACCCGGGG CCTGGTGGGG GTCCGGGAGG	780
	CCAGTTATTC CACCATCGCG CCCACTCTCA TTGOCGACCT CTTTGTGGCC GACCAGCGGA	840
15	CCGGATGCTC AGCATCTTCT ACTTTGCCAT TCCGGTGGGC AGTGGTCTGG GCTACATTGC	900
	AGGCTCCAAA GTGAAGGATA TGGCTGGAGA CTGGCACTGG GCTCTGAGGG TGACACCGGG	960
20	TCTAGGAGTG GTGGCCGTTC TGCTGTGTT CCTGGTAGTG CGGGAGCCGC CAAGGGGAGC	1020
	CGTGGAGCGC CACTCAGATT TGCCACCCCT GAACCCACC TCGTGGTGGG CAGATCTGAG	1080
	GGCTCTGSCA AGAAATCCTA GTTCTGTCTT GTCTTCCCTG GGCTTCACTG CTGTGGCCTT	1140
25	TGTACCGGGC TCCCTGGCTC TGTGGGCTCC GGCATTCTTG CTGCGTCCCG GCGTGGTCTT	1200
	TGGGGAGACC CCACCCCTGC TTCCCGGAGA CTCTGTCTCT TCCTCTGACA GTCTCATCTT	1260
30	TGGACTCATC ACCTGCCTGA CCGGAGTCTT GGGTGTGGGC CTGGGTGTGG AGATCAGCCG	1320
	CGGGCTCCGC CACTCCAACC CCCGGGCTGA TCCCTGGTTC TGTGCCACTG GCCTCCTGGG	1380
	CTCTGCACCC TTCTCTTCC TGTCCCTTGC CTGCGCCCGT GGTAGCATCG TGGCCACTTA	1440
35	TATTTTATC TTCTATGGAG AGACCTCTCT GTCCATGAAC TGGGCCATCG TGGCCGACAT	1500
	TCTGTGTAC GTGGTGTACC CTACCCGACG CTCCACCGCC GAGGCCTTCC AGATCTGTCT	1560
40	GTCCCACTG CTGGGTGATG CTGGGAGCCC CTACCTCATT GGCTGATCT CTGACCGCCT	1620
	GCGCCGAAC TGGCCCCCTT CCTTCTTGTG CGAGTTCGG GCTCTGCAGT TCTCGTCTAT	1680
	GCTCTGCGCG TTTGTGGGG CACTGGGCGG CGCACTTTCC TGGGCACCGC CATCTTCATT	1740
45	GAGGCCGACC GCCGGCGGGC ACAGCTGCAC GTGCAGGGCC TGCTGCACGA AGCAGGGTCC	1800
	ACAGACGACC GGATTGTGGT GCCCCAGCG GCGCGCTCCA CCCGCGTGC CGTGGCCAGT	1860
50	GTGCTCATCT GAGARGCTGC CGCTCACCTA CCTGCACATC TGCCACAGCT GGCCCTGGGC	1920
	CCACCCACG AAGGGCCTGG GCCTAACCCC TTGGCCTGGC CCAGCTTCCA GAGGGACCCCT	1980
	GGGCGTGTG CCAGCTCCCA GACACTACMT GGGTAGCTCA GGGGAGGAGG TGGGGTCCA	2040
55	GGAGGGGAT CCTCTCCAC AGGGGCAGCC CCAAGGGCTC GGTGCTATTT GTAACGGAAT	2100
	AAAATTGTGA GCCAGACCCC AGGTGCCTGC TCTGTCTTT CTCTGGGTGG CCTCTGATCT	2160
60	TGCACCCCGT CTTCACCCCA GGGCTCCTGA AGACTGTGGG T	2201

(2) INFORMATION FOR SEQ ID NO: 241:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1661 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 241:

5	GTCTTCCCG ACATCGAGCA GTTCTTCAAC ATCGGGGACA GTAGCTCTGG GCTCATCCAG	60
10	ACCGTGTTC TCTCCAGTTA CATGGTGTGT GCACCTGTGT TTGGCTACCT GGGTGACAGG	120
15	TACAATCGGA AGTATCTCAT GTGCGGGGGC ATTGCCTTCT GGTCCCTGGT GAACTGGGG	180
20	TCATCTTCA TCCCCGGAGA GCATTTCTGG CTGCTCTCTC TGACCCGGGG CCTGGTGGGG	240
25	GTGCGGGAGG CCAGTTATTC CACCATGCG CCCACTCTCA TTGCCGACCT CTTTGTGGCC	300
30	GACCAGCGGA SCGGATGCTC AGCATCTTCT ACTTTGCCAT TCCGGTGGGC AGTGGTCTGG	360
35	GCTACATGC AGGCTCCAAA GTGAAGGATA TGGCTGGAGA CTGGCACTGG GCTCTGAGGG	420
40	TGACACCGGG TCTAGGAGTG GTGGCCCTTC TGCTGCTGTT CCTGGTAGTG CGGGAGCCGC	480
45	CAAGGGGAGC CGTGGAGCGC CACTCAGATT TGCCACCCCT GAACCCACCC TCGTGGTGGG	540
50	CAGATYTGAG GGCTCTGGCA AGAAATCCTA GTTTCGTCTT GTCTTCCCTG GGCTTCACTG	600
55	CTGTGGCCTT TGTACCGGC TCCCTGGCTC TGTGGGCTCC GGCATTCCTG CTGCGTTCCC	660
60	GCGTGGTCTT TGGGAGACC CCACCCTGCC TTCCCGGAGA CTCTGCTCT TCTCTGACA	720
65	GTCTCATCTT TGGACTCATC ACCTGCTGA CCGGAGTCTT GGGTGTGGGC CTGGGTGTGG	780
70	AGATCAGCCG CCGGYTCCGC CACTCCAACC CCCGGGCTGA TCCCTGGTTC TGTGCCACTG	840
75	GCCTCTGGG CTCTGCACCC TTCCTCTTCC TGTCCCTTGC CTGCGCCGT GGTAGCATCG	900
80	TGGCCACTTA TATTTTCATC TTCATGGAG AGACCCCTCT GTCCATGAAC TGGGCCATCG	960
85	TGGCCGACAT TCTGCTGTAC GTGGTGATCC CTACCCGACG CTCCACCGCC GAGGCCTTCC	1020
90	AGATCGTGCT GTCCACCTG CTGGGTGATG CTGGGAGCCC CTACCTCATT GGCTGATCT	1080
95	CTGACCGCCT GCGCCGAAC TGGCCCCCTT CCTTCTTGTG CGAGTTCCGG GCTCTGCAGT	1140
100	TCTCGTTCAT GCTCTGCGG TTTGTGTGGG CACTGGGCGG CGCACTTTCC TGGGCACCGN	1200
105	CATCTTCATT GAGCCGACC GCCGGCGGCG ACAGCTGCAC GTGCAGGGCC TGCTGCACGA	1260
110	AGCAGGGTCC ACAGACGACC GGATTGTGGT GCGCCAGCGG GGCGGCTCCA CCCGCGTGCC	1320
115	CGTGGCCAGT GTGCTCATCT GAGAGGCTGC CGCTCACCTA CCTGCACATC TGCCACAGCT	1380
120	KGCCCTGGGC CCACCCACG AAGGGCCTGG GCCTAACCCC TTGGCCTGGC CCAGCTTCCA	1440

5 GAGGGACCGT GGGCCGTGTG CCAGCTCCCA GACACTACMT GGGTAGCTCA GGGGAGGAGG 1500
 TGGGGGTCCA GGAGGGGGAT CCTCTCCAC AGGGGNCACC CCAAGGGCTC GGTGCTATTT 1560
 10 GTAACGGAAT AAAATTTGTA GCCAGACCCC AGGTGCCTGC TCTCGTCTTT CTCTGGGTGG 1620
 CCTCTGATCT TGCACCCCGT CTTCACCCCA GGGCTCCTGA A 1661

(2) INFORMATION FOR SEQ ID NO: 242:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1146 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 242:

NGACAGAAAA GCAGAAGATG AGACTCTGTT CATTCACTTT TCCTAGGCCC ATCCTGTGGT 60
 25 CATCTTTCCC CCTCCCATCA TACCTCCTCC TTCCTGGAGC CTCGCCGGC TTGGCTGTAA 120
 TGGTGGCACT TACCTGGATA TTTCAGTGGG AGGATGAAAG GCGAGACTCA CCCTACGGCG 180
 30 TGGGACAGAT GGGGAGAGGA AAAAGGCAGA GATNGCCAGG AGAGGGGTGC AGGACAAACC 240
 AGAGAGGTTG GGTGAGGGGA AAAGTGTNGG GAGAAAGTGG GGTGCAGGCC CTGCAGGCCG 300
 GTTTAGCCAG CAGCTGCGGC CTCGCCGGC CCTTGGCATC CAACTTCGCA GACAGGGTAC 360
 35 CAGCCTCCTG GTGTGTATCA TAGGATTTGT TCACATAGTG TTATGCATGA TCTTCGTAAG 420
 GTTAAGAAGC CGTGGTGGTG CACCATGACA TCCAACCCGT ATATATAAAG ATAAATATAT 480
 40 ATATATATGT ATGTAAATTA TAGCACTGAG GGGCCTGCTG CCTGCTGGA CCAAGCAAAA 540
 CTAAGCCITT TGGTTTGGGT ATTATGTTTC GTTTTGTAT TTGTTTGT TTGTGGCTTG 600
 TCTTATGTG TGATAGCACA AGTGCCAGTC GGATGCTCT GTATTACAGA ATAGTGTITT 660
 45 TAATTCATCA ATGTTCTAGT TAATGTCTAC CTCAGCACCT CCTCTAGCC TAATTTTAGG 720
 AGGTGCCCCA ATTTTGTTC TTCAATTTTA CTGGTTACTT TTTTGTACAA ATCAATCTCT 780
 50 TTCTCTCTTT CTCTCCTCCC CACCTCTCAC CCTTCCCCTC TCCATCTCCC TCTCCCGCCC 840
 TCCCTCCTC CCTCTGGCTC CCGTCTCAT TTCTGTCCAC TCCATCTCT CTCCCTCTCT 900
 CCTGCCCTCT GCTGCCCCCT CCCCAGCCCA CTTSCCCGAG TTGTGCTTGC CGCTCCTTAT 960
 55 CTGTTCTAGT TCCGAAGCAG TTTCACCTGA AGTTGTGCAG TCCTGGTTGC AGCTTTCCGC 1020
 ATCTGCCCTC GTTTCGTGTA GATTGACGCG TTTCTTTGTA ATTTCACTGT TTCTGACAAG 1080
 60 ATTTAAAAAA AAAAAAGGA AAAAAA AAAA AAAAAC TCGAGGGGGG GCCCCGTACC 1140

CAATG

1146

5

(2) INFORMATION FOR SEQ ID NO: 243:

(i) SEQUENCE CHARACTERISTICS:

10

(A) LENGTH: 1350 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 243:

AA	CCCCACGGC	TGCTGCGCA	GGCGTGGAG	GGCAGAGGC	CGCGGAGGCG	CAGTTGCAAA	60
CAT	GGCTCAG	AGCAGAGAG	GCGGAAACCC	GTCGCGGAG	CCCAGCGAGC	TGACAACCC	120
CTT	TACCCA	CCACAGCCT	ATGAGCCTCC	AGCCCCTGCC	CCATTGCCCTC	CACCCCTCAGC	180
TC	CTCCTTG	CAGCCCTGA	GAAAGCTCAG	CCCCACAGAA	CCTAAGAACT	ATGGCTCATA	240
CAG	CACTCAG	GCCTCAGCTG	CAGCAGCCAC	AGCTGAGCTG	CTGAAGAAAC	AGGAGGAGCT	300
CA	ACCGGAAG	GCAGAGGAGT	TGGACCGAAG	GAGNCGAGAG	CTGCAGCATG	CTGCCCTGGG	360
RG	GCACAGCT	ACTGACAGA	ACAATTGGCC	CCCTCTACCT	TCTTTTGTGTC	CAGTTCAGCC	420
CT	GCTTTTTC	CAGGACATCT	CCATGGAGAT	CCCCCAAGAA	TTTCAGAAGA	CTGTATCCAC	480
CAT	GTA	CTACTAC	CTCTGGATGT	GCAGCAGCST	GGCTCTCTC	CTGAACCTCC	540
TC	GGCAGCTTC	TGTGTGAAA	CCAACAATGG	CGCAGGCTTT	GGGCTTTCTA	TCCTCTGGGT	600
CCT	CTTTTTC	ACTCCCTGCT	CCTTTGTCTG	CTGGTACCGC	CCCATGTATA	AGGCTTTCCG	660
GAG	TGACAGT	TCATTCAATT	TCTTCGTTTT	CTTCTTCATT	TTCTTCGTCC	AGGATGTGCT	720
CTT	TGTCCTC	CAGGCATTG	GTATCCCAGG	TGGGGATTC	AGTGGCTGGA	TCTCTGCTCT	780
GG	TGGTGCCG	AAGGCAACAC	AGCAGTATCC	GTGCTCATGC	TGCTGGTCCG	CCTGCTCTTC	840
ACT	TGGCATTG	CTGTGCTAGG	AATGTGCATG	CTGAAACGGA	TCCACTCCTT	ATACCGCCGC	900
AC	AGGTGCCA	GCTTTCAGAA	GGCCAGCAA	GAATTGCTG	CTGGTGCTTT	CTCCAACCTT	960
GCG	TGCGAA	CCGCARCTTG	CCAATGCAGC	CGCTGGGGCT	GCTGAAAATG	CCTTCCGGGC	1020
CCC	GTGACCC	CTGACTGGGA	TGCCCTGGCC	CTGCTACTTG	AGGGAGCTGA	CTTAGCTCCC	1080
GT	CCCTAAGG	TCTCTGGGAC	TTGGAGAGAC	ATCACTAACT	GATGGCTCCT	CCGTAGTGCT	1140
CCC	AATCCTA	TGGCCATGAC	TGCTGAACCT	GACAGGCGTG	TGGGGAGTTC	ACTGTGACCT	1200
AG	TCCCCCA	TCAGGCCACA	CTGCTGCCAC	CTCTCACAGC	CCCCAACCCA	GCTTCCCTCT	1260
GCT	TGCCAC	GGCTGTGCT	TGGTTATTT	AAATAAAAAG	AAAGTGAAC	TGAAAAAAA	1320
AA	AAAAAAA	AAAAAAAAG	GGGGNCCNC				1350

5 (2) INFORMATION FOR SEQ ID NO: 244:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 1529 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 244:

15 TCCAGAGGC CGGGGGTTC CAGCTCTGCC TGTAGCAGAG CCCTGAGGAG GAGGAGGAAG 60
AGGATGTGCT GAAATACGTC CGGGAGATCT TTTTCAGCTA GGGCATAAAC TGTGCACTGA 120
ACTGTCTGCC GAGAGCAGCT GGAGGACAGC TGAGCTTCCA CTGGTGCTGC TGGGCCGACC 180
20 GCCTGTGGGA ATGGGGCTCT CTGTGCTCCT ACCTTTGTGC CTTCCTGGGC CTGGCAGATT 240
CACCTCAGGC CAGAAGCCCC TGGACACTCC GGGCCTTGGG GTGCCGTTCT GAGTGTGCGG 300
25 AAGGCAGGAC TCAAAATGAG ATCCCATTTG ACTCCCTCTG TATGTACTGT GCCCTCTCCT 360
GGCTCTTGAG GCTCTGGAGT CCCAATTGTC TGTGTTAGTC AGTGACCAGG TTCCAGGGAA 420
AATRATGTCA TGTGGTGGTC CAACTTACTG GAACCAAGA GACAGTACTT TGCAAAGAAA 480
30 AGGATCACTG CCAGGTGCAC TGAATTGCT ACAGTTTAGT CCGCATGATC TCTCCTGAAG 540
GAGGAAGCCT GTTCAAAAA TAGTTCCAT CATGAGTCTA TCAATGAGCT CCCACCTCTC 600
35 CAGCCAGCCT AGAAAGCAAA CGAGCTGCCC ACAGTTCTCT GCCCTGTCTG GGAGGTTGAG 660
GCCACAGTGT ATAGACTGGT AAGCCAGACA GGCCTCCTCC CGCAAGCTGC TACCTTGCTT 720
TCACCTGTAC CTTGGTCCCC GGGCAGCTAG CTATAAGCA AGAGGGACAG GAGCCCAGAA 780
40 GAGACACTGA GGACAAGAGA TCACACCAGA GTACATGTCT CTGCCTCTGT TTTCACTGTG 840
GCTTTGGACA GGAATATATG AATAAATCAC TGCCATACAG GTTTTCCAAT ACACAAGTGC 900
45 TAGAAAATAC ACACAATTCC CCAATGCGTA AGTTGTGCTA ATGTCTTTCC AAGTTCTGGG 960
TTGGGAAGTG GAGGGTGGCA GCGTTTGTTT GTGCGCAACC GTCCAGTCTT GTTCACAGCG 1020
AGGATTTGGA GTCCCTCCAGG GTCTCATCAT GGGAGTGATT TGTACGCGGA CGCCTCTGCC 1080
50 CTGTCTGGCT TCAGGTCCAG GGAAGCTTTG AAGCAGTCAA GCCTTGCTTT TGTACCCCAT 1140
GTGTCTGTCT TTTGTTGAGT CACTCAGAGA TCACTCCTGG ACCTCTGGGG TTGGAGTTCC 1200
55 AGTGATGGCT TATGGCGGCC CACTCACTAT GGTGGGCTGA GTGGAAGCTC CTTAACCATG 1260
TCCCAGAGA CACTGAGGTG CTCGCTCTTT TAATGTCTTC GTTTGTTGCC GTAAGTTCTT 1320
TGCTAGGTTT CATTTTGGCA TTTGGCAAAT CAGCCTGGAA GTCTGGCCCC ATGACAGCAA 1380
60

TCACTCCCTC CCCACCTCC TGAAGCTAGA GGAAGATTG CTCAGATCCA TTAATTAAAG 1440
CAGGAATTGG TGTGACAATG AGCTGCATGG TTTAGGGAGT CTTTGGGAGC CTTGGAAGTC 1500
5 CTGAAGGACA AACAATCTTG TACTAAGAA 1529

10 (2) INFORMATION FOR SEQ ID NO: 245:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1537 base pairs
(B) TYPE: nucleic acid
15 (C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 245:

20 GTGCGAGGTC CCCGCCAGCC CCCAGCGGCC TTCCCGGCC GGGCGCTCC CAGAGCAAAC 60
GAGGCCCCTG AGAGCTCCAC CTAGTTCACA GGATAAATC CCACAGCAGA ACTCGGAGTC 120
25 AGCAATGGCT AAGCCCCAGG TGGTTGTAGC TCCTGTATTA ATGTCTAAGC TGTCTGTGAA 180
TGCCCTGAA TTTTACCCTT CAGGTTATTC TTCCAGTTAC ACAGAATCCT ATGAGGATGG 240
TTGTGAGGAT TATCCTACTC TATCAGAATA TGTTCAAGAT TTTTGAATC ATCTTACAGA 300
30 GCAGCTGGC AGTTTTGAAA CTGAAATTGA ACAGTTTGCA GAGACCTGA ATGGTTGTGT 360
TACAACAGAT GATGCTTTGC AAGAACTTGT GGAATCATC TATCAACAGG CCACATCTAT 420
35 CCCAAATTTC TCTTATATGG GAGCTCGCCT GTGTAATTAC CTGTCCCATC ATCTGACAAT 480
TAGCCACAG AGTGGCAACT TCCGCCAATT GCTACTTCAA AGATGTCGA CTGAATATGA 540
AGTTAAAGAT CAAGCTGCAA AAGGGATGA AGTTACTCGA AAACGATTTC ATGCATTTGT 600
40 ACTCTTTCTG GGAGAACTTT ATCTTAACCT GGAGATCAAG GGAACAAATG GACAGGTTAC 660
AAGAGCAGAT ATTCTTCAGG TTGGTCTCG AGAATGCTG AATGCCCTGT TTTCTAATCC 720
45 TATGGATGAC AATTTAATTT GTGCAGTAAA ATTGTTAAAG TTGACAGGAT CAGTTTGGGA 780
AGATGCTTGG AAGGAAAAAG GAAAGATGA TATGGAAGAA ATTATTGAGA GAATTGAAAA 840
CGTTGTCTTA GATGCAAACT GCAGTAGAGA TGTAAACAG ATGCTCTTGA AGCTTGTAGA 900
50 ACTCCGGTCA AGTAACTGGG GCAGAGTCCA TGCAACTTCA ACATATAGAG AAGCAACACC 960
AGAAAAATGAT CCTAACTACT TTATGAATGA ACCAACATTT TATACATCTG ATGGTGTTC 1020
55 TTTCACTGCA GCTGATCCAG ATTACCAAGA GAAATACCAA GAATTACTTG AAAGAGAGGA 1080
CTTTTTTCCA GATTATGAAG AAAATGGAAC AGATTATATCC GGGCTGGTG ATCCATACTT 1140
GGATGATATT GATGATGAGA TGGACCCAGA GATAGAAGAA GCTTATGAAA AGTTTGTGTT 1200
60 GGAATCAGAG CGTAAGCGAA AACAGTAAAG TTAAATTTCA GCATATCAGT TTTATAAAGC 1260

AGTTTAGGTA TGGTGATTTA GCAGAACACA AGAGAGCAAG AAAATGTGTC ACATCTATAC 1320
CAAAATTRAGG ATGTTGAGTT ATGTTACTAA TGTATGCAAC TTTAATTTTG TTTAACACTA 1380
5 TCTGCCAAAA TAAACTTTAT TCCCTATAAC TTAANAATGTG TATATATATA TAATAGTTTA 1440
TTATGTACAG TTAATCTAC TGTTTGGCT GCAATAAAT CGATTTTGAA ATAAAWRAAA 1500
10 AAAAAAAAAA AAGGGNGGCC GCTCTAGAGG ANCCAAG 1537

15 (2) INFORMATION FOR SEQ ID NO: 246:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 506 base pairs
(B) TYPE: nucleic acid
20 (C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 246:

25 TGCAGGATTT GCCCAGGACC CSCCGGGTG GCGGTGCTA TGCCTCGCA GAACCTACTC 60
AGGCAGCCAG CTGAGAAGAG TTGAGGGAAA GTGCTGCTGC TGGGTCTGCA GACGCGATGG 120
ATAACGTGCA GCCGAAAATA AAACATCGCC CCTTCTGCTT CAGTGTGAAA GGCCACGTGA 180
30 AGATGCTGCG GCTGGATATT ATCAACTCAC TGGTAACAAC AGTATTCATG CTCATCGTAT 240
CTGTGTGGC ACTGATACCA GAAACCACAA CATTGACAGT TGGTGGAGGG GTGTTTGCAC 300
35 TTGTGACAGC AGTATGCTGT CTGCGGACG GGGCCCTTAT TTACCGGAAG CTTCTGTICA 360
ATCCCAGCGG TCCTTACCAG AAAAAGCCTG TGCATGAAA AAAAGAAGTT TTGTAATTTT 420
ATATTACTTT TTAGTTTGAT ACTAAGTATT AAACATATTT CTGKATTATT CCAAAAAAAAA 480
40 AAAAAAAAAA AAAAAAAAAATT TGGTGG 506

45

(2) INFORMATION FOR SEQ ID NO: 247:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1348 base pairs
50 (B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 247:

55 GTCTTCTTTT TNCTGTTTGT AGTTGGTGAG TGAGTGAATA GGGTAACATG GGCCTTCAGG 60
ATGACCCCTT GGAACGTGTC CGAGTTCCTT AAATCTCAGC TGGGATCCTG GACCTGGGAG 120
60 GCCCTGTGA GGGCCAGCTC TGGAAAAACC TGGGAGTTGA TGCCGAGGY TGGGAAGAAC 180

	TCTGCTCGAG GGCAGGGTGC CCTGGAACAC TGGTAGTTCT GGGGCTGGGA GGGAGAGGGG	240
5	CTCCGGCTTT CTCTGAAATG AACACTGCTC TTCAGCAGTT CAAGTACTTG TTCTCAAAAC	300
	ATTTTCTAAT TGATTGGTAG GTTTTCATAA GCATTGTTTC TTAAAGGCAT GGAAAGGGAA	360
	GAATGCTCAA GCAAGTCATG TTTGTTTCA GTGGGATGGG CCGCGTTCT CACTGCTGGG	420
10	GGCTTCCCT TGCATGTGGC ACCTTTGTGC AGGGCCACCA GGCAGACTCT TCCCACCTTC	480
	TCCCACGTAA GCACCAAGGG GCTTGAACCG TAATTTGGCT AATCAGAGGC ATTTTTTTTG	540
15	TCCTAGTATC TTTACACATT GTCCAACCGT CTTATTTTTT TAAAAGTTCT GTTGCTTGTA	600
	TTAACACGAA ACTAGAGAGA AATAGTTTCT GAAGCCAGTT TATTGTGAAG ATCCCCAAGG	660
	GGAGGTTCCG TAGAGAAAA TAGTAAGCTG GTTTAGAAAC TGACGAGGGC AAACAGCCAG	720
20	GACGCATTGG AGAGGAATTT GCCAAAGATC TACCCGTAGA TAACGCCTGT CCAGTGTCTT	780
	CACCACGTGA ATAACCAGCG CTCCAAAGTG TTTTCTGCT TTGAAAAAA AAATTCCACA	840
25	AGCTTTTAAA GGTCATTTA AGAATCCATG TGACTTTAGA ATGGAACTGC CGGCCCTGGC	900
	AACTGTCACG TGTGCTAGAA GGTTCGATGC CTCTGGAATG CATGTGATAC TCATCTCCAT	960
	TTTGTTCCT TGATTGCATT TTTGTCTTT TAGCAGATCT GTCCCTGTGG GTGGTGCTA	1020
30	AGAAGTCGGA CACCTTGTT TTTGTGTTAG ATTGAGCTGG GCAGCTGCAA TCAGCTTCTT	1080
	TATATGCAA TTAGGCACGA CCCATCTGTG GTTCCCTGGT TGGTGGCTAA TGAAGTGAGG	1140
35	GGAGGGAGGG ATGTCACCCC AAAAGTAGGC CCTCCCATTG GCTTTGGCCA GGCCAGACAC	1200
	TTCACATCGT TTACATGGTT CTGTGTAATT TTAAAGTTTA TGTGTATAAA CGGAAGCTGT	1260
	TTCTGTGAAA CTGTATATTT TGTAAATAAA TATATTGCTA CTTTGAGAWR AAAAAAAAAA	1320
40	AAAAACTCGA GGGGGGCCCG GTACCCAA	1348

45 (2) INFORMATION FOR SEQ ID NO: 248:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 1766 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 248:

55	GTGCCGAATC GGCAGAGCGG CACGAGCGG CACGAGAGCA GCGGAGTAA AGGGAATTGA	60
	GCGAGCCAGT TGCCGATTA TTCTATTTCC CCTCCCTCTC TCCCGCCCCG TATCTCTTTT	120
60	CACCCCTCTC CCACCTCGC TCGGTASCA TGGCGGAGCG TGGCGGCCA CTCAGTCCCA	180

	TTCCATCTCC TCGTCGTCTT TCGGAGCCGA GCCGTCCGCG CCGGCGGGG GCGGGAGCCC	240
	AGGAGCCTGC CCGGCCCTGG GGACGAAGAG CTGCAGCTCC TCCTGTGCGG TGCAOGATCT	300
5	GATTTTCTGG AGAGATGTGA AGAAGACTGG GTTTGTCTTT GGCACCACGC TGATCATGCT	360
	GCTTTCCTCG GCAGCTTTCA GTGTATCAG TGTGGTTTCT TACCTCATCC TGGCTCTTCT	420
10	CTCTGTACCC ATCAGCTTCA GGATCTACAA GTCCGTATC CAAGCTGTAC AGAAGTCAGA	480
	AGAAGGCCAT CCATTCAAAG CCTACCTGGA CGTAGACATT ACTCTGTCTT CAGAAGCTTT	540
	CCATAATTAC ATGAATGCTG CCATGGTGCA CATCAACAGG GCCCTGAAAC TCATTATTGG	600
15	TCTCTTTCTG GTAGAAGATC TGGTTGACTC CTGAAGCTG GCTGTCTTCA TGTGGCTGAT	660
	GACCTATGTT GGTGCTGTCT TTAACGGAAT CACCCTCTTA ATTCTGTCTG AACTGCTCAT	720
20	TTTCAGTGTG CCGATTGTCT ATGAGAAGTA CAAGACCCAG ATTGATCACT ATGTTGGCAT	780
	CGCCCGAGAT CAGACCAAGT CAATTGTTGA AAAGATCCAA GCAAAACTCC CTGGAATCGC	840
	CAAAAAAAG GCAGAATAAG TACATGAAA CCAGAAATGC AACAGTTACT AAAACACCAT	900
25	TAAATAGTTA TAACGTCGTT ACTTGTACTA TGAAGGAAA TACTCAGTGT CAGCTTGAGC	960
	CTGCATTCCA AGCTTTTTTT TTAATTTGGT GTTTTCTCCC ATCCTTTCCC TTAAACCTC	1020
30	AGTATCAAGC AAAAAATTG ATGGACTGAT AAAAGAACTA TCTTAGAACT CAGAAGAAGA	1080
	AAGAATCAAA TTCATAGGAT AAGTCAATAC CTTAATGGTG GTAGAGCCTT TACCTGTAGC	1140
	TTGAAAGGGG AAAGATTGGA GGTAAGAGAG AAAATGAAAG AACACCTCTG GGTCTTCTG	1200
35	TCCAGTTTTC AGCACTAGTC TTAATCAGCT ATCCATTATA GTTTTGCCCT TAAGAAGTCA	1260
	TGATTAACTT ATGAAAAAAT TATTGGGGA CAGGAGTGTG ATACCTTCCT TGGTTTTTTT	1320
40	TTGCAGCCCT CAAATCCTAT CTTCCTGCCC CACAATGTGA GCAGCTACCC CTGATACTCC	1380
	TTTTCTTTAA TGATTAACT ATCAACTTGA TAAATAACTT ATAGGTGATA GTGATAATTC	1440
	CTGATTCCAA GAATGCCATC TGATAAAAAA GAATAGAAAT GGAAAGTGGG ACTGAGAGGG	1500
45	AGTCAGCAGG CATGCTGCGG TGGCGGTCAC TCCCTCTGCC ACTATCCCA GGAAGGAAA	1560
	RGCTCCGCCA TTTGGGAAAG TGGTTTCTAC GTCAGTGGAC ACCGGTCTG AGCATTAGTT	1620
50	TGAGAACTCG TTCCCGAATG TGCTTCTCTC CCTCTCCCCT GCCCACCTCA AGTTTAATAA	1680
	ATAAGGTGT ACTTTTCTTA CTATAAAATA AAAAAAAAAA AACTCGAGGG GGGCCCGTA	1740
	CCCAAATCGC CGGATATGAT CGTAAA	1766
55		

(2) INFORMATION FOR SEQ ID NO: 249:

60

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2664 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 249:

	AGTGTCTCTCG GAGCAGGCGG AGTAAAGGGA CTTGAGCGAG CCAGTTGCCG GATTATCTTA	60
10	TTTCCCTCC CTCTCTCCG CCCGTATCT CTTTTCACCC TTCTCCACC CTCGCTCGG	120
	TASCATGGCG GAGCGTCGGC GGCCACTCAG TCCCATTTCA TCTCCTCGTC GTCCTTGGGA	180
15	GCGAGCCGT CCGGCCCCG CGGGGGGGG AGCCAGGAG CCTGCCCCG CCTGGGGACG	240
	AAGAGCTGCA GCTCTCTCTG TCGGTGCAC GATCTGATTT TCTGGAGAGA TGTGAAGAAG	300
	ACTGGGTTTG TCTTTGGCAC CACGCTGATC ATGCTGCTTT CCCTGGCAGC TTTCAGTGTC	360
20	ATCAGTGTGG TTCTTACCT CATCTGGCT CTTCTCTCTG TCACCATCAG CTTCAGGATC	420
	TACAAGTCCG TCATCCAAGC TGTACAGAAG TCAGAAGAAG GCCATCCATT CAAAGCCTAC	480
25	CTGGACGTAG ACATTACTCT GTCTCAGAA GCTTTCCATA ATTACATGAA TGCTGCCATG	540
	GTGCACATCA ACAGGGCCCT GAAACTCATT ATTCTCTCT TTCTGGTAGA AGATCTGGTT	600
	GACTCCTTGA AGCTGGCTGT CTTTATGTGG CTGATGACCT ATGTTGGTGC TGTTTTAAAC	660
30	GGAATCACCC TTCTAATTCT TGCTGAACTG CTCATTTTCA GTGTCCGAT TGTCTATGAG	720
	AAGTACAAGA CCCAGATTGA TCACTATGTT GGCATCGCCC GAGATCAGAC CAAGTCAATT	780
35	GTTGAAAAGA TCCAAGCAA ACTCCCTGGA ATCGCCAAA AAAAGGCAGA ATAAGTACAT	840
	GGAAACCAGA AATGCAACAG TTAATAAAC ACCATTTAAT AGTTATAACG TCGTTACTTG	900
	TACTATGAAG GAAAATACTC AGTGTACGCT TGAGCCTGCA TTCCAAGCTT TTTTTTAAT	960
40	TTGGTGTTTT CTCCATCCT TTCCCTTAA CCCTCAGTAT CAAGCACAAA AATTGATGGA	1020
	CTGATAAAG AACTATCTTA GAACTCAGAA GAAGAAAGAA TCAAATTCAT AGGATAAGTC	1080
45	AATACCTTAA TGGTGGTAGA GCCTTTACCT GTAGCTTGAA AGGGGAAAGA TTGGAGGTAA	1140
	GAGAGAAAAT GAAAGAACAC CTCGGGTCC TTCTGTCCAG TTTCAGCAC TAGTCTTACT	1200
	CAGCTATCCA TTATAGTTTT GCCCTAAGA AGTCATGATT AACTTATGAA AAAATTATTT	1260
50	GGGACAGGA GTGTGATACC TTCTTGGTT TTTTPTTGCA GCCCTCAAAT CCTATCTTCC	1320
	TGCCCCACAA TGTGAGCAGC TACCCCTGAT ACTCCTTTTC TTTAATGATT TAACTATCAA	1380
55	CTTGATAAAT AACTTATAGG TGATAGTGAT AATTCCTGAT TCCAAGAATG CCATCTGATA	1440
	AAAAGAATA GAAATGAAA GTGGACTGA GAGGGAGTCA GCAGGCATGC TCGGTGGCG	1500
	GTCACCTCCT CTGCCACTAT CCCCAGGAA GGAAARGCTC CGCCATTGCG GAAAGTGGTT	1560
60	TCTACGTAC TGGACACCGG TTCTGAGCAT TAGTTTGAGA ACTCGTTCCC GAATGTGCTT	1620

	TCCTCCCTCT CCCCTGCCA CCTCAAGTTT AATAAATAAG GTGTACTTT TCITACTATA	1680
5	AAATAAATGT CTGTAACGTC TGTGCACTGC TGTAACCTTG TTAGAGAAAA AAATAACCTG	1740
	CATGTGGGCT CCTCAGTTAT TGAGTTTTTG TGATCCTATC TCAGTCTGGG GGGGAACATT	1800
	CTCAAGAGGT GAAATACAGA AAGCCTTTTT TTCTTGATCT TTCCCGAGA TTCAAATCTC	1860
10	CGATTCCCAT TTGGGGGCAA GTTTTTTTCT TCACCTTCAA TATGAGAATT CAGCGAAGCTT	1920
	GAAAGAAAA TCATCTGTGA GTTCCTTCAG GTTCTCACTC ATAGTCATGA TCCTTCAGAG	1980
15	GGAAATATGA CTGGCGAGTT TAAAGTAAGG GCTATGATAT TTGATGGTCC CAAAGTACGG	2040
	CAGCTGCAAA AAGTAGTGA AGGAAATTGT CTACGTGCTC TGGAAAAATT AGTTAGGAAT	2100
	TTGGATGGGT AAAAGGTACC CTGCGCTTAC TCCATCTTAT TTTCTTAGCC CCCTTTGAGT	2160
20	GTTTTAACTG GTTTCATGTC CTAGTAGGAA GTGCATCTC CATCCTCATC CTCTGCCCTC	2220
	CCAGGAAGTC AGTGATTGTC TTTTGGGCT TCCCCTCAA AGGACCTTCT GCAGTGAAG	2280
25	TGCCACATCC AGTCTTTTC TTTTGTGCT GCTGTGTTA GATAATTGAA GAGATCTTTG	2340
	TGCCACACAG GATTTTTTTT TTTTTAAGA AAAACCTATA GATGAAAAAT TACTAATGAA	2400
	ACTGTGTGTA CGTGTCTGTG CGTGCAACAT AAAAATACAG TAGCACCTAA GGAGCTTGAA	2460
30	TCTTGGTTCC TGTAATAATT CAAATTGATG TGGTATTAAT AAAAAAAAAA AAAACAMAA	2520
	AAAAAAAAA AAAAGGGCGG CCGCTCTAGA GGATCCAAGC TTACGTACGC GTGCATGCCA	2580
35	CGTCCATAGC TCTTCTATA GGGTCCCCC AAATCCATT CACGGGCGC TCGGTTTTAN	2640
	AAAGGTCGTG ANTGGGGGAA ANCC	2664

40

(2) INFORMATION FOR SEQ ID NO: 250:

(i) SEQUENCE CHARACTERISTICS:

45

- (A) LENGTH: 865 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 250:

	CGTGGGAGTG AGGTACCAGA TTCAGCCCAT TTGGCCCCGA CGCCTCTKTT CTCGGAATCC	60
	GGGTGCTGCG GATTGAGGTC CCGGTTCCTA ACGGTGGGAT CGGTGTCCTC GGGATGAGAT	120
55	TTGGCGTTTC CTCGGGGCTT TGGTGGGATC GGTGTCTCA GGATGAGATT TAGGGTTTCC	180
	TGGGGGCTTT CGGGATCTTC ACCTAATATC CGGACTGCAA GATGGAGGAA GCGGGGAACC	240
60	TAGGAGGCCT GATTAAATG GTCCATCTAC TGGTCTTGTC AGGTGCCTGG GGCATGCAAA	300

TGTGGGTGAC CTTGCTCTCA GGCTTCCTGC TTTTCCGAAG CCTTCCCCGA CATACCTTCG 360
 GACTAGTGCA GAGCAAATC TTCCCCCTTCT ACTTCCACAT CTCCATGGGC TGTGCTTCA 420
 5 TCAACCTCTG CATCTTGGCT TCACAGCATG CTTGGGCTCA GCTCACATTC TGGGAGGCCA 480
 GCCAGCTTTA CTGCTGTTC CTGAGCCTTA CGCTGGCCAC TGTCAAAGCC CGCTGGCTGG 540
 AACCCCGCAC CACAGCTGCC ATGTGGGCCG TGCAAACCGT GGAGAAGGAG CGAGGCTGG 600
 10 GTGGGGAGGT ACCAGGCAGC CACCAGGGTC CGATCCCTA CCGCCAGCTG CGAGAGAAGG 660
 ACCCCAAGTA CAGTGTCTC CGCCAGAAAT TCTTCCGCTA CCATGGGCTG TCCTCTCTTT 720
 15 GCAATCTGGG CTGCTGCTG AGCAATGGGC TGTGTCTCGC TGGCCTTGCC CTGGAATAA 780
 GGAGCCTCTA GCATGGGCCG TGCATGCTAA TAAATGCTTC TTCAGAAAAA AAAAAAAAAA 840
 AACTCGAGG GGGGCCCGGT ACCCA 865
 20

(2) INFORMATION FOR SEQ ID NO: 251:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2082 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

30

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 251:

TGGGGGGGN AATGGGTGTC TGGCTCANGG ATTGCCNAAT CTGGAAATTC TCCATAACTT 60
 35 GCTAGCTTGT TTTTTTTTTT TTTTTTTACA CCCCCCGCC CCACCCCGG ACTTGACAA 120
 TGTTCATGA TCTCAGCAGA GTTCTTCATG TGAACGTTG ATCACCTTTG AAGCCTGCAT 180
 40 CATTACATA TTTTTTCTC TTCTTCCCCT TCAGTTCATG AACTGGTGT CATTTTCTGT 240
 GTGTGTGTGT GTTTTATTTT GTTTGGATTT TTTTTTTTAA TTTTACTTTT AGAGCTTGCT 300
 GTGTGCCCCA CCTTTTTTCC AACCTCCACC CTCACTCCTT CTCAACCCAT CTCTTCOGAG 360
 45 ATGAAAGAAA AAAAAAAGCA AAGTTTTTTT TTCTTCTCCT GAGTCTTCA TGTGAGATTG 420
 AGCTTGCAAA GGAAAAAAA ATGTGAAATG TTATAGACTT GCAGCGTGCC GAGTTCCATC 480
 50 GGGTTTTTTT TTTAGCATG TTATGCTAAA ATAGAGAAAA AAATGCTCAT GAACCTTCCA 540
 CAATCAAGCC TGCATCAACC TTCTGGGTGT GACTTGTGAG TTTTGGCCTT GTGATGCCAA 600
 ATCTGAGAGT TTAGTCTGCC ATTAAAAAAA CTCATTCTCA TCTCATGCAT TATTATGCTT 660
 55 GCTACTTTGT CTTAGCAACA ATGAACTATA ACTGTTTCAA AGACTTTATG GAAAAGAGAC 720
 ATTATATTAA TAAAAAAA AAGCCTGCAT GCTGGACATG TATGGTATAA TTATTTTTTC 780
 60 CTTTTTTTTT CCTTTTGGCT TGGAAATGGA CGTTCGAAGA CTTATAGCAT GGCATTCTATA 840

	CTTTTGTTTT ATGCCCTCAT GACTTTTTTG AGTTTAGAAC AAAACAGTGC AACCGTAGAG	900
5	CCTTCTTCCC ATGAAATTTT GCATCTGCTC CAAAACAGCT TTGAGTTACT CAGAACTTCA	960
	ACCTCCCAAT GCACTGAAGG CATTCCTTGT GCAAAGATAC CAGAAATGGT TACACATTTA	1020
	ACCTGGCAAA CATTGAAGAA CTCITRATGT TTTCTTTTTA ATAAGAATGA CGCCCCACTT	1080
10	TGGGGACTAA AATTGTGCTA TTGCCGAGAA GCAGTCTAAA ATTTATTTTT TAAAAAGAGA	1140
	AACTGCCCA TTATTTTTGG TTGTTTTAT TTTTATTTA TATTTTTGG CTTTGGTCA	1200
15	TTGTCAAATG TGAATGCTC TGGGTTCTA GTATATAATT TAATCTAGT TTTTATAATC	1260
	TGTTAGCCCA GTTAAATGT ATGCTACAGA TAAAGGAATG TTATAGATAA ATTTGAAAGA	1320
	GTTAGGCTG TTTAGCTGTA GATTTTTTAA ACGATTGATG CACTAAATG TTTACTATTG	1380
20	TGATGTTAAG GGGGTTAGAG TTGCAAGGG GACTGTTTAA AAAAAGTAGC TTATACAGCA	1440
	TGTGCTGCA ACTTAAATAT AAGTGGGTA TGTGTAGTCT TTGCTATACC ACTGACTGTA	1500
25	TTGAAAACCA AAGTATTAAG AGGGGAAACG CCCCTGTTTA TATCTGTAGG GGTATTTTAC	1560
	ATTCAAAAT GTATGTTTTT TTTCTTTTC AAAATTAAAG TATTTGGGAC TGAATTGCAC	1620
	TAAGATATAA CCTGCAAGCA TATAATACAA AAAAAAATG CAAAACGTT TAGAACGCTA	1680
30	ATAAAATTTA TGCAATTATA AAAATGGCAT TACTGCACAG TTTTAAGATG ATGCAGATTT	1740
	TTTTACAGTT GTATTGTGGT GCAGAACTGG ATTTTCTGTA ACTTAAAAA AAATCCACAG	1800
35	TTTTAAAGC AATAATCAGT AAATGTTATT TTCAGGACT GACATCCTGT CTTTAAAAAG	1860
	AAATGAAAG TAAATCTTAC CACAATAAAT ATAAAAAAT CTTGTCAGTT ACTTTTCTTT	1920
	TACATATTTT GCTGTGCAA ATTGTTTTAT ATCTTGAGTT ACTAACTAAC CACCGCTGT	1980
40	GTTCTATGT GCTTTCTTT CATTTTCAAT TCTGTTATA TCAAGAAAAG AATAATCTAC	2040
	AATAATAAAC GGCATTTTTT TTGAAAAA AAAAAAAAAA AA	2082

45

(2) INFORMATION FOR SEQ ID NO: 252:

50

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1482 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 252:

	CAGGCAGGCT GGGCCGGGG ACTTCTCTCT GGCCCTGCTC CCTCCGAGCG CTCGCCGTT	60
60	GGCCGCTGG CCCCTACGGA GTCCCTAGCC AGGATGGAGG CTGTTGTGAA CTTGTACCAA	120

	GAGGTGATGA AGCAGCAGA TCCCCGGATC CAGGGCTACC CTCTGATGGG GTCCCCCTTG	180
	CTAATGACCT CCATTCCTCT GACCTACGTG TACTTCGTTC TCTCACTTGG GCCTGGCATC	240
5	ATGGCTAATC GGAAGCCCTT CCAGCTCCGT GGCTTCATGA TTGTCTACAA CTCTCACTG	300
	GTGGCACTCT CCTCTACAT TGCTATGAG TTCTGATGT CGGGCTGGCT GAGCACCTAT	360
10	ACCTGGCGCT GTGACCTGT GGACTATTCC AACAGCCCTG AGGCACTTAG GATGGTTCCG	420
	GTGGCCCTGGC TCTTCCTCTT CTCCAAGTTC ATTGAGCTGA TGGACACAGT GATCTTTATT	480
	CTCCGAAAGA AAGACGGGCA GGTGACCTTC CTACATGTCT TCCATCACTC TGTGCTTCCC	540
15	TGGAGCTGGT GGTGGGGGGT AAAGATTGCC CCGGGAGGAA TGGGCTCTTT CCATGCCATG	600
	ATAAACTCTT CCGTGCAATG CATAATGTAC CTGTACTACG GATTATCTGC CTTTGGCCCT	660
20	GTGGCACAAC CCTACCTTTG GTGGAAAAAG CACATGACAG CCATTCAGCT GATCCAGTTT	720
	GTCTGGTCT CACTGCACAT CTCCAGTAC TACTTTATGT CCAGCTGTAA CTACCACTAC	780
	CCAGTCATTA TTCACCTCAT CTGGATGTAT GGCACCATCT TCTTCATGCT GTTCTCCAAC	840
25	TTCTGGTATC ACTCTTATAC CAAGGGCAAG CGGCTGCCCC GTGCACTTCA GCAAAATGGA	900
	GCTCCAGGTA TTGCCAAGGT CAAGGCCAAC TGAGAAGCAT GGCTAGATA GGCGCCACC	960
30	TAAGTGCTC AGGACTGCAC CTTAGGGCAG TGTCCGTGAG TGCCCTCTCC ACCTACACCT	1020
	GTGACCAAGG CTATGTGGT CAGGACTGAG CAGGGGACTG GCGCTCCCT CCCACAGCT	1080
	GCTCTACAGG GACCAAGCT TTGGTTCTTC ACCCACTTCC CCGGGGAGC TCCAGGGATG	1140
35	TGGCTCATT GCTGTCTGCC ACTCCAGAGC TGGGGGCTAA AAGGGCTGTA CAGTATTTC	1200
	CCCTCCCTG CCTTAAACT TGGGAGAGGA GCACTCAGG CTGGCCCCAC AAAGGGTCTC	1260
40	GTGGCTTTT TCCTCACACA GAAGAGGTCA GCAATAATGT CACTGTGGAC CCAGTCTCAC	1320
	TCCTCCACCC CACACACTGA AGCAGTAGCT TCTGGGCCAA AGGTCAGGGT GGGCGGGGC	1380
	CTGGGAATAC AGCTGTGGA GGCTGCTTAC TCAACTTGTG TCTTAATTAA AAGTGACAGA	1440
45	GGAAACCAAA AAAAAAAAAA AAAAACTCGA GGGGGGCCG TA	1482

50 (2) INFORMATION FOR SEQ ID NO: 253:

(i) SEQUENCE CHARACTERISTICS:

- 55 (A) LENGTH: 834 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 253:

60 GGCACGAGCG CCGTGGCCG CCTGGCCCT ACGAGTCTT TAGCCAGGAT GGAGGCTGTT 60

5 GTGAACCTTGT ACCAAGAGGT GATGAAGCAC GCAGATCCCC GGATCCAGGG CTACCCCTCTG 120
 ATGGGGTCCC CCTTGCTAAT GACCTCCATT CTCCTGACCT ACGTGTACTT CGTTCTCTCA 180
 CTGGGGCTC GCATCATGGC TAATCGGAAG CCTTCCAGC TCCGTGGCTT CATGATTGTC 240
 TACAACCTCT CACTGGTGGC ACTCTCCCTC TACATGTCT ATGAGTTCTT GATGTCGGGC 300
 10 TGGCTGAGCA CCTATACCTG GCGCTGTGAC CCTCAGGACT GCACCTTAGG GCAGTGTCCG 360
 TCACTGCCCT CTCAMCTAC ACCTGTGACC AAGGCTTATG TGGTCAGGAC TGAGCAGGGG 420
 ACTGGCCCTC CCTCCCCAC AGCTGCTCTA CAGGGACCAC GGCTTTGGTT CCTCACCAC 480
 15 TTCCCCGGG CAGCTCCAGG GATGTGGCTT CATGTCTGTC TGCCACTCCA GAGCTGGGGG 540
 CTAAAAGGC TGTACAGTTA TTTCCCCCTC CCTGCCTTAA AACTTGGGAG AGGAGCACTC 600
 20 AGGGCTGGCC CCACAAAGG TCTCGTGGCC TTTTCTCTCA CACAGAAGAG GTCAGCAATA 660
 ATGTCACGTG GGACCCAGTC TCACTCCTCC ACCCCACACA CTGAAGCAGT AGCTTCTGGG 720
 CCAAAGGTCA GGGTGGGCGG GGGCCTGGGA ATACAGCCTG TGGAGGCTGC TTACTCAACT 780
 25 TGTGTCTTAA TTAAGAGTGA CAGAGGAAAC CACGAAAAA AAAAAAAAAA AAAA 834

30

(2) INFORMATION FOR SEQ ID NO: 254:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1508 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 254:

TTGAACCTTT AAAATTTTAG ATCAGCAAAC TCTAAGATCC TAGAATGGAA GCTGTTCTCTC 60
 ATTTCTCCAT GCTCACCCTC CCAGGTCAGC GAGATGGTGA AGAAGCTGCA CCGGCAACA 120
 45 CCACCAACGT TCGGAGTGA CCTCATCAAT GAGCTTGTGG AGAACTTTGG CAGATGTCC 180
 AAGTGGTCTG GTCGGCAAGC CTTGTCTTT GTCTGCCAGA CTGTCAITGA GGATGACTGC 240
 CTTCCCATGG ACCAGTTTGC TGTGCATCTC ATGCCGCATC TGCTAACCTT AGCAAATGAC 300
 50 AGGGTTCTTA ACGTGCAGT GCTGCTTGCA AAGACATTAA GACAACTCT ACTAGAAAAA 360
 GACTATTTCT TGGCCTCTGC CAGCTGCCAC CAGGAGGCTG TGGAGCAGAC CATCATGGCT 420
 55 CTTCAGATGG ACCGTGACAG CGATGTCAAG TATTTTGCAA GCATCCACCC TGCCAGTACC 480
 AAAATCTCCG AAGATGCCAT GAGCACAGCG TCCTCAACCT ACTAGAAGGC TTGAATCTCG 540
 60 GTGTCTTTCC TGCTTCCATG AGAGCCGAGG TTCAGTGGGC ATTGCCACG CATGTGACCT 600

	GGGATAGCTT TCGGGGAGG AGAGACCTTC CTCCTCTGCG GACTTCATTG CAGGTGCAAG	660
	TTGCCTACAC CCAATACCAG GGATTTCAG AGTCAAGAGA AAGTACAGTA AACACTATTA	720
5	TCTTATCTTG ACTTTAAGGG GAAATAATTT CTCAGAGGAT TATAATTGTC ACCGAAGCCT	780
	TAAATCCTTC TGTCTTCTG ACTGAATGAA ACTTGAATTG GCAGAGCAIT TTCCTTATGG	840
10	AAGGGATGAG ATTCCCAGAG ACCTGCATTG CTTTCTCTG GTTTTATTTA ACAATCGACA	900
	AATGAAATTC TTACAGCCTG AAGGCAGACG TGTGCCCAGA TGTGAAAGAG ACCTTCAGTA	960
	TCAGCCCTAA CTCTTCTCTC CCAGGAAGGA CTGCTGGGC TCTGTGGCCA GCTGTCCAGC	1020
15	CCAGCCCTGT GTGTGAATCG TTTGTGACGT GTGCAAATGG GAAAGGAGGG GTTTTACAT	1080
	CTCTAAAGG ACCTGATGCC AACACAAGTA GGATTGACTT AAACCTCTTA GCGCAGCATA	1140
20	TTGCTGTACA CATTTACAGA ATGGTTGCTG AGTGTCTGTG TCTGATTTT TCATGCTGGT	1200
	CATGACCTGA AGGAAATTTA TTAGACGTAT AATGTATGTC TGGTGTTTT AACCTGATCA	1260
	TGATCAGCTC TGAGGTGCAA CTTCTTCACA TACTGTACAT ACCTGTGACC ACTCTGGGA	1320
25	GTGCTGCAGT CTTTAATCAT GCTGTTTAAA CTGTTGTGGC ACAAGTCTC TTGTCCAAAT	1380
	AAAATTTATT AATAAGATCT ATAGAGAGAG ATATATACAC TTTTGATTGT TTTCTAGATG	1440
30	TCTACCAATA AATGCAATTT GTGACCTGTA TTAACAAAAA NTAAAAAAC TCGAGGGGGG	1500
	CCCGGTAC	1508

35

(2) INFORMATION FOR SEQ ID NO: 255:

(i) SEQUENCE CHARACTERISTICS:

40

- (A) LENGTH: 2514 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 255:

	GAGAGACTCA CACTTCTTTT CCATTATCAC TGACGATGTA GTGGACATAG CAGGGGAAGA	60
	GCACCTACCT GTGTGGTGA GGTTGTGTA TGAATCTCAT AACCTAAGAG AGGAATTTAT	120
50	AGGCTTCCTG CCTTATGAAG CGATGCAGA AATTTTGGCT GTGAAATTTT AACTATGAT	180
	AACTGAGAAG TGGGGATTAA ATATGGAGTA TTGCTGTGGC CAGGCTTACA TTGWCTCTAG	240
55	TGGATTTTCT TCCAAATGA AAGTTGTTGC TTCTAGACTT TTAGAGAAAT ATCCCCAAGC	300
	TATCTACACA CTCTGCTCTT CCTGTGCCTT AAATATGTGG TTGGCAAAT CAGTACCTGT	360
	TATGGGAGTA TCTGTTGCAT TAGGAACAAT TGAGGAAGTT TGTCTTTTTT TCCATCGATC	420
60	ACCACAACCTG CTTTATAGAAC TTGACAACGT AATTTCTGTT CTTTTTCAGA ACAGTAAAGA	480

	AAGGGTAAA GAACTGAAGG AAATCTGCCA TTCTCAGTGG ACAGGCAGGC ATGATGCTTT	540
5	TGAAATTTTA GTGGAAGCTCC TGCAAGCACT TGTTTTATGT TTAGATGGTA TAAATAGTGA	600
	CACAAATATT AGATGGAATA ACTATATAGC TGGCCGAGCA TTTGTACTCT GCAGTGCAGT	660
	GTCAGATTTT GATTTTCATTG TTACTATTGT TGTTCCTAAA AATGTCCTAT CTTTTACAAG	720
10	AGCCTTTGGG AAAAACCTCC AGGGGCAAAC CTCTGATGTC TTCTTTGCGG CCGGTAGCTT	780
	GACTGCAGTA CTGCATTAC TCAACGAAGT GATTGGAAAA TATTGAAGTT TATCATGAAT	840
15	TTTGGTTTGA GGAAGCCACA AATTTGGCAA CCAAAGTTGA TATTCAAATG AAACCTCCCTG	900
	GGAAATTCOG CAGAGCTCAC CAGGGTAACT TGGAACTCTCA GCTAACCTCT GAGAGTTACT	960
	ATAAAGAAAC CCTAAGTGTC CCAACAGTGG AGCACATTAT TCAGGAACCTT AAAGATATAT	1020
20	TCTCAGAACA GCACCTCAA GCTCTTAAAT GCTTATCTCT GGTACCTCA GTCATGGGAC	1080
	AACTCAAATT CAATACGTGG GAGGAACACC ATGCTGACAT GTATAGAAGT GACTTACCCA	1140
25	ATCCTGACAC GCTGTCAGCT GAGCTTCATT GTTGGAGAAT CAAATGGAAA CACAGGGGGA	1200
	AAGATATAGA GCTTCCGTCC ACCATCTATG AAGCCCTCCA CCTGCCTGAC ATCAAGTTT	1260
	TTCTTAATGT GTATGCATG CTGAAGGTCC TGTGTATTCT TCCTGTGATG AAGTTTGAGA	1320
30	ATGAGCGSTA TGAAATGGA CGAAAGCGTC TTAAAGCATA TTTGAGGAAC ACTTTGACAG	1380
	ACCAAGGTC AAGTAACTTG GCTTTGCTTA ACATAAATTT TGATATAAAA CACGACCTGG	1440
35	ATTTAATGGT GGACACATAT ATTAACTCT ATACAAGTAA GTCAGAGCTT CCTACAGATA	1500
	ATTCGGAAAC TGTGGAAAT ACCTAAGAGA CTTTTAAAA TAGGCTTTCT TATATTTGAT	1560
	ATTTGGAAGA AAAAGCCGTA AGTGTATGTA GACCACTTAA TCACTAAATA TCTTTGCCTA	1620
40	TAGGACTCCA TTGAATACAT TAGCCATTGA TAATCTACCT GTTTAAATGG CCCTGTTTG	1680
	AACTCTCAAG CTTTGAAGAC CTACCTGTTT TTCCAGAAGA GAACGTTGAA AGTGCCATGT	1740
45	TTCTTTTTCG GTGATCTCTG TTGATGGCAC TCTGGAATTG TTTCACTTAA GTCATTTTAG	1800
	ACATAGCATT TATTATCACT GTGGATCTCT ACTTGTGGG TGTATGAAT TCTTTGAAGA	1860
	AATATATTTT GAAGAGGTGT GGGAGGAAG AATACATTTT ATAAATGTT GTAGTGAAGC	1920
50	CCACAATTGA CCTTTGACTA ATAGGAGTTT TAAGTATGTT AAAAATCTAT ACTGGACAGT	1980
	TACAAGAAAT TACCGGAGAA AAGCTTGTGA GCTCACCAA CAAGATTTC AGTGTAGATT	2040
55	TTGTCCTTCT TGAAGTAAA GAAACAAATG ACAAAGTTTG AATGGAAAAG CCTGCTGTTG	2100
	TTCCACATCT CGTTGCTGTT TACATTCCTT TGTGGAGCCT ACATCTTCCT AAGCTTTTAA	2160
	GCAGGTATAT GTTGAACACT TCTGTTTCAT GGTGAGACA GAATCAGAGG CCATGGATAC	2220
60	TGACAACTGA TTTGTCTGTT TTTTCTCTCT GTCTTTTCC ATGACTCTTA TATACTGCCT	2280

5 CATCTTGATT TATAAGCAAA ACCTGGAAAA CCTACAAAAT AAGTGTGTG GTTTATCTAG 2340
AAAAATATGG AAAATATTGC TGTATTPTT GGTGAAGAAA ATCAATTTG TATAGTTTAT 2400
TTCAATCTAA ATAAAATGTG AATTTTGTTT AAAGCTTAGG CACATTATTT TTTGTGGGGT 2460
10 CAAAACATTC TTGTGTAAAT TCTCTTAAAC ATTTGATAAA CAGCTTCACA ATTC 2514

(2) INFORMATION FOR SEQ ID NO: 256:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2357 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
20 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 256:

CTGCCTTATG AAGCCGATGC AGAAATTTTG GCTGTGAAAT TTCACACTAT GATAACTGAG 60
25 AAGTGGGGAT TAAATATGGA GTATTGTCGT GGCCAGGCTT ACATTGTCTC TAGTGGATTT 120
TCTTCCAAAA TGAAAGTTGT TGCTTCTAGA CTMTTAGAGA AATATCCCA AGCTATCTAC 180
ACACTCTGCT CTTCCTGTGC CTTAAATATG TGGTTGGCA AATCAGTACC TGTATGGGA 240
30 GTATCTGTTG CATTAGGAAC AATTGAGGAA GTTGTCTCTT TTTCCATCG ATCACCACAA 300
CTGCTTTTAG AACTTGACAA CGTAATTYCT GTTCTTTTTC AGAACAGTAA AGAAAGGGGT 360
35 AAAGAACTGA AGGAAATCTG CCATTCTCAG TGGACAGGCA GGCATGATGC TTTTGAAATT 420
TTAGTGGAAC TCCTGCAAGC ACTTGTTTTA TGTTTAGATG GTATAAATAG TGACACAAAT 480
ATTAGATGGA ATAACTATAT AGCTGGCCGA GCATTTGTAC TCTGCAGTGC AGTGTGAGAT 540
40 TTTGATTTC A TTGTTACTAT TGTGTCTCTT AAAAATGTCC TATCTTTTAC AAGAGCCTTT 600
GGGAAAAACC TCCAGGGGCA AACCTCTGAT GTCTTCTTTG CGGCCGGTAG CTGACTGCA 660
45 GTACTGCATT CACTCAACGA AGTGANITGA AAATATTGAA GTTTATCATG AATTTTGGTT 720
TGAGGAAGCC ACAAATTTGG CAACCAAACT TGATATTCAA ATGAAACTCC CTGGGAAATT 780
COGCAGAGCT CACCAGGTA ACTTGAATC TCAGCTAACC TCTGAGAGTT ACTATAAAGA 840
50 AACCTAAGT GTCCCAACAG TGGAGCACAT TATTTCAGGA CTAAAGATA TATTCTCAGA 900
ACAGCACCTC AAAGCTCTTA AATGCTTATC TCTGGTACCC TCAGTCATGG GACAACTCAA 960
55 ATTCAATACG TGGAGGAAC ACCATGCTGA CATGTATAGA AGTGACTTAC CCAATCCTGA 1020
CACGCTGTCA GCTGAGCTTC ATTTGTGGAG AATCAAATGG AAACACAGGG GGAAAGATAT 1080
AGAGCTTCCG TCCACCATCT ATGAAGCCCT CCACCTGCCT GACATCAAGT TTTTCTCTAA 1140
60

	TGTGTATGCA TTGCTGAAGG TCCTGTGTAT TCTTCCTGTG ATGAAGGTTG AGAATGAGCG	1200
	GTATGAAAT GGACGAAAGC GTCTTAAAGC ATATTGAGG AACACTTTGA CAGACCAAAG	1260
5	GTCAAGTAAC TTGGCTTTGC TTAACATAAA TTTTGATATA AAACACGACC TGGATTTAAT	1320
	GGTGGACACA TATATTAAAC TCTATACAAG TAAGTCAGAG CTTCTACAG ATAATTCCGA	1380
10	AACCTGTGAA AATACCTAAG AGACTTTTAA AAATAGGCTT TCTTATATTT GATATTTGGA	1440
	AGAAAAAGCC GTAAGTGTAT GTAGACCACT TAATCACTAA ATATCTTTGC CTATAGGACT	1500
	CCATTGAATA CATTAGCCAT TGATAATCTA CCTGTTTAAA TGGCCCCGTG TTGAACTCTC	1560
15	AAGCTTTGAA GACCTACCTG TTCTCCAGA AGAGAAGCTT GAAAGTGCCA TGTTCCTTT	1620
	TGCGTGATCT CTGTTGATGG CACTCTGGAA TTGTTTCAGT TAAGTCATTT TAGACATAGC	1680
20	ATTTATTATC ACTGTGGATC TCTACTTGTT GGGTGTTATG AATTCTTTGA AGAAATATAT	1740
	TTTGAAGAGG TGTGGGAGGA AGGAATACAT TTTATAAAAT GTTGTAGTGA AGCCACAAT	1800
	TGACCTTTGA CTAATAGGAG TTTTAAGTAT GTTAAAAATC TATACTGGAC AGTTACAAGA	1860
25	AATTACCGGA GAAAAGCTTG TGAGCTCACC AAACAAGGAT TTCAGTGTAG ATTTTGTCTT	1920
	TCTTGAACCT AAAGAAACAA ATGACAAAGT TTGAATGGAA AAGCCTGCTG TTGTTCCACA	1980
30	TCTCGTTGCT GTTACATTC CTTGTGGAG CCTACATCTT CCTAAGCTTT TTAGCAGGTA	2040
	TATGTTGAAC ACTTCTGTTT CATGGTTGAG ACAGAATCAG AGGCCATGGA TACTGACAAC	2100
	TGATTTGTCT GTTTTTTTTC TCTGTCTTTT TCCATGACTC TTATATACTG CCTCATCTTG	2160
35	ATTTATAAGC AAAACCTGGA AAACCTACAA AATAAGTGT GTGGTTTATC TAGAAAAATA	2220
	TGGAAAAATAT TGCTGTTATT TTTGGTGAAG AAAATCAATT TTGTATAGTT TATTTCAATC	2280
40	TAAATAAAAT GTGAATTTTG TTAAAGCTT AGGCACATTA TTTTTGTGG GGTCAAAACA	2340
	TTCTGTGTGA AATTCTC	2357

45

(2) INFORMATION FOR SEQ ID NO: 257:

(i) SEQUENCE CHARACTERISTICS:

50

- (A) LENGTH: 689 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 257:

55

ACTTTCGGT GCAAAAAGAT GTTCAAGCCT TATTTTATAC TGGCTGCCC CTTTCTCTTT	60
CATTTATTGG AGTGAGCTGC AGCTCTAAGA AGACCTGTTT TTTTGAATGG AGAGTAGCAT	120
CAGGAACCAG GATGTGGGTG CGAGGCGTGC TCCTGGCTGT TGCAGATTGC TGCACCCGGG	180

60

AGCTCTTAGT GGACAGAGCT AGAGGATATG TGCACGTACT TCCATCTCTC TCTCTGTCTC 240
 CGATTTTAGC CCAGCAACCAC AGGGTACGTT CCAGTTTTC TCTCTTTCCA TAGCTGTAAG 300
 5 GCCCTTTCG GGAATGGTTC TCATTCTCCT TAATCTATTA TTGGGTCAGT TTTCCTGCAT 360
 GTCCCCAGCC TCCCATCACT GCCACCCACT CCCACACAG AGCCCTGCT CATCCGACTG 420
 10 GGGCTTTGAC TCCCACACTG TGTACCCCTC TTGTGTGGAC GCCCTGCTGC CAAAACCTTC 480
 AGCAACAGC TTTCCAAATG GAAGTTGTCA CTGTCAAGGS CTTTACAATC AGCAACAGCA 540
 AAATCTACAT GCTGCTGAGG GTCCCTGCCCTC ATTAAGATGC AATAAATATG TAAGTACATA 600
 15 AAAACAGCAA TAGAAGAAAC GTAATGCTTT ATTCTCAAAT ATGNATGTCT ACATAGAAAA 660
 GCCAAAATTA TTAAGAATAG TAAGGAATT 689

20

(2) INFORMATION FOR SEQ ID NO: 258:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2377 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 258:

TCGACCCAGC CGTCCGCCGA TGTGATGATT CCTGCGTATT CCAAGAACCG GGCCTATGCC 60
 35 ATCTTCTTCA TAGTCTTCAC TGTGATAGGG GACGCCCCCG GCGCTGTGCT ATCTGTGACC 120
 GGCCACCTT GCGTTGGTTT TGCTGCTGTA CTGGTGGCGC CCTGACCGT GGCTGTCTCC 180
 TCTTGAAGGA AGCCTGTTTC TGATGAACCT GCTGACAGCC ATCATCTACA GTCAGTTCCG 240
 40 GGGCTACCTG ATGAAATCTC TCCAGACCTC GCTGTTCGG AGGCGGGTGG GAACCCGGCT 300
 GCCTTGAAG TCCTATCCTC CATGGTGGGG GAGGGAGGAG CCTTCCCTCA GGCAGTTGGG 360
 45 GTGAAGCCCC AGAATCTGCT GCAGGTGCTT CAGAAGGTCC AGCTGGACAG CTCCACAGA 420
 CAGGCCATGA TGGAGAAGGT GCGTTCCTAT GGCAGTGTTC TGCTCTCAGC TGAGGAGTTT 480
 CAGAAGCTCT TCAACGAGCT TGACAGAAGT GTGGTTAAAG AGCACCCGCC GAGGCCCGAG 540
 50 TACCAGTCTC CGTTTCTGCA GAGCGNCCCA GTTCCTCTTC GGCCACTNAC TACTTTGACT 600
 ACCTGGGGAA CCTCATCGCC CTGGCAAACC TGGTGTCCAT TTGCGTGTTC CTGGTGTGG 660
 55 ATGCAGATGT TGCTGCCTGC TGAGCGTGAT GACTTCATCC TGGGGGTCT CAACTGGGTC 720
 TTCATTGTGT ACTACCTGTT GGAGATGCTG GCTCAAGGTC TTTTGCCCTG GGGCCTGCGA 780
 RGGTACYKKT CCTAACCCCA RCAAMGTGTT TTGAACGGGC TCCTCAMEGT TTGTCTGGC 840
 60

	TGGWWKRGSM GATCTCAACT CTGGCTGTGT ACCGATTGCC ACACCCAGGC TGGAGGCCGG	900
	ANATGGTGGG CCTGCTGTCTG CTGTGGGACA TGACCCGCAT ACTGAACATG CTCATCGTGT	960
5	TCCGCTTCCT GCGTATCATC CCCAGCATGA AGCCGATGGC CGTGGTGGCC AGTACCGTCC	1020
	TGGGCCTGGT GCAAAACATG CGTGGCTTTG GCGGGATCCT GGTGGTGGTC TACTACGTAT	1080
10	TTGCCATCAT TGGGATCAAC TTGTTAGAG GCGTCATTGT GGCTCTTCCT GGAAACAGCA	1140
	GCCTGGCCCC TGCCAATAGG TCGGCGCCCT GTGGGAGCTT CGAGCAGCTG GAGTACTGGG	1200
	CCAACAACCTT CGATGACTTT GCGGCTGCCC TGGTCACTCT GTGGAACITG ATGGTGGTGA	1260
15	ACAACTGGCA GGTGTTCTG GATGCATATC GCGCTACTA AGGCCCGTGG TCCAAGATCT	1320
	ATTTTGTATT GTGGTGGCTG GTGTGCTCTG TCATCTGGGT CAACCTGTTT CTGGCCCTGA	1380
20	TTCTGGAGAA CTTCCTTCAC AAGTGGGACC CCCGCAGCCA CCTGCAGCCC CTGTCTGGGA	1440
	CCCCAGAGGC CACCTACCAG ATGACTGTGG AGCTCCTGTT CAGGGATATT CTGGAGGAGC	1500
	CCGGGGAGGA TGAGCTCACA GAGAGGCTGA GCCAGCACCC GCACCTGTGG CTGTGCAGGT	1560
25	GACGTCCGGG TCTGCCATCC CAGCAGGGGC GGCAGGAGAG AGAGGCTGGC ATAACACAGG	1620
	TGCCCATCAT GGAAGAGGCG GCCATGCTGT GGCAGCCAG GCAGGAAGAG ACCTTTCTCTC	1680
30	TGACGGACCA CTAAGCTGGG GACAGGAACC AAGTCCTTTG CGTGTGGCCC AACCAACCATT	1740
	TACAGAACAG CTGCTGGTGC TTCAGGGAGG CGCCGTGCCC TCCGCTTTCT TTTATAGCTG	1800
	CTTCAGTGAG AATTCCTTTG TCGACTCCAC AGGGACCTTT CAGACAAAA TGCAAGAAGC	1860
35	AGCGGCTCC CCTGTCCCTT GCAGCTTCG TGGTGCTTTT GCTGCCGGCA GCCCTTGGG	1920
	ACCACAGGCC TGACCAGGGC CTGCACAGGT TAACCGTCAG ACTTCCGGG CATTCAGCTG	1980
40	GGAATGATAC TAATACCTCC GATTTTAGCC CAGCACCACA GGTACGTTT CAGTTTTTAT	2040
	TTCTTTCCAT AGCTGTAAGG CCTTTCTGG GAATGGTTAT CATTCTCCTT AATCTATTAT	2100
	TGGGTCAGTT TTCTGCATG TCCCAGCCT CCATCACTG CCAOCCACTC CCCACAGAGA	2160
45	TGCCCTGCTC ATCCGACTGG GGCTTTGACT CCCACACTGT GTACCCCTCT TGTGTGGACG	2220
	CCCTGCTGCC AAAACCTTCA GCAAACAGCT TTCCAAATGG AAGTTGTCAC TGTACAGGCC	2280
50	TTTACAATCA GCAACAGCAA AATCTACATG CTGCTGAGGG TCCTGCCTCA TTAAGATGCA	2340
	ATAAATATGT AAGTACATAA AAAAAAAAAA AAAAAA	2377

55

(2) INFORMATION FOR SEQ ID NO: 259:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1193 base pairs

(B) TYPE: nucleic acid

60

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 259:

5
TCTGNTGCC GTGCCCCGC COCTGGCCTT TGCCCGGTG GGGGGACTT CCTGTGTGT 60
ATTTCOAAGG ACTCCAAAGC GAGGCCGGG ACTGAAGGTG TGGGTGTGA GCCCTCTGGC 120
10 AGAGGGTTAA CCTGGGTCAA ATGCACGGAT TCTCACCTCG TACAGTTACG CTCTCCCGCG 180
GCACGTCCGC GAGGMYTTGA AGTCCTGAGC GCTCAAGTTT GTCCGTAGTC GAGAGAAGGC 240
CATGGAGGTG CCGCCACCGG CACCGCGGAG CTTTCTCTGT AGAGCATTGT GCCTATTTCC 300
15 COGAGTCTTT GCTGCCGAAG CTGTGACTGC CGATTCCGAA GTCCTTGAGG AGCGTCAGAA 360
GGGGCTTCCC TACGTCCAG AGCCCTATTA CCGGAATCT GGATGGGACC GCCTCCGGGA 420
20 GCTGTTTGGC AAAGACACAG TGAACACTAG TCTGAATGTA TACCGAAATA AAGATGCCCTT 480
AAGCCATTTT GTAATTGCAG GAGCTGTAC GGAAGTCTT TTTAGGATAA ACGTAGGCCT 540
GCGTGGCTGG TGGCTGGTGG CATAATTGGA GCCTTGCTGG GCACTCCTGT AGGAGGCCTG 600
25 CTGATGGCAT TTCAGAAGTA CTCTGGTGA ACTGTTGAGG AAAGAAAACA GAAGGATCGA 660
AAGGCACTCC ATGAGCTAAA ACTGGAAGAG TGGAAAGGCA GACTACAAGT TACTGAGCAC 720
30 CTCCCTGAGA AAATTGAAAG TAGTTTACAG GAAGATGAAC CTGAGAATGA TGCTAAGAAA 780
ATTGAAGCAC TGCTAAACCT TCCTAGAAAC CCTTCAGTAA TAGATAAACA AGACAAGGAC 840
TGAAAGTGCT CTGAAGTTGA AACTCACTGG AGAGCTGAAG GGAGCTGCCA TGTCCGATGA 900
35 ATGCCAACAG ACAGGCCACT CTTTGGTCAG CTGCTGACA AATTTAAGTG CTGGTACCTG 960
TGGTGGCAGT GGCTTGCTCT TGCTTTTTT TTTCTTTTT AACTAAGAAT GGGGCTGTG 1020
40 TACTCTCACT TTAATTATCC TTAATTTAA ATACATACTT ATGTTTGTAT TAATCTATCA 1080
ATATATGCAT ACATGAATAT ATCCACCAC CTAGATTTTA AGCAGTAAAT AAAACATTTT 1140
GCAAAAGATT AAAGTTGAAT TTTACAGTTA AAAAAAAAAA AAAAAAAAAA AAA 1193
45

(2) INFORMATION FOR SEQ ID NO: 260:

50

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1262 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 260:

60

GAAAAACCCA AAGATGCAGA CAATCTCTTT GAACATGAAT TGGGGGCTCT CAATATGGCT 60

	GCATTACTAC GAAAAGAAGA AAGAGCAAGT CTTCTTAGTA ATCTTGGCCC ATGTTGTAAG	120
	GCGTTGTGCT TCAGACGGGA TTCTGCAATT CGAAAGCAGC TTGTTAAAAA TGAGAAGGGC	180
5	ACCATAAAAC AAGCTTACAC GAGTSCCTCCA ATGGTAGACA ATGAATTACT TCGATTGAGT	240
	CTTCGGTTAT TTAAGCGGAA GACTACTTGC CATGCTCCAG GACATGAAAA GACTGAAGAT	300
10	AATAAACTTT CACAGTCCAG TATCCAACAG GAACTGTGTG TGTCTTAAGA CCGAAGTTCA	360
	ATATGGTATT TTTGGTACTG TCTTCCTTCA GCAGTGCATA TTCTTTTGCA AAGTTCCTTG	420
	GTTTGACAAG CATTAGTGAC AAAGGCAGAA AAGATTTATC AGCCATGCTA AAAGAGTGAA	480
15	GAATTTTGAT CTTTAGAGAC ACTAGTTTTC GCCAACTTAA GATTTTACGT TAATTTTAC	540
	ATAGTATTTC ACACCTCATGC AAAATAATGT GAAAACATCT AGATTTAGTA GTTTATTCTG	600
20	CGCCTTTTGT TAAAACGTAA GATTTTGGAA AATGGTTGTC ACTGCTCTTC CAGCCTATGA	660
	ATATTTTGT GAAATGGAAC CATGGATTTA TGTCTGGATC ATCCATACAG AACCAACAAT	720
	TTTATTCAAA AACAAATGTT TCATCAAAGT AATTGCTCAC ATTGTGCAGT ACTATGTTGT	780
25	ACAGACCACG TGAAAGGGAA TGCTGGTCTA GCTGGCGTGG TATGTTTATA GGCGAATTTC	840
	AGCAGAAGGA AGCCAAAATA GTTTTTCCT TTTGAAAGTT TTTTAAAAAT TATTTTCATGG	900
30	GTCTTTTTTT TAATTAATAT GTGTGCATTG TTACAATGTA TGTGGATGT CTTTGGACCC	960
	TAAATGCTTT TTTTGTATC AGAGATTGTG TACTATTTT ATTTTAAATA AATGTATCTT	1020
	CCCTTTCCTT GTTTTAGATT TACTTTGCTC TTCGTTAATC TTATTCCTGA TGATCTAGAA	1080
35	CATTAGTCAT CAACATTACA TGTTCATGC TTCAGATAIT TTAGTGCTTG TGTCTTATT	1140
	GTTGGACAGC TTAAACAGA GTTGATGGTA CTTCAAATAT AGCTCATTGA TACTTAAGGG	1200
40	CANCTTCCTT GGGATGTGGG CTTTTTGGAA GGAAAAAAT TNCCTCAAG GCAAATCCCA	1260
	GT	1262

45

(2) INFORMATION FOR SEQ ID NO: 261:

(i) SEQUENCE CHARACTERISTICS:

50

- (A) LENGTH: 1179 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 261:

55

GGCAAACTTT CCCCCAANGC TTCGAACTT GCAAGCCGAA ACCTTGAATC GTTAAAAGTT	60
GGGTTCGNC GCGCCCTGG CCCGAAGAAG CGCAATTGGC GTTCCGCGAA CGTTGGCCCT	120
CAACGGCTCG GCAGCCAGCC ATGTCCTGCA CCCAGGACAG CGGCCCTGGG CTACAAGGAC	180

	CTGGACCTCA TCTTCCTGCG CCGACCTGCG CGGGGAAGGG GAGTTTCAGA CTGTGAAGGA	240
5	CGTCGTGCTG GACTGCCTGT TGGACTTCTT ACCCGAGGGG GTGAACAAAG AGAAGATCAC	300
	ACCACTCAG CTCAAGGAAG CTTATGTGCA GAAAATGGTT AAAGTGTGCA ATGACTCTGA	360
	CCGATGGAGT CTTATATCCC TGTCAAACAA CAGTGGCAAA AATGTGGAAC TGAAATTGT	420
10	GGATTCCCTC CGGAGGCAGT TTGAATTCAG TGTAGATTCT TTTCAAATCA AATTAGACTC	480
	TCTTCTGCTC TTTTATGAAT GTTCAGAGAA CCAATGACT GAGACATTTC ACCCCACAAT	540
15	AATCGGGGAG AGCGTCTATG GCGATTTCGA GGAAGCCTTT GATCACCTTT GTAACAAGAT	600
	CAITGCCACC AGGAACCCAG AGGAAATCCG AGGGGAGGC CTGCTTAAGT ACTGCAACCT	660
	CTTGGTGAGG GGCTTTAGGC CCGCCTCTGA TGAAATCAAG ACCCTTCAAA GGTATATGTG	720
20	TTCCAGGTTT TTCATCGACT TCTCAGACAT TGGAGAGCAG CAGAGAAAAC TGGAGTCTTA	780
	TTTGCAGAAC CACTTTGTGG GATTGGAAGA CCGCAAGTAT GAGTATCTCA TGACCCCTCA	840
25	TGGAGTGGTA AATGAGAGCA CAGTGTGCCT GATGGGACAT GAAAGAAGAC AGACTTTAAA	900
	CCTTATCACC ATGCTGGCTA TCCGGGTGTT AGCTGACCAA AATGTCATT CTAATGTGGC	960
	TAATGTCACT TGCTATTACC AGCCAGCCCC CTATGTAGCA GATGCCAACT TTAGCAATTA	1020
30	CTACATGCA CAGGTTTCAGC CAGTATTACG GTGCCAGCAA CAGACCTACT CCACTTGGCT	1080
	ACCCTGCAAT TAAGAATCAT TTAATAATGT CCTGTGGGGA AGCCATTTC GACAAGACAG	1140
35	GAGAGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAGAGC	1179

40 (2) INFORMATION FOR SEQ ID NO: 262:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1162 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 262:

50	GGCAAACTTT CCCCCAANGC TTCGAAACTT GCAAGCCGAA ACCTTGAATC GTTAAAAGTT	60
	GGGTTCGNC GCGGCCCTGG CCCGAAGAAG CGCAATTGGC GTTCCGCGAA CGTTGGCCCT	120
	CAACGGCTCG GCAGCCAGCC ATGTCCTGCA CCCAGGACAG CGGCCCTGGG CTACAAGGAC	180
55	CTGGACCTCA TCTTCCTGCG CCGACCTGCG CGGGGAAGGG GAGTTTCAGA CTGTGAAGGA	240
	CGTCGTGCTG GACTGCCTGT TGGACTTCTT ACCCGAGGGG GTGAACAAAG AGAAGATCAC	300
60	ACCACTCAG CTCAAGGAAG CTTATGTGCA GAAAATGGTT AAAGTGTGCA ATGACTCTGA	360

	CCGATGGAGT CTTATATCCC TGTCAAACAA CAGTGGCAAA AATGTGGAAC TGAAATTTGT	420
	GGATTCCTC CGGAGGCAGT TTGAATTCAG TGTAGATTCT TTTCAAATCA AATTAGACTC	480
5	TCTTCTGCTC TTTTATGAAT GTTCAGAGAA CCCAATGACT GAGACATTTC ACCCCACAAT	540
	AATCGGGGAG AGCGTCTATG GCGATTTCOA GGAAGCCTTT GATCACCTTT GTAACAAGAT	600
	CATTGCCACC AGGAACCCAG AGGAAATCCG AGGGGGAGGC CTGCTTAAGT ACTGCAACCT	660
10	CTTGGTGAGG GGCTTTAGGC CCGCCTCTGA TGAAATCAAG ACCCTTCAAA GGTATATGTG	720
	TTCCAGGTTT TTCATGACT TCTCAGACAT TGGAGAGCAG CAGAGAAAAC TGGAGTCCTA	780
15	TTTGCAGAAC CACTTTGTGG GATTGGAAGA CCGCAAGTAT GAGTATCTCA TGACCCTTCA	840
	TGGAGTGGTA AATGAGAGCA CAGTGTGCCT GATGGGACAT GAAAGAAGAC AGACTTTAAA	900
	CCTTATCACC ATGCTGGCTA TCCGGGTGTT AGCTGACCAA AATGTCATT CTAATGTGGC	960
20	TAATGTCACT TGCTATTACC AGCCAGCCCC CTATGTAGCA GATGCCAACT TTAGCAATTA	1020
	CTACATTGCA CAGGTTACG CAGTATTAC GTGCCAGCAA CAGACCTACT CCACTTGGCT	1080
25	ACCCTGCAAT TAAGAATCAT TTAAAAATGT CCTGTGGGGA AGCCATTTC GACAAGACAG	1140
	GAGAGAAAAA NAANGAAAAG AG	1162

30

(2) INFORMATION FOR SEQ ID NO: 263:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 735 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 263:

	CGGGCTGGGT ATTTGCCTCG CACCATGGCG CCCAAGGGCA AAGTGGGCAC GAGAGGGAAG	60
	AAGCAGATAT TTGAAGAGAA CAGAGAGACT CTGAAGTTCT ACCTGCGGAT CATACTGGGG	120
45	GCCAATGCCA TTTACTGCCT TGTGACGTTG GTCTTCTTTT ACTCATCTGC CTCATTTTGG	180
	GCCTGGTTGG CCTTGGGCTT TAGTCTGGCA GTGTATGGGG CCAGCTACCA CTCTATGAGC	240
50	TCGATGGCAC GAGCAGCGTT CTCTGAGGA TGGGGCCCTG ATGGATGGTG GCACGAGCTC	300
	AACATGGAGC AGGGCATGGC AGAGCACCTT AAGGATGTGA TCCTACTGAC AGCCATCGTG	360
	CAGGTGCTCA GCTGCTTCTC TCTCTATGTC TGGTCTTCT GGCTTCTGGC TCCAGGCCGG	420
55	GCCCTTTACC TCCTGTGGGT GAATGTGCTG GGCCCTGGT TCACTGCAGA CAGTGGCACC	480
	CCAGCACCAG AGCACAATGA GAAACGGCAG CGCCGACAGG AGCGGCGGCA GATGAAGCGG	540
60	TTATAGCCAT TGACATTGTG GCCACAGGCC ACTGGCCCTG GGTGGCTCTG TCAGGGTGCA	600

5 CAGCCCCCTCA TGCCTGGAGC AATGAGGGTC TAGTCCAGGG GCCAAAAGCA GTCTGAGGTA 660
TTGGGTATAC TTATACTCTA TAGGGTCGTT GAATAAATGG CTTAGAATGT GAAAAAAAAA 720
AAAAAAAAAA ATTTT 735

10

(2) INFORMATION FOR SEQ ID NO: 264:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 783 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 264:

20

AAGTGCATGA GCTGCCGATG TGGTGCTTAG TGATTGCGGT TTCGGTCGCT CTCCCGTGTT 60
TCCCGGGCTG GGTATTTGCC TCGCACCATG GCGCCCAAGG GCAAAGTGGG CACGAGAGGG 120
25 AAGAAGCAGA TATTTGAAGA GAACAGAGAG ACTCTGAAGT TCTACCTGGG GATCATACTG 180
GGGGCCAATG CCATTTACTG CCTGTGACG TTGGTCTTCT TTTACTCATC TGCCTCATTT 240
TGGGCCTGGT TGGCCTGGG TTTAGTCTGG CAGTGTATGG GGCCAGCTAC CACTCTATGA 300
GCTCGATGGC ACGAGCAGCG TTCTCTGAGG ATGGGGCCCT GATGGATGGT GGCATGGACC 360
TCAACATGGA GCAGGGCATG GCAGAGTGAG TGTCCCCAC CGCCAGCCCA GGCACCTTAA 420
35 GGATGTGATC CTACTGACAG CCATCGTGCA GGTGCTCAGC TGCTTCTCTC TCTATGTCTG 480
GTCCCTCTGG CTCTCTGCTC CAGGCCGGGC CCTTTAOCCT CTGTGGGTGA ATGTGCTGGG 540
CCCCTGGTTC ACTGCAGACA GTGGCACCCC AGCACCAGAG CACAATGAGA AACGGCAGCG 600
40 CCGACAGGAG CGGCGGCAGA TGAAGCGGTT ATAGCCATTG ACGATTTKGC SACNRGCCAC 660
TGGCCTGGG TGGCTCTGTC AGGGTGCACA GCCCCTCATG CCTGGAGCAA TGAGGGTCTA 720
45 GTCCAGGGGC CAAAAGCAGT CTGAGGTATT GGTATACTT ATACTCTATA GGGTCGTGA 780
ATA 783

50

(2) INFORMATION FOR SEQ ID NO: 265:

(i) SEQUENCE CHARACTERISTICS:

55

- (A) LENGTH: 1638 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 265:

	GGCACGAGGC GCGGCGAGCG GTGGGGGCGG CGCCCCCGG CGGGAGCCGT NCCCTTTCCC	60
5	GTCGGGGAGC GCGGGGYCGG GGYCCAGGG ANCCCGGMC ACGGAGAGCG GGAAGAGGAT	120
	GGATTGCCCG GCCCTCCCC COGGATGGAA GAAGGAGGAA GTGATCCGAA AATCTGGGCT	180
	AAGTGCTGGC AAGAGCGATG TCTACTACTT CAGTCCAAGT GGTAAAGAGT TCAGAAGCAA	240
10	GCCTCAGTTG GCAAGGTACC TGGGAAATAC TGTGTATCTC AGCAGTTTTG ACTTCAGAAC	300
	TGGAAAGATG ATGCCTAGTA AATTACAGAA GAACAAACAG AGACTGCGAA ACGATCCTCT	360
15	CAATCAAAAT AAGGTAAC CAGACTTGAA TACAACATTG CCAATTAGAC AAACAGCATC	420
	AATTTTCAAA CAACCGGTAA CCAAAGTCAC AAATCATCCT AGTAATAAAG TGAAATCAGA	480
	CCCACAACGA ATGAATGAAC AGCCACGTCA GCTTTTCTGG GAGAAGAGGC TACAAGGACT	540
20	TAGTGATCA GATGTAACAG AACAAATTAT AAAAACCATG GAACTACCCA AAGGTCTTCA	600
	AGGAGTTGGT CCAGGTAGCA ATGATGAGAC CCTTTTATCT GCTGTTGCCA GTGCTTTGCA	660
25	CACAAGCTCT GCGCCAATCA CAGGCAAGT CTCCGCTGCT GTGGAAAAGA ACCCTGCTGT	720
	TTGGCTTAAC ACATCTCAAC CCTCTGCAA AGCTTTTATT GTCACAGATG AAGACATCAG	780
	GAAACAGGAA GAGCGAGTAC AGCAAGTACG CAAGAAATTG GAAGAAGCAC TGATGCGAGA	840
30	CATCTGTGCG CGAGCTGCTG ATACAGAAGA GATGGATATT GAAATGGACA GTGGAGATGA	900
	AGCCTAAGAA TATGATCAGG TAACCTTCCA CCGACTTTCC CCAAGAGAAA ATTCTTAGAA	960
35	ATTGAACAAA AATGTTTCCA CTGGCTTTTG CCTGTAAGAA AAAAAATGTA CCCGAGCACA	1020
	TAGAGCTTTT TAATAGCACT AACCAATGCC TTTTATAGATG TATTTTTGAT GTATATATCT	1080
	ATTATTCAAA AAATCATGTT TATTTTGAGT CCTAGGACTT AAAATTAGTC TTTTGTAAATA	1140
40	TCAAGCAGGA CCTAAGATG AAGCTGAGCT TTTGATGCCA GGTGCAATCT ACTGGAAATG	1200
	TAGCACTTAC GTAAAACATT TGTTCCTCCC ACAGTTTAA TAAGAACAGA TCAGGAATTC	1260
45	TAAATAAATT TCCAGTTAA AGATTATTGT GACTTCACTG TATATAAACA TATTTTATA	1320
	CTTTATTGAA AGGGACACC TGTACATTCT TCCATCRICA CTGTAAAGAC AAATAAATGA	1380
	TTATATTAC AGACTGATTG GAATTCCTTC TGTGAAAAG CACACACAAT AAAGAACCCC	1440
50	TGTTAGCCT TCCTCTGATT TACATTCAAC TCTGATCCCG GGGCCTTAGG TTTGACATGG	1500
	GAGGTGGGAG GAAGATAGCG CATATATTG CAGTATGAAC TATGCTCT GGGACGTTGT	1560
55	GAGGAATTGT GCTTTCACCA GAATTTCTAA GGATTTCTGG CTTAAATATC ACCTAGCCTG	1620
	TGGTAATTTT TTTTCCT	1638

(2) INFORMATION FOR SEQ ID NO: 266:

(i) SEQUENCE CHARACTERISTICS:

5

- (A) LENGTH: 1455 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 266:

10

CGTGGTACT	GCCATGCAGG	TACGGGGTCC	GGAATGCCA	GGGTGACCC	ACGGTCCGC	60
TCAGTTGGCA	AGGTACCTGG	GAAATACTGT	TGATCTCAGC	AGTTTGTACT	TCAGAACTGG	120
AAAGATGATG	CCTAGTAAAT	TACAGAAGAA	CAAACAGAGA	CTGCGAAACG	ATCCTCTCAA	180
TCAAAATAAG	GGTAAACCAG	ACTTGAATAC	AACATTGCCA	ATTAGACAAA	CAGCATCAAT	240
TTTCAAACAA	COGGTAACCA	AAGTCACAAA	TCATCCTAGT	AATAAAGTGA	AATCAGACCC	300
ACAACGAATG	AATGAACAGC	CACGTCAOCT	TTTCTGGGAG	AAGAGGCTAC	AAGGACTTAG	360
TGCATCAGAT	GTAACAGAAC	AAATTATAAA	AACCATGGAA	CTACCCAAAG	GTCTTCAAGG	420
AGTTGGTCCA	GGTAGCAATG	ATGAGACCCT	TTTATCTGCT	GTTGCCAGTG	CTTTGCACAC	480
AAGCTCTGCG	CCAATCACAG	GGCAAGTCTC	CGCTGCTGTG	GAAAAGAACC	CTGCTGTTTG	540
GCTTAACACA	TCTCAACCCC	TCTGCAAAGC	TTTTATTGTC	ACAGATGAAG	ACATCAGGAA	600
ACAGGAAGAG	CGAGTACAGC	AAGTACGCAA	GAAATTGGAA	GAAGCACTGA	TGGCAGACAT	660
CTTGTCGCGA	GCTGCTGATA	CAGAAGAGAT	GGATATTGAA	ATGGACAGTG	GAGATGAAGC	720
CTAAGAATAT	GATCAGGTAA	CTTTCGACCG	ACTTTCCTCA	AGAGAAAATT	CCTAGAAATT	780
GAACAAAAT	GTTTCCACTG	GCTTTTGCCT	GTAAGAAAAA	AAATGTACCC	GAGCACATAG	840
AGCTTTTAA	TAGCACTAAC	CAATGCCTTT	TTAGATGTAT	TTTTGATGTA	TATATCTATT	900
ATTCAAAAAA	TCATGTTTAT	TTTGAGTCTT	AGGACTTAAA	ATTAGTCTTT	TGTAATATCA	960
AGCAGGACCC	TAAGATGAAG	CTGAGCTTTT	GATGCCAGGT	GCAATCTACT	GGAAATGTAG	1020
CACTTACGTA	AAACATTTGT	TTCCCCCACA	GTTTAAATAA	GAACAGATCA	GGAATTCTAA	1080
ATAAAATTCC	CAGTTAAAGA	TTATTGTGAC	TTCAGTGTAT	ATAAACATAT	TTTTTACTTT	1140
TATTGAAAGG	GGACACCTGT	ACATTCTTCC	ATCCTCACTG	TAAAGACAAA	TAAATGATTA	1200
TATTCACAGA	CTGATTGGAA	TTCTTTCTGT	TGAAAAGCAC	ACACAATAAA	GAACCCCTCG	1260
TTAGCCTTCC	TCTGATTTAC	ATTCAACTCT	GATCCCGGGG	CCTTAGGTTT	GACATGGGAG	1320
GTGGGAGGAA	GATAGCGCAT	ATATTTGCAG	TATGAACTAT	TGCTCTGGG	ACGTTGTGAG	1380
GAATTGTGCT	TTCAACAGAA	TTTCTAAGGA	TTTCTGGCTT	AAATATCACC	TAGCCTGTGG	1440
TAATTTTTTT	TCCCT					1455

60

(2) INFORMATION FOR SEQ ID NO: 267:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1086 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 267:

CGCCTGCAGT ACCGGTCCGG AATTCCCGGG TCGACCCACG CGTCGCTGAC CCAGGAGAAG 60
CTGCCCTGTCT ACATCAGCCT GGGCTGCAGC GCGCTGCCGC CGCGGGGCCG GCAGCTGAAC 120
TATGTGCTCT TCAGGGCGGG CACCGTGTG CATTCATCTT TGTACCCCCA GCATCTAGCA 180
GTGTTGGCAT GTAGTAGGCA CTCAAGAAAT GTGTGTTGAA TGAACGATGC CTGTGACAAG 240
CAAGCGGACT TTATTCCTTC CTGACCCCTG CTCTATGAC ACACCTCCTC CTGACTGCCA 300
CTGTCACTCC TTCAGAGCAG AACTCCTCTA GGGAACTGG ATGGGAAACA GCCATGGCCA 360
AGGACATCCT GGGTGAAGCA GGGCTACACT TTGATGAACT GAACAAGCTG AGGGTGTGTTG 420
ACCCAGAGGT TACCCAGCAG ACCATAGAGC TGAAGGAAGA GTGCAAAGAC TTTGTGGACA 480
AAATTGGCCA GTTTCAGAAA ATAGTTGGTG GTTTAATTGA GCTTGTGAT CAACTTGCAA 540
AAGAAGCAGA AAATGAAAAG ATGAAGGCCA TCGTGCTCG GAACTTGCTC AAATCTATAG 600
CAAAGCAGAG AGAAGCTCAA CAGCAGCAAC TTCAAGCCCT AATAGCAGAA AAGAAAATGC 660
AGCTAGAAAG GTATCGGGT GAATATGAAG CTTTGTGTAA AGTAGAAGCA GAACAAAATG 720
AATTTATTGA CCAATTATT TTTCAGAAAT GAACTGAAA TTTCGCTTTT ATAGTAGGAA 780
GGCAAAACAA AAAAAAGCCT CTCAAAACCA AAAAAACCTC TGTAGCATTC CAGCGGCTTG 840
ACCAATGACC TATGTCACAA GAGTGCCGT GTAAGGAATG CAGCCCCCTG AAGACAGCAC 900
TACAAGTCTG GGGGAGCCAG TTTTAACATC AGTGCACAGC TGCTGCTGGT GGCCCTGCAG 960
TGTAAGTCTT CACCTCTTAT GCTTAGTTGG AACTAAGCAG TTTGTAACT TTCATCCTTT 1020
TTTTTGTAAG TTCACAAAGC TTTGGAAGGA GARGCAATAA ATTTTGTGTT TCNAAATGGC 1080
TTGATG 1086

(2) INFORMATION FOR SEQ ID NO: 268:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1003 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 268:

5 GGCAOGGGAG CAGCOGGGCT GGTCTGCTG CGAGCCGGCG GCCCGGAGTG GGGGGGGGA 60
 GCAAACATGA ACGTTGGAGT TGCCACAGT GAAGTGAATC CAAATACCG TGTCATGAAC 120
 AGCCGGGGTA TGTGGCTGAC ATATGCATTG GGAGTTGGCT TGCTTCATAT TGTCTTACTC 180
 10 AGCATTCCTT TCCTCAGTGT TCCTGTGCT TGGACTTTAA CAAATATTAT ACATAATCTG 240
 GGGATGTACG TATTTTTGCA TGCAGTGAAA GGAACACCTT TCGAAACTCC TGACCAGGGT 300
 15 AAAAGCAAGG CTCCTAATC ATTGGAACA ACTGGACTAT GGAGTACAGT TTACATCTTC 360
 ACGGAAGTTT TTCACAATTT CTCCAATAAT TCTATATTTT CTGGCAAGTT TCTATACGAA 420
 GTATGATCCA ACTCACTTCA TCCTAAACAC AGCTTCTCTC CTGAGTGTAC TAATTCCCAA 480
 20 AATGCCACAA CTACATGGTG TTCGGATCTT TGGAAATTAAT AAGTATTGAA ATGTTTIGAA 540
 ACTGAAAAAA AATTTTACAG CTA CTGAATT TCTTATAAGG AAGGAGTGGT TAGTAACTG 600
 25 CACTGTTTCT CTGATAATGT GAAATGAGAA GTATTTACAT TGGAGGGCCA ATGGCTGGTC 660
 CTTCAAGTGC TGTTTTGAAG TGCAGATTTC CATTAATGA TGCTCTGTT TAATACACCT 720
 GGTACATTTT TGAAGAGGGG CTTTATAAGC AGGCTGGGCA GGCCAGCTT ATAAGTTAAA 780
 30 GGGCATCACA GTGAGGGTGT AGTAGATAAA TTCAAGGAAA TAAGAGATTT GTAAGAACT 840
 AGGACCAGCT TAACTTATAA TGAATGGGCA TTGTGTTAAG AAAAGAACAT TTCCAGTCAT 900
 35 TCAGCTGTGG TTATTTAAAG CAGACTTACA TGTAACCGG AATCTCTCT ATACAAGTTT 960
 ATTAAAGATT ATTTTTATTA CCGTAAAAAA AAAAAAAAA AAA 1003

40

(2) INFORMATION FOR SEQ ID NO: 269:

(i) SEQUENCE CHARACTERISTICS:

45

- (A) LENGTH: 1234 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 269:

ATCAGCATCT ACAAGTAGCA TATTTTGGAT GGTGTTGTG TGCTACTTCA AAGTAACTAG 60
 GAAAAAATAA TCCTCGCAAC ACAGGTACCT TGTATGTCA GAATTGGGGG TGTTAGGTTG 120
 55 CCAGTGTAT CAGTGTGAT TCATTTTATT ACTTCTTACA GAGCAACAT GAAGTTGGA 180
 GTTGCCACA GTGAAGTGAA TCCAATACC CGTGTATGA ACAGCCGGG TATGTGGCTG 240
 60 ACATATGCAT TGGGAGTTGG CTGCTTCAT ATTGTCTTAC TCAGCATTC CTTCTTCAGT 300

	GTTCCTGTTG CTTGGACTTT AACAAATATT ATACATAATC TGGGGATGTA CGTATTTTTG	360
5	CATGCAGTGA AAGGAACACC TTTCGAACT CCTGACCAGG GTAAAGCAAG GCTCCTAACT	420
	CATTGGGAAC AACTGGACTA TGGAGTACAG TTTACATCTT CACGGAAGTT TTTCACAATT	480
	TCTCCAATAA TTCTATATTT TCTGGCAAGT TTCTATACGA AGTATGATCC AACTCACTTC	540
10	ATCCTAAACA CAGCTTCTCT CCTGAGTGT CTAATTCCTA AAATGCCACA ACTACATGGT	600
	GTTCGGATCT TTGGAATTAA TAAGTATTGA AATGTTTTGA AACTGAAAAA AAATTTTACA	660
15	GCTACTGAAT TTCTTATAAG GAAGGAGTGG TTAGTAACT GCACTGTTTC TSTGATAATG	720
	TGAAATGAGA AGTATTTACA TTGGAGGGCC AATGGCTGGT CCTTCAAGTG CTGTTTTGAA	780
	GTGCAGATTT CCATTAAATG ATGCTCTGT TTAATACACC TGGTACATTT CTGAAGAGGG	840
20	GCTTTATAAG CARGCTGGGC AGGCCAGCT TATAAGTTAA AGGGCATCAC AGTGAGGGTG	900
	TAGTAGATAA ATTCAAGGAA ATAAGAGATT TGTAAGAAAC TAGGACCAGC TTAACCTATA	960
25	ATGAATGGGC ATTGTGTTAA GAAAAGAACA TTCCAGTCA TTCAGCTGTG GTTATTTAAA	1020
	GCAGACTTAC ATGTAAACCG GAATCCTCTC TATACAAGTT TATTAAAGAT TATTTTTATT	1080
	ACCTACATA TTTCKCTGT TTTATGTAAG YGGAIGTATA TCCTCTTGTT TTATACAAGC	1140
30	CAGTCCAC TTATGAGGGT ACTTTTTTGG TTTTGCTGGG CTTAATATTG TGTATTGGTC	1200
	AATGAGGCCA TTTTACANT TATTAACGTT ACAG	1234

35

(2) INFORMATION FOR SEQ ID NO: 270:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 574 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 270:

	NGAGGTGCGT TCTGAGCCGT CTGTCTGCG CCAAGATGCT TCAAAGTATT ATTAAAAACA	60
	TATGGATCCC CATGAAGCCC TACTACACCA AAGTTTACCA GGAGATTGG ATAGGAATGG	120
50	GGCTGATGGG CTTTCATGTT TATAAAATCC GGGCTGCTGA TAAAAGAAGT AAGGCTTTGA	180
	AAGCTTCAGC GCCTGCTCCT GGTCACTACT AACCAGATTT ACTTGGAGTA CATGTGAAAG	240
55	AAAACGTCAG TCTGCCTGTA AATTTACGCA AGCCGTGTTA GATGGGAGC GTGGAACGTC	300
	ACTGTACACT TGTATAAGTA CCGTTTACTT CATGGCATGA ATAAATGGAT CTGTGAGATG	360
60	CACTGCTACC TGGTACTGCT TTCAGTGTGT TCCCCCTCAG CCTCCGGCG TGTCAGGCAT	420

	ACTCTGAGTA GATAATTGT CATGCAGCGC ATGCAATCAG AATCTCACTG AGCCACCCAT	480
	CATTGTGAAA TAATTACCTC AGTTGTACAG GACTTGGTGA TCAGGATCCA GGCACCTACT	540
5	TGTATTCTAC TGCTCAATAA ACGTTTATTA AACT	574
10	(2) INFORMATION FOR SEQ ID NO: 271:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 1731 base pairs	
	(B) TYPE: nucleic acid	
15	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 271:	
20	GCTGCAAGGT GCGCCTCGTG CCGCTGCAGA TCCAGCTCAC TACCCCTGGGA AATCTTACAC	60
	CTTCAAGCAC TGTGTTTTTC TGCTGTGATA TGCAGGAAAG GTTCAGACCA GCCATCAAGT	120
25	ATTTTGGGGA TATTATTAGC GTGGACAGA GATTGTGCA AGGGGCCCGG ATTTTAGGAA	180
	TTCTGTATAT TGTAAACAGAA CAATACCCTA AAGGTCTTGG GAGCACGGTT CAAGAAATTG	240
	ATTTAACAGG TGTAAACTG GTACTTCCAA AGACCAAGTT TTCAATGGTA TTACCAGAAG	300
30	TAGAAGCGGC ATTAGCAGAG ATTCCCGGAG TCAGGAGTGT TGTATTATTT GGAGTAGAAA	360
	CTCATGTGTG CATCCAACAA ACTGCCCTGG AGCTAGTTGG CCGAGGAGTC GAGGTTTACA	420
35	TTGTTGCTGA TGCCACCTCA TCAAGAAGCA TGATGGACAG GATGTTTGCC CTCGAGCGTC	480
	TCGCTCRARC CNGGGATCAT AGTGACCACG AGTGNAGGCT GTTCTGCTTC AGCTGGTAGC	540
	TGATAAGGAC CATCCAAAAT TCAAGGAAAT TCAGAATCTA ATTAAGGCGA GTGCTCCAGA	600
40	GTCGGGCTCG CTTTCCAAAG TATAGGACAT TTGAAGAACT GGTATGCTAC TCACTGGTGA	660
	AGGACAGTCA GGTGAAGGAC TGTAAGCCCA CACAAGCTCT TCTTATCTCT ACTAGAATTA	720
45	AAATGTTAAG TCAAAAACGG CTCCTTTTTT GCGCCTCCTA GTGAACCTAA CCAGCTAGAC	780
	CATTTGAGTA CCAGCATTTA GTTACAAACG TCAAAGGCTT CCGGTGCTGC TTACCTTCCT	840
	TTTTTGTTAA TGTGCTTTTA TTTATTAAAA AAAATTACAA TGAAGATGCC TGTPTTGTCT	900
50	CTACTGTGTA CTCTGATCGT ATCTTTCCAA AGTGCAGACT CTGTGAAGT TTTCTTAAAT	960
	TGTTCACTTT AAAGAAAATG ACGTACCAAC AATGATTTGG CTTTTATATT ACTGTAAGAT	1020
55	GTTATAATGT TAATGTGGAT GTAGTGCTTT TACTTTACAG ATGATGGA ATAAGATTAT	1080
	TGCATATGAA TTTACCCACA GGACTCTGAA TCATGTTACC CACTCCCTC ACAATGTTGT	1140
	CCACTTAGTG AGTTGCATTG ATCTATCCGT ACCAAATGAT GTTGAATAAT TACATATCTT	1200
60	TCTKGACTAT ACTGATTTCT TATTTTGGTC ACTATTACTA AATCTCTGTT AATATTCTCT	1260

5 CTTTAACTG AAAAGGGATG GGATAGAAGG GTTTCGAATG OCATATTATT GGTGGAGGGC 1320
 TGTTTTAACTG TCTTTGAAGT ATGGCTTGCT GAATATCTTT ACCAACATCT TGAATATATA 1380
 TTCTAGTGTG CACAAGATTT AGCAAAAAGA TAAAGCTTGG GTGGAATATC ATTTTAAAAT 1440
 GTTCATGTTT TGTCTATAT TTTCTTCACC TACTCTCCAA ATATGTGAAT GCAAAAAGTC 1500
 10 TCAGTAATGA TTTGGTAGTA TTAATTTTGT GGTTCATGTT TCTCTTCGAT AAATTTATTT 1560
 TCATTAAATA CTTRTTAGAG GGTTTTGAAA TGTTTTTCAA ATATGTGAAA TGTGAAACTG 1620
 15 CTGCTTTTTA TATTAAAGTA ATTAAAGAAA ATGTATGTG ATTGAAATTA TTTGNCCTC 1680
 CACAAGATGG CTCTATGAGT ATTCTTCCAG GGATTCTAAT ATTTATTTAA G 1731

20

(2) INFORMATION FOR SEQ ID NO: 272:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1320 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 272:

CTGCTTAGGA AGAGAAGGTC AGAGTTCGCG GGGGCAGAGG CATTCCTTGCC GCTGGCCCAG 60
 TCACTATGTA GTGGAGGGGC AGACACCCTC CCGCAAATTC TGAAGGTTT TTAGTCTCGA 120
 35 CTAGGGCAGT AGCCCAGGAC TCCTAGTCGC CGGCTTCAGG TCACTGCCGG CTGAACGGAG 180
 CTGCCGTCGC CATGTTTGGC TGCTTGGTGG CGGGGAGGCT GGTGCAAACA GCTGCACAGC 240
 AAGTGGCAGA GGATAAATTT GTTTTGGACT TACCTGATTA TGAAAGTATC AACCATGTTG 300
 40 TGGTTTTTAT GCTGGGAACA ATCCCATTTT CTGAGGGAAT GGGAGGATCT GTCTACTTTT 360
 CTTATCCTGA TTCAAATGGA ATGCCAGTAT GGMAACTCCT AGGATTGTGTC ACGAATGGGA 420
 45 AGCCAAGTGC CATCTTCAAA ATTTTCAGGTC TTAAATCTGG AGAAGGAAGC CAACATCCTT 480
 TTGGAGCCAT GAATATTGTC CGAACTCCAT CTGTTGCTCA GATTGGAATT TCAGTGGAAAT 540
 TATTAGACAG TATGGCTCAG CAGACTCCTG TAGGTAATGC TGCTGTATCC TCAGTTGACT 600
 50 CATTCACCTA GTTCACACAA AAGATGTTGG ACAATTTCTA CAATTTTGCT TCATCATTG 660
 CTGCTCTCTA GGCCCAGATG ACACCAAGCC CATCTGAAAT GTTCATTCGG GCAAATGTGG 720
 55 TTCTGCAAAT GGTATGAGGC ATTTTCTGTC TCCAATATTA AGGCTTTTTT TAACTGAATA 780
 TCTATTTTGT CTATGAATAT ATTCCTTTTT TGACATTTAA ACATATCTTT TTATGTGAA 840
 60 CATCAGCACT GCATGCCATT AAAGTATGTA CTATAGAGAT CTGATGAGAA ACAGTTCTTA 900

COCTAAATAT TTTGTTATAT TGTCGCCATT ATGAATTTAT AAAGACAGGA AAATATAGTT 960
GCCTATGTTT TAGGGACCAC TATTAAAGCT TATAAATATT TGTTGATTTT CATTTAGAAG 1020
5 TACCATCTAT GAGAGTAGTT TATACTGCAC TGTGTACATG AATGGCTAAT GAATCTATTT 1080
TCCAACTTTC CCGTGTTTTA TAGATATTTT TTTTCACTTT GAGTATCCTA GAGATGGGAG 1140
GATGCCTAGG AAGAGTTTGT TGAGAAGTGG TACCATGGTG TAGCATGGGA GAGCATGGG 1200
10 AATGCACTAG GTTTGAATTT GGCATAATGG TAGCTATGTG ACCCTGAGCA AATTTCCTC 1260
ATCTGCTCAT CTGANGAATG AGGAAATAGG AGTGAATTTG ATNTTTCCTA GGTCCNICTA 1320
15

(2) INFORMATION FOR SEQ ID NO: 273:

- 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 515 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
25 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 273:

CCCTGGAGAG GGGCTGCTGT GCCAGCTTGG GGAGGGTCTG GGATGGGGCT GCCCCTGATG 60
30 GCCCCTGATGT GGAGTACCTT GCCAGCATCT GCTGGGGTGA ACTTTATTTT AGCCCTTCCC 120
TTGTGTGTCT TATGAAGAAC AGAGGAGGGG TGGGCAGGTC AGTGATGTCA GCAGTGAGTA 180
TTCCAGCAC AGCGGCTCTG GAAGAGGCAT GAGGCATTTT TTTAGGAAA TGRTCAATTAT 240
35 TCAGCCAGAA GGCAITCAIT AAGTAAGTCC TGACTTTGTG CCCAGCTCTG TGTATAGGC 300
CCTTGGCGAG ACTCAGGAGG GGCARAGGAC GCTAGKTTKT AGWTAACACG GAACCTCARA 360
40 GGWTATATGG TCCAAGAAGA CCCGGGGGCG GTGAAAACCC TGTGGACTAA TGCTCACGGG 420
AGCCCGAGGT CACACTTTGA CTTTGCTACC ATGGGCTGTG TCTANGNACG TATATATGCT 480
GGTAAATTAT TACAGAGGCA GTCCATGTGC ATTGT 515
45

(2) INFORMATION FOR SEQ ID NO: 274:

- 50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2995 base pairs
(B) TYPE: nucleic acid
55 (C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 274:

60 TGACACCCAT AAGGAATTCA TGAAGAAAGT AGAAGAAAAG CGAGTGGACG TTAACCTAGC 60

	AGTAGCCATG GGAGAAGTCA TCCTGGCTGT CTGCCACCCC GATTGCATCA CAACCATCAA	120
	ACACTGGATC ACCATCATCC GAGCTCGCTT CGAGGAGGTC CTGACATGGG CTAAGCAGCA	180
5	CCAGCAGCGT CTTGAAACGG CCTTGTGAGA ACTGGTGGCT AATGCTGAGC TCCTGGAAGA	240
	ACTTCTGGCA TGGATCCAGT GGGCTGAGAC CACCCTCATT CAGCGGGATC AGGAGCCAAT	300
10	CCCGCAGAAC ATTGACCGAG TTAAAGCCCT TATCGCTGAG CATCAGACAT TTATGGAGGA	360
	GATGACTCGC AAACAGCCTG ACGTGGACCG GGTCAACCAAG ACATACAAA GGAAAAACAT	420
	AGAGCCTACT CACGCGCCTT TCATAGAGAA ATCCCGCAGC GGAGGCAGGA AATCCCTAAG	480
15	TCAGCCAACC CCTCTCCCA TGCCAATCCT TTCACAGTCT GAAGCAAAA ACCCACGGAT	540
	CAACCAGCTT TCTGCCCCCT GGCAGCAGGT GTGGCTGTTA GCACTGGAGC GGCAAAGGAA	600
20	ACTGAATGAT GCCTTGGATC GGCTGGAGGA GTGAAAGAA TTTGCCAACT TTGACTTTGA	660
	TGTCGGAGG AAAAAGTATA TGCGTTGGAT GAATCACAAA AAGTCTCGAG TGATGGATT	720
	CTTCGGGCGC ATTGATAAGG ACCAGGATGG GAAGATAACA CGTCAGGAGT TTATCGATGG	780
25	CATTTTAGCA TCCAAGTCC CCAACCACAA GTTAGAGATG ACTGCTGTGG CTGACATTTT	840
	CGACCGAGAT GGGGATGTT ACATTGATTA TTATGAATTT GTGGCTGCTC TTCATCCCAA	900
30	CAAGGATGCG TATCGACCAA CAACCGATGC AGATAAAATC GAAGATGAGG TTACAAGACA	960
	AGTGGCTCAG TGCAAATGTG CAAAAAGTTC TCAGGTGGAG CAGATCGGAG AGAATAAATA	1020
	CCGGTCTTC CTCGGCAATC AGTTTGGGA TTCTCAGCAG TTGGGGCTGG TCCGTATTCT	1080
35	GCGCAACCGT GATGGTTCC GTTGGTGGAG GATGGATGGC CTTGGATGAA TTTTITAGTA	1140
	AAAATGATCC CTGCCGAGCA CGAGGTAGAA CTAACATTGA ACTTAGAGAG AAATTCATCC	1200
40	TACCAGAGGG AGCATCCAG GGAATGACCC CCTTCGCTC ACGGGGTCGA AGGTCCAAAC	1260
	CATCTTCCCG GGCAGCTTC CCTACTGTT CCAGCTCCAG TGCTAGTCAG AGTAACCACA	1320
	GCTGTACATC CATGCCATCT TCTCCAGCCA CCCCAGCCAG TGAACCAAG GTTATCCCAT	1380
45	CATCAGGTAG CAAGTTGAAA CGACCAACAC CAACTTTTCA TTCTAGTCGG ACATCCCTTG	1440
	CTGGTGATAC CAGCAATTAG TTCTTCCCG GCCTCCACAG GTGCCAAAAC TAATCGGGCA	1500
50	GACCCTAAAA AGTCTGCCAG TCGCCCTGGG AGTCGGGCTG GGAGTCGAGC CGGGAGTCGA	1560
	GCCAGCAGCC GCGAGGAAG TGACGCTTCT GACTTTGACC TCTTAGAGAC GCATTGCTTG	1620
	TTCCGACACT TCAGAAAGCA GCGCTGCAGG GGGCCAAGGC AACTCCAGGA GAGGGCTAAA	1680
55	CAAACTTCC AAAATCCCAA CCATGTCTAA GAAGACCACC ACTGCCCTCC CCAGGACTCC	1740
	AGGTCCCAAG CGATAACACT GTCTAAGCAC CCCCAGCCA CTATCCACTT TGAATCCTGC	1800
60	TCCATACATT GGGTGATAT TTATTCTGAA CGGGAGAAGT TATATTGTTA AAAGTGTA	1860

	AGAATAATTG TGTATGAAG CTGCTTATT TTTTTCCTT TTGTAAGTGA CTATTTTCAT	1920
	GTGAATATTT ATGTAGATAA AATTTCCTC CTGTAACCC TGTAAATGGAT GGGGCCAGA	1980
5	AATGAAATAT TTGAGAAAA CAAGTGAAAA GGTCAAGATA CAAATGTGTA TTAACAAAAA	2040
	AAAAGCCTAT TAATAGGGTT TCTGCCGGT GCAGGGTGT AAACCTGCTT TATCTTTAG	2100
10	GATTATTCCT AAATGCATCT TCTTTATAAA CTGACTTGC TATCTCAGCA AGATAAATTA	2160
	TATTAAAAAA ATAAGAATCC TGCAGTGT T AAGGAATCT TTTTGTGTA ATCACGGACA	2220
	CCTCAATTAG CAAGAACTGA GGGAGGGCT TTTTCCATG TTTAATGTT TGTGATTTT	2280
15	AGCTAAAGAG AGGGAACCTC ATCTAAGTAA CATTTGCACA TGGATACAGC AAAAGGAGTT	2340
	CATTCGAATA CTGCTTTTG ATATTGTTT AGTACTGGT GTTTAAAGGA CAAATAGCTG	2400
20	CTAGAATTCA GGGGTAAATG TAAGTGTTC GAAAACGTCA GAACATTTGG GGTTTTAAAC	2460
	TGATTGTGTG CTCCTATCC AGCCTAGACA CCAGTAACTC TTGTGTTTAC CAGGACCCAG	2520
	ACCCTTGGCA AGGGATAGC TCGTTGGTGA CATGTGAAT TTCAGATTG TTTTATCCAC	2580
25	TTTTTTGCT ATTTATTTAA ATGGTCATC AACTTCCAC AACTGAGGA ATGAATTCCA	2640
	CGAGCCTGTT CTGAAATGT GGACGTAAGA CAAACCGTG CTCGTCCTT AATGGAGTT	2700
30	ACCAGCACAC TTGTTAACA GTCTGTTTG CTTCGCTT TTTTGTGCG TAATAAAGTC	2760
	AACTGACCAA GTGACCATGA AAAGGGCTG TCTGGGCTC CTGTTTTTA GCTGCTGTC	2820
	TTCAGTCCG ACCATGTTG TGTGTGATTA TCTCAATTG TTTAATTGA GGCAGAACT	2880
35	GAAGCTCTAC CAATGAATG TTTAGAAACA AGACACACTT TTGTATTAAA ATTGCTTGCA	2940
	GTAACAAAAA AAAAAAAAAA AAAAAAAAAA AAAAACTCG AGGGGGGCC GGTAC	2995

40

(2) INFORMATION FOR SEQ ID NO: 275:

- 45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1990 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

- 50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 275:

	GGGACCCGCG CGSCTCCCGG GGATGGTGAG CAAGGCGCTG CTGCNCGTG TCTGCCGTCA	60
55	ACCGCAGAGG ATGAAGCTGC TGCTGGGCAT CGCTTGCTG GCCTACGTG CCTCTGTTG	120
	GGGCAACTTC GTTAATATGA GGTCTATCCA GGAAATGGT GAACTAAAA TTGAAGCAA	180
	GATTGAAGAG ATGGTTGAAC CACTAAGAGA GAAATCAGA GATTTAGAAA AAAGCTTTAC	240
60	CCAGAAATAC CCACCACTAA AGTTTTTATC AGAAAAGGAT CGGAAAAGAA TTTTGAWTAA	300

	CAGGAGGGC AGKGTTCGTG GGCTCCCATC TKAACGTACA AACTCATGAT GGACGGCCAC	360
5	GAGGTGACCG TGGTGGACAA TTTCTTCACG GGCAGGAAGA GAAACGTGGA GCACTGGATC	420
	GGACATGAGA ACTTCGAGTT GATTAAACCAC GACGTGTGGG AGCCCTCTA CATCGAGGTT	480
	GACCAGATAT ACCATCTGGC ATCTCCAGCC TCCCTCCAA ACTACATGTA TAATCCTATC	540
10	AAGACATTAA AGACCAATAC GATTGGGACA TTAAACATGT TGGGGCTGGC AAAACGAGTC	600
	GGTGCCCGTC TGCTCCTGGC CTCCACATCG GAGGTGTATG GAGATCCTGA AGTCCACCTT	660
15	CAAAGTGAGG ATTACTGGGG CCACGTGAAT CCAATAGGAC CTCGGGCTG CTACGATGAA	720
	GGCAACGTC TTGCAGAGAC CATGTGCTAT GCCTACATGA AGCAGGAAGG CGTGGAAAGT	780
	CGAGTGGCCA GAATCTTCAA CACCTTTGGG CCACGCATGC ACATGAACGA TGGGCGAGTA	840
20	GTCAGCAACT TCATCCTGCA GCGCTCCAG GGGGAGCCAC TCACGGTATA CGGATCCGGG	900
	TCTCAGACAA GGGCGTTCCA GTACGTCAGC GATCTAGTGA ATGGCCTCGT GGCTCTCATG	960
25	AACAGCAACG TCAGCAGCCC GGTCAACCTG GGAACCCAG AAGAACACAC AATCCTAGAA	1020
	TTTGCTCAGT TAATTAAAAA CCTGTGTGGT AGCGGAAGTG AAATTCAGTT TCTCTCCGAA	1080
	GCCCAGGATG ACCACAGAA AAGAAAACCA GACATCAAAA AAGCAAAGCT GATGCTGGGG	1140
30	TGGGAGCCCG TGGTCCCGCT GGAGGAAGGT TTAAACAAAG CAATTCACCTA CTTCCGTAAA	1200
	GAACTCGAGT ACCAGGCAAA TAATCAGTAC ATCCCCAAAC CAAAGCCTGC CAGAATAAAG	1260
35	AAAGGACGGA CTCGCCACAG CTGAACCTCT CACTTTTAGG ACACAAGACT ACCATTGTAC	1320
	ACTTGATGGG ATGTATTTTT GGCTTTTTTT TGTGTGCTT TAAAGAAAGA CTTTAACAGG	1380
	TGTCATGAAG AACAACTGG AATTTCATTC TGAAGCTTC TTTAATGAAA TGGATGTGCC	1440
40	TAAAAGCTCC CCTCAAAAAA CTGCAGATTT TGCCTTGCAC TTTTGAATC TCTCTTTTAA	1500
	TGTAAATAG CGTAGATGCA TCTCTGCGTA TTTTCAAGTT TTTTATCTT GCTGTGAGAG	1560
45	CATATGTGTG GACTGTGCTT GACAGTTTAA TTTACTGGTT TCTTTGTGAA GCTGAAAAGG	1620
	AACATTAAGC GGGACAAAAA ATGCCGATTT TATTTATAAA AGTGGTACT TAATAAATGA	1680
	GTCGTTATAC TATGCATAAA GAAAAAYCCT AGCAGTATTG TCAGGTGGTG GTGCGCCGGC	1740
50	ATTGATTTTA GGCAGATAA AAGAATCTG TGTGAGAGCT TTATGTTTCT CTTTAAATTC	1800
	AGAGTTTTTC CAAGGTCTAC TTTTGAGTTG CAAACTTGAC TTTGAAATAT TCCTGTGGT	1860
55	CATGATCAAG GATATTTGAA ATCACTACTG TGTTTTGCTG CGTATCTGGG GCGGGGGCAG	1920
	GTTGGGGGGC ACAAAGTTAA CATATCTTG GTTAACCATG GTTAAATATG CTATTTTAAT	1980
60	AAAATATTGA	1990

(2) INFORMATION FOR SEQ ID NO: 276:

5	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 2436 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
10	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 276:	
	AACTTCGCTT AGCTCTCCAG GGTNAAACGG GTGAGNCCTT AAAACAGAA GAGAACAAGA	60
15	TTTAAAGTCC GTTGCAATGA AAATAACAAA CAATATCAAT GTTTAATCA AGGATCTCTT	120
	CCACATTCCT CTTCTTATA AGAGCACAGT AACACTATCC TGGAAACCTG TACAAAAGGT	180
20	TGAGATTGGG CAAAAGAGAG CCAAGTGAAGA TACAACTTCA GGTTCAACCAC CCAAGAAATC	240
	TTCAGCAGGA CCAAAAAGAG ATGCCAGGCA GATTTATAAC CCTCCAGTG GGAAATATAG	300
	CAGCAATTG GCAACTTTA ATTATGAGCA GAGAGGAGCC TTCAGGGGAA GTAGAGGTGG	360
25	CCGAGGTGG GGCACACGAG GAAATCGTAG TCGGGGAAGA CTCTACTGAA TAAGACATCA	420
	GCATTCCTCA GCATTGTCAT GAGCTTAATA TACTTAAATT CTACTACTCA TTGGATTGCC	480
30	GGGGATGTCC CTTTAAACAG ACTGCTGCCT TCAGCTAAAA ACTTAATGTT CTTTATACCT	540
	TTGTATGAT GACCTACTTT TGTAAACAGC CATGGTTGTG TCCAAGGTAA AACCACAGTG	600
	ATATTTTGG ATGCTTTGTC TGCAATCTTG ACTTGTTTT GCAGTATCAT TATTCAGACT	660
35	TCAAATGTG AATCTTTTAA ACATCTTGAT AATTGTGTG TGAGAGCTGT TCATTCTAAA	720
	ATGTAATGAA ATTCACTCTA GTTCTGCTGA TAAAGATCAT CAGTTTGTAA AGGTTACTGA	780
40	TTTTCTCTT CCCTCTTAGT TTTTACCCA ATATATGGAG AAGAGTAATG GTCAATCTTA	840
	ACATTTTGT TTAATGTGTT AATAAAGCTG CTGGGCAGTG GTGCAGCATT CCTACCTAGT	900
	GTCATAAAG CAAAATACCT ACATAGCTTT CTTAAATAT AGGAATGACA TTACATTTTT	960
45	AGGAGAAAGT AAGTTGCTTT GCACCGCCTA CTTAATCTTT TTCCATATAT TGTGATACAA	1020
	ACTTTTGAAT ATGGAATCTT ACTATTGAA TAGAAATGTG TATGTATAAT ATACATACAT	1080
50	ACATAAGCAT ATATGTGTG GTGTGTGTG ATATATATAT ATATGCATGC TGTGAAACTT	1140
	GACTACACAA CATAAATCAC TTTTAAATT CCAGGAACGG GTAGTCTGAC ACGGTGATTA	1200
	TCCTTTGAG GCTGAATCCG TTATTAACCT GTTATTTAGG TTTTACTCC CAGTAGCAAG	1260
55	GGATTCTAAG TTAGTTGCAC TTACATGATT ATTGTTATTT AAACTAAGA ATAAAGGCTG	1320
	CATTTTCAAA GATAAATGG AATTGCTGTT GGTGAAATAA CAACCAAAT ACTGAATCTG	1380
60	ATGTACATAC AGGTTTCTAC AGGAAGAGAT GGTATAATTT ACAATTTGGA GATTTAATAA	1440

	CCAGGGCTAC CCAGAAAAAG TGACTTGATA ACATGGTACC AATAAGTAAG GGATGCTCTC	1500
	TCGGTTTGCT TTGCCACTT TCAAGATTTT AACTTCTCAG GTTATTAATC AAAATTATTG	1560
5	TATAAGTTAG CCAATAGAAT TTTTAGGTTA AAACAACAGA TGGGGGGTTT GTGGAGTGT	1620
	TAATGTCATG GGCATTTTTA GTAGCATAGA CCTTTTGTTC TGCATTTGAA TGTTCGTAT	1680
10	ATTTTGTGTT CACAGTTAAT CTTCCTCCC CAAGTTTGCT ATTCAAATCA ACTGCCTGAA	1740
	TGACATTTCT AGTAGTCTGA TGTATTTTTC TGAGGAATAG TTTGTGATTC CAATGCAGGT	1800
	GTCTTCATTA CCATTACCTC TACACTGCAG AAGAAGCAAA ACTCCTTTAT TAGAATTACT	1860
15	GCACATGCT ATGGGGAAAA TAGTCTGAA AGGCTAGAAT GATACAAGTG AGCAAAAGTT	1920
	GGTCAGCTTG GCTATGGAGT GGTGGCAATA ATCTCTAAAC ATTCCAAAAG ACCATGAGCT	1980
20	GAACCTAAAC TCCCTTGGA TCTGAACAAA GGAATATAAA ATTGCCATTT GAAAACGTAC	2040
	CAGCTAATCT GGACCTCAGA GATAGATCAG CCAGTGGCCC AAAGCCATTT CAAGTACAGA	2100
	AATTATAGAG ACTACAGCTA AATAAATTTG AACATTAAAT ATAATTTTAC CACTTTTGT	2160
25	CTTTATAAGC ATATTTGTAA ACTCAGAACT GAGCAGAAGT GACTTTACTT TCTCAAGTTT	2220
	GATACTGAGT TGACTGTTCC CTATCCCTC ACCCTTCCC TTCCCTTTC TAAGGCAATA	2280
30	GTGCACAACT TAGGTTATTT TTGCTTCCGA ATTTGAATGA AAAACTTAAT GCCATGGATT	2340
	TTTTTCTTTT GCAAGACACC TGTTTATCAT CTGTGTTTAA TGTAATGTC CCCTTATGCT	2400
	TTTGAAATAA ATTTCTTTT GTAATTTTAA AAAAAA	2436

35

(2) INFORMATION FOR SEQ ID NO: 277:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 782 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 277:

	GCCACTGACT TCTCCACCC TTCTGTCTCC CCCATAATAG TTTATTGGT TGGTCTGGAC	60
50	TCACTTGTTG CCTTTRATTA AATTCTTAAG GGGCTGAAG AAGACATTTT TACTGCAGAG	120
	GGTTAGAGGC ACTTGAGCAA GGCCCCACA TCCCACTCT GGGAGTTGTG GTGGGAGGAG	180
55	GCACTTCTGG GGGATAGGAC CAGACAAGAT AACAGGAGCT CACATGGNAA GCAGAAGCTG	240
	TGACAAGTTT AGTAGTCCCA AAATGGGTTA TATCCCTTCC CCCTTTACAT CAGAATCTTG	300
	TGAAATGGGA AAACAACAGA AGGAGGGGAT CAAAGATAGC TGATCTCACA TGCTTCCCAG	360
60	GCAGGGCARG GGTGGGAGTC AAACCGGGT GACAGGTGGG TGGAGAGCCC TGTTTGAGGT	420

5 TGTCGCTGAT CCTCTCTGG TATTAGTTT TCCCTGGGA GCAGGAAGCC CTAGGAAGAG 480
 GGGACTGCAG GGTCCCCRGG GGATCTTTCC TCCCTCCCCCT GCATGAGGCA GAGGCAAGCT 540
 GCCTGCCAAC CCCCTCCCTC AAGGAATGGC CTTGCCCAGG AATGCCCAACC ACACATACCC 600
 TCTCTTTTT TTCTAGTCAA ACTCTTGTTT ATTCTTTGGC TTGCTCCCT CCTTCTCCC 660
 10 CTCTCAACCT TTAATTCTGA TTCTATTTC ATGGAATTG GGATTGAAGT TAAACTACAA 720
 CAGTCCCGCC AACACCAAGT CTTGCAGGAA AAAAATACAA AGAAATTAA CAAAAAAAAA 780
 AA 782
 15

20 (2) INFORMATION FOR SEQ ID NO: 278:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 961 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 278:

30 GAGTTCGGC TGGAGACCCG TGCTCTGGC CGCGCCTTC ACCATGGCCT CGGCAGAGCT 60
 GGACTACACC ATCGAGATCC CGGATCAGCC CTGCTGGAGC CAGAAGAACA GCCCCAGCCC 120
 AGGTGGGAAG GAGGCAGAAA CTCGGCAGCC TGTGGTGATT CTYTTGGGCT GGGGTGGCTG 180
 35 CAAGGACAAG AACCTTGCCA AGTACAGTGC CATCTACCAC AAAAGGGGCT GCATCGTAAT 240
 CCGATACACA GCCCCGTGGC ACATGGTCTT CTTCTCGAG TCACTGGGTA TCCCTTCACT 300
 TCGTGTMTTG GCCCAGAAGC TGCTCGAGCT GCTCTTTGAT TATGAGATTG AGAAGGAGCC 360
 40 CCTGCTCTTC CATGTCTTCA GCAACGGTGG CGTCATGCTG TACCGCTACG TGCTGGAGCT 420
 CCTGCAGACC CGTCGCTTCT GCGCCCTGCG TGTGGTGGG ACCATCTTTG ACAGCGCTCC 480
 45 TGGTGACAGC AACCTGGTAG GGGCTCTGCG GGCCCTGGCA GCCATCCTGG AGCGCCGGGC 540
 CGCCATGCTG CGCCTGTTGC TGCTGGTGGC CTTTGCCCTG GTGGTCGTCC TGTTCACGT 600
 CCTGCTTGCT CCCATCACAG CCTCTTCCA CACCCACTTC TATGACAGGC TACAGGACGC 660
 50 GGGCTCTCGC TGGCCCGAGC TCTACCTCTA YTCAGGGGCT GACGAAGTAG TCCTGGCCAG 720
 AGACATAGAA CGCATGGTGG AGGCAGCCTT GGCACGCCGG GTCTTGGGCG GTTCTGTGGA 780
 55 TTTCGTGTC TCTGCACAG TCAGCCACCT CCGTGACTAC CCTACTTACT ACACAAGCCT 840
 CTGTGTGAC TTCATGCGCA ACTGCGTCCG CTGCTGAGGC CATGTCTCCA TCTCAMCTCT 900
 60 GCTCCAGAAA TAAATGCCTG ACAMCTCCCC AAAAAAAAAA AAAAAAAAAA ACTCGAGGGG 960

G

961

5

(2) INFORMATION FOR SEQ ID NO: 279:

(i) SEQUENCE CHARACTERISTICS:

10

(A) LENGTH: 1228 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 279:

CGCGCTTTGC AGTTCGGTCT CCTGGGTAC GGCCAACGCC AAGTAGGGGA TTGCGTTCCC	60
TCCAGTCGCA GCCCTATCAG ATTGGATAT GTCCCTCATA TTGATTGGA TTTACAGTGG	120
TTTCAGCAGT GTGCTACAGT TTTTAGGATT ATATAAGAAA ACTGGTAAAC TGGTATTCTT	180
TGGATTGGAT AATGCAGGAA AAACAACATT GCTACACATG CTAAAAGATG ACAGACTTGG	240
ACAACATGTC CCAACATTAC ATCCCACTTC CGAAGAAGTG ACCATTGCTG GCATGACGTT	300
TACAACTTTT GATCTGGGTG GACATGTTCA AGCTCGAAGA GTGTGGAAAA ACTACCTTCC	360
TGCTATCAAT GGCAITGTAT TTCCTGGTGA TTGTGCAGAC CACGAAAGGC TGTTAGAGTC	420
AAAAGAAGAA CTTGATTAC TAATGACAGA TGAAACCAAT GCTAATGTGC CTATACTGAT	480
TCTTGGGAAT AAGATCGACA GACCTGAAGC CATCAGTGAA GAGAGGTTGC GAGAGATGTT	540
TGGTTTATAT GGTGAGACAA CAGGAAAGGG GAGTATATCT CTGAAAGAAC TGAATGCCCG	600
ACCCCTAGAA GTTTTCATGT GTAGTGTGCT CAAAAGACAA GGTACGGAG AAGGCTTCCG	660
CTGGATGGCA CAGTACATG ATTAACACAA ACTCACATG GTTCCAGGTC TCAACGTTCA	720
GGCTTACTCA GAGATTGAT TGCTCAACAT GCATAACTTG AATTCAATAG ACTTTTGCTG	780
GTTATAAAAC AGATGTTTTT TAGATTATTA ATATTAAATC AACTTAATTT GAATGAGAAT	840
TGAAACTGA TTCAAGTAAG TTGAGTATC ACAATGTTAG CTTTCTAATT CCATAAAAGT	900
ACTTGGTTTT TACAGTTTAT AATCTGACAT CACCCAGCG CCATTGTGTA AGAGCAACTT	960
TCCAGCAGTA CATTGAAGC ACTTTTAAAC AACATGAAC TATAAACCAT ATTTAAAAGC	1020
TCATCATGTT AAATTTTTTA TGTACTTTTC TGGAACTAGT TTTTAAATTT TAGATTATAT	1080
GTCCACCTAT CKTAAGTGTA CAGTTAATAA TTAGCTTATT CAATGATTGC ATGATGCCTT	1140
ACAGTTTCA ATAACTTTTT TTCTTATGCA AACGTCATGC AATAAAACAA ACTCTAATGT	1200
TTGGCAAAAA AAAAAAAAAA AAANTCGA	1228

60

(2) INFORMATION FOR SEQ ID NO: 280:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1327 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 280:

10 TCTCGGGTCT CGGACAGGT GAGCACCTG ATGAAGGCCA CGGTCTTGAT GCGGCACCTG 60
 GCGGGGTGCA GGAGATCGTG GCGGCCCTCC GCAAGGGCGS CGGAGACCGG TTACAGGTGA 120
 15 TTTCTGATTT TRACATGACC TTGAGCAGGT TTGCATATAA TGGAAAGCGA TGCCCTTCTT 180
 CTTACAATAT TCTGGATAAT AGCAAGATCA TCAGTGAGGA GTGTGCGAAA GAGCTCACAG 240
 CGCTCCTTCA CCACTATTAC CCAATTGAGA TCGACCCACA CCGGACCGTC AAGGAGAAGC 300
 20 TACCTCATAT GGTGGAATGG TGGACCAAAG CGCACAATCT CCTATGTCAG CAGAAGATTC 360
 AGAAGTTTCA GATAGCCCGAG GTGGTTAGAG AGTCCAATGC AATGCTCAGG GAGGGATATA 420
 25 AGACCTTCTT CAACACACTC TACCATAACA ACATTCCTCT TTTCATCTTT TCTGCGGGCA 480
 TTGGTGATAT CCTGGAAGAA ATTATCCGAC AGATGAAAGT GTTCCACCCC AACATCCACA 540
 TCGTGTCTAA CTACATGGAT TTAAATGAAG ATGGTTTCTT CCAGGGATTT AAGGGCCAGC 600
 30 TGATACACAC ATACAACAAG AACAGCTCTG TGTGTGAGAA CTGTGGTTAC TTCCAGCAAC 660
 TTGAGGGCAA AACCAATGTC ATCCTGCTGG GAGACTCTAT CGGGGACCTC ACCATGGCCG 720
 35 ATGGGGTTC TGGTGTGAG AACATTCTCA AAATGGCTT CCTGAATGAC AAGGTGGAGG 780
 AGCGGCGGGA NCGCTAACAT GGACTCCTAT GACATCGTGC TGGAGAAGGA CGAGACTCTG 840
 GATGTGGTCA ACGGGCTACT GCAGCACATC CTGTGCCNAG GGGGTCCAGC TGGAGATGCA 900
 40 AGGCCCCGTA AGGCGCAGGC TCCNAAGKCC SCTGCAGGCC GTGGTGAGGA GGGGCGCCTC 960
 CCCAGAGTCT GCTCCCCCGT GAACACAGAG CAGAGCCAGG GTGGCCAGCA GTGGCTGGGT 1020
 45 CCTCCCGGC CCCTCCGTCC TCCTTCCCT GAGCACCTTC ATCACCAGAG GCTTGAAGGA 1080
 ACCCGGCCAT GTGGCAGGC ACAGGCACTG TTCTGGTGA ACCTTGGACC ACAGCATGTC 1140
 AGTGCTCTAG GGATGTGCTA CTCCAGGGAT TTTCTTCAAA ATTTTAAAC ATGGGAAGTT 1200
 50 CAAACAAATA TAATGTGTGA AACAGATCAA AATTTTAAAA ATGAAAAAA AGCTGCTCTG 1260
 ATTCAGGGGA TGTGGGTCGG GGTAGAACCT GGACCTCTTG GCCTGGGGGC ACATGGGATG 1320
 55 CTCTCTAG 1327

60 (2) INFORMATION FOR SEQ ID NO: 281:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 799 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 281:

10 TCACCCCTGCC TACAGCGTGG AGCTCAGATG ACTGCGCCCT CCACGGTCAC TGTGAGCAGG 60
TGGTATTCAC AGCCTGCATG ACCCTCACGG CCAGCCCTGG GGTGTTCCCC GTCAGTGTGT 120
GGCTTTGGCT GAAGCCTAAT TCCACAGCTC CTGTGTTTTT GAGAGAGACT GAGAGAACCA 180
15 TAATCCTTGC CTGCTGAACC CAGCCTGGGC CTGGATGCTC TGTGAATACA TTATCTTGCG 240
ATGTGGGTT ATTCCAGCCA AAGACATTTC AAGTGCCCTGT AACTGATTGT TACATATTTA 300
20 TAAAAATCTA TTCAGAAATT GTTCCAATAA TGCACGTGCT TTGCCCTGGG TACAGCCAGA 360
GCCCTTCAAC CCCACCTTGG ACTTGAGGAC CTACCTGATG GGACGTTTCC ACGTGTCTCT 420
AGAGAAGGAT TCCTGGATCT AGCTGGTCAC GACGATGTTT TCACCAAGGT CACAGGAGCA 480
25 TTGCGTCGCT GATGGGGTTG AAGTTTGGTT TGGTTCTTGT TTCAGCCCAA TATGTAGAGA 540
ACATTTGAAA CAGTCTGCAC CTTTGATACG GTATTGCATT TCCAAAGCCA CCAATCCATT 600
30 TTGTGGATTT TATGTGCTCG TGGCTTAATA ATCATAGTAA CAACAATAAT ACCTTTTTCT 660
CCATTTTGCT TGCAGGAAAC ATACCTTAAG TTTTMTTGT TTTGTTTTTG TTTTMTTGT 720
TTTTGTTTTT CTTTATGAAG AAAAAATAAA ATAGTCACAT TTTTAATACY AAAAAATGGA 780
35 CAAAAAAGT CGAGGGGG 799

40

(2) INFORMATION FOR SEQ ID NO: 282:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2196 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 282:

50

AAAGACTCTA ACATCCATGA GCTTGAACAT GAGCAAGAGC CTACTTGTGC CKSCCAGATG 60
GCTGAGCCCT TCCGTACCTT CCGAGATGGA TGGGTCTCCT ACTACAACCA GCCTGTGTTT 120
55 CTGGCTGGCA TGGGTCTTGC TTTCTTTTAT ATGACTGTCC TGGGCTTTGA CTGCATCACC 180
ACAGGGTACG CCTACACTCA GGGACTGAGT GGTTCATCC TCAGTATTTT GATGGGAGCA 240
TCAGCTATAA CTGGAATAAT GGGAACTGTA GCTTTTACTT GGCTACGTCG AAAATGTGGT 300
60

	TTGGTTCCGA CAGGTCTGAT CTCAGGATTG GCACAGCTTT CCTGTTTGAT CTTGTGTGTG	360
	ATCTCTGTAT TCATGCCTGG AAGCCCCCTG GACTTGTCCG TTTCTCCTTT TGAAGATATC	420
5	CGATCAAGGT TCATTCAAGG AGAGTCAATT ACACCTACCA AGATACCTGA AATTACAAC	480
	GAAATATACA TGTCTAATGG GTCTAATTCT GCTAATATTG TCCCGGAGAC AAGTCCTGAA	540
10	TCTGTGCCA TAATCTCTGT CAGTCTGCTG TTTCAGGCG TCATTGCTGC TAGAATCGGT	600
	CTTTGGTCTT TTGATTAAAC TGTGACACAG TTGCTGCAAG AAAATGTAAT TGAATCTGAA	660
	AGAGGCATTA TAAATGGTGT ACAGAACTCC ATGAACTATC TTCTTGATCT TCTGCATTTC	720
15	ATCATGGTCA TCCTGGCTCC AAATCCTGAA GCTTTTGGCT TGCTCGTATT GATTTCAGTC	780
	TCCTTTGTGG CAATGGGCCA CATTATGTAT TTCCGATTTC CCCAAAATAC TCTGGGAAAC	840
20	AAGCTCTTTG CTGCGGTCC TGATGCAAAA GAAGTTAGGA AGGAAAATCA AGCAAATACA	900
	TCTGTGTGTT GAGACAGTTT AACTGTGTCT ATCCTGTTAC TAGATTATAT AGAGCACATG	960
	TGCTTATTTT GTAGTCAGA ATTCCAATAA ATGGCTGGGT GTTTTGCTCT GTTTTACCA	1020
25	CAGCTGTGCC TTGAGAACTA AAAGCTGTTT AGGAAACCTA AGTCAGCAGA AATTAACTGA	1080
	TTAATTTCCC TTATGTTGAG GCATGGAAAA AAAATTGGAA AAGAAAACT CAGTTTAAAT	1140
30	ACGGAGACTA TAATGATAAC ACTGAATTCC CCTATTTCTC ATGAGTAGAT ACAATCTTAC	1200
	GTAAAAGAGT GGTAGTCAC GTGAATTCAG TTATCATTTG ACAGATTCTT ATCTGTACTA	1260
	GAATTCAGAT ATGTCAGTTT TCTGCAAAAC TCACCTTGT TCAAGACTAG CTAATTTATT	1320
35	TTTTTGATC TTAGTTATTT TTA AAAACAA ATTCITCAAG TATGAAGACT AAATTTTGAT	1380
	AACTAATATT ATCCTTATTG ATCCTATTGA TCTTAAGGTA TTTACATGTA TGTGGAAAAA	1440
40	CAAAACACTT AACTAGAATT CTCTAATAAG GTTTATGGTT TAGCTTAAAG AGCACCTTTG	1500
	TATTTTATT ATCAGATGGG GCAACATATT GTATGAAGCA TATGTAGCAC TTCACAGCAT	1560
	GGTTATCATG TAAGCTGCAG GTAGAAGCAA AGCTGTAAAG TAGATTATC ACACAATGAC	1620
45	TGCATACAGA CTTCAAATAT GTCAATAGTT TGGTCATAGA ACCTAGAAGC CAAAAGCCAC	1680
	ACAGAAGGGC AAGAATCCCA ATTAACTCA TGTATCATC ATTAGTGATC TGTGTTGTAG	1740
50	AACATGAGGG TGTAAGCCTT CAGCCTGGCA AGTTACATGT AGAAAGCCCA CACTTGTGAA	1800
	GGTTTGTGTT TACAAATCAC TTGATTAAAC ACCTCAGGT AGAATATTTT TATTTTACT	1860
	GTTTTATACC CAGAAGTTAT TTCTACATTG TTCTACAGCA AGAATATTCA TAAAAGTATC	1920
55	CCTTTCAAAT GCCTTTGAGA AGAATAGAAG AAAAAAGTT TGTATATATT TAAAAAATT	1980
	GTTTTAAAAG TCAGTTTGCA ACATGTCGT ACCAAGATGG TACTTTGCCT TAACCGTTTA	2040
60	TATGCACTTT CATGGAGACT GCAATACGTT GCTATGAGCA CTTTCTTTAT CCTTGGAGTT	2100

TAATCCTTTG CTTTCATCTT CTACAGTATG ACATAATGAT TTGCTATGTT GTAAAATCTT 2160

TGTAAAAAAT TTCTATATAA AATATTGAA ACTTAA 2196

5

(2) INFORMATION FOR SEQ ID NO: 283:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1185 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 283:

GCAGTTAAGG CTTCTGATAA GGAAAGAGAG TCTGAACAGA GCACACACAT CTGGAGCTCC 60

20 AGGAGTGGGG GATGCAGCAT CAGATTCCAT CTTGAATTTC TGCTAAAATA CTTTGTACTC 120

ATAATGGATC TCAACAAAGA TCTGTATTTC ATCTGTGGCT CCATCTTCCC TCTGGGTCAA 180

25 GTAGATGTTA AGCTGGACCT TGGCAGCCT CTTAACATGA AGAGATCTAG CTAGACAGAC 240

AGACTCCCC ATTTATGGGA ACAAGAATTC AATTTATTCT CTATTTATAA AACATTTTTT 300

TAAAGTGCCT TGGGTATAAA AATCTAAATG TCTGCGGTGT GATCAGTCAG GAGCACGTAA 360

30 CTATCACTCT TCGCATCCTT TGGTCACTGG GAGATCCTTT GGGGGCTGGG AGGTCTTCT 420

GTCCCAGGCT AAAGGAAAAG CTTCAAAAG GTAAGAGCCA CAGAACCCTC GGCAAGAAAG 480

35 GCCCGTCAGG GAGAATGAAT GGTACAGAGA GGAAAGGAAG GAAAGGGGT GGAACAGAGG 540

TAGAAGGCAA GGAAGGGATG CCGCACTGGA GACCGATGGG GACACTCTAA TTGTGCAAGA 600

GGGAGGATCT TCCTTCTTGA ATGCTGAACA CAGCTAGTCT GAACCTTCCT TGGAAAGTCC 660

40 AGCTGTTTGC CCATGCATAG GGCCAACCTCT CCTGCAAAG CAGCAAATGT GGCTTCTATC 720

AGGAAGGAAA AGTATCCATC AGTGTGACAA GAGGTCACCT TCGAACTTGC ATGAACTCCT 780

45 TGCGCAGCCA CAAAGAGTCC TGGTAGAAGT GAGGATCGCC TAGTCTTACG GCTGTCCGTT 840

TATAGAAGTA GCAGTACAAC ACTGCTGCTA GTCTCTGGAA TACAAACAGC ATTTGAAGTC 900

CATCTGTCCA TATGAAGCTG TTGGAGTTTT TCCAGCGTAA GTTCATGACC CAGACATGAA 960

50 GGGAGATGCT GAGGGCAAAG TACACAGCTG TCAGGATGAT GGTCCCTTTG AACTTATGGA 1020

ATAGGAGGTT GACCAGGCCA GCCTGGAAGA CGAAGGTGTT GAAGAACATG AGGAAAATGA 1080

55 TGATGATGTT GAAGAGGACT GCAATATCCT GGATGCACTG AGGGAGAGGY TTCTAGTTCC 1140

TTTGAATGAG AGCTGTTTCC CTGCTCTAA GGCAAGCACC TCCAA 1185

60

(2) INFORMATION FOR SEQ ID NO: 284:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1634 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 284:

10
AGGGAAAGGG GAGGGTAGCG GGAGGGTAGC AGGTGAGTTC CTAGGGCTGG AAGGTTTAGC 60
AGCAGCCTGG TGCAGTGCCC TGTCATCAAG ACAAAACCAC GGTCCTMCTG GGTGCCTACC 120
15 AAGCTTGTTT TGTACAAAAG CAAGGTGGGA GTCTATTTTT GTACATGAGA TACATCACAC 180
TTACCTGTGG GCCAGTATTG TGAAGTGAGT CTGAGTTGTT TACACTGATG CCTTCCCTGC 240
CCACCACAAA TTGTGTACAT AGTCTTCAGA TGATACCACC CCTTTCCCCA GCTCCCAACC 300
20 AAGAGCTGGT TCTAGGCCCTG TGTATATATG CATATTTAGC STTTTATATAT ATGACCTTTG 360
ATTCTGTGTG TTTGTATTTT AGCACAGTGT ATGCACCTTC ATTTAAATAC ATCTGTGTGC 420
25 ATACAGATAC GCATATATGT GTGTGCGTAT GCATATATCT CTCATCTGTA GTTCCAAGA 480
GTCAGCTGA AGCAGATGGA GTCCTGCAGC CCAGGAGACA CCCTGCATCC CTGCTAATAG 540
TGTTTGCCAC AAGTATTAGT GAGTCTTCCT TATTAATATT TTCATTTAGC AAGACTGAAG 600
30 CAAAGCTGAT AGTGTTTGCT GTTCTTTTGG CAGCTAAGTG AGGGTCTTGG GATGACTTGC 660
TGTTGTCTC AAGCTGCACT TTGGGGCCAT CTCTGCAGTA TTAGCCCCCT TTTTGCTTGG 720
35 TGGTACTCTG TCTGTGCCCTG TGTGTGTGTG TGATAGTCAC TCTTGCATGG CTTCATGTC 780
TGGTTTGTGG CATTTGGGGA TAAGGTGCTG AAGCCAGAGC ATTTGCAGTT TGTGTGAGGC 840
CTCGTTGCCA ATGATAGATC ACTCCTGTTG ACCTGGTATG TCTGCTTGCT TGCTGCTTTT 900
40 CCTTGCTTTC TCTTGAAGA GGAAAGGACT CTGGTCAGGC CCAGGCTGAG TGAGATGAGC 960
TGCAGCTGGC TCATGGCCTT CTTAGAGCAG AGAGAGGAGT ATGTCATTTT ACTAAGTTCC 1020
45 TAAACAAACA TTTATGCAGG CAACACTCCT TGCAGATCCA GAAACTGAGG CACAATAGGG 1080
TTATGACTTG CTCAAGAATA TGTAGCTGCT AGGGGGTAAA TCAAGGCATC ACAATTCTG 1140
TTCAGCGGGC AGGAATAGGC TGTGAATTGC TAGCACTTTT TTTTTTTAAG CAATTACTTT 1200
50 TTGACTTGTT CCTCTGAAAG TGCAAGAGGC GTACACCTTT CCCAAATGTA GACTAGAATC 1260
TGCAGGATGC CACCCACTGT ATAGTTCTGC TTTCCCAGAG AGGAAGAACT TTTAGAAACC 1320
55 AAATGATCTT AATGTATTAT GCCCACCCCT GGCTTTTCCG GGTAGAAAAT TCACAGTAGG 1380
AATGATGTGTT AAGAGAGAGT GCTTGAAGC ATGGGTTAAC AGGAAAGGCT ACCTAACTTC 1440
ACATATCTGC AACCAGAGCA GCCACCAAGC ATTACTTAGC AGCAGGAAAA TGATTGTATT 1500
60

	TGAGTTCTTG TGTGTCCAAA ACTGAGGCAC CATGTTCTTT GAAACATGC CACCTCAAGG	1560
	CTGGGCGCGG TGGCTCACAC CTGTAATCCC AGCAYTTTGG GGAGGCSAG GCGGGGCGG	1620
5	RTTCACCGGG GGTC	1634
10	(2) INFORMATION FOR SEQ ID NO: 285:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 1795 base pairs	
	(B) TYPE: nucleic acid	
15	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 285:	
20	TTCCCCCAG GTTGGCTTCC TTCGATTCCT TTTCTTGGTA TCAACGTTTG ATTGGAAGAA	60
	CAACCCCTC TTTGTCAACC TCAATAATGA GCTCACTGTG GAGGAGCAGC TCGGGCACAG	120
25	CTCMCCGYA TGGTCATTGT TACCCCCCAA GACCGCAAAA ACTCTGTGTG GACACAGGAT	180
	GGACCTCAG CCCAGATCCT GCAGCAGCTT GTGGTCTGG CAGCTGAAGC CCTGCCCATG	240
	TTAGAGAAGC AGCTCATGGA TCCCCGGGA CCTGGGGACA TCAGGACAGT GTTCCGGCCG	300
30	CCCTTGGACA TTTACGACGT GCTGATTCGC CTGTYTCTC GCCATATCCC GCGGCACCGC	360
	AGGCTTGTGG ACTCGCCAGY TGCTCCTTC TGCGGGGCC TGCTCAGCCA GCGGGGGCCC	420
35	TCATCCCTGA TGCCCGTGCT GGGINATGAT CCTNCTCAGC TCTATCTGAC GCAGCTCAGG	480
	GAGGCCTTTG GGGATCTGGC CCTTTTCTTC TATGACCAGC ATGGTGGAGA GGTGATTGGT	540
	GTCTCTGGA AGCCACCCAG CTTCAGCCG CAGCCCTTCA AGGCCTCCAG CACAAAGGGG	600
40	CGCATGGTGA TGTCTCGAGG TGGGGAGCTA GTAATGGTGC CCAATGTGA AGCAATCCTG	660
	GAGGACTTTG CTGTGCTGGG TGAAGGCCTG GTGCAGACTG TGGAGGCCCG AAGTGAGAGG	720
45	TGGACTGTGT GATCCAGCT CTGGAGCAAG CTGTAGACGG ACAGCAGGAC ATTGGACCTC	780
	TAGAGCAAGA TGTCAGTAGG ATGACCTCCA CCTCCTTGG ACATGAATCC TCCATGGAGG	840
	GCTGCTGGC TGAACATGCT GAATCATCTC CAACAAAACC CAGCCCCAAC TTTCTCTCTG	900
50	ATGCTCCAGC ATTGGGGCAG GGGCATGGTG GCCCATGTAG TCTCCTGGGC CTCACCATCC	960
	CAGAAGAGGA GTGGGAGCCA GCTCAGAGAA GGAAGTGAAC CCAGGAGATC CATCCACCTA	1020
55	TTAGCCCTGG GCCTGGACCT CCCTGCGATT TCCCACTCCT TTCTTAGTCT TCTTCCAGAA	1080
	ACAGAGAAGG GGATGTGTGC CTGGGAGAGG CTCGTCTCC TTCTGCTGC CAGGACCTGT	1140
	GCCTAGACTT AGCATGCCCT TCACTGCAGT GTCAGGCCTT TAGATGGGAC CCAGCGAAAA	1200
60	TGTGGCCCTT CTGAGTCACA TCACCGACAC TGAGCAGTGC AAAGGGGCTA TATGTGTATG	1260

AATAGACCAC ATTGAAGGAG CACAATGCCC TCCTGTGTG ATGCCACTTC CCAGGGTGGA 1320
 5 GACAGTGGAA AAGAACOGAG GACAGGAAAG GATTGGGTAG GTGAAGGGGT CAGGGGACTG 1380
 GTAGTCACCC AATCTTGGAG AGGTGCAAAA AGCACTGGGG GCTACCGTT AGCTGCATCT 1440
 GCCCTGGCTG TTTGCCCGTT CATGTCACAA ACTGCCACTA CTATGTACCT GCAGTGGGGT 1500
 10 TGCAGAGATG GGGGAGACTC AAGTCTTACT CCCCAGGAGC TCCCAGGGCC CAAGGAGGAG 1560
 AATGCTGCCT CCTTTCAGTC TGGTCTACAC CCACCTTCTG GTAGCCTCTC TGCTTCCTGT 1620
 AATTCTGGCT GTTTTTCAG ACTCAGCTCA AATAGTGGCC CTCTTAAGC CCATCCCTCG 1680
 15 CCCCCAGCCT GAGGTGATCT TTCCCTCTC TGAAGTATTA GAGCAGTTAC TGTCTGTTC 1740
 GTTCGTTTGG CAGGCACACA CAGTGGCATA AATCTATTTG TTTTGAAGTC TGATT 1795

20

(2) INFORMATION FOR SEQ ID NO: 286:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 858 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 286:

TCTGCTTTCG GTGCTGCGTG TACTGCTGGG CGGCTTCTTC GCGCTCGTGG GGTGGCCAA 60
 35 GCTCTCGGAG GAGATCTCGG CTCCAGTTTC GGAGCGGATG AATGCCCTGT TCGTGCAGTT 120
 TGCTGAGGTG TTCCCGCTGA AGGTATTTGG CTACCAGCCA GATCCCTGA ACTACCAAAT 180
 40 AGCTGTGGGC TTTCTGGAAC TGCTGGCTGG GTTGTCTGCTG GTCATGGGCC CACCGATGCT 240
 GCAAGAGATC AGTAACTTGT TCTTGATTCT GCTCATGATG GGGGCTATCT TCACCTTGGC 300
 AGCTCTGAAA GAGTCACTAA GCACCTGTAT CCCAGCCATT GTCTGCCTGG GGTTCCTGCT 360
 45 GCTGCTGAAT GTCGGCCAGC TCTTAGCCCA GACTAAGAAG GTGGTCAGAC CCACTAGGAA 420
 GAAGACTCTA AGTACATCA AGGAATCCTG GAAGTAGAGC ATCTCTGTCT CTTTATGCCA 480
 TGCAGCTGTC ACAGCAGGAA CATGGTAGAA CACAGAGTCT ATCATCTTGT TACCAGTATA 540
 50 ATATCCAGGG TCAGCCAGTG TTGAAAGAGA CATTTTGTCT ACCTGGCACT GCTTCTCTT 600
 TTTAGCTTTA CTACTCTTTT GTGAGGAGTA CATGTTATGC ATATTAACAT TCCTCATGTC 660
 55 ATATGAAAAT ACAAATAAG CAGAAAAGAA ATTTAAATCA ACCAAAATTC TGATGCCCCA 720
 AATAACCACT TTTAATGCCT TGGTGTAAAT ATACCTCTGA ACTTTTCTCT GTGCCCTTAA 780
 60 ACAGATATAT ATTTTCTTTT AATGAAAATA AAACCATATA TCCTATTTTA TTTCTCTCTT 840

TTAAAACCTT ATAAACTA

858

5

(2) INFORMATION FOR SEQ ID NO: 287:

(i) SEQUENCE CHARACTERISTICS:

10

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 287:

15

GAATTCGGCA CGAGCGCGGC CATGGCGCTC CTGCTTTTCGG TGCTGCGTGT ACTGCTGGGC	60
GGCTTCTTCG CGCTCGTGGG GTTGGCCAAG CTCTCGGAGG AGATCTCGGC TCCAGTTTCG	120
20 GAGCGGATGA ATGCCCTGTT CGTGCAGTTT GCTGAGGTGT TCCCGCTGAA GGTATTTGGC	180
TACCAGCCAG ATCCCCTGAA CTACCAAATA GCTGTGGGCT TTCTGGAAGT GCTGGCTGGG	240
25 TTGCTGCTGG TCATGGGCCC ACGATGCTG CAAGAGATCA GTAAC TTGTT CTTGATTCTG	300
CTCATGATGG GGGCTATCTT CACCTTGGCA GCTCTGAAAG AGTCACTAAG CACCTGTATC	360
CCAGCCATTG TCTGCCTGGG GTTCTGCTG CTGCTGAAATG TCGGCCAGCT CTTAGCCAG	420
30 ACTAAGAAGG TGGTCAGACC CACTAGGAAG AAGACTCTAA GTACATTCAA GGAATCCTGG	480
AAGTAGAGCA TCTCTGTCTC TTTATGCCAT GCAGCTGTCA CAGCAGGAAC ATGGTAGAAC	540
ACAGAGTCTA TCATCTTGTT ACCAGTATAA TATCCAGGT CAGCCAGTGT TGAAGAGAC	600
35 ATTTTGCTA CCTGGCACTG CTTTCTCTTT TTAGCTTTAC TACTCTTTTG TGAGGAGTAC	660
ATGTTATGCA TATTAACATT CCTCATGTCA TATGAAATA CAAAATAAGC AGAAAAGAAA	720
40 TTAAATCAA CCAAATTTCT GATGCCCAA ATAACCACTT TTAATGCCTT GGTGTAAGTA	780
TACCTCTGAA CTTTTTCTG TGCTTTTAAA CAGATATATA TTTTTTTTWA ATGAAAATAA	840
AACCATATAT CCTATTTTAT TTCTCCTTT TAAAACCTTA TAACTATAA MAAAAAAAAA	900
45 AAAAAAAAAA CTCGA	915

50

(2) INFORMATION FOR SEQ ID NO: 288:

(i) SEQUENCE CHARACTERISTICS:

55

(A) LENGTH: 1517 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 288:

60

	CCTGTGGCA ACTAGTGGGT CCCCCGGCT GCAGNAATTC GGCAGTGGT TCTGNGTCTG	60
	AAGATACTCT GAGTTCCTCT GAGAGATCCA AAGGCTCCGG GAGCAGACCC CCAACCCCCA	120
5	AAAGCAGCCC TCAGAAGACC AGGAAGAGCC CTCAGGTGAC CAGGGGTAGC CCTCAGAAGA	180
	CCAGCTGTAG CCCTCAGAAG ACCAGGCAGA GCCCTCAGAC GCTGAAGCGG AGCCGAGTGA	240
10	CCACCTCACT TGAAGCTTTG CCCACAGGAC AGTGCTGACA GACAAGAGTG GCGACAGTG	300
	GAAGCTGAAG TCCTTCCAGA CCAGGGACAA CCAGGGCATT CTCTATGAAG CTGCACCCAC	360
	CTCCACCCTC ACCTGTGACT CAGGACCACA GAAGCAAAAG TTCTCACTCA AACTGGATGC	420
15	CAAGGATGGG CGCTTGTTC A TGAGCAGAA CTTCTTCCAG CGGGCCGCCA AGCCTCTGCA	480
	AGTCAACAAG TGAAGAAGC TGTACTCGAC CCCACTGCTG GCCATCCTTA CCTGCATGGG	540
20	TTTCGGTGT CACCAGGACA AATACAGGTT CTGGTGTTA CCCAGCCTGG GGAGGAGCCT	600
	TCAGTCGGCC CTGGATGTCA GCCCAAAGCA TGTGCTGTGC AGAGAGGTCT GTGCTGCAGG	660
	TGGCCTGCCG GCTGCTGGAT GCCCTGGAGT TCCTCCATGA GAATGAGTAT GTTCATGGAA	720
25	ATGTGACAGC TGAAAATATC TTTGTGGATC CAGAGGACCA GAGTCAGGTG ACTTTGGCAG	780
	GCTATGGCTT CGCMTCCGC TATTGCCCAA GTGGCAAACA CGTGGCCTAC GTGGAAGGCA	840
30	GCAGGAGCCY TCACGAGGGG GACCTTGAGT TTCATTAGCA TGGACCTGCA CAAGGGATGC	900
	GGGCCCTCCC GCCGCRGYGA CCTCCAGAGC CTGGGYTAMT GCATGCTGAA GTGGYTCTAM	960
	GGGTTTCTGC CATGGACAAA TTGCCTTCCA AMAMTGAGGA CATCATGAAG CAAAAACAGA	1020
35	AGTTCGCTTG GGATTCATTT TAATGTAAGC TKGACTTTGT CATGCCAGAA ACAAGGCTCG	1080
	GTCACCGTCA GCAGTTTGCA GTTTTCACC TCCWCCAGT TCCTCCGTGT GGTGACCCA	1140
40	GATATCTCCG TTATGCAGCC GCCTCCGGGG GACCACCTCC CTCCCTTTGA GTCAGCCACA	1200
	GACAGCCTAC TTGACGGCCC CGCTGGCCCC CACATTCAC TGAAGTGTGC GGATGCCACA	1260
	GTGACCCCTC CTCAGGCACA GCATGACCTC CTGAAGTGA GCCTGCTTGC TTTGAACCTA	1320
45	CCAGTTAAAA TCTCTCAAA ATGTTTGGAT ACCGCCATT GGCCCCCTAC AGCCACGAGC	1380
	TCCCTGACCA GTGTGCGTGT GTGTGTGTGT GTGTGTCTGT GTGTGTGCTT GGGACGGGTG	1440
50	GGGAGGTAC CTTTGGGTGT GCGGTGTGCC CCCAGGACCT GTAAGTAATA AAATCTTTAT	1500
	TTCCAAAAAA AAAAAA	1517

55

(2) INFORMATION FOR SEQ ID NO: 289:

(i) SEQUENCE CHARACTERISTICS:

60

(A) LENGTH: 3865 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 289:

5	TGGAGGGGGG GAGCTTCCTT GAGCAGTGGG CCCAGGCCTG GCCCTCCACA CTTCAATTCTC	60
	TGACCTTTCT CTCTCCTCAT TTCGGTGCAT GTCCTTTCTG CAGCTGCCTT TCAGCACAGG	120
10	TGGTTCCACT GGGGGCAGCT AACGCTGAGT GACAAGGATG GGAAGCCACA GGTGCATTTT	180
	ACTCAAGTCT TCTCTAGTCA ATGAGGGGCA CCCAGTGCCT CTAGGGCAGG CTGGGTGGTG	240
15	GTCCCCTAGG TATCAGCCTC TCTTACTGTA CTCTCCGGGA ATGTTAACCT TTCTATTTTC	300
	AGCCTGTGCC ACCTGTCTAG GCAAGCTGGC TTCCCCATTG GCCCCTGTGG GTCCACAGCA	360
	GGGTGGCTSC CCCCCAGGCG CACCGCTTCT TTCTTGATCC TCTTTCCTTA ACAGTGACTT	420
20	GGGCTTGAGT CTGGCAAGGA ACCTTGCTTT TAGCTTCACC ACCAAGGAGA GAGGTTGACA	480
	TGACCTCCCC GCCCCTCAC CAAGGCTGGG AACAGAGGGG ATGTGGTGAG AGCCAGGTTT	540
25	CTCTGGCCCT CTCCAGGGTG TTTTCCACTA GTCCTACTG TCTTCTCCTT GTAGCTAATC	600
	AATCAATATT CTTCCTTGC CTGTGGGCAG TNGGAGAGTG CTGCTGGGTG TACGCTGCAC	660
	CTGCCCCACTG AGTMTGGGAA AGAGGATAAT CAGTGAGCAC TGTTCCTGCTC AGAGCTCCTG	720
30	ATCTACCCCA CCCCCTAGGA TCCAGGACTG GGTCAAAGCT GCATGAAACC AGGCCCTGGC	780
	AGCAACCCCTG GGAATGGCTG GAGGTGGGAG AGAACCTGAC TTCTCTTTCC CTCTCCCTCC	840
35	TCCAACATTA CTGGAAGTCT ATCCTGTTAG GATCTTCTGA GCTTGTTTCC CTGCTGGGTG	900
	GGACAGAGGA CAAAGGAGAA GGGAGGGTCT AGAAGAGGCA GCCCTTCTTT GTCCCTCTGGG	960
	GTAATGAGC TTGACCTAGA GTAAATGGAG AGACCAAAG CCTCTGATTT TTAATTCCA	1020
40	TAAATGTTA GAAGTATATA TATACATATA TATATTTCTT TAAATTTTGT AGTCTTTGAT	1080
	ATGTCTAAAA ATCCATTCCC TCTGCCCTGA AGCCTGAGTG AGACACATGA AGAAACTGT	1140
45	GTTCATTTTA AAGATGTTAA TTAAATGATT GAAACTTGGC TGTGGCTACT GCTTCTTAAT	1200
	GTGCGGGGGA CAGGGCAGTG GTCTGGGCC ACATTTAGAA GGGAAAATGT TTTGCCTGCT	1260
	GCACACATTG GACCCAAGTA TGGGCCTCTT CTGCCTAGTA CTGCCAAAGG GACTGTTAAG	1320
50	GTGTCTGTG CATCTTCTAC CCCCACCCC CCATTACGGG TAAAGGRAAC CCCAGACTAG	1380
	GTGAGGGGCC AGCAGCTGCC TCACATTGTG TTCTCTCCTG AGATGGTCCA GCTCACATCC	1440
55	AGACACCTTG TTCAGACATT TTATTTGAAT TTATGACAGT GATGGGATT TGACTGAGAT	1500
	GCCTTATGGA GAAGTACCCC ACCCTCTATG AAGACAGAAT CACTCTCTGC CATTCATTCT	1560
	GCCTGATGCT AACAACACGC AGCTGATTTA GGGAGTGTCC CAGCCTAGCT GGATCAAGGG	1620
60	AAATCCAGG AGCCCTGGGG CAGGCCCTGG NCCCAGTGC CAAGCCTCAG AGTAAGCAGA	1680

	CATTGGGAAA GTTGCCAACC ACTTGGTAGA CCACTAGGTT CTCTGTTTTT CCTTCCCTTT	1740
5	CCTTTTCAAA TCCCACAGTT TCCTGTGGG GAGAAGCTGT AATTAGCCTA GTCCAGGTAC	1800
	CAGATCCCAG CTAGGGGCGC AGCTGNCCTG GATAACTCCA AGAAAACCTG GGCACCAGTA	1860
	TTTTTCCAAT TATAAGGACT GTGGCATAAA TTTTAAATG AGTTATATTG AAACCAGATT	1920
10	TCTCCAGCTG CCAAGGGAAG AAGGTAGGCG TGGACTCCCT GCTGTGGCCC AGCCCTTGTT	1980
	AGGGGTGGT CTCTCACTGC AGCCAGACAG GATGATCCTG GGTCTGGGG AGGGTAAGCT	2040
15	GCCCTTGCC GAGTTCTGCA CCGAATAAAG AGTCCAAACC CGCTGCTTC GTGTCTGAG	2100
	AGATGGGTAA ATGGGTGATG GATGGAGCAG ACTGAAGAGA CAGCAGATGA CTCAGTGGTG	2160
	GAAGAAGGGG GGAAGATGCT GGGCTGGCTA GCTAATGTTT CCCCTTTCA GCGATTACA	2220
20	GGAAATGGAG CCCAGCTGG TCATGAAGTT GGTTCCTTC CACTGTGCGA TGCACTCCTC	2280
	AGAAATTTTG AAGTCAGCCT GCACTTCTC GAAGACTTTC TTCTTGGGCT TGAGCTCCTC	2340
25	ATCTGGTTGG CCTTTTCAT AGCCCTTCAC AAACACGTGC TCACCAGGAG CAGAGCCTGC	2400
	CGGAGGGTCC AGAGGTCAA CTGGCGGTTT ATCCCTTCTA TAGAAGCACA CAGAAGCATG	2460
	CCTTGGGACT CGACTCCTCT CATCTCTGG GGTTCAGGT TGCACAGCAC CACTACCAGC	2520
30	CTGTCTGCA GTTCTCCTT GGGCAGAAC TGTACCAGGC CGCTCACCAC AGTCCGTGGT	2580
	TCAGCTTCCC CCACGTCAAT CTCTCTACA TACAGGCTGT CTGCATCTGG GTGCTTCTCC	2640
35	ACAGTGATGA TTTTCCCCAC ACGGATAATC AGCCGGGATG GGATGACCTC CTCTGGTTCT	2700
	GAATCTTGG CAGGCCCTTG GCCATTGGCT TCTGCTTTGA GGGATCTGGG TAGGCAGCGC	2760
	TGGCCAGTTT TTTTCAAGGCA GGGTATTAA ACTTTTCCCG GATTGGATCC AGCAACTTGT	2820
40	TCAGTGGGAC TTCAACAGAA TTCTTCAGGT CTCCAGGATG TACAACCTCA GCAGCAAAGT	2880
	CCTTTTCCAG GTCCAGTAA GCTGTGTAGG TTTTGTTC ACCCCATTTC TCATCTGTGA	2940
45	GGATCAGAAA CTGGACTTA AGGGGAAAAA GGACATGCTT GATGAAGGAC AGAACCCCAT	3000
	TGTTCTCCAC ATTTCTGGC TCACAGAAGG CCTTCTTCAG TTTTCTTTC ACATCTCCT	3060
	TCCGATCAAG GAGATCAATC TTGGACTCCT CTCTGAAGA GCTCATTTTG CTGCCTGTGA	3120
50	ATCCTGGAAC CATAGGATTC ATCAGATGGA CCCGTTTGA ATAGCCAAGT GCAGGGAGGT	3180
	ACTTCTCTGC AAAGGTGAAA ATCTTCTCT GATCAATGCC TCCAAATGG GCATCTACTT	3240
55	TTAAATACTC TTCATCCAAA GCCTGCAGTC CGGGGTATAA GAGGCCACTC AGCAAAGGGT	3300
	GCTCCACCTG CTTTACCACC TCAGCTCCAG CCTTCTTGA ATCGTGCTGT GTGACCACGG	3360
	AGGAGAGTCT GTACACATCT AGTGTGACT CTTTGCTGAG CTGGTAATCA GTGCCTTTGA	3420
60	TGAACTTGAG CTCTCCAAG GGCACACCAA TGCTCTCCAG CATTGCTTTG ATCACAATTCT	3480

CATAGTAACT GACTCGGAGT TCTAGAAGTT CCCATGGGGC TTTCATGTTA TCCAGGTATG 3540
CGTGGAGGTC CGCAAACAGA ATTGTTACCT CACACCCCTGC CTTTAAGAAG TCTGCAATCT 3600
5 TTGACATGGG CACAAAGTAA GCCACATGTG GTTGGCCCGT GGTGCGCGTT CCCAGTAAA 3660
TTTAAAGTTC CCGCTCCTTC AGTATCTCCT TCAGCTTCCTC TTCCCCCAGA ACCTCCTGCA 3720
10 GGTTCGCGGT GATAAGGTGC AGTTTCTCTT CAGGGCTGGG AGCGTCCCC ATGGTCCGCT 3780
ACCCCTGCTT CCCCCGCTCA GCCCGGCACC AGAGCCCTT CCGGGTCAC CGTCCCGCC 3840
GCGTCCCGG AACTGTCACG CGAGT 3865
15

(2) INFORMATION FOR SEQ ID NO: 290:
20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1910 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 290:

AGGGAGAGGA GGAGAGGGG TCTGCGCGG GCCGCTACCC AGAAGCCAGC GGACGGCAGC 60
30 ACGGAGTGGG CTGTCCCGA GCCAGCCCC GAGCGAGCCC CCCCCCGCC CCGMAGGAC 120
GCGCTYCCA GCCAGCCGA CTCCTAGGAG GAGGGAGGC GGAAGAGCAG CTCAGCCTC 180
35 ACCCACC GCC CTGCCCCAG CCCCCTACT CCCAGGCTCC TCGGACTCG GCGGTCTC 240
CTGGAGTCT CGGAGGGAC CGNCTGTGCA GAGCCATGG AGTTGGTGT GGTCTTCTC 300
TGCAGCTGC TGGCCCCAT GGTCTGGCC AGTGCAGCTG AAAAGGAGAA GGAAATGGAC 360
40 CCTTTTCATT ATGATTACCA GACCCTGAGG ATTGGGGGAC TGGTGTTCG TGTGGTCTC 420
TTCTGGGTG GGATCCTCT TATCCTAAGT CGCAGGTGCA AGTGCAGTTT CAATCAGAAG 480
45 CCCCCGGCCC CAGGAGATGA GGAAGCCAG GTGGAGAACC TCATCACCGC CAATGCAACA 540
GAGCCCCAGA AAGCAGAGAA CTGAAGTGCA GCCATCAGGT GGAAGCCTCT GGAACCTGAG 600
GCGGCTGCTT GAACCTTTGG ATGCAAATGT CGATGCTTAA GAAACCGGC CACTTCAGCA 660
50 ACAGCCCTTT CCCCAGGAGA AGCCAAGAAC TTGTGTGTCC CCCACCCTAT CCCCTCTAAC 720
ACCATTCTC CACCTGATGA TGCAACTAAC ACTTGCCTCC CCACTGCAGC CTGCGGTCT 780
55 GCCACCTCC CGTGATGTGT GTGTGTGTGT GTGTGTGTGT GACTGTGTGT GTTTGCTAAC 840
TGTTGCTTT GTGGCTACTT GTTTGTGGAT GGTATTGTGT TTGTTAGTGA ACTGTGGACT 900
CGCTTTCCA GGCAGGGGCT GAGCCACATG GCCATCTGCT CTTCCCTGCC CCGTGGCCC 960
60

	TCCATCACCT TCTGCTCCTA GGAGGCTGCT TGTGCCCCGA GACCAGCCCC CTCOCCTGAT	1020
	TTAGGGATGC GTAGGTAAG AGCACGGGCA GTGGTCTTCA GTCGTCTTGG GACCTGGGAA	1080
5	GGTTGACAGC ACTTTGTCAT CATCTCTCAT GGA CTCTTTT CACTCTTTA AAAAAACCT	1140
	TGCTTCCTTA TCCCACCTGA TCCAGTCTG AAGGTCTCTT AGCAACTGGA GATACAAAGC	1200
10	AAGGAGCTGG TGAGCCAGC GTGACGTCA GGCAGGCTAT GCCCTTCCGT GGTAAATTTC	1260
	TTCCAGGGG CTTCACGAG GAGTCCCAT CTGCCCCGC CCTTCACAGA GCGCCCGGG	1320
	ATCCAGGCC CAGGGCTTCT ACTCTGCCCC TGGGGAATGT GTCCCTGCA TATCTTCTCA	1380
15	GCAATAACTC CATGGGCTCT GGCACCTAC CCTTCCAAC CTTCCTGCT TCTGAGACTT	1440
	CAATCTACAG CCCAGCTCAT CCAGATGCAG ACTACAGTCC CTGCAATTGG GTCTCTGGCA	1500
20	GGCAATAGTT GAAGGACTCC TGTTCGGTTG GGGCCAGCAC ACCGGGATGG ATGGAGGGAG	1560
	AGCAGAGGCC TTTGCTTCTC TGCCTACGTC CCTTAGATG GGCAGCAGAG GCAACTCCCG	1620
	CATCCTTGC TCTGCCTGTC GGTGGTCAGA GCGGTGAGCG AGGTGGGTTG GAGACTCAGC	1680
25	AGGCTCCGTG CAGCCCTTGG GAACAGTGAG AGGTGAAGG TCATAACGAG AGTGGGAACT	1740
	CAACCCAGAT CCCGCCCTC CTGTCTCTG TGTCCCGCG GAAACCAACC AAACCGTCCG	1800
30	CTGTGACCCA TTGCTGTCT CTGTATCGTG ATCTATCCTC AACAACAACA GAAAAAAGGA	1860
	ATAAATATC CTTTGTTCM TAAAAA AAAAAGG AGGGGGGGG	1910

35

(2) INFORMATION FOR SEQ ID NO: 291:

(i) SEQUENCE CHARACTERISTICS:

40

- (A) LENGTH: 3276 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 291:

45

GCGACCGTCG TTTGAGTCGT CGCTGCCGCT GCCGTGCCA CTGCCACTGC CACCTCGCGG	60
ATCAGGAGCC AGCGTTGTTT GCCGACGCC TCGCTGCCG TGGAGGAAG CGAGAGGGAA	120
50 GCGCTTGCG GGTTTGTGCG CGCTGCTCGC CCACCGCTG GAAGAGCCGA GCCCGGCC	180
AGTCGGTCGC TTGCCACCGC TCGTAGCGT TACCGCGGG CCGCCACAGC CGCCGGCCG	240
GAGAGGCGCG CGCCATGGCT TCTGGAGCCG ATTCAAAAGG TGATGACCTA TCAACAGCCA	300
55 TTCTCAACA GAAGAACCGT CCAATCGGT TAATTGTTGA TGAAGCCATC AATGAGGACA	360
ACAGTGTGGT GTCCITGTCC CAGCCCAAGA TGGATGAATT GCAGTTGTTT CGAGGTGACA	420
60 CAGTGTGCT GAAAGGAAAG AAGAGACGAG AAGCTGTTTG CATCGTCTT TCTGATGATA	480

	CTGTGTTCTGA TGAGAAGATT CGGATGAATA GAGTTGTTTCG GAATAACCTT CGTGTACGCC	540
5	TAGGGGATGT CATCAGCATC CAGCCATGCC CTGATGTGAA GTACGGCAAA CGTATCCATG	600
	TGCTGCCCAT TGATGACACA GTGGAAGGCA TTA CTGTTGAG GTATACCTTA	660
	AGCCGTACTT CCTGGAAGCG TATCGACCCA TCCGAAAGG AGACATTTT CTGTCCGTG	720
10	GTGGGATGCG TGCTGTGGAG TTCAAAGTGG TGGAAACAGA TCCTAGCCCT TATTGCATTG	780
	TTGCTCCAGA CACAGTGATC CACTGCGAAG GGGAGCCTAT CAAACGAGAG GATGAGGAAG	840
15	AGTCCTTGAA TGAAGTAGGG TATGATGACA TTGGTGGCTG CAGGAAGCAG CTAGCTCAGA	900
	TAAAGGAGAT GGTGGAAGTGG CCCCTGAGAC ATCTGCCCC CTTTAAGGCA ATTGGTGTGA	960
	AGCCTCCTAG AGGAATCCTG CTTTACGGAC CTCTGGAAC AGGAAAGACC CTGATTGCTC	1020
20	GAGCTGTAGC AAATGAGACT GGAGCCTTCT TCTTCTTGAT CAATGGTCTT GAGATCATGA	1080
	GCAAATTGGC TGGTGAAGTCT GAGAGCAACC TTCGTAAAGC CTTTGAGGAG GCTGAGAAGA	1140
25	ATGCTCCTGC CATCATCTTC ATTGATGAGC TAGATGCCAT CGCTCCCAA AGAGAGAAAA	1200
	CTCATGGCGA GGTGGAGCGG CGCATTGTAT CACAGTGTGT GACCCCTCATG GATGGCCTAA	1260
	AGCAGAGGGC ACATGTGATT GTTATGGCAG CAACCAACAG ACCCAACAGC ATTGACCCAG	1320
30	CTCTACGGCG ATTTGGTGGC TTTGACAGGG AGGTAGATAT TGGAAATCCT GATGCTACAG	1380
	GACGCTTAGA GATTCTTCAG ATCCATACCA AGAACATGAA GCTGGCAGAT GATGTGGACC	1440
35	TGGAACAGTA GCCAATGAGA CTCACGGGCA TGTGGGTGCT GACTTAGCAG CCCTGTGCTC	1500
	AGAGGCTGCT CTGCAAGCCA TCCGCAAGAA GATGGATCTC ATTGACCTAG AGGATGAGAC	1560
	CATTGATGCC GAGGTATGA ACTCTCTAGC AGTTACTATG GATGACTTCC GGTGGGCCCT	1620
40	GAGCCAGAGT AACCCATCAG CACTGCGGGA AACCGTGGTA GAGGTGCCAC AGGTAACCTG	1680
	GGAAGACATC GGGGGCCTAG AGGATGTCAA ACGTGAGCTA CAGGAGCTGG TCCAGTATCC	1740
45	TGTGGAGCAC CCAGACAAAT TCCTGAAGTT TGGCATGACA CCTTCCAAGG GAGTTCTGTT	1800
	CTATGGACCT CCTGGCTGTG GGAAAACCTT GTTGGCCAAA GCCATTGCTA ATGAATGCCA	1860
	GGCCAACTTC ATCTCCATCA AGGGTCTGA GCTGCTCACC ATGTGGTTTG GGGAGTCTGA	1920
50	GGCCAATGTC AGAGAAATCT TTGACAAGGC CCGCCAAGCT GCGCCCTGTG TGCTATTCTT	1980
	TGATGAGCTG GATTGATTG CCAAGGCTCG TGGAGGTAAC ATTGGAGATG GTGGTGGGGC	2040
55	TGCTGACCGA GTCATCAACC AGATCCTGAC AGAAATGGAT GGCATGTCCA CAAAAAAAAA	2100
	TGTGTTTATC ATTGGCGCTA CCAACCGGCC TGACATCAT GATCCTGCCA TCCTCAGACC	2160
	TGGCCGTCTT GATCAGCTCA TCTACATCCC ACTTCCTGAT GAGAAGTCCC GTGTGCCAT	2220
60	CCTCAAGGCT AACCTGCGCA AGTCCCCAGT TGCCAAGGAT GTGGACTTGG AGTTCTGGC	2280

	TAAAATGACT AATGGCTTCT CTGGAGCTGA CCTGACAGAG ATTTGCCAGC GTGCTTGCAA	2340
5	GCTGGCCATC CGTGAATCCA TCGAGAGTGA GATTAGGCGA GAACGAGAGA GGCAGACAAA	2400
	CCCATCAGCC ATGGAGGTAG AAGAGGATGA TCCAGTGCCT GAGATCCGTC GAGATCACTT	2460
	TGAAGAAGCC ATGGGCTTTG CGCGCCGTC TGTCACTGAC AATGACATTC GGAAGTATGA	2520
10	GATGTTTGCC CAGACCCCTC AGCAGAGTCG GGGCTTTGGC AGCTTCAGAT TCCCTTCAGG	2580
	GAACCAGGCT GGAGCTGGCC CCACTCAGGG CAGTGGAGGC GGCACAGGTG GCAGTGTATA	2640
15	CACAGAAGAC AATGATGATG ACCTGTATGG CTAAGTGGTG GTGGCCAGCG TGCAGTGAGC	2700
	TGGCTGCCT GGACCTTGTT CCCTGGGGGT GGGGGCGCTT GCCCAGGAGA GGGACCAGGG	2760
	GTGCGCCAC AGCCTGCTCC ATTCTCCAGT CTGAACAGTT CAGCTACAGT CTGACTCTGG	2820
20	ACAGGGGGTT TCTGTGCAA AAATACAAAA CAAAAGCGAT AAAATAAAG CGATTTTCAT	2880
	TTGGTAGGCG GAGAGTGAAT TACCAACAGG GAATTGGGCC TTGGGCTATG CCATTTCTGT	2940
25	TGTAGTTTGG GGCAGTGCAG GGGACCTGTG TGGGTGTGA ACCAAGGCAC TACTGCCACC	3000
	TGCCACAGTA AAGCATCTGC ACTTGACTCA ATGCTGCCCG AGCCCTCCCT TCCCCCTATC	3060
	CAACCTGGGT AGGTGGGTAG GGGCCACAGT TGCTGGATGT TTATATAGAG AGTAGGTTGA	3120
30	TTTATTTTAC ATGCTTTTGA GTTAATGTTG GAAACTAAT CACAAGCAGT TTCTAAACCA	3180
	AAAAATGACA TGTGTAAAA GGACAATAAA CGTTGGGTCTN AAATGGGWRA AAAAAAAAAA	3240
35	AAAAAAGGGG GGCCCTCTA AAGNNCCANN CTTCGT	3276

40 (2) INFORMATION FOR SEQ ID NO: 292:

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 1695 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 292:

50	TTGCAATGGT TGAATTCCTC TCCTCAGGCC AGCTAGGAG AAGAAGTTG TAGTCCCAGA	60
	GGTGAGGCAG GAGCGGCAG TTCTGGCGG GTGAGGCGG AGCTGAAGTG ACAGCGGAGG	120
	CGGAAGCAAC GGTGGTGGG GCGGAGAAGG GGGCTGGCCC CAGGAGGAGG AGGAAACCTT	180
55	TCCGAGAAAA CAGCAACAAG CTGAGCTGCT GTGACAGAGG GGAACAAGAT GCGGCGCCG	240
	AAGGGAGCCT CTGGGTGAGG ACCCAACTGG GGCTCCGCC GCTGCTGCTG CTGACCATGG	300
60	CCTTGGCCGG AGGTTGGGG ACCGCTTCGG CTGAAGCATT TGAATCGGTC TTGGGTGATA	360

	CGGCGTCTTG CCACGGGGCC TGTCA GTTGA CCTACCCCTT GCACACCTAC CCTAAGGAAG	420
	AGGAGTTGTA CGCATGTCAG AGAGGTTGCA GGCTGTTTTT AATTGTGTCAG TTTGTGGATG	480
5	ATGGAATTGA CTTAAATCGA ACTAAATTGG AATGTGAATC TGCATGTACA GAAGCATATT	540
	CCCAATCTGA TGAGCAATAT GCTTGCCATC TTGGTTGCCA GAATCAGCTG CCATTCGCTG	600
10	AACTGAGACA AGAACAACTT ATGTCCCTGA TGCCAAAAAT GCACCTACTC TTTCTCTTAA	660
	CTCTGGTGAG GTCATTCTGG AGTGACATGA TGGACTCCGC ACAGAGCTTC ATAACCTCTT	720
	CATGGACTTT TTATCTTCAA GCCGATGACG GAAAAATAGT TATATTCCAG TCTAAGCCAG	780
15	AAATCCAGTA CGCACCACAT TTGGAGCAGG AGCCTACAAA TTTGAGAGAA TCATCTCTAA	840
	GCAAAATGTC CTATCTGCAA ATGAGAAATT CACAAGCGCA CAGGAATTTT CTTGAAGATG	900
20	GAGAAAGTGA TGGCTTTTTA AGATGCCCTCT CTCTTAACTC TGGGTGGATT TTAACCTACAA	960
	CTCTTGTCCT CTCGGTGATG GTATTGCITT GGATTGTGTG TGCAACTGTT GCTACAGCTG	1020
	TGGAGCAGTA TGTTCCTCTT GAGAAGCTGA GTATCTATGG TGACTTGGAG TTTATGAATG	1080
25	AACAAAAGCT AACAGATAT CCAGCTTCTT CTCTTGTGGT TGTTAGATCT AAAACTGAAG	1140
	ATCATGAAGA AGCAGGGCCT CTACCTACAA AAGTGAATCT TGCTCATTCT GAAATTTAAG	1200
30	CATTTTTCTT TTAAAAGACA AGTGTAATAG ACATCTAAAA TTCCACTCCT CATAGAGCTT	1260
	TTAAAATGGT TTCATTGGAT ATAGGCCTTA AGAAATCACT ATAAAAATGCA AATAAAGTTA	1320
	CTCAAACTCG TGAAGACTGT ATTTGCTATA ACTTTATTGG TATTGTTTTT GTAGTAATTT	1380
35	AAGAGGTGGA TGTTTGGGAT TGTATTATTA TTTTACTAAT ATCTGTAGCT ATTTTGTTTT	1440
	TTGCTTTGGT TATTGTTTTT TTCCCTTTTC TTAGCTATGA GCTGATCATT GCTCCTTCTC	1500
40	ACCTCCTGCC ATGATACTGT CAGTTACCTT AGTTAACAAG CTGAATATTT AGTAGAAATG	1560
	ATGCTTCTGC TCAGGAATGG CCCACAAATC TGTAATTTGA AATTTAGCAG GAAATGACCT	1620
	TTAATGACAC TACATTTTCA GGAAGTGAAT TCATTAAAAT TTTATTTGAA TAATTAAAAA	1680
45	AAAAAAAAAA AANCT	1695

50 (2) INFORMATION FOR SEQ ID NO: 293:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1501 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 293:

60 CACTTTCAGC AGTCCTTTGC TCTCTTTGCT TCTACCTCAA ATAGCCCCAG GAGTGGGCTT 60

	TAGTCTCCAA TATGGAGCAT CTCAAGCTTC TCCTGGGGGA TGGGGATTGG GATGGGCAGA	120
5	ATCTGTTTTG GWTCTCCGGG TTATTTCCAG TGGGTGTAAA AGCAGAGCTG GGCCTTTCCC	180
	TCTCTTATCC CTGAGGGTGG GTAAGAAGGA CTGTATCTAC ACCTGTTCTT CCCTACCTTC	240
	TCTTTTGTTA GGGAGGCCTC ATTCTAAGTT CCTCAAGAGA GTCCTTGGCT TAAAGCTGTA	300
10	GCAAGGGTGT GCTAGGTGGG GGATTGGAG CAAAACCGTC GAGTAGGCAT GATACTGGTA	360
	TGGAGTGGGC CTGCAAAATC AGACAGAAAT GGCTTGAGAA GCCGCAGGGG AGCATGCCTG	420
15	TCTCTCAGTG ATAGAGTATG GGAGGGACCT CCTAGCTTG GAAAATGAGA ATTGAAGGGG	480
	TTATGAACAA ATAGGATGCC TAGTTGAGGA TGTTCCTAAA GTTTTGTTCA ATCTTATCAT	540
	TAGTAGATT TATAAGCCAC AGAGACAAAC CAGAAACGGA ATAATGTTAC TTTGGATGCT	600
20	TTATTTTTTT GTTCTAGGTG TGGCTTTGTA CATGCAGAAG AATGCTATAT GCTGCACATT	660
	TTGCCCTTAA AGTCTTACGA CTTTCCCAT TTTAGTCTAA TGGGAAGATA CAGATGTGCA	720
25	AGTCTGCTTT TTGTTTTTT GTTATTATTT TTTTTTTTTT GCTCTGTGTT ATGGACATTT	780
	TCAGACATGC ACAGAAGTGG AGAGGATGGT CCTTGGACCC MATGTGTCCA TCACCTAGCT	840
	GCATCACTTA TCAGCTATGG TCAACCTGGT TTCATCTGTA TCTCTCTCTT TTCACCTGTA	900
30	TTGTTTATTG AAAATCCAAG ACACTATGCC AATGCAACCG TGACTACTTT GGGAGATTGG	960
	TAGTCTCTTT TGATGGTGAT AGTGATGGG TGCATATCA TAATCACATC AGGTCTGCTT	1020
35	TTTGCTTTTA ATGTTAACTA ATGAAGTCC AGAGATGGGC CTTAGAAATG TGTTTTAAGA	1080
	ATTAACAAGG AGTCTCAAAA AGAAATGAGA GGGATGCCTC CTTTNCCTT GCATCTACAA	1140
	AACMAGAGAG AGACTGTTCT GTGTAAAAC TCTTTCAAAA ATTCTGATAT GGTAAAGTAC	1200
40	TTGAGACCCCT TCACCAGAAT GTCAATCTTT TTTTCTGTGT AACATGGAAA CTTGTGTGAC	1260
	CATTAGCATT GTTATCAGCT TGTACTGGTC TCATACTCT GGTTTTGGAA GAATAATTTG	1320
45	GAAATGTGTG CTGTGTTCTG TGAAAATAAC CTCCTCAAAA TAATTAGTAA CTGGTTGTTC	1380
	TACTTGGTAA TTTGACACCC TGTTAATAAC GCAATTATTT CTGTGTTCTT AAACAGTATA	1440
	AATAGTTGTA AGTTTGATG CATGATGGAA AAATAAAAAC CTGTATCTCT GTTAAAAAAA	1500
50	A	1501

55 (2) INFORMATION FOR SEQ ID NO: 294:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2683 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

60

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 294:

5	TGANTGTGGT CCGGGGTGCN GATGGGCAGN GCCTCCGCCG CGGCTCGTGG TTGTCCCGCC	60
	ATGGCACTGT CGCGGGGGCT GCCCGGGGAG CTGGCTGAGG CGGTGGCCCG GGGCCGGGTR	120
10	CTGGTGGTGG GGGCGGGCGG CATCGGCTGC GAGCTCCTCA AGAATCTCGT GCTCACCGGT	180
	TTCTCCACA TCGACCTGAT TGATCTGGAT ACTATTGATG TAAGCAACCT CAACAGACAG	240
	TTTTTGTTC AAAAGAAACA TGTGGAAGA TCAAAGGCAC AGGTGCCAA GGAAAGTGTA	300
15	CTGCAGTTTT ACCCGAAAGC TAATATCGTT GCCTACCATG ACAGCATCAT GAACCCTGAC	360
	TATAATGTGG AATTTTTCCG ACAGTTTATA CTGGTTATGA ATGCTTTAGA TAACAGAGCT	420
20	GCCCGAAACC ATGTTAATAG AATGTGCCTG GCAGCTGATG TTCCTCTTAT TGAAAGTGGA	480
	ACAGCTGGGT ATCTTGACA AGTAATACT ATCAAAAAGG GTGTGACCGA GTGTTATGAG	540
	TGTCATCCTA AGCCGACCCA GAGAACCTTT CCTGGCTGTA CAATGCTAA CACACCTTCA	600
25	GAACCTATAC ATTGCATCGT TGGGCAAAG TACTTGTICA ACCAGTTGTT TGGGAAGAA	660
	GATGCTGATC AAGAAGTATC TCCTGACAGA GCTGACCCTG AAGCTGCCTG GGAACCAACG	720
30	GAAGCCGAAG CCAGAGCTAG AGCATCTAAT GAAGATGGTG ACATTAAACG TATTTCTACT	780
	AAGGAATGGG CTAAATCAAC TGGATATGAT CCAGTTNAAA CTTTTTACCA AGCTTTTTTAA	840
	AGATGACATC AGGTATCTGT TGACAATGGA CAACTATGG CGGAAAAGGA AACCTCCAKT	900
35	TCCGTTGGAC TGGGCTGAAG TACAAAGTCA AGGAGAAGAA ACGAATGCAT CAGATCAACA	960
	GAATGAACCC CAGTTAGGCC TGAAAGACCA GCAGGTCTA GATGTAAAGA GCTATGCACG	1020
40	TCTTTTTTCA AAGAGCATCG AGACTTTGAG AGTTCAITTA GCAGAAAAGG GGGATGGAGC	1080
	TGAGCTCATA TGGGATAAGG ATGACCCATC TGCAATGGAT TTTGTACCT CTGCTGCAA	1140
	CCTCAGGATG CATATTTTCA GTATGAATAT GAAGAGTAGA TTTGATATCA AATCAATGGC	1200
45	AGGGAACATT ATTCTCTGTA TTGCTACTAC TAATGCAGTA ATTGCTGGGT TGATAGTATT	1260
	GGAAGGATTG AAGATTTTAT CAGGAAAAAT AGACCACTGC AGAACAATTT TTTTGAATAA	1320
50	ACAACCAAAC CCAAGAAAGA AGCTTCTTGT GCCTTGTCGA CTGGATCCTC CCAACCCCAA	1380
	TTGTTATGTA TGTGCCAGCA AGCCAGAGGT GACTGTGCGG CTGAATGTCC ATAAAGTGAC	1440
	TGTTCTCACC TTACAAGACA AGATAGTGAA AGAAAAATTT GCTATGGTAG CACCAGATGT	1500
55	CCAAATTGAA GATGGGAAAG GAACAATCCT AATATCTTCC GAAGAGGGAG AGACGGAAGC	1560
	TAATAATCAC AAGAAGTTGT CAGAATTTGG AATTAGAAAT GGCAGCCGGC TTCAAGCAGA	1620
60	TGACTTCCTC CAGGACTATA CTTTATTGAT CAACATCCTT CATAGTGAAG ACCTAGGAAA	1680

	GGACGTTGAA TTTGAAGTTG TTGGTGATGC CCCGGAAAAA GTGGGSSCCA AACAGCTGA	1740
	AGATGCTGCC AAAAGCATAA CCAATGGGCA GTGATGATGG AGCTCAGCCC TCCACCTCCA	1800
5	CAGCTCAAGA GCAAGATGAC GTTCTCATAG TTGATTGGGA TGAAGAAGAT TCTTCAAATA	1860
	ATGCCGACGT CATGAAGAAG AGAGAAGCCG CAAGAGGAAA TTAGATGAGA AAGAGAATCT	1920
10	CAGTGCAAAG AGGTCACGTA TAGAACAGAA GGAAGAGCTT GATGATGTCA TAGCATTAGA	1980
	TTGAACAGAA ATGCCTCTAA ACAGAACCCCT CTTACTATTT AGTTTATCTG GGCAGAACCA	2040
	GATTGTTATG TCCTTTGTTC CAAAGGGAAA AAATTGACAG CAGTGACTTG AAAATGATTG	2100
15	TGCTCCCTTT GAAAGCATTG ATTTTGCTAG AACTGTTAGA CACATTGCAG TATGCTGTAT	2160
	TGAAAGTAGG AATATAGTTT TAAAAACCCCT TTGAACAAAG TGTGTGCATA ACCAGTCATG	2220
20	AGATAAACA ACACAATGCA TGTTCCTTTT TTAATGTAAA TACCCTTAGG TATCATTAAAT	2280
	AGTTTCAAAA TATTGTGGTT TAGTAAAGTT GATACCTGGT TATAAATATT ATGCCCTTAT	2340
	TTTTCGGCTAG AAGAAGAATT ATTTTTCAGC TAGATCTAAC CATTTTCATA CTCTTAACTG	2400
25	ATTGAAACAG ATTCAAAGAA GTATCGAGTG CTATGCATTG AAACCTGTTT TTAAATGTTA	2460
	GATGGCACTA TGTATATTAA TGTAACAAAC TGTTAATTTA CTCAAGTTTT CAGTTTGTAC	2520
30	CGCCTGGTAT GTCTGTGTAA GAAGCCAATT TTTGTGTATT GTTACAGTTT CAGGTTATTT	2580
	ATATTCGATG TTTTGTAAAA CTCAAATAAC GACTATACTT ATGGACCAAA TAAATGGCAY	2640
	TGCATTCTKG TKAAAAAAN NACAGAAAAA AAAAAAACA AGA	2683
35		

(2) INFORMATION FOR SEQ ID NO: 295:

- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1454 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 295:

	GGACTCGGGG TGGCTCTAAG GGGCAGGGAT AGGGCTGGGG AGCGCCGGCC TGTGGCCCTG	60
50	ACCAGCCCTT TCTCGTGAG GTCCACCCC GATGCAGGTG GTCACGTGCT TGACGCGGGA	120
	CAGCTACCTG ACGCACTGCT TCCTCCAGCA CCTCATGGTC GTGCTGTCTT CTCTGGAACG	180
55	CACGCCCTCG CCGGAGCCTG TTGACAAGGA CTTCCTACTCC GAGTTTGGGA ACAAGACCAC	240
	AGGGAAGATG GAGAACTACG AGCTGATCCA CTCTAGTCGC GTCAAGTTTA CCTACCCAG	300
	TGAGGAGGAG ATTGGGGACC TGACGTTTAC TGTGGCCCAA AAGATGGCTG AGCCAGAGAA	360
60	GGCCCCAGCC CTCAGCATCC TGCTGTACGT GCAGGCCTTC CAGGTGGGCA TGCCACCCCC	420

	TGGGTGCTGC AGGGGCCCC TGCGCCCCAA GACACTCCTG CTCACCAGCT CCGAGATCTT	480
5	CCTCCTGGAT GAGGACTGTG TCCACTACCC ACTGCCCGAG TTTGCCAAAG AGCCGCGCA	540
	GAGAGACAGG TACCGGCTGG ACGATGGCCG CCGCGTCCGG GACCTGGACC GAGTGCTCAT	600
	GGGCTACCAG ACCTACCCGC AGCCCTCACC CTGTYTTTCG ATGACGTGCA AGGTCATGAC	660
10	CTCATGGGCA GTGTACCCCT GGACCACTTT GGGGAGGTGC CAGGTGGCCC GGCTAGAGCC	720
	AGCCAGGGCC GTGAAGTCCA GTGGCAGGTG TTTGTCCCCA GTGCTGAGAG CAGAGAGAAG	780
15	CTCATCTCGC TGTGTGCTCG CCAGTGGGAG GCCCTGTGTG GCCTGAGCTG CCTGTGAGC	840
	TCACCGGCTA GCCCAGGCCA CAGCCAGCCT GTCGTGTCCA GCCTGACGCC TACTGGGGCA	900
	GGGCAGCAGG CTTTGTGTGT CTCTAAAAAT GTTTTATCCT CCCTTTGGTA CCTTAATTTG	960
20	ACTGTCTCTG CAGAAATGTG AACATGTGTG TGTGTGTGT TAATTCCTTC TCATGTTGGG	1020
	AGTGAGAATG CCGGGCCCCCT CAGGGCTGTT CCGTGTGCTG TCAGCCTCCC ACAGGTGGTA	1080
25	CAGCCGTGCA CACCAGTGTG GTGTCTGCTG TTGTGGGACC GTTGTTAACA CGTGACACTG	1140
	TGGGTCTGAC TTTTCTTCT ACACGTCTT TCCTGAAGTG TCGAGTCCAG TCCTTTGTTG	1200
	CTGTGCTGTG TGCTGTGCT GTTGTGTTG GCATCTTGCT GCTAATCCTG AGGCTGGTAG	1260
30	CAGAATGCAC ATTGGAAGCT CCCACCCCAT ATTGTCTTTC AAAGTGGAGG TCTCCCTGA	1320
	TCCAGACAAG TGGGAGAGCC CGTGGGGCA GGGGACCTGG AGCTGCCAGC ACCAAGCGTG	1380
35	ATTCTGTCTG CCTGTATTCT CTATTCCAAT AAAGCAGAGT TTGACACCGW MAAAAAAAAA	1440
	AAAAAAAAAA AACN	1454

40

(2) INFORMATION FOR SEQ ID NO: 296:

(i) SEQUENCE CHARACTERISTICS:

45

- (A) LENGTH: 828 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 296:

50

ACCCCTGGCAT GCCCACAAC CAGATACCA GCCAGCTTAC ACAGGCATTA ACTCTCTCA	60
ATGAGGAAGA ATCATTCACA ACTGAGCAAG ACATTCATAT GATCATTTAA GGAAGTGTIT	120
CCCTTATGTG TTAGCAAGTA TAATCGGCTA ACTCCTAAAT CCCAATGAAT AGTCCTAGGC	180
TGGACAGCAA TGGGCTGCAA TTAGGCAGAT AAAGACATCA GTCCAGTAA ATGAATCCAT	240
AGACTCATCT AGCACCAACT ACCATTAGCA CTATGTTAGG AGCTGCAAGG CCCCAAAGTA	300

60

GAAGATGTGC ATAATGTCCTG CTCTTGTTGA GCTCAGGAGA CAATTCAGC ACAGACACTA 360
 CAGTTAAGCG TGAAGTCAG CTGCAAGTAA TAGCAWGAAC AGTCAGAAAA ATACCTTATG 420
 5 AGGGGGCAGG GCTGAAGCTG GGCCTTGAAG GATGGATGAA ATTTGGATAG AGAATGAGGA 480
 AGACAGAGGG NCTCCAAGTG AGAGAAGCAT GAAAAATGAG CARGGGCCTG GATCAGTGGG 540
 GTGTATTTCAG AGCACCTTTC CAGATGCACC ATGCATGCTC ACAGTCCCTT GCCTATGTGT 600
 10 GGCAGAGTGT CCCAGCCAGA TGTGTGCCCC CACCCCATGT CCATTTACAT GTCCTTCAAT 660
 GCCACCTCA AAAGGYACYT CTTCTGTAAA GCTTTCCTK GGTATCAGGA ATCAAAATTA 720
 15 ATCAGGGATC TTTTCACACT GCTGTTTTTT CCTCTTTGGT CCTTCTATCA CTAAAATCA 780
 TCTCATTCAG CCTTACAGCA TAACTAATTA TTTGTTTTCC TCACTACA 828

20

(2) INFORMATION FOR SEQ ID NO: 297:

(i) SEQUENCE CHARACTERISTICS:
 25 (A) LENGTH: 2416 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 297:

TCAATTTCCA TTAAGTCAGA TCAGCCATTG TGATTCACCA TTTGTCAGGC TCTCAGGTTT 60
 AACAAAACCT ACTATCACCA TCATCCTTCA ACAGCCACAG TCTGAATTGA GCCAACATTT 120
 35 TTTTTCCTTT GAGAAAGAAG TGGACTGGGG CACAACCTTT AGTCTGAGGG GAGCTAGTGG 180
 AAATCTAGAC AATAGAAGTC ATCGATAGCA GCTTTTCCTC AAATGTGTGA CTCCTCAGGG 240
 40 GCTAAACTGC TCTTAGCTTA GAATTATGCT TTAGTAGAGA TCTAGCAGAT AAGTGGGTTA 300
 ATCACTACCA TCCTGTAACT AGTTATATAG CTTCAGACA TGAGGGAGAC ATCAAAACAGG 360
 GATGGAAGCA ACCCCAAGGA TATGCAAGAA GGCATGATG AACCCCTTC CCTCTGGCAG 420
 45 GAGAACAAGG CCAACCAAGG GACAGACTGG AAAGCACTTA GATGTTTAAG GAGGAGAAAG 480
 GGAAGCTTT GACCAGTCCT TGCCTTTTCG CAAGTTCAGC CAGTTCTCCG CTGCTTGCAA 540
 50 CCTCTAGCGC AGTAACATTT GCAGAATTGC AGATTTTCCC CCAGATACTA GGAGGAAAGG 600
 GACTTTGGGG GGTGGGGAAG GGTGCTGGT GTTTTAAAAG CATAAGTTAC CTGTTTGCAC 660
 TGTTTTAAGA TAGGAAAAAA AAATAGTGGG CAAGGTGAAC ATCAGACGTA AATTTGTGTG 720
 55 TTTTATTTT GTCATGCTCT TGAAATGTT TGACCATTTG TAGTATACAC AGTGAACTT 780
 GATTCTCTGT TGCATAAAAC ACTATATTTT TTTGAAATG TTAGTGCCA AAAGCCTCTT 840
 60 CCTCCCTTT CCTTTTCTA TGTACTTCCT TCATACTGTC TTTACTGATC AGCCAGGCAA 900

	TAGCCATCCA AGAGCTAGAG CATGAAACAG GGCCCTTTC AAGTAGGCTC TGGGTGTCCT	960
5	AAGCCAGCGT GTGCCCTCTG GTTTAGTGAG TGTAAATAGAG TCCCTGGCAC CTTTCTTTGC	1020
	AAATGAGGCT AACAGACCAG ACTGCAGCAA GTTATCAGAT TCCTCAATCA GATGCACTAG	1080
	GAGTGAGGAG CCCAGGGATG GAGGGGGTTC CTGAAGTATT GCAGTTGGCT GTAGTAGCTG	1140
10	AGTTCTTTTC CATGTTACCG AAACGTAGC CAGTTACAGT TTACTCAGGA AAACGGTAGA	1200
	TCAATTCAGC CATGGTAGTG CTGGTTGGCA GGGATGGTA ACGGAGAGAA CTGCTCATCA	1260
15	GCCAAACTC AAGCCTTGCC TTTTAGGAGG CCACCAGCAG AGGGACTTGG TCCTCCTTGT	1320
	CTGGTACTTG TGTACATGCC GGTGACCTGA GGACTCCACT CACACTGGCG AGCAAAAAGG	1380
	GAGCAGTGAT TCTCTTTTCT CTCCCCACC CCTGCCCTTT GTTACCAACA CCAGTTTCCC	1440
20	AGGGGGTACA TGAGTTTCTG AATTTTAA AAATGTTTTT GGTTTGGTTT TTCTGGGGAC	1500
	TGATAAGTGC TTAAAGCAAT GTCCATACCC CGTCAAGACT CCCAGCTTAG TCATTTTCTT	1560
25	GTATTTTCT GTTCACAGTA TTTGTGTGTG TGCTTGTITT GGCAGCTCAT TTTGGCTGTA	1620
	TTATATATTG AGTGATGAAT TGATCCTCTT TTTTCCCTAA GGGATATGAA TTGTTTTTCT	1680
	TGTGTTATAT TCTGCTTGTG AATAGCTGGA GCAAACCTGG GGCTGACACG CGTAAGSTAG	1740
30	GGCTGCAAR CGAGAAGAGA GCGGTGGAG TGTACTTGTC CCTGACAGGC TGACCTACCT	1800
	GAGTCTCTGA GCTTTTCAGT CCAAATCTTT GCAAGGCTCA AAATGCCACA GAACCTCTCC	1860
35	TCTTCTCCCC ACTCCCCATG GCAGGGACCG GACCATCCCT ACATGCAACA TGCTGTTCTT	1920
	CCAGCCCCTC CCATTGCCAT GGCAAAACAG GTACCTTTGG GGCATGGGGG CATTACATGG	1980
	GATGCTTGTG TAATCGACCA CCTAGCCTTC TCTCTCCCT CCCGTCTCTC CCCAGAATCA	2040
40	CTTCCTAGGA CACCCGAGCT GCTTGCCAG GGTCTGTTT CCCTGCTAAC TCCAGAGAAG	2100
	CATCCAGGG CTTTGTGACA GTCTCTAATT CCCTTCCCTT CTCGTAAAGA ATCATATTGT	2160
45	ATAGTAGCTT TCAGACCATA CAGTATTCAT TGGGTACTC CTATTATTAT CAAGTAGCTG	2220
	GAATTGTGAA GGTGGGAGTA GTTAGATCTT TAGCTTTTAT TCCTTATTTT TTTGTATTAC	2280
	TCTCCATGTG TATAAATTAT TGATCATGTT GCTGGCTTTT ATAAACTCTA AGCGAAGGAG	2340
50	GAGCACTGCC TCAGCCTTTG CACATGGTAA TGAAGCACTG TTTTAAATA AAAGRGRGAA	2400
	MMCCAAAAA AAAAAA	2416

55

(2) INFORMATION FOR SEQ ID NO: 298:

60

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 545 base pairs

- (B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 298:

GAATTCGGCA CGAGCCATGC YTGGCCTCTC CTTGATTCTT ACAGTCACTT TGTGCGCTGT 60
TTCTGACTCA GCAGCTACCT GCATTGTGGC CAAAGGATGA CCTATTCCTT CTCAGGAGGG 120
10 CAAAAATGTG GAATAGTGTG TGTCCATGCC TCTCCTCATG GGCTACCACC TCTGCCACCG 180
TGGTTAATCA GTAACAACCA GGAGAGAAGC TGCTGGAAC TACCTCTGGG AACTCCCTGG 240
15 ATGTTTGGT GCAGGAATGT AGTAGGCATA CACGTGGTGT CGTGGATCTG GGCCCTCCTG 300
ATGTGAGTAG AGAGGTAAAA GGSCACCATC TCCTTGACCT YTGCGGAAC CATCCACAAA 360
GAAGATGTTT CCAAGATGCT TCTGAAGATT GSCTAAAAAT AGCCGGTTTC CACCCCGTGT 420
20 AATGCATCCA TTCTAGAATG CTCCTTCACC AGGACCAGAG AACTGATTTA CAGAAGTGAC 480
ATGAAAACAT TCCATCCAG AATTGCAAT ACCTCAAATT NAATTTCTAC CTATTAAAAA 540
25 NAAAA 545

30 (2) INFORMATION FOR SEQ ID NO: 299:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1530 base pairs
(B) TYPE: nucleic acid
35 (C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 299:

40 GGCTCTGCTG GGCATCATAC TTGTCACTGG GTAAACAGTT TGCCCACTTA CCGCAGATGA 60
AGCTGCTTGC CAGGGCTCTC CGGCTCTGTG AGTTTGGGAG GCAGGCATCT TCCAGGAGGC 120
TGTTGGCTGG CCAGGGATGT GTGGGGCCCC GCGAGGGTG CTGCGCTCCC GTCCAGGTGG 180
45 TTGGGCCAG GGCTGATCTC CCACCTGTG GAGCCTGCAT TACTGGAAGG ATCATGCGGC 240
CAGATGATGC CAACGTGGCC GGCAATGTCC ACGGGGGAC CATCCTGAAG ATGATCGAGG 300
50 AGGCAGGCGC CATCATCAGC ACCCGGCATT GCAACAGCCA GAACGGGGAG CGCTGTGTGG 360
CCGCCCTGGC TGTGTGAGAG CGCACCAGCT TCCTGTCTCC CATGTGCATC GGTGAGGTGG 420
CGCATGTGAG CGCGGAGATC ACCTACACCT CCAAGCACTC TGTGGAGGTG CAGGTCAACG 480
55 TGATGTCCGA AAACATCTC ACAGGTGCCA AAAAGCTGAC CAATAAGGCC ACCCTGTGGT 540
ATGTGCCCT GTGCTGAAG AATGTGGACA AGGTCTCGA GTGCTCTCT GTTGTGTATT 600
60 CCGGCGANGA GCAGGAGGAG GAGGGCCGA AGCGGTATGA AGCCAGAAG CTGGAGCGCA 660

	TGGAGACCAA GTGGAGGAAC GGGGACATCG TCCAGCCAGT CCTCAACCCA GAGCCGAACA	720
5	CTGTCAGCTA CAGCCAGTCC AGCTTGATCC ACCTGGTGGG GCCTTCAGAC TGCACCCCTGC	780
	ACGGCTTTGT GCACGGAGGT GTGACCATGA AGCTCATGGA TGAGGTGCCC GGGATCGTGG	840
	CTGCACGCCA CTGCAAGACC AACATCGTCA CAGCTTCCGT GGAAGCCATT AATTTTCATG	900
10	ACAAGATCAG AAAAGGCTGC GTCATCACC A TCTCGGGACG CATGACCTTC ACGAGCAATA	960
	AGTCCATGGA GATCGAGGTG TTGGTGGACG CCGACCCCTGT TGTGGACAGC TCTCAGAAGC	1020
15	GCTACCGGGC CGCCAGTGCC TTCTTCACCT ACGTGTGCT GAGCCAGGAA GGCAGGTCCG	1080
	TGCTGTGCC CCAGCTGGTG CCGAGACCG AGGACGAGAA GAAGCGCTTT GAGGAAGGCA	1140
	AAGGGCGGTA CCTGCAGATG AAGGCGAAGC GACAGGGCCA CGCGGAGCCT CAGCCCTAGA	1200
20	CTCCCTCCTC CTGCCACTGG TGCTCGAGT AGCCATGGCA ACGGGCCAG TGTCCAGTCA	1260
	CTTAGAAGTT CCCCCCTGG CCAAAAACCC AATTCACATT GAGAGCTGGT GTTGTCTGAA	1320
25	GTTTTCTGAT CACAGTGTTA ACCTGTACTC TCTCTGCAA ACCTACACAC CAAAGCTTTA	1380
	TTTATATCAT TCCAGTATCA ATGCTACACA GTGTGTCCC GAGCGCCGG AGGCGTTGGG	1440
	CAGAAACCCCT CGGGAATGCT TCCGAGCAG CTGTAGGGTA TGGGAAGAAC CCAGCACCAC	1500
30	TMATAAAGCT GNTGCTTGGC TGGGAAGNA	1530

35 (2) INFORMATION FOR SEQ ID NO: 300:

(i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 997 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 300:

45	AGGTAGTGAG AGACACATTA CACCTAACCA ACAAGAAGAA GGATCCTCCC CCTTATAATT	60
	TAACATATGTT TACAGGGAAT GCGTACATTG TGGCTTCCCG AGNATTTCTG CCAACATGTT	120
50	TTGAAGAACC CTAAATCCCA ACAACTGATT GAATGGGTAA AAGACACTTA TAGCCCAGAT	180
	GAACACCTCT GGGCCACCTT TCAGCGTGCA CGGTGGATGC CTGGCTCTGT TCCCAACCAC	240
	CCCAAGTACG ACATCTTCAG ACATGACTTC TATTGCCAGG CTGGTCAAGT GGCAGGGTCA	300
55	TGAGGGAGAC ATCGATAAGG GTGCTCCTTA TGCTCCCTGC TCTGGAATCC ACCAGCGGGC	360
	TATCTGCGTT TATGGGGCTG GGGACTTGAA TTGGATGCTT CAAAACCATC ACCTGTGGC	420
60	CAACAAGTTT GACCCAAAGG TAGATGATAA TGCTCTTCAG TGCTTAGAAG AATACCTACG	480

TTATAAGGCC ATCTATGGGA CTGAACTTTG AGACACACTA TGAGAGCGTT GCTACCTGTG 540
 GGGCAAGAGC ATGTACAAAC ATGCTCAGAA CTTGCTGGGA CAGTGTGGGT GGGAGACCAG 600
 5 GGCTTTGCAA TTCGTGGCAT CCTTTAGGAT AAGAGGGCTG MTATTAGATT GTGGGTAAGT 660
 AGATCTTTTG CCTTGCAAAT TGCTGCCTGG GTGRATGCTG CTTGTTCTCT CACCCCTAAC 720
 10 CCTAGTAGTT CCTCCACTAA CTTTCTCACT AAGTGAGAAT GAGAACTGCT GTGATAGGGA 780
 GAGTGAAGGA GGGATATGTG GTAGAGCACT TGATTTCACT TGAATGCCTG CTGGTAGCTT 840
 TTCCATTCTG TGGAGCTGCC GTTCTAATA ATTCCAGGTT TGGTAGCGTG GAGGAGAACT 900
 15 TTGATGGAAA GAGAACCTTC CCTTCTGTAC TGTTAACCTA AAAATAAATA GCTCCTGATT 960
 CAAAGTAAGG AAAAAA AAAAGAAAAA AACTCGA 997

20

(2) INFORMATION FOR SEQ ID NO: 301:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2345 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 301:

TTGAGGCCGA CGCTAGGGGC CCGGAAGRAA ACTGCGAGGC GAAGGTGACC GGGGACCGAG 60
 CATTTTCAGAT CTGCTGGTA GACCTGGTGC ACCACCACCA TGTGGCTGC AAGGCTGGTG 120
 35 TGCTCCGGA CACTACCTTC TAGGGTTTTC CACCCAGCTT TCACCAAGGC CTCCTCTGTT 180
 GTGAAGAATT CCATCAGGAA GAATCAATGG CTGTTAACAC CTAGCAGGGA ATATGCCACC 240
 40 AAAACAAGAA TTGGGATCCG GCGTGGGAGA ACTGGCCAAG AACTCAAAGA GGCAGCATTG 300
 GAACCATCGA TGGAAAAAT ATTTAAATTT GATCAGATGG GAAGATGGTT TGTGCTGGA 360
 GGGGCTGCTG TTGGTCTGG AGCATGTGC TACTATGGCT TGGGACTGTC TAATGAGATT 420
 45 GGAGCTATTG AAAAGGCTGT AATTGGCCT CAGTATGTCA AGGATAGAAT TCATTCCACC 480
 TATATGTA CTAGCAGGGAG TATTGGTTTA ACAGCTTTGT CTGCCATAGC AATCAGCAGA 540
 50 ACGCCTGTTT TCATGAACCT CATGATGAGA GGCTCTTGGG TGACAATTGG TGTGACCTTT 600
 GCAGCCATGG TTGGAGCTGG AATGCTGGTA CGATCAATAC CATATGACCA GAGCCCAGGC 660
 CCAAAGCATC TTGCTTGGTT GCTACATTCT GGTGTGATGG GTGCAGTGGT GGCTCCTCTG 720
 55 ACAATATTAG GGGTCTCTCT TCTCATCAGA GCTGCATGGT ACACAGCTGG CATGTGTTGA 780
 GGCTCTCCA CTGTGGCCAT GTGTGCGCCC AGTGAAGT TTCTGAACAT GGGTGCACCC 840
 60 CTGGGAGTGG GCCTGGGTCT CGTCTTGTG TCCTCATGG GATCTATGTT TCTTCCACCT 900

	ACCACCGTGG CTGGTGCCAC TCTTTACTCA GTGGCAATGT ACGGTGGATT AGTTCTTTTC	960
5	AGCATGTTCC TTCTGTATGA TACCCAGAAA GTAATCAAGC GTGCAGAAGT ATCACCAATG	1020
	TATGGAGTTC AAAAATATGA TOCCATTAACT TCGATGCTGA GTATCTACAT GGATACATTA	1080
	AATATATTTA TGCGAGTTGC AACTATGCTG GCAACTGGAG GCAACAGAAA GAAATGAAGT	1140
10	GACTCAGCTT CTGGCTTCTC TGCTACATCA AATATCTTGT TTAATGGGGC AGATATGCAT	1200
	TAAATAGTTT GTACAAGCAG CTTTCGTTGA AGTTTAGAAG ATAAGAAACA TGTCATCATA	1260
15	TTTAAATGTT CCGGTAATGT GATGCCCTCAG GTCTGCCCTT TTTTCTGGAG AATAAATGCA	1320
	GTAATCCTCT CCCAAATAAG CACACACATT TTCAATTCTC ATGTTTGAGT GATTTTAAAA	1380
	TGTTTTGGTG AATGTGAAAA CTAAAGTTTG TGTCATGAGA ATGTAAGTCT TTTTCTACT	1440
20	TTAAAATTTA GTAGGTTTAC TGAGTAACTA AAATTTAGCA AACCTGTGTT TGCATATTTT	1500
	TTTGGAGTGC AGAATATTGT AATTAATGTC ATAAGTGATT TGGAGCTTTG GTAAAGGGAC	1560
25	CAGAGAGAAG GAGTCACCTG CAGTCTTTTG TTTTTTTAAA TACTTAGAAC TTAGCACTTG	1620
	TGTTATTGAT TAGTGAGGAG CCAGTAAGAA ACATCTGGGT ATTTGGAAAC AAGTGGTCAT	1680
	TGTTACATTC ATCTGCTGAA CTTAACAAAA CTGTTTCATCC TGAAACAGGC ACAGGTGATG	1740
30	CATTCTCCTG CTGTTGCTTC TCAGTCTCTT CTTTCCAATA TAGATGTGGT CATGTTTGAC	1800
	TTGTACAGAA TGTTAATCAT ACAGAGAATC CTTGATGGAA TTATATATGT GTGTTTTACT	1860
35	TTTGAATGTT ACAAAGGAA ATAACTTTAA AACTATTCTC AAGAGAAAAT ATTCAAAGCA	1920
	TGAAATATGT TGCTTTTTCC AGAATACAAA CAGTATACTC ATGATTGCTA AGTGTTTTTT	1980
	TATTTTTGCA TATTTATTGA ACTGTCTAAT TGAATACAGC TTGCTCTTGT CACCTCTTCA	2040
40	AGCTTTCAAG CCTTTATAGA AAAGCTTCTT TGTGGCTTAC ACTGGAAATT ATGAAAGCAG	2100
	TTTTCTCCTT AAGACTTTTG GTTCTGCA TTGCTCTCA GACTAAGCAC TAAAAAGCAA	2160
45	AGCAAAACAG AACTAGTINCT GTCTTAATGA AATATATCAA CCCAAAAGTG TAATGAGGAA	2220
	AATGCTTCAT TAGTTTCCCC TAGCAGACTT TTAATCTCTT TAACTGCTA CACCATTACT	2280
	TTCTTGAGAC ATTTGTAAGT CCTTGATAC AGAAGAGTTA TATTTAGGAG GNCCTTAATG	2340
50	AAGGG	2345

55 (2) INFORMATION FOR SEQ ID NO: 302:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2369 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

60

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 302:

5	TTTTTTTTTT TTTTTTTTTT TTTTTCNCAAG ATCATTGTTT ATTTATTACT TCAGATAAAA	60
	AGATAGTATA CATATTAGGG AATCCCTTAA AATTCAACTC TAGAGTTATA CACCATCTAG	120
10	TACTTTTGCA ATGAATGTTA ACAACAACAA AAAAAATCTC TAAACACCTG AAAGCCOCAC	180
	TATTAACATG GACTATGGTA ATAAAAAATT TTGACATTTA ATTTGTTCAA CATATAGTAT	240
	TTACATTATG AAACCAATGG TGATGATACA ATAAAGTGAT AAAGAAATAG TAAAAATAAA	300
15	CTTTAAAAAG CAAAGGTTTA TAGTCTGACA ATGCTAATTA TCCTAATTGT ATATAAAAAA	360
	TTAAAAACATA GAGCTTTCCTG TTACAAAATT CTTAATCCTC TGGGTTGTAA TCATTACTTG	420
20	CTACCAATTT ACATGCAACA TCTGCTAGGA CTGACATTG ATTTTTCCTC CCAAGAATGT	480
	GTGAGTAGAT AAATGACATT TCAGAGCAGA TATTAATTTA CTTGTGGACA GAAAAAGAAA	540
	CTCAAGATTG GTACTGGTCA CAAGCCTCTT CCCAATAGAA ATTATAAAAA CAGTAAGATA	600
25	AAATTTAAAA AAAATCTAAA AAGGGGATGC ATAGGCCAAG AGTACCATAA ATGGCACAGC	660
	TCAAAAAATC CCAGGACCAA TCAGACACAC ATCTTTTCTC TCTCCTTCAG CGACAAGAGG	720
30	TCGATTTTGC CATCAAATAA CCATGATTGA AGCAAGCGAG GGGCACCAGG TGTACAACTG	780
	ATTAGATCTT GCAAAATACT AAGATGGGAG CAGGGGTGGC CAGAAGAAGG GGTAATTTAT	840
	ATATAATTCA AACTATATAC AGCATAAATG GAATGCAGCC CATCCCAAAC TGGCTCTGIG	900
35	AAACAATTGG ACCTTTATAG TTAAAATTAT AACAAGTGTA ATAATACAAT AGATTTACAT	960
	GGGAAGCAAA ATCCAAGGGA CATTTTATAT TAAGTATTTA CTGTGCTGTT TCAATTTAAA	1020
40	AATAATTTTG CTAAGTATAC ATCTCAACTG AAGTCTATGT AAAAAATGTC CTAATAGATA	1080
	CAGATATTTA CCTTTGGTGA GTTGAAGGCC TTTTGTGAC TTCTGTCTGA ACTGTAGGCA	1140
	GAATGCTAGA TGTACATGCA CATATGGAGA AACTCAAGCT GAGGTCATCC AAAAGCTGTG	1200
45	CGTATGAGGA GGCTGGAGGT ACTTTGAAAG TCAAAGTAGA CCAGAAACCC AAAACAGGTA	1260
	ACAGTGAGGA TGGCAACAGG GAATGGAATG CCAATATGGC AGTAAACTT TTTTAAAAA	1320
50	CAGAAAGAGG AAGGCCTCTC GTACCAGCAG AATCCTGTAC ACGTACAAAA AAGAAAAAGC	1380
	CACCCACCAT TTTGTAAAC AGAAGCCAAT TATAGTGTGG GAAAGTACAA ATTACAGAAA	1440
	ACCAGAAGTC AACAGAAGAA AACTACTGG TTTACTTGAG AGAAAGGAGA ATGGTTCACC	1500
55	CCGAGCAGAG TTAATTGGTG AACGCCGCCA CCACCGCCA CAGAACCTCA TTGGTGTGG	1560
	CCTTCAGACA TTCCACTTCA GGGTCTAAGT CGAGAARNIG CCGCACTCTC TTGGTAGCCA	1620
60	AATCATACTG CTCGTCCAGA AGAGGAGCAA AAGCATCTC CAGGACGTCC GAGGCATGAG	1680

	CCAGGTAAAT GAGGGCCAGC AAGCGCCTGT CCATGCGGTG AGGGTCATTC ACCCATTTGT	1740
	CAAGAACGGC TTCTGTACT TTCTTGATGA GCGCTGCTT AATGTTGTTA TTGGTGAGGG	1800
5	GATGIGTGT CATGTCAAAA AGTAGGAAGT TCTGTTTC TC GTTGTCAT ACACCCTTTT	1860
	CCACCAGGTT TTTAGCTAAT CGTCCCGTA CATTTCTTAA CTGATAATGC AATTTTAATG	1920
10	GATTCCATGT CTCACCACTA AGTAATTCAA TCCAGTTCTG GACCGTTTCT GGAGGCTGAG	1980
	TTTCCCTAAC ATGCTTCAGA GCTTCATCAA GAAGAACATC CCTGTGTGGA GCATCTGACT	2040
	TACAGATTAC CTTTCTTGTT AATAGACTTT TACGTCTCAT TCCACAAGCC TCTAGTTGTA	2100
15	ACCTTCTCT CAATGCTAAT TCAATTAACA TACAGCCAG TAATCCAGAT GATATACAGT	2160
	CATTCCAAAA TGATGTGTAA ACCTTCGCGG TCCTTGAGGC CCAGCAGGAG CACTTCTCTC	2220
20	ATCAGGTCA GCGCGTTTC CTGGAGTGC CCTTGTGCT CGTCGTCTG CTGTCGCGG	2280
	CGGCTCTGCG CGTCGTCTC GCTGCTAGCC GCGCGCGCG CCGCGCGCG CTCTGTGTCG	2340
	GCGCGTTGC GGGAGGCTC GGTGCGCG	2369
25		

(2) INFORMATION FOR SEQ ID NO: 303:

- 30 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1181 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - 35 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 303:

	GGGACGTGTG GTPTCAGCTC GTGGCCCTCC CCGTGGGTTT GCGACGTTTA GCGACTATTG	60
40	CGCCTGCGCC ACGCCGCTG CGAGACTGGG GCGGTGGYTG CTGGTCCCGG GTGATGCTAG	120
	GCGGCTCCCT GGGCTCCAGG CTGTTGCGGG GTGTAGGTGG GAGTCACGA CGGTTGGGG	180
45	CCCAGGTGT CCGGAAGGT GGCGCACATG GGCGGCAGG GAGAGCATGG CTCAGCGGAT	240
	GGTCTGGGTG GACCTGGAGA TGACAGGATT GGACATTGAG AAGGACCAGA TTATTGAGAT	300
	GGCCTGTCTG ATAACTGACT CTGATCTCAA CATTTTGGCT GAAGGTCTTA ACCTGATTAT	360
50	AAAACAACCA GATGAGTGC TGGACAGCAT GTCAGATTGG TGTAAAGGAGC ATCACGGGAA	420
	GTCTGGCCTT ACCAAGGCAG TGAAGGAGAG TACAATTACA TTGCAGCAGG CAGAGTATGA	480
55	ATTTCTGTCC TTTGTACGAC AGCAGACTCC TCCAGGCTC TGTCCACTTG CAGGAAATTC	540
	AGTTTCATGAA GATAAGAAGT TTCTTGACAA ATACATGCC CAGTTCATGA AACATCTTCA	600
	TTATAGAATA ATTGATGTGA GCACTGTTAA AGAACTGTGC AGACGCTGGT ATCCAGAAGA	660
60	ATATGAATTT GCACCAAAGA AGGCTGCTTC TCATAGGCA CTTGATGACA TTAGTGAAAG	720

CATCAAAGAG CTTCAAGTTT ACOGAAATAA CATCTTCAAG AAAAAAATAG ATGAAAAGAA 780
 5 GAGGAAAATT ATAGAAAATG GGGAAAATGA GAAGACCGTG AGTTGATGCC AGTTATCATG 840
 CTGCCACTAC ATCGTTATCT GGAGGCAACT TCTGGTGGTT TTTTTCCTC ACGCTGATGG 900
 CTTGGCAGAG CMCTCGGTT AACTTGCATC TCCAGATTGA TTA CTCAAGC AGACAGCACA 960
 10 CGAAATACTA TTTTCTCCT AATATGCTGT TTCCATTATG ACACAGCAGC TCCTTTGTAA 1020
 GTACCAGGTC ATGTCCATCC CTGGTACAT ATATGCATTT GCTTTTAAAC CATTTCTTTT 1080
 15 GTTTAAATAA ATAAATAAGT AAATAAGCT AGTTCTATTG AAATGCAAAA AAAAAAAAAA 1140
 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA N 1181

20

(2) INFORMATION FOR SEQ ID NO: 304:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 1537 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 304:

30 CTTTITGTGT TCGGCCGAT CCCACCTCTC CTCGACCCTG GACGTCTACC TTCCGGAGGC 60
 CCACATCTTG CCCACTCCGC GCGCGGGGCT AGCGCGGGTT TCAGCGACGG GAGCCCTCAA 120
 35 GGGACATGGC AACTACAGCG GCGCGGGCG GCGCGCCCG AANATGGAGC TGGCCCGGAA 180
 TGGGGAGGGT TCGAAGAAAA CATCCAGGGC GGAGGCTCAG CTGTGATTGA CATGGAGAAC 240
 ATGGATGATA CCTCAGGCTC TAGCTTCGAG GATATGGGTG AGCTGCATCA GCGCCTGCGC 300
 40 GAGGAAGAAG TAGACGCTGA TGCAGCTGAT GCAGCTGCTG CTGAAGAGGA GGATGGAGAG 360
 TTCTTGGCA TGAAGGGCTT TAAGGGACAG CTGAGCCGGC AGGTGGCAGA TCAGATGTGG 420
 45 CAGGCTGGGA AAAGACAAGC CTCCAGGGCC TTCAGCTTGT ACGCCAACAT CGACATCCTC 480
 AGACCTACT TTGATGTGGA GCCTGCTCAG GTGCGAACAG GGCTCCTGGA GTCCATGATC 540
 CCTATCAAGA TGGTCAACTT CCCCAGAAA ATTGCAGGTG AACTCTATGG ACCTCTCATG 600
 50 CTGGTCTTCA CTCTGGTTC TATCCTACTC CATGGGATGA AGACGTCTGA CACTATTATC 660
 CGGGAGGGCA CCTGATGGG CACAGCCATT GGCACCTGCT TCGGCTACTG GCTGGGAGTC 720
 55 TCATCCTTCA TTTACTTCCT TGCCCTACCTG TGCAACGCCC AGATCACCAT GCTGCAGATG 780
 TTGGCACTGC TGGGCTATGG CCTCTTTGGG CATTGCAATTG TCCTGTTCAT CACCTATAAT 840
 60 ATCCACCTCC ACGCCCTCTT CTACCTCTTC TGGCTGTGG TGGGTGGACT GTCCCACTG 900

	CGCATGGTAG CAGTGTGGT GTCTCGGACC GTGGGCCCCA CACAGGGGCT GCTCCTCTGT	960
	GGCACCCCTGG CTGCCCTACA CATGCTCTTC CTGCTCTATC TGCATTTTGC CTACCACAAA	1020
5	GTGNTAGAGG GGATCCTGGA CACACTGGAG GGCCCCAACA TCCCGCCCAT CCAGAGGGTC	1080
	CCCAGAGACA TCCCTGCCAT GCTCCCTGCT GCTGGGCTTC CCACCACCGT CCTCAAAGCC	1140
10	ACAGCCAAAG CTGTTGCGGT GACCCCTGCAG TCACACTGAC CCCACCTGAA ATTCTTGGCC	1200
	AGTCCTCTTT CCCGCAGCTG CAGAGAGGAG GAAGACTATT AAAGGACAGT CCTGATGACA	1260
	TGTTTCGTAG ATGGGGTTTG CAGCTGCCAC TGAGCTGTAG CTGOGTAAGT ACCTCCTTGN	1320
15	AGCTGTGGC ACTTCTGAAA GCACAAGGCC AAGAACTCCT GGCCAGGACT GCAAGGCTCT	1380
	GCAGCCAATG CAGAAAATGG GTCAGCTCCT TTGAGAACCC CTCGCCACTT ACCCCTTCCT	1440
20	TCTCTTTTAT CTCTCCACA TTGTCTTGCT AAATATAGAC TTGGTAATTA AAAAAAAAAA	1500
	AAAAAAAAA AAAAAAAAAA AAAAAAGGGG GGNCCCC	1537

25

(2) INFORMATION FOR SEQ ID NO: 305:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1493 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 305:

	TGCATGCCAA AACCAATGCC TGCCAAACAA AATCTTAGAC ATCCCAATAT AATATGTTAG	60
	TTATATTTCT ATTACATCA TTATTGAAAA TACCCAGCTC AGTGCCCTGGC TTAATAAATG	120
40	TTTAATTCCC TTACCTACTC TTGCTCTATT TTTTATTG AAATGGAGAT GAGCAAAATA	180
	ACACATTCAT GGCTGAAGCA ATTTTTTGA CATTCTTGT TACCAAAAGA TCTATAATCA	240
45	GGATGATCCT GAGCTGTICA AACAAAGCTGT ATATAAACAG ACAATGAAAC TCTTTGCAGA	300
	GCTGGAAATT AAAAGGAAAG AGAGAGAAGC CAAAGAGATG CATGAAAGGA AACGACAAAG	360
	GGAAGAAGAG ATTGAAGCTC AAGAAAAAGC CAAACGGGAA AGAGAGTGGC AGAAAACTT	420
50	TGAGGAAAGT CGAGATGGTC GTGTGGACAG CTGGCGAAAC TTCCAAGCCA ATACGAAGGG	480
	GAAGAAAGAG AAGAAAAATC GGACCTTCCT GAGACCACCG AAAGTAAAAA TGGAGCAACG	540
55	TGAGTGACCG CCCAAGGTCA CAGGCACAGA ACCTTTCCCC TGCTATCTCC CTTCCTGCTT	600
	CGAAGGACTC ATTCTTTCTT CCCACTTCCA CCCAACATA GAGTAGTATT TGCTTTTTAG	660
	TCCATTTTGT TTTCAATACG ATTTAATATC GATCAGAGTA ATTCTTTTGT ACATTGAAAT	720
60	GAGGGGCTTG GTTTAAAAA AGACCTTTCC CTCTCCCTGC CCTAGAACA ACCAGTATTA	780

	GAAGGTGCCA CCATTGGTGC TGCCCTCTCT TCCCACAGCC TGTAAGTCAG TGTTTTGTAC	840
5	TTCACTGAAT TGTGATGGTT AGAACTTCG TGGATAGTTT GTGGAAATCA TCCAATTAAA	900
	CATACTGCTT AAAACAGTGT TGCTGTGACT TCAGAGACAA GCCTGGAAGG GGCACCTTAG	960
	GAAGCCCCCT CGCTTCAGTT GCTCGCTTCT GGGTGTGCTC CCTTCGAAGG CCCAGATAAG	1020
10	ACAGGGAACA CTGTGAGCA CACAGAGCAG CATCTGATGC CCTGTGGTGT TTGGCATGTG	1080
	CCCCCTGTCT ACTGACCAAT CAGTGTGGCA TGAGGCCAC GCCACCCAAA CCTTTCACCT	1140
15	TCAAAGAGC TAGCCGTCCT CCACCCAGTA CCATGTCCTA GCCTGTCTGC ATTTGTTAGT	1200
	GGTAATATTC TTTATGTATA ATAAATTTT ATACCCAAGC CATGTAGTA CTTTTCCTTG	1260
	TACTCTCCCT TGTGGTCCC TTGCTGGCT TGGCTGAACC CCAAAATGCT TTGGGGTTGG	1320
20	ACAGACCTGG CTGAACCTTA GTTCTTCAT CTATGAAATG GGAATATGAA TTACTGCAGC	1380
	AGCTTTTAGG GCAGATTTGC CATGGCATAT ACAAGGTAAC TACCATAGTG CTCCTTGGGT	1440
25	ATTGCCAATA TCCTATTAT TCTGTGTAAA ATGAAGATAC TGATTGTTTT GAG	1493

30 (2) INFORMATION FOR SEQ ID NO: 306:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 577 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 306:

40	AATTGGGCAG AGGNATTATA TACACTATAC TGGCATTAC TGTTTCACCC AGCCCGGAAA	60
	GTCAGAGATG TATATTGGAA AATTTACAAC TCCATCTACA TTGGTTCCCA GGACGCTCTC	120
	ATAGCACATT ACCCAAGAAT CTACAACGAT GATAAGAACA CCTATATTGG TTATGAACTT	180
45	GACTATATCT TATAATTTTA TTGTTTATTT TGTTTAAAT GCACAGCTAC TTCACACCTT	240
	AAACTTGCTT TGATTGGTG ATGTAACTT TTAAACATTG CAGATCAGTG TAGAACTGGT	300
50	CATAGAGGAA GAGCTAGAAA TCCAGTAGCA TGATTTTAA ATAACCTGTC TTTGTTTTTG	360
	ATGTTAAACA GTAAATGCCA GTAGTGACCA AGAACACAGT GATTATATAC ACTATACTGG	420
	AGGGATTTCA TTTTAAATC ATCTTTATGA AGATTTAGAA CTCATTCCCT GTGTTTAAAG	480
55	GGAATGTTA ATTGAGAAAT AAACATTTGT GWACAAAATG YTAAAAAAA AAAAAAAA	540
	AAAAAAA AAAAAAAA AAAAAAAA AACTCGA	577

(2) INFORMATION FOR SEQ ID NO: 307:

(i) SEQUENCE CHARACTERISTICS:

5

- (A) LENGTH: 2860 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 307:

	GTGTGACCG CTCTCNCAAT ATGGCTCCCC CGGGCTGGCA GWRRTCRGT CWCKRGTGGC	60
	TAGCCTGTCC TGACAGGGGA GAGTTAAGCT CCCGTTCTCC ACCGTGCCCG CTGGCCAGGT	120
15	GGGCTGAGGG TGACCGAGAG ACCAGAACCT GCTTGCTGGA GCTTAGTGCT CAGAGCTGGG	180
	GAGGGAGGTT CGCCGCTCC TCTGCTGTCA GCGCCGGCAG CCCCTCCCCG CTTCACCTCC	240
20	TCCCGCAGCC CCTGCTACTG AGAAGCTCCG GGATCCACAG AGCCGCCACG CCCTGGCCTC	300
	AGCCTGCGGG GCTTCCAGTC AGGCCAACAC CGACGCGCAC TGGGGAGGAA GACAGGACCC	360
	TTGACATCTC CATCTGCACA GAGGTCTGG CTGGAACCGA GCAGCCTCTT CCTCCTAGGA	420
25	TGACCTCACC CTCCAGCTCT CCAGTTTTCG GGTGGAGAC ATTAGATGGA GGCCAAGAAG	480
	ATGGCTCTGA GCGCGACAGA GGAAAGCTGG ATTTTGGGAG CGGGCTGCCT CCCATGGAGT	540
30	CACAGTTCCA GGGCGAGGAC CGGAAATTCG CCCCTTCAGA TAAGAGTCAA CCTCCAACTA	600
	CCGAAAGGGA ACAGGTGCCA GTCAGCOGGA TCCAAACCGA TTTGACOGAG ATCGGCTCTT	660
	CAATGCGGTC TCCCGGGGTG TCCCGGAGGA TCTGGCTGGA CTTCAGAGT ACCTGAGCAA	720
35	GACCAGCAAG TACCTCACCG ACTTCGAAA TACACAGAGG GCTCCACAGG TAAGACGGCC	780
	TGATGAAGGC TGTGCTGAAA CCTTAAGGAC GGGGTCAATG CCTGCATTCT GCCACTGCTG	840
40	CAGATCGACC GGGACTCTGG CAATCCTCAG CCCCTGGTAA ATGCCCAGTG CACAGATGAC	900
	TATTACCGAG GCCACAGCGC TCTGCACATC GCCATTGAGA AAGAGGAGTC TGCAGTGTGT	960
	GAAGCTCCTG GTGGAGAATG GGGCCAATGT GCATGCCCGG GTCTGCGGCG ACTTCTTCCA	1020
45	GAAGGGCCAA GGGACTTGCT TTTATTTGGG TGAGCTACCC CTCTCTTTGG CCGCTTGAC	1080
	CAAGCAGTGG GATGTGGTAA GCTACCTCCT GGAGAACCCA CACCAGCCCC CCAGCCTGCA	1140
50	GGCCACTGAC TCCAGGGCA ACACAGTCTT GCATGCCCTA GTGGATGATC TCGGACAACT	1200
	CAGCTGAGAA CATGCACTG GTGACCAGCA TGTATGATGG GCTCCTCCAA GCTKGGGSCC	1260
	SCCTCTGCC CTACCGTGCA GCTTGAGGAC ATCGCAACC TGCAGGATCT CACGCTCTG	1320
55	AAGCTGGCCG CCAAGGAGG CAAGATOGAG ATTTTCAGGC ACATCCTGCA GCGGGAGTTT	1380
	TCAGGACTGA GCCACCTTTC CCGAAAGTTC ACCGAGTGGT GCTATGGGCC TGTCCGGGTG	1440
60	TCGCTGTATG ACCTGGCTTC TGTGGACAGC TGTGAGGAGA ACTCAGTGCT GGAGATCATT	1500

	GCCTTTCATT GCAAGAGCCC GCACCGACAC CGAATGGTCG TTTTGGAGCC CCTGAACAAA	1560
5	CTGCTGCAGG CGAAATGGGA TCTGCTCATC CCCAAGTTCT TCTTAACTT CCTGTGTAAT	1620
	CTGATCTACA TGTTTCATCTT CACCGCTGTT GCCTACCATC AGCCTACCCCT GAAGAAGCAG	1680
	GCCGCCCCCTC ACCTGAAAGC GGAGGTGGA AACTCCATGC TGCTGAOGGG CCACATCCTT	1740
10	ATCCTGCTAG GGGGATCTA CCTCCTCGTG GGGCCAGCTG TGGTACTTCT GCGGGCCCA	1800
	CGTGTTCATC TGGATCTCGT TCATAGACAG CTACTTTGGA AATCCTCTTC CTGTTCCAGG	1860
15	CCCTGCTTCA CAGTGGTGTG CCAGGTGCTG TGTTTCTGG GCCATCGAGT GGTACCTGCC	1920
	CCTGCTTGTC TCTGCGCTG TGGCTGGCT GGCTGAACCT GCTTTACTAA TACACGTGGC	1980
	GTTCACGAC ACAGGCAGTC TACAGTTTCA TGWTCCTGA AGCCCTGGTG AGCCTGAGCC	2040
20	AGGAGGCTG GCGCCCGAA GCTCCTACAG GCCCAATGC CACAGAGTCA GTGCAGCCCA	2100
	TGGAGGGACA GGAGGACGAG GGCAACGGG CCCAGTACAG GGGTATCCTG GAAGCCTCCT	2160
25	TGGAGCTCTT CAAATTACAC ATCGGCATGG GCGAGCTGGC CTTCCAGGAG CAGCTGCACT	2220
	TCCGCGGCAT GGTGCTGCTG CTGCTGCTG CCTACGTGCT GCTCACCTAC ATCCTGCTGC	2280
	TCAACATGCT CATGCCCCTC ATGAAGCGAA CGTCACAGTG TCGCCACTGA CAGCTGGAGC	2340
30	ATCTGGAAGC TGCAGAAAGC CATCTCTGTC CTGGAGATGG AGAATGGCTA TTGGTGGTGC	2400
	AGGAAAAAGC AGCGGGCAGG TGTGATGCTG ACCGTTGGCA CTAAGCCAG ATGGCAGCC	2460
35	CGATGAGCGC TGGTGTCTCA GGGTGGAGGA GGTGAAGTGG GCTTCATGGG GAGCAGAGC	2520
	TGCCTACGCT GTGTGAGGAC CGTCAGGGG CAGGTGTCCC TCGAACTCTC GAGAACCCTG	2580
	TCCTGGCTTC CCTCCCAAG GAGGATGAGG ATGGTGCCTC TGAGGAAAAC TATGTGCCCG	2640
40	TCCAGCTCCT CCAGTCCAAC TGATGGCCCA GATGCAGCAG GAGGCCAGAG GACAGAGCAG	2700
	AGGATCTTTC CAACCACATC TGCTGGCTCT GGGGTCCCAG TGAATTCTGG TGGCAAATAT	2760
45	ATATTTTCAC TAACTCAAAA AAAAAAAAAA AAAAAAAAAA AAAAVGAGGG GGGGCCCGT	2820
	ASCCAAWTTC GCCCTATAAG TGAGTGCCWA TTACGATAAA	2860

50

(2) INFORMATION FOR SEQ ID NO: 308:

(i) SEQUENCE CHARACTERISTICS:

55

- (A) LENGTH: 876 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 308:

	CTGCTTGTGT CTGGCTGGT GCTGGGCTGG CTGAACCTGC TTTACTATAC ACGTGGCTTC	60
	CAGCACACAG GCATCTACAG TGTATGATC CAGAAGCCCT GGTGAGCCTG AGCCAGGANN	120
5	TTGGCGCCCC GAAGCTCCTA CAGGCCCAAA TGCCACAGAG TCAGTGACGC CCATGGAGGG	180
	ACAGGAGGAC GAGGGCAACG GGGCCCACTA CAGGGGTATC CTGGAAGCCT CCTTGGAGCT	240
10	CTTCAAATTC ACCATCGGCA TGGCGGAGCT GGCTTTCCAG GAGCAGCTGC ACTTCGCGG	300
	CATGGTGTCTG CTGCTGTCTG TGGCTACGT GCTGCTCACC TACATCCTGC TGCTCAACAT	360
	GCTCATCGCC CTCATGNAGC GAGACCGWCA ACAGTGTGCG CACTGACAGC TGGAGCATCT	420
15	GGAAGCTGCA GAAAGCCATC TCTGTCTGG AGATGGAGAA TGGCTATTGG TGGTGCAGGA	480
	AGAAGCAGCG GGCAGGTGTG ATGCTGACCG TTGGCACTAA GCCAGATGGC AGCCCCGATG	540
20	AGCGCTGGTG CTTCAAGGTG GAGGAGGTGA ACTGGGCTTC ATGGGAGCAG ACGCTGCCTA	600
	CGCTGTGTGA GGACCCGTC A GGGCAGGTG TCCCTCGAAC TCTCGAGAAC CCTGTCTCTGG	660
	CTTCCCTCC CAAGGAGGAT GAGGATGGTG CCTCTGAGGA AACTATGTG CCCGTCCAGC	720
25	TCCTCCAGTC CAACTGATGG CCCAGATGCA GCAGGAGGCC AGAGGACAGA GCAGAGGATC	780
	TTTCCAACCA CATCTGCTGG CTCTGGGGTC CCACTGAATT CTGGTGGCAA ATATATATTT	840
30	TCACTAAMMM AAAAAAAAAA AAAAAAAAAA ACTOGA	876
35	(2) INFORMATION FOR SEQ ID NO: 309:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 2025 base pairs	
	(B) TYPE: nucleic acid	
40	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 309:	
45	CATGACCCGC CTGATGCGAT CCGCACAGC CTCTGGTTCC AGCGTCACTT CTCTGGATGG	60
	CACCCGCAGC CGTCCCAACA CCAGCGAGGG CACCCGAAGC CGTCCCAACA CCAGCGAGGG	120
	CACCCGCAGC CGTCCCAACA CCAGCGAGGG GGGCCACCTG GACATCACCC CCAACTCGGG	180
50	TGCTGCTGGG AACASGCCGG GCCCAAGTCC ATGGAGGTCT CCTGCTAGGC GGCCTGCCCA	240
	GCTGCCGCCC CCGGACTCTG ATCTCTGTAG TGGCCCCCTC CTCCCCGGCC CCTTTTCGCC	300
55	COCTGCCTGC CATACTGCGC CTAATCGGT ATTAATCCAA AGCTTATTTT GTAAGAGTGA	360
	GCTCTGGTGG AGACAAATGA GGTCTATTAC GTGGGTGCCC TCTCCAAAGG CGGGGTGGCG	420
	GTGGACCAA GGAAGGAAGC AAGCATCTCC GCATCGCATC CTCTTCCATT AACCAGTGGC	480
60	CGGTTGCCAC TCTCTCCCC TCCCTCAGAG ACACCAAACCT GCCAAAACA AGACGCGTAC	540

	AGCACACACT TCACAAAGCC AAGCCTAGGC CGCCTGAGC ATCCTGGTTC AAACGGGTGC	600
5	CTGGTCAGAA GGCAGCCGC CCACCTCCCG TTCTCTCTT AACTGAGGAG AAGCTGATCC	660
	AGTTTCCGA AACAAAATCC TTTTCTCATT TGGGAGGGG GGTAAATAGT ACATGCAGGC	720
	ACCTCTTTTA AACAGGCAA ACAGGAAGGG GGAAAAGGTG GGATTCATGT CGAGGCTAGA	780
10	GGCATTGGA ACAACAAATC TACGTAGTTA ACTTGAAGAA ACCGATTTTT AAAGTTGGTG	840
	CATCTAGAAA GCTTGAATG CAGAAGCAA CAAGCTTGAT TTTCTAGCA TCCTCTTAAT	900
15	GTGACAGAA AGCAGGCRAC AAAATCTCCT GGCTTTACAG AAAAAATAT TTCAGCAAC	960
	GTGGGCATC ATGGTTTGTG AAGGCTTTAG TTCTGCTTTC TGCTCTCCT CCACAGCCCC	1020
	AACCTCCAC CCTGATACA TGAGCCAGT ATTATCTTG TTCAGGAGA AGATCATTTA	1080
20	GATTGTGTTT GCATTCTTA GAATGGAGG CAACATTCCA CAGCTGCCCT GGCTGTGATG	1140
	AGTGTCTTG CAGGGGCGG AGTAGGAGCA CTGGGGTGG GCGGAATTG GGGTTACTCG	1200
25	ATGTAAGGA TTCTTGTTG TTGTGTGAG ATCCAGTGA GTGTGATTT CTGTGGATCC	1260
	CAGCTTGGTT CCAGGAATTT TGTGTGATT GCTTAAATCC AGTTTTCAT CTTCGACAGC	1320
	TGGCTGGAA CGTGAATCA GTAGCTGAAC CTGTCTGACC CGGTACGTT CTGGATCCT	1380
30	CAGAACTCTT TGCTCTGTG GGGGTGGGG TGGGAATCA CGTGGGAGC GGTGGCTGAG	1440
	AAAATGTAAG GATTCTGGA TACATATTCC ATGGGACTTT CCTTCCCTCT CTGCTTCCT	1500
35	CTTTCTCTG TCCTAACCT TTGCGGAAT GGGGAGCAC CACTGACGTT TCTGGGCGGC	1560
	CAGTGGGCT GCCAGGTTCC TGTACTACTG CCTGTACTT TTCATTTTGG CTCACCGTGG	1620
	ATTTTCTCAT AGGAAGTTG GTCAGAGTGA ATTGAATATT GTAAGTCAGC CACTGGGACC	1680
40	CGAGGATTTC TGGGACCCCG CAGTTGGGAG GAGGAAGTAG TCCAGCCTTC CAGGTGGCGT	1740
	GAGAGGCAAT GACTCGTTAC CTGCCGCCA TCACCTTGA GGCCTTCCCT GGCCTTGAGT	1800
45	AGAAAAGTCG GGGATCGGG CAAGAGAGGC TGAGTACGA TGGGAACTA TTGTGCACAA	1860
	GTCTTTCCAG AGGAGTTTCT TAATGAGATA TTGTATTTA TTTCCAGACC AATAAATTG	1920
	TAACTTTCGA AAAAAAAAA AAAAAAAAA AAAAAAAAA AAAAAAACTC	1980
50	GAGGGGGGCC CGTACCCAAT TCGCGTATA TGATCGTAAA CAATC	2025

55 (2) INFORMATION FOR SEQ ID NO: 310:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3026 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

60

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 310:

5	TAGGCAGCAC TGAAATATCC TAACCCCTA AGCTCCAGGT GCCTGTGGN ACGAGCAACT	60
	GGACTATAGC AGGGCTGGGC TCTGTCTTCC TGGTCATAGG CTCACTCTTT CCCCCAAATC	120
10	TTCTCTGGA GCTTTGCAGC CAAGGTGCTA AAAGGAATAG GTAGGAGACC TCTTCTATCT	180
	AATCCTTAAA AGCATAATGT TGAACATTCA TTCAACAGCT GATGCCCTAT AACCCCTGCC	240
	TGGATTCTCT CCTATTAGGC TATAAGAGT AGCAAGATCT TTACATAATT CAGAGTGGTT	300
15	TCATTGCCTT CCTACCTCT CTAATGGCCC CTCCATTTAT TTGACTAAAG CATCACACAG	360
	TGGCACTAGC ATTATACCAA GAGTATGAGA AATACAGTGC TTTATGGCTC TAACATTACT	420
20	GCCTTCAGTA TCAAGGCTGC CTGGAGAAAG GATGGCAGCC TCAGGGCTTC CTTATGTCTT	480
	CCACCACAAG AGCTCCTTGA TGAAGGTCAT CTTTTCCTCC TATCCTGTTC TTCCCTTCCC	540
	CGCTCCTAAT GGTACGTGGG TACCCAGGCT GGTCTTGGG CTAGGTAGTG GGGACCAAGT	600
25	TCATTACCTC CCTATCAGTT CTAGCATAGT AACTACGGT ACCAGTGTA GTGGGAAGAG	660
	CTGGGTCTTC CTAGTATACC CACTGCATCC TACTCCTACC TGGTCAACCC GCTGCTTCCA	720
30	GGTATGGGAC CTGCTAAGTG TGGAATTACC TGATAAGGA GAGGAAATA CAAGGAGGGC	780
	CTCTGGTGTT CCTGGCTCA GCCAGCTGCC CACAAGCCAT AAACCAATAA AACAAGAATA	840
	CTGAGTCAGT TTTTATCTG GGTCTCTTC ATTCCTACTG CACTTGGTGC TGCTTTGGCT	900
35	GACTGGGAAC ACCCCATAAC TACAGAGTCT GACAGGAAGA CTGGAGACTG TCCACTTCTA	960
	GCTCGGAAT TACTGTGTAA ATAACTTTC AGAACTGCTA CCATGAAGTG AAAATGCCAC	1020
40	ATTTTGCTTT ATAATTCTA CCCATGTTGG GAAAACTGG CTTTTTCCCA GCCCTTTCCA	1080
	GGGCATAAAA CTCAACCCCT TCGATAGCAA GTCCCATCAG CCTATTATTT TTTTAAAGAA	1140
	AACTGCACT TGTCTTCTT TTTACAGTGA CTTCCTTCCT GCCCCAAAT TATAAACTCT	1200
45	AAGTGTAATA AAAAGTCTTA ACAACAGCTT CTGCTGTGA AAAATATGTA TTATACATCT	1260
	GTATTTTAA ATCTGTCTCC TGAAAAATGA CTGTCCCAT CTCCACTCAC TGCAATTGGG	1320
50	GCCTTTCCCA TTGGTCTGCA TGTCTTTTAT CATTGCAGG CAGTGGACAG AGGAGAAGG	1380
	GAGAACAGG GTGCCAACA CTTGTGTGC TTTCTGACTG ATCCTGAACA AGAAAGAGTA	1440
	ACACTGAGG GCTGGCTCCC ATGCACAACT CTCCAAAACA CTTATCTCC TGCAAGAGTG	1500
55	GGCTTTCCAG GGTCTTACT GGAAGCAGT TAAGCCCCCT CTCACCCCT TCCTTTTTTC	1560
	TTTCTTACT CTTTGGCTT CAAAGGATTT TGAAGAGAA ACAATATGCT TTCACTCAT	1620
60	TTTCAATTTC TAAATTGCA GGGGATACTG AAAAAACGG CAGGTGGCCT AAGGCTGCTG	1680

	TAAAGTTGAG GGGAGAGGAA ATCTTAAGAT TACAAGATAA AAAACGAATC CCCTAAACAA	1740
	AAAGAACAAT AGAACTGGTC TTCCATTTTG CCACCTTTCC TGTTCATGAC AGCTACTAAC	1800
5	CTGGAGACAG TAACATTTCA TTAACCAAAG AAAGTGGGTC ACCTGACCTC TGAAGAGCTG	1860
	AGTACTCAGG CCACTCCAAT CACCCTACAA GATGCCAAGG AGGTCCCAGG AAGTCCAGCT	1920
10	CCTTAAACTG ACGCTAGNMA ATAAACCTGG GCAAGTGAGG CAAGAGAAAT GAGGAAGAAT	1980
	CCATCTGTGA GGTGAYAGGC AAGGATGAAA GACAAAGAAG GAAAAGAGTA TCAAAGGCAG	2040
	AAAGGAGATC ATTTAGTTGG GTCTGAAAGG AAAAGTCTTT GCTATCCGAC ATGTACTGCT	2100
15	AGTACCTGTA AGCATTTTAG GTCCCAGAAT GGAAAAAAA ATCAGCTATT GGTAAATATAA	2160
	TAAATGCTTT TCCCTGGAGT CAGTTTTTTT AAAAAGTTAA CTCTTAGTTT TTACTTGTTT	2220
20	AATTCTAAAA GAGAAGGGAG CTGAGGCCAT TCCCTGTAGG AGTAAAGATA AAAGGATAGG	2280
	AAAAGATTCA AAGCTCTAAT AGAGTCACAG CTTTCCCAGG TATAAAACCT AAAATTAAGA	2340
	AGTACAATAA GCAGAGGTGG AAAATGATCT AGTTCCTGAT AGCTACCCAC AGAGCAAGTG	2400
25	ATTTATAAAT TTGAAATCCA AACTACTTTC TTAATATCAC TTGGTCTCC ATTTTTCCCA	2460
	GGACAGGAAA TATGTCCCCC CTTAACTTTC TTGCTTCAAA AATTAAAAATC CAGCATCCCA	2520
30	AGATCATTTCT ACAAGTAATT TTGCACAGAC ATCTCCTCAC CCCAGTGCCT GTCTGGAGCT	2580
	CACCCAAGGT CANCCAAACA ACTTGGTTGT GAACCCAACT GCCTTAACCT TCTGGGGGAG	2640
	GGGGATTAGC TAGACTAGGA GACCCAGAAG TGAATGGGAA AGGGTGAGGA CTTCACAATG	2700
35	TTGGCCTGTC AGAGCTTGAT TAGAAGCCAA GACAGTGGCA GCAAAGGAAG ACTTGGCCCA	2760
	GGAAAAACCT GTGGGTGTG CTAATTTCTG TCCAGAAAAT AGGGTGGACA GAAGCTTGTG	2820
40	GGGTGCATGG AGGAATGGG ACCTGGTTAT GTGTATTTC TCGACTGTG AATTTTGGTG	2880
	ATGTAAAACA GAATATTCTG TAAACCTAAT GTCTGTATAA ATAATGAGCG TTAACACAGT	2940
	AAAATATTCA ATAAGAAGTC AAAAAAAAAA AAAAAAACT CGAGGGGGGG CCCGGTACCC	3000
45	AATTINCCAA ATAGAGATNG TATTAC	3026

50 (2) INFORMATION FOR SEQ ID NO: 311:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 712 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 311:

60 GCAGGCTTTG TGCTCACCTA CAAGCTGGGT GAGCAGGGTG CCAGCAGCCT GTTTCCTCTT 60

CTCCTGCTGG ACCACGGCGT TTCTGCTCCC GAGTTGGGAC TGTTGAATGG TGTOGGTGCT 120
GTGGTCTGCT CCATCGCTGG CTCCTCCCTG GGTGGGACCT TGCTGGCCAA GCACTGGAAA 180
5 CTGCTGCCTC TGTTGARGTC GGTGCTGGGC TTCCGCTCG GGGGCTAGC CTGTCAGACT 240
GCCTTGGTCT TCCACCTGGA CACCTGGGG GCCAGCATGG ACGCTGGCAC AATCTTGAGA 300
10 GGGTCAGCCT TGCTGAGCCT ATGTCTGCAG CACTTCTTGG GAGGCTGGT CACCACAGTC 360
ACCTTCACTG GGATGATGCG CTGCAGCCAG CTGGCCCCCA GGGCTGCGAG GCCACACACT 420
ACAGCCTTCT GGCCACGCTG GAGCTGCTGG GGAAGCTGCT GCTGGGCACT CTGCGGAGGC 480
15 CTGGCTGATG GGTGGGGCC ACATCCCTGC TTCTGCTCC TGCTCATCCT CTCTGCCTTT 540
CCCGTTCTGT ACCTGGACCT AGCACCAGC ACCTTCTCT GAGCTGAGTG GCTGGAGTGG 600
20 TCAATAAAGC CACATGTGCC TGTTGGCCAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 660
AACTGGAGGG GGGCCCCGT ACCCAAATCG CCGGATATGA TCGTAAACAA TC 712

25

(2) INFORMATION FOR SEQ ID NO: 312:

(i) SEQUENCE CHARACTERISTICS:
30 (A) LENGTH: 1289 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 312:

CAAAATTTCA GAACCTTCAG GAGGCAAGA GAATATCAAA CAAAGATTTC TGGAGTATT 60
TIGCCAACCT TCTGGTTGAG CTGCAAGAAA ATATTTATGG TGAGAACTTT TCTGTTTCCC 120
40 GTTATGGGT TTTTGGTTGG TTTTGTGTTG TTTTTTACTA TGCTTTGGTC TGTA AAAATA 180
TGCAACTGAA CTACATTCAG AAGGAAATAT TGCTACATA GAATATTATA TGAAGTGGT 240
45 ACATAATTCT GATGAGGAAA AAAATCTTT GCAATCTTT AAGCCATATT GTGT TTTTTC 300
TGTGTGTTT TCCCTGGATG AAAATATCAG TATTAAGTAG ACAGCATATT ATTCAAGTGT 360
TTAGACTTAT TAATATGTC TTGCTCTGTA TTTATACATA TGTTATTITT GGAAAGTATT 420
50 GCCTTTTSTA AGGAAGCTA TAATTCGATA CATAGTGAAA AAGGAATGG TGACCCCTTT 480
GTGCTCTTC CACTGAGGAT AACAAACAGC ATTGTAATCC ATTCTCTTGC ACCTTCTTCT 540
55 TCTTATCTTG TTATTACGT TTTATTAATT TTGTAGAGGG ACAGGGAGTG GGCAAGGGGA 600
AGAAGCAGCT TATTTGACTA ACCAGCCCT CTGTGGTCCA CCAGCGTCTT GCCTTGGTGG 660
GAGGGCTCTC AATCAGCAGG GCCCCAGGAG GGAAGAAGAA GTGGGGCAA GCCTGGCCTC 720
60

GCGCTGGG AGCTTTGCCA TCTGAGCCAC GCTTCCTCCA GGCCATGCTC CTTGAACTTG 780
 GAAATGTCAA CCGGAGCCCT TACACCAGCC CTCCAGCATC TAATAGACTT GAATCTACTC 840
 5 TAAACGAATA TTTAATCCAA CCTCACTACA TTGTAGCTCA GTCCAACGAC TAACCTGAA 900
 ATGGGGGTGT TCCAGCCTTC AGCGAGATGG CCAAGCGGTC CCTTGGGGGC TGTGGCAGCG 960
 10 GGCTTATCCT TCTCTGTGTC CAACCTTGCC GTCCGACCTC CTCGCCCCC ATGCGGTGAC 1020
 CCGTCCGTG TCTGTGCTG TCCATACTG TGAGTCCAGC TAAAAAGACA AAACAGAACC 1080
 CGTGGGCCCA GCTCGGAAGG TGCCTGGAGA AGGCTCCGAC GTCTCCGAAG TGCAGCCCTT 1140
 15 GGGATGGCAT TCCGTGTGT GCCTTATTC TGGAGAATCT GTATACGGCT CGCCTATAGA 1200
 AATATAGCCT CTTATGCTG TATTAAAGG ACTTTTAAAA GCAAAAAAAA AAAAAAAAAA 1260
 CTTGAGGGGG GGNCCGTAC CCAATTTC 1289
 20

25 (2) INFORMATION FOR SEQ ID NO: 313:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 313:

Met Phe Leu Ile Phe Val Tyr Phe Leu Lys Ile Leu Phe Ser Ser Ser
 1 5 10 15

35 Leu Pro Phe Leu Trp Leu
 20

40 (2) INFORMATION FOR SEQ ID NO: 314:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 128 amino acids

(B) TYPE: amino acid

45 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 314:

Met Met Phe Leu Thr Gln Gly Gly Pro Leu Pro Ser Thr Arg Ala Arg
 1 5 10 15

50 Pro Thr Cys Gln Ala Gly Ala Leu Pro Lys Pro Ser Gly Leu Leu Gly
 20 25 30

55 Val Thr Cys Trp Asn Gly Leu Lys Gly Pro Leu Cys Gly Asn Arg Cys
 35 40 45

Ser Pro Asn Thr Leu Leu Leu Ala Ala Arg Gln Ala Leu Trp Lys Gly
 50 55 60

60 Arg Gly Arg Thr His Gln Asp Leu Pro Gly Pro Leu Gln Gly Arg Gln

	65					70						75					80
	Leu	Gly	Pro	Glu	Pro	Lys	His	Leu	Ala	Leu	Leu	Pro	Pro	Arg	Gly	Gln	
					85					90					95		
5																	
	Glu	Ala	Ser	Trp	Ala	Ser	Ser	Leu	Pro	Gly	Gln	Gly	Pro	Leu	Pro	Leu	
					100				105					110			
10																	
	Pro	His	Ile	Asn	Cys	Thr	Val	Phe	Ser	Leu	Lys	Ala	Ser	Phe	Ile	Lys	
					115			120					125				

15

(2) INFORMATION FOR SEQ ID NO: 315:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 315:

25 Met Gln Phe Leu Leu Thr Ala Phe Leu Leu Val Pro Leu Leu Ala Leu
1 5 10 15

30 Cys Asp Val Pro Ile Ser Leu Gly Phe Ser Pro Ser
20 25

(2) INFORMATION FOR SEQ ID NO: 316:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 316:

Met Asp Gly Phe Ser Ser Arg Leu Phe Ser Ser Leu Pro Phe Val Ala
1 5 10 15

Leu Gln Trp Phe Ile Val Ile Ser His Leu Leu Ser Leu Ser Leu Ser
45 20 25 30

Ala Cys Cys Tyr Gln Thr His Cys Ser Leu Xaa Gln Leu Ser Ser Ala
35 40 45

50 Phe Ser Xaa Met Gly Glu Ser Cys Val Gly Glu Arg Glu Tyr Xaa Phe
50 55 60

55

(2) INFORMATION FOR SEQ ID NO: 317:

60 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 317:

5

Met Pro Leu Ile Asn Leu Leu Leu Tyr Tyr Val Pro Asn Gly Gly
 1 5 10 15

10

Lys Gln Asp Lys Lys
 20

15

(2) INFORMATION FOR SEQ ID NO: 318:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 318:

Met Gly Arg His Leu Val Leu Val Met Phe Ile Thr Thr Ser Leu His
 1 5 10 15

25

Ser Gly Thr Pro Val Pro Glu Asn Val Ile Cys Gly Val Thr Lys Gly
 20 25 30

Pro Gln Gly Lys Lys Lys Lys
 35

30

(2) INFORMATION FOR SEQ ID NO: 319:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 319:

Met Leu Trp Trp Ser Arg Asp Tyr Thr Met Val Phe Leu Leu Phe Thr
 1 5 10 15

45

Met Val Phe Thr Gly Asp Leu Val Ile Arg Gly Arg Thr Glu Leu Ser
 20 25 30

Leu

50

(2) INFORMATION FOR SEQ ID NO: 320:

55

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 88 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 320:

60

Met Val Cys Ser Ser Leu Cys Asp Ile Gly Gly Ile Ile Thr Pro Phe

20 (2) INFORMATION FOR SEQ ID NO: 321:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 321:

35

(2) INFORMATION FOR SEQ ID NO: 322:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 322:

50

(2) INFORMATION FOR SEQ ID NO: 323:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 323:

60 Met Cys Leu Glu Cys Trp Ala Glu Asn Leu Gly Pro His His Thr Ser

1 5 10 15
 Ser Leu Leu Asn Pro Arg His Leu Pro Ser Ile Pro Ala Met Phe Pro
 20 25 30
 5 Val Ser Ser Gly Cys Phe Gln Glu Gln Gln Glu Met Asn Lys Ser Leu
 35 40 45
 10 Val Ser Cys Leu Phe Val Leu His Phe Val Leu His Cys Ile Phe Xaa
 50 55 60
 15
 (2) INFORMATION FOR SEQ ID NO: 324:
 (i) SEQUENCE CHARACTERISTICS:
 20 (A) LENGTH: 196 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 324:
 25 Met Leu Ser Thr Ser Glu Tyr Ser Gln Ser Pro Lys Met Glu Ser Leu
 1 5 10 15
 Ser Ser His Arg Ile Asp Glu Asp Gly Glu Asn Thr Gln Ile Glu Asp
 20 25 30
 30 Thr Glu Pro Met Ser Pro Val Leu Asn Ser Lys Phe Val Pro Ala Glu
 35 40 45
 35 Asn Asp Ser Ile Leu Met Asn Pro Ala Gln Asp Gly Glu Val Gln Leu
 50 55 60
 Ser Gln Asn Asp Asp Lys Thr Lys Gly Asp Asp Thr Asp Thr Arg Asp
 65 70 75 80
 40 Asp Ile Ser Ile Leu Ala Thr Gly Cys Lys Gly Arg Glu Glu Thr Val
 85 90 95
 Ala Glu Glu Val Cys Ile Asp Leu Thr Cys Asp Ser Gly Ser Gln Ala
 100 105 110
 45 Val Pro Ser Pro Ala Thr Arg Ser Glu Ala Leu Ser Ser Val Leu Asp
 115 120 125
 50 Gln Glu Glu Ala Met Glu Ile Lys Glu His His Pro Glu Glu Gly Ser
 130 135 140
 Ser Gly Ser Glu Val Glu Glu Ile Pro Glu Thr Pro Cys Glu Ser Gln
 145 150 155 160
 55 Gly Glu Glu Leu Lys Glu Glu Asn Met Glu Ser Val Pro Leu His Leu
 165 170 175
 Ser Leu Thr Glu Thr Gln Ser Gln Gly Leu Cys Leu Arg Arg His Pro
 180 185 190
 60

Lys Lys Lys Lys
195

5

(2) INFORMATION FOR SEQ ID NO: 325:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 252 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 325:

15 Met Gly Gly Asp Leu Val Leu Gly Leu Gly Ala Leu Arg Arg Arg Lys
1 5 10 15

Arg Leu Leu Glu Gln Glu Lys Ser Leu Ala Gly Trp Ala Leu Val Leu
20 25 30

20 Ala Xaa Xaa Gly Ile Gly Leu Met Val Leu His Ala Glu Met Leu Trp
35 40 45

Phe Gly Gly Cys Ser Ala Val Asn Ala Thr Gly His Leu Ser Asp Thr
25 50 55 60

Leu Trp Leu Ile Pro Ile Thr Phe Leu Thr Ile Gly Tyr Gly Asp Val
65 70 75 80

30 Val Pro Gly Thr Met Trp Gly Lys Ile Val Cys Leu Cys Thr Gly Val
85 90 95

Met Gly Val Cys Cys Thr Ala Leu Leu Val Ala Val Val Ala Arg Lys
100 105 110

35 Leu Glu Phe Asn Lys Ala Glu Lys His Val His Asn Phe Met Met Asp
115 120 125

Ile Gln Tyr Thr Lys Glu Met Lys Glu Ser Ala Ala Arg Val Leu Gln
40 130 135 140

Glu Ala Trp Met Phe Tyr Lys His Thr Arg Arg Lys Glu Ser His Ala
145 150 155 160

45 Ala Arg Xaa His Gln Arg Xaa Leu Leu Ala Ala Ile Asn Ala Phe Arg
165 170 175

Gln Val Arg Leu Lys His Arg Lys Leu Arg Glu Gln Val Asn Ser Met
180 185 190

50 Val Asp Ile Ser Lys Met His Met Ile Leu Tyr Asp Leu Gln Gln Asn
195 200 205

Leu Ser Ser Ser His Arg Ala Leu Glu Lys Gln Ile Asp Thr Leu Ala
55 210 215 220

Gly Lys Leu Asp Ala Leu Thr Glu Leu Leu Ser Thr Ala Leu Gly Pro
225 230 235 240

60 Arg Gln Leu Pro Glu Pro Ser Gln Gln Ser Lys Xaa
245 250

5 (2) INFORMATION FOR SEQ ID NO: 326:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 68 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 326:

Met Trp Arg Cys Arg Gly Lys Leu Ser Phe Pro Leu Phe Ala Val Val
1 5 10 15

15 Ile Val Ser Cys Arg Lys Asp Gly Pro Asp Ala Ala Ala Ala Pro Ala
20 25 30

Val Ile Lys Asn Asn Ser His Tyr Gln Thr Ser Lys Ala Leu Glu Leu
35 40 45

20 Glu Lys Thr Thr Glu Asn Lys Glu Ser Asn Pro Phe Ile Leu Gln Val
50 55 60

25 Asn Lys Leu Xaa
65

30 (2) INFORMATION FOR SEQ ID NO: 327:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 84 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 327:

Met Gly Glu Gly Lys Asn Gly Phe Gly Gly Phe Val His Thr Ala Asp
1 5 10 15

40 Ala Cys Trp Glu Gly Val His Ser Glu Pro Val Cys Arg Thr Val His
20 25 30

Thr Val His Thr Cys His His Gln Ala Phe Leu Val Leu Ile Gly Trp
35 40 45

45 Ser Lys Ser Gly Lys Glu Arg Lys Glu Ala Phe Leu Thr Ala Ile Ile
50 55 60

50 Leu Asn Ser Arg Ser Ile His Ile Ser Cys Ser Trp Pro Pro Ser Pro
65 70 75 80

Val Pro Gln Xaa

55

(2) INFORMATION FOR SEQ ID NO: 328:

(i) SEQUENCE CHARACTERISTICS:

60 (A) LENGTH: 36 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 328:

5 Met Leu Leu Ile Asn Leu Leu Trp Leu Val Thr Met Ile Lys Ser Val
 1 5 10 15
 Ile Asn Asn Asn Ile Ile Leu Phe Leu Lys Lys Lys Ser Leu Phe Phe
 20 25 30
 10 Ile Asp Ser Val
 35

15

(2) INFORMATION FOR SEQ ID NO: 329:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 63 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 329:

25 Met Thr Phe Pro Phe Glu Lys Lys Ile Val Ala Phe Ser Ala Phe Tyr
 1 5 10 15
 Leu Ile Pro Gly Glu Ser Arg Leu Ala Pro Thr Phe Asn Pro Ser Ala
 20 25 30
 30 Asp Met Thr Val Ile Leu Arg Gly Arg Ala Gln His Lys Thr Ala Met
 35 40 45
 Leu Glu Ser Tyr Asn Trp Lys Val Ser Cys Gln Leu Arg Glu Xaa
 50 55 60
 35

(2) INFORMATION FOR SEQ ID NO: 330:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 330:

45 Met His Ser Lys Gly Ser Ser Leu Leu Leu Phe Leu Pro Gln Leu Ile
 1 5 10 15
 Leu Ile Leu Pro Val Cys Ala His Leu His Glu Glu Leu Asn Cys Cys
 50 20 25 30
 Phe His Arg
 35

55

(2) INFORMATION FOR SEQ ID NO: 331:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

60

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 331:

5 Met Gly Ala Leu Val Leu Leu Leu Cys Leu Leu Val Gly Val Gln Gln
 1 5 10 15
 Ser Gly Ser Val Trp Asp Ser
 20

10

(2) INFORMATION FOR SEQ ID NO: 332:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 40 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 332:

20 Met Gln Ser Ala Glu Ile Leu Ser Trp Thr Asp Val Leu His Asp Phe
 1 5 10 15
 25 Leu Phe Ser Leu Phe Leu Trp Pro Ala Phe Glu Asp Arg Ala Leu Leu
 20 25 30
 Ile Phe Thr Leu Asn Gln Ile Val
 35 40

30

(2) INFORMATION FOR SEQ ID NO: 333:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 111 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 333:

40 Met Gln Ser Leu Val Gln Trp Gly Leu Asp Ser Tyr Asp Tyr Leu Gln
 1 5 10 15
 Asn Ala Pro Pro Gly Phe Phe Pro Arg Leu Gly Val Ile Gly Phe Ala
 20 25 30
 45 Gly Leu Ile Gly Leu Leu Leu Ala Arg Gly Ser Lys Ile Lys Lys Leu
 35 40 45
 Val Tyr Pro Pro Gly Phe Met Gly Leu Ala Ala Ser Leu Tyr Tyr Pro
 50 50 55 60
 Gln Gln Ala Ile Val Phe Ala Gln Val Ser Gly Glu Arg Leu Tyr Asp
 65 70 75 80
 55 Trp Gly Leu Arg Gly Tyr Ile Val Ile Glu Asp Leu Trp Lys Glu Asn
 85 90 95
 Phe Gln Lys Pro Gly Asn Val Lys Asn Ser Pro Gly Thr Lys Xaa
 100 105 110

60

(2) INFORMATION FOR SEQ ID NO: 334:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 106 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 334:

Met Ala Pro Ser Leu Leu Leu Leu Ala Pro Leu Cys Ser Leu Glu Ala
 1 5 10 15
 Val Leu Ser Ser Pro Leu Glu Lys Gln Cys Gln Leu Pro Gly Ile Phe
 20 25 30
 Cys Gln Leu Gln Leu Pro Cys Pro Leu Leu Leu Ser Ala Gln Leu Leu
 35 40 45
 Lys Gly Ile Val Xaa Pro Arg Cys Pro Ala Ser Leu Pro Gln Pro Pro
 50 55 60
 His Pro Ala Pro Ser Trp His Leu Pro Leu His Cys Thr Glu Arg Xaa
 65 70 75 80
 Pro His His Leu Pro Leu Gln Gly Gly Ser Ser Asn Met Glu Glu Xaa
 85 90 95
 Asn Tyr Arg Gly Tyr Xaa Asp Ala Gln Leu
 100 105

35

(2) INFORMATION FOR SEQ ID NO: 335:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 335:

Met Thr Thr Cys Leu Phe Gly Leu Leu Ser Cys Glu Met Ser Ala Gln
 1 5 10 15
 Val Ser Gln Lys Ser Cys Val Tyr Asp Glu Ser Glu Cys Phe Ser Ser
 20 25 30
 Val Gly Gln Leu Leu Ala Leu Leu Ile Leu Val Tyr Val Leu Pro Ser
 35 40 45
 Ile Xaa
 50

55

(2) INFORMATION FOR SEQ ID NO: 336:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 amino acids

60

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 336:

5 Met Leu Trp Lys Cys Ser Gln Asn Ile Ala Arg Cys Leu Leu Leu Leu
 1 5 10 15

Leu Ala Leu Val Glu Ile Lys Leu Glu Asp Leu Gln Ser Gln Leu His
 20 25 30

10 Pro Thr Trp Lys Ser Ile Pro Gly Pro Ser Pro Arg Asn Gln His Arg
 35 40 45

15

(2) INFORMATION FOR SEQ ID NO: 337:

20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 41 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 337:

Met Leu Ile Pro Leu Gln Cys Leu Phe Ser Ser Asp Arg Met Leu Thr
 1 5 10 15

30 Phe Leu Thr Pro Trp Gln Lys Gly Glu Lys Cys Val Leu Gly Trp Val
 20 25 30

Thr Lys Phe Leu Ser Glu Ile Ser Xaa
 35 40

35

(2) INFORMATION FOR SEQ ID NO: 338:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 76 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 338:

45

Met Thr Phe Ser Ser Leu Lys Leu Phe Val Leu Thr Cys Ile Ile Lys
 1 5 10 15

Gly Leu Glu Arg Phe Ile Ile Leu Arg Glu Val Cys Asn Gln Glu Ile
 20 25 30

50 Gln Arg Ser Leu Ser Ser Asn Leu Val His Val Leu Leu Gln Pro Ala
 35 40 45

55 Thr Phe Lys Asp Val Leu Val Thr Glu Ile Ile Cys Leu Cys Met Cys
 50 55 60

Leu Tyr Ser Ile Lys Tyr Met Pro Pro Gln Lys Lys
 65 70 75

60

(2) INFORMATION FOR SEQ ID NO: 339:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 31 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 339:

10 Lys Val Tyr Ile Phe Leu Ile Phe Met Val Leu Ile Leu Pro Ser Leu
 1 5 10 15
 Gly Leu Thr Arg Tyr Met Pro Pro Xaa Ser Xaa Leu Asn Ser Glu
 15 20 25 30

(2) INFORMATION FOR SEQ ID NO: 340:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 42 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 340:

Met Ala Lys Ile Ser Pro Phe Glu Val Val Lys Arg Thr Ser Val Pro
 1 5 10 15
 30 Val Leu Val Gly Leu Val Ile Val Ile Val Ala Thr Glu Leu Met Val
 20 25 30
 Pro Gly Thr Ala Ala Ala Val Thr Gly Lys
 35 40

35

(2) INFORMATION FOR SEQ ID NO: 341:

- 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 341:

45 Met Arg Leu Phe Phe Ile Gly Phe Leu Leu Leu Phe Ser Phe Gly Leu
 1 5 10 15
 Leu Arg Gln Pro Ser Leu Ser Ala Glu His
 20 25

50

(2) INFORMATION FOR SEQ ID NO: 342:

- 55 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 342:

Met Val Phe Ser Val Ser Ser Ala Leu Ala Leu Leu Leu Met Leu Leu
 1 5 10 15

5 Arg Ser Ser Asp Leu Ala Lys Lys Thr Glu
 20 25

10 (2) INFORMATION FOR SEQ ID NO: 343:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 157 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 343:

Met Ser Leu Glu Phe Tyr Gln Lys Lys Lys Ser Arg Trp Pro Phe Ser
 1 5 10 15

20 Asp Glu Cys Ile Pro Trp Glu Val Trp Thr Val Lys Val His Val Val
 20 25 30

Ala Leu Ala Thr Glu Gln Glu Arg Gln Ile Cys Arg Glu Lys Val Gly
 35 40 45

25 Glu Lys Leu Cys Glu Lys Ile Ile Asn Ile Val Glu Val Met Asn Arg
 50 55 60

30 His Glu Tyr Leu Pro Lys Met Pro Thr Gln Ser Glu Val Asp Asn Val
 65 70 75 80

Phe Asp Thr Gly Leu Arg Asp Val Gln Pro Tyr Leu Tyr Lys Ile Ser
 85 90 95

35 Phe Gln Ile Thr Asp Ala Leu Gly Thr Ser Val Thr Thr Thr Met Arg
 100 105 110

Arg Leu Ile Lys Asp Thr Leu Pro Ser Glu Arg Arg Trp Ile Ser Gly
 115 120 125

40 Ser Ser Leu Met Ala Pro Arg Pro Trp Leu Leu Gly Ile Ala Leu Leu
 130 135 140

45 Gly Leu Trp Ala Leu Glu Pro Ala Leu Gly His Trp Xaa
 145 150 155

50 (2) INFORMATION FOR SEQ ID NO: 344:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 520 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 344:

Met Phe Leu Leu Pro Leu Pro Ala Ala Gly Arg Val Val Val Arg Arg
 1 5 10 15

60 Leu Ala Val Arg Arg Phe Gly Ser Arg Ser Leu Ser Thr Ala Asp Met

	20	25	30
	Thr Lys Gly Leu Val Leu Gly Ile Tyr Ser Lys Glu Lys Glu Asp Asp		
	35	40	45
5	Val Pro Gln Phe Thr Ser Ala Gly Glu Asn Phe Asp Lys Leu Leu Ala		
	50	55	60
10	Gly Lys Leu Arg Glu Thr Leu Asn Ile Ser Gly Pro Pro Leu Lys Ala		
	65	70	75
	Gly Lys Thr Arg Thr Phe Tyr Gly Leu His Gln Asp Phe Pro Ser Val		
	85	90	95
15	Val Leu Val Gly Leu Gly Lys Lys Ala Ala Gly Ile Asp Glu Gln Glu		
	100	105	110
	Asn Trp His Glu Gly Lys Glu Asn Ile Arg Ala Ala Val Ala Ala Gly		
	115	120	125
20	Cys Arg Gln Ile Gln Asp Leu Glu Leu Ser Ser Val Glu Val Asp Pro		
	130	135	140
25	Cys Gly Asp Ala Gln Ala Ala Ala Glu Gly Ala Val Leu Gly Leu Tyr		
	145	150	155
	Glu Tyr Asp Asp Leu Lys Gln Lys Lys Lys Met Ala Val Ser Ala Lys		
	165	170	175
30	Leu Tyr Gly Ser Gly Asp Gln Glu Ala Trp Gln Lys Gly Val Leu Phe		
	180	185	190
	Ala Ser Gly Gln Asn Leu Ala Arg Gln Leu Met Glu Thr Pro Ala Asn		
	195	200	205
35	Glu Met Thr Pro Thr Arg Phe Ala Glu Ile Ile Glu Lys Asn Leu Lys		
	210	215	220
40	Ser Ala Ser Ser Lys Thr Glu Val His Ile Arg Pro Lys Ser Trp Ile		
	225	230	235
	Glu Glu Gln Ala Met Gly Ser Phe Leu Ser Val Ala Lys Gly Ser Asp		
	245	250	255
45	Glu Pro Pro Val Phe Leu Glu Ile His Tyr Lys Gly Ser Pro Asn Ala		
	260	265	270
	Asn Glu Pro Pro Leu Val Phe Val Gly Lys Gly Ile Thr Phe Asp Ser		
	275	280	285
50	Gly Gly Ile Ser Ile Lys Ala Ser Ala Asn Met Asp Leu Met Arg Ala		
	290	295	300
55	Asp Met Gly Gly Ala Ala Thr Ile Cys Ser Ala Ile Val Ser Ala Ala		
	305	310	315
	Lys Leu Asn Leu Pro Ile Asn Ile Ile Gly Leu Ala Pro Leu Cys Glu		
	325	330	335
60	Asn Met Pro Ser Gly Lys Ala Asn Lys Pro Gly Asp Val Val Arg Ala		

340 345 350
 Lys Asn Gly Lys Thr Ile Gln Val Asp Asn Thr Asp Ala Glu Gly Arg
 355 360 365
 5 Leu Ile Leu Ala Asp Ala Leu Cys Tyr Ala His Thr Phe Asn Pro Lys
 370 375 380
 Xaa Ile Leu Asn Ala Ala Thr Leu Thr Gly Ala Met Asp Val Ala Leu
 10 385 390 395 400
 Gly Ser Gly Ala Thr Gly Val Phe Thr Asn Ser Ser Trp Leu Trp Asn
 405 410 415
 15 Lys Leu Phe Glu Ala Ser Ile Glu Thr Gly Asp Arg Val Trp Arg Met
 420 425 430
 Pro Leu Phe Glu His Tyr Thr Arg Gln Val Val Asp Cys Gln Leu Ala
 20 435 440 445
 Asp Val Asn Asn Ile Gly Lys Tyr Arg Ser Ala Gly Ala Cys Thr Ala
 450 455 460
 25 Ala Ala Phe Leu Lys Glu Phe Val Thr His Pro Lys Trp Ala His Leu
 465 470 475 480
 Asp Ile Ala Gly Val Met Thr Asn Lys Asp Glu Val Pro Tyr Leu Arg
 485 490 495
 30 Lys Gly Met Thr Gly Arg Pro Thr Arg Thr Leu Ile Glu Phe Leu Leu
 500 505 510
 Arg Phe Ser Gln Asp Asn Ala Xaa
 35 515 520

(2) INFORMATION FOR SEQ ID NO: 345:

- 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 39 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 345:

Thr Ile Leu Phe Leu Phe Leu Gln Leu Ser Ala Leu Arg Leu Ile Val
 1 5 10 15
 Gly Lys Asp Ser Ile Asp Ile Asp Ile Ser Ser Arg Arg Arg Glu Asp
 50 20 25 30
 Gln Ser Leu Arg Leu Asn Ala
 35

55

(2) INFORMATION FOR SEQ ID NO: 346:

- 60 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 234 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 346:

5 Met Thr Ser Glu Leu Asp Ile Phe Val Gly Asn Thr Thr Leu Ile Asp
 1 5 10 15
 Glu Asp Val Tyr Arg Leu Trp Leu Asp Gly Tyr Ser Val Thr Asp Ala
 20 25 30
 10 Val Ala Leu Arg Val Arg Ser Gly Ile Leu Glu Gln Thr Gly Ala Thr
 35 40 45
 Ala Ala Val Leu Gln Ser Asp Thr Met Asp His Tyr Arg Thr Phe His
 15 50 55 60
 Met Leu Glu Arg Leu Leu His Ala Pro Pro Lys Leu Leu His Gln Leu
 65 70 75 80
 20 Ile Phe Gln Ile Pro Pro Ser Arg Gln Ala Leu Leu Ile Glu Arg Tyr
 85 90 95
 Tyr Ala Phe Asp Glu Ala Phe Val Arg Glu Val Leu Gly Lys Lys Leu
 100 105 110
 25 Ser Lys Gly Thr Lys Lys Asp Leu Asp Asp Ile Ser Thr Lys Thr Gly
 115 120 125
 Ile Thr Leu Lys Ser Cys Arg Arg Gln Phe Asp Asn Phe Lys Arg Val
 30 130 135 140
 Phe Lys Val Val Glu Glu Met Arg Gly Ser Leu Val Asp Asn Ile Gln
 145 150 155 160
 35 Gln His Phe Leu Leu Ser Asp Arg Leu Ala Arg Asp Tyr Ala Ala Ile
 165 170 175
 Val Phe Phe Ala Asn Asn Arg Phe Glu Thr Gly Lys Lys Lys Leu Gln
 180 185 190
 40 Tyr Leu Ser Phe Gly Asp Phe Ala Phe Cys Ala Glu Leu Met Ile Gln
 195 200 205
 Asn Trp Thr Leu Gly Pro Val Asp Ser Gln Met Asp Asp Met Asp Met
 45 210 215 220
 Asp Leu Asp Arg Asn Phe Ser Arg Thr Xaa
 225 230
 50

(2) INFORMATION FOR SEQ ID NO: 347:

(i) SEQUENCE CHARACTERISTICS:

55 (A) LENGTH: 169 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 347:

60 Met Ala Ala Ala Val Ala Gly Met Leu Arg Gly Gly Leu Leu Pro Gln

1 5 10 15

Ala Gly Arg Leu Pro Thr Leu Gln Thr Val Arg Tyr Gly Ser Lys Ala
20 25 30

5 Val Thr Arg His Arg Arg Val Met His Phe Gln Arg Gln Lys Leu Met
35 40 45

Ala Val Thr Glu Tyr Ile Pro Pro Lys Pro Ala Ile His Pro Ser Cys
10 50 55 60

Leu Pro Ser Pro Pro Ser Pro Pro Gln Glu Glu Ile Gly Leu Ile Arg
65 70 75 80

15 Leu Leu Arg Arg Glu Ile Ala Ala Val Phe Gln Asp Asn Arg Met Ile
85 90 95

Ala Val Cys Gln Asn Val Ala Leu Ser Ala Glu Asp Lys Leu Leu Ile
100 105 110

20 Ala Thr Pro Ala Ala Glu Thr Gln Asp Pro Asp Glu Gly Leu Pro Gln
115 120 125

Pro Gly Pro Glu Ser Pro Ser Trp Arg Ile Pro Ser Thr Lys Ile Cys
25 130 135 140

Cys Pro Phe Leu Trp Gly Thr Thr Cys Cys Trp Ser Val Lys Ser Pro
145 150 155 160

30 Arg Ser Arg Arg Trp Tyr Gly Ser Xaa
165

35 (2) INFORMATION FOR SEQ ID NO: 348:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 348:

Met Lys Arg Ser Phe Leu Leu Pro Leu Leu Val Gly Phe Leu Asp
1 5 10 15

45 Thr Ala His Leu Ile Leu Leu Glu Thr Leu Ser Val Cys Leu Trp Leu
20 25 30

Pro Ser Leu Ile Asp Ser Arg Cys Val Met Ser
50 35 40

55 (2) INFORMATION FOR SEQ ID NO: 349:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 78 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 349:

Met Lys Glu Gly Pro Pro Cys Lys Arg His His Tyr Tyr Gln Asn Cys
 1 5 10 15
 5 Gly Ala Lys Leu Leu Val Ser Leu Phe Gly Glu Thr Asn Gln Ile His
 20 25 30
 Leu Leu Glu Thr Gln Val Gly Thr Glu Lys Gly Gly Glu Arg Ile Trp
 35 40 45
 10 Glu Glu Lys Trp Arg Ile Ser Ser Thr Val Leu Phe Ile Ser Val Asn
 50 55 60
 Ser Tyr Val Glu Gly Ser Val Leu Glu Ile Lys Leu Phe Tyr
 15 65 70 75

- (2) INFORMATION FOR SEQ ID NO: 350:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 350:

Met Ser Glu Ile Leu Ser Leu Leu Phe Cys Leu Leu Gly Pro Ala Leu
 1 5 10 15
 30 Asp Glu Arg Arg Glu Glu Lys Asp
 20

- (2) INFORMATION FOR SEQ ID NO: 351:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 274 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 351:

Met Ser Ser Ala Gly Thr Ala Thr Pro Leu Glu Met Asp His Lys Leu
 1 5 10 15
 45 Thr Ser Gln Pro Gly Arg Pro Ser Phe Tyr Cys Asn Ser Arg His Ser
 20 25 30
 Ile Val Gly Ser Ser His Gln Leu Gly Phe Trp Phe Ser His Leu Glu
 50 35 40 45
 Ser Ser Gly Leu Lys Val Phe Gln Val Ser Leu Pro Cys Glu Cys Val
 50 55 60
 55 Asn Leu Pro Thr Arg Ile Ala Ser Val Val Leu Ser Leu Met Ser Leu
 65 70 75 80
 Leu Val Val Gly Gln Ala Pro Ala Trp Glu Gly Ser Leu Leu Arg Gly
 85 90 95
 60

Arg Pro Ala Gly Gly Ala His Leu Cys Ala Met Xaa Val Ile Glu Gly
 100 105 110
 5 Leu Val Val Asp Val Gly Glu Arg Ile Leu His Gly Gln Arg Glu Val
 115 120 125
 Gly Gln Val Ser Gln Val Leu Pro Ala Leu Ser Leu Gly Leu Val Phe
 130 135 140
 10 Leu Cys Gln Gly Thr Val Glu Lys Val Ser Gly Ala Ala His Cys Ser
 145 150 155 160
 Ser Leu Leu Cys Cys Leu Pro Trp Gln Cys Ser Gly Gly Gly Phe Pro
 165 170 175
 15 Thr Xaa Arg Cys Ser Arg Pro Tyr Phe Ser Ser His Lys Gly Val Ala
 180 185 190
 Ala Thr Leu Ala Leu Thr Cys His Cys Asp Lys Val His Val Ala Gly
 195 200 205
 20 Leu Gly Lys Asp Trp Ala Ile Glu Gln Arg Arg Arg Thr Cys Glu Ser
 210 215 220
 25 Asp Xaa Glu Xaa Xaa Pro Phe Thr Leu Ala Gly Leu Val Leu Val Leu
 225 230 235 240
 Arg Phe Cys Gln Val Val Leu Val Trp Ile Pro Gln Leu Gly Asp Lys
 245 250 255
 30 His Trp Arg Gly Met Thr Arg Leu Gly Arg Val Ser Leu Thr Ser Ser
 260 265 270
 35 Ile Xaa

40 (2) INFORMATION FOR SEQ ID NO: 352:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 352:

Met Ile Phe Thr Ser Val Thr Lys Gly Ile Leu Leu Ile Ala Leu Trp
 1 5 10 15

50 Val Pro Leu Phe His Phe Met Leu Ile Asp Ser Ile Leu Gly Pro Ser
 20 25 30

Arg Leu Leu Thr Asp Gly Val Pro Phe Asn Pro Trp His Val Xaa
 35 40 45

55

(2) INFORMATION FOR SEQ ID NO: 353:

60 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 353:

5

Met Lys Thr

1

10

(2) INFORMATION FOR SEQ ID NO: 354:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 52 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 354:

20 Met Ser Ile Ser Gly Thr Asp Gly Leu Ile Leu Leu Val Gly Leu
1 5 10 15

Glu Ala Xaa Val Arg Ser Ser Lys Lys Trp Ile Pro Lys Ala Leu Xaa
20 25 30

25 Val Thr Gln Ala Lys Trp Asn Ser Trp Pro Ser Arg Arg Asn Ala Gly
35 40 45

Phe Ala Leu His
50

30

(2) INFORMATION FOR SEQ ID NO: 355:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 132 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 355:

40

Met Glu His Cys Leu Tyr His Ser Val His Gly Ile Asn Pro Tyr Ile
1 5 10 15

45 His Lys Asn Thr His Pro Ser Ile Asn Ile Tyr Met Val Trp Asp Glu
20 25 30

Gln Val Asn Ser Phe Glu Arg Glu Phe Val Pro Phe Phe Phe Leu Ile
35 40 45

50 Ile Leu Leu Asn Cys Cys Gln Leu Ser Asn Lys Gln Thr Glu Lys Leu
50 55 60

55 Phe Gly Lys Thr Leu His Thr Pro Phe Leu Ser Ser Ala Leu Lys Tyr
65 70 75 80

Arg Leu Asn Thr His Ile Leu Pro Val Phe Ser Tyr Ser Asp Ser Ile
85 90 95

60 Leu Thr Cys His Leu Ile Leu Ala Ser Tyr Phe Ser His Val Tyr Leu
100 105 110

Pro Val Thr Cys Ile Cys Tyr Leu Asn Arg Lys Lys Asn Ile Gln Lys
 115 120 125

5 Lys Lys Asn Xaa
 130

10 (2) INFORMATION FOR SEQ ID NO: 356:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 204 amino acids

(B) TYPE: amino acid

15 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 356:

Met Gly Ser Arg Asp His Leu Phe Lys Val Leu Val Val Gly Asp Ala
 1 5 10 15
 20 Ala Val Gly Lys Thr Ser Leu Val Gln Asp Tyr Ser Gln Asp Ser Phe
 20 25 30
 25 Ser Lys His Tyr Lys Ser Thr Val Gly Val Asp Phe Ala Leu Lys Val
 35 40 45
 Leu Gln Trp Ser Asp Tyr Glu Ile Val Arg Leu Gln Leu Trp Asp Ile
 50 55 60
 30 Ala Gly Gln Glu Arg Phe Thr Ser Met Thr Arg Leu Tyr Tyr Arg Asp
 65 70 75 80
 Ala Ser Ala Cys Val Ile Met Phe Asp Val Thr Asn Ala Thr Thr Phe
 85 90 95
 35 Ser Asn Ser Gln Arg Trp Lys Gln Asp Leu Asp Ser Lys Leu Thr Leu
 100 105 110
 40 Pro Asn Gly Glu Pro Val Pro Cys Leu Leu Leu Ala Asn Lys Cys Asp
 115 120 125
 Leu Ser Pro Trp Ala Val Ser Arg Asp Gln Ile Asp Arg Phe Ser Lys
 130 135 140
 45 Glu Asn Gly Phe Thr Gly Trp Thr Glu Thr Ser Val Lys Glu Asn Lys
 145 150 155 160
 Asn Ile Asn Glu Ala Met Arg Val Leu Ile Glu Lys Met Met Arg Asn
 165 170 175
 50 Ser Thr Glu Asp Ile Met Ser Leu Ser Thr Gln Gly Asp Tyr Ile Asn
 180 185 190
 55 Leu Gln Thr Lys Ser Ser Ser Trp Ser Cys Cys Xaa
 195 200

60 (2) INFORMATION FOR SEQ ID NO: 357:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 357:

Met Ile Ser Leu Ile Phe Gln Leu Glu Glu Glu Lys Leu Val Glu Lys
 1 5 10 15

10 Phe Phe Phe Phe Leu Phe Phe Phe Leu Lys Lys Gly Ser Gln Gly Ser
 20 25 30

Asn Leu Lys Ile Val Pro Arg His Met Arg Val Val Leu Arg Gly
 35 40 45

15

(2) INFORMATION FOR SEQ ID NO: 358:

20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 73 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 358:

Met Thr Tyr Val Thr Cys Leu His Val Cys Leu Leu Val Glu Phe Leu
 1 5 10 15

30 Asn Ser Gln Leu Thr Asn His Arg Lys Tyr Tyr Phe Leu Ser Tyr Gly
 20 25 30

Phe Trp Phe Thr Gly Leu Arg Gly Phe Ser Glu Tyr Leu Trp Pro Gln
 35 40 45

35 Gln His Thr Ser Phe His Pro Asn Arg Asn Glu Ile Asn Phe Val Ser
 50 55 60

Thr Asp Asn Arg Ile Trp Val Thr Xaa
 65 70

40

(2) INFORMATION FOR SEQ ID NO: 359:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 359:

Met Ser Asp Gln Glu Ala Lys Pro Ser Thr Glu Asp Leu Gly Asp Lys
 1 5 10 15

55 Lys Glu Gly Glu Tyr Ile Lys Leu Lys Val Ile Gly Gln Asp Ser Ser
 20 25 30

Glu Ile His Phe Lys Val Lys Met Thr Thr His Leu Lys Lys Leu Lys
 35 40 45

60 Glu Ser Tyr Cys Gln Arg Gln Gly Val Pro Met Asn Ser Leu Arg Phe

Met Gly Phe Pro Gln Trp His Leu Gly Asn His Ala Val Glu Pro Val
1 5 10 15
25 Thr Ser Ile Leu Leu Leu Phe Leu Leu Met Met Leu Gly Val Arg Gly
20 25 30
Leu Leu Leu Val Gly Leu Val Tyr Leu Val Ser His Leu Ser Gln Arg
35 40 45

45	Met	Ser	Ala	Glu	Val	Lys	Val	Thr	Gly	Gln	Asn	Gln	Glu	Gln	Phe	Leu
	1				5					10					15	
	Leu	Leu	Ala	Lys	Ser	Ala	Lys	Gly	Ala	Ala	Leu	Ala	Thr	Leu	Ile	His
				20				25						30		
50	Gln	Val	Leu	Glu	Ala	Pro	Gly	Val	Tyr	Val	Phe	Gly	Glu	Leu	Leu	Asp
		35					40						45			
	Met	Pro	Asn	Val	Arg	Glu	Leu	Ala	Glu	Ser	Asp	Phe	Ala	Ser	Thr	Phe
		50					55					60				
55	Arg	Leu	Leu	Thr	Val	Phe	Ala	Tyr	Gly	Thr	Tyr	Ala	Asp	Tyr	Leu	Ala
	65					70					75					80
	Glu	Ala	Arg	Asn	Leu	Pro	Pro	Leu	Thr	Glu	Ala	Gln	Lys	Asn	Lys	Leu
60					85					90					95	

Arg His Leu Ser Val Val Thr Leu Ala Ala Lys Val Lys Cys Ile Pro
 100 105 110

5 Tyr Ala Val Leu Leu Glu Ala Leu Ala Leu Arg Asn Val Arg Gln Leu
 115 120 125

Glu Asp Leu Val Ile Glu Ala Val Tyr Ala Asp Val Leu Arg Gly Ser
 130 135 140

10 Leu Asp Gln Arg Asn Gln Arg Leu Glu Val Asp Tyr Ser Ile Gly Arg
 145 150 155 160

15 Asp Ile Gln Arg Gln Asp Leu Ser Ala Ile Ala Arg Thr Leu Xaa Lys
 165 170 175

Asn His Xaa

20

(2) INFORMATION FOR SEQ ID NO: 362:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 362:

30 Met Lys Ser Ser Ser Leu Phe Phe Phe Phe Leu Ala His Phe Ile His
 1 5 10 15

Ser His Asp Leu Pro Gly Leu Cys Arg
 20 25

35

(2) INFORMATION FOR SEQ ID NO: 363:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 224 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 363:

45

Met Lys Phe Ala Ala Ser Gly Xaa Phe Leu His His Met Ala Gly Leu
 1 5 10 15

50

Ser Ser Ser Lys Leu Ser Met Ser Lys Ala Leu Pro Leu Thr Lys Val
 20 25 30

Val Gln Asn Asp Ala Tyr Thr Ala Pro Ala Leu Pro Ser Ser Ile Arg
 35 40 45

55

Thr Lys Ala Leu Thr Asn Met Ser Arg Thr Leu Val Asn Lys Glu Glu
 50 55 60

60

Pro Pro Lys Glu Leu Pro Ala Ala Glu Pro Val Leu Ser Pro Leu Glu
 65 70 75 80

	Gly	Thr	Lys	Met	Thr	Val	Asn	Asn	Leu	His	Pro	Arg	Val	Thr	Glu	Glu
							85				90					95
5	Asp	Ile	Val	Glu	Leu	Phe	Cys	Val	Cys	Gly	Ala	Leu	Lys	Arg	Ala	Arg
				100					105					110		
	Leu	Val	His	Pro	Gly	Val	Ala	Glu	Val	Val	Phe	Val	Lys	Lys	Asp	Asp
			115					120					125			
10	Ala	Ile	Thr	Ala	Tyr	Lys	Lys	Tyr	Asn	Asn	Arg	Cys	Leu	Asp	Gly	Gln
			130				135					140				
	Pro	Met	Lys	Cys	Asn	Leu	His	Met	Asn	Gly	Asn	Val	Ile	Thr	Ser	Asp
15	145					150					155					160
	Gln	Pro	Ile	Leu	Leu	Arg	Leu	Ser	Asp	Ser	Pro	Ser	Met	Lys	Lys	Glu
				165						170					175	
20	Ser	Glu	Leu	Pro	Arg	Arg	Val	Asn	Ser	Ala	Ser	Ser	Ser	Asn	Pro	Pro
				180					185					190		
	Ala	Glu	Val	Asp	Pro	Asp	Thr	Ile	Leu	Lys	Ala	Leu	Phe	Lys	Ser	Ser
			195					200					205			
25	Gly	Ala	Ser	Xaa	Thr	Thr	Gln	Pro	Thr	Glu	Phe	Lys	Ile	Lys	Leu	Xaa
		210					215					220				

30

(2). INFORMATION FOR SEQ ID NO: 364:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 349 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 364:

```

40 Met Ser Lys Asn Cys Ile Lys Leu Leu Cys Glu Asp Pro Val Phe Ala
    1                      5                      10                      15

45 Glu Tyr Ile Lys Cys Ile Leu Met Asp Glu Arg Thr Phe Leu Asn Asn
    20                      25                      30

    Asn Ile Val Tyr Thr Phe Met Thr His Phe Leu Leu Lys Val Gln Ser
    35                      40                      45

50 Gln Val Phe Ser Glu Ala Asn Cys Ala Asn Leu Ile Ser Thr Leu Ile
    50                      55                      60

    Thr Asn Leu Ile Ser Gln Tyr Gln Asn Leu Gln Ser Asp Phe Ser Asn
    65                      70                      75                      80

55 Arg Val Glu Ile Ser Lys Ala Ser Ala Ser Leu Asn Gly Asp Leu Arg
    85                      90                      95

    Ala Leu Ala Leu Leu Leu Ser Val His Thr Pro Lys Gln Leu Asn Pro
    100                      105                      110

```

Ala Leu Ile Pro Thr Leu Gln Glu Leu Leu Ser Lys Cys Arg Thr Cys
 115 120 125

5 Leu Gln Gln Arg Asn Ser Leu Gln Glu Gln Glu Ala Lys Glu Arg Lys
 130 135 140

Thr Lys Asp Asp Glu Gly Ala Thr Pro Ile Lys Arg Arg Arg Val Ser
 145 150 155 160

10 Ser Asp Glu Glu His Thr Val Asp Ser Cys Ile Ser Asp Met Lys Thr
 165 170 175

15 Glu Thr Arg Glu Val Leu Thr Pro Thr Ser Thr Ser Asp Asn Glu Thr
 180 185 190

Arg Asp Ser Ser Ile Ile Asp Pro Gly Thr Glu Gln Asp Leu Pro Ser
 195 200 205

20 Pro Glu Asn Ser Ser Val Lys Glu Tyr Arg Met Glu Val Pro Ser Ser
 210 215 220

Phe Ser Glu Asp Met Ser Asn Ile Arg Ser Gln His Ala Glu Glu Gln
 225 230 235 240

25 Ser Asn Asn Gly Arg Tyr Asp Asp Cys Lys Glu Phe Lys Asp Leu His
 245 250 255

30 Cys Ser Lys Asp Ser Thr Leu Ala Glu Glu Glu Ser Glu Phe Pro Ser
 260 265 270

Thr Ser Ile Ser Ala Val Leu Ser Asp Leu Ala Asp Leu Arg Ser Cys
 275 280 285

35 Asp Gly Gln Ala Leu Pro Ser Gln Asp Pro Glu Val Ala Leu Ser Leu
 290 295 300

Ser Cys Gly His Ser Arg Gly Leu Phe Ser His Met Gln Gln His Asp
 305 310 315 320

40 Ile Leu Asp Thr Leu Cys Arg Thr Ile Glu Ser Thr Ile His Val Val
 325 330 335

45 Thr Arg Ile Ser Gly Lys Gly Asn Gln Ala Ala Ser Xaa
 340 345

50 (2) INFORMATION FOR SEQ ID NO: 365:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 467 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 365:
 Met Leu His Gln Asp His Ile Thr Phe Ala Met Leu Leu Ala Arg Ile
 1 5 10 15

60 Lys Leu Lys Gly Thr Val Gly Glu Pro Thr Tyr Asp Ala Glu Phe Gln

	20	25	30
5	His Phe Leu Arg Gly Asn Glu Ile Val Leu Ser Ala Gly Ser Thr Pro 35 40 45		
	Arg Ile Gln Gly Leu Thr Val Glu Gln Ala Glu Ala Val Val Arg Leu 50 55 60		
10	Ser Cys Leu Pro Ala Phe Lys Asp Leu Ile Ala Lys Val Gln Ala Asp 65 70 75 80		
	Glu Gln Phe Gly Ile Trp Leu Asp Ser Ser Ser Pro Glu Gln Thr Val 85 90 95		
15	Pro Tyr Leu Trp Ser Glu Glu Thr Pro Ala Thr Pro Ile Gly Gln Ala 100 105 110		
	Ile His Arg Leu Leu Leu Ile Gln Ala Phe Arg Pro Asp Arg Leu Leu 115 120 125		
20	Ala Met Ala His Met Phe Val Ser Thr Asn Leu Gly Glu Ser Phe Met 130 135 140		
	Ser Ile Met Glu Gln Pro Leu Asp Leu Thr His Ile Val Xaa Thr Glu 145 150 155 160		
25	Val Lys Pro Asn Thr Pro Val Leu Met Cys Ser Val Pro Gly Tyr Asp 165 170 175		
30	Ala Ser Gly His Val Glu Asp Leu Ala Ala Glu Gln Asn Thr Gln Ile 180 185 190		
	Thr Ser Ile Ala Ile Gly Ser Ala Glu Gly Phe Asn Gln Ala Asp Lys 195 200 205		
35	Ala Ile Asn Thr Ala Val Lys Ser Gly Arg Trp Val Met Leu Lys Asn 210 215 220		
	Val His Leu Ala Pro Gly Trp Leu Met Gln Leu Glu Lys Lys Leu His 225 230 235 240		
40	Ser Leu Gln Pro His Ala Cys Phe Arg Leu Phe Leu Thr Met Glu Ile 245 250 255		
45	Asn Pro Lys Val Pro Val Asn Leu Leu Arg Ala Gly Arg Ile Phe Val 260 265 270		
	Phe Glu Pro Pro Pro Gly Xaa Lys Ala Asn Met Leu Arg Thr Phe Ser 275 280 285		
50	Ser Ile Pro Val Ser Arg Ile Cys Lys Ser Pro Asn Glu Arg Ala Arg 290 295 300		
	Leu Tyr Phe Leu Leu Ala Trp Phe His Ala Ile Ile Gln Glu Arg Leu 305 310 315 320		
55	Arg Tyr Ala Pro Leu Gly Trp Ser Lys Lys Tyr Glu Phe Gly Glu Ser 325 330 335		
60	Asp Leu Arg Ser Xaa Cys Asp Thr Val Asp Thr Trp Leu Asp Asp Thr		

(2) INFORMATION FOR SEQ ID NO: 366:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 152 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 366:

	Met	Ala	Asp	Glu	Ala	Thr	Arg	Arg	Val	Val	Ser	Glu	Ile	Pro	Val	Leu
	1				5					10					15	
40	Lys	Thr	Asn	Ala	Gly	Pro	Arg	Asp	Arg	Glu	Leu	Trp	Val	Gln	Arg	Leu
				20					25					30		
	Lys	Glu	Glu	Tyr	Gln	Ser	Leu	Ile	Arg	Tyr	Val	Glu	Asn	Asn	Lys	Asn
45		35						40					45			
	Ala	Asp	Asn	Asp	Trp	Phe	Arg	Leu	Glu	Ser	Asn	Lys	Glu	Gly	Thr	Arg
	50						55					60				
50	Trp	Phe	Gly	Lys	Cys	Trp	Tyr	Ile	His	Asp	Leu	Leu	Lys	Tyr	Glu	Phe
	65					70					75					80
	Asp	Ile	Glu	Phe	Asp	Ile	Pro	Ile	Thr	Tyr	Pro	Thr	Thr	Ala	Pro	Glu
					85					90					95	
55	Ile	Ala	Val	Pro	Glu	Leu	Asp	Gly	Lys	Thr	Ala	Lys	Met	Tyr	Arg	Gly
				100					105					110		
	Gly	Lys	Ile	Cys	Leu	Thr	Asp	His	Phe	Lys	Pro	Leu	Trp	Gly	Gln	Glu
60			115					120					125			

Cys Ala Gln Ile Trp Thr Ser Ser Ser His Gly Ser Gly Ala Gly Ser
 130 135 140

5 Met Xaa Gly Ser Gly Asn Pro Xaa
 145 150

(2) INFORMATION FOR SEQ ID NO: 367:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 373 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 367:

Met Tyr Asp Gly Thr Lys Glu Val Pro Met Asn Pro Val Lys Ile Tyr
 1 5 10 15

20 Gln Val Cys Asp Ile Pro Gln Pro Gln Gly Ser Ile Ile Asn Pro Gly
 20 25 30

25 Ser Thr Gly Ser Ala Pro Trp Asp Glu Lys Asp Asn Asp Val Asp Glu
 35 40 45

Glu Asp Glu Glu Asp Glu Leu Asp Gln Ser Gln His His Val Pro Ile
 50 55 60

30 Gln Asp Thr Phe Pro Phe Leu Asn Ile Asn Gly Ser Pro Met Ala Pro
 65 70 75 80

Ala Ser Val Gly Asn Cys Ser Val Gly Asn Cys Ser Pro Glu Ala Val
 85 90 95

35 Trp Pro Lys Thr Glu Pro Leu Glu Met Glu Val Pro Gln Ala Pro Ile
 100 105 110

Gln Pro Phe Tyr Ser Ser Pro Glu Leu Trp Ile Ser Ser Leu Pro Met
 115 120 125

40 Thr Asp Leu Asp Ile Lys Phe Gln Tyr Arg Gly Lys Glu Tyr Gly Gln
 130 135 140

45 Thr Met Thr Val Ser Asn Pro Gln Gly Cys Arg Leu Phe Tyr Gly Asp
 145 150 155 160

Leu Gly Pro Met Pro Asp Gln Glu Glu Leu Phe Gly Pro Val Xaa Leu
 165 170 175

50 Glu Gln Val Lys Phe Pro Gly Pro Glu His Ile Thr Asn Glu Lys Gln
 180 185 190

Lys Leu Phe Thr Ser Lys Leu Leu Asp Val Met Asp Arg Gly Leu Ile
 195 200 205

55 Leu Glu Val Ser Gly His Ala Ile Tyr Ala Ile Arg Leu Cys Gln Cys
 210 215 220

60 Lys Val Tyr Trp Ser Gly Pro Cys Ala Pro Ser Leu Val Ala Pro Asn
 225 230 235 240

Leu Ile Glu Arg Gln Lys Lys Val Lys Leu Phe Cys Leu Glu Thr Phe
 245 250 255
 5 Leu Ser Asp Leu Ile Ala His Gln Lys Gly Gln Ile Glu Lys Gln Pro
 260 265 270
 Pro Phe Glu Ile Tyr Leu Cys Phe Gly Glu Glu Trp Pro Asp Gly Lys
 275 280 285
 10 Pro Leu Glu Arg Lys Leu Ile Leu Val Gln Val Ile Pro Val Val Ala
 290 295 300
 Arg Met Ile Tyr Glu Met Phe Ser Gly Asp Phe Thr Arg Ser Phe Asp
 15 305 310 315 320
 Ser Gly Ser Val Arg Leu Gln Ile Ser Thr Pro Asp Ile Lys Asp Asn
 325 330 335
 20 Ile Val Ala Gln Leu Lys Gln Leu Tyr Arg Ile Leu Gln Thr Gln Glu
 340 345 350
 Ser Trp Gln Pro Met Gln Pro Thr Pro Ser Met Gln Leu Pro Pro Ala
 25 355 360 365
 Leu Pro Pro Gln Xaa
 370

30

(2) INFORMATION FOR SEQ ID NO: 368:

(i) SEQUENCE CHARACTERISTICS:

35

(A) LENGTH: 83 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 368:

40 Met Gly Ser Ser Val Leu Pro Phe Cys Val Cys Val Thr Ser Pro Ser
 1 5 10 15
 Leu Gly Gly Arg Cys Ile Gln Gly Arg Phe Ala Ser His Ser Lys Phe
 20 25 30
 45 Trp Gly Phe Gly Arg Lys Thr Ala Ser Phe Gly Ala Val Gly Glu Thr
 35 40 45
 Pro Pro Asp Gln Glu Pro Gln Lys Glu Thr Glu Pro Ala Thr Ser Ser
 50 55 60
 55 His Ala Arg Pro Trp Ala Arg Val Ile Gly Leu Arg Ile Trp Pro Gln
 65 70 75 80
 Pro Asn Xaa

60

(2) INFORMATION FOR SEQ ID NO: 369:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 369:

Met Leu Leu Ser Val Ala Ile Phe Ile Leu Leu Thr Leu Val Tyr Ala
 1 5 10 15

10 Tyr Trp Thr Met Xaa
 20

15 (2) INFORMATION FOR SEQ ID NO: 370:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 227 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 370:

Met Gly Ala Ser Ala Arg Leu Leu Arg Ala Val Ile Met Gly Ala Pro
 1 5 10 15

25 Gly Ser Gly Lys Gly Thr Val Ser Ser Arg Ile Thr Thr His Phe Glu
 20 25 30

30 Leu Lys His Leu Ser Ser Gly Asp Leu Leu Arg Asp Asn Met Leu Arg
 35 40 45

Gly Thr Glu Ile Gly Val Leu Ala Lys Ala Phe Ile Asp Gln Gly Lys
 50 55 60

35 Leu Ile Pro Asp Asp Val Met Thr Arg Leu Ala Leu His Glu Leu Lys
 65 70 75 80

Asn Leu Thr Gln Tyr Ser Trp Leu Leu Asp Gly Phe Pro Arg Thr Leu
 85 90 95

40 Pro Gln Ala Glu Ala Leu Asp Arg Ala Tyr Gln Ile Asp Thr Val Ile
 100 105 110

45 Asn Leu Asn Val Pro Phe Glu Val Ile Lys Gln Arg Leu Thr Ala Arg
 115 120 125

Trp Ile His Pro Ala Ser Gly Arg Val Tyr Asn Ile Glu Phe Asn Pro
 130 135 140

50 Pro Lys Thr Val Gly Ile Asp Asp Leu Thr Gly Glu Pro Leu Ile Gln
 145 150 155 160

Arg Glu Asp Asp Lys Pro Glu Thr Val Ile Lys Arg Leu Lys Ala Tyr
 165 170 175

55 Glu Asp Gln Thr Lys Pro Val Leu Glu Tyr Tyr Gln Lys Lys Gly Val
 180 185 190

60 Leu Glu Thr Phe Ser Gly Thr Glu Thr Asn Lys Ile Trp Pro Tyr Val
 195 200 205

Tyr Ala Phe Leu Gln Thr Lys Val Pro Gln Arg Ser Gln Lys Ala Ser
 210 215 220

5 Val Thr Pro
 225

10 (2) INFORMATION FOR SEQ ID NO: 371:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 79 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 371:

Met Phe Leu Asn Cys Glu Ile Leu Glu Tyr Cys Tyr Tyr Leu Thr Gln
 1 5 10 15

20 Leu Lys Ile Ser Met Gly Lys Tyr Leu Ser Ile Pro Thr Val Leu Leu
 20 25 30

25 Lys Ile Ile Arg Cys Ser Ile Thr Ala Val Ser Asp Ser Ser Thr Ser
 35 40 45

Trp Ala Ile Lys Ala Gln Leu Lys Ile Glu Asn Lys Asp Leu Asp Asn
 50 55 60

30 Lys Thr Ala Lys Gly Gly Gly Gln Glu Ala Leu Thr Cys Thr Xaa
 65 70 75

35 (2) INFORMATION FOR SEQ ID NO: 372:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 51 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 372:

Met Arg Ala Val Phe Pro Cys Cys Pro Phe Leu Thr Leu Met Leu Pro
 1 5 10 15

45 Leu Leu Glu Cys Leu Val Gly Met Ile Met Cys Tyr Leu Gly Ile Ser
 20 25 30

50 Phe Thr Asp Thr Arg Lys Thr Ala Gly Leu Lys Lys Lys Lys Lys
 35 40 45

Lys Xaa Xaa
 50

55

(2) INFORMATION FOR SEQ ID NO: 373:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 61 amino acids

60

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 373:

5 Met Phe Leu Met Arg Met His Leu Cys Phe Cys Lys Tyr Cys Cys Ser
 1 5 10 15
 Phe Ile Val Thr Pro Thr Ser Thr Ser Asn Thr Ala Ser Tyr Leu Trp
 20 25 30
 10 Pro Trp Ile Ser Ala Ser Met Ala Gly Arg Gly Ser Ser Trp Ala Cys
 35 40 45
 Thr Leu Asn Ala Val Thr Arg Glu Gly Leu Pro Glu Xaa
 15 50 55 60

(2) INFORMATION FOR SEQ ID NO: 374:

20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 40 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 374:

Met Ser Leu Leu Asn Thr His Thr Leu Cys Phe Val Leu Phe Cys Phe
 1 5 10 15
 30 Thr Leu Ser Ile Asn Gln Glu Lys Leu Ala Asn His Leu Ala Phe Arg
 20 25 30
 Ile Leu Phe Phe Ile Val Phe Xaa
 35 40

35

(2) INFORMATION FOR SEQ ID NO: 375:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 44 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 375:

Met Cys Ser Gly Gln Ser Gln Val Trp Lys Met Ala Leu Gln Ala Leu
 1 5 10 15
 50 Asp Ser Glu Thr Val Val Ile Leu Pro Asp Met His Leu Ile Leu Ser
 20 25 30
 Leu Arg Leu Ile His Asn Ala Arg Pro Cys Leu Xaa
 35 40

55

(2) INFORMATION FOR SEQ ID NO: 376:

60

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 203 amino acids

578

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 376:

5 Met Leu Ile Ser Glu Glu Glu Ile Pro Phe Lys Asp Asp Pro Arg Asp
 1 5 10 15
 Glu Thr Tyr Lys Pro His Leu Glu Arg Glu Thr Pro Lys Pro Arg Arg
 20 25 30
 10 Lys Ser Gly Lys Val Lys Glu Glu Lys Glu Lys Lys Glu Ile Lys Val
 35 40 45
 Glu Val Glu Val Glu Val Lys Glu Glu Glu Asn Glu Ile Arg Glu Asp
 15 50 55 60
 Glu Glu Pro Pro Arg Lys Arg Gly Arg Arg Arg Lys Asp Asp Lys Ser
 65 70 75 80
 20 Pro Arg Leu Pro Lys Arg Arg Lys Lys Pro Pro Ile Gln Tyr Val Arg
 85 90 95
 Cys Glu Met Glu Gly Cys Gly Thr Val Leu Ala His Pro Arg Tyr Leu
 100 105 110
 25 Gln His His Ile Lys Tyr Gln His Leu Leu Lys Lys Lys Tyr Val Cys
 115 120 125
 Pro His Pro Ser Cys Gly Arg Leu Phe Arg Leu Gln Lys Gln Leu Leu
 30 130 135 140
 Arg His Ala Lys His His Thr Asp Gln Arg Asp Tyr Ile Cys Glu Tyr
 145 150 155 160
 35 Cys Ala Arg Ala Phe Lys Ser Ser His Asn Leu Ala Val His Arg Met
 165 170 175
 Ile His Thr Gly Glu Lys His Tyr Asn Val Arg Ser Val Asp Leu Leu
 180 185 190
 40 Val Asp Lys Arg His Leu Leu Ile Gly Thr Xaa
 195 200

45

(2) INFORMATION FOR SEQ ID NO: 377:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids

50

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 377:

55 Met Leu Pro Arg Arg Thr Phe Tyr Phe Tyr Phe Ile Phe Ile Phe Phe
 1 5 10 15
 Leu Ala Ser Phe Trp Gly Phe Thr Leu Arg Ala Ser Phe
 20 25

60

(2) INFORMATION FOR SEQ ID NO: 378:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 136 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 378:

5
 10 Met Phe Asp Ser Leu Ser Tyr Phe Lys Gly Ser Ser Leu Leu Leu Met
 1 5 10 15
 Leu Lys Thr Tyr Leu Ser Glu Asp Val Phe Gln His Ala Val Val Leu
 20 25 30
 15 Tyr Leu His Asn His Ser Tyr Ala Ser Ile Gln Ser Asp Asp Leu Trp
 35 40 45
 20 Asp Ser Phe Asn Glu Val Thr Asn Gln Thr Leu Asp Val Lys Arg Met
 50 55 60
 Met Lys Thr Trp Thr Leu Gln Lys Gly Phe Pro Leu Val Thr Val Gln
 65 70 75 80
 25 Lys Lys Gly Lys Glu Leu Phe Ile Gln Gln Glu Arg Phe Phe Leu Asn
 85 90 95
 Met Lys Pro Glu Ile Gln Pro Ser Asp Thr Arg Tyr Met Pro Ser Phe
 100 105 110
 30 Phe Ser Cys His Leu Phe Cys Thr Leu Arg Trp Lys Tyr Phe Glu Val
 115 120 125
 35 Phe Tyr Asn His Lys Phe Leu Xaa
 130 135

(2) INFORMATION FOR SEQ ID NO: 379:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 41 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 379:

40
 45
 50 Met Ala Trp Arg Arg Arg Glu Pro Ala Ser Gly Leu Ala Ala Cys Trp
 1 5 10 15
 Leu Trp Arg Cys Ser Pro Trp Pro Cys Ala Cys Pro Gly Pro Gly Ala
 20 25 30
 Gly Leu Ser Ser Gly Ser Arg Pro Trp
 35 40
 55

(2) INFORMATION FOR SEQ ID NO: 380:

(i) SEQUENCE CHARACTERISTICS:

580

(A) LENGTH: 468 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 380:

5 Met Glu Phe Leu Lys Val Ala Arg Arg Asn Lys Arg Glu Gln Leu Glu
 1 5 10 15
 10 Gln Ile Gln Lys Glu Leu Ser Val Leu Glu Glu Asp Ile Lys Arg Val
 20 25 30
 Glu Glu Met Ser Gly Leu Tyr Ser Pro Val Ser Glu Asp Ser Thr Val
 35 40 45
 15 Pro Gln Phe Glu Ala Pro Ser Pro Ser His Ser Ser Ile Ile Asp Ser
 50 55 60
 Thr Glu Tyr Ser Gln Pro Pro Gly Phe Ser Gly Ser Ser Gln Thr Lys
 65 70 75 80
 20 Lys Gln Pro Trp Tyr Asn Ser Thr Leu Ala Ser Arg Arg Lys Arg Leu
 85 90 95
 Thr Ala His Phe Glu Asp Leu Glu Gln Cys Tyr Phe Ser Thr Arg Met
 100 105 110
 25 Ser Arg Ile Ser Asp Asp Ser Arg Thr Ala Ser Gln Leu Asp Glu Phe
 115 120 125
 30 Gln Glu Cys Leu Ser Lys Phe Thr Arg Tyr Asn Ser Val Arg Pro Leu
 130 135 140
 Ala Thr Leu Ser Tyr Ala Ser Asp Leu Tyr Asn Gly Ser Ser Ile Val
 145 150 155 160
 35 Ser Ser Ile Glu Phe Asp Arg Asp Cys Asp Tyr Phe Ala Ile Ala Gly
 165 170 175
 Val Thr Lys Lys Ile Lys Val Tyr Glu Tyr Asp Thr Val Ile Gln Asp
 180 185 190
 40 Ala Val Asp Ile His Tyr Pro Glu Asn Glu Met Thr Cys Asn Ser Lys
 195 200 205
 45 Ile Ser Cys Ile Ser Trp Ser Ser Tyr His Lys Asn Leu Leu Ala Ser
 210 215 220
 Ser Asp Tyr Glu Gly Thr Val Ile Leu Trp Asp Gly Phe Thr Gly Gln
 225 230 235 240
 50 Arg Ser Lys Val Tyr Gln Glu His Glu Lys Arg Cys Trp Ser Val Asp
 245 250 255
 Phe Asn Leu Met Asp Pro Lys Leu Leu Ala Ser Gly Ser Asp Asp Ala
 260 265 270
 55 Lys Val Lys Leu Trp Ser Thr Asn Leu Asp Asn Ser Val Ala Ser Ile
 275 280 285
 60 Glu Ala Lys Ala Asn Val Cys Cys Val Lys Phe Ser Pro Ser Ser Arg

581

290 295 300

5 Tyr His Leu Ala Phe Gly Cys Ala Asp His Cys Val His Tyr Tyr Asp
305 310 315 320

Leu Arg Asn Thr Lys Gln Pro Ile Met Val Phe Lys Gly His Arg Lys
325 330 335

10 Ala Val Ser Tyr Ala Lys Phe Val Ser Gly Glu Glu Ile Val Ser Ala
340 345 350

Ser Thr Asp Ser Gln Leu Lys Leu Trp Asn Val Gly Lys Pro Tyr Cys
355 360 365

15 Leu Arg Ser Phe Lys Gly His Ile Asn Glu Lys Asn Phe Val Gly Leu
370 375 380

Ala Ser Asn Gly Asp Tyr Ile Ala Cys Gly Ser Glu Asn Asn Ser Leu
385 390 395 400

20 Tyr Leu Tyr Tyr Lys Gly Leu Ser Lys Thr Leu Leu Thr Phe Lys Phe
405 410 415

25 Asp Thr Val Lys Ser Val Leu Asp Lys Asp Arg Lys Glu Asp Asp Thr
420 425 430

Asn Glu Phe Val Ser Ala Val Cys Trp Arg Ala Leu Pro Asp Gly Glu
435 440 445

30 Ser Asn Val Leu Ile Ala Ala Asn Ser Gln Gly Thr Ile Lys Val Leu
450 455 460

Glu Leu Val Xaa
465

35

(2) INFORMATION FOR SEQ ID NO: 381:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 381:

Met Arg Lys Glu Asp Gly Phe Trp Phe Phe Phe Leu Phe Phe Phe
1 5 10 15

50

Val Val Gly Ser Lys Phe Val Asn Gly Asn Lys Leu Val
20 25

55

(2) INFORMATION FOR SEQ ID NO: 382:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 382:

Met Pro Leu Ala Pro Tyr Cys Asp Leu Leu Val Ala Leu Ser Phe Ala
 1 5 10 15
 5 Leu Val Leu Glu Ser Pro Val Asp Ser Ser Asp Phe Thr
 20 25

10 (2) INFORMATION FOR SEQ ID NO: 383:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 138 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 383:

Met Asn Ser Leu Val Ser Trp Gln Leu Leu Leu Phe Leu Cys Ala Thr
 1 5 10 15
 20 His Phe Gly Glu Pro Leu Glu Lys Val Ala Ser Val Gly Asn Ser Arg
 20 25 30
 25 Pro Thr Gly Gln Gln Leu Glu Ser Leu Gly Leu Leu Ala Pro Gly Glu
 35 40 45
 Gln Ser Leu Pro Cys Thr Glu Arg Lys Pro Ala Ala Thr Ala Arg Leu
 50 55 60
 30 Ser Arg Arg Gly Thr Ser Leu Ser Pro Pro Pro Glu Ser Ser Gly Ser
 65 70 75 80
 Pro Gln Gln Pro Gly Leu Ser Ala Pro His Ser Arg Gln Ile Pro Ala
 85 90 95
 35 Pro Gln Gly Ala Val Leu Val Gln Arg Glu Lys Asp Leu Pro Asn Tyr
 100 105 110
 40 Asn Trp Asn Ser Phe Gly Leu Arg Phe Gly Lys Arg Glu Ala Ala Pro
 115 120 125
 Gly Asn His Gly Arg Ser Ala Gly Arg Gly
 130 135

45

(2) INFORMATION FOR SEQ ID NO: 384:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 74 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 384:

Met Ser Cys Phe Ile Asp Ser Xaa Asp Ser Lys Ile Leu His Leu Leu
 1 5 10 15
 Val Val Ser Phe Ile Cys Xaa Leu Phe Leu Leu Ile Leu Thr His Gly
 20 25 30
 60

Ile Leu Ile Leu Arg Xaa Phe Phe Ser Val Xaa Xaa His Ser Leu Lys
 35 40 45
 Asn Asn Leu Glu Glu Tyr Leu Ile Leu Met Asn Lys Ala Leu Leu Thr
 5 50 55 60
 Arg Glu Asp Phe Phe Val Leu Pro Xaa Ala
 65 70
 10
 (2) INFORMATION FOR SEQ ID NO: 385:
 (i) SEQUENCE CHARACTERISTICS:
 15 (A) LENGTH: 521 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 385:
 20 Met Ser Ala Gly Glu Val Glu Arg Leu Val Ser Glu Leu Ser Gly Gly
 1 5 10 15
 Thr Gly Gly Asp Glu Glu Glu Glu Trp Leu Tyr Gly Asp Glu Asn Glu
 20 25 30
 25 Val Glu Arg Pro Glu Glu Glu Asn Ala Ser Ala Asn Pro Pro Ser Gly
 35 40 45
 30 Ile Glu Asp Glu Thr Ala Glu Asn Gly Val Pro Lys Pro Lys Val Thr
 50 55 60
 Glu Thr Glu Asp Asp Ser Asp Ser Asp Ser Asp Asp Glu Asp Asp
 65 70 75 80
 35 Val His Val Thr Ile Gly Asp Ile Lys Thr Gly Ala Pro Gln Tyr Gly
 85 90 95
 Ser Tyr Gly Thr Ala Pro Val Asn Leu Asn Ile Lys Thr Gly Gly Arg
 100 105 110
 40 Val Tyr Gly Thr Thr Gly Thr Lys Val Lys Gly Val Asp Leu Asp Ala
 115 120 125
 Pro Gly Ser Ile Asn Gly Val Pro Leu Leu Glu Val Asp Leu Asp Ser
 45 130 135 140
 Phe Glu Asp Lys Pro Trp Arg Lys Pro Gly Ala Asp Leu Ser Asp Tyr
 145 150 155 160
 50 Phe Asn Tyr Gly Phe Asn Glu Asp Thr Trp Lys Ala Tyr Cys Glu Lys
 165 170 175
 Gln Lys Arg Ile Arg Met Gly Leu Glu Val Ile Pro Val Thr Ser Thr
 180 185 190
 55 Thr Asn Lys Ile Thr Val Gln Gln Gly Arg Thr Gly Asn Ser Glu Lys
 195 200 205
 Glu Thr Ala Leu Pro Ser Thr Lys Ala Glu Phe Thr Ser Pro Pro Ser
 60 210 215 220

Leu Phe Lys Thr Gly Leu Pro Pro Ser Arg Arg Leu Pro Gly Ala Ile
 225 230 235 240
 5 Asp Val Ile Gly Gln Thr Ile Thr Ile Ser Arg Val Glu Gly Arg Arg
 245 250 255
 Arg Ala Asn Glu Asn Ser Asn Ile Gln Val Leu Ser Glu Arg Ser Ala
 260 265 270
 10 Thr Glu Val Asp Asn Asn Phe Ser Lys Pro Pro Pro Phe Phe Pro Pro
 275 280 285
 Gly Ala Pro Pro Thr His Leu Pro Pro Pro Pro Phe Leu Pro Pro Pro
 15 290 295 300
 Pro Thr Val Ser Thr Ala Pro Pro Leu Ile Pro Pro Pro Gly Phe Pro
 305 310 315 320
 20 Pro Pro Pro Gly Ala Pro Pro Pro Ser Leu Ile Pro Thr Ile Glu Ser
 325 330 335
 Gly His Ser Ser Gly Tyr Asp Ser Arg Ser Ala Arg Ala Phe Pro Tyr
 25 340 345 350
 Gly Asn Val Ala Phe Pro His Leu Pro Gly Ser Ala Pro Ser Trp Pro
 355 360 365
 Ser Leu Val Asp Thr Ser Lys Gln Trp Asp Tyr Tyr Ala Arg Arg Glu
 30 370 375 380
 Lys Asp Arg Asp Arg Glu Arg Asp Arg Asp Arg Glu Arg Asp Arg Asp
 385 390 395 400
 35 Arg Asp Arg Glu Arg Glu Arg Thr Arg Glu Arg Glu Arg Glu Arg Asp
 405 410 415
 His Ser Pro Thr Pro Ser Val Phe Asn Ser Asp Glu Glu Arg Tyr Arg
 420 425 430
 40 Tyr Arg Glu Tyr Ala Glu Arg Gly Tyr Glu Arg His Arg Ala Ser Arg
 435 440 445
 Glu Lys Glu Glu Arg His Arg Glu Arg Arg His Arg Glu Lys Glu Glu
 45 450 455 460
 Thr Arg His Lys Ser Ser Arg Ser Asn Ser Arg Arg Arg His Glu Ser
 465 470 475 480
 50 Glu Glu Gly Asp Ser His Arg Arg His Lys His Lys Lys Ser Lys Arg
 485 490 495
 Ser Lys Glu Gly Lys Glu Ala Gly Ser Glu Pro Ala Pro Glu Gln Glu
 500 505 510
 55 Ser Thr Glu Ala Thr Pro Ala Glu Xaa
 515 520
 60

(2) INFORMATION FOR SEQ ID NO: 386:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 137 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 386:

5
 10 Met Asn Ser Arg Gly Ile Trp Leu Ala Tyr Ile Ile Leu Val Gly Leu
 1 5 10 15
 Leu His Met Val Leu Leu Ser Ile Pro Phe Phe Ser Ile Pro Val Val
 20 25 30
 15 Trp Thr Leu Thr Asn Val Ile His Asn Leu Ala Thr Tyr Val Phe Leu
 35 40 45
 His Thr Val Lys Gly Thr Pro Phe Glu Thr Pro Asp Gln Gly Lys Ala
 50 55 60
 20 Arg Leu Leu Thr His Trp Glu Gln Met Asp Tyr Gly Leu Gln Phe Thr
 65 70 75 80
 25 Ser Ser Arg Lys Phe Leu Ser Ile Ser Pro Ile Val Leu Tyr Leu Leu
 85 90 95
 Ala Ser Phe Tyr Thr Lys Tyr Asp Ala Ala His Phe Leu Ile Asn Thr
 100 105 110
 30 Ala Ser Leu Leu Ser Val Leu Leu Pro Lys Leu Pro Gln Phe His Gly
 115 120 125
 Val Arg Val Phe Gly Ile Asn Lys Tyr
 130 135
 35

(2) INFORMATION FOR SEQ ID NO: 387:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 186 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 387:

40
 45 Met Ala Ala Gln Lys Asp Gln Gln Lys Asp Ala Glu Ala Glu Gly Leu
 1 5 10 15
 Ser Gly Thr Thr Leu Leu Pro Lys Leu Ile Pro Ser Gly Ala Gly Arg
 20 25 30
 Glu Trp Leu Glu Arg Arg Arg Ala Thr Ile Arg Pro Trp Ser Thr Phe
 35 40 45
 55 Val Asp Gln Gln Arg Phe Ser Arg Pro Arg Asn Leu Gly Glu Leu Cys
 50 55 60
 Gln Arg Leu Val Arg Asn Val Glu Tyr Tyr Gln Ser Asn Tyr Val Phe
 65 70 75 80
 60

586

Val Phe Leu Gly Leu Ile Leu Tyr Cys Val Val Thr Ser Pro Met Leu
85 90 95

5 Leu Val Ala Leu Ala Val Phe Phe Gly Ala Cys Tyr Ile Leu Tyr Leu
100 105 110

Arg Thr Leu Glu Ser Lys Leu Val Leu Phe Gly Arg Glu Val Ser Pro
115 120 125

10 Ala His Gln Tyr Ala Leu Ala Gly Gly Ile Ser Phe Pro Phe Phe Trp
130 135 140

Leu Ala Gly Ala Gly Ser Ala Val Phe Trp Val Leu Gly Ala Thr Leu
145 150 155 160

15 Val Val Ile Gly Ser His Ala Ala Phe His Gln Ile Glu Ala Val Asp
165 170 175

Gly Glu Glu Leu Gln Met Glu Pro Val Xaa
180 185

25 (2) INFORMATION FOR SEQ ID NO: 388:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 388:

Met
1

35

(2) INFORMATION FOR SEQ ID NO: 389:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 299 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 389:

45 Met Leu Ser Ile Phe Tyr Phe Ala Ile Pro Val Gly Ser Gly Leu Gly
1 5 10 15

Tyr Ile Ala Gly Ser Lys Val Lys Asp Met Ala Gly Asp Trp His Trp
20 25 30

50 Ala Leu Arg Val Thr Pro Gly Leu Gly Val Val Ala Val Leu Leu Leu
35 40 45

Phe Leu Val Val Arg Glu Pro Pro Arg Gly Ala Val Glu Arg His Ser
55 60

Asp Leu Pro Pro Leu Asn Pro Thr Ser Trp Trp Ala Asp Leu Arg Ala
65 70 75 80

60 Leu Ala Arg Asn Pro Ser Phe Val Leu Ser Ser Leu Gly Phe Thr Ala

587

	85	90	95
5	Val Ala Phe Val Thr Gly Ser Leu Ala Leu Trp Ala Pro Ala Phe Leu 100 105 110		
	Leu Arg Ser Arg Val Val Leu Gly Glu Thr Pro Pro Cys Leu Pro Gly 115 120 125		
10	Asp Ser Cys Ser Ser Ser Asp Ser Leu Ile Phe Gly Leu Ile Thr Cys 130 135 140		
	Leu Thr Gly Val Leu Gly Val Gly Leu Gly Val Glu Ile Ser Arg Arg 145 150 155 160		
15	Leu Arg His Ser Asn Pro Arg Ala Asp Pro Leu Val Cys Ala Thr Gly 165 170 175		
	Leu Leu Gly Ser Ala Pro Phe Leu Phe Leu Ser Leu Ala Cys Ala Arg 180 185 190		
20	Gly Ser Ile Val Ala Thr Tyr Ile Phe Ile Phe Ile Gly Glu Thr Leu 195 200 205		
25	Leu Ser Met Asn Trp Ala Ile Val Ala Asp Ile Leu Leu Tyr Val Val 210 215 220		
	Ile Pro Thr Arg Arg Ser Thr Ala Glu Ala Phe Gln Ile Val Leu Ser 225 230 235 240		
30	His Leu Leu Gly Asp Ala Gly Ser Pro Tyr Leu Ile Gly Leu Ile Ser 245 250 255		
	Asp Arg Leu Arg Arg Asn Trp Pro Pro Ser Phe Leu Ser Glu Phe Arg 260 265 270		
35	Ala Leu Gln Phe Ser Leu Met Leu Cys Ala Phe Val Gly Ala Leu Gly 275 280 285		
40	Gly Ala Leu Pro Gly His Arg His Leu His Xaa 290 295		

45 (2) INFORMATION FOR SEQ ID NO: 390:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 49 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 390:

Met Gly Pro Gln Gly Trp Val Arg Pro Leu Lys Thr Ala Pro Lys Leu
1 5 10 15

55 Gly Glu Ala Ile Arg Leu Ile Leu Phe Leu Asn Phe Val Lys Gln Cys
20 25 30

Ile Ala Ser Val Asn Leu Cys Ile Leu Arg Leu Asn Ile Thr Pro Leu
35 40 45

Leu

5

(2) INFORMATION FOR SEQ ID NO: 391:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 61 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 391:

15 Met Tyr Val Asn Tyr Gly Thr Arg Asn Tyr Ser Thr Glu Gly Pro Ala
 1 5 10 15
 Ala Leu Leu Asp Gln Ala Lys Leu Ser Leu Leu Val Trp Val Leu Cys
 20 25 30
 20 Phe Val Leu Leu Phe Val Cys Phe Cys Gly Leu Ser Tyr Val Val Ile
 35 40 45
 Ala Gln Val Pro Val Gly Leu Leu Cys Ile Thr Glu Xaa
 50 55 60

25

(2) INFORMATION FOR SEQ ID NO: 392:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 79 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 392:

35

40 Met Leu Trp Phe Ala Asn Phe Phe Thr Tyr Leu Phe Leu Ser Gln Ser
 1 5 10 15
 Val Ala Phe Val His Ile Ser His Ile Gly Val Arg Gln Val Asn Thr
 20 25 30
 Asn Cys Tyr Phe Ser Arg Lys Ser Tyr Cys Tyr Gly Ile Leu Asn Pro
 35 40 45
 45 Ile Asn Cys Ile Lys Gly Lys Lys Lys Lys Lys Lys Lys Lys Lys
 50 55 60
 Lys Lys Lys Lys Ile Pro Ala Gly Arg Xaa Leu Phe Pro Phe Gly
 65 70 75

50

(2) INFORMATION FOR SEQ ID NO: 393:

55

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 393:

60

Met Pro Gly Ala Phe Ser Glu Thr Val Ile Asn Asp Leu Leu Ser Leu
 1 5 10 15

5 Phe Leu Val Leu Pro Ala Glu Leu Ser Tyr Ser Thr Leu Ser Gly Val
 20 25 30

Tyr Arg Asn Ala
 35

10

(2) INFORMATION FOR SEQ ID NO: 394:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 180 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 394:

20 Met Ala Gln Ser Arg Asp Gly Gly Asn Pro Phe Ala Glu Pro Ser Glu
 1 5 10 15

Leu Asp Asn Pro Phe Gln Asp Pro Ala Val Ile Gln His Arg Pro Ser
 20 25 30

25 Arg Gln Tyr Ala Thr Leu Asp Val Tyr Asn Pro Phe Glu Thr Arg Glu
 35 40 45

30 Pro Pro Pro Ala Tyr Glu Pro Pro Ala Pro Ala Pro Leu Pro Pro Pro
 50 55 60

Ser Ala Pro Ser Leu Gln Pro Ser Arg Lys Leu Ser Pro Thr Glu Pro
 65 70 75 80

35 Lys Asn Tyr Gly Ser Tyr Ser Thr Gln Ala Ser Ala Ala Ala Thr
 85 90 95

Ala Glu Leu Leu Lys Lys Gln Glu Glu Leu Asn Arg Lys Ala Glu Glu
 100 105 110

40 Leu Asp Arg Arg Ser Glu Ser Cys Ser Met Leu Pro Trp Xaa Ala Gln
 115 120 125

Leu Leu Asp Arg Thr Ile Gly Pro Leu Tyr Leu Leu Phe Val Gln Phe
 130 135 140

Ser Pro Ala Phe Ser Arg Thr Ser Pro Trp Arg Ser Pro Lys Asn Phe
 145 150 155 160

50 Arg Arg Leu Tyr Pro Pro Cys Thr Thr Ser Gly Cys Ala Ala Arg Trp
 165 170 175

Xaa Phe Ser Xaa
 180

55

(2) INFORMATION FOR SEQ ID NO: 395:

60 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 395:

5

Met Pro Thr Pro Cys Thr Ser Leu Pro Ser Cys Cys Gln His Arg Ser
 1 5 10 15

10

Ile Thr Met Thr Leu
 20

15

(2) INFORMATION FOR SEQ ID NO: 396:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 60 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 396:

Met Pro Leu Phe Ile Pro Leu Ile Phe Phe Leu Ser Leu Leu His Cys
 1 5 10 15

25

Gln Ser Lys His Pro Ile Gln Met Ser Leu Cys Met Cys Val Asn Ile
 20 25 30

30

Ser Leu Val Trp Ser Pro Val Arg Trp Ile Phe Gly Ser Lys Gly Leu
 35 40 45

Phe Ser Val His Leu Gln Ser Ser Gln Arg Pro Ser
 50 55 60

35

(2) INFORMATION FOR SEQ ID NO: 397:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 152 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 397:

Met Ala Gly Pro Arg Pro Xaa Trp Arg Asp Gln Leu Leu Phe Met Ser
 1 5 10 15

Ile Ile Val Leu Val Ile Val Val Ile Cys Leu Met Leu Tyr Ala Leu
 20 25 30

50

Leu Trp Glu Ala Gly Asn Leu Thr Asp Leu Pro Asn Leu Arg Ile Gly
 35 40 45

Phe Tyr Asn Phe Cys Leu Trp Asn Glu Asp Thr Ser Thr Leu Gln Cys
 50 55 60

55

His Gln Phe Pro Glu Leu Glu Ala Leu Gly Val Pro Arg Val Gly Leu
 65 70 75 80

60

Gly Leu Ala Arg Leu Gly Val Tyr Gly Ser Leu Val Leu Thr Leu Phe
 85 90 95

Ala Pro Gln Pro Leu Leu Leu Ala Gln Cys Asn Xaa Asp Glu Arg Ala
 100 105 110

5 Trp Arg Leu Ala Val Gly Phe Leu Ala Val Ser Ser Val Leu Leu Ala
 115 120 125

Gly Gly Leu Gly Leu Phe Leu Ser Tyr Val Trp Asn Gly Ser Xaa Ser
 130 135 140

10 Pro Ser Arg Gly Leu Gly Phe Xaa
 145 150

15

(2) INFORMATION FOR SEQ ID NO: 398:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 480 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 398:

25 Met Ser Asp Gly Phe Asp Arg Ala Pro Gly Ala Gly Arg Gly Arg Xaa
 1 5 10 15

Arg Gly Leu Gly Arg Gly Gly Gly Gly Pro Xaa Gly Gly Gly Phe Pro
 20 25 30

30 Xaa Gly Xaa Xaa Pro Ala Glu Arg Xaa Arg His Gln Pro Pro Gln Pro
 35 40 45

Lys Ala Pro Gly Phe Leu Gln Pro Xaa Pro Leu Arg Gln Pro Arg Thr
 50 55 60

35 Thr Pro Pro Pro Gly Ala Gln Cys Glu Val Pro Ala Ser Pro Gln Arg
 65 70 75 80

40 Pro Ser Arg Pro Gly Ala Leu Pro Glu Gln Thr Arg Pro Leu Arg Ala
 85 90 95

Pro Pro Ser Ser Gln Asp Lys Ile Pro Gln Gln Asn Ser Glu Ser Ala
 100 105 110

45 Met Ala Lys Pro Gln Val Val Val Ala Pro Val Leu Met Ser Lys Leu
 115 120 125

Ser Val Asn Ala Pro Glu Phe Tyr Pro Ser Gly Tyr Ser Ser Ser Tyr
 130 135 140

50 Thr Glu Ser Tyr Glu Asp Gly Cys Glu Asp Tyr Pro Thr Leu Ser Glu
 145 150 155 160

Tyr Val Gln Asp Phe Leu Asn His Leu Thr Glu Gln Pro Gly Ser Phe
 165 170 175

Glu Thr Glu Ile Glu Gln Phe Ala Glu Thr Leu Asn Gly Cys Val Thr
 180 185 190

60 Thr Asp Asp Ala Leu Gln Glu Leu Val Glu Leu Ile Tyr Gln Gln Ala

592

	195	200	205
	Thr Ser Ile Pro Asn Phe Ser Tyr Met Gly Ala Arg Leu Cys Asn Tyr		
	210	215	220
5	Leu Ser His His Leu Thr Ile Ser Pro Gln Ser Gly Asn Phe Arg Gln		
	225	230	235 240
	Leu Leu Leu Gln Arg Cys Arg Thr Glu Tyr Glu Val Lys Asp Gln Ala		
10		245	250 255
	Ala Lys Gly Asp Glu Val Thr Arg Lys Arg Phe His Ala Phe Val Leu		
	260	265	270
15	Phe Leu Gly Glu Leu Tyr Leu Asn Leu Glu Ile Lys Gly Thr Asn Gly		
	275	280	285
	Gln Val Thr Arg Ala Asp Ile Leu Gln Val Gly Leu Arg Glu Leu Leu		
20		295	300
	Asn Ala Leu Phe Ser Asn Pro Met Asp Asp Asn Leu Ile Cys Ala Val		
	305	310	315 320
	Lys Leu Leu Lys Leu Thr Gly Ser Val Leu Glu Asp Ala Trp Lys Glu		
25		325	330 335
	Lys Gly Lys Met Asp Met Glu Glu Ile Ile Gln Arg Ile Glu Asn Val		
	340	345	350
30	Val Leu Asp Ala Asn Cys Ser Arg Asp Val Lys Gln Met Leu Leu Lys		
	355	360	365
	Leu Val Glu Leu Arg Ser Ser Asn Trp Gly Arg Val His Ala Thr Ser		
35		375	380
	Thr Tyr Arg Glu Ala Thr Pro Glu Asn Asp Pro Asn Tyr Phe Met Asn		
	385	390	395 400
	Glu Pro Thr Phe Tyr Thr Ser Asp Gly Val Pro Phe Thr Ala Ala Asp		
40		405	410 415
	Pro Asp Tyr Gln Glu Lys Tyr Gln Glu Leu Leu Glu Arg Glu Asp Phe		
	420	425	430
45	Phe Pro Asp Tyr Glu Glu Asn Gly Thr Asp Leu Ser Gly Ala Gly Asp		
	435	440	445
	Pro Tyr Leu Asp Asp Ile Asp Asp Glu Met Asp Pro Glu Ile Glu Glu		
50		455	460
	Ala Tyr Glu Lys Phe Cys Leu Glu Ser Glu Arg Lys Arg Lys Gln Xaa		
	465	470	475 480

55

(2) INFORMATION FOR SEQ ID NO: 399:

60

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 423 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 399:

Met Glu Pro Lys Thr Ile Thr Asp Ala Leu Ala Ser Ser Ile Ile Lys
 1 5 10 15
 10 Ser Val Leu Pro Asn Phe Leu Pro Tyr Asn Val Met Leu Tyr Ser Asp
 20 25 30
 Ala Pro Val Ser Glu Leu Ser Leu Glu Leu Leu Leu Gln Val Val
 35 40 45
 15 Leu Pro Ala Leu Leu Glu Gln Gly His Thr Arg Gln Trp Leu Lys Gly
 50 55 60
 20 Leu Val Arg Ala Trp Thr Val Thr Ala Gly Tyr Leu Leu Asp Leu His
 65 70 75 80
 Ser Tyr Leu Leu Gly Asp Gln Glu Glu Asn Glu Asn Ser Ala Asn Gln
 85 90 95
 25 Gln Val Asn Asn Asn Gln His Ala Arg Asn Asn Asn Ala Ile Pro Val
 100 105 110
 Val Gly Glu Gly Leu His Ala Ala His Gln Ala Ile Leu Gln Gln Gly
 115 120 125
 30 Gly Pro Val Gly Phe Gln Xaa Tyr Arg Arg Pro Leu Asn Phe Pro Leu
 130 135 140
 35 Arg Ile Phe Leu Leu Ile Val Phe Met Cys Ile Thr Leu Leu Ile Ala
 145 150 155 160
 Ser Leu Ile Cys Leu Thr Leu Pro Val Phe Ala Gly Arg Trp Leu Met
 165 170 175
 40 Ser Phe Trp Thr Gly Thr Ala Lys Ile His Glu Leu Tyr Thr Ala Ala
 180 185 190
 Cys Gly Leu Tyr Val Cys Trp Leu Thr Ile Arg Ala Val Thr Val Met
 195 200 205
 45 Val Ala Trp Met Pro Gln Gly Arg Arg Val Ile Phe Gln Lys Val Lys
 210 215 220
 50 Glu Trp Ser Leu Met Ile Met Lys Thr Leu Ile Val Ala Val Leu Leu
 225 230 235 240
 Ala Gly Val Val Pro Leu Leu Leu Gly Leu Leu Phe Glu Leu Val Ile
 245 250 255
 55 Val Ala Pro Leu Arg Val Pro Leu Asp Gln Thr Pro Leu Phe Tyr Pro
 260 265 270
 Trp Gln Asp Trp Ala Leu Gly Val Leu His Ala Lys Ile Ile Ala Ala
 275 280 285
 60

594

Ile Thr Leu Met Gly Pro Gln Trp Trp Leu Lys Thr Val Ile Glu Gln
 290 295 300

5 Val Tyr Ala Asn Gly Ile Arg Asn Ile Asp Leu His Tyr Ile Val Arg
 305 310 315 320

Lys Leu Ala Ala Pro Val Ile Ser Val Leu Leu Leu Ser Leu Cys Val
 325 330 335

10 Pro Tyr Val Ile Ala Ser Gly Val Val Pro Leu Leu Gly Val Thr Ala
 340 345 350

Glu Met Gln Asn Leu Val His Arg Arg Ile Tyr Pro Phe Leu Leu Met
 355 360 365

15 Val Val Val Leu Met Ala Ile Leu Ser Phe Gln Val Arg Gln Phe Lys
 370 375 380

20 Arg Leu Tyr Glu His Ile Lys Asn Asp Lys Tyr Leu Val Gly Gln Arg
 385 390 395 400

Leu Val Asn Tyr Glu Arg Lys Ser Gly Lys Gln Gly Ser Ser Pro Pro
 405 410 415

25 Pro Pro Gln Ser Ser Gln Glu
 420

30 (2) INFORMATION FOR SEQ ID NO: 400:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 78 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 400:

Met Leu Arg Leu Asp Ile Ile Asn Ser Leu Val Thr Thr Val Phe Met
 1 5 10 15

40 Leu Ile Val Ser Val Leu Ala Leu Ile Pro Glu Thr Thr Thr Leu Thr
 20 25 30

45 Val Gly Gly Gly Val Phe Ala Leu Val Thr Ala Val Cys Cys Leu Ala
 35 40 45

Asp Gly Ala Leu Ile Tyr Arg Lys Leu Leu Phe Asn Pro Ser Gly Pro
 50 55 60

50 Tyr Gln Lys Lys Pro Val His Glu Lys Lys Glu Val Leu Xaa
 65 70 75

55 (2) INFORMATION FOR SEQ ID NO: 401:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 74 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 401:

5 Met Leu Lys Gln Val Met Phe Val Phe Ser Gly Met Gly Pro Arg Ser
 1 5 10 15
 His Cys Trp Gly Leu Pro Leu His Val Ala Pro Leu Cys Arg Gly His
 20 25 30
 10 Gln Ala Asp Ser Ser His Leu Leu Pro Leu Lys His Gln Gly Ala Trp
 35 40 45
 Asn Arg Asn Leu Ala Asn Gln Arg His Phe Phe Cys Pro Ser Ile Phe
 50 55 60
 15 His Thr Cys Pro Thr Val Leu Phe Phe Xaa
 65 70

20 (2) INFORMATION FOR SEQ ID NO: 402:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 402:

30 Ala Arg Thr Ile Leu Val Leu Tyr Leu Ser Leu Gln Arg Leu Glu Asn
 1 5 10 15
 Leu Ala Tyr His
 20

35 (2) INFORMATION FOR SEQ ID NO: 403:

(i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 87 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 403:

45 Met Pro Leu Pro Ser Val Pro Ile Leu Gly Ile Phe Ser Phe Leu Ile
 1 5 10 15
 Pro Ser Ser Gln Gly Val Ser Tyr Thr Lys Leu Pro Ile Ser Ser Pro
 20 25 30
 50 Gln Tyr Ser Pro Phe Val Asn Asp His Phe Ser Phe Leu Asn Pro Phe
 35 40 45
 Pro Val Gln Ile His Thr Gly Phe Ala Arg Val Gly Ser Tyr Met Gln
 50 55 60
 55 Met Pro Leu Val His Leu Cys Leu Leu Gln Thr Ser Leu Met Lys Asn
 65 70 75 80
 60 Ser Gly Val Gln Gln Gly Ser
 85

(2) INFORMATION FOR SEQ ID NO: 404:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 92 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 404:

Met Asn Ala Ala Met Val His Ile Asn Arg Ala Leu Lys Leu Ile Ile
 1 5 10 15

15

Arg Leu Phe Leu Val Glu Asp Leu Val Asp Ser Leu Lys Leu Ala Val
 20 25 30

20

Phe Met Trp Leu Met Thr Tyr Val Gly Ala Val Phe Asn Gly Ile Thr
 35 40 45

Leu Leu Ile Leu Ala Glu Leu Leu Ile Phe Ser Val Pro Ile Val Tyr
 50 55 60

25

Glu Lys Tyr Lys Thr Gln Ile Asp His Tyr Val Gly Ile Ala Arg Asp
 65 70 75 80

Gln Thr Lys Ser Ile Val Glu Lys Ile Pro Ser Lys
 85 90

30

(2) INFORMATION FOR SEQ ID NO: 405:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 405:

40

Met Ala Cys Ser Cys Leu Met Ile Gln Ser Phe Ser Thr Ser Ala Leu
 1 5 10 15

Val Leu Phe Tyr Gly
 20

45

(2) INFORMATION FOR SEQ ID NO: 406:

50

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 174 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 406:

55

Met Glu Glu Gly Gly Asn Leu Gly Gly Leu Ile Lys Met Val His Leu
 1 5 10 15

60

Leu Val Leu Ser Gly Ala Trp Gly Met Gln Met Trp Val Thr Phe Val
 20 25 30

Ser Gly Phe Pro Ala Phe Pro Lys Pro Ser Pro Thr Tyr Leu Arg Thr
 35 40 45
 5 Ser Ala Glu Gln Thr Leu Pro Leu Leu Leu Pro His Leu His Gly Leu
 50 55 60
 Cys Leu His Gln Pro Leu His Leu Gly Phe Thr Ala Cys Leu Gly Ser
 65 70 75 80
 10 Ala His Ile Leu Gly Gly Gln Pro Ala Leu Pro Ala Val Pro Glu Pro
 85 90 95
 Tyr Ala Gly His Cys Gln Arg Pro Leu Ala Gly Thr Pro His His Ser
 100 105 110
 15 Cys His Val Gly Pro Ala Asn Arg Gly Arg Arg Ser Glu Ala Trp Val
 115 120 125
 20 Gly Arg Tyr Gln Ala Ala Asn Arg Phe Pro Ile Leu Asn Ala Xaa Cys
 130 135 140
 Glu Arg Arg Thr Pro Ser Thr Val Leu Ser Ala Arg Ile Ser Ser Ala
 145 150 155 160
 25 Thr Met Gly Cys Pro Leu Phe Ala Ile Trp Ala Ala Ser Xaa
 165 170

30

(2) INFORMATION FOR SEQ ID NO: 407:

(i) SEQUENCE CHARACTERISTICS:

35

- (A) LENGTH: 64 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 407:

40

Met Ala Phe Ile Leu Leu Phe Tyr Cys Leu Met Thr Phe Leu Ser Leu
 1 5 10 15
 Glu Gln Asn Ser Ala Thr Val Glu Pro Ser Ser His Glu Ile Leu His
 20 25 30
 45 Leu Leu Gln Asn Cys Phe Glu Leu Leu Arg Thr Ser Thr Ser Gln Cys
 35 40 45
 Thr Glu Gly Ile Pro Cys Gln Arg Tyr Gln Asn Gly Leu His Ile Xaa
 50 55 60

50

55

(2) INFORMATION FOR SEQ ID NO: 408:

(i) SEQUENCE CHARACTERISTICS:

60

- (A) LENGTH: 280 amino acids
 (B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 408:

5 Met Glu Ala Val Val Asn Leu Tyr Gln Glu Val Met Lys His Ala Asp
 1 5 10 15
 Pro Arg Ile Gln Gly Tyr Pro Leu Met Gly Ser Pro Leu Leu Met Thr
 20 25 30
 10 Ser Ile Leu Leu Thr Tyr Val Tyr Phe Val Leu Ser Leu Gly Pro Arg
 35 40 45
 Ile Met Ala Asn Arg Lys Pro Phe Gln Leu Arg Gly Phe Met Ile Val
 50 55 60
 15 Tyr Asn Phe Ser Leu Val Ala Leu Ser Leu Tyr Ile Val Tyr Glu Phe
 65 70 75 80
 Leu Met Ser Gly Trp Leu Ser Thr Tyr Thr Trp Arg Cys Asp Pro Val
 85 90 95
 Asp Tyr Ser Asn Ser Pro Glu Ala Leu Arg Met Val Arg Val Ala Trp
 100 105 110
 25 Leu Phe Leu Phe Ser Lys Phe Ile Glu Leu Met Asp Thr Val Ile Phe
 115 120 125
 Ile Leu Arg Lys Lys Asp Gly Gln Val Thr Phe Leu His Val Phe His
 130 135 140
 30 His Ser Val Leu Pro Trp Ser Trp Trp Trp Gly Val Lys Ile Ala Pro
 145 150 155 160
 Gly Gly Met Gly Ser Phe His Ala Met Ile Asn Ser Ser Val His Val
 165 170 175
 Ile Met Tyr Leu Tyr Tyr Gly Leu Ser Ala Phe Gly Pro Val Ala Gln
 180 185 190
 40 Pro Tyr Leu Trp Trp Lys Lys His Met Thr Ala Ile Gln Leu Ile Gln
 195 200 205
 Phe Val Leu Val Ser Leu His Ile Ser Gln Tyr Tyr Phe Met Ser Ser
 210 215 220
 45 Cys Asn Tyr Gln Tyr Pro Val Ile Ile His Leu Ile Trp Met Tyr Gly
 225 230 235 240
 Thr Ile Phe Phe Met Leu Phe Ser Asn Phe Trp Tyr His Ser Tyr Thr
 245 250 255
 Lys Gly Lys Arg Leu Pro Arg Ala Leu Gln Gln Asn Gly Ala Pro Gly
 260 265 270
 55 Ile Ala Lys Val Lys Ala Asn Xaa
 275 280

60 (2) INFORMATION FOR SEQ ID NO: 409:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 284 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 409:

5 Met Xaa Leu Trp Pro Gln Thr Cys Ser Gly Lys Phe Asp Gly Thr Leu
 1 5 10 15
 10 Ala Phe Ser Ile His Xaa Leu Ala Val Ile Leu Gly Asp Gln Leu Thr
 20 25 30
 15 Ala Ala Asp Leu Val Pro Ile Phe Asn Gly Phe Leu Lys Asp Leu Asp
 35 40 45
 Glu Val Arg Ile Gly Val Leu Lys His Leu His Asp Phe Leu Lys Leu
 50 55 60
 20 Leu His Ile Asp Lys Arg Arg Glu Tyr Leu Tyr Gln Leu Gln Glu Phe
 65 70 75 80
 Leu Val Thr Asp Asn Ser Arg Asn Trp Arg Phe Arg Ala Glu Leu Ala
 85 90 95
 25 Glu Gln Leu Ile Leu Leu Leu Glu Leu Tyr Ser Pro Arg Asp Val Tyr
 100 105 110
 30 Asp Tyr Leu Arg Pro Ile Ala Leu Asn Leu Cys Ala Asp Lys Val Ser
 115 120 125
 Ser Val Arg Trp Ile Ser Tyr Lys Leu Val Ser Glu Met Val Lys Lys
 130 135 140
 35 Leu His Ala Ala Thr Pro Pro Thr Phe Gly Val Asp Leu Ile Asn Glu
 145 150 155 160
 Leu Val Glu Asn Phe Gly Arg Cys Pro Lys Trp Ser Gly Arg Gln Ala
 165 170 175
 40 Phe Val Phe Val Cys Gln Thr Val Ile Glu Asp Asp Cys Leu Pro Met
 180 185 190
 45 Asp Gln Phe Ala Val His Leu Met Pro His Leu Leu Thr Leu Ala Asn
 195 200 205
 Asp Arg Val Pro Asn Val Arg Val Leu Leu Ala Lys Thr Leu Arg Gln
 210 215 220
 50 Thr Leu Leu Glu Lys Asp Tyr Phe Leu Ala Ser Ala Ser Cys His Gln
 225 230 235 240
 Glu Ala Val Glu Gln Thr Ile Met Ala Leu Gln Met Asp Arg Asp Ser
 245 250 255
 55 Asp Val Lys Tyr Phe Ala Ser Ile His Pro Ala Ser Thr Lys Ile Ser
 260 265 270
 60 Glu Asp Ala Met Ser Thr Ala Ser Ser Thr Tyr Xaa
 275 280

5 (2) INFORMATION FOR SEQ ID NO: 410:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 187 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 410:

Met Leu Phe Leu Phe Phe Val Ile Ile Phe Leu Phe Val Phe Leu Ile
1 5 10 15

15 Leu Ile Ile Gln Phe Ser Lys Pro Leu Thr Asn Pro His Pro Pro Ala
20 25 30

Gly Xaa Ser Asp Arg Arg Arg Arg Tyr Ser Ser Tyr Arg Ser His Asp
35 40 45

20 His Tyr Gln Arg Gln Arg Val Leu Gln Lys Glu Arg Ala Ile Glu Glu
50 55 60

25 Arg Arg Val Val Phe Ile Gly Lys Ile Pro Gly Arg Met Thr Arg Ser
65 70 75 80

Glu Leu Lys Gln Arg Phe Ser Val Phe Gly Glu Ile Glu Glu Cys Thr
85 90 95

30 Ile His Phe Arg Val Gln Gly Asp Asn Tyr Gly Phe Val Thr Tyr Arg
100 105 110

Tyr Ala Glu Glu Ala Phe Ala Ala Ile Glu Ser Gly His Lys Leu Arg
115 120 125

35 Gln Ala Asp Glu Gln Pro Phe Asp Leu Cys Phe Gly Gly Arg Arg Xaa
130 135 140

40 Xaa Cys Lys Arg Ser Tyr Ser Asp Leu Asp Ser Asn Arg Glu Asp Phe
145 150 155 160

Asp Pro Ala Pro Val Lys Ser Lys Phe Asp Ser Leu Asp Phe Asp Thr
165 170 175

45 Leu Leu Lys Gln Ala Gln Lys Asn Leu Arg Arg
180 185

50 (2) INFORMATION FOR SEQ ID NO: 411:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 237 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 411:

Met Lys Leu Pro Gly Lys Phe Arg Arg Ala His Gln Gly Asn Leu Glu
1 5 10 15

601

Ser Gln Leu Thr Ser Glu Ser Tyr Tyr Lys Glu Thr Leu Ser Val Pro
 20 25 30
 5 Thr Val Glu His Ile Ile Gln Glu Leu Lys Asp Ile Phe Ser Glu Gln
 35 40 45
 His Leu Lys Ala Leu Lys Cys Leu Ser Leu Val Pro Ser Val Met Gly
 50 55 60
 10 Gln Leu Lys Phe Asn Thr Ser Glu Glu His His Ala Asp Met Tyr Arg
 65 70 75 80
 Ser Asp Leu Pro Asn Pro Asp Thr Leu Ser Ala Glu Leu His Cys Trp
 85 90 95
 15 Arg Ile Lys Trp Lys His Arg Gly Lys Asp Ile Glu Leu Pro Ser Thr
 100 105 110
 Ile Tyr Glu Ala Leu His Leu Pro Asp Ile Lys Phe Phe Pro Asn Val
 115 120 125
 Tyr Ala Leu Leu Lys Val Leu Cys Ile Leu Pro Val Met Lys Val Glu
 130 135 140
 25 Asn Glu Arg Tyr Glu Asn Gly Arg Lys Arg Leu Lys Ala Tyr Leu Arg
 145 150 155 160
 Asn Thr Leu Thr Asp Gln Arg Ser Ser Asn Leu Ala Leu Leu Asn Ile
 165 170 175
 30 Asn Phe Asp Ile Lys His Asp Leu Asp Leu Met Val Asp Thr Tyr Ile
 180 185 190
 Lys Leu Tyr Thr Xaa Xaa Ser Xaa Leu Xaa Thr Xaa Xaa Ser Xaa Xaa
 195 200 205
 Val Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa
 210 215 220
 40 Asp Xaa Xaa Xaa Arg Glu Lys Ala Val Arg Cys Met Xaa
 225 230 235

45 (2) INFORMATION FOR SEQ ID NO: 412:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 192 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 412:

Met Lys Pro Met Ala Val Val Ala Ser Thr Val Leu Gly Leu Val Gln
 1 5 10 15
 55 Asn Met Arg Ala Phe Gly Gly Ile Leu Val Val Val Tyr Tyr Val Phe
 20 25 30
 60 Ala Ile Ile Gly Ile Asn Leu Phe Arg Gly Val Ile Val Ala Leu Pro
 35 40 45

Gly Asn Ser Ser Leu Ala Pro Ala Asn Gly Ser Ala Pro Cys Gly Ser
 50 55 60
 5 Phe Glu Gln Leu Glu Tyr Trp Ala Asn Asn Phe Asp Asp Phe Ala Ala
 65 70 75 80
 Ala Leu Val Thr Leu Trp Asn Leu Met Val Val Asn Asn Trp Gln Val
 85 90 95
 10 Phe Leu Asp Ala Tyr Arg Arg Tyr Ser Gly Pro Trp Ser Lys Ile Tyr
 100 105 110
 15 Phe Val Leu Trp Trp Leu Val Ser Ser Val Ile Trp Val Asn Leu Phe
 115 120 125
 Leu Ala Leu Ile Leu Glu Asn Phe Leu His Lys Trp Asp Pro Arg Ser
 130 135 140
 20 His Leu Gln Pro Leu Ala Gly Thr Pro Glu Ala Thr Tyr Gln Met Thr
 145 150 155 160
 Val Glu Leu Leu Phe Arg Asp Ile Leu Glu Glu Pro Gly Glu Asp Glu
 165 170 175
 25 Leu Thr Glu Arg Leu Ser Gln His Pro His Leu Trp Leu Cys Arg Xaa
 180 185 190

30

35 (2) INFORMATION FOR SEQ ID NO: 413:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 413:

Asn Val Val Val Val Ala Phe Gly Leu Ile Leu Ile Ile Glu Ser Leu
 1 5 10 15

45 Gly Glu Gln Cys Pro
 20

50 (2) INFORMATION FOR SEQ ID NO: 414:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 51 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 414:

Met Asn Trp Gly Leu Ser Ile Trp Leu His Tyr Tyr Glu Lys Lys Lys
 1 5 10 15

60

Glu Gln Val Phe Leu Val Ile Leu Ala His Val Val Arg Arg Cys Ala
 20 25 30
 5 Ser Asp Gly Ile Leu Gln Phe Glu Ser Ser Leu Leu Lys Met Arg Arg
 35 40 45
 Ala Pro Xaa
 50
 10
 (2) INFORMATION FOR SEQ ID NO: 415:
 (i) SEQUENCE CHARACTERISTICS:
 15 (A) LENGTH: 32 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 415:
 20 Met Leu Ile Ile Ser Leu Arg Pro Gln Phe Pro Ser Leu Ile Val Gln
 1 5 10 15
 Leu Glu Cys Ser Val Leu Phe Leu Pro Ile Ser Leu Asn Leu Leu Leu
 20 25 30
 25
 30
 (2) INFORMATION FOR SEQ ID NO: 416:
 (i) SEQUENCE CHARACTERISTICS:
 35 (A) LENGTH: 163 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 416:
 40 Met Val Lys Val Cys Asn Asp Ser Asp Arg Trp Ser Leu Ile Ser Leu
 1 5 10 15
 Ser Asn Asn Ser Gly Lys Asn Val Glu Leu Lys Phe Val Asp Ser Leu
 20 25 30
 45 Arg Arg Gln Phe Glu Phe Ser Val Asp Ser Phe Gln Ile Lys Leu Asp
 35 40 45
 Ser Leu Leu Leu Phe Tyr Glu Cys Ser Glu Asn Pro Met Thr Glu Thr
 50 55 60
 50 Phe His Pro Thr Ile Ile Gly Glu Ser Val Tyr Gly Asp Phe Gln Glu
 65 70 75 80
 Ala Phe Asp His Leu Cys Asn Lys Ile Ile Ala Thr Arg Asn Pro Glu
 85 90 95
 55 Glu Ile Arg Gly Gly Gly Leu Leu Lys Tyr Cys Asn Leu Leu Val Arg
 100 105 110
 60 Gly Phe Arg Pro Ala Ser Asp Glu Ile Lys Thr Leu Gln Arg Tyr Met

115 120 125

Cys Ser Arg Phe Phe Ile Asp Phe Ser Asp Ile Gly Glu Gln Gln Arg
130 135 140

5 Lys Leu Glu Ser Tyr Leu Gln Asn His Phe Val Gly Ile Gly Arg Pro
145 150 155 160

10 Gln Val Xaa

15 (2) INFORMATION FOR SEQ ID NO: 417:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 174 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 417:

Met Ala Pro Lys Gly Lys Val Gly Thr Arg Gly Lys Lys Gln Ile Phe
1 5 10 15

25 Glu Glu Asn Arg Glu Thr Leu Lys Phe Tyr Leu Arg Ile Ile Leu Gly
20 25 30

Ala Asn Ala Ile Tyr Cys Leu Val Thr Leu Val Phe Phe Tyr Ser Ser
35 40 45

30 Ala Ser Phe Trp Ala Trp Leu Ala Leu Gly Phe Ser Leu Ala Val Tyr
50 55 60

35 Gly Ala Ser Tyr His Ser Met Ser Ser Met Ala Arg Ala Ala Phe Ser
65 70 75 80

Glu Asp Gly Ala Leu Met Asp Gly Gly Met Asp Leu Asn Met Glu Gln
85 90 95

40 Gly Met Ala Glu His Leu Lys Asp Val Ile Leu Leu Thr Ala Ile Val
100 105 110

Gln Val Leu Ser Cys Phe Ser Leu Tyr Val Trp Ser Phe Trp Leu Leu
115 120 125

45 Ala Pro Gly Arg Ala Leu Tyr Leu Leu Trp Val Asn Val Leu Gly Pro
130 135 140

50 Trp Phe Thr Ala Asp Ser Gly Thr Pro Ala Pro Glu His Asn Glu Lys
145 150 155 160

Arg Gln Arg Arg Gln Glu Arg Arg Gln Met Lys Arg Leu Xaa
165 170

55

(2) INFORMATION FOR SEQ ID NO: 418:

(i) SEQUENCE CHARACTERISTICS:

60 (A) LENGTH: 50 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 418:

5 Met Glu Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Val Ala Met Met
 1 5 10 15
 Arg Pro Phe Tyr Leu Leu Leu Pro Val Leu Cys Thr Gln Ala Leu Arg
 20 25 30
 10 Gln Ser Gln Gly Lys Ser Pro Leu Leu Trp Lys Arg Thr Cys Cys Leu
 35 40 45
 15 Ala Xaa
 50

(2) INFORMATION FOR SEQ ID NO: 419:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 120 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 419:

20 Met Leu Gly Lys Gly Gly Gly Arg Ala Gly Leu Leu Arg Tyr Arg Leu
 1 5 10 15
 30 Leu Tyr Phe Thr Leu Val Val Gly Glu Gly Glu Pro Gly Glu Asn Lys
 20 25 30
 Val Thr Ile Pro Phe Phe Glu Thr Gly Lys Lys Ile Ile Phe Cys Ser
 35 40 45
 35 Val Lys Met Val Glu Asn Ser Asn Val Pro Ser His Lys Gly Pro Val
 50 55 60
 40 Pro Leu Arg Ser Glu Gln Trp Glu Leu Lys Ile Ser Glu Thr Leu Gly
 65 70 75 80
 Glu Gly Lys Ile Gly Phe Leu Leu Ile Gly Arg Cys Ser Ser Gly Xaa
 85 90 95
 45 Gly Gly Leu Cys Phe Cys Trp Asp Val Leu Cys Cys Met Tyr Ala Tyr
 100 105 110
 50 Met Asp Arg Ser Leu Leu Ser Leu
 115 120

(2) INFORMATION FOR SEQ ID NO: 420:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 159 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 420:

60

606

Met Thr His Leu Leu Leu Thr Ala Thr Val Thr Pro Ser Glu Gln Asn
 1 5 10 15
 5 Ser Ser Arg Glu Pro Gly Trp Glu Thr Ala Met Ala Lys Asp Ile Leu
 20 25 30
 Gly Glu Ala Gly Leu His Phe Asp Glu Leu Asn Lys Leu Arg Val Leu
 35 40 45
 10 Asp Pro Glu Val Thr Gln Gln Thr Ile Glu Leu Lys Glu Glu Cys Lys
 50 55 60
 Asp Phe Val Asp Lys Ile Gly Gln Phe Gln Lys Ile Val Gly Gly Leu
 65 70 75 80
 15 Ile Glu Leu Val Asp Gln Leu Ala Lys Glu Ala Glu Asn Glu Lys Met
 85 90 95
 20 Lys Ala Ile Gly Ala Arg Asn Leu Leu Lys Ser Ile Ala Lys Gln Arg
 100 105 110
 Glu Ala Gln Gln Gln Gln Leu Gln Ala Leu Ile Ala Glu Lys Lys Met
 115 120 125
 25 Gln Leu Glu Arg Tyr Arg Val Glu Tyr Glu Ala Leu Cys Lys Val Glu
 130 135 140
 Ala Glu Gln Asn Glu Phe Ile Asp Gln Phe Ile Phe Gln Lys Xaa
 145 150 155
 30
 (2) INFORMATION FOR SEQ ID NO: 421:
 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 154 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 421:
 40 Met Asn Val Gly Val Ala His Ser Glu Val Asn Pro Asn Thr Arg Val
 1 5 10 15
 45 Met Asn Ser Arg Gly Met Trp Leu Thr Tyr Ala Leu Gly Val Gly Leu
 20 25 30
 Leu His Ile Val Leu Leu Ser Ile Pro Phe Phe Ser Val Pro Val Ala
 35 40 45
 50 Trp Thr Leu Thr Asn Ile Ile His Asn Leu Gly Met Tyr Val Phe Leu
 50 55 60
 His Ala Val Lys Gly Thr Pro Phe Glu Thr Pro Asp Gln Gly Lys Ala
 65 70 75 80
 55 Arg Leu Leu Thr His Trp Glu Gln Leu Asp Tyr Gly Val Gln Phe Thr
 85 90 95
 60 Ser Ser Arg Lys Phe Phe Thr Ile Ser Pro Ile Ile Leu Tyr Phe Leu
 100 105 110

Ala Ser Phe Tyr Thr Lys Tyr Asp Pro Thr His Phe Ile Leu Asn Thr
 115 120 125

5 Ala Ser Leu Leu Ser Val Leu Ile Pro Lys Met Pro Gln Leu His Gly
 130 135 140

Val Arg Ile Phe Gly Ile Asn Lys Tyr Xaa
 145 150

10

(2) INFORMATION FOR SEQ ID NO: 422:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 204 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 422:

20 Met Val Cys Gly Gly Phe Ala Cys Ser Lys Asn Cys Leu Cys Ala Leu
 1 5 10 15

25 Asn Leu Leu Tyr Thr Leu Val Ser Leu Leu Leu Ile Gly Ile Ala Ala
 20 25 30

Trp Gly Ile Gly Phe Gly Leu Ile Ser Ser Leu Arg Val Val Gly Val
 35 40 45

30 Val Ile Ala Val Gly Ile Phe Leu Phe Leu Ile Ala Leu Val Gly Leu
 50 55 60

Ile Gly Ala Val Lys His His Gln Val Leu Leu Phe Phe Tyr Met Ile
 65 70 75 80

35 Ile Leu Leu Leu Val Phe Ile Val Gln Phe Ser Val Ser Cys Ala Cys
 85 90 95

40 Leu Ala Leu Asn Gln Glu Gln Gln Gly Gln Leu Leu Glu Val Gly Trp
 100 105 110

Asn Asn Thr Ala Ser Ala Arg Asn Asp Ile Gln Arg Asn Leu Asn Cys
 115 120 125

45 Cys Gly Phe Arg Ser Val Asn Pro Asn Asp Thr Cys Leu Ala Ser Cys
 130 135 140

Val Lys Ser Asp His Ser Cys Ser Pro Cys Ala Pro Ile Ile Gly Glu
 145 150 155 160

50 Tyr Ala Gly Glu Val Leu Arg Phe Val Gly Gly Ile Gly Leu Phe Phe
 165 170 175

Ser Phe Thr Glu Ile Leu Gly Val Trp Leu Thr Tyr Arg Tyr Arg Asn
 180 185 190

Gln Lys Asp Pro Arg Ala Asn Pro Ser Ala Phe Leu
 195 200

60

(2) INFORMATION FOR SEQ ID NO: 423:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 67 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 423:

10 Met Leu Gln Ser Ile Ile Lys Asn Ile Trp Ile Pro Met Lys Pro Tyr
 1 5 10 15
 Tyr Thr Lys Val Tyr Gln Glu Ile Trp Ile Gly Met Gly Leu Met Gly
 20 25 30
 15 Phe Ile Val Tyr Lys Ile Arg Ala Ala Asp Lys Arg Ser Lys Ala Leu
 35 40 45
 20 Lys Ala Ser Ala Pro Ala Pro Gly His His Asn Gln Ile Tyr Leu Glu
 50 55 60
 Tyr Met Xaa
 65

25

(2) INFORMATION FOR SEQ ID NO: 424:

- 30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 424:

35 Met Leu Gly Val Ser Leu Phe Leu Leu Val Val Leu Tyr His Tyr Val
 1 5 10 15
 Ala Val Asn Asn Pro Lys Lys Gln Glu
 20 25
 40

(2) INFORMATION FOR SEQ ID NO: 425:

- 45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 299 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 425:

50 Met Ala Ala Xaa Glu Pro Ala Val Leu Ala Leu Pro Asn Ser Gly Ala
 1 5 10 15
 55 Gly Gly Ala Gly Ala Pro Ser Gly Thr Val Pro Val Leu Phe Cys Phe
 20 25 30
 Ser Val Phe Ala Arg Pro Ser Ser Val Pro His Gly Ala Gly Tyr Glu
 35 40 45
 60 Leu Leu Ile Gln Lys Phe Leu Ser Leu Tyr Gly Asp Gln Ile Asp Met

609

50 55 60
 His Arg Lys Phe Val Val Gln Leu Phe Ala Glu Glu Trp Gly Gln Tyr
 65 70 75 80
 5 Val Asp Leu Pro Lys Gly Phe Ala Val Ser Glu Arg Cys Lys Val Arg
 85 90 95
 10 Leu Val Pro Leu Gln Ile Gln Leu Thr Thr Leu Gly Asn Leu Thr Pro
 100 105 110
 Ser Ser Thr Val Phe Phe Cys Cys Asp Met Gln Glu Arg Phe Arg Pro
 115 120 125
 15 Ala Ile Lys Tyr Phe Gly Asp Ile Ile Ser Val Gly Gln Arg Leu Leu
 130 135 140
 Gln Gly Ala Arg Ile Leu Gly Ile Pro Val Ile Val Thr Glu Gln Tyr
 20 145 150 155 160
 Pro Lys Gly Leu Gly Ser Thr Val Gln Glu Ile Asp Leu Thr Gly Val
 165 170 175
 25 Lys Leu Val Leu Pro Lys Thr Lys Phe Ser Met Val Leu Pro Glu Val
 180 185 190
 Glu Ala Ala Leu Ala Glu Ile Pro Gly Val Arg Ser Val Val Leu Phe
 195 200 205
 30 Gly Val Glu Thr His Val Cys Ile Gln Gln Thr Ala Leu Glu Leu Val
 210 215 220
 Gly Arg Gly Val Glu Val His Ile Val Ala Asp Ala Thr Ser Ser Arg
 35 225 230 235 240
 Ser Met Met Asp Arg Met Phe Ala Leu Glu Arg Leu Ala Xaa Xaa Gly
 245 250 255
 40 Ile Ile Val Thr Thr Ser Glu Ala Val Leu Leu Gln Leu Val Ala Asp
 260 265 270
 Lys Asp His Pro Lys Phe Lys Glu Ile Gln Asn Leu Ile Lys Ala Ser
 275 280 285
 45 Ala Pro Glu Ser Gly Leu Leu Ser Lys Val Xaa
 290 295

50 (2) INFORMATION FOR SEQ ID NO: 426:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 426:

Met Arg Asp Leu Gly Thr Leu Leu Ser Pro Val Cys Ser
 1 5 10

60

(2) INFORMATION FOR SEQ ID NO: 427:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 198 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 427:

Met Phe Gly Cys Leu Val Ala Gly Arg Leu Val Gln Thr Ala Ala Gln
 1 5 10 15
 Gln Val Ala Glu Asp Lys Phe Val Phe Asp Leu Pro Asp Tyr Glu Ser
 20 25 30
 Ile Asn His Val Val Val Phe Met Leu Gly Thr Ile Pro Phe Pro Glu
 35 40 45
 Gly Met Gly Gly Ser Val Tyr Phe Ser Tyr Pro Asp Ser Asn Gly Met
 50 55 60
 Pro Val Trp Gln Leu Leu Gly Phe Val Thr Asn Gly Lys Pro Ser Ala
 65 70 75 80
 Ile Phe Lys Ile Ser Gly Leu Lys Ser Gly Glu Gly Ser Gln His Pro
 85 90 95
 Phe Gly Ala Met Asn Ile Val Arg Thr Pro Ser Val Ala Gln Ile Gly
 100 105 110
 Ile Ser Val Glu Leu Leu Asp Ser Met Ala Gln Gln Thr Pro Val Gly
 115 120 125
 Asn Ala Ala Val Ser Ser Val Asp Ser Phe Thr Gln Phe Thr Gln Lys
 130 135 140
 Met Leu Asp Asn Phe Tyr Asn Phe Ala Ser Ser Phe Ala Val Ser Gln
 145 150 155 160
 Ala Gln Met Thr Pro Ser Pro Ser Glu Met Phe Ile Pro Ala Asn Val
 165 170 175
 Val Leu Lys Trp Tyr Glu Asn Phe Gln Arg Arg Leu Ala Gln Asn Pro
 180 185 190
 Xaa Phe Trp Xaa Thr Xaa
 195

50

(2) INFORMATION FOR SEQ ID NO: 428:

55

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 428:

60

Met Gly Leu Pro Leu Met Ala Leu Met Trp Ser Thr Leu Pro Ala Ser

1 5 10 15
 Ala Gly Val Asn Phe Ile Leu Ala Leu Pro Leu Leu Leu Trp Lys
 20 25 30
 5 Asn Arg Gly Gly Val Gly Arg Ser Val Met Ser Ala Val Glu Xaa
 35 40 45
 10
 (2) INFORMATION FOR SEQ ID NO: 429:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 370 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 429:
 20 Met Lys Lys Val Glu Glu Lys Arg Val Asp Val Asn Ser Ala Val Ala
 1 5 10 15
 Met Gly Glu Val Ile Leu Ala Val Cys His Pro Asp Cys Ile Thr Thr
 20 25 30
 25 Ile Lys His Trp Ile Thr Ile Ile Arg Ala Arg Phe Glu Val Leu
 35 40 45
 Thr Trp Ala Lys Gln His Gln Gln Arg Leu Glu Thr Ala Leu Ser Glu
 50 55 60
 30 Leu Val Ala Asn Ala Glu Leu Leu Glu Glu Leu Leu Ala Trp Ile Gln
 65 70 75 80
 35 Trp Ala Glu Thr Thr Leu Ile Gln Arg Asp Gln Glu Pro Ile Pro Gln
 85 90 95
 Asn Ile Asp Arg Val Lys Ala Leu Ile Ala Glu His Gln Thr Phe Met
 100 105 110
 40 Glu Glu Met Thr Arg Lys Gln Pro Asp Val Asp Arg Val Thr Lys Thr
 115 120 125
 Tyr Lys Arg Lys Asn Ile Glu Pro Thr His Ala Pro Phe Ile Glu Lys
 130 135 140
 45 Ser Arg Ser Gly Gly Arg Lys Ser Leu Ser Gln Pro Thr Pro Pro Pro
 145 150 155 160
 50 Met Pro Ile Leu Ser Gln Ser Glu Ala Lys Asn Pro Arg Ile Asn Gln
 165 170 175
 Leu Ser Ala Arg Trp Gln Gln Val Trp Leu Leu Ala Leu Glu Arg Gln
 180 185 190
 55 Arg Lys Leu Asn Asp Ala Leu Asp Arg Leu Glu Glu Leu Lys Glu Phe
 195 200 205
 Ala Asn Phe Asp Phe Asp Val Trp Arg Lys Lys Tyr Met Arg Trp Met
 210 215 220
 60

Asn His Lys Lys Ser Arg Val Met Asp Phe Phe Arg Arg Ile Asp Lys
 225 230 235 240
 5 Asp Gln Asp Gly Lys Ile Thr Arg Gln Glu Phe Ile Asp Gly Ile Leu
 245 250 255
 Ala Ser Lys Phe Pro Thr Thr Lys Leu Glu Met Thr Ala Val Ala Asp
 260 265 270
 10 Ile Phe Asp Arg Asp Gly Asp Gly Tyr Ile Asp Tyr Tyr Glu Phe Val
 275 280 285
 Ala Ala Leu His Pro Asn Lys Asp Ala Tyr Arg Pro Thr Thr Asp Ala
 290 295 300
 15 Asp Lys Ile Glu Asp Glu Val Thr Arg Gln Val Ala Gln Cys Lys Cys
 305 310 315 320
 20 Ala Lys Arg Phe Gln Val Glu Gln Ile Gly Glu Asn Lys Tyr Arg Phe
 325 330 335
 Phe Leu Gly Asn Gln Phe Gly Asp Ser Gln Gln Leu Arg Leu Val Arg
 340 345 350
 25 Ile Leu Arg Asn Arg Asp Gly Ser Arg Trp Trp Arg Met Asp Gly Leu
 355 360 365
 Gly Xaa
 30 370

(2) INFORMATION FOR SEQ ID NO: 430:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 430:

Met Asn Val Lys Thr Phe Ser Xaa Asp His Met His Phe Leu Cys Cys
 1 5 10 15
 45 Leu Tyr Leu Arg Tyr Val Thr Phe Val Tyr Leu Asn Leu Phe
 20 25 30

(2) INFORMATION FOR SEQ ID NO: 431:

- 50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 431:

Met Glu Pro His Leu Arg Cys Arg Val Thr Arg Val Arg Gly Ser Leu
 1 5 10 15
 60 Gly Asn Thr Gly Arg Trp Leu Leu

20

5 (2) INFORMATION FOR SEQ ID NO: 432:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 53 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 432:

Met His Tyr Leu Val Leu Gly Gly Leu Gly Val Phe Leu Phe Phe Ser
 1 5 10 15
 Cys Phe Val Phe Leu Phe Phe Xaa Phe Ser Phe Ala Phe Phe Pro Phe
 20 25 30
 Tyr Leu Glu Gly Met Gly Gly Ser Gly Asn Arg Glu Val Gly Gly Gly
 35 40 45
 Phe Cys Leu Phe Phe
 50

25

(2) INFORMATION FOR SEQ ID NO: 433:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 176 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 433:

Met Val Ser Lys Ala Leu Leu Arg Leu Val Ser Ala Val Asn Arg Arg
 1 5 10 15
 Arg Met Lys Leu Leu Leu Gly Ile Ala Leu Leu Ala Tyr Val Ala Ser
 20 25 30
 Val Trp Gly Asn Phe Val Asn Met Arg Ser Ile Gln Glu Asn Gly Glu
 35 40 45
 Leu Lys Ile Glu Ser Lys Ile Glu Glu Met Val Glu Pro Leu Arg Glu
 50 55 60
 Lys Ile Arg Asp Leu Glu Lys Ser Phe Thr Gln Lys Tyr Pro Pro Val
 65 70 75 80
 Lys Phe Leu Ser Glu Lys Asp Arg Lys Arg Ile Leu Ile Thr Gly Gly
 85 90 95
 Ala Gly Phe Val Gly Ser His Leu Thr Asp Lys Leu Met Met Asp Gly
 100 105 110
 His Glu Val Thr Val Val Asp Asn Phe Phe Thr Gly Arg Lys Arg Asn
 115 120 125
 Val Glu His Trp Ile Gly His Glu Asn Phe Glu Leu Ile Asn His Asp
 130 135 140

60

Val Trp Ser Pro Ser Thr Ser Arg Leu Thr Arg Tyr Thr Ile Trp His
 145 150 155 160

5 Leu Gln Pro Pro Leu Gln Thr Thr Cys Ile Ile Leu Ser Arg His Xaa
 165 170 175

10

(2) INFORMATION FOR SEQ ID NO: 434:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 77 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 434:

20

Met Leu Arg Cys Trp Pro Leu Phe Trp Leu Pro Leu Val Ser Pro Phe
 1 5 10 15

25

Cys Ser Leu Phe Trp Leu Leu Val Glu Trp Phe Gly Thr Asn Ile Asp
 20 25 30

Arg Glu Ser Tyr Asp Ala Ile Gly Gly Pro Ser Trp Met Thr Ala Ser
 35 40 45

30

Ser Phe Cys Leu Ser Asn Ser Asn Ile Trp Ser Leu Glu Ile Ser Ser
 50 55 60

Gly Ser Thr Ser Val Val His Ser Gln Gln Ala Met Asp
 65 70 75

35

(2) INFORMATION FOR SEQ ID NO: 435:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 435:

45

Met Arg Ser Cys Glu Ile Gln Leu Cys Val Trp Leu Leu Val Ser Ser
 1 5 10 15

50

His Val Asp Met Val Leu Gly Gly Ser Pro Ser Thr Leu Tyr Met Met
 20 25 30

55

(2) INFORMATION FOR SEQ ID NO: 436:

60

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 436:

5 Met Val Val Asn Ser Leu Cys Phe Leu Ser Leu Leu Leu Val Ile Leu
 1 5 10 15
 Glu Leu Ser Thr Asp Ser Ser Ala Arg Leu Leu Tyr His Glu
 20 25 30
 10

(2) INFORMATION FOR SEQ ID NO: 437:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 69 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 437:

20 Met Asp Lys Gln Lys His Leu Glu Val Arg Arg Ser Val Phe Lys Ile
 1 5 10 15
 25 Gln Gly Lys Ile Ala Phe Ser Leu Met Phe Val Leu Lys Asp Leu Ser
 20 25 30
 Pro Thr Ile Phe Ser His Ser Ile Leu Leu Leu Leu Pro His His Val
 35 40 45
 30 Leu Pro Cys Thr Pro Gln Met Val Arg Gly Val Thr Gln Val Leu Arg
 50 55 60
 Glu Phe Gly Asp Gln
 65
 35

(2) INFORMATION FOR SEQ ID NO: 438:

40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 438:

45 Met Pro Leu Cys Phe Phe Ser Phe Leu Cys Cys Trp Val Leu Val Phe
 1 5 10 15
 Lys Leu Ile
 50

(2) INFORMATION FOR SEQ ID NO: 439:

55 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 43 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 439:

60

Met Lys Phe Ser Leu Val Leu Leu Ile Lys Ile Ile Ser Phe Glu Arg
 1 5 10 15
 5 Leu Leu Ile Phe Leu Phe Pro Leu Ser Phe Leu Pro Asn Ile Trp Arg
 20 25 30
 Arg Val Met Val Asn Leu Asn Ile Leu Phe Xaa
 35 40
 10

(2) INFORMATION FOR SEQ ID NO: 440:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 33 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 440:

20 Met Leu Leu Phe Pro Ser Leu Leu Phe Ala Ala Thr Tyr Asn Val Ala
 1 5 10 15
 25 Asn Pro Ser Arg Leu Ile Leu Tyr Met Ile Ser Ala Gly Ala Asp Ser
 20 25 30
 Gln

30

(2) INFORMATION FOR SEQ ID NO: 441:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 53 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 441:

40 Met Trp Gln Val Arg Gly Leu Pro Pro Val Pro Leu Leu Leu Thr Met
 1 5 10 15
 Ser Pro Pro Pro Cys Leu Ser Ser Pro Phe Pro Phe Ile Ser Val Pro
 20 25 30
 45 Leu Phe Glu Ala Val Pro Ile Ser Val Ser Asp Gln Pro Ser Pro Xaa
 35 40 45
 Leu Thr Thr Leu Leu
 50 50

(2) INFORMATION FOR SEQ ID NO: 442:

- 55 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 64 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 442:

Met Ile Thr Ser Val Leu Val Phe Leu Ile Phe Phe Phe Pro Tyr Leu
 1 5 10 15
 5 Ser Leu Val Thr Leu Leu Gln Ala Arg Asn Leu Trp Val Ile His Arg
 20 25 30
 Ala Ala Leu Cys Glu Ser Gly Leu Phe His Trp Arg Lys Gly Ile Glu
 35 40 45
 10 Asn Gln Leu Glu Pro Met Tyr Phe Leu Pro His Gly Thr Leu Phe Leu
 50 55 60

15

(2) INFORMATION FOR SEQ ID NO: 443:

20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 443:

Met Leu Tyr Ser Cys Glu Pro Tyr Leu Ile Ile Leu Asn Ile Tyr Ser
 1 5 10 15
 30 Gln Lys Ala Phe Tyr Phe Tyr Phe Phe Glu Gly Ser Phe Ser Val Cys
 20 25 30
 Thr Leu

35

(2) INFORMATION FOR SEQ ID NO: 444:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 89 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 444:

Met Arg Gln Arg Gln Ala Ala Cys Gln Pro Pro Pro Ser Arg Asn Gly
 1 5 10 15
 50 Leu Ala Gln Glu Cys Pro Pro His Ile Pro Ser Ser Phe Phe Leu Val
 20 25 30
 Lys Leu Leu Phe Ile Pro Trp Leu Ala Ser Leu Leu Ser Ser Pro Leu
 35 40 45
 55 Asn Leu Leu Leu Leu Val Ser Ile Ser Trp Asp Leu Gly Leu Lys Leu
 50 55 60
 Asn Leu Gln Gln Cys Arg Gln His Gln Val Leu Gln Glu Lys Asn Thr
 65 70 75 80

60

Lys Lys Phe Asn Lys Lys Lys Lys
85

5

(2) INFORMATION FOR SEQ ID NO: 445:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 350 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 445:

Met Asp Phe Ile Thr Ser Thr Ala Ile Leu Pro Leu Leu Phe Gly Cys
1 5 10 15

Leu Gly Val Phe Gly Leu Phe Arg Leu Leu Gln Trp Val Arg Gly Lys
20 25 30

Ala Tyr Leu Arg Asn Ala Val Val Val Ile Thr Gly Ala Thr Ser Gly
35 40 45

Leu Gly Lys Glu Cys Ala Lys Val Phe Tyr Ala Ala Gly Ala Lys Leu
50 55 60

Val Leu Cys Gly Arg Asn Gly Gly Ala Leu Glu Glu Leu Ile Arg Glu
65 70 75 80

Leu Thr Ala Ser His Ala Thr Lys Val Gln Thr His Lys Pro Tyr Leu
85 90 95

Val Thr Phe Asp Leu Thr Asp Ser Gly Ala Ile Val Ala Ala Ala Ala
100 105 110

Glu Ile Leu Gln Cys Phe Gly Tyr Val Asp Ile Leu Val Asn Asn Ala
115 120 125

Gly Ile Ser Tyr Arg Gly Thr Ile Met Asp Thr Thr Val Asp Val Asp
130 135 140

Lys Arg Val Met Glu Thr Asn Tyr Phe Gly Pro Val Ala Leu Thr Lys
145 150 155 160

Ala Leu Leu Pro Ser Met Ile Lys Arg Arg Gln Gly His Ile Val Ala
165 170 175

Ile Ser Ser Ile Gln Gly Lys Met Ser Ile Pro Phe Arg Ser Ala Tyr
180 185 190

Ala Ala Ser Lys His Ala Thr Gln Ala Phe Phe Asp Cys Leu Arg Ala
195 200 205

Glu Met Glu Gln Tyr Glu Ile Glu Val Thr Val Ile Ser Pro Gly Tyr
210 215 220

Ile His Thr Asn Leu Ser Val Asn Ala Ile Thr Ala Asp Gly Ser Arg
225 230 235 240

Tyr Gly Val Met Asp Thr Thr Thr Ala Gln Gly Arg Ser Pro Val Glu
245 250 255

Val Ala Gln Asp Val Leu Ala Ala Val Gly Lys Lys Lys Lys Asp Val
 260 265 270

5 Ile Leu Ala Asp Leu Leu Pro Ser Leu Ala Val Tyr Leu Arg Thr Leu
 275 280 285

Ala Pro Gly Leu Phe Phe Ser Leu Met Pro Pro Gly Pro Glu Lys Ser
 290 295 300

10 Gly Asn Pro Arg Thr Pro Ser Thr Leu Thr Ser Gln Gly Gln Gly Arg
 305 310 315 320

15 Glu Ala Ala Leu Leu Gly Leu Leu Thr Leu Gln Gly Thr Val Ala Phe
 325 330 335

Val Glu Thr Leu Met Glu Ile Cys Leu Thr Ser Gly Lys Asp
 340 345 350

20

(2) INFORMATION FOR SEQ ID NO: 446:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 49 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 446:

30 Met Val Phe Leu Pro Arg Gly Val Val Val Ser Gly Gly Ala Ala Cys
 1 5 10 15

Leu Trp Leu Thr Phe Ile Leu Glu Thr Glu Val Tyr Leu Asp Leu Ala
 20 25 30

35 Thr Glu Ala Arg Ala His Ser Arg Met Gly Leu Gly Leu Trp Pro Pro
 35 40 45

40 Asn

45 (2) INFORMATION FOR SEQ ID NO: 447:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 278 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 447:

Met Ala Ser Ala Glu Leu Asp Tyr Thr Ile Glu Ile Pro Asp Gln Pro
 1 5 10 15

55 Cys Trp Ser Gln Lys Asn Ser Pro Ser Pro Gly Gly Lys Glu Ala Glu
 20 25 30

Thr Arg Gln Pro Val Val Ile Leu Leu Gly Trp Gly Gly Cys Lys Asp
 35 40 45

60

620

Lys Asn Leu Ala Lys Tyr Ser Ala Ile Tyr His Lys Arg Gly Cys Ile
 50 55 60
 Val Ile Arg Tyr Thr Ala Pro Trp His Met Val Phe Phe Ser Glu Ser
 5 65 70 75 80
 Leu Gly Ile Pro Ser Leu Arg Val Leu Ala Gln Lys Leu Leu Glu Leu
 85 90 95
 10 Leu Phe Asp Tyr Glu Ile Glu Lys Glu Pro Leu Leu Phe His Val Phe
 100 105 110
 Ser Asn Gly Gly Val Met Leu Tyr Arg Tyr Val Leu Glu Leu Leu Gln
 115 120 125
 15 Thr Arg Arg Phe Cys Arg Leu Arg Val Val Gly Thr Ile Phe Asp Ser
 130 135 140
 Ala Pro Gly Asp Ser Asn Leu Val Gly Ala Leu Arg Ala Leu Ala Ala
 145 150 155 160
 Ile Leu Glu Arg Arg Ala Ala Met Leu Arg Leu Leu Leu Leu Val Ala
 165 170 175
 25 Phe Ala Leu Val Val Val Leu Phe His Val Leu Leu Ala Pro Ile Thr
 180 185 190
 Ala Xaa Phe His Thr His Phe Tyr Asp Arg Leu Gln Asp Ala Gly Ser
 195 200 205
 30 Arg Trp Pro Glu Leu Tyr Leu Tyr Ser Arg Ala Asp Glu Val Val Leu
 210 215 220
 Ala Arg Asp Ile Glu Arg Met Val Glu Ala Arg Leu Ala Arg Arg Val
 225 230 235 240
 Leu Ala Arg Ser Val Asp Phe Val Ser Ser Ala His Val Ser His Leu
 245 250 255
 40 Arg Asp Tyr Pro Thr Tyr Tyr Thr Ser Leu Cys Val Asp Phe Met Arg
 260 265 270
 Asn Cys Val Arg Cys Xaa
 275
 45

(2) INFORMATION FOR SEQ ID NO: 448:

50

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 199 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 448:

60

Met Ser Phe Ile Phe Asp Trp Ile Tyr Ser Gly Phe Ser Ser Val Leu
 1 5 10 15
 Gln Phe Leu Gly Leu Tyr Lys Lys Thr Gly Lys Leu Val Phe Leu Gly
 20 25 30

Leu Asp Asn Ala Gly Lys Thr Thr Leu Leu His Met Leu Lys Asp Asp
 35 40 45
 5 Arg Leu Gly Gln His Val Pro Thr Leu His Pro Thr Ser Glu Glu Leu
 50 55 60
 Thr Ile Ala Gly Met Thr Phe Thr Thr Phe Asp Leu Gly Gly His Val
 65 70 75 80
 10 Gln Ala Arg Arg Val Trp Lys Asn Tyr Leu Pro Ala Ile Asn Gly Ile
 85 90 95
 15 Val Phe Leu Val Asp Cys Ala Asp His Glu Arg Leu Leu Glu Ser Lys
 100 105 110
 Glu Glu Leu Asp Ser Leu Met Thr Asp Glu Thr Ile Ala Asn Val Pro
 115 120 125
 20 Ile Leu Ile Leu Gly Asn Lys Ile Asp Arg Pro Glu Ala Ile Ser Glu
 130 135 140
 Glu Arg Leu Arg Glu Met Phe Gly Leu Tyr Gly Gln Thr Thr Gly Lys
 145 150 155 160
 25 Gly Ser Ile Ser Leu Lys Glu Leu Asn Ala Arg Pro Leu Glu Val Phe
 165 170 175
 30 Met Cys Ser Val Leu Lys Arg Gln Gly Tyr Gly Glu Gly Phe Arg Trp
 180 185 190
 Met Ala Gln Tyr Ile Asp Xaa
 195

35

(2) INFORMATION FOR SEQ ID NO: 449:

- 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 258 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 449:

45 Met Thr Leu Ser Arg Phe Ala Tyr Asn Gly Lys Arg Cys Pro Ser Ser
 1 5 10 15
 Tyr Asn Ile Leu Asp Asn Ser Lys Ile Ile Ser Glu Glu Cys Arg Lys
 20 25 30
 50 Glu Leu Thr Ala Leu Leu His His Tyr Tyr Pro Ile Glu Ile Asp Pro
 35 40 45
 55 His Arg Thr Val Lys Glu Lys Leu Pro His Met Val Glu Trp Trp Thr
 50 55 60
 Lys Ala His Asn Leu Leu Cys Gln Gln Lys Ile Gln Lys Phe Gln Ile
 65 70 75 80
 60 Ala Gln Val Val Arg Glu Ser Asn Ala Met Leu Arg Glu Gly Tyr Lys

622

85 90 95
 Thr Phe Phe Asn Thr Leu Tyr His Asn Asn Ile Pro Leu Phe Ile Phe
 100 105 110
 5 Ser Ala Gly Ile Gly Asp Ile Leu Glu Glu Ile Ile Arg Gln Met Lys
 115 120 125
 10 Val Phe His Pro Asn Ile His Ile Val Ser Asn Tyr Met Asp Phe Asn
 130 135 140
 Glu Asp Gly Phe Leu Gln Gly Phe Lys Gly Gln Leu Ile His Thr Tyr
 145 150 155 160
 15 Asn Lys Asn Ser Ser Val Cys Glu Asn Xaa Gly Tyr Phe Gln Gln Leu
 165 170 175
 Glu Gly Lys Thr Asn Val Ile Leu Leu Gly Asp Ser Ile Gly Asp Leu
 180 185 190
 20 Thr Met Ala Asp Gly Val Pro Gly Val Gln Asn Ile Leu Lys Ile Gly
 195 200 205
 25 Phe Leu Asn Asp Lys Val Glu Glu Arg Arg Xaa Arg Tyr Met Asp Ser
 210 215 220
 Tyr Asp Ile Val Leu Glu Lys Asp Glu Thr Leu Asp Val Val Asn Gly
 225 230 235 240
 30 Leu Leu Gln His Ile Leu Cys Gln Gly Val Gln Leu Glu Met Gln Gly
 245 250 255
 Pro Xaa

35

(2) INFORMATION FOR SEQ ID NO: 450:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 87 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 450:

Met Ser His Val Leu Leu Cys Pro Ser Leu Ser Cys Ser Asn Leu Leu
 1 5 10 15
 50 Pro Pro Ser His Ser Leu Gly Thr Met Gly Ser Leu Ser Pro His Leu
 20 25 30
 Cys Gly His Thr Met Cys Pro Val Asn Pro Glu Leu Pro Leu Ser Ser
 35 40 45
 55 Arg Leu Thr Thr Asp Gln Pro Gln Pro Asp Ala Cys Ser Pro Thr Leu
 50 55 60
 60 Leu Thr Leu Pro Leu Pro Ser Ser Phe Leu Pro His Ser Lys Pro Thr
 65 70 75 80

Phe Xaa His Pro Cys Ser Pro
85

5

(2) INFORMATION FOR SEQ ID NO: 451:

(i) SEQUENCE CHARACTERISTICS:

10

(A) LENGTH: 315 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 451:

15 Met Phe Ser Ile Asn Pro Leu Glu Asn Leu Lys Val Tyr Ile Ser Ser
1 5 10 15

Arg Pro Pro Leu Val Val Phe Met Ile Ser Val Xaa Pro Met Ala Ile
20 25 30

20 Ala Phe Leu Thr Leu Gly Tyr Phe Phe Lys Ile Lys Glu Ile Lys Ser
35 40 45

Pro Glu Met Ala Glu Asp Trp Asn Thr Phe Leu Leu Arg Phe Asn Asp
25 50 55 60

Leu Asp Leu Cys Val Ser Glu Asn Glu Thr Leu Lys His Leu Thr Asn
65 70 75 80

30 Asp Thr Thr Thr Pro Glu Ser Thr Met Thr Ser Gly Gln Ala Arg Ala
85 90 95

Ser Thr Gln Ser Pro Gln Ala Leu Glu Asp Ser Gly Pro Val Asn Ile
100 105 110

35 Ser Val Ser Ile Thr Leu Thr Leu Asp Pro Leu Lys Pro Phe Gly Gly
115 120 125

Tyr Ser Arg Asn Val Thr His Leu Tyr Ser Thr Ile Leu Gly His Gln
40 130 135 140

Ile Gly Leu Ser Gly Arg Glu Ala His Glu Glu Ile Asn Ile Thr Phe
145 150 155 160

45 Thr Leu Pro Thr Ala Trp Ser Ser Asp Asp Cys Ala Leu His Gly His
165 170 175

Cys Glu Gln Val Val Phe Thr Ala Cys Met Thr Leu Thr Ala Ser Pro
180 185 190

50 Gly Val Phe Pro Val Thr Val Gln Pro Pro His Cys Val Pro Asp Thr
195 200 205

Tyr Ser Asn Ala Thr Leu Trp Tyr Lys Ile Phe Thr Thr Ala Arg Asp
55 210 215 220

Ala Asn Thr Lys Tyr Ala Gln Asp Tyr Asn Pro Phe Trp Cys Tyr Lys
225 230 235 240

60 Gly Ala Ile Gly Lys Val Tyr His Ala Leu Asn Pro Lys Leu Thr Val
245 250 255

Ile Val Pro Asp Asp Arg Ser Leu Ile Asn Leu His Leu Met His
 260 265 270

5 Thr Ser Tyr Phe Leu Phe Val Met Val Ile Thr Met Phe Cys Tyr Ala
 275 280 285

Val Ile Lys Gly Arg Pro Ser Lys Leu Arg Gln Ser Asn Pro Glu Phe
 290 295 300

10 Cys Pro Glu Lys Val Ala Leu Ala Glu Ala Xaa
 305 310 315

15

(2) INFORMATION FOR SEQ ID NO: 452:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 52 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 452:

25 Met Pro Gly Leu Ser Leu Ala Leu Leu Pro Phe Gly Pro Gly Cys Thr
 1 5 10 15

Glu Ala Leu His Ala Gly Cys Phe Pro Ala Phe Ala Ser Ala Thr Arg
 20 25 30

30 Val Asn Gly Glu Ala Ala Leu Ser Pro Gly Leu Cys Asp Pro Ile Ser
 35 40 45

Val Pro Tyr Val
 50

35

(2) INFORMATION FOR SEQ ID NO: 453:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 383 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 453:

45 Met Ala Val Gly Gln Ile Met Thr Phe Gly Ser Pro Val Ile Gly Cys
 1 5 10 15

50 Gly Phe Ile Ser Gly Trp Asn Leu Val Ser Met Cys Val Glu Tyr Val
 20 25 30

Leu Leu Trp Lys Val Tyr Gln Lys Thr Pro Ala Leu Ala Val Lys Ala
 35 40 45

55 Gly Leu Lys Glu Glu Glu Thr Glu Leu Lys Gln Leu Asn Leu His Lys
 50 55 60

Asp Thr Glu Pro Lys Pro Leu Glu Gly Thr His Leu Met Gly Val Lys
 65 70 75 80

60

625

Asp Ser Asn Ile His Glu Leu Glu His Glu Gln Glu Pro Thr Cys Ala
 85 90 95
 5 Ser Gln Met Ala Glu Pro Phe Arg Thr Phe Arg Asp Gly Trp Val Ser
 100 105 110
 Tyr Tyr Asn Gln Pro Val Phe Leu Ala Gly Met Gly Leu Ala Phe Leu
 115 120 125
 10 Tyr Met Thr Val Leu Gly Phe Asp Cys Ile Thr Thr Gly Tyr Ala Tyr
 130 135 140
 Thr Gln Gly Leu Ser Gly Phe His Pro Gln Tyr Phe Asp Gly Ser Ile
 145 150 155 160
 15 Ser Tyr Asn Trp Asn Asn Gly Asn Cys Ser Phe Tyr Leu Ala Thr Ser
 165 170 175
 Lys Met Trp Phe Gly Ser Ala Gly Leu Ile Ser Gly Leu Ala Gln Leu
 180 185 190
 Ser Cys Leu Ile Leu Cys Val Ile Ser Val Phe Met Pro Gly Ser Pro
 195 200 205
 25 Leu Asp Leu Ser Val Ser Pro Phe Glu Asp Ile Arg Ser Arg Phe Ile
 210 215 220
 Gln Gly Glu Ser Ile Thr Pro Thr Lys Ile Pro Glu Ile Thr Thr Glu
 225 230 235 240
 30 Ile Tyr Met Ser Asn Gly Ser Asn Ser Ala Asn Ile Val Pro Glu Thr
 245 250 255
 Ser Pro Glu Ser Val Pro Ile Ile Ser Val Ser Leu Leu Phe Ala Gly
 260 265 270
 Val Ile Ala Ala Arg Ile Gly Leu Trp Ser Phe Asp Leu Thr Val Thr
 275 280 285
 40 Gln Leu Leu Gln Glu Asn Val Ile Glu Ser Glu Arg Gly Ile Ile Asn
 290 295 300
 Gly Val Gln Asn Ser Met Asn Tyr Leu Leu Asp Leu Leu His Phe Ile
 305 310 315 320
 45 Met Val Ile Leu Ala Pro Asn Pro Glu Ala Phe Gly Leu Leu Val Leu
 325 330 335
 Ile Ser Val Ser Phe Val Ala Met Gly His Ile Met Tyr Phe Arg Phe
 340 345 350
 Ala Gln Asn Thr Leu Gly Asn Lys Leu Phe Ala Cys Gly Pro Asp Ala
 355 360 365
 55 Lys Glu Val Arg Lys Glu Asn Gln Ala Asn Thr Ser Val Val Xaa
 370 375 380

60 (2) INFORMATION FOR SEQ ID NO: 454:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 186 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 454:

5 Met Arg Ser Ile Gly Asn Lys Asn Thr Ile Leu Leu Gly Leu Gly Phe
 1 5 10 15
 10 Gln Ile Leu Gln Leu Ala Trp Tyr Gly Phe Gly Ser Glu Pro Trp Met
 20 25 30
 15 Met Trp Ala Ala Gly Ala Val Ala Ala Met Ser Ser Ile Thr Phe Pro
 35 40 45
 Ala Val Ser Ala Leu Val Ser Arg Thr Ala Asp Ala Asp Gln Gln Gly
 50 55 60
 20 Val Val Gln Gly Met Ile Thr Gly Ile Arg Gly Leu Cys Asn Gly Leu
 65 70 75 80
 Gly Pro Ala Leu Tyr Gly Phe Ile Phe Tyr Ile Phe His Val Glu Leu
 85 90 95
 25 Lys Glu Leu Pro Ile Thr Gly Thr Asp Leu Gly Thr Asn Thr Ser Pro
 100 105 110
 30 Gln His His Phe Glu Gln Asn Ser Ile Ile Pro Gly Pro Pro Phe Leu
 115 120 125
 Phe Gly Ala Cys Ser Val Leu Leu Ala Leu Leu Val Ala Leu Phe Ile
 130 135 140
 35 Pro Glu His Thr Asn Leu Ser Leu Arg Ser Ser Ser Trp Arg Lys His
 145 150 155 160
 Cys Gly Ser His Ser His Pro His Asn Thr Gln Ala Pro Gly Glu Ala
 165 170 175
 40 Lys Glu Pro Leu Leu Gln Asp Thr Asn Val
 180 185

45

(2) INFORMATION FOR SEQ ID NO: 455:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 163 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 455:

55 Met Leu Gln Thr Ser Asn Tyr Ser Leu Val Leu Ser Leu Gln Phe Leu
 1 5 10 15
 Leu Leu Ser Tyr Asp Leu Phe Val Asn Ser Phe Ser Glu Leu Leu Gln
 20 25 30
 60 Lys Thr Pro Val Ile Gln Leu Val Leu Phe Ile Ile Gln Asp Ile Ala

35 40 45
 Val Leu Phe Asn Ile Ile Ile Ile Phe Leu Met Phe Phe Asn Thr Phe
 50 55 60
 5 Val Phe Gln Ala Gly Leu Val Asn Leu Leu Phe His Lys Phe Lys Gly
 65 70 75 80
 10 Thr Ile Ile Leu Thr Ala Val Tyr Phe Ala Leu Ser Ile Ser Leu His
 85 90 95
 Val Trp Val Met Asn Leu Arg Trp Lys Asn Ser Asn Ser Phe Ile Trp
 100 105 110
 15 Thr Asp Gly Leu Gln Met Leu Phe Val Phe Gln Arg Leu Ala Ala Val
 115 120 125
 Leu Tyr Cys Tyr Phe Tyr Lys Arg Thr Ala Val Arg Leu Gly Asp Pro
 130 135 140
 20 His Phe Tyr Gln Asp Ser Leu Trp Leu Arg Lys Glu Phe Met Gln Val
 145 150 155 160
 25 Arg Arg Xaa

30 (2) INFORMATION FOR SEQ ID NO: 456:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 456:

Met Arg Ile Gln Val Phe Ile Leu Leu Leu Gly Ala Gly Gly Thr Ser
 1 5 10 15
 40 Gln Phe Thr Lys Pro Pro Ser Leu Pro Leu Glu Pro Glu Pro Ala Val
 20 25 30
 Glu Ser Ser Pro Thr Glu Thr Ser Glu Gln Ile Arg Glu Lys
 35 40 45
 45

(2) INFORMATION FOR SEQ ID NO: 457:

50 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 105 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 457:

Met Ser Tyr Leu Ala Phe Leu Tyr Met Thr Phe Asp Phe Cys Cys Leu
 1 5 10 15
 60 Tyr Phe Ser Thr Val Tyr Ala Pro Ser Phe Lys Tyr Ile Cys Val His
 20 25 30

Thr Asp Thr His Ile Cys Val Cys Val Cys Ile Tyr Leu Ser Ser Val
 35 40 45
 5 Val Ser Lys Ser Ser Ala Glu Ala Asp Gly Val Leu Gln Pro Arg Arg
 50 55 60
 His Pro Ala Ser Leu Leu Ile Val Phe Ala Thr Ser Ile Ser Glu Ser
 65 70 75 80
 10 Ser Leu Leu Ile Phe Ser Phe Gln Lys Thr Glu Ala Lys Leu Ile Val
 85 90 95
 15 Phe Ala Val Ser Leu Ala Ala Lys Xaa
 100 105

20 (2) INFORMATION FOR SEQ ID NO: 458:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 70 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 458:

Met Leu Pro Pro Phe Ser Leu Val Tyr Thr His Phe Leu Val Ala Ser
 1 5 10 15
 30 Leu Leu Pro Val Ile Leu Ala Val Phe Pro Asp Ser Ala Gln Ile Val
 20 25 30
 Pro Leu Leu Lys Pro Ile Pro Arg Pro Gln Pro Glu Val Ile Phe Pro
 35 40 45
 35 Ser Ser Glu Leu Leu Glu Gln Leu Leu Ser Val Gln Phe Val Trp Gln
 50 55 60
 40 Ala His Thr Val Ala Xaa
 65 70

45 (2) INFORMATION FOR SEQ ID NO: 459:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 459:

Met Ala Leu Leu Leu Ser Val Leu Arg Val Leu Leu Gly Gly Phe Phe
 1 5 10 15
 55 Ala Leu Val Gly Leu Ala Lys Leu Ser Glu Glu Ile Ser Ala Pro Val
 20 25 30
 Ser Glu Arg Met Asn Ala Leu Phe Val Gln Phe Ala Glu Val Phe Pro
 35 40 45
 60

Leu Lys Val Phe Gly Tyr Gln Pro Asp Pro Leu Asn Tyr Gln Ile Ala
 50 55 60

5 Val Gly Phe Leu Glu Leu Leu Ala Gly Leu Leu Leu Val Met Gly Pro
 65 70 75 80

Pro Met Leu Gln Glu Ile Ser Asn Leu Phe Leu Ile Leu Leu Met Met
 85 90 95

10 Gly Ala Ile Phe Thr Leu Ala Ala Leu Lys Glu Ser Leu Ser Thr Cys
 100 105 110

Ile Pro Ala Ile Val Cys Leu Gly Phe Leu Leu Leu Leu Asn Val Gly
 115 120 125

15 Gln Leu Leu Ala Gln Thr Lys Lys Val Val Arg Pro Thr Arg Lys Lys
 130 135 140

20 Thr Leu Ser Thr Phe Lys Glu Ser Trp Lys Xaa
 145 150 155

(2) INFORMATION FOR SEQ ID NO: 460:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 332 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 460:

Met Lys Leu Gly Arg Ala Val Leu Gly Leu Leu Leu Leu Ala Pro Ser
 1 5 10 15

35 Val Val Gln Ala Val Glu Pro Ile Ser Leu Gly Leu Ala Leu Ala Gly
 20 25 30

Val Leu Thr Gly Tyr Ile Tyr Pro Arg Leu Tyr Cys Leu Phe Ala Glu
 35 40 45

40 Cys Cys Gly Gln Lys Arg Ser Leu Ser Arg Glu Ala Leu Gln Lys Asp
 50 55 60

Leu Asp Asp Asn Leu Phe Gly Gln His Leu Ala Lys Lys Ile Ile Leu
 45 65 70 75 80

Asn Ala Val Phe Gly Phe Ile Asn Asn Pro Lys Pro Lys Lys Pro Leu
 85 90 95

50 Thr Leu Ser Leu His Gly Trp Thr Gly Thr Gly Lys Asn Phe Val Ser
 100 105 110

Lys Ile Ile Ala Glu Asn Ile Tyr Glu Gly Gly Leu Asn Ser Asp Tyr
 115 120 125

55 Val His Leu Phe Val Ala Thr Leu His Phe Pro His Ala Ser Asn Ile
 130 135 140

60 Thr Leu Tyr Lys Asp Gln Leu Gln Leu Trp Ile Arg Gly Asn Val Ser
 145 150 155 160

Ala Cys Ala Arg Ser Ile Phe Ile Phe Asp Glu Met Asp Lys Met His
 165 170 175

5 Ala Gly Leu Ile Asp Ala Ile Lys Pro Phe Leu Asp Tyr Tyr Asp Leu
 180 185 190

Val Asp Gly Val Ser Tyr Gln Lys Ala Met Phe Ile Phe Leu Ser Asn
 195 200 205

10 Ala Gly Ala Glu Arg Ile Thr Asp Val Ala Leu Asp Phe Trp Arg Ser
 210 215 220

Gly Lys Gln Arg Glu Asp Ile Lys Leu Lys Asp Ile Glu His Ala Leu
 15 225 230 235 240

Ser Val Ser Val Phe Asn Asn Lys Asn Ser Gly Phe Trp His Ser Ser
 245 250 255

20 Leu Ile Asp Arg Asn Leu Ile Asp Tyr Phe Val Pro Phe Leu Pro Leu
 260 265 270

Glu Tyr Lys His Leu Lys Met Cys Ile Arg Val Glu Met Gln Ser Arg
 275 280 285

25 Gly Tyr Glu Ile Asp Glu Asp Ile Val Ser Arg Val Ala Glu Glu Met
 290 295 300

Thr Phe Phe Pro Lys Glu Glu Arg Val Phe Ser Asp Lys Gly Cys Lys
 30 305 310 315 320

Thr Val Phe Thr Lys Leu Asp Tyr Tyr Tyr Asp Asp
 325 330

35

(2) INFORMATION FOR SEQ ID NO: 461:

- 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 461:

45 Met Leu Lys Cys Ile
 1 5

50 (2) INFORMATION FOR SEQ ID NO: 462:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 462:

Met Ile Leu Thr Leu Leu Ser Val Val Ser Thr Met Ala Ser
 1 5 10

60

(2) INFORMATION FOR SEQ ID NO: 463:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 285 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 463:

Met Lys Leu His Pro Pro Pro Pro Ser Pro Val Thr Gln Asp His Arg
 1 5 10 15
 Ser Lys Ser Ser His Ser Asn Trp Met Pro Arg Met Gly Ala Cys Ser
 15 20 25 30
 Met Ser Arg Thr Ser Ser Ser Gly Pro Pro Ser Leu Cys Lys Ser Thr
 35 40 45
 Ser Gly Arg Ser Cys Thr Arg Pro His Cys Trp Pro Ser Leu Pro Ala
 50 55 60
 Trp Val Ser Val Phe Thr Arg Thr Asn Thr Gly Ser Trp Cys Tyr Pro
 65 70 75 80
 Ala Trp Gly Gly Ala Phe Ser Arg Pro Trp Met Ser Ala Gln Ser Met
 85 90 95
 Cys Cys Ala Glu Arg Ser Val Leu Gln Val Ala Cys Arg Leu Leu Asp
 100 105 110
 Ala Leu Glu Phe Leu His Glu Asn Glu Tyr Val His Gly Asn Val Thr
 115 120 125
 Ala Glu Asn Ile Phe Val Asp Pro Glu Asp Gln Ser Gln Val Thr Leu
 130 135 140
 Ala Gly Tyr Gly Phe Ala Phe Arg Tyr Cys Pro Ser Gly Lys His Val
 145 150 155 160
 Ala Tyr Val Glu Gly Ser Arg Ser Pro His Glu Gly Asp Leu Glu Phe
 165 170 175
 Ile Ser Met Asp Leu His Lys Gly Cys Gly Pro Ser Arg Arg Xaa Asp
 180 185 190
 Leu Gln Ser Leu Gly Tyr Cys Met Leu Lys Trp Leu Tyr Gly Phe Leu
 195 200 205
 Pro Trp Thr Asn Cys Leu Pro Xaa Xaa Glu Asp Ile Met Lys Gln Lys
 210 215 220
 Gln Lys Phe Val Asp Lys Pro Gly Pro Phe Val Gly Pro Cys Gly His
 225 230 235 240
 Trp Ile Arg Pro Ser Glu Thr Leu Gln Lys Tyr Leu Lys Val Val Met
 245 250 255
 Ala Leu Thr Tyr Glu Glu Lys Pro Pro Tyr Ala Met Leu Arg Asn Asn
 260 265 270

Leu Glu Ala Leu Leu Gln Asp Leu Arg Val Ser Pro Tyr
 275 280 285

5

(2) INFORMATION FOR SEQ ID NO: 464:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 80 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 464:

15

Met Thr Ser Pro Pro Pro His Gln Gly Trp Glu Gln Arg Gly Cys Gly
 1 5 10 15

Glu Ser Gln Val Pro Leu Ala Leu Ser Arg Val Phe Ser Thr Ser His
 20 25 30

20

Tyr Cys Leu Leu Leu Val Ala Asn Gln Ser Ile Phe Phe Pro Cys Leu
 35 40 45

25

Trp Ala Val Glu Arg Leu Leu Gly Val Arg Cys Thr Cys Pro Leu Ser
 50 55 60

Trp Gly Lys Arg Ile Ile Ser Glu His Cys Ser Ala Gln Ser Ser Xaa
 65 70 75 80

30

35

(2) INFORMATION FOR SEQ ID NO: 465:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 465:

40

Met His Thr Trp Tyr Asn Asp Arg Arg Gln Asn Cys His Cys Leu Leu
 1 5 10 15

45

Phe Phe Leu Ile Tyr Leu Arg Lys Ile Tyr Gln Val Val Pro His Val
 20 25 30

50

Pro Leu Leu Val Lys Cys Arg Gly Arg Leu Lys Gly Val Asn Ile
 35 40 45

55

(2) INFORMATION FOR SEQ ID NO: 466:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 96 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 466:

Met Glu Leu Val Leu Val Phe Leu Cys Ser Leu Leu Ala Pro Met Val
 1 5 10 15
 5 Leu Ala Ser Ala Ala Glu Lys Glu Lys Glu Met Asp Pro Phe His Tyr
 20 25 30
 Asp Tyr Gln Thr Leu Arg Ile Gly Gly Leu Val Phe Ala Val Val Leu
 35 40 45
 10 Phe Ser Val Gly Ile Leu Leu Ile Leu Ser Arg Arg Cys Lys Cys Ser
 50 55 60
 15 Phe Asn Gln Lys Pro Arg Ala Pro Gly Asp Glu Glu Ala Gln Val Glu
 65 70 75 80
 Asn Leu Ile Thr Ala Asn Ala Thr Glu Pro Gln Lys Ala Glu Asn Xaa
 85 90 95
 20
 25 (2) INFORMATION FOR SEQ ID NO: 467:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 399 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 467:
 30
 Met Ala Ser Gly Ala Asp Ser Lys Gly Asp Asp Leu Ser Thr Ala Ile
 1 5 10 15
 35 Leu Lys Gln Lys Asn Arg Pro Asn Arg Leu Ile Val Asp Glu Ala Ile
 20 25 30
 40 Asn Glu Asp Asn Ser Val Val Ser Leu Ser Gln Pro Lys Met Asp Glu
 35 40 45
 Leu Gln Leu Phe Arg Gly Asp Thr Val Leu Leu Lys Gly Lys Lys Arg
 50 55 60
 45 Arg Glu Ala Val Cys Ile Val Leu Ser Asp Asp Thr Cys Ser Asp Glu
 65 70 75 80
 Lys Ile Arg Met Asn Arg Val Val Arg Asn Asn Leu Arg Val Arg Leu
 85 90 95
 50 Gly Asp Val Ile Ser Ile Gln Pro Cys Pro Asp Val Lys Tyr Gly Lys
 100 105 110
 55 Arg Ile His Val Leu Pro Ile Asp Thr Val Glu Gly Ile Thr Gly
 115 120 125
 Asn Leu Phe Glu Val Tyr Leu Lys Pro Tyr Phe Leu Glu Ala Tyr Arg
 130 135 140
 60 Pro Ile Arg Lys Gly Asp Ile Phe Leu Val Arg Gly Met Arg Ala

634

145 150 155 160
 Val Glu Phe Lys Val Val Glu Thr Asp Pro Ser Pro Tyr Cys Ile Val
 165 170 175
 5 Ala Pro Asp Thr Val Ile His Cys Glu Gly Glu Pro Ile Lys Arg Glu
 180 185 190
 10 Asp Glu Glu Glu Ser Leu Asn Glu Val Gly Tyr Asp Asp Ile Gly Gly
 195 200 205
 Cys Arg Lys Gln Leu Ala Gln Ile Lys Glu Met Val Glu Leu Pro Leu
 210 215 220
 15 Arg His Pro Ala Leu Phe Lys Ala Ile Gly Val Lys Pro Pro Arg Gly
 225 230 235 240
 Ile Leu Leu Tyr Gly Pro Pro Gly Thr Gly Lys Thr Leu Ile Ala Arg
 245 250 255
 20 Ala Val Ala Asn Glu Thr Gly Ala Phe Phe Phe Leu Ile Asn Gly Pro
 260 265 270
 Glu Ile Met Ser Lys Leu Ala Gly Glu Ser Glu Ser Asn Leu Arg Lys
 25 275 280 285
 Ala Phe Glu Glu Ala Glu Lys Asn Ala Pro Ala Ile Ile Phe Ile Asp
 290 295 300
 30 Glu Leu Asp Ala Ile Ala Pro Lys Arg Glu Lys Thr His Gly Glu Val
 305 310 315 320
 Glu Arg Arg Ile Val Ser Gln Leu Leu Thr Leu Met Asp Gly Leu Lys
 35 325 330 335
 Gln Arg Ala His Val Ile Val Met Ala Ala Thr Asn Arg Pro Asn Ser
 340 345 350
 40 Ile Asp Pro Ala Leu Arg Arg Phe Gly Arg Phe Asp Arg Glu Val Asp
 355 360 365
 Ile Gly Ile Pro Asp Ala Thr Gly Arg Leu Glu Ile Leu Gln Ile His
 370 375 380
 45 Thr Lys Asn Met Lys Leu Ala Asp Asp Val Asp Leu Glu Gln Xaa
 385 390 395

- 50 (2) INFORMATION FOR SEQ ID NO: 468:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear
- 55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 468:

Leu
1

60

(2) INFORMATION FOR SEQ ID NO: 469:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 273 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 469:

Met Ala Ala Pro Lys Gly Ser Leu Trp Val Arg Thr Gln Leu Gly Leu
1 5 10 15

Pro Pro Leu Leu Leu Leu Thr Met Ala Leu Ala Gly Gly Ser Gly Thr
15 20 25 30

Ala Ser Ala Glu Ala Phe Asp Ser Val Leu Gly Asp Thr Ala Ser Cys
35 40 45

His Arg Ala Cys Gln Leu Thr Tyr Pro Leu His Thr Tyr Pro Lys Glu
50 55 60

Glu Glu Leu Tyr Ala Cys Gln Arg Gly Cys Arg Leu Phe Ser Ile Cys
65 70 75 80

Gln Phe Val Asp Asp Gly Ile Asp Leu Asn Arg Thr Lys Leu Glu Cys
85 90 95

Glu Ser Ala Cys Thr Glu Ala Tyr Ser Gln Ser Asp Glu Gln Tyr Ala
100 105 110

Cys His Leu Gly Cys Gln Asn Gln Leu Pro Phe Ala Glu Leu Arg Gln
115 120 125

Glu Gln Leu Met Ser Leu Met Pro Lys Met His Leu Leu Phe Pro Leu
130 135 140

Thr Leu Val Arg Ser Phe Trp Ser Asp Met Met Asp Ser Ala Gln Ser
145 150 155 160

Phe Ile Thr Ser Ser Trp Thr Phe Tyr Leu Gln Ala Asp Asp Gly Lys
165 170 175

Ile Val Ile Phe Xaa Ser Lys Pro Arg Asn Pro Arg Tyr Ala Pro His
180 185 190

Leu Glu Pro Gly Ala Leu Pro Asn Leu Xaa Xaa Xaa Ser Leu Ser Lys
195 200 205

Met Ser Xaa Xaa Ser Xaa Met Arg Asn Ser Gln Ala His Arg Asn Phe
210 215 220

Leu Glu Asp Gly Glu Ser Asp Gly Phe Leu Arg Cys Leu Ser Leu Asn
225 230 235 240

Ser Gly Trp Ile Leu Thr Thr Thr Leu Val Leu Ser Val Met Val Leu
245 250 255

Leu Trp Ile Cys Cys Ala Thr Cys Cys Tyr Thr Leu Leu Asp Ala Val
260 265 270

Xaa

5

(2) INFORMATION FOR SEQ ID NO: 470:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 192 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 470:

15

Met Met Val Leu Ser Leu Gly Ile Ile Leu Ala Ser Ala Ser Phe Ser
 1 5 10 15

20

Pro Asn Phe Thr Gln Val Thr Ser Thr Leu Leu Asn Ser Ala Tyr Pro
 20 25 30

Phe Ile Gly Pro Phe Phe Phe Ile Ile Ser Gly Ser Leu Ser Ile Ala
 35 40 45

25

Thr Glu Lys Arg Leu Thr Lys Leu Leu Val His Ser Ser Leu Val Gly
 50 55 60

Ser Ile Leu Ser Ala Leu Ser Ala Leu Val Gly Phe Ile Ile Leu Ser
 65 70 75 80

30

Val Lys Gln Ala Thr Leu Asn Pro Ala Ser Leu Gln Cys Glu Leu Asp
 85 90 95

35

Lys Asn Asn Ile Pro Thr Arg Ser Tyr Val Ser Tyr Phe Tyr His Asp
 100 105 110

Ser Leu Tyr Thr Thr Asp Cys Tyr Thr Ala Lys Ala Ser Leu Ala Gly
 115 120 125

40

Xaa Leu Ser Leu Met Leu Ile Cys Thr Leu Leu Glu Phe Cys Leu Ala
 130 135 140

Val Leu Thr Ala Val Leu Arg Trp Lys Gln Ala Tyr Ser Asp Phe Pro
 145 150 155 160

45

Gly Ser Val Leu Phe Leu Pro His Ser Tyr Ile Gly Asn Ser Gly Met
 165 170 175

Ser Ser Lys Met Thr His Asp Cys Gly Tyr Glu Glu Leu Leu Thr Ser
 180 185 190

50

55

(2) INFORMATION FOR SEQ ID NO: 471:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 234 amino acids

(B) TYPE: amino acid

60

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 471:

5 Met Arg Lys Thr Arg Leu Trp Gly Leu Leu Trp Met Leu Phe Val Ser
 1 5 10 15
 Glu Leu Arg Ala Ala Thr Lys Leu Thr Glu Glu Lys Tyr Glu Leu Lys
 20 25 30
 10 Glu Gly Gln Thr Leu Asp Val Lys Cys Asp Tyr Thr Leu Glu Lys Phe
 35 40 45
 Ala Ser Ser Gln Lys Ala Trp Gln Ile Ile Arg Asp Gly Glu Met Pro
 50 55 60
 15 Lys Thr Leu Ala Cys Thr Glu Arg Pro Ser Lys Asn Ser His Pro Val
 65 70 75 80
 20 Gln Val Gly Arg Ile Ile Leu Glu Asp Tyr His Asp His Gly Leu Leu
 85 90 95
 Arg Val Arg Met Val Asn Leu Gln Val Glu Asp Ser Gly Leu Tyr Gln
 100 105 110
 25 Cys Val Ile Tyr Gln Pro Pro Lys Glu Pro His Met Leu Phe Asp Arg
 115 120 125
 Ile Arg Leu Val Val Thr Lys Gly Phe Ser Gly Thr Pro Gly Ser Asn
 130 135 140
 30 Glu Asn Ser Thr Gln Asn Val Tyr Lys Ile Pro Pro Thr Thr Thr Lys
 145 150 155 160
 35 Ala Leu Cys Pro Leu Tyr Thr Ser Pro Arg Thr Val Thr Gln Ala Pro
 165 170 175
 Pro Lys Ser Thr Ala Asp Val Ser Thr Pro Asp Ser Glu Ile Asn Leu
 180 185 190
 40 Thr Asn Val Thr Asp Ile Ile Arg Val Pro Val Phe Asn Ile Val Ile
 195 200 205
 Leu Leu Ala Gly Gly Phe Leu Ser Lys Ser Leu Val Phe Ser Val Leu
 210 215 220
 45 Phe Ala Val Thr Leu Arg Ser Phe Val Pro
 225 230

50

(2) INFORMATION FOR SEQ ID NO: 472:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 105 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 472:

60 Met Leu His Ile Leu Pro Leu Lys Ser Tyr Asp Phe Pro His Phe Ser
 1 5 10 15

20

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 473:

35

(2) INFORMATION FOR SEQ ID NO: 474:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 474:

50

55

60

Lys Lys His Val Gly Arg Ser Lys Ala Gln Val Ala Lys Glu Ser Val
 65 70 75 80
 5 Leu Gln Phe Tyr Pro Lys Ala Asn Ile Val Ala Tyr His Asp Ser Ile
 85 90 95
 Met Asn Pro Asp Tyr Asn Val Glu Phe Phe Arg Gln Phe Ile Leu Val
 100 105 110
 10 Met Asn Ala Leu Asp Asn Arg Ala Ala Arg Asn His Val Asn Arg Met
 115 120 125
 Cys Leu Ala Ala Asp Val Pro Leu Ile Glu Ser Gly Thr Ala Gly Tyr
 130 135 140
 15 Leu Gly Gln Val Thr Thr Ile Lys Lys Gly Val Thr Glu Cys Tyr Glu
 145 150 155 160
 Cys His Pro Lys Pro Thr Gln Arg Thr Phe Pro Gly Cys Thr Ile Arg
 165 170 175
 20 Asn Thr Pro Ser Glu Pro Ile His Cys Ile Val Trp Ala Lys Tyr Leu
 180 185 190
 25 Phe Asn Gln Leu Phe Gly Glu Glu Asp Ala Asp Gln Glu Val Ser Pro
 195 200 205
 Asp Arg Ala Asp Pro Glu Ala Ala Trp Glu Pro Thr Glu Ala Glu Ala
 210 215 220
 30 Arg Ala Arg Ala Ser Asn Glu Asp Gly Asp Ile Lys Arg Ile Ser Thr
 225 230 235 240
 Lys Glu Trp Ala Lys Ser Thr Gly Tyr Asp Pro Val Lys Leu Phe Thr
 245 250 255
 35 Lys Leu Phe Lys Asp Asp Ile Arg Tyr Leu Leu Thr Met Asp Lys Leu
 260 265 270
 Trp Arg Lys Arg Lys Pro Pro Val Pro Leu Asp Trp Ala Glu Val Gln
 275 280 285
 Ser Gln Gly Glu Glu Thr Asn Ala Ser Asp Gln Gln Asn Glu Pro Gln
 290 295 300
 45 Leu Gly Leu Lys Asp Gln Gln Val Leu Asp Val Lys Ser Tyr Ala Arg
 305 310 315 320
 Leu Phe Ser Lys Ser Ile Glu Thr Leu Arg Val His Leu Ala Glu Lys
 325 330 335
 50 Gly Asp Gly Ala Glu Leu Ile Trp Asp Lys Asp Asp Pro Ser Ala Met
 340 345 350
 Asp Phe Val Thr Ser Ala Ala Asn Leu Arg Met His Ile Phe Ser Met
 355 360 365
 55 Asn Met Lys Ser Arg Phe Asp Ile Lys Ser Met Ala Gly Asn Ile Ile
 370 375 380
 60

640

Pro Ala Ile Ala Thr Thr Asn Ala Val Ile Ala Gly Leu Ile Val Leu
 385 390 395 400
 5 Glu Gly Leu Lys Ile Leu Ser Gly Lys Ile Asp Gln Cys Arg Thr Ile
 405 410 415
 Phe Leu Asn Lys Gln Pro Asn Pro Arg Lys Lys Leu Leu Val Pro Cys
 420 425 430
 10 Ala Leu Asp Pro Pro Asn Pro Asn Cys Tyr Val Cys Ala Ser Lys Pro
 435 440 445
 Glu Val Thr Val Arg Leu Asn Val His Lys Val Thr Val Leu Thr Leu
 450 455 460
 15 Gln Asp Lys Ile Val Lys Glu Lys Phe Ala Met Val Ala Pro Asp Val
 465 470 475 480
 Gln Ile Glu Asp Gly Lys Gly Thr Ile Leu Ile Ser Ser Glu Glu Gly
 485 490 495
 20 Glu Thr Glu Ala Asn Asn His Lys Lys Leu Ser Glu Phe Gly Ile Arg
 500 505 510
 25 Asn Gly Ser Arg Leu Gln Ala Asp Asp Phe Leu Gln Asp Tyr Thr Leu
 515 520 525
 Leu Ile Asn Ile Leu His Ser Glu Asp Leu Gly Lys Asp Val Glu Phe
 530 535 540
 30 Glu Val Val Gly Asp Ala Pro Glu Lys Val Gly Xaa Lys Gln Ala Glu
 545 550 555 560
 35 Asp Ala Ala Lys Ser Ile Thr Asn Gly Gln Xaa
 565 570

40 (2) INFORMATION FOR SEQ ID NO: 475:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 312 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 475:

Met Gln Val Val Thr Cys Leu Thr Arg Asp Ser Tyr Leu Thr His Cys
 1 5 10 15
 50 Phe Leu Gln His Leu Met Val Val Leu Ser Ser Leu Glu Arg Thr Pro
 20 25 30
 Ser Pro Glu Pro Val Asp Lys Asp Phe Tyr Ser Glu Phe Gly Asn Lys
 35 40 45
 55 Thr Thr Gly Lys Met Glu Asn Tyr Glu Leu Ile His Ser Ser Arg Val
 50 55 60
 60 Lys Phe Thr Tyr Pro Ser Glu Glu Glu Ile Gly Asp Leu Thr Phe Thr
 65 70 75 80

Val Ala Gln Lys Met Ala Glu Pro Glu Lys Ala Pro Ala Leu Ser Ile
 85 90 95
 5 Leu Leu Tyr Val Gln Ala Phe Gln Val Gly Met Pro Pro Pro Gly Cys
 100 105 110
 Cys Arg Gly Pro Leu Arg Pro Lys Thr Leu Leu Leu Thr Ser Ser Glu
 115 120 125
 10 Ile Phe Leu Leu Asp Glu Asp Cys Val His Tyr Pro Leu Pro Glu Phe
 130 135 140
 Ala Lys Glu Pro Pro Gln Arg Asp Arg Tyr Arg Leu Asp Asp Gly Arg
 15 145 150 155 160
 Arg Val Arg Asp Leu Asp Arg Val Leu Met Gly Tyr Gln Thr Tyr Pro
 165 170 175
 20 Gln Pro Ser Pro Ser Ser Ser Met Thr Cys Lys Val Met Thr Ser Trp
 180 185 190
 Ala Val Ser Pro Trp Thr Thr Leu Gly Arg Cys Gln Val Ala Arg Leu
 25 195 200 205
 Glu Pro Ala Arg Ala Val Lys Ser Ser Gly Arg Cys Leu Ser Pro Val
 210 215 220
 30 Leu Arg Ala Glu Arg Ser Ser Ser Arg Cys Trp Leu Ala Ser Gly Arg
 225 230 235 240
 Pro Cys Val Ala Val Ser Cys Leu Ser Ser Ser Pro Ala Ser Pro Gly
 245 250 255
 35 His Ser Gln Pro Val Val Ser Ser Leu Thr Pro Thr Gly Ala Gly Gln
 260 265 270
 Gln Ala Phe Val Phe Ser Lys Asn Val Leu Ser Ser Leu Trp Tyr Leu
 40 275 280 285
 Asn Leu Thr Val Leu Ala Glu Asn Val Asn Met Cys Val Cys Cys Val
 290 295 300
 45 Asn Ser Phe Ser Cys Trp Glu Xaa
 305 310

50 (2) INFORMATION FOR SEQ ID NO: 476:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 329 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 476:

Met Ala Gln His His Leu Trp Ile Leu Leu Leu Cys Leu Gln Thr Trp
 1 5 10 15
 60 Pro Glu Ala Ala Gly Lys Asp Ser Glu Ile Phe Thr Val Asn Gly Ile

20 25 30
 Leu Gly Glu Ser Val Thr Phe Pro Val Asn Ile Gln Glu Pro Arg Gln
 35 40 45
 5 Val Lys Ile Ile Ala Trp Thr Ser Lys Thr Ser Val Ala Tyr Val Thr
 50 55 60
 10 Pro Gly Asp Ser Glu Thr Ala Pro Val Val Thr Val Thr His Arg Asn
 65 70 75 80
 Tyr Tyr Glu Arg Ile His Ala Leu Gly Pro Asn Tyr Asn Leu Val Ile
 85 90 95
 15 Ser Asp Leu Arg Met Glu Asp Ala Gly Asp Tyr Lys Ala Asp Ile Asn
 100 105 110
 Thr Gln Ala Asp Pro Tyr Thr Thr Thr Lys Arg Tyr Asn Leu Gln Ile
 115 120 125
 20 Tyr Arg Arg Leu Gly Lys Pro Lys Ile Thr Gln Ser Leu Met Ala Ser
 130 135 140
 25 Val Asn Ser Thr Cys Asn Val Thr Leu Thr Cys Ser Val Glu Lys Glu
 145 150 155 160
 Glu Lys Asn Val Thr Tyr Asn Trp Ser Pro Leu Gly Glu Glu Gly Asn
 165 170 175
 30 Val Leu Gln Ile Phe Gln Thr Pro Glu Asp Gln Glu Leu Thr Tyr Thr
 180 185 190
 Cys Thr Ala Gln Asn Pro Val Ser Asn Asn Ser Asp Ser Ile Ser Ala
 195 200 205
 35 Arg Gln Leu Cys Ala Asp Ile Ala Met Gly Phe Arg Thr His His Thr
 210 215 220
 Gly Leu Leu Ser Val Leu Ala Met Phe Phe Leu Leu Val Leu Ile Leu
 225 230 235 240
 Ser Ser Val Phe Leu Phe Arg Leu Phe Lys Arg Arg Gln Asp Ala Ala
 245 250 255
 45 Ser Lys Lys Thr Ile Tyr Thr Tyr Ile Met Ala Ser Arg Asn Thr Gln
 260 265 270
 Pro Ala Glu Ser Arg Ile Tyr Asp Glu Ile Leu Gln Ser Lys Val Leu
 275 280 285
 50 Pro Ser Lys Glu Glu Pro Val Asn Thr Val Tyr Ser Glu Val Gln Phe
 290 295 300
 55 Ala Asp Lys Met Gly Lys Ala Ser Thr Gln Asp Ser Lys Pro Pro Gly
 305 310 315 320
 Thr Ser Ser Tyr Glu Ile Val Ile Xaa
 325
 60

(2) INFORMATION FOR SEQ ID NO: 477:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 178 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 477:

10 Met Lys Leu Gln Cys Val Ser Leu Trp Leu Leu Gly Thr Ile Leu Ile
 1 5 10 15
 Leu Cys Ser Val Asp Asn His Gly Leu Arg Arg Cys Leu Ile Ser Thr
 20 25 30
 15 Asp Met His His Ile Glu Glu Ser Phe Gln Glu Ile Lys Arg Ala Ile
 35 40 45
 Gln Ala Lys Asp Thr Phe Pro Asn Val Thr Ile Leu Ser Thr Leu Glu
 50 55 60
 20 Thr Leu Gln Ile Ile Lys Pro Leu Asp Val Cys Cys Val Thr Lys Asn
 65 70 75 80
 25 Leu Leu Ala Phe Tyr Val Asp Arg Val Phe Lys Asp His Gln Glu Pro
 85 90 95
 Asn Pro Lys Ile Leu Arg Lys Ile Ser Ser Ile Ala Asn Ser Phe Leu
 100 105 110
 30 Tyr Met Gln Lys Thr Leu Arg Gln Cys Gln Glu Gln Arg Gln Cys His
 115 120 125
 Cys Arg Gln Glu Ala Thr Asn Ala Thr Arg Val Ile His Asp Asn Tyr
 130 135 140
 35 Asp Gln Leu Glu Val His Ala Ala Ala Ile Lys Ser Leu Gly Glu Leu
 145 150 155 160
 40 Asp Val Phe Leu Ala Trp Ile Asn Lys Asn His Glu Val Met Ser Ser
 165 170 175
 Ala Xaa

45

(2) INFORMATION FOR SEQ ID NO: 478:

- 50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 52 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 478:

55 Asp Thr Ala Ile Arg Val Ala Leu Ala Val Ala Val Leu Lys Thr Val
 1 5 10 15
 60 Ile Leu Gly Leu Leu Cys Leu Leu Leu Cys Gly Gly Gly Glu Gly Lys
 20 25 30

Val Ala Gly Arg Gln Ala Val Thr Ser Asp Gln Gln Ser Val Gly Arg
 35 40 45

5 Arg Asp Val Tyr
 50

10 (2) INFORMATION FOR SEQ ID NO: 479:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 62 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 479:

Met Gln Lys Lys Asn Ser Leu Phe Phe Phe Phe Ala Phe Tyr Tyr Glu
 1 5 10 15

20 Asn Lys Thr Asn Ala Pro Gly Glu Gly Ser Met Ile Thr Arg Asn Ile
 20 25 30

25 Lys Glu Tyr Phe Leu Pro Phe Leu Phe Cys Cys Val Glu Ala Ser Ile
 35 40 45

Ala Ile Asn Lys Leu Asn Tyr Leu His Trp Thr His Phe Gln
 50 55 60

30

(2) INFORMATION FOR SEQ ID NO: 480:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 480:

40 Met Pro Gly Leu Ser Leu Ile Leu Thr Val Thr Leu Leu Ala Val Ser
 1 5 10 15

45 Asp Ser Ala Ala Thr Cys Ile Val Ala Lys Gly
 20 25

(2) INFORMATION FOR SEQ ID NO: 481:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 339 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 481:

55

Met Ser Gly Pro Asp Val Glu Thr Pro Ser Ala Ile Gln Ile Cys Arg
 1 5 10 15

60 Ile Met Arg Pro Asp Asp Ala Asn Val Ala Gly Asn Val His Gly Gly
 20 25 30

Thr Ile Leu Lys Met Ile Glu Glu Ala Gly Ala Ile Ile Ser Thr Arg
 35 40 45
 5 His Cys Asn Ser Gln Asn Gly Glu Arg Cys Val Ala Ala Leu Ala Arg
 50 55 60
 Val Glu Arg Thr Asp Phe Leu Ser Pro Met Cys Ile Gly Glu Val Ala
 65 70 75 80
 10 His Val Ser Ala Glu Ile Thr Tyr Thr Ser Lys His Ser Val Glu Val
 85 90 95
 Gln Val Asn Val Met Ser Glu Asn Ile Leu Thr Gly Ala Lys Lys Leu
 100 105 110
 15 Thr Asn Lys Ala Thr Leu Trp Tyr Val Pro Leu Ser Leu Lys Asn Val
 115 120 125
 20 Asp Lys Val Leu Glu Val Pro Pro Val Val Tyr Ser Arg Xaa Glu Gln
 130 135 140
 Glu Glu Glu Gly Arg Lys Arg Tyr Glu Ala Gln Lys Leu Glu Arg Met
 145 150 155 160
 25 Glu Thr Lys Trp Arg Asn Gly Asp Ile Val Gln Pro Val Leu Asn Pro
 165 170 175
 30 Glu Pro Asn Thr Val Ser Tyr Ser Gln Ser Ser Leu Ile His Leu Val
 180 185 190
 Gly Pro Ser Asp Cys Thr Leu His Gly Phe Val His Gly Gly Val Thr
 195 200 205
 35 Met Lys Leu Met Asp Glu Val Ala Gly Ile Val Ala Ala Arg His Cys
 210 215 220
 Lys Thr Asn Ile Val Thr Ala Ser Val Asp Ala Ile Asn Phe His Asp
 225 230 235 240
 40 Lys Ile Arg Lys Gly Cys Val Ile Thr Ile Ser Gly Arg Met Thr Phe
 245 250 255
 45 Thr Ser Asn Lys Ser Met Glu Ile Glu Val Leu Val Asp Ala Asp Pro
 260 265 270
 Val Val Asp Ser Ser Gln Lys Arg Tyr Arg Ala Ala Ser Ala Phe Phe
 275 280 285
 50 Thr Tyr Val Ser Leu Ser Gln Glu Gly Arg Ser Leu Pro Val Pro Gln
 290 295 300
 Leu Val Pro Glu Thr Glu Asp Glu Lys Lys Arg Phe Glu Glu Gly Lys
 305 310 315 320
 55 Gly Arg Tyr Leu Gln Met Lys Ala Lys Xaa Gln Gly His Ala Xaa Xaa
 325 330 335
 60 Gln Pro Xaa

(2) INFORMATION FOR SEQ ID NO: 482:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 482:

Met Leu Asn Ser Asn Ile Asn Asp Leu Leu Met Val Thr Tyr Leu Ala
 1 5 10 15

15 Asn Leu Thr Gln Ser Gln Ile Ala Leu Asn Glu Lys Leu Val Asn Leu
 20 25 30

20

(2) INFORMATION FOR SEQ ID NO: 483:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 483:

Met Arg Glu Thr Ser Ile Arg Val Leu Leu Met Leu Pro Ala Leu Glu
 1 5 10 15

35 Ser Thr Ser Gly Leu Ser Ala Phe Met Gly Leu Gly Thr Arg Ile Gly
 20 25 30

Cys Phe Lys Thr Ile Thr Cys Trp Pro Thr Ser Leu Thr Gln Arg Xaa
 35 40 45

40

45 (2) INFORMATION FOR SEQ ID NO: 484:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 484:

Met Tyr Met Tyr Ser Leu Asn Val Phe Leu Ser Phe Ile Phe Leu Ala
 1 5 10 15

55

Leu Val Phe Lys Cys Val His Val Cys Gln Gly Ala Asn Ala Phe Leu
 20 25 30

60

Phe Leu Lys Leu Val Phe
 35

(2) INFORMATION FOR SEQ ID NO: 485:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 61 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 485:

Met Gly Leu Arg Leu Ile Cys Leu Glu Leu Thr Met Val Lys Ala Leu
 1 5 10 15

15

Val Cys Glu Met Phe Leu Phe Phe Leu Met Thr Gln Lys Leu Ile Trp
 20 25 30

20

Gln Glu Cys Thr Glu Lys Phe Ala Lys Leu Leu Val Gln Leu Ile Ser
 35 40 45

Leu Val Phe Ala Trp Glu Phe Phe Ser Glu Asp Thr Pro
 50 55 60

25

(2) INFORMATION FOR SEQ ID NO: 486:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 346 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 486:

Met Leu Ala Ala Arg Leu Val Cys Leu Arg Thr Leu Pro Ser Arg Val
 1 5 10 15

Phe His Pro Ala Phe Thr Lys Ala Ser Pro Val Val Lys Asn Ser Ile
 20 25 30

40

Thr Lys Asn Gln Trp Leu Leu Thr Pro Ser Arg Glu Tyr Ala Thr Lys
 35 40 45

Thr Arg Ile Gly Ile Arg Arg Gly Arg Thr Gly Gln Glu Leu Lys Glu
 50 55 60

45

Ala Ala Leu Glu Pro Ser Met Glu Lys Ile Phe Lys Ile Asp Gln Met
 65 70 75 80

50

Gly Arg Trp Phe Val Ala Gly Gly Ala Ala Val Gly Leu Gly Ala Leu
 85 90 95

Cys Tyr Tyr Gly Leu Gly Leu Ser Asn Glu Ile Gly Ala Ile Glu Lys
 100 105 110

55

Ala Val Ile Trp Pro Gln Tyr Val Lys Asp Arg Ile His Ser Thr Tyr
 115 120 125

Met Tyr Leu Ala Gly Ser Ile Gly Leu Thr Ala Leu Ser Ala Ile Ala
 130 135 140

60

648

Ile Ser Arg Thr Pro Val Leu Met Asn Phe Met Met Arg Gly Ser Trp
 145 150 155 160
 5 Val Thr Ile Gly Val Thr Phe Ala Ala Met Val Gly Ala Gly Met Leu
 165 170 175
 Val Arg Ser Ile Pro Tyr Asp Gln Ser Pro Gly Pro Lys His Leu Ala
 180 185 190
 10 Trp Leu Leu His Ser Gly Val Met Gly Ala Val Val Ala Pro Leu Thr
 195 200 205
 Ile Leu Gly Gly Pro Leu Leu Ile Arg Ala Ala Trp Tyr Thr Ala Gly
 210 215 220
 15 Ile Val Gly Gly Leu Ser Thr Val Ala Met Cys Ala Pro Ser Glu Lys
 225 230 235 240
 Phe Leu Asn Met Gly Ala Pro Leu Gly Val Gly Leu Gly Leu Val Phe
 245 250 255
 20 Val Ser Ser Leu Gly Ser Met Phe Leu Pro Pro Thr Thr Val Ala Gly
 260 265 270
 25 Ala Thr Leu Tyr Ser Val Ala Met Tyr Gly Gly Leu Val Leu Phe Ser
 275 280 285
 Met Phe Leu Leu Tyr Asp Thr Gln Lys Val Ile Lys Arg Ala Glu Val
 290 295 300
 30 Ser Pro Met Tyr Gly Val Gln Lys Tyr Asp Pro Ile Asn Ser Met Leu
 305 310 315 320
 Ser Ile Tyr Met Asp Thr Leu Asn Ile Phe Met Arg Val Ala Thr Met
 325 330 335
 Leu Ala Thr Gly Gly Asn Arg Lys Lys Xaa
 340 345

40

(2) INFORMATION FOR SEQ ID NO: 487:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 237 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 487:

50

Met Glu Glu Val Leu Leu Leu Gly Leu Lys Asp Arg Glu Gly Tyr Thr
 1 5 10 15

Ser Phe Trp Asn Asp Cys Ile Ser Ser Gly Leu Arg Gly Cys Met Leu
 20 25 30

55

Ile Glu Leu Ala Leu Arg Gly Arg Leu Gln Leu Glu Ala Cys Gly Met
 35 40 45

60

Arg Arg Lys Ser Leu Leu Thr Arg Lys Val Ile Cys Lys Ser Asp Ala
 50 55 60

Pro Thr Gly Asp Val Leu Leu Asp Glu Ala Leu Lys His Val Lys Glu
 65 70 75 80
 5 Thr Gln Pro Pro Glu Thr Val Gln Asn Trp Ile Glu Leu Leu Ser Gly
 85 90 95
 Glu Thr Trp Asn Pro Leu Lys Leu His Tyr Gln Leu Arg Asn Val Arg
 100 105 110
 10 Glu Arg Leu Ala Lys Asn Leu Val Glu Lys Gly Val Leu Thr Thr Glu
 115 120 125
 Lys Gln Asn Phe Leu Leu Phe Asp Met Thr Thr His Pro Leu Thr Asn
 130 135 140
 Asn Asn Ile Lys Gln Arg Leu Ile Lys Lys Val Gln Glu Ala Val Leu
 145 150 155 160
 20 Asp Lys Trp Val Asn Asp Pro His Arg Met Asp Arg Arg Leu Leu Ala
 165 170 175
 Leu Ile Tyr Leu Ala His Ala Ser Asp Val Leu Glu Asn Ala Phe Ala
 180 185 190
 25 Pro Leu Leu Asp Glu Gln Tyr Asp Leu Ala Thr Lys Arg Val Arg Gln
 195 200 205
 Leu Leu Asp Leu Asp Pro Glu Val Glu Cys Leu Lys Ala Asn Thr Asn
 210 215 220
 Glu Val Leu Trp Ala Val Val Ala Ala Phe Thr Lys Xaa
 225 230 235
 35

(2) INFORMATION FOR SEQ ID NO: 488:

- 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 200 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 488:

45 Met Ala Gln Arg Met Val Trp Val Asp Leu Glu Met Thr Gly Leu Asp
 1 5 10 15
 Ile Glu Lys Asp Gln Ile Ile Glu Met Ala Cys Leu Ile Thr Asp Ser
 20 25 30
 50 Asp Leu Asn Ile Leu Ala Glu Gly Pro Asn Leu Ile Ile Lys Gln Pro
 35 40 45
 Asp Glu Leu Leu Asp Ser Met Ser Asp Trp Cys Lys Glu His His Gly
 50 55 60
 55 Lys Ser Gly Leu Thr Lys Ala Val Lys Glu Ser Thr Ile Thr Leu Gln
 65 70 75 80
 60 Gln Ala Glu Tyr Glu Phe Leu Ser Phe Val Arg Gln Gln Thr Pro Pro

85

90

95

Gly Leu Cys Pro Leu Ala Gly Asn Ser Val His Glu Asp Lys Lys Phe
100 105 110

5

Leu Asp Lys Tyr Met Pro Gln Phe Met Lys His Leu His Tyr Arg Ile
115 120 125

10

Ile Asp Val Ser Thr Val Lys Glu Leu Cys Arg Arg Trp Tyr Pro Glu
130 135 140

Glu Tyr Glu Phe Ala Pro Lys Lys Ala Ala Ser His Arg Ala Leu Asp
145 150 155 160

15

Asp Ile Ser Glu Ser Ile Lys Glu Leu Gln Phe Tyr Arg Asn Asn Ile
165 170 175

Phe Lys Lys Lys Ile Asp Glu Lys Lys Arg Lys Ile Ile Glu Asn Gly
180 185 190

20

Glu Asn Glu Lys Thr Val Ser Xaa
195 200

25

(2) INFORMATION FOR SEQ ID NO: 489:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 351 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 489:

35

Met Ala Thr Thr Ala Ala Pro Ala Gly Gly Ala Arg Asn Gly Ala Gly
1 5 10 15

Pro Glu Trp Gly Gly Phe Glu Glu Asn Ile Gln Gly Gly Gly Ser Ala
20 25 30

40

Val Ile Asp Met Glu Asn Met Asp Asp Thr Ser Gly Ser Ser Phe Glu
35 40 45

Asp Met Gly Glu Leu His Gln Arg Leu Arg Glu Glu Glu Val Asp Ala
50 55 60

45

Asp Ala Ala Asp Ala Ala Ala Ala Glu Glu Glu Asp Gly Glu Phe Leu
65 70 75 80

50

Gly Met Lys Gly Phe Lys Gly Gln Leu Ser Arg Gln Val Ala Asp Gln
85 90 95

Met Trp Gln Ala Gly Lys Arg Gln Ala Ser Arg Ala Phe Ser Leu Tyr
100 105 110

55

Ala Asn Ile Asp Ile Leu Arg Pro Tyr Phe Asp Val Glu Pro Ala Gln
115 120 125

Val Arg Thr Gly Leu Leu Glu Ser Met Ile Pro Ile Lys Met Val Asn
130 135 140

60

651

Phe Pro Gln Lys Ile Ala Gly Glu Leu Tyr Gly Pro Leu Met Leu Val
 145 150 155 160
 5 Phe Thr Leu Val Ala Ile Leu Leu His Gly Met Lys Thr Ser Asp Thr
 165 170 175
 Ile Ile Arg Glu Gly Thr Leu Met Gly Thr Ala Ile Gly Thr Cys Phe
 180 185 190
 10 Gly Tyr Trp Leu Gly Val Ser Ser Phe Ile Tyr Phe Leu Ala Tyr Leu
 195 200 205
 Cys Asn Ala Gln Ile Thr Met Leu Gln Met Leu Ala Leu Leu Gly Tyr
 210 215 220
 15 Gly Leu Phe Gly His Cys Ile Val Leu Phe Ile Thr Tyr Asn Ile His
 225 230 235 240
 Leu His Ala Leu Phe Tyr Leu Phe Trp Leu Leu Val Gly Gly Leu Ser
 245 250 255
 20 Thr Leu Arg Met Val Ala Val Leu Val Ser Arg Thr Val Gly Pro Thr
 260 265 270
 25 Gln Arg Leu Leu Cys Gly Thr Leu Ala Ala Leu His Met Leu Phe
 275 280 285
 Leu Leu Tyr Leu His Phe Ala Tyr His Lys Val Val Glu Gly Ile Leu
 290 295 300
 30 Asp Thr Leu Glu Gly Pro Asn Ile Pro Pro Ile Gln Arg Val Pro Arg
 305 310 315 320
 35 Asp Ile Pro Ala Met Leu Pro Ala Ala Arg Leu Pro Thr Thr Val Leu
 325 330 335
 Asn Ala Thr Ala Lys Ala Val Ala Val Thr Leu Gln Ser His Xaa
 340 345 350
 40

(2) INFORMATION FOR SEQ ID NO: 490:

(i) SEQUENCE CHARACTERISTICS:

45 (A) LENGTH: 265 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 490:

50 Met Arg Gly Ser Arg Gly Gly Trp Ala Gly Glu Met Ala Ala Ser Gly
 1 5 10 15
 Glu Ser Gly Thr Ser Gly Gly Gly Gly Ser Thr Glu Glu Ala Phe Met
 20 25 30
 55 Thr Phe Tyr Ser Glu Val Lys Gln Ile Glu Lys Arg Asp Ser Val Leu
 35 40 45
 60 Thr Ser Lys Asn Gln Ile Glu Arg Leu Thr Arg Pro Gly Ser Ser Tyr
 50 55 60

Phe Asn Leu Asn Pro Phe Glu Val Leu Gln Ile Asp Pro Glu Val Thr
 65 70 75 80
 5 Asp Glu Glu Ile Lys Lys Arg Phe Arg Gln Leu Ser Ile Leu Val His
 85 90 95
 Pro Asp Lys Asn Gln Asp Asp Ala Asp Arg Ala Gln Lys Ala Phe Glu
 100 105 110
 10 Ala Val Asp Lys Ala Tyr Lys Leu Leu Leu Asp Gln Glu Gln Lys Lys
 115 120 125
 Arg Ala Leu Asp Val Ile Gln Ala Gly Lys Glu Tyr Val Glu His Thr
 130 135 140
 15 Val Lys Glu Arg Lys Lys Gln Leu Lys Lys Glu Gly Lys Pro Thr Ile
 145 150 155 160
 20 Val Glu Glu Asp Asp Pro Glu Leu Phe Lys Gln Ala Val Tyr Lys Gln
 165 170 175
 Thr Met Lys Leu Phe Ala Glu Leu Glu Ile Lys Arg Lys Glu Arg Glu
 180 185 190
 25 Ala Lys Glu Met His Glu Arg Lys Arg Gln Arg Glu Glu Glu Ile Glu
 195 200 205
 Ala Gln Glu Lys Ala Lys Arg Glu Arg Glu Trp Gln Lys Asn Phe Glu
 210 215 220
 30 Glu Ser Arg Asp Gly Arg Val Asp Ser Trp Arg Asn Phe Gln Ala Asn
 225 230 235 240
 35 Thr Lys Gly Lys Lys Glu Lys Lys Asn Arg Thr Phe Leu Arg Pro Pro
 245 250 255
 Lys Val Lys Met Glu Gln Arg Glu Xaa
 260 265
 40

(2) INFORMATION FOR SEQ ID NO: 491:

- 45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 491:

Asp Ser Met Pro Thr Cys Pro Leu Xaa Ala Ser Leu Glu Cys Gly Pro
 1 5 10 15
 Leu Leu Pro Val Arg Leu Cys Cys Leu
 20 25
 55

60 (2) INFORMATION FOR SEQ ID NO: 492:

653

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 159 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 492:

Met Asn Glu Tyr Arg Val Pro Glu Leu Asn Val Gln Asn Gly Val Leu
 1 5 10 15

10 Lys Ser Leu Ser Phe Leu Phe Glu Tyr Ile Gly Glu Met Gly Lys Asp
 20 25 30

Tyr Ile Tyr Ala Val Thr Pro Leu Leu Glu Asp Ala Leu Met Asp Arg
 35 40 45

15 Asp Leu Val His Arg Gln Thr Ala Ser Ala Val Val Gln His Met Ser
 50 55 60

20 Leu Gly Val Tyr Gly Phe Gly Cys Glu Asp Ser Leu Asn His Leu Leu
 65 70 75 80

Asn Tyr Val Trp Pro Asn Val Phe Glu Thr Ser Pro His Val Ile Gln
 85 90 95

25 Ala Val Met Gly Ala Leu Glu Gly Leu Arg Val Ala Ile Gly Pro Cys
 100 105 110

Arg Met Leu Gln Tyr Cys Leu Gln Gly Leu Phe His Pro Ala Arg Lys
 115 120 125

30 Val Arg Asp Val Tyr Trp Lys Ile Tyr Asn Ser Ile Tyr Ile Gly Ser
 130 135 140

35 Gln Asp Ala Leu Ile Ala His Tyr Pro Arg Ile Tyr Gln Arg Xaa
 145 150 155

40 (2) INFORMATION FOR SEQ ID NO: 493:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 279 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 493:

Met Ile Ser Asp Asn Ser Ala Glu Asn Ile Ala Leu Val Thr Ser Met
 1 5 10 15

50 Tyr Asp Gly Leu Leu Gln Ala Gly Ala Arg Leu Cys Pro Thr Val Gln
 20 25 30

Leu Glu Asp Ile Arg Asn Leu Gln Asp Leu Thr Pro Leu Lys Leu Ala
 35 40 45

55 Ala Lys Glu Gly Lys Ile Glu Ile Phe Arg His Ile Leu Gln Arg Glu
 50 55 60

60 Phe Ser Gly Leu Ser His Leu Ser Arg Lys Phe Thr Glu Trp Cys Tyr
 65 70 75 80

654

Gly Pro Val Arg Val Ser Leu Tyr Asp Leu Ala Ser Val Asp Ser Cys
 85 90 95
 5 Glu Glu Asn Ser Val Leu Glu Ile Ile Ala Phe His Cys Lys Ser Pro
 100 105 110
 His Arg His Arg Met Val Val Leu Glu Pro Leu Asn Lys Leu Leu Gln
 115 120 125
 10 Ala Lys Trp Asp Leu Leu Ile Pro Lys Phe Phe Leu Asn Phe Leu Cys
 130 135 140
 Asn Leu Ile Tyr Met Phe Ile Phe Thr Ala Val Ala Tyr His Gln Pro
 15 145 150 155 160
 Thr Leu Lys Lys Gln Ala Ala Pro His Leu Lys Ala Glu Val Gly Asn
 165 170 175
 20 Ser Met Leu Leu Thr Gly His Ile Leu Ile Leu Leu Gly Gly Ile Tyr
 180 185 190
 Leu Leu Val Gly Gln Leu Trp Tyr Phe Trp Arg Arg His Val Phe Ile
 195 200 205
 25 Trp Ile Ser Phe Ile Asp Ser Tyr Phe Glu Ile Leu Phe Leu Phe Gln
 210 215 220
 Ala Leu Leu Thr Val Val Ser Gln Val Leu Cys Phe Leu Xaa Ile Glu
 30 225 230 235 240
 Trp Tyr Leu Pro Leu Leu Val Ser Ala Leu Val Leu Gly Trp Leu Asn
 245 250 255
 35 Leu Leu Tyr Tyr Thr Arg Gly Phe Gln His Thr Gly Ile Tyr Ser Val
 260 265 270
 Met Ile Gln Lys Pro Trp Xaa
 275
 40

(2) INFORMATION FOR SEQ ID NO: 494:

45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 193 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 494:
 Met Ile Arg Cys Gly Leu Ala Cys Glu Arg Cys Arg Trp Ile Leu Pro
 1 5 10 15
 Leu Leu Leu Leu Ser Ala Ile Ala Phe Asp Ile Ile Ala Leu Ala Gly
 55 20 25 30
 Arg Gly Trp Leu Gln Ser Ser Asp His Gly Gln Thr Ser Ser Leu Trp
 35 40 45
 60 Trp Lys Cys Ser Gln Glu Gly Gly Gly Ser Gly Ser Tyr Glu Glu Gly

655

30

(2) INFORMATION FOR SEQ ID NO: 495:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 205 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 495:

```

40      Met Ala Ala Gly Asp Gln Val Phe Ser Gly Ala Gly His Val Xaa Glu
          1                      5                      10                      15

      His Val Ala Gly Gly Arg His Ala Trp Leu Leu Thr Trp Gln Ser Ala
                                20                      25                      30

45      Cys Pro Ala Asn Arg Leu Ser Leu Val Pro Leu Val Pro Ser Ala Ser
          35                      40                      45

      Met Thr Arg Leu Met Arg Xaa Arg Thr Ala Ser Gly Ser Ser Val Ile
          50                      55                      60

      Leu Trp Met Ala Pro Ala Ala Ala Pro Thr Pro Ala Arg Ala Pro Glu
          65                      70                      75                      80

55      Ala Ala Pro Thr Pro Ala Arg Ala Pro Ala Ala Ala Arg Thr Pro Ala
                                85                      90                      95

      Arg Gly Pro Thr Trp Thr Ser Pro Pro Thr Arg Val Leu Leu Gly Thr
          100                      105                      110

```

60

656

Xaa Pro Gly Pro Ser Pro Trp Arg Ser Pro Ala Arg Arg Pro Ala Gln
115 120 125

5 Leu Pro Pro Pro Asp Ser Asp Leu Cys Ser Gly Pro Leu Leu Pro Gly
130 135 140

Pro Phe Ser Pro Pro Ala Cys His Thr Ala Pro Asn Ser Val Leu Ile
145 150 155 160.

10 Gln Ser Leu Phe Cys Lys Ser Glu Leu Trp Trp Arg Gln Met Arg Ser
165 170 175

Ile Thr Trp Val Pro Ser Pro Lys Ala Gly Trp Arg Trp Thr Lys Gly
180 185 190

15 Arg Lys Gln Ala Ser Pro His Arg Ile Leu Phe His Xaa
195 200 205

20

(2) INFORMATION FOR SEQ ID NO: 496:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 147 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 496:

30 Met Ala Leu Thr Leu Leu Pro Ser Val Ser Arg Leu Pro Gly Glu Arg
1 5 10 15

Met Ala Ala Ser Gly Leu Pro Tyr Val Leu His His Lys Ser Ser Leu
20 25 30

35 Met Lys Val Ile Phe Phe Pro Tyr Pro Val Leu Pro Leu Pro Ala Pro
35 40 45

40 Asn Gly Thr Trp Val Pro Arg Leu Val Leu Gly Leu Gly Ser Gly Asp
50 55 60

Gln Val His Tyr Leu Pro Ile Ser Ser Ser Ile Val Asn Tyr Gly Thr
65 70 75 80

45 Ser Val Ser Gly Lys Ser Trp Val Phe Leu Val Tyr Pro Leu His Pro
85 90 95

Thr Pro Thr Trp Ser Thr Arg Cys Phe Gln Val Trp Asp Leu Leu Ser
100 105 110

50 Val Glu Leu Pro Asp Lys Gly Glu Gly Asn Thr Arg Arg Ala Ser Gly
115 120 125

55 Val Pro Gly Leu Ser Gln Leu Pro Thr Ser His Lys Pro Ile Lys Gln
130 135 140

Glu Tyr Xaa
145

60

(2) INFORMATION FOR SEQ ID NO: 497:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 497:

5 Met Val Trp Val Leu Trp Ser Ala Pro Ser Leu Ala Pro Pro Trp Val
 10 1 5 10 15
 Gly Pro Cys Trp Pro Ser Thr Gly Asn Cys Cys Leu Cys Glu Val Gly
 20 25 30
 15 Ala Ala Leu Pro Pro Arg Gly Pro Ser Leu Ser Asp Cys Leu Gly Leu
 35 40 45
 Pro Pro Trp Thr Pro Trp Gly Pro Ala Trp Thr Leu Ala Gln Ser Xaa
 20 50 55 60

25

(2) INFORMATION FOR SEQ ID NO: 498:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 94 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 498:

30 Met Ser Thr Gly Ala Leu Asn Thr Ser Pro Pro Ala Ser Asn Arg Leu
 35 1 5 10 15
 Glu Ser Thr Leu Asn Glu Tyr Leu Ile Gln Pro Gln Leu His Cys Ser
 20 25 30
 40 Ser Val Gln Arg Leu Thr Leu Lys Trp Gly Cys Ser Ser Leu Gln Arg
 35 40 45
 Asp Gly Gln Ala Val Pro Trp Gly Leu Trp Gln Arg Ala Tyr Pro Ser
 45 50 55 60
 Leu Leu Pro Thr Leu Pro Ser Asp Leu Leu Arg Pro His Ala Val Thr
 65 70 75 80
 50 Pro Ser Val Ser Val Ser Val His Thr Cys Glu Ser Ser Xaa
 85 90

55

(2) INFORMATION FOR SEQ ID NO: 499:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 499:

60

Met Phe Leu Ile Phe Val Tyr Phe Leu Lys Xaa Leu Phe Ser Ser Ser
 1 5 10 15

5 Leu Pro Phe Leu Trp Leu
 20

10 (2) INFORMATION FOR SEQ ID NO: 500:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 amino acids

(B) TYPE: amino acid

15 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 500:

Arg Gly Gly Leu Cys Pro Leu Leu Val Pro Gly Pro Leu Ala Arg Gln
 1 5 10 15

20 Glu Pro Ser Pro Ser Leu Gln Gly Cys Ser Glu Ser Pro Val Gly Met
 20 25 30

25 Asp

30 (2) INFORMATION FOR SEQ ID NO: 501:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 501:

Met Gln Phe Leu Leu Thr Ala Phe Leu Leu Val Pro Leu Leu Ala Leu
 1 5 10 15

40 Cys Asp Val Pro Ile Ser Leu Gly Phe Ser Pro Ser
 20 25

45 (2) INFORMATION FOR SEQ ID NO: 502:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

50 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 502:

Pro Gly Lys Pro Gln Ala Cys Pro Glu Leu Thr Ser Val Leu Pro
 1 5 10 15

55

(2) INFORMATION FOR SEQ ID NO: 503:

60 (i) SEQUENCE CHARACTERISTICS:

659

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 503:

Asn Lys Ser Leu Xaa Ser Cys Leu Phe Val Leu His Phe Val Leu His
 1 5 10 15

Cys Xaa Phe

(2) INFORMATION FOR SEQ ID NO: 504:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 504:

Met Glu Lys Thr His Arg Leu Arg Ile Arg Asn Pro Cys Leu Gln Phe
 1 5 10 15

Ser Ile Leu Asn Leu Phe Leu Leu Lys Met Ile Val Ser
 20 25

(2) INFORMATION FOR SEQ ID NO: 505:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 75 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 505:

Met Val Asp Ile Ser Lys Met His Met Ile Leu Tyr Asp Leu Gln Gln
 1 5 10 15

Asn Leu Ser Ser Ser His Arg Ala Leu Glu Lys Gln Ile Asp Thr Leu
 20 25 30

Ala Gly Lys Leu Asp Ala Leu Thr Glu Leu Leu Ser Thr Ala Leu Gly
 35 40 45

Pro Ser Ser Phe Gln Asn Pro Ala Ser Ser Pro Ser Ser Trp Thr His
 50 55 60

Glu Glu Glu Pro Gly Tyr Phe Pro Gln Tyr Xaa
 65 70 75

(2) INFORMATION FOR SEQ ID NO: 506:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 506:

Leu Pro Leu Ala Glu Leu Lys Asn Trp Val
1 5 10

5

(2) INFORMATION FOR SEQ ID NO: 507:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 207 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 507:

15

Met Leu Trp Phe Gly Gly Cys Ser Ala Val Asn Ala Thr Gly His Leu
1 5 10 15

20

Ser Asp Thr Leu Trp Leu Ile Pro Ile Thr Phe Leu Thr Ile Gly Tyr
20 25 30

Gly Asp Val Val Pro Gly Thr Met Trp Gly Lys Ile Val Cys Leu Cys
35 40 45

25

Thr Gly Val Met Gly Val Cys Cys Thr Ala Leu Leu Val Ala Val Val
50 55 60

30

Ala Arg Lys Leu Glu Phe Asn Lys Ala Glu Lys His Val His Asn Phe
65 70 75 80

Met Met Asp Ile Gln Tyr Thr Lys Glu Met Lys Glu Ser Ala Ala Arg
85 90 95

35

Val Leu Gln Glu Ala Trp Met Phe Tyr Lys His Thr Arg Arg Lys Glu
100 105 110

Ser His Ala Ala Arg Arg His Gln Arg Xaa Leu Leu Ala Ala Ile Asn
115 120 125

40

Ala Phe Arg Gln Val Arg Leu Lys His Arg Lys Leu Arg Glu Gln Val
130 135 140

45

Asn Ser Met Val Asp Ile Ser Lys Met His Met Ile Leu Tyr Asp Leu
145 150 155 160

Gln Gln Asn Leu Ser Ser Ser His Arg Ala Leu Glu Lys Gln Ile Asp
165 170 175

50

Thr Leu Ala Gly Lys Leu Asp Ala Leu Thr Glu Leu Leu Ser Thr Ala
180 185 190

Leu Gly Pro Arg Gln Leu Pro Glu Pro Ser Gln Gln Ser Lys Xaa
195 200 205

55

(2) INFORMATION FOR SEQ ID NO: 508:

60

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 508:

5 Met Trp Arg Cys Arg Gly Lys Leu Ser Phe Pro Leu Phe Ala Val Val
 1 5 10 15
 Ile Val Ser Cys Arg Lys Asp Gly Pro Asp Ala Ala Ala Pro Ala
 20 25 30
 10 Val Xaa Lys Lys
 35

15

(2) INFORMATION FOR SEQ ID NO: 509:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

20

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 509:

25 Met Ala Leu Val Ala Leu Phe Thr Gln Leu Met Arg Xaa Leu Gly Arg
 1 5 10 15
 Cys Pro Gln

30

(2) INFORMATION FOR SEQ ID NO: 510:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 amino acids

35

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 510:

40 Met Thr Phe Pro Phe Glu Lys Glu Asn Ser Cys Phe Gln Cys Leu Leu
 1 5 10 15
 Phe Asp Ser Trp Arg Glu Gln Thr Arg Thr Asn Ile Gln Pro Gln Arg
 20 25 30
 45

50

(2) INFORMATION FOR SEQ ID NO: 511:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 amino acids

55

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 511:

60 Met His Leu Leu Asp Phe Phe Arg Asp Leu Val Leu Leu Val Leu Leu
 1 5 10 15

Ala Leu Leu Asp Ser Phe Trp Leu Glu Val Gln Lys
 20 25

5

(2) INFORMATION FOR SEQ ID NO: 512:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 512:

15

Met Cys Leu Ile His Phe Ile Lys Ile Ile Leu Val Phe Ile Leu Lys
 1 5 10 15

Leu Trp Leu Tyr Ser Gln Lys Cys Pro Lys
 20 25

20

(2) INFORMATION FOR SEQ ID NO: 513:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 513:

30

Met Ile His Val His Glu Trp Asn Asp Gln Met Leu Met Val Tyr Ile
 1 5 10 15

35

Phe Leu Tyr Pro Val Ser Ile Thr Phe Leu Asn Leu Cys Ser Leu Thr
 20 25 30

Cys

40

(2) INFORMATION FOR SEQ ID NO: 514:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 514:

50

Leu Asn Glu Ser Tyr Val Ser Arg Ala Gly Gly Trp Phe Ser Met Phe
 1 5 10 15

Xaa Leu Ile Phe Phe Leu Leu Ala Leu Gly Ser Xaa Leu Cys Leu Leu
 20 25 30

55

Leu Cys Leu Pro Ser Phe Asn Lys Thr Arg Arg Lys Gln Lys Pro
 35 40 45

60

(2) INFORMATION FOR SEQ ID NO: 515:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 515:

5 Ser Ser Lys Thr Pro Leu Pro Ser Glu Arg Arg Trp Ile Ser Gly Ser
 10 1 5 10 15
 Ser Leu Met Ala Pro Arg Pro Trp Leu Leu Gly Ile Ala Leu Leu Gly
 20 25 30
 15 Leu Trp Ala Leu Glu Pro Ala Leu Gly His Trp
 35 40

20 (2) INFORMATION FOR SEQ ID NO: 516:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 516:

25 Leu Asn Trp
 1
 30

(2) INFORMATION FOR SEQ ID NO: 517:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 174 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 517:

35 Phe Ala Phe Cys Ala Glu Leu Met Ile Gln Asn Trp Thr Leu Gly Ala
 1 5 10 15
 45 Val Asp Ser Gln Met Asp Asp Met Asp Met Asp Leu Asp Lys Glu Phe
 20 25 30
 Leu Gln Asp Leu Lys Glu Leu Lys Val Leu Val Ala Asp Lys Asp Leu
 35 40 45
 50 Leu Asp Leu His Lys Ser Leu Val Cys Thr Ala Leu Arg Gly Lys Leu
 50 55 60
 Gly Val Phe Ser Glu Met Glu Ala Asn Phe Lys Asn Leu Ser Arg Gly
 55 65 70 75 80
 Leu Val Asn Val Ala Ala Lys Leu Thr His Asn Lys Asp Val Arg Asp
 85 90 95
 60 Leu Phe Val Asp Leu Val Glu Lys Phe Val Glu Pro Cys Arg Ser Asp
 100 105 110

His Trp Pro Leu Ser Asp Val Arg Phe Phe Leu Asn Gln Tyr Ser Ala
115 120 125

5 Ser Val His Ser Leu Asp Gly Phe Arg His Gln Ala Ser Gly Thr Ala
130 135 140

Thr Trp Ala Pro Ser Ala Ala Ala Ser Cys Ala Cys Ile Met Thr Glu
145 150 155 160

10 Val Pro Pro Asn Ala Pro Pro Thr Leu Thr Ile Lys Leu Leu
165 170

15

(2) INFORMATION FOR SEQ ID NO: 518:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 518:

25 Met Trp Lys Asn Leu Gly Ser Gly Ser Val Phe Val Thr Trp Phe Ser
1 5 10 15

Leu Val Met Ile Leu Ser Gly Ile Gly Pro Leu Gly Asp Ala Glu Asp
20 25 30

30 Ser Ile Ser Asp Val Ser His Arg Leu Arg Pro
35 40

35

(2) INFORMATION FOR SEQ ID NO: 519:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 519:

Phe Gln Phe Pro Leu Leu Thr Ile Ala Leu Gln Phe Leu
1 5 10

45

(2) INFORMATION FOR SEQ ID NO: 520:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 520:

55

Met His Tyr Val Ile Val Leu Ser Leu Phe Val Val Leu Glu Lys Lys
1 5 10 15

60

Asn Lys Met Gly Ser Asp Gly Cys Leu Arg Lys Asn Gly Ser
20 25 30

(2) INFORMATION FOR SEQ ID NO: 521:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 521:

Met Ser Arg Ser Ile Val Leu Arg Gly Ser Leu Phe Leu Phe Phe Ser
 1 5 10 15
 His Tyr Thr Leu Lys Leu Leu Ser Val Ile Lys Gln Thr Asn Arg Lys
 20 25 30
 Ile Val Trp Glu Lys Pro Cys Ile Arg Leu Phe Tyr Xaa Val Leu
 35 40 45

20

(2) INFORMATION FOR SEQ ID NO: 522:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 522:

Met Pro Leu Pro Val Leu Leu Cys Leu Thr Leu Pro Met Pro Leu Pro
 1 5 10 15
 Ser Ala Thr Ala Arg Gly Gly Asn Arg Thr
 20 25

35

(2) INFORMATION FOR SEQ ID NO: 523:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 58 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 523:

Ser Ser Ile Pro Val Ser Ile Leu Ile Gly Met Lys Leu Ile Leu Tyr
 1 5 10 15
 Leu Leu Ile Thr Glu Ser Gly Ser His Glu Lys Lys Ser Phe Tyr Pro
 20 25 30
 Ser Phe Lys Tyr Met Phe Lys Ile Ile Ile Tyr Val Ser Ala Tyr Cys
 35 40 45
 Arg Thr Ala Leu Arg Ala Thr Val Ser His
 50 55

55

60

(2) INFORMATION FOR SEQ ID NO: 524:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 524:

Asn Arg Thr Leu Leu Phe Leu Ile Leu Phe Val Leu Phe Gly Leu Gly
 1 5 10 15
 Tyr Gly Phe

(2) INFORMATION FOR SEQ ID NO: 525:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 40 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 525:

Met Phe Leu Leu Val Leu Ser Val Phe Cys Asp Phe Met Cys Ser Ile
 1 5 10 15
 Ala Pro Arg Cys His Ala Leu Ser Leu Val Ser Leu Arg Ala Gln His
 20 25 30
 Leu Ser Leu Phe Ile Thr Cys His
 35 40

(2) INFORMATION FOR SEQ ID NO: 526:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 526:

Met Leu Leu Phe Ile Leu Leu Thr Leu Ser Ser Gly Cys Arg Leu Leu
 1 5 10 15
 Val Ser Ser Trp Lys Thr Phe Leu Pro His Phe Ser Leu Pro Gly Pro
 20 25 30
 Arg Glu His Pro Glu Gly Ser Arg Thr Trp Phe Phe Arg Tyr Trp Glu
 35 40 45
 Pro Gly Ala His Cys Leu His Cys Ala
 50 55

(2) INFORMATION FOR SEQ ID NO: 527:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 527:

5 Ala Arg Leu Leu Leu Phe Leu Ser Ser Val His Pro Ser Ile Met Pro
 1 5 10 15
 10 Ser Cys Asn Gln Leu
 20

(2) INFORMATION FOR SEQ ID NO: 528:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 528:

20 Met Ser Leu Thr Ser Ser Leu Thr Phe Leu Ser His Ile Leu Leu Leu
 1 5 10 15
 25 Pro Gln Lys Leu Gln Phe Leu Ser Trp Met Glu Arg Gln Gln Arg Cys
 20 25 30
 30 Thr Gly Val Ala Lys Tyr Ala
 35

(2) INFORMATION FOR SEQ ID NO: 529:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 128 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 529:

40 Met Val Leu Arg Leu Ile Gln Leu Ile Phe Leu Ile Phe Phe Ile His
 1 5 10 15
 45 Ile Ile Ile Leu Leu Ile Pro Gly Ser Arg Pro Cys Gly Ser Trp Val
 20 25 30
 Asn Asp Arg Xaa Leu Gly Leu Arg Asp Val Thr His Leu Ile Tyr Leu
 35 40 45
 50 His Trp Val His Gly His Leu Pro Trp Cys His Pro Tyr Ile Gln Val
 50 55 60
 Glu Phe Ser Ala Leu Ile Glu Ser Thr Ala Gln Leu Gly Leu Pro Phe
 65 70 75 80
 55 Ser Trp Val Arg Val Ile His Pro Phe Leu Val Leu Pro Cys Leu Tyr
 85 90 95
 60 Ser Pro Gly Leu Lys Asn Gly Ile Phe Leu Phe Leu Leu Arg Ala Met
 100 105 110

Pro Gly Gly Met Phe Pro Gly Asn Leu Glu Ala Phe Arg Val Pro Val
 115 120 125

5

10 (2) INFORMATION FOR SEQ ID NO: 530:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 82 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 530:

Met Gly Ser Ser Val Leu Pro Phe Cys Val Cys Val Thr Ser Pro Ser
 1 5 10 15

20

Leu Gly Gly Arg Cys Ile Gln Gly Arg Phe Ala Ser His Ser Lys Phe
 20 25 30

25

Trp Gly Phe Gly Xaa Lys Thr Ala Ser Phe Gly Ala Val Gly Glu Thr
 35 40 45

Pro Pro Asp Gln Glu Pro Gln Lys Glu Thr Glu Pro Ala Thr Ser Ser
 50 55 60

30

His Ala Arg Pro Trp Ala Arg Val Ile Gly Leu Arg Ile Trp Pro Gln
 65 70 75 80

Pro Asn

35

(2) INFORMATION FOR SEQ ID NO: 531:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 531:

45

Met Leu Leu Ser Val Ala Ile Phe Ile Leu Leu Thr Leu Val Tyr Ala
 1 5 10 15

50

Tyr Trp Thr Met
 20

(2) INFORMATION FOR SEQ ID NO: 532:

55

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 75 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 532:

Asn Cys Glu Ile Leu Glu Tyr Cys Tyr Tyr Leu Thr Gln Leu Lys Ile
 1 5 10 15
 5 Ser Met Gly Lys Tyr Leu Ser Ile Pro Thr Val Leu Leu Lys Ile Ile
 20 25 30
 Arg Cys Ser Ile Thr Ala Val Ser Asp Ser Ser Thr Ser Trp Ala Ile
 35 40 45
 10 Lys Ala Gln Leu Lys Ile Glu Asn Lys Asp Leu Asp Asn Lys Thr Ala
 50 55 60
 15 Lys Gly Gly Gly Gln Glu Ala Leu Thr Cys Thr
 65 70 75

20 (2) INFORMATION FOR SEQ ID NO: 533:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 60 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 533:

Met Phe Leu Met Arg Met His Leu Cys Phe Cys Lys Tyr Cys Cys Ser
 1 5 10 15
 30 Phe Ile Val Thr Pro Thr Ser Thr Ser Asn Thr Xaa Ser Tyr Leu Trp
 20 25 30
 Pro Trp Ile Ser Ala Ser Met Ala Gly Arg Gly Ser Xaa Trp Ala Cys
 35 40 45
 35 Thr Leu Asn Ala Val Thr Arg Glu Gly Leu Pro Glu
 50 55 60

40

(2) INFORMATION FOR SEQ ID NO: 534:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 39 amino acids
 45 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 534:

Met Ser Leu Leu Asn Thr His Thr Leu Cys Phe Val Leu Phe Cys Phe
 1 5 10 15
 Thr Leu Ser Ile Asn Gln Glu Lys Leu Ala Asn His Leu Ala Phe Arg
 20 25 30
 55 Ile Leu Phe Phe Ile Val Phe
 35

60 (2) INFORMATION FOR SEQ ID NO: 535:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 535:

Met Leu

1

(2) INFORMATION FOR SEQ ID NO: 536:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 536:

Met Asp Gln Phe Lys Ile Phe Tyr Phe Leu Lys Ala Phe Phe Ala Cys
1 5 10 15

Cys Asn Val Gln Asp Pro Ser Pro Phe Met Gly Glu Thr Gly Ser Tyr
20 25 30

Leu Asn Ile Gly
35

(2) INFORMATION FOR SEQ ID NO: 537:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 537:

Met Phe Asp Phe Leu Ser Tyr Phe Lys Asp Leu Leu Ser Cys
1 5 10

(2) INFORMATION FOR SEQ ID NO: 538:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 538:

Met Gly Phe Gly Phe Val Leu Asn Ile Phe Ser Phe Phe Leu Xaa Pro
1 5 10 15

Pro Leu

(2) INFORMATION FOR SEQ ID NO: 539:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 539:

Leu Leu Leu Trp Thr Leu Leu Ala Xaa Tyr Xaa
 1 5 10

(2) INFORMATION FOR SEQ ID NO: 540:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 108 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 540:

Met Ala Ala Gln Lys Asp Gln Gln Lys Asp Ala Glu Ala Glu Gly Leu
 1 5 10 15
 Ser Gly Thr Thr Leu Leu Pro Lys Leu Ile Pro Ser Gly Ala Gly Arg
 20 25 30
 Glu Trp Leu Glu Arg Arg Arg Ala Thr Ile Arg Pro Trp Ser Thr Phe
 35 40 45
 Val Asp Gln Gln Arg Phe Ser Arg Pro Arg Asn Leu Gly Glu Leu Cys
 50 55 60
 Gln Arg Leu Val Arg Asn Val Glu Tyr Tyr Gln Ser Asn Tyr Val Phe
 65 70 75 80
 Val Phe Leu Gly Leu Ile Leu Tyr Cys Val Val Thr Ser Pro Met Leu
 85 90 95
 Leu Val Ala Leu Ala Val Phe Phe Gly Ala Cys Xaa
 100 105

(2) INFORMATION FOR SEQ ID NO: 541:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 106 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 541:

Phe Val Phe Leu Gly Leu Ile Leu Tyr Cys Val Val Thr Ser Pro Met
 1 5 10 15
 Leu Leu Val Ala Leu Ala Val Phe Phe Gly Ala Cys Tyr Ile Leu Tyr
 20 25 30
 Leu Arg Thr Leu Glu Ser Lys Leu Val Leu Phe Gly Arg Glu Val Ser
 35 40 45

Pro Ala His Gln Tyr Ala Leu Ala Gly Gly Ile Ser Phe Pro Phe Phe
 50 55 60

5 Trp Leu Ala Gly Ala Gly Ser Ala Val Phe Trp Val Leu Gly Ala Thr
 65 70 75 80

Leu Val Val Ile Gly Ser His Ala Ala Phe His Gln Ile Glu Ala Val
 85 90 95

10 Asp Gly Glu Glu Leu Gln Met Glu Pro Val
 100 105

15

(2) INFORMATION FOR SEQ ID NO: 542:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 136 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 542:

20 Met Asp Arg Phe Thr Val Ala Gly Val Leu Pro Asp Ile Glu Gln Phe
 1 5 10 15

Phe Asn Ile Gly Asp Ser Ser Ser Gly Leu Ile Gln Thr Val Phe Ile
 20 25 30

30 Ser Ser Tyr Met Val Leu Ala Pro Val Phe Gly Tyr Leu Gly Asp Arg
 35 40 45

Tyr Asn Arg Lys Tyr Leu Met Cys Gly Gly Ile Ala Phe Trp Ser Leu
 50 55 60

35 Val Thr Leu Gly Ser Ser Phe Ile Pro Gly Glu His Phe Trp Leu Leu
 65 70 75 80

40 Leu Leu Thr Arg Gly Leu Val Gly Val Gly Glu Ala Ser Tyr Ser Thr
 85 90 95

Ile Ala Pro Thr Leu Ile Ala Asp Leu Phe Val Ala Asp Gln Arg Thr
 100 105 110

45 Gly Cys Ser Ala Ser Ser Thr Leu Pro Phe Arg Trp Ala Val Val Trp
 115 120 125

Ala Thr Leu Gln Ala Pro Lys Xaa
 130 135

50

(2) INFORMATION FOR SEQ ID NO: 543:

55 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 424 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 543:

Met Ala Gly Asp Trp His Trp Ala Leu Arg Val Thr Pro Gly Leu Gly
 1 5 10 15
 5 Val Val Ala Val Leu Leu Leu Phe Leu Val Val Arg Glu Pro Pro Arg
 20 25 30
 Gly Ala Val Glu Arg His Ser Asp Leu Pro Pro Leu Asn Pro Thr Ser
 35 40 45
 10 Trp Trp Ala Asp Leu Arg Ala Leu Ala Arg Asn Pro Ser Phe Val Leu
 50 55 60
 Ser Ser Leu Gly Phe Thr Ala Val Ala Phe Val Thr Gly Ser Leu Ala
 65 70 75 80
 15 Leu Trp Ala Pro Ala Phe Leu Leu Arg Ser Arg Val Val Leu Gly Glu
 85 90 95
 Thr Pro Pro Cys Leu Pro Gly Asp Ser Cys Ser Ser Ser Asp Ser Leu
 100 105 110
 Ile Phe Gly Leu Ile Thr Cys Leu Thr Gly Val Leu Gly Val Gly Leu
 115 120 125
 25 Gly Val Glu Ile Ser Arg Arg Xaa Arg His Ser Asn Pro Arg Ala Asp
 130 135 140
 Pro Leu Val Cys Ala Thr Gly Leu Leu Gly Ser Ala Pro Phe Leu Phe
 145 150 155 160
 30 Leu Ser Leu Ala Cys Ala Arg Gly Ser Ile Val Ala Thr Tyr Ile Phe
 165 170 175
 35 Ile Phe Ile Gly Glu Thr Leu Leu Ser Met Asn Trp Ala Ile Val Ala
 180 185 190
 Asp Ile Leu Leu Tyr Val Val Ile Pro Thr Arg Arg Ser Thr Ala Glu
 195 200 205
 40 Ala Phe Gln Ile Val Leu Ser His Leu Leu Gly Asp Ala Gly Ser Pro
 210 215 220
 Tyr Leu Ile Gly Leu Ile Ser Asp Arg Leu Arg Arg Asn Trp Pro Pro
 225 230 235 240
 45 Ser Phe Leu Ser Glu Phe Arg Ala Leu Gln Phe Ser Leu Met Leu Cys
 245 250 255
 50 Ala Phe Val Gly Ala Leu Gly Gly Ala Leu Ser Trp Ala Pro Xaa Ser
 260 265 270
 Ser Leu Arg Pro Thr Ala Gly Gly His Ser Cys Thr Cys Arg Ala Cys
 275 280 285
 55 Cys Thr Lys Gln Gly Pro Gln Thr Thr Gly Leu Trp Cys Pro Ser Gly
 290 295 300
 60 Ala Ala Pro Pro Ala Cys Pro Trp Pro Val Cys Ser Ser Glu Arg Leu
 305 310 315 320

Pro Leu Thr Tyr Leu His Ile Cys His Ser Xaa Pro Trp Ala His Pro
 325 330 335

5 Thr Lys Gly Leu Gly Leu Thr Pro Trp Pro Gly Pro Ala Ser Arg Gly
 340 345 350

Thr Leu Gly Arg Val Pro Ala Pro Arg His Tyr Xaa Gly Ser Ser Gly
 355 360 365

10 Glu Glu Val Gly Val Gln Glu Gly Asp Pro Ser Pro Gln Gly Xaa Pro
 370 375 380

Gln Gly Leu Gly Ala Ile Cys Asn Gly Ile Lys Phe Val Ala Arg Pro
 385 390 395 400

15 Gln Val Pro Ala Leu Val Phe Leu Trp Val Ala Ser Asp Leu Ala Pro
 405 410 415

20 Arg Leu His Pro Arg Ala Pro Glu
 420

(2) INFORMATION FOR SEQ ID NO: 544:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 544:

Met Phe Arg Phe Val Ile Cys Leu Phe Leu Trp Leu Val Leu Cys Arg
 1 5 10 15

35

Asp Ser Thr Ser Ala Ser Arg Ile Ala Leu Tyr Tyr Arg Ile Val Phe
 20 25 30

Leu Ile His Gln Cys Ser Ser
 35

40

(2) INFORMATION FOR SEQ ID NO: 545:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 58 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 545:

Met Leu Pro Trp Xaa Ala Gln Leu Leu Asp Arg Thr Ile Gly Pro Leu
 1 5 10 15

55

Tyr Leu Leu Phe Val Gln Phe Ser Pro Ala Phe Ser Arg Thr Ser Pro
 20 25 30

Trp Arg Ser Pro Lys Asn Phe Arg Arg Leu Tyr Pro Pro Cys Thr Thr
 35 40 45

60

Ser Gly Cys Ala Ala Arg Trp Leu Phe Ser

50

55

5 (2) INFORMATION FOR SEQ ID NO: 546:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 546:

Met Gly Leu Ser Val Leu Leu Pro Leu Cys Leu Leu Gly Pro Gly Arg
 1 5 10 15

15

Phe Thr Ser Gly Gln Lys Pro Leu Asp Thr Pro Gly Leu Gly Val Pro
 20 25 30

Phe

20

25 (2) INFORMATION FOR SEQ ID NO: 547:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 367 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 547:

Met Ala Lys Pro Gln Val Val Val Ala Pro Val Leu Met Ser Lys Leu
 1 5 10 15

35

Ser Val Asn Ala Pro Glu Phe Tyr Pro Ser Gly Tyr Ser Ser Ser Tyr
 20 25 30

Thr Glu Ser Tyr Glu Asp Gly Cys Glu Asp Tyr Pro Thr Leu Ser Glu
 35 40 45

40

Tyr Val Gln Asp Phe Leu Asn His Leu Thr Glu Gln Pro Gly Ser Phe
 50 55 60

Glu Thr Glu Ile Glu Gln Phe Ala Glu Thr Leu Asn Gly Cys Val Thr
 65 70 75 80

45

Thr Asp Asp Ala Leu Gln Glu Leu Val Glu Leu Ile Tyr Gln Gln Ala
 85 90 95

50

Thr Ser Ile Pro Asn Phe Ser Tyr Met Gly Ala Arg Leu Cys Asn Tyr
 100 105 110

Leu Ser His His Leu Thr Ile Ser Pro Gln Ser Gly Asn Phe Arg Gln
 115 120 125

55

Leu Leu Leu Gln Arg Cys Arg Thr Glu Tyr Glu Val Lys Asp Gln Ala
 130 135 140

60

Ala Lys Gly Asp Glu Val Thr Arg Lys Arg Phe His Ala Phe Val Leu
 145 150 155 160

Phe Leu Gly Glu Leu Tyr Leu Asn Leu Glu Ile Lys Gly Thr Asn Gly
 165 170 175
 5 Gln Val Thr Arg Ala Asp Ile Leu Gln Val Gly Leu Arg Glu Leu Leu
 180 185 190
 Asn Ala Leu Phe Ser Asn Pro Met Asp Asp Asn Leu Ile Cys Ala Val
 195 200 205
 10 Lys Leu Leu Lys Leu Thr Gly Ser Val Leu Glu Asp Ala Trp Lys Glu
 210 215 220
 Lys Gly Lys Met Asp Met Glu Glu Ile Ile Gln Arg Ile Glu Asn Val
 225 230 235 240
 15 Val Leu Asp Ala Asn Cys Ser Arg Asp Val Lys Gln Met Leu Leu Lys
 245 250 255
 20 Leu Val Glu Leu Arg Ser Ser Asn Trp Gly Arg Val His Ala Thr Ser
 260 265 270
 Thr Tyr Arg Glu Ala Thr Pro Glu Asn Asp Pro Asn Tyr Phe Met Asn
 275 280 285
 25 Glu Pro Thr Phe Tyr Thr Ser Asp Gly Val Pro Phe Thr Ala Ala Asp
 290 295 300
 30 Pro Asp Tyr Gln Glu Lys Tyr Gln Glu Leu Leu Glu Arg Glu Asp Phe
 305 310 315 320
 Phe Pro Asp Tyr Glu Glu Asn Gly Thr Asp Leu Ser Gly Ala Gly Asp
 325 330 335
 35 Pro Tyr Leu Asp Asp Ile Asp Asp Glu Met Asp Pro Glu Ile Glu Glu
 340 345 350
 40 Ala Tyr Glu Lys Phe Cys Leu Glu Ser Glu Arg Lys Arg Lys Gln
 355 360 365

(2) INFORMATION FOR SEQ ID NO: 548:

45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 77 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 548:
 50 Met Leu Arg Leu Asp Ile Ile Asn Ser Leu Val Thr Thr Val Phe Met
 1 5 10 15
 55 Leu Ile Val Ser Val Leu Ala Leu Ile Pro Glu Thr Thr Thr Leu Thr
 20 25 30
 Val Gly Gly Gly Val Phe Ala Leu Val Thr Ala Val Cys Cys Leu Ala
 35 40 45
 60 Asp Gly Ala Leu Ile Tyr Arg Lys Leu Leu Phe Asn Pro Ser Gly Pro

5

10

15

20

25

30

35

40

45

50

55

60

Tyr Glu Lys Tyr Lys Thr Gln Ile Asp His Tyr Val Gly Ile Ala Arg
130 135 140

Asp Gln Thr Lys Ser Ile Val Glu Lys Ile Gln Ala Lys Leu Pro Gly
 145 150 155 160

5 Ile Ala Lys Lys Lys Ala Glu Xaa
 165

10 (2) INFORMATION FOR SEQ ID NO: 551:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 124 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 551:

Ser Val Pro Phe His Leu Leu Val Val Leu Arg Ser Arg Ala Val Arg
 1 5 10 15

20 Ala Arg Arg Arg Arg Glu Pro Arg Ser Leu Pro Arg Pro Gly Asp Glu
 20 25 30

25 Glu Leu Gln Leu Leu Leu Cys Gly Ala Arg Ser Asp Phe Leu Glu Arg
 35 40 45

Cys Glu Glu Asp Trp Val Cys Leu Trp His His Ala Asp His Ala Ala
 50 55 60

30 Phe Pro Gly Ser Phe Gln Cys His Gln Cys Gly Phe Leu Pro His Pro
 65 70 75 80

Gly Ser Ser Leu Cys His His Gln Leu Gln Asp Leu Gln Val Arg His
 85 90 95

35 Pro Ser Cys Thr Glu Val Arg Arg Arg Pro Ser Ile Gln Ser Leu Pro
 100 105 110

40 Gly Arg Arg His Tyr Ser Val Leu Arg Ser Phe Pro
 115 120

45 (2) INFORMATION FOR SEQ ID NO: 552:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 177 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 552:

Met Val His Leu Leu Val Leu Ser Gly Ala Trp Gly Met Gln Met Trp
 1 5 10 15

55 Val Thr Phe Val Ser Gly Phe Leu Leu Phe Arg Ser Leu Pro Arg His
 20 25 30

60 Thr Phe Gly Leu Val Gln Ser Lys Leu Phe Pro Phe Tyr Phe His Ile
 35 40 45

Ser Met Gly Cys Ala Phe Ile Asn Leu Cys Ile Leu Ala Ser Gln His
 50 55 60
 5 Ala Trp Ala Gln Leu Thr Phe Trp Glu Ala Ser Gln Leu Tyr Leu Leu
 65 70 75 80
 Phe Leu Ser Leu Thr Leu Ala Thr Val Asn Ala Arg Trp Leu Glu Pro
 85 90 95
 10 Arg Thr Thr Ala Ala Met Trp Ala Leu Gln Thr Val Glu Lys Glu Arg
 100 105 110
 Gly Leu Gly Gly Glu Val Pro Gly Ser His Gln Gly Pro Asp Pro Tyr
 115 120 125
 15 Arg Gln Leu Arg Glu Lys Asp Pro Lys Tyr Ser Ala Leu Arg Gln Asn
 130 135 140
 Phe Phe Arg Tyr His Gly Leu Ser Ser Leu Cys Asn Leu Gly Cys Val
 145 150 155 160
 Leu Ser Asn Gly Leu Cys Leu Ala Gly Leu Ala Leu Glu Ile Arg Ser
 165 170 175
 25 Leu

30 (2) INFORMATION FOR SEQ ID NO: 553:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 72 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 553:

Met Ala Phe Ile Leu Leu Phe Tyr Cys Leu Met Thr Phe Leu Ser Leu
 1 5 10 15
 40 Glu Gln Asn Ser Ala Thr Val Glu Pro Ser Ser His Glu Ile Leu His
 20 25 30
 45 Leu Leu Gln Asn Cys Phe Glu Leu Leu Arg Thr Ser Thr Ser Gln Cys
 35 40 45
 Thr Glu Gly Ile Pro Cys Ala Lys Ile Pro Glu Trp Val Thr His Leu
 50 55 60
 50 Thr Trp Gln Thr Leu Lys Asn Ser
 65 70

55 (2) INFORMATION FOR SEQ ID NO: 554:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 554:

5 Val Leu Arg Ile Ile Cys Leu Trp Pro Cys Gly Thr Thr Leu Pro Leu
 1 5 10 15
 Val Glu Lys Ala His Asp Ser His Ser Ala Asp Pro Val Cys Pro Gly
 20 25 30
 10 Leu Thr Ala His Leu Pro Val Leu Leu Tyr Val Gln Leu
 35 40 45

(2) INFORMATION FOR SEQ ID NO: 555:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 251 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 555:

Met Lys His Ala Asp Pro Arg Ile Gln Gly Tyr Pro Leu Met Gly Ser
 1 5 10 15
 25 Pro Leu Leu Met Thr Ser Ile Leu Leu Thr Tyr Val Tyr Phe Val Leu
 20 25 30
 Ser Leu Gly Pro Arg Ile Met Ala Asn Arg Lys Pro Phe Gln Leu Arg
 35 40 45
 30 Gly Phe Met Ile Val Tyr Asn Phe Ser Leu Val Ala Leu Ser Leu Tyr
 50 55 60
 35 Ile Val Tyr Glu Phe Leu Met Ser Gly Trp Leu Ser Thr Tyr Thr Trp
 65 70 75 80
 Arg Cys Asp Pro Gln Asp Cys Thr Leu Gly Gln Cys Pro Ser Val Pro
 85 90 95
 40 Ser Pro Xaa Thr Pro Val Thr Lys Ala Tyr Val Val Arg Thr Glu Gln
 100 105 110
 Gly Thr Gly Pro Pro Leu Pro Thr Ala Ala Leu Gln Gly Pro Arg Leu
 115 120 125
 45 Trp Phe Leu Thr His Phe Pro Arg Ala Ala Pro Gly Met Trp Pro His
 130 135 140
 50 Cys Cys Leu Pro Leu Gln Ser Trp Gly Leu Lys Gly Leu Tyr Ser Tyr
 145 150 155 160
 Phe Pro Leu Pro Ala Leu Lys Leu Gly Arg Gly Ala Leu Arg Ala Gly
 165 170 175
 55 Pro Thr Lys Gly Leu Val Ala Phe Phe Leu Thr Gln Lys Arg Ser Ala
 180 185 190
 60 Ile Met Ser Leu Trp Thr Gln Ser His Ser Ser Thr Pro His Thr Glu
 195 200 205

Ala Val Ala Ser Gly Pro Lys Val Arg Val Gly Gly Gly Leu Gly Ile
 210 215 220

5 Gln Pro Val Glu Ala Ala Tyr Ser Thr Cys Val Leu Ile Lys Ser Asp
 225 230 235 240

Arg Gly Asn His Glu Lys Lys Lys Lys Lys
 245 250

10

(2) INFORMATION FOR SEQ ID NO: 556:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 556:

20 Gly Leu Ala Gly Leu Cys Gly Gln Leu Ser Ser Pro Ala Leu Cys Val
 1 5 10 15

Asn Arg Leu

25

(2) INFORMATION FOR SEQ ID NO: 557:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 217 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 557:

35 Met Ile Thr Glu Lys Trp Gly Leu Asn Met Glu Tyr Cys Arg Gly Gln
 1 5 10 15

40 Ala Tyr Ile Xaa Ser Ser Gly Phe Ser Ser Lys Met Lys Val Val Ala
 20 25 30

Ser Arg Leu Leu Glu Lys Tyr Pro Gln Ala Ile Tyr Thr Leu Cys Ser
 35 40 45

45 Ser Cys Ala Leu Asn Met Trp Leu Ala Lys Ser Val Pro Val Met Gly
 50 55 60

50 Val Ser Val Ala Leu Gly Thr Ile Glu Glu Val Cys Ser Phe Phe His
 65 70 75 80

Arg Ser Pro Gln Leu Leu Leu Glu Leu Asp Asn Val Ile Ser Val Leu
 85 90 95

55 Phe Gln Asn Ser Lys Glu Arg Gly Lys Glu Leu Lys Glu Ile Cys His
 100 105 110

Ser Gln Trp Thr Gly Arg His Asp Ala Phe Glu Ile Leu Val Glu Leu
 115 120 125

60 Leu Gln Ala Leu Val Leu Cys Leu Asp Gly Ile Asn Ser Asp Thr Asn

130 135 140

Ile Arg Trp Asn Asn Tyr Ile Ala Gly Arg Ala Phe Val Leu Cys Ser
 145 150 155 160

5 Ala Val Ser Asp Phe Asp Phe Ile Val Thr Ile Val Val Leu Lys Asn
 165 170 175

10 Val Leu Ser Phe Thr Arg Ala Phe Gly Lys Asn Leu Gln Gly Gln Thr
 180 185 190

 Ser Asp Val Phe Phe Ala Ala Gly Ser Leu Thr Ala Val Leu His Ser
 195 200 205

15 Leu Asn Glu Val Ile Gly Lys Tyr Xaa
 210 215

20 (2) INFORMATION FOR SEQ ID NO: 558:

 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 82 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 558:

Leu Leu Lys Val Leu Cys Ile Leu Pro Val Met Lys Val Glu Asn Glu
 1 5 10 15

30 Arg Tyr Glu Asn Gly Arg Lys Arg Leu Lys Ala Tyr Leu Arg Asn Thr
 20 25 30

35 Leu Thr Asp Gln Arg Ser Ser Asn Leu Ala Leu Leu Asn Ile Asn Phe
 35 40 45

 Asp Ile Lys His Asp Leu Asp Leu Met Val Asp Thr Tyr Ile Lys Leu
 50 55 60

40 Tyr Thr Ser Lys Ser Glu Leu Pro Thr Asp Asn Ser Glu Thr Val Glu
 65 70 75 80

 Asn Thr

45

(2) INFORMATION FOR SEQ ID NO: 559:

50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 95 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 559:

Met Val Leu Ile Leu Leu Asn Leu Leu Leu Gly Gln Phe Ser Cys Met
 1 5 10 15

60 Ser Pro Ala Ser His His Cys His Pro Leu Pro Thr Glu Met Pro Cys
 20 25 30

683

Ser Ser Asp Trp Gly Phe Asp Ser His Thr Val Tyr Pro Ser Cys Val
 35 40 45

5 Asp Ala Leu Leu Pro Lys Pro Ser Ala Asn Ser Phe Pro Asn Gly Ser
 50 55 60

Cys His Cys Gln Gly Leu Tyr Asn Gln Gln Gln Gln Asn Leu His Ala
 65 70 75 80

10 Ala Glu Gly Pro Ala Ser Leu Arg Cys Asn Lys Tyr Val Ser Thr
 85 90 95

15

(2) INFORMATION FOR SEQ ID NO: 560:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 54 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 560:

25 Met Ile Pro Ala Tyr Ser Lys Asn Arg Ala Tyr Ala Ile Phe Phe Ile
 1 5 10 15

Val Phe Thr Val Ile Gly Asp Ala Pro Gly Ala Val Leu Ser Cys Ala
 20 25 30

30 Gly His Pro Cys Val Gly Phe Ala Ala Val Leu Val Ala Pro Leu Thr
 35 40 45

Val Ala Val Ser Ser Xaa
 50

35

(2) INFORMATION FOR SEQ ID NO: 561:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 108 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 561:

45

Met Glu Val Pro Pro Pro Ala Pro Arg Ser Phe Leu Cys Arg Ala Leu
 1 5 10 15

50 Cys Leu Phe Pro Arg Val Phe Ala Ala Glu Ala Val Thr Ala Asp Ser
 20 25 30

Glu Val Leu Glu Glu Arg Gln Lys Arg Leu Pro Tyr Val Pro Glu Pro
 35 40 45

55 Tyr Tyr Pro Glu Ser Gly Trp Asp Arg Leu Arg Glu Leu Phe Gly Lys
 50 55 60

Asp Thr Val Asn Thr Ser Leu Asn Val Tyr Arg Asn Lys Asp Ala Leu
 65 70 75 80

60

684

Ser His Phe Val Ile Ala Gly Ala Val Thr Gly Ser Leu Phe Arg Ile
 85 90 95

5 Asn Val Gly Leu Arg Gly Trp Trp Leu Val Ala Xaa
 100 105

10 (2) INFORMATION FOR SEQ ID NO: 562:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 562:

Met Asn Trp Gly Leu Ser Ile Trp Leu His Tyr Tyr Glu Lys Lys Lys
 1 5 10 15

20 Glu Gln Val Phe Leu Val Ile Leu Ala His Val Val Arg Arg Cys Ala
 20 25 30

Ser Asp Gly Ile Leu Gln Phe Glu Ser Ser Leu Leu Lys Met Arg Arg
 35 40 45

25 Ala Pro
 50

30

(2) INFORMATION FOR SEQ ID NO: 563:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 253 amino acids

35 (B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 563:

40 Met Val Lys Val Cys Asn Asp Ser Asp Arg Trp Ser Leu Ile Ser Leu
 1 5 10 15

Ser Asn Asn Ser Gly Lys Asn Val Glu Leu Lys Phe Val Asp Ser Leu
 20 25 30

45 Arg Arg Gln Phe Glu Phe Ser Val Asp Ser Phe Gln Ile Lys Leu Asp
 35 40 45

Ser Leu Leu Leu Phe Tyr Glu Cys Ser Glu Asn Pro Met Thr Glu Thr
 50 55 60

50 Phe His Pro Thr Ile Ile Gly Glu Ser Val Tyr Gly Asp Phe Gln Glu
 65 70 75 80

55 Ala Phe Asp His Leu Cys Asn Lys Ile Ile Ala Thr Arg Asn Pro Glu
 85 90 95

Glu Ile Arg Gly Gly Gly Leu Leu Lys Tyr Cys Asn Leu Leu Val Arg
 100 105 110

60 Gly Phe Arg Pro Ala Ser Asp Glu Ile Lys Thr Leu Gln Arg Tyr Met

115 120 125

Cys Ser Arg Phe Phe Ile Asp Phe Ser Asp Ile Gly Glu Gln Gln Arg
130 135 140

5 Lys Leu Glu Ser Tyr Leu Gln Asn His Phe Val Gly Leu Glu Asp Arg
145 150 155 160

10 Lys Tyr Glu Tyr Leu Met Thr Leu His Gly Val Val Asn Glu Ser Thr
165 170 175

Val Cys Leu Met Gly His Glu Arg Arg Gln Thr Leu Asn Leu Ile Thr
180 185 190

15 Met Leu Ala Ile Arg Val Leu Ala Asp Gln Asn Val Ile Pro Asn Val
195 200 205

Ala Asn Val Thr Cys Tyr Tyr Gln Pro Ala Pro Tyr Val Ala Asp Ala
210 215 220

20 Asn Phe Ser Asn Tyr Tyr Ile Ala Gln Val Gln Pro Val Phe Thr Cys
225 230 235 240

25 Gln Gln Gln Thr Tyr Ser Thr Trp Leu Pro Cys Asn Xaa
245 250

(2) INFORMATION FOR SEQ ID NO: 564:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 564:

Met Ser Phe Leu Met Trp Leu Met Ser Leu Ala Ile Thr Ser Gln Pro
1 5 10 15

40

Pro Met

(2) INFORMATION FOR SEQ ID NO: 565:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 80 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 565:

Met Ala Pro Lys Gly Lys Val Gly Thr Arg Gly Lys Lys Gln Ile Phe
1 5 10 15

55

Glu Glu Asn Arg Glu Thr Leu Lys Phe Tyr Leu Arg Ile Ile Leu Gly
20 25 30

60

Ala Asn Ala Ile Tyr Cys Leu Val Thr Leu Val Phe Phe Tyr Ser Ser
35 40 45

Ala Ser Phe Trp Ala Trp Leu Ala Leu Gly Phe Ser Leu Ala Val Tyr
 50 55 60

5 Gly Ala Ser Tyr His Ser Met Ser Ser Met Ala Arg Ala Ala Phe Phe
 65 70 75 80

10

(2) INFORMATION FOR SEQ ID NO: 566:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 73 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 566:

His Leu Lys Asp Val Ile Leu Leu Thr Ala Ile Val Gln Val Leu Ser
 1 5 10 15

25

Cys Phe Ser Leu Tyr Val Trp Ser Phe Trp Leu Leu Ala Pro Gly Arg
 20 25 30

Ala Leu Tyr Leu Leu Trp Val Asn Val Leu Gly Pro Trp Phe Thr Ala
 35 40 45

30

Asp Ser Gly Thr Pro Ala Pro Glu His Asn Glu Lys Arg Gln Arg Arg
 50 55 60

Gln Glu Arg Arg Gln Met Lys Arg Leu
 65 70

35

(2) INFORMATION FOR SEQ ID NO: 567:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 263 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 567:

Met Asp Cys Pro Ala Leu Pro Pro Gly Trp Lys Lys Glu Glu Val Ile
 1 5 10 15

50

Arg Lys Ser Gly Leu Ser Ala Gly Lys Ser Asp Val Tyr Tyr Phe Ser
 20 25 30

Pro Ser Gly Lys Lys Phe Arg Ser Lys Pro Gln Leu Ala Arg Tyr Leu
 35 40 45

55

Gly Asn Thr Val Asp Leu Ser Ser Phe Asp Phe Arg Thr Gly Lys Met
 50 55 60

Met Pro Ser Lys Leu Gln Lys Asn Lys Gln Arg Leu Arg Asn Asp Pro
 65 70 75 80

60

687

Leu Asn Gln Asn Lys Gly Lys Pro Asp Leu Asn Thr Thr Leu Pro Ile
 85 90 95
 5 Arg Gln Thr Ala Ser Ile Phe Lys Gln Pro Val Thr Lys Val Thr Asn
 100 105 110
 His Pro Ser Asn Lys Val Lys Ser Asp Pro Gln Arg Met Asn Glu Gln
 115 120 125
 10 Pro Arg Gln Leu Phe Trp Glu Lys Arg Leu Gln Gly Leu Ser Ala Ser
 130 135 140
 Asp Val Thr Glu Gln Ile Ile Lys Thr Met Glu Leu Pro Lys Gly Leu
 15 145 150 155 160
 Gln Gly Val Gly Pro Gly Ser Asn Asp Glu Thr Leu Leu Ser Ala Val
 165 170 175
 20 Ala Ser Ala Leu His Thr Ser Ser Ala Pro Ile Thr Gly Gln Val Ser
 180 185 190
 Ala Ala Val Glu Lys Asn Pro Ala Val Trp Leu Asn Thr Ser Gln Pro
 195 200 205
 25 Leu Cys Lys Ala Phe Ile Val Thr Asp Glu Asp Ile Arg Lys Gln Glu
 210 215 220
 Glu Arg Val Gln Gln Val Arg Lys Lys Leu Glu Glu Ala Leu Met Ala
 30 225 230 235 240
 Asp Ile Leu Ser Arg Ala Ala Asp Thr Glu Glu Met Asp Ile Glu Met
 245 250 255
 35 Asp Ser Gly Asp Glu Ala Xaa
 260
 (2) INFORMATION FOR SEQ ID NO: 568:
 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 70 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 568:
 Met Met Arg Pro Phe Tyr Leu Leu Leu Pro Val Leu Cys Thr Gln Ala
 1 5 10 15
 50 Leu Arg Gln Ser Gln Gly Lys Ser Pro Leu Leu Trp Lys Arg Thr Leu
 20 25 30
 Leu Phe Gly Leu Thr His Leu Asn Pro Ser Ala Lys Leu Leu Leu Ser
 35 40 45
 55 Gln Met Lys Thr Ser Gly Asn Arg Lys Ser Glu Tyr Ser Lys Tyr Ala
 50 55 60
 60 Arg Asn Trp Lys Lys His
 65 70

(2) INFORMATION FOR SEQ ID NO: 569:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 569:

Met Pro Val Thr Ser Lys Arg Thr Leu Phe Phe Pro Asp Pro Cys Ser
 1 5 10 15
 Tyr Asp Thr Pro Pro Pro Asp Cys His Cys His Ser Phe Arg Ala Glu
 20 25 30

Leu Leu

(2) INFORMATION FOR SEQ ID NO: 570:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 104 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 570:

Met Asn Ser Arg Gly Met Trp Leu Thr Tyr Ala Leu Gly Val Gly Leu
 1 5 10 15

Leu His Ile Val Leu Leu Ser Ile Pro Phe Phe Ser Val Pro Val Ala
 20 25 30

Trp Thr Leu Thr Asn Ile Ile His Asn Leu Gly Met Tyr Val Phe Leu
 35 40 45

His Ala Val Lys Gly Thr Pro Phe Glu Thr Pro Asp Gln Gly Lys Ser
 50 55 60

Lys Ala Pro Asn Ser Leu Gly Thr Thr Gly Leu Trp Ser Thr Val Tyr
 65 70 75 80

Ile Phe Thr Glu Val Phe His Asn Phe Ser Asn Asn Ser Ile Phe Ser
 85 90 95

Gly Lys Phe Leu Tyr Glu Val Xaa
 100

(2) INFORMATION FOR SEQ ID NO: 571:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 132 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 571:

Met Trp Leu Thr Tyr Ala Leu Gly Val Gly Leu Leu His Ile Val Leu
 1 5 10 15
 5 Leu Ser Ile Pro Phe Phe Ser Val Pro Val Ala Trp Thr Leu Thr Asn
 20 25 30
 Ile Ile His Asn Leu Gly Met Tyr Val Phe Leu His Ala Val Lys Gly
 35 40 45
 10 Thr Pro Phe Glu Thr Pro Asp Gln Gly Lys Ala Arg Leu Leu Thr His
 50 55 60
 15 Trp Glu Gln Leu Asp Tyr Gly Val Gln Phe Thr Ser Ser Arg Lys Phe
 65 70 75 80
 Phe Thr Ile Ser Pro Ile Ile Leu Tyr Phe Leu Ala Ser Phe Tyr Thr
 85 90 95
 20 Lys Tyr Asp Pro Thr His Phe Ile Leu Asn Thr Ala Ser Leu Leu Ser
 100 105 110
 Val Leu Ile Pro Lys Met Pro Gln Leu His Gly Val Arg Ile Phe Gly
 115 120 125
 25 Ile Asn Lys Tyr
 130

30

(2) INFORMATION FOR SEQ ID NO: 572:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 32 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 572:

35

40 Met Asn Lys Trp Ile Cys Glu Met His Cys Tyr Leu Val Leu Leu Ser
 1 5 10 15
 Val Cys Ser Pro Ser Ala Leu Arg Arg Val Arg His Thr Leu Ser Arg
 20 25 30

45

50

(2) INFORMATION FOR SEQ ID NO: 573:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 28 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 573:

55

60 Met Pro Val Leu Ser Leu Leu Cys Thr Leu Ile Val Ser Phe Gln Ser
 1 5 10 15

Ala Asp Ser Cys Glu Val Phe Leu Asn Cys Ser Leu
20 25

5

(2) INFORMATION FOR SEQ ID NO: 574:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 40 amino acids

10

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 574:

15 Met Lys Val Ser Thr Met Leu Trp Phe Leu Cys Trp Glu Gln Ser His
1 5 10 15

Phe Leu Arg Glu Trp Glu Asp Leu Ser Thr Phe Leu Ile Leu Ile Gln
20 25 30

20 Met Glu Cys Gln Tyr Gly Asn Ser
35 40

25

(2) INFORMATION FOR SEQ ID NO: 575:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 amino acids

30

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 575:

35 Met Gly Leu Pro Leu Met Ala Leu Met Trp Ser Thr Leu Pro Ala Ser
1 5 10 15

Ala Gly Val Asn Phe Ile Leu Ala Leu Pro Leu Leu Xaa Leu
20 25 30

40

(2) INFORMATION FOR SEQ ID NO: 576:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids

45

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 576:

50 Met Lys Arg Gly Cys Leu Gly Leu Leu Phe Phe Ser Cys Cys Ser Ser
1 5 10 15

Ala Pro Thr Met Leu Leu Cys Asp Tyr Leu Asn Trp Phe
20 25

55

(2) INFORMATION FOR SEQ ID NO: 577:

(i) SEQUENCE CHARACTERISTICS:

60

(A) LENGTH: 92 amino acids

691

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 577:

5 Met Lys Leu Leu Leu Gly Ile Ala Leu Leu Ala Tyr Val Ala Ser Val
 1 5 10 15
 Trp Gly Asn Phe Val Asn Met Arg Ser Ile Gln Glu Asn Gly Glu Leu
 20 25 30
 10 Lys Ile Glu Ser Lys Ile Glu Glu Met Val Glu Pro Leu Arg Glu Lys
 35 40 45
 15 Ile Arg Asp Leu Glu Lys Ser Phe Thr Gln Lys Tyr Pro Pro Val Lys
 50 55 60
 Phe Leu Ser Glu Lys Asp Arg Lys Arg Ile Leu Xaa Asn Arg Arg Arg
 65 70 75 80
 20 Xaa Val Arg Gly Leu Pro Ser Xaa Leu Thr Asn Ser
 85 90

25 (2) INFORMATION FOR SEQ ID NO: 578:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 42 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 578:

35 Met Lys Phe Ser Leu Val Leu Leu Ile Lys Ile Ile Ser Phe Glu Arg
 1 5 10 15
 Leu Leu Ile Phe Leu Phe Pro Leu Ser Phe Leu Pro Asn Ile Trp Arg
 20 25 30
 40 Arg Val Met Val Asn Leu Asn Ile Leu Phe
 35 40

45 (2) INFORMATION FOR SEQ ID NO: 579:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 70 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 579:

55 Leu Ala Gln Glu Cys Pro Pro His Ile Pro Ser Ser Phe Phe Leu Val
 1 5 10 15
 Lys Leu Leu Phe Ile Pro Trp Leu Ala Ser Leu Leu Pro Pro Leu Ser
 20 25 30
 60 Thr Phe Thr Ser Asp Phe Tyr Phe Met Glu Phe Gly Ile Glu Val Lys
 35 40 45

Leu Gln Gln Cys Arg Gln His Gln Val Leu Gln Glu Lys Asn Thr Lys
 50 55 60

5 Lys Phe Asn Lys Lys Lys
 65 70

(2) INFORMATION FOR SEQ ID NO: 580:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 110 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 580:

Met Leu Arg Leu Leu Leu Val Ala Phe Ala Leu Val Val Val Leu
 1 5 10 15

20 Phe His Val Leu Leu Ala Pro Ile Thr Ala Leu Phe His Thr His Phe
 20 25 30

25 Tyr Asp Arg Leu Gln Asp Ala Gly Ser Arg Trp Pro Glu Leu Tyr Leu
 35 40 45

Tyr Ser Arg Ala Asp Glu Val Val Leu Ala Arg Asp Ile Glu Arg Met
 50 55 60

30 Val Glu Ala Arg Leu Ala Arg Arg Val Leu Ala Arg Ser Val Asp Phe
 65 70 75 80

Val Ser Ser Ala His Val Ser His Leu Arg Asp Tyr Pro Thr Tyr Tyr
 85 90 95

35 Thr Ser Leu Cys Val Asp Phe Met Arg Asn Cys Val Arg Cys
 100 105 110

(2) INFORMATION FOR SEQ ID NO: 581:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 581:

Met Phe Lys Leu Glu Glu Cys Gly Lys Thr Thr Phe Leu Leu Ser Met
 1 5 10 15

Ala Leu Tyr Phe Trp Trp Ile Val Gln Thr Thr Lys Gly Cys
 20 25 30

(2) INFORMATION FOR SEQ ID NO: 582:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 71 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 582:

5 Met Glu Ser Asp Ala Leu Leu Leu Thr Ile Phe Trp Ile Ile Ala Arg
 1 5 10 15
 Ser Ser Val Arg Ser Val Gly Lys Ser Ser Gln Arg Ser Phe Thr Thr
 20 25 30
 10 Ile Thr Gln Leu Arg Ser Thr His Thr Gly Pro Ser Arg Arg Ser Tyr
 35 40 45
 Leu Ile Trp Trp Asn Gly Gly Pro Lys Arg Thr Ile Ser Tyr Val Ser
 50 55 60
 15 Arg Arg Phe Arg Ser Phe Arg
 65 70

20

(2) INFORMATION FOR SEQ ID NO: 583:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 47 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 583:

30 Val Gly Leu Phe Gln Pro Lys Thr Phe Gln Val Pro Val Thr Asp Leu
 1 5 10 15
 Tyr Ile Phe Ile Lys Ile Tyr Ser Glu Ile Gly Pro Ile Met His Val
 20 25 30
 35 Leu Cys Pro Gly Tyr Ser Gln Ser Pro Ser Thr Pro Pro Trp Thr
 35 40 45

40

(2) INFORMATION FOR SEQ ID NO: 584:

(i) SEQUENCE CHARACTERISTICS:

45 (A) LENGTH: 39 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 584:

50 Met Trp Phe Gly Ser Asp Arg Ser Asp Leu Arg Ile Gly Thr Ala Phe
 1 5 10 15
 Leu Phe Asp Leu Val Cys Asp Leu Cys Ile His Ala Trp Lys Pro Pro
 20 25 30
 55 Gly Leu Val Arg Phe Ser Phe
 35

60

(2) INFORMATION FOR SEQ ID NO: 585:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 585:

Met Leu Asn Thr Ala Ser Leu Asn Leu Pro Trp Lys Val Gln Leu Phe
1 5 10 15

10 Ala His Ala

15 (2) INFORMATION FOR SEQ ID NO: 586:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 586:

Met Ser Ala Cys Leu Leu Leu Phe Leu Ala Phe Ser Trp Lys Arg Lys
1 5 10 15

25

Gly Leu Trp Ser Gly Pro Gly
20

30

(2) INFORMATION FOR SEQ ID NO: 587:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 69 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 587:

Met Leu Pro Pro Phe Ser Leu Val Tyr Thr His Phe Leu Val Ala Ser
1 5 10 15

40

Leu Leu Pro Val Ile Leu Ala Val Phe Pro Asp Ser Ala Gln Ile Val
20 25 30

Pro Leu Leu Lys Pro Ile Pro Arg Pro Gln Pro Glu Val Ile Phe Pro
35 40 45

Ser Ser Glu Leu Leu Glu Gln Leu Leu Ser Val Gln Phe Val Trp Gln
50 55 60

50

Ala His Thr Val Ala
65

55

(2) INFORMATION FOR SEQ ID NO: 588:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 77 amino acids

(B) TYPE: amino acid

60

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 588:

5 Met Gly Pro Pro Met Leu Gln Glu Ile Ser Asn Leu Phe Leu Ile Leu
1 5 10 15

Leu Met Met Gly Ala Ile Phe Thr Leu Ala Ala Leu Lys Glu Ser Leu
20 25 30

10 Ser Thr Cys Ile Pro Ala Ile Val Cys Leu Gly Phe Leu Leu Leu Leu
35 40 45

Asn Val Gly Gln Leu Leu Ala Gln Thr Lys Lys Val Val Arg Pro Thr
50 55 60

15 Arg Lys Lys Thr Leu Ser Thr Phe Lys Glu Ser Trp Lys
65 70 75

20

(2) INFORMATION FOR SEQ ID NO: 589:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 589:

30 Met Ala Leu Leu Leu Ser Val Leu Arg Val Leu Leu Gly Gly Phe Phe
1 5 10 15

Ala Leu Val Gly Leu Ala Lys Leu Ser Glu Glu Ile Ser Ala Pro Val
20 25 30

35 Ser Glu Arg Met Asn Ala Leu Phe Val Gln Phe Ala Glu Val Phe Pro
35 40 45

Leu Lys Val Phe Gly Tyr Gln Pro Asp Pro Leu Asn Tyr Gln Ile Ala
50 55 60

40 Val Gly Phe Leu Glu Leu Leu Ala Gly Leu Leu Leu Val Met Gly Pro
65 70 75 80

45 Pro Met Leu Gln Glu Ile Ser Asn Leu Phe Leu Ile Leu Leu Met Met
85 90 95

Gly Ala Ile Phe Thr Leu Ala Ala Leu Lys Glu Ser Leu Ser Thr Cys
100 105 110

50 Ile Pro Ala Ile Val Cys Leu Gly Phe Leu Leu Leu Leu Asn Val Gly
115 120 125

Gln Leu Leu Ala Gln Thr Lys Lys Val Val Arg Pro Thr Arg Lys Lys
130 135 140

55 Thr Leu Ser Thr Phe Lys Glu Ser Trp Lys Xaa
145 150 155

60

(2) INFORMATION FOR SEQ ID NO: 590:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 590:

Met Pro Glu Thr Arg Leu Gly His Arg Gln Gln Phe Ala Val Phe His
 1 5 10 15

Leu Xaa Pro Val Pro Pro Cys Gly
 20

15

(2) INFORMATION FOR SEQ ID NO: 591:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 591:

Met Leu Thr Phe Leu Phe Ser Ala Cys Ala Thr Cys Leu Gly Lys Leu
 1 5 10 15

Ala Ser Pro Leu Ala Pro Val Gly Pro Gln Gln Arg Gly Xaa Pro Pro
 20 25 30

30

Gly Pro Pro Leu Leu Ser
 35

35

(2) INFORMATION FOR SEQ ID NO: 592:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 69 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 592:

Met Asp Pro Phe His Tyr Asp Tyr Gln Thr Leu Arg Ile Gly Gly Leu
 1 5 10 15

Val Phe Ala Val Val Leu Phe Ser Val Gly Ile Leu Leu Ile Leu Ser
 20 25 30

50

Arg Arg Cys Lys Cys Ser Phe Asn Gln Lys Pro Arg Ala Pro Gly Asp
 35 40 45

Glu Glu Ala Gln Val Glu Asn Leu Ile Thr Ala Asn Ala Thr Glu Pro
 50 55 60

55

Gln Lys Ala Glu Asn
 65

60

(2) INFORMATION FOR SEQ ID NO: 593:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 308 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 593:

10	Asn	Leu	Arg	Val	Arg	Leu	Gly	Asp	Val	Ile	Ser	Ile	Gln	Pro	Cys	Pro
	1					5										15
	Asp	Val	Lys	Tyr	Gly	Lys	Arg	Ile	His	Val	Leu	Pro	Ile	Asp	Asp	Thr
				20					25					30		
15	Val	Glu	Gly	Ile	Thr	Gly	Asn	Leu	Phe	Glu	Val	Tyr	Leu	Lys	Pro	Tyr
			35					40					45			
	Phe	Leu	Glu	Ala	Tyr	Arg	Pro	Ile	Arg	Lys	Gly	Asp	Ile	Phe	Leu	Val
		50					55					60				
20	Arg	Gly	Gly	Met	Arg	Ala	Val	Glu	Phe	Lys	Val	Val	Glu	Thr	Asp	Pro
	65					70					75					80
	Ser	Pro	Tyr	Cys	Ile	Val	Ala	Pro	Asp	Thr	Val	Ile	His	Cys	Glu	Gly
25				85						90					95	
	Glu	Pro	Ile	Lys	Arg	Glu	Asp	Glu	Glu	Glu	Ser	Leu	Asn	Glu	Val	Gly
			100					105						110		
30	Tyr	Asp	Asp	Ile	Gly	Gly	Cys	Arg	Lys	Gln	Leu	Ala	Gln	Ile	Lys	Glu
		115					120						125			
	Met	Val	Glu	Leu	Pro	Leu	Arg	His	Pro	Ala	Leu	Phe	Lys	Ala	Ile	Gly
35		130					135					140				
	Val	Lys	Pro	Pro	Arg	Gly	Ile	Leu	Leu	Tyr	Gly	Pro	Pro	Gly	Thr	Gly
	145					150					155					160
	Lys	Thr	Leu	Ile	Ala	Arg	Ala	Val	Ala	Asn	Glu	Thr	Gly	Ala	Phe	Phe
40					165					170					175	
	Phe	Leu	Ile	Asn	Gly	Pro	Glu	Ile	Met	Ser	Lys	Leu	Ala	Gly	Glu	Ser
			180						185					190		
45	Glu	Ser	Asn	Leu	Arg	Lys	Ala	Phe	Glu	Glu	Ala	Glu	Lys	Asn	Ala	Pro
		195					200						205			
	Ala	Ile	Ile	Phe	Ile	Asp	Glu	Leu	Asp	Ala	Ile	Ala	Pro	Lys	Arg	Glu
50		210				215					220					
	Lys	Thr	His	Gly	Glu	Val	Glu	Arg	Arg	Ile	Val	Ser	Gln	Leu	Leu	Thr
	225				230						235					240
	Leu	Met	Asp	Gly	Leu	Lys	Gln	Arg	Ala	His	Val	Ile	Val	Met	Ala	Ala
55				245					250						255	
	Thr	Asn	Arg	Pro	Asn	Ser	Ile	Asp	Pro	Ala	Leu	Arg	Arg	Phe	Gly	Arg
		260							265					270		
60	Phe	Asp	Arg	Glu	Val	Asp	Ile	Gly	Ile	Pro	Asp	Ala	Thr	Gly	Arg	Leu

275 280 285

Glu Ile Leu Gln Ile His Thr Lys Asn Met Lys Leu Ala Asp Asp Val
 290 295 300

5 Asp Leu Glu Gln
 305

10

(2) INFORMATION FOR SEQ ID NO: 594:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 594:

20 Met Gln Ile Lys Leu Leu Lys Ser Val Lys Thr Val Phe Ala Ile Thr
 1 5 10 15

Leu Leu Val Leu Phe Leu
 20

25

(2) INFORMATION FOR SEQ ID NO: 595:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 595:

35 Met Phe Pro Lys Phe Cys Pro Ile Leu Ser Leu Val Asp Phe Ile Ser
 1 5 10 15

His Arg Asp Lys Pro Glu Thr Glu
 20

40

(2) INFORMATION FOR SEQ ID NO: 596:

45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 596:

Met Leu Ile Glu Cys Ala Trp Gln Leu Met Phe Leu Leu Leu Lys Val
 1 5 10 15

55

Glu Gln Leu Gly Ile Leu Asp Lys
 20

60

(2) INFORMATION FOR SEQ ID NO: 597:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 597:

Met

1

10

(2) INFORMATION FOR SEQ ID NO: 598:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 598:

20 Met Cys Ile Met Ser Ala Leu Val

1

5

25 (2) INFORMATION FOR SEQ ID NO: 599:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 599:

Met Phe Leu Val Trp Phe Phe Trp Gly Leu Ile Ser Ala Leu Ser Asn

1

5

10

15

35

Val His Thr Pro Ser Arg Leu Pro Ala

20

25

40

(2) INFORMATION FOR SEQ ID NO: 600:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 600:

50 Met Xaa Gly Leu Ser Leu Ile Leu Thr Val Thr Leu Leu Ala Val Ser

1

5

10

15

Asp Ser Ala Ala Thr Cys Ile Val Ala Lys Gly

20

25

55

(2) INFORMATION FOR SEQ ID NO: 601:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 61 amino acids

60

700

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 601:

5 Met Trp Thr Arg Ser Ser Arg Cys Leu Leu Leu Cys Ile Pro Gly Xaa
 1 5 10 15

Ser Arg Arg Arg Arg Ala Gly Ser Gly Met Lys Pro Arg Ser Trp Ser
 20 25 30

10 Ala Trp Arg Pro Ser Gly Gly Thr Gly Thr Ser Ser Ser Gln Ser Ser
 35 40 45

15 Thr Gln Ser Arg Thr Leu Ser Ala Thr Ala Ser Pro Ala
 50 55 60

(2) INFORMATION FOR SEQ ID NO: 602:

20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 602:

Met Arg Glu Thr Ser Ile Arg Val Leu Leu Met Leu Pro Ala Leu Glu
 1 5 10 15

30 Ser Thr Ser Gly Leu Ser Ala Phe Met Gly Leu Gly Thr
 20 25

(2) INFORMATION FOR SEQ ID NO: 603:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 69 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 603:

Met Pro Pro Lys Gln Glu Leu Gly Ser Gly Val Gly Glu Leu Ala Lys
 1 5 10 15

45 Asn Ser Lys Arg Gln His Trp Asn His Arg Trp Lys Lys Tyr Leu Lys
 20 25 30

50 Leu Ile Arg Trp Glu Asp Gly Leu Leu Glu Gly Leu Leu Val
 35 40 45

Leu Glu His Cys Ala Thr Met Ala Trp Asp Cys Leu Met Arg Leu Glu
 50 55 60

55 Leu Leu Lys Arg Leu
 65

(2) INFORMATION FOR SEQ ID NO: 604:

60

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 604:

Lys Ile Val Tyr Ile Leu Gly Asn Pro Leu Lys Phe Asn Ser Arg Val
 1 5 10 15
 Ile His His Leu Val Leu Leu Gln
 20

(2) INFORMATION FOR SEQ ID NO: 605:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 605:

Met Asn Leu His Gln Arg Arg Leu Leu Leu Ile Gly His Leu Met Thr
 1 5 10 15
 Leu Val Lys Ala Ser Lys Ser Phe Ser Phe Thr Glu Ile Thr Ser Ser
 20 25 30
 Arg Lys Lys
 35

(2) INFORMATION FOR SEQ ID NO: 606:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 130 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 606:

Leu Leu Gly Tyr Gly Leu Phe Gly His Cys Ile Val Leu Phe Ile Thr
 1 5 10 15
 Tyr Asn Ile His Leu His Ala Leu Phe Tyr Leu Phe Trp Leu Leu Val
 20 25 30
 Gly Gly Leu Ser Thr Leu Arg Met Val Ala Val Leu Val Ser Arg Thr
 35 40 45
 Val Gly Pro Thr Gln Arg Leu Leu Leu Cys Gly Thr Leu Ala Ala Leu
 50 55 60
 His Met Leu Phe Leu Leu Tyr Leu His Phe Ala Tyr His Lys Val Xaa
 65 70 75 80
 Glu Gly Ile Leu Asp Thr Leu Glu Gly Pro Asn Ile Pro Pro Ile Gln
 85 90 95

Arg Val Pro Arg Asp Ile Pro Ala Met Leu Pro Ala Ala Arg Leu Pro
 100 105 110

5 Thr Thr Val Leu Asn Ala Thr Ala Lys Ala Val Ala Val Thr Leu Gln
 115 120 125

Ser His
 130

10

(2) INFORMATION FOR SEQ ID NO: 607:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 23 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 607:

20 Met Leu Val Ile Phe Leu Phe Thr Ser Leu Leu Lys Ile Pro Ser Ser
 1 5 10 15

Val Pro Gly Leu Ile Asn Val
 20

25

(2) INFORMATION FOR SEQ ID NO: 608:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 608:

Glu Leu Asp Tyr Ile Leu
 1 5

40

(2) INFORMATION FOR SEQ ID NO: 609:

45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 232 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 609:

50 Met Ala Pro Pro Gly Trp Gln Xaa Xaa Xaa Xaa Trp Leu Ala Cys
 1 5 10 15

Pro Asp Arg Gly Glu Leu Ser Ser Arg Ser Pro Pro Cys Arg Leu Ala
 20 25 30

55 Arg Trp Ala Glu Gly Asp Arg Glu Thr Arg Thr Cys Leu Leu Glu Leu
 35 40 45

Ser Ala Gln Ser Trp Gly Gly Arg Phe Arg Arg Ser Ser Ala Val Ser
 50 55 60

60

703

Ala Gly Ser Pro Ser Arg Leu His Phe Leu Pro Gln Pro Leu Leu Leu
65 70 75 80

5 Arg Ser Ser Gly Ile Pro Ala Ala Ala Thr Pro Trp Pro Gln Pro Ala
85 90 95

Gly Leu Pro Val Arg Pro Thr Pro Thr Arg Thr Gly Glu Glu Asp Arg
100 105 110

10 Thr Leu Asp Ile Ser Ile Cys Thr Glu Val Leu Ala Gly Thr Glu Gln
115 120 125

Pro Pro Pro Pro Arg Met Thr Ser Pro Ser Ser Ser Pro Val Phe Arg
130 135 140

15 Leu Glu Thr Leu Asp Gly Gly Gln Glu Asp Gly Ser Glu Ala Asp Arg
145 150 155 160

20 Gly Lys Leu Asp Phe Gly Ser Gly Leu Pro Pro Met Glu Ser Gln Phe
165 170 175

Gln Gly Glu Asp Arg Lys Phe Ala Pro Ser Asp Lys Ser Gln Pro Pro
180 185 190

25 Thr Thr Glu Arg Glu Gln Val Pro Val Ser Arg Ile Gln Thr Asp Leu
195 200 205

Thr Glu Ile Gly Ser Ser Met Arg Ser Pro Gly Val Ser Pro Arg Ile
210 215 220

30 Trp Leu Asp Phe Gln Ser Thr Xaa
225 230

35

(2) INFORMATION FOR SEQ ID NO: 610:

(i) SEQUENCE CHARACTERISTICS:

40

(A) LENGTH: 34 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 610:

45 Met Val Leu Leu Leu Leu Leu Ala Tyr Val Leu Leu Thr Tyr Ile Leu
1 5 10 15

Leu Leu Asn Met Leu Ile Ala Leu Met Xaa Arg Asp Arg Gln Gln Cys
20 25 30

50

Arg His

55

(2) INFORMATION FOR SEQ ID NO: 611:

(i) SEQUENCE CHARACTERISTICS:

60

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 611:

Met Val Phe Glu Gly Phe Ser Ser Ala Phe Cys Leu Ser Ser Thr Ala
1 5 10 15
Pro Thr Ser His Pro
20

10

(2) INFORMATION FOR SEQ ID NO: 612:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 612:

Gly Lys Lys Asn Gln Leu Leu Val Ile
1 5

20

(2) INFORMATION FOR SEQ ID NO: 613:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 613:

Met Val Trp Val Leu Trp Ser Ala Pro Ser Leu Ala Pro Pro Trp Val
1 5 10 15

35

Gly Pro Cys Trp Pro Ser Thr Gly Asn Cys Cys Leu Cys
20 25

40

(2) INFORMATION FOR SEQ ID NO: 614:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 614:

Met Ala Lys Arg Ser Pro Gly Gly Cys Gly Ser Gly Leu Ile Leu Leu
1 5 10 15

50

Cys Cys Gln Pro Cys Arg Pro Thr Ser Ser Ala Pro Met Arg
20 25 30

55

(2) INFORMATION FOR SEQ ID NO: 615:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 113 amino acids

(B) TYPE: amino acid

60

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 615:

5	Ile Thr Ile Ala Ile Gln Met Ile Cys Leu Val Asn Xaa Glu Leu Tyr	1 5 10 15
	Pro Thr Phe Val Arg Asn Xaa Gly Val Met Val Cys Ser Ser Leu Cys	20 25 30
10	Asp Ile Gly Gly Ile Ile Thr Pro Phe Ile Val Phe Arg Leu Arg Glu	35 40 45
	Val Trp Gln Ala Leu Pro Leu Ile Leu Phe Ala Val Leu Gly Leu Leu	50 55 60
15	Ala Ala Gly Val Thr Leu Leu Leu Pro Glu Thr Lys Gly Val Ala Leu	65 70 75 80
	Pro Glu Thr Met Lys Asp Ala Glu Asn Leu Gly Arg Lys Ala Lys Pro	85 90 95
20	Lys Glu Asn Thr Ile Tyr Leu Lys Val Gln Thr Ser Glu Pro Ser Gly	100 105 110
25	Thr	

30 (2) INFORMATION FOR SEQ ID NO: 616:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 616:

40 Thr Met Lys Asp Ala Glu Asn Leu Gly Arg Lys Ala Lys Pro Lys Glu
1 5 10 15
Asn Thr

45
(2) INFORMATION FOR SEQ ID NO: 617:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 617:

55 Pro Arg Val Arg Asn Ser Pro Glu Asp Leu Gly Leu Ser Leu Thr Gly
 1 5 10 15

Asp Ser Cys Lys Leu
 20

(2) INFORMATION FOR SEQ ID NO: 618:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 52 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 618:

5
 10 Gln Ala Asp Asp Leu Gln Ala Thr Val Ala Ala Leu Cys Val Leu Arg
 1 5 10 15
 Gly Gly Gly Pro Trp Ala Gly Ser Trp Leu Ser Pro Lys Thr Pro Gly
 20 25 30
 15 Ala Met Gly Gly Asp Leu Val Leu Gly Leu Gly Ala Leu Arg Arg Arg
 35 40 45
 20 Lys Arg Leu Leu
 50

(2) INFORMATION FOR SEQ ID NO: 619:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 232 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 619:

25
 30 Glu Gln Glu Lys Ser Leu Ala Gly Trp Ala Leu Val Leu Ala Xaa Xaa
 1 5 10 15
 35 Gly Ile Gly Leu Met Val Leu His Ala Glu Met Leu Trp Phe Gly Gly
 20 25 30
 Cys Ser Ala Val Asn Ala Thr Gly His Leu Ser Asp Thr Leu Trp Leu
 35 40 45
 40 Ile Pro Ile Thr Phe Leu Thr Ile Gly Tyr Gly Asp Val Val Pro Gly
 50 55 60
 Thr Met Trp Gly Lys Ile Val Cys Leu Cys Thr Gly Val Met Gly Val
 45 65 70 75 80
 Cys Cys Thr Ala Leu Leu Val Ala Val Val Ala Arg Lys Leu Glu Phe
 85 90 95
 50 Asn Lys Ala Glu Lys His Val His Asn Phe Met Met Asp Ile Gln Tyr
 100 105 110
 Thr Lys Glu Met Lys Glu Ser Ala Ala Arg Val Leu Gln Glu Ala Trp
 115 120 125
 55 Met Phe Tyr Lys His Thr Arg Arg Lys Glu Ser His Ala Ala Arg Xaa
 130 135 140
 60 His Gln Arg Xaa Leu Leu Ala Ala Ile Asn Ala Phe Arg Gln Val Arg
 145 150 155 160

Leu Lys His Arg Lys Leu Arg Glu Gln Val Asn Ser Met Val Asp Ile
 165 170 175
 5 Ser Lys Met His Met Ile Leu Tyr Asp Leu Gln Gln Asn Leu Ser Ser
 180 185 190
 Ser His Arg Ala Leu Glu Lys Gln Ile Asp Thr Leu Ala Gly Lys Leu
 195 200 205
 10 Asp Ala Leu Thr Glu Leu Leu Ser Thr Ala Leu Gly Pro Arg Gln Leu
 210 215 220
 Pro Glu Pro Ser Gln Gln Ser Lys
 15 225 230

(2) INFORMATION FOR SEQ ID NO: 620:
 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 36 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 620:

Tyr Gln Ala His His Val Ser Arg Asn Lys Arg Gly Gln Val Val Gly
 1 5 10 15
 30 Thr Arg Gly Gly Phe Arg Gly Cys Thr Val Trp Leu Thr Gly Leu Ser
 20 25 30
 Gly Ala Gly Lys
 35 35

(2) INFORMATION FOR SEQ ID NO: 621:
 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 57 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 621:
 Leu Gln Cys Glu Ile Cys Gly Phe Thr Cys Arg Gln Lys Ala Ser Leu
 1 5 10 15
 50 Asn Trp His Met Lys Lys His Asp Ala Asp Ser Phe Tyr Gln Phe Ser
 20 25 30
 Cys Asn Ile Cys Gly Lys Lys Phe Glu Lys Lys Asp Ser Val Val Ala
 35 40 45
 55 His Lys Ala Lys Ser His Pro Glu Val
 50 55

60 (2) INFORMATION FOR SEQ ID NO: 622:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 622:

Ile Thr Ser Thr Asp Ile Leu Gly Thr Asn Pro Glu Ser Leu Thr Gln
1 5 10 15

Pro Ser Asp

(2) INFORMATION FOR SEQ ID NO: 623:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 623:

Asn Ser Thr Ser Gly Glu Cys Leu Leu Leu Glu Ala Glu Gly Met Ser
1 5 10 15

Lys Ser Tyr

(2) INFORMATION FOR SEQ ID NO: 624:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 624:

Cys Ser Gly Thr Glu Arg Val Ser Leu Met Ala Asp Gly Lys Ile Phe
1 5 10 15

Val Gly Ser Gly Ser Ser Gly Gly Thr Glu Gly Leu Val Met Asn Ser
20 25 30

Asp Ile Leu Gly Ala Thr Thr Glu Val Leu Ile Glu Asp Ser Asp Ser
35 40 45

Ala Gly Pro
50

(2) INFORMATION FOR SEQ ID NO: 625:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 60 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 625:

Ile Gln Tyr Val Arg Cys Glu Met Glu Gly Cys Gly Thr Val Leu Ala
 1 5 10 15

5 His Pro Arg Tyr Leu Gln His His Ile Lys Tyr Gln His Leu Leu Lys
 20 25 30

Lys Lys Tyr Val Cys Pro His Pro Ser Cys Gly Arg Leu Phe Arg Leu
 35 40 45

10 Gln Lys Gln Leu Leu Arg His Ala Lys His His Thr
 50 55 60

15

(2) INFORMATION FOR SEQ ID NO: 626:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 626:

25 Asp Gln Arg Asp Tyr Ile Cys Glu Tyr Cys Ala Arg Ala Phe Lys Ser
 1 5 10 15

Ser His Asn Leu Ala Val His Arg Met Ile His Thr Gly Glu Lys
 20 25 30

30

(2) INFORMATION FOR SEQ ID NO: 627:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 627:

40 Arg Ser Ser Arg Ser Lys Thr Gly Ser Leu Gln Leu Ile Cys Lys Ser
 1 5 10 15

Glu Pro Asn Thr Asp Gln Leu Asp Tyr
 20 25

45

(2) INFORMATION FOR SEQ ID NO: 628:

50

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 183 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 628:

55

Leu Gln Cys Glu Ile Cys Gly Phe Thr Cys Arg Gln Lys Ala Ser Leu
 1 5 10 15

60

Asn Trp His Met Lys Lys His Asp Ala Asp Ser Phe Tyr Gln Phe Ser
 20 25 30

710

Cys Asn Ile Cys Gly Lys Lys Phe Glu Lys Lys Asp Ser Val Val Ala
 35 40 45
 5 His Lys Ala Lys Ser His Pro Glu Val Xaa Ile Thr Ser Thr Asp Ile
 50 55 60
 Leu Gly Thr Asn Pro Glu Ser Leu Thr Gln Pro Ser Asp Xaa Asn Ser
 65 70 75 80
 10 Thr Ser Gly Glu Cys Leu Leu Leu Glu Ala Glu Gly Met Ser Lys Ser
 85 90 95
 Tyr Xaa Cys Ser Gly Thr Glu Arg Val Ser Leu Met Ala Asp Gly Lys
 100 105 110
 15 Ile Phe Val Gly Ser Gly Ser Ser Gly Gly Thr Glu Gly Leu Val Met
 115 120 125
 20 Asn Ser Asp Ile Leu Gly Ala Thr Thr Glu Val Leu Ile Glu Asp Ser
 130 135 140
 Asp Ser Ala Gly Pro Xaa Gln Arg Asp Tyr Ile Cys Glu Tyr Cys Ala
 145 150 155 160
 25 Arg Ala Phe Lys Ser Ser His Asn Leu Ala Val His Arg Met Ile His
 165 170 175
 30 Thr Gly Glu Lys His Tyr Xaa
 180

- 35 (2) INFORMATION FOR SEQ ID NO: 629:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 60 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 629:

Gln Tyr Val Arg Cys Glu Met Glu Gly Cys Gly Thr Val Leu Ala His
 1 5 10 15
 45 Pro Arg Tyr Leu Gln His His Ile Lys Tyr Gln His Leu Leu Lys Lys
 20 25 30
 Lys Tyr Val Cys Pro His Pro Ser Cys Gly Arg Leu Phe Arg Leu Gln
 35 40 45
 50 Lys Gln Leu Leu Arg His Ala Lys His His Thr Asp
 50 55 60

- 55 (2) INFORMATION FOR SEQ ID NO: 630:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 amino acids
 60 (B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 630:

5 Pro Phe Lys Asp Asp Pro Arg Asp Glu Thr Tyr Lys Pro His Leu Glu
 1 5 10 15

Arg Glu Thr Pro Lys Pro Arg Arg Lys Ser Gly
 20 25

10

(2) INFORMATION FOR SEQ ID NO: 631:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 110 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 631:

20	Glu Met Phe Asp Ser Leu Ser Tyr Phe Lys Gly Ser Ser Leu Leu	1	5	10	15
	Met Leu Lys Thr Tyr Leu Ser Glu Asp Val Phe Gln His Ala Val Val	20	25	30	
25	Leu Tyr Leu His Asn His Ser Tyr Ala Ser Ile Gln Ser Asp Asp	35	40	45	
	Trp Asp Ser Phe Asn Glu Val Thr Asn Gln Thr Leu Asp Val Lys Arg	50	55	60	
30	Met Met Lys Thr Trp Thr Leu Gln Lys Gly Phe Pro Leu Val Thr Val	65	70	75	80
	Gln Lys Lys Gly Lys Glu Leu Phe Ile Gln Gln Glu Arg Phe Phe Leu	85	90	95	
35	Asn Met Lys Pro Glu Ile Gln Pro Ser Asp Thr Arg Tyr Met	100	105	110	

40

(2) INFORMATION FOR SEQ ID NO: 632:

45

(i) **SEQUENCE CHARACTERISTICS:**

(A) LENGTH: 24 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 632:

50

Leu Glu Lys Val Ala Ser Val Gly Asn Ser Arg Pro Thr Gly Gln Gln
1 5 10 15

55

Leu Glu Ser Leu Gly Leu Leu Ala
20

60

(2) INFORMATION FOR SEQ ID NO: 633:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 633:

Val His Arg Glu Glu Ala Ser Cys Tyr Cys Gln Ala Glu Pro Ser Gly
1 5 10 15

10 Asp Leu

15 (2) INFORMATION FOR SEQ ID NO: 634:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 634:

Arg Pro Ala Leu Arg Gln Ala Gly Gly Gly Thr Arg Glu Pro Arg Gln
1 5 10 15

25 Lys Arg Trp Ala Gly Leu
20

30

(2) INFORMATION FOR SEQ ID NO: 635:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 635:

40 Ala Val Asn Phe Arg Pro Gln Arg Ser Gln Ser Met
1 5 10

45 (2) INFORMATION FOR SEQ ID NO: 636:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 636:

Met Ile Thr Asp Val Gln Leu Ala Ile Phe Ala Asn Met Leu Gly Val
1 5 10 15

55 Ser Leu Phe Leu Leu Val Val Leu Tyr His Tyr Val Ala Val Asn Asn
20 25 30Pro Lys Lys Gln Glu
35

60

(2) INFORMATION FOR SEQ ID NO: 637:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 342 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 637:

Glu Glu Met Ala Asp Ser Val Lys Thr Phe Leu Gln Asp Leu Ala Arg
 1 5 10 15
 Gly Ile Lys Asp Ser Ile Trp Gly Ile Cys Thr Ile Ser Lys Leu Asp
 15 20 25 30
 Ala Arg Ile Gln Gln Lys Arg Glu Glu Gln Arg Arg Arg Arg Ala Ser
 35 40 45
 Ser Val Leu Ala Gln Arg Arg Ala Gln Ser Ile Glu Arg Lys Gln Glu
 20 50 55 60
 Ser Glu Pro Arg Ile Val Ser Arg Ile Phe Gln Cys Cys Ala Trp Asn
 25 65 70 75 80
 Gly Gly Val Phe Trp Phe Ser Leu Leu Leu Phe Tyr Arg Val Phe Ile
 85 90 95
 Pro Val Leu Gln Ser Val Thr Ala Arg Ile Ile Gly Asp Pro Ser Leu
 30 100 105 110
 His Gly Asp Val Trp Ser Trp Leu Glu Phe Phe Leu Thr Ser Ile Phe
 115 120 125
 Ser Ala Leu Trp Val Leu Pro Leu Phe Val Leu Ser Lys Val Val Asn
 35 130 135 140
 Ala Ile Trp Phe Gln Asp Ile Ala Asp Leu Ala Phe Glu Val Ser Gly
 40 145 150 155 160
 Arg Lys Pro His Pro Phe Pro Ser Val Ser Lys Ile Ile Ala Asp Met
 165 170 175
 Leu Phe Asn Leu Leu Leu Gln Ala Leu Phe Leu Ile Gln Gly Met Phe
 45 180 185 190
 Val Ser Leu Phe Pro Ile His Leu Val Gly Gln Leu Val Ser Leu Leu
 195 200 205
 His Met Ser Leu Leu Tyr Ser Leu Tyr Cys Phe Glu Tyr Arg Trp Phe
 50 210 215 220
 Asn Lys Gly Ile Glu Met His Gln Arg Leu Ser Asn Ile Glu Arg Asn
 55 225 230 235 240
 Trp Pro Tyr Tyr Phe Gly Phe Gly Leu Pro Leu Ala Phe Leu Thr Ala
 245 250 255
 Met Gln Ser Ser Tyr Ile Ile Ser Gly Cys Leu Phe Ser Ile Leu Phe
 60 260 265 270

Pro Leu Phe Ile Ile Ser Ala Asn Glu Ala Lys Thr Pro Gly Lys Ala
 275 280 285
 5 Tyr Leu Phe Gln Leu Arg Leu Phe Ser Leu Val Val Phe Leu Ser Asn
 290 295 300
 Arg Leu Phe His Lys Thr Val Tyr Leu Gln Ser Ala Leu Ser Ser Ser
 305 310 315 320
 10 Thr Ser Ala Glu Lys Phe Pro Ser Pro His Pro Ser Pro Ala Lys Leu
 325 330 335
 Lys Ala Thr Ala Gly His
 15 340
 (2) INFORMATION FOR SEQ ID NO: 638:
 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 529 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 638:
 Met Ala Lys Phe Met Thr Pro Val Ile Gln Asp Asn Pro Ser Gly Trp
 1 5 10 15
 30 Gly Pro Cys Ala Val Pro Glu Gln Phe Arg Asp Met Pro Tyr Gln Pro
 20 25 30
 Phe Ser Lys Gly Asp Arg Leu Gly Lys Val Ala Asp Trp Thr Gly Ala
 35 35 40 45
 Thr Tyr Gln Asp Lys Arg Tyr Thr Asn Lys Tyr Ser Ser Gln Phe Gly
 50 55 60
 40 Gly Gly Ser Gln Tyr Ala Tyr Phe His Glu Glu Asp Glu Ser Ser Phe
 65 70 75 80
 Gln Leu Val Asp Thr Ala Arg Thr Gln Lys Thr Ala Tyr Gln Arg Asn
 85 90 95
 45 Arg Met Arg Phe Ala Gln Arg Asn Leu Arg Arg Asp Lys Asp Arg Arg
 100 105 110
 Asn Met Leu Gln Phe Asn Leu Gln Ile Leu Pro Lys Ser Ala Lys Gln
 115 120 125
 50 Lys Glu Arg Glu Arg Ile Arg Leu Gln Lys Lys Phe Gln Lys Gln Phe
 130 135 140
 Gly Val Arg Gln Lys Trp Asp Gln Lys Ser Gln Lys Pro Arg Asp Ser
 145 150 155 160
 Ser Val Glu Val Arg Ser Asp Trp Glu Val Lys Glu Glu Met Asp Phe
 165 170 175
 60 Pro Gln Leu Met Lys Met Arg Tyr Leu Glu Val Ser Glu Pro Gln Asp

	180	185	190
	Ile Glu Cys Cys Gly Ala Leu Glu Tyr Tyr Asp Lys Ala Phe Asp Arg		
	195	200	205
5	Ile Thr Thr Arg Ser Glu Lys Pro Leu Arg Xaa Xaa Lys Arg Ile Phe		
	210	215	220
10	His Thr Val Thr Thr Thr Asp Asp Pro Val Ile Arg Lys Leu Ala Lys		
	225	230	235 240
	Thr Gln Gly Asn Val Phe Ala Thr Asp Ala Ile Leu Ala Thr Leu Met		
		245	250 255
15	Ser Cys Thr Arg Ser Val Tyr Ser Trp Asp Ile Val Val Gln Arg Val		
		260	265 270
	Gly Ser Lys Leu Phe Phe Asp Lys Arg Asp Asn Ser Asp Phe Asp Leu		
		275	280 285
20	Leu Thr Val Ser Glu Thr Ala Asn Glu Pro Pro Gln Asp Glu Gly Asn		
		290	295 300
	Ser Phe Asn Ser Pro Arg Asn Leu Ala Met Glu Ala Thr Tyr Ile Asn		
		305	310 315 320
25	His Asn Phe Ser Gln Gln Cys Leu Arg Met Gly Lys Glu Arg Tyr Asn		
		325	330 335
30	Phe Pro Asn Pro Asn Pro Phe Val Glu Asp Asp Met Asp Lys Asn Glu		
		340	345 350
	Ile Ala Ser Val Ala Tyr Arg Tyr Arg Ser Gly Lys Leu Gly Asp Asp		
		355	360 365
35	Ile Asp Leu Ile Val Arg Cys Glu His Asp Gly Val Met Thr Gly Ala		
		370	375 380
	Asn Gly Glu Val Ser Phe Ile Asn Ile Lys Thr Leu Asn Glu Trp Asp		
		385	390 395 400
40	Ser Arg His Cys Asn Gly Val Asp Trp Arg Gln Lys Leu Asp Ser Gln		
		405	410 415
45	Arg Gly Ala Val Ile Ala Thr Glu Leu Lys Asn Asn Ser Tyr Lys Leu		
		420	425 430
	Ala Arg Trp Thr Cys Cys Ala Leu Leu Ala Gly Ser Glu Tyr Leu Lys		
		435	440 445
50	Leu Gly Tyr Val Ser Arg Tyr His Val Lys Asp Ser Ser Arg His Val		
		450	455 460
	Ile Leu Gly Thr Gln Gln Phe Lys Pro Asn Glu Phe Ala Ser Gln Ile		
		465	470 475 480
55	Asn Leu Ser Val Glu Asn Ala Trp Gly Ile Leu Arg Cys Val Ile Asp		
		485	490 495
60	Ile Cys Met Lys Leu Glu Glu Gly Lys Tyr Leu Ile Leu Lys Asp Pro		

500 505 510

Asn Lys Gln Val Ile Arg Val Tyr Ser Leu Pro Asp Gly Thr Phe Ser
 515 520 525

5 Ser

10 (2) INFORMATION FOR SEQ ID NO: 639:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 194 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 639:

20 Lys Lys Arg His Thr Asp Val Gln Phe Tyr Thr Glu Val Gly Glu Ile
 1 5 10 15

Thr Thr Asp Leu Gly Lys His Gln His Met His Asp Arg Asp Asp Leu
 20 25 30

25 Tyr Ala Glu Gln Met Glu Arg Glu Met Arg His Lys Leu Lys Thr Ala
 35 40 45

Phe Lys Asn Phe Ile Glu Lys Val Glu Ala Leu Thr Lys Glu Glu Leu
 50 55 60

30 Glu Phe Glu Val Pro Phe Arg Asp Leu Gly Phe Asn Gly Ala Pro Tyr
 65 70 75 80

35 Arg Ser Thr Cys Leu Leu Gln Pro Thr Ser Ser Ala Leu Val Asn Ala
 85 90 95

Thr Glu Trp Pro Pro Phe Val Val Thr Leu Asp Glu Val Glu Leu Ile
 100 105 110

40 His Phe Xaa Arg Val Gln Phe His Leu Lys Asn Phe Asp Met Val Ile
 115 120 125

Val Tyr Lys Asp Tyr Ser Lys Lys Val Thr Met Ile Asn Ala Ile Pro
 130 135 140

45 Val Ala Ser Leu Asp Pro Ile Lys Glu Trp Leu Asn Ser Cys Asp Leu
 145 150 155 160

50 Lys Tyr Thr Glu Gly Val Gln Ser Leu Asn Trp Thr Lys Ile Met Lys
 165 170 175

Thr Ile Val Asp Asp Pro Glu Gly Phe Phe Glu Gln Gly Gly Trp Ser
 180 185 190

55 Phe Leu

60 (2) INFORMATION FOR SEQ ID NO: 640:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 70 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 640:

Arg Ser Gly Leu Gly Leu Gly Ile Thr Ile Ala Phe Leu Ala Thr Leu
 1 5 10 15
 Ile Thr Gln Phe Leu Val Tyr Asn Gly Val Tyr Gln Tyr Thr Ser Pro
 20 25 30
 Asp Phe Leu Tyr Ile Arg Ser Trp Leu Pro Cys Ile Phe Phe Ser Gly
 35 40 45
 Gly Val Thr Val Gly Asn Ile Gly Arg Gln Leu Ala Met Gly Val Pro
 50 55 60
 Glu Lys Pro His Ser Asp
 65 70

(2) INFORMATION FOR SEQ ID NO: 641:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 101 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 641:

Val Thr Gln Pro Lys His Leu Ser Ala Ser Met Gly Gly Ser Val Glu
 1 5 10 15
 Ile Pro Phe Ser Phe Tyr Tyr Pro Trp Glu Leu Ala Xaa Xaa Pro Xaa
 20 25 30
 Val Arg Ile Ser Trp Arg Arg Gly His Phe His Gly Gln Ser Phe Tyr
 35 40 45
 Ser Thr Arg Pro Pro Ser Ile His Lys Asp Tyr Val Asn Arg Leu Phe
 50 55 60
 Leu Asn Trp Thr Glu Gly Gln Glu Ser Gly Phe Leu Arg Ile Ser Asn
 65 70 75 80
 Leu Arg Lys Glu Asp Gln Ser Val Tyr Phe Cys Arg Val Glu Leu Asp
 85 90 95
 Thr Arg Arg Ser Gly
 100

(2) INFORMATION FOR SEQ ID NO: 642:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 233 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 642:

5 Met Glu Ala Gln Gln Val Asn Glu Ala Glu Ser Ala Arg Glu Gln Leu
 1 5 10 15
 Gln Xaa Leu His Asp Gln Ile Ala Gly Gln Lys Ala Ser Lys Gln Glu
 20 25 30
 10 Leu Glu Thr Glu Leu Glu Arg Leu Lys Gln Glu Phe His Tyr Ile Glu
 35 40 45
 Glu Asp Leu Tyr Arg Thr Lys Asn Thr Leu Gln Ser Arg Ile Lys Asp
 50 55 60
 15 Arg Asp Glu Glu Ile Gln Lys Leu Arg Asn Gln Leu Thr Asn Lys Thr
 65 70 75 80
 Leu Ser Asn Ser Ser Gln Ser Glu Leu Glu Asn Arg Leu His Gln Leu
 85 90 95
 Thr Glu Thr Leu Ile Gln Lys Gln Thr Met Leu Glu Ser Leu Ser Thr
 100 105 110
 25 Glu Lys Asn Ser Leu Val Phe Gln Leu Glu Arg Leu Glu Gln Gln Met
 115 120 125
 Asn Ser Ala Ser Gly Ser Ser Ser Asn Gly Ser Ser Ile Asn Met Ser
 130 135 140
 30 Gly Ile Asp Asn Gly Glu Gly Thr Arg Leu Arg Asn Val Pro Val Leu
 145 150 155 160
 Phe Asn Asp Thr Glu Thr Asn Leu Ala Gly Met Tyr Gly Lys Val Arg
 165 170 175
 Lys Ala Ala Ser Ser Ile Asp Gln Phe Ser Ile Arg Leu Gly Ile Phe
 180 185 190
 40 Leu Arg Arg Tyr Pro Ile Ala Arg Val Phe Val Ile Ile Tyr Met Ala
 195 200 205
 Leu Leu His Leu Trp Val Met Ile Val Leu Leu Thr Tyr Thr Pro Glu
 210 215 220
 45 Met His His Asp Gln Pro Tyr Gly Lys
 225 230

50

(2) INFORMATION FOR SEQ ID NO: 643:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 643:

60 Ile Arg His Glu Gln His Pro Asn Phe Ser Leu Glu Met His Ser Lys
 1 5 10 15

Gly Ser Ser Leu Leu Leu Phe Leu Pro Gln Leu Ile Leu Ile Leu Pro
 20 25 30

5 Val Cys Ala His Leu His Glu Glu Leu Asn Cys
 35 40

10 (2) INFORMATION FOR SEQ ID NO: 644:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 63 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 644:

Ser Phe Phe Ile Ser Glu Glu Lys Gly His Leu Leu Leu Gln Ala Glu
 1 5 10 15

20 Arg His Pro Trp Val Ala Gly Ala Leu Val Gly Val Ser Gly Gly Leu
 20 25 30

25 Thr Leu Thr Thr Cys Ser Gly Pro Thr Glu Lys Pro Ala Thr Lys Asn
 35 40 45

Tyr Phe Leu Lys Arg Leu Leu Gln Glu Met His Ile Arg Ala Asn
 50 55 60

30

35

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>116</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97897
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div> <div style="text-align: center;">Susan White PCT International Division</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div>
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>116</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit May 15, 1997	Accession Number 209043
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div> <div style="text-align: center;">Susan White PCT International Division</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div>
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>119</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit September 4, 1997	Accession Number 209235
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div> <div style="text-align: center;">Susan White PCT International Division</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div>
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>122</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97898
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div> <div style="text-align: center;">Susan White PCT International Division</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div>
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>122</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit May 15, 1997	Accession Number 209044
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div> <div style="text-align: center;">Susan White PCT International Division</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div>
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>126</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97899
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="display: flex; align-items: center;"><div style="flex: 1;">Authorized officer</div><div style="text-align: center; flex: 2;">Susan White PCT International Division</div></div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="display: flex; align-items: center;"><div style="flex: 1;">Authorized officer</div><div style="flex: 2;"></div></div>
---	---

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>126</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit May 15, 1997	Accession Number 209045
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="text-align: center;">For receiving Office use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">Authorized officer <div style="text-align: center;">Susan White PCT International Division</div></div>	<div style="text-align: center;">For International Bureau use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">Authorized officer</div>
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>130</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit April 28, 1997	Accession Number 209011
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div> <div style="text-align: center;">Susan White PCT International Division</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div>
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>131</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97900
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="checked" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <div style="text-align: center;">Susan White PCT International Division</div>	Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>137</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <p style="text-align: center;">American Type Culture Collection</p>	
Address of depositary institution (including postal code and country) <p>12301 Parklawn Drive Rockville, Maryland 20852 United States of America</p>	
Date of deposit <u>February 26, 1997</u>	Accession Number <u>97901</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="checked" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <p style="text-align: center;">Susan White PCT International Division</p>	Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>131</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <p style="text-align: center;">American Type Culture Collection</p>	
Address of depositary institution (including postal code and country) <p>12301 Parklawn Drive Rockville, Maryland 20852 United States of America</p>	
Date of deposit <u>May 15, 1997</u>	Accession Number <u>209046</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer Susan White PCT International Division</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>137</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit May 15, 1997	Accession Number 209047
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="text-align: center;">For receiving Office use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">Authorized officer Susan White PCT International Division</div>	<div style="text-align: center;">For International Bureau use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">Authorized officer</div>
--	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>137</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit May 22, 1997	Accession Number 209076
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="text-align: center;">For receiving Office use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">Authorized officer <div style="text-align: center;">Susan White PCT International Division</div></div>	<div style="text-align: center;">For International Bureau use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">Authorized officer</div>
--	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>140</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 -- United States of America	
Date of deposit August 21, 1997	Accession Number 209215
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div> <div style="text-align: center;">Susan White PCT International Division</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div>
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>160</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97904
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="padding: 5px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-top: 1px solid black; padding: 5px;">Authorized officer Susan White PCT International Division</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="padding: 5px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-top: 1px solid black; padding: 5px;">Authorized officer</div>
---	---

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>154</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit July 3, 1997	Accession Number 209139
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="padding: 5px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-top: 1px solid black; padding: 5px;">Authorized officer Susan White PCT International Division</div>	<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="padding: 5px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-top: 1px solid black; padding: 5px;">Authorized officer</div>
--	---

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>153</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit May 15, 1997	Accession Number 209049
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="padding: 5px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-top: 1px solid black; padding: 5px;">Authorized officer <div style="text-align: center; margin-top: 10px;">Susan White PCT International Division</div></div>	<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="padding: 5px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-top: 1px solid black; padding: 5px;">Authorized officer</div>
---	---

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>153</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97903
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="checked" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Susan White PCT International Division	Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>142</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit <u>June 12, 1997</u>	Accession Number <u>209119</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="checked" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <div style="text-align: center;">Susan White PCT International Division</div>	Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>146</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97902
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer Susan White PCT International Division</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div>
--	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>146</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit May 15, 1997	Accession Number 209048
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g. "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input checked="checked" type="checkbox"/> This sheet was received with the international application</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div> <div style="text-align: center;">Susan White PCT International Division</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="display: flex; align-items: center; margin-bottom: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-bottom: 1px solid black; margin-bottom: 10px;">Authorized officer</div>
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>160</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <p style="text-align: center;">American Type Culture Collection</p>	
Address of depositary institution (including postal code and country) <p>12301 Parklawn Drive Rockville, Maryland 20852 United States of America</p>	
Date of deposit <u>May 15, 1997</u>	Accession Number <u>209050</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit") 	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer Susan White PCT International Division</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>142</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>12301 Parklawn Drive</u> <u>Rockville, Maryland 20852</u> <u>United States of America</u>	
Date of deposit <u>February 12, 1998</u>	Accession Number <u>209627</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="padding: 5px;"><input checked="" type="checkbox"/> This sheet was received with the international application</div> <div style="border-top: 1px solid black; padding: 5px;">Authorized officer Susan White PCT International Division</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="padding: 5px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-top: 1px solid black; padding: 5px;">Authorized officer</div>
--	---

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group
5 consisting of:

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

10 (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
20 having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

25 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the
30 polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included
35 in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

5

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

10

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

15

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

20

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

25

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

30

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

35

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

- (g) a variant of SEQ ID NO:Y;
- (h) an allelic variant of SEQ ID NO:Y; or
- (i) a species homologue of the SEQ ID NO:Y.

5 12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

10 13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15 15. A method of making an isolated polypeptide comprising:
(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
(b) recovering said polypeptide.

20 16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

25 18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

30 (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

35 (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

- 5 (a) contacting the polypeptide of claim 11 with a binding partner; and
(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

10 22. A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO:X in a cell;
(b) isolating the supernatant;
(c) detecting an activity in a biological assay; and
15 (d) identifying the protein in the supernatant having the activity.


23. The product produced by the method of claim 22.

Applicant's or agent's file reference number	PS001PCT	International application No. Unassigned	PCT US 98/04493
--	----------	--	-----------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
 (PCT Rule 13bis)

REC'D 03 APR 1998
 WIPO PCT

A. The indications made below relate to the microorganism referred to in the description on page 160, line N/A	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97904
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer  Stephen W. Price PCT International Division </p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file
reference number

PS002PCT

International applicat-- No. Unassigned

PCT US 98/04493

REC'D 03 APR 1998

WIPO

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description
on page 116, line N/A

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☒

Name of depositary institution American Type Culture Collection

Address of depositary institution (including postal code and country)

12301 Parklawn Drive
Rockville, Maryland 20852
United States of America

Date of deposit May 15, 1997

Accession Number 209043

C. ADDITIONAL INDICATIONS (leave blank if not applicable)

This information is continued on an additional sheet ☐

In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")

For receiving Office use only



This sheet was received with the international application

Authorized officer

Susan White
PCT International Division

For International Bureau use only



This sheet was received by the International Bureau on:

Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned
		PC US 98/04493

REC'D 03 APR 1998
WIPO PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 116, line N/A	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97897
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Susan White PCT International Division	Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned	PCT JS 98/04493
--	----------	--	-----------------

REC'D	03 APR 1998
WIPO	PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>119</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>12301 Parklawn Drive</u> <u>Rockville, Maryland 20852</u> <u>United States of America</u>	
Date of deposit <u>September 4, 1997</u>	Accession Number <u>209235</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input checked="" type="checkbox"/> This sheet was received with the international application	
Authorized officer <u>Susan White</u> PCT International Division	

For International Bureau use only	
<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer	

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file
reference number

PS002PCT

International application No. Unassigned

PCT US 98/04493

REC'D 03 APR 1998

WIPO

PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description
on page 122, line N/A

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☒

Name of depositary institution American Type Culture Collection

Address of depositary institution (including postal code and country)

12301 Parklawn Drive
Rockville, Maryland 20852
United States of America

Date of deposit May 15, 1997

Accession Number 209044

C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ☐

In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")

For receiving Office use only



This sheet was received with the international application

Authorized officer

Susan White
PCT International Division

For International Bureau use only



This sheet was received by the International Bureau on:

Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.


SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned
		PCT US 98/04493



INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>122</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>12301 Parklawn Drive</u> <u>Rockville, Maryland 20852</u> <u>United States of America</u>	
Date of deposit <u>February 26, 1997</u>	Accession Number <u>97898</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input checked="" type="checkbox"/>	This sheet was received with the international application
Authorized officer	<u>Susan White</u> <u>PCT International Division</u>

For International Bureau use only	
<input type="checkbox"/>	This sheet was received by the International Bureau on:
Authorized officer	

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file
reference number

PS002PCT

International application No. Unassigned

PCT US 98/04493

REC'D 03 APR 1998

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>126</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>12301 Parklawn Drive</u> <u>Rockville, Maryland 20852</u> <u>United States of America</u>	
Date of deposit <u>May 15, 1997</u>	Accession Number <u>209045</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <u>Susan White</u> <u>PCT International Division</u>	Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No.	Unassigned
		PCT	HS 98/04493
		REC'D	03 APR 1998
		WIPO	PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>126</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>12301 Parklawn Drive</u> <u>Rockville, Maryland 20852</u> <u>United States of America</u>	
Date of deposit <u>February 26, 1997</u>	Accession Number <u>97899</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer <u>Susan White</u> <u>PCT International Division</u> </p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file
reference number

PS002PCT

International application No. Unassigned

PC US 98/04493

REC'D 03 APR 1998

WIPO PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description
on page 130, line N/A

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☒

Name of depositary institution American Type Culture Collection

Address of depositary institution (including postal code and country)

12301 Parklawn Drive
Rockville, Maryland 20852
United States of America

Date of deposit April 28, 1997

Accession Number 209011

C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ☐

In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")

For receiving Office use only

☒ This sheet was received with the international application

Authorized officer

Susan White
PCT International Division

For International Bureau use only

☐ This sheet was received by the International Bureau on:

Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned	PCT US 98/04493
--	----------	--	-----------------

REC'D 03 APR 1998
WIPO PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 131, line N/A	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit May 15, 1997	Accession Number 209046
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input checked="" type="checkbox"/> This sheet was received with the international application	
Authorized officer	Susan White PCT International Division

For International Bureau use only	
<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer	

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned	PC /US-98/04493
--	----------	--	-----------------

REC'D 03 APR 1998

WIPO

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 131, line N/A	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97900
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Susan White PCT International Division	Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned PCT US 98/04493
---	----------	---

REC'D 03 APR 1998
WIPO PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>137</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>12301 Parklawn Drive</u> <u>Rockville, Maryland 20852</u> <u>United States of America</u>	
Date of deposit <u>May 22, 1997</u>	Accession Number <u>209076</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<p style="text-align: center;">For receiving Office use only</p> <div style="border: 1px solid black; padding: 5px;"> <input checked="" type="checkbox"/> This sheet was received with the international application </div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> Authorized officer Susan White PCT International Division </div>	<p style="text-align: center;">For International Bureau use only</p> <div style="border: 1px solid black; padding: 5px;"> <input type="checkbox"/> This sheet was received by the International Bureau on: </div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> Authorized officer </div>
---	--

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned	PCT US 98/04493
--	----------	--	-----------------

REC'D 03 APR 1998

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>137</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>12301 Parklawn Drive</u> <u>Rockville, Maryland 20852</u> <u>United States of America</u>	
Date of deposit <u>May 15, 1997</u>	Accession Number <u>209047</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer <u>Susan White</u> <u>PCT International Division</u></p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	---

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned PC US 98/04493
--	----------	--

REC'D 03 APR 1998

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 137, line N/A	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97901
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input checked="" type="checkbox"/> This sheet was received with the international application	
Authorized officer	Susan White PCT International Division

For International Bureau use only	
<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer	

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file
reference number

PS002PCT

International application No. Unassigned

PCT US 98/04493

REC'D 03 APR 1998

WIPO

PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>140</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>12301 Parklawn Drive</u> <u>Rockville, Maryland 20852</u> <u>United States of America</u>	
Date of deposit <u>August 21, 1997</u>	Accession Number <u>209215</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <u>Susan White</u> PCT International Division	Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned	PCT US 98/04493
--	----------	--	-----------------

REC'D	03 APR 1998
WIPO	PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 142, line N/A	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit June 12, 1997	Accession Number 209119
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Susan White PCT International Division	Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned	PC 115 98/04493
--	----------	--	-----------------

REC'D	03 APR 1998
WIPO	PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 142, line N/A	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 12, 1998	Accession Number 209627
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input checked="" type="checkbox"/> This sheet was received with the international application	
Authorized officer Susan White PCT International Division	

For International Bureau use only	
<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer	

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.


SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned
		PCT US 98/04493



INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 146, line N/A	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit May 15, 1997	Accession Number 209048
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input checked="" type="checkbox"/>	This sheet was received with the international application
Authorized officer	Cusan White PCT International Division

For International Bureau use only	
<input type="checkbox"/>	This sheet was received by the International Bureau on:
Authorized officer	

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned
		PCT US 98/04493

REC'D 03 APR 1998

WIPO PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 146, line N/A	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit February 26, 1997	Accession Number 97902
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Susan White PCT International Division	Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned	PCT US 98/04493
--	----------	--	-----------------

REC'D	03 APR 1998
WIPO	PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>153</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>12301 Parklawn Drive</u> <u>Rockville, Maryland 20852</u> <u>United States of America</u>	
Date of deposit <u>May 15, 1997</u>	Accession Number <u>209049</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Susan White PCT International Division	Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned	PC 115 98/04493
--	----------	--	-----------------

REC'D	03 APR 1998
WIPO	PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>153</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>12301 Parklawn Drive</u> <u>Rockville, Maryland 20852</u> <u>United States of America</u>	
Date of deposit <u>February 26, 1997</u>	Accession Number <u>97903</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
(Blank space for designated states)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	
(Blank space for separate indications)	

For receiving Office use only	
<input checked="" type="checkbox"/> This sheet was received with the international application	
Authorized officer <u>Susan White</u> <u>PCT International Division</u>	

For International Bureau use only	
<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer	

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned
		PCT US 98/04493
		REC'D 03 APR 1998
		WIPO PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>154</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>12301 Parklawn Drive</u> <u>Rockville, Maryland 20852</u> <u>United States of America</u>	
Date of deposit <u>July 3, 1997</u>	Accession Number <u>209139</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<p>In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).</p>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<p style="text-align: center;">For receiving Office use only</p> <div style="border: 1px solid black; padding: 5px;"> <input checked="" type="checkbox"/> This sheet was received with the international application </div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> Authorized officer <u>Susan White</u> <u>PCT International Division</u> </div>	<p style="text-align: center;">For International Bureau use only</p> <div style="border: 1px solid black; padding: 5px;"> <input type="checkbox"/> This sheet was received by the International Bureau on: </div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> Authorized officer </div>
--	--

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PS002PCT	International application No. Unassigned	PCT US 98/04493
--	----------	--	-----------------

REC'D 03 APR 1998

WIPO

PCT

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 160, line N/A	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit May 15, 1997	Accession Number 209050
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Susan White PCT International Division	Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

Page 2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.